

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 November 2000 (30.11.2000)

PCT

(10) International Publication Number
WO 00/71577 A1

(51) International Patent Classification⁷: **C07K 14/00,**
C12P 21/00

(21) International Application Number: **PCT/US00/14462**

(22) International Filing Date: **25 May 2000 (25.05.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:

09/318,208	25 May 1999 (25.05.1999)	US
60/144,882	20 July 1999 (20.07.1999)	US
60/147,823	10 August 1999 (10.08.1999)	US
09/373,658	13 August 1999 (13.08.1999)	US
60/171,503	22 December 1999 (22.12.1999)	US
60/183,792	22 February 2000 (22.02.2000)	US

Lane, Devon, PA 19333 (US). **TRULLI, Stephen, H.** [US/US]; 2015 Belvedere Avenue, Havertown, PA 19083 (US). **FORNWALD, James, A.** [US/US]; 2849 Ringneck Road, Norristown, PA 19403 (US). **TERRETT, Jonathan, A.** [GB/GB]; 20 Sandford Close, Abingdon, Oxon OX14 2PX (GB).

(74) Agents: **STEFFE, Eric, K.**; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue N.W., Washington, DC 20005-3934 et al. (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicants (*for all designated States except US*): **HUMAN GENOME SCIENCES, INC.** [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). **SMITHKLINE BEECHAM CORPORATION** [US/US]; 709 Swedeland Road, Mail Code - UM2220, King of Prussia, PA 19406 (US). **BETH ISRAEL DEACONESS MEDICAL CENTER** [US/US]; 330 Brookline Avenue, Boston, MA 02215 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicants and

(72) Inventors: **IRUELA-ARISPE, Luisa** [ES/US]; 1342 Holmby Avenue, Los Angeles, CA 90024 (US). **HASTINGS, Gregg, A.** [US/US]; 31919 Richgrove Court, Westlake Village, CA 91321 (US). **RUBEN, Steven, M.** [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). **JONAK, Zdenka, L.** [US/US]; 28 Ladderback

(54) Title: **METH1 AND METH2 POLYNUCLEOTIDES AND POLYPEPTIDES**

(57) Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 and METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.

WO 00/71577 A1

B7

METH1 and METH2 Polynucleotides and Polypeptides

Background of the Invention

Statement as to Rights to Inventions Made Under Federally-Sponsored Research and Development

5 Part of the work performed during development of this invention utilized U.S. Government funds. The U.S. Government may have certain rights in this invention.

Field of the Invention

10 The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2 (ME, for metalloprotease, and TH, for thrombospondin). METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are
15 methods for inhibiting angiogenesis using METH1 or METH2.

Related Art

20 Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a tightly regulated process in normal adults. Under physiological circumstances, growth of new capillaries is tightly controlled by an interplay of growth regulatory proteins which act either to stimulate or to inhibit blood vessel growth. Normally, the balance between these forces is tipped in favor of inhibition and consequently blood vessel growth is restrained. Under certain pathological circumstances, however, local inhibitory controls are unable to restrain the increased activity of angiogenic inducers. Angiogenesis is a key step in the metastasis of cancer (Folkman, *Nature Med.* 1:27-31
25 (1995)) and in abnormal wound healing, inflammation, rheumatoid arthritis, psoriasis, and diabetic retinopathy, it is integral to the pathology (Folkman *et al.*, *Science* 235:442-

447 (1987)), engendering the hope that these pathological entities could be regulated by pharmacological and/or genetic suppression of blood vessel growth (Iruela-Arispe *et al.*, *Thromb. Haem.* 78:672-677 1997)).

Thrombospondin-1 (TSP-1) is a 450 kDa, anti-angiogenic adhesive glycoprotein released from activated platelets and secreted by growing cells (reviewed in Adams, *Int. J. Biochem. Cell. Biol.* 29:861-865 (1997)). TSP-1 is a homotrimer, with each subunit comprised of a 1152 amino acid residue polypeptide, post-translationally modified by *N*-linked glycosylation and beta-hydroxylation of asparagine residues.

TSP-1 protein and mRNA levels are regulated by a variety of factors. TSP-1 protein levels are downregulated by IL-1 alpha and TNF alpha. TSP-1 mRNA and protein levels are upregulated by polypeptide growth factors including PDGF, TGF-beta, and bFGF (Bornstein, *Faseb J.* 6:3290-3299 (1992)) and are also regulated by the level of expression of the p53 tumor suppressor gene product (Dameron *et al.*, *Science* 265:1582-1584 (1994)). At least four other members of the thrombospondin family have been identified: TSP-2, TSP-3, TSP-4, and TSP-5 (also called COMP). There is a need in the art to identify other molecules involved in the regulation of angiogenesis.

Summary of the Invention

The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding the METH1 polypeptide having the amino acid sequence shown in SEQ ID NO:2 or the amino acid sequence encoded by the cDNA clone deposited in a bacterial host as ATCC Deposit Number 209581 on January 15, 1998.

The present invention also provides isolated nucleic acid molecules comprising a polynucleotide encoding the METH2 polypeptide having the amino acid sequence shown in SEQ ID NO:4 or the amino acid sequence encoded by the cDNA clone deposited in a bacterial host as ATCC Deposit No. 209582 on January 15, 1998 or ATCC Deposit No. PTA 1478 on March 14, 2000.

The present invention also relates to recombinant vectors, which include the isolated nucleic acid molecules of the present invention, and to host cells containing the

recombinant vectors, as well as to methods of making such vectors and host cells and for using them for production of METH1 or METH2 polypeptides or peptides by recombinant techniques.

The invention further provides an isolated METH1 or METH2 polypeptide having an amino acid sequence encoded by a polynucleotide described herein.

The invention further provides a diagnostic method useful during diagnosis or prognosis of cancer.

An additional aspect of the invention is related to a method for treating an individual in need of an increased level of METH1 or METH2 activity in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an isolated METH1 or METH2 polypeptide of the invention or an agonist thereof.

Brief Description of the Figures

Figure 1A-C show the nucleotide (SEQ ID NO:1) and deduced amino acid (SEQ ID NO:2) sequences of METH1. The protein has a predicted leader sequence of about 28 amino acid residues (underlined).

Figures 2A-B show the nucleotide (SEQ ID NO:3) and deduced amino acid (SEQ ID NO:4) sequences of METH2. The protein has a predicted leader sequence of about 23 amino acid residues (underlined).

Figures 3A-C show a comparison of the amino acid sequence of METH1 (SEQ ID NO:2) and METH2 (SEQ ID NO:4) with that of their closest homologue, a bovine metalloprotease (pNPI) (SEQ ID NO:5). Identical amino acids are boxed. Functional domains predicted by sequence and structural homology are labeled, including the signal peptide (single line), the potential cleavage site for mammalian subtilisin (double underlined), the zinc-binding-site (dotted line; amino acids 383-395 in METH1 and 363-375 in METH2) in the metalloprotease domain, and the putative disintegrin loops (arrows).

Figure 4 shows the primary structure of METH1, METH2 and pNPI which includes a prodomain, a catalytic metalloprotease domain, a cysteine rich disintegrin domain, a TSP-like domain, a spacer region and a different number of TSP-like domains, three for METH1, two for METH2, and four for pNPI.

Figure 5 shows a comparison of the TSP-like domain of METH1 (SEQ ID NO:2) and METH2 (SEQ ID NO:4) with those of TSP1 (SEQ ID NOs:6, 7, and 8) and TSP2 (SEQ ID NOs:9, 10, and 11), cysteines are numbered 1 to 6, tryptophans are marked by asterisks.

Figures 6A-6D show that peptides and recombinant protein derived from the TSP-like domain of METH1 and METH2 block VEGF-induced angiogenesis. Angiogenesis was induced on CAMs from 12-14-day-old embryos using a nylon mesh containing VEGF casted on matrigel and in the presence or absence of the peptides or recombinant protein. Capillary density was evaluated as described in Example 4. Positive and negative control included VEGF alone and vehicle alone, respectively. (A) Quantification of the angiogenic response induced by VEGF in the presence of recombinant proteins. TSP1, purified platelet TSP1, GST, purified GST, GST-TSP1, GST-METH1, and GST-METH2 are described in Example 4. (B) Quantification of the angiogenic response induced by VEGF in the presence or absence of the peptides; P-TSP1, P-METH1, and P-METH2 (peptide derived from the Type I repeats of TSP, METH1 and METH2, respectively); SC1 and SC2 are scramble peptides used as controls. (C) Dose-response of the VEGF-induced angiogenesis in the presence of GST-METH1. (D) Dose-response of the VEGF-induced angiogenesis in the presence of GST-METH2. The angiogenic index was expressed considering the vascular response from the VEGF-matrigel as 100% and subtracting the background levels (matrigel alone). Assays were repeated, at least, twice. Each treatment was done in triplicate. Values represent the mean, bars indicate standard deviations. * $p < 0.001$.

Figures 7A-E show the effect of METH1 and METH2 recombinant proteins on bFGF-stimulated cell proliferation. Cells were cultured on 24-well plates in media containing bFGF and the recombinant protein to be tested (3 μ g/ml, unless indicated in the graph). Controls included vehicle or GST recombinant protein alone. (A), HDEC,

human dermal endothelial cells; (B), HMEC, human mammary epithelial cells; (C), HDF, human dermal fibroblasts; (D), SMC, smooth muscle cells; (E) Dose-response of GST-METH1 and GST-METH2 on HDEC proliferation. Experiments were repeated, at least, twice. Each treatment was done in triplicate. Values represent the mean, bars indicate standard deviations. * $p < 0.01$.

Figure 8 shows a schematic representation of the pHE4-5 expression vector (SEQ ID NO:12) and the subcloned METH1 or METH2 cDNA coding sequence. The locations of the kanamycin resistance marker gene, the METH1 or METH2 coding sequence, the oriC sequence, and the *lacIq* coding sequence are indicated.

Figure 9 shows the nucleotide sequence of the regulatory elements of the pHE promoter (SEQ ID NO:13). The two *lac* operator sequences, the Shine-Delgarno sequence (S/D), and the terminal *HindIII* and *NdeI* restriction sites (italicized) are indicated.

Figure 10 shows an analysis of the METH1 amino acid sequence. Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic regions; flexible regions; antigenic index and surface probability are shown, and all were generated using the default settings. In the "Antigenic Index or Jameson-Wolf" graph, the positive peaks indicate locations of the highly antigenic regions of the METH1 or METH2 protein, i.e., regions from which epitope-bearing peptides of the invention can be obtained. The domains defined by these graphs are contemplated by the present invention. Tabular representation of the data summarized graphically in Figure 10 can be found in Table 1.

Figure 11 shows an analysis of the METH2 amino acid sequence. Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic regions; flexible regions; antigenic index and surface probability are shown, and all were generated using the default settings. In the "Antigenic Index or Jameson-Wolf" graph, the positive peaks indicate locations of the highly antigenic regions of the METH1 or METH2 protein, i.e., regions from which epitope-bearing peptides of the invention can be obtained. The domains defined by these graphs are contemplated by the present invention. Tabular representation of the data summarized graphically in Figure 11 can be found in Table 2.

Table 1

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Met	1	A	A	0.41	*	.	.	-0.30	0.60
Gly	2	.	A	C	0.91	*	.	.	0.50	0.81
Asn	3	A	A	0.71	*	.	.	0.75	1.24
Ala	4	A	A	0.89	*	.	.	1.09	1.26
Glu	5	A	A	0.93	*	.	F	1.58	1.97
Arg	6	.	A	B	1.23	.	.	F	1.92	1.21
Ala	7	.	.	B	.	.	T	.	1.69	.	.	F	2.66	1.61
Pro	8	T	T	.	1.39	.	.	F	3.40	1.82
Gly	9	T	T	.	1.28	.	.	F	3.06	1.25
Ser	10	T	T	.	0.93	.	.	F	2.42	1.07
Arg	11	T	T	.	0.61	.	*	F	1.93	0.68
Ser	12	T	T	.	0.34	*	.	F	1.74	1.07
Phe	13	.	.	B	.	.	T	.	0.34	*	.	F	0.25	0.59
Gly	14	.	.	B	.	.	T	.	0.38	*	.	F	0.25	0.47
Pro	15	.	.	B	B	.	.	.	-0.13	*	.	F	-0.45	0.50
Val	16	.	.	B	B	.	.	.	-1.06	*	.	F	-0.45	0.48
Pro	17	.	.	B	B	.	.	.	-1.57	.	.	F	-0.45	0.40
Thr	18	.	A	B	-1.68	.	.	F	-0.45	0.21
Leu	19	.	A	B	-1.92	.	.	.	-0.60	0.24
Leu	20	A	A	-2.30	.	.	.	-0.60	0.15

5

10

15

20

-7-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	21	A	A	-2.03	.	.	.	-0.60	0.11
Leu	22	A	A	-2.63	.	.	.	-0.60	0.13
Ala	23	A	A	-3.13	.	.	.	-0.60	0.13
Ala	24	A	A	-2.91	.	.	.	-0.60	0.13
Ala	25	A	A	-2.96	.	.	.	-0.60	0.16
Leu	26	A	A	.	B	.	.	.	-2.44	.	.	.	-0.60	0.12
Leu	27	A	A	.	B	.	.	.	-1.63	.	.	.	-0.60	0.16
Ala	28	A	A	.	B	.	.	.	-1.63	.	.	.	-0.30	0.26
Val	29	A	A	.	B	.	.	.	-1.86	.	.	.	-0.30	0.32
Ser	30	A	A	-1.61	*	*	.	-0.30	0.32
Asp	31	A	A	-0.69	*	*	F	-0.15	0.31
Ala	32	A	A	-0.09	.	*	F	0.75	0.83
Leu	33	.	A	C	0.20	*	.	F	1.55	0.96
Gly	34	.	A	C	1.06	*	*	F	1.85	0.77
Arg	35	T	C	1.36	*	*	F	2.70	1.32
Pro	36	T	C	1.36	*	*	F	3.00	2.76
Ser	37	T	C	1.94	*	.	F	2.70	4.66
Glu	38	A	T	.	2.76	*	.	F	2.20	4.12
Glu	39	A	A	2.29	*	*	F	1.50	4.61
Asp	40	A	A	1.32	*	*	F	1.20	2.84
Glu	41	A	A	0.68	.	.	F	0.90	1.22

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Glu	42	A	A	0.77	.	.	F	0.75	0.52
Leu	43	A	A	0.77	.	.	.	0.60	0.48
Val	44	A	A	-0.04	.	.	.	0.60	0.48
Val	45	A	A	-0.04	*	.	.	-0.30	0.23
Pro	46	A	A	0.07	*	.	.	-0.30	0.48
Glu	47	A	-0.52	*	.	F	1.10	1.27
Leu	48	A	0.08	*	.	F	1.41	1.73
Glu	49	A	0.59	*	.	F	1.72	1.73
Arg	50	A	1.41	*	.	F	1.88	0.99
Ala	51	A	T	.	1.28	*	.	F	2.24	1.64
Pro	52	T	T	.	0.97	*	.	F	3.10	0.93
Gly	53	T	T	.	1.47	*	*	F	2.49	0.69
His	54	T	C	1.58	*	*	F	1.38	0.98
Gly	55	C	0.66	*	*	F	1.62	1.25
Thr	56	C	1.36	.	*	F	0.71	1.04
Thr	57	.	A	B	0.76	.	*	F	0.60	1.49
Arg	58	.	A	B	1.07	.	*	F	0.60	1.25
Leu	59	.	A	B	0.51	.	*	.	0.45	1.17
Arg	60	.	A	B	0.16	.	*	.	0.30	0.82
Leu	61	.	A	B	0.47	.	*	.	-0.30	0.36
His	62	.	A	B	0.78	.	*	.	-0.30	0.74

5

10

15

20

-9-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	63	A	A	0.67	.	*	.	0.30	0.65
Phe	64	A	A	0.67	.	*	.	-0.15	1.37
Asp	65	A	A	0.56	.	*	F	-0.15	0.83
Gln	66	A	A	0.56	.	*	F	0.60	1.37
Gln	67	A	A	0.59	.	*	F	0.60	1.30
Leu	68	A	A	0.37	*	*	F	0.90	1.35
Asp	69	A	A	1.18	*	*	.	0.30	0.64
Leu	70	.	A	B	0.97	.	*	.	0.94	0.73
Glu	71	.	A	B	0.97	.	*	.	1.43	1.37
Leu	72	.	A	B	0.67	.	*	.	1.77	1.37
Arg	73	T	C	1.18	*	*	F	2.86	2.22
Pro	74	T	T	.	0.48	*	*	F	3.40	1.72
Asp	75	T	T	.	0.48	.	*	F	2.76	1.80
Ser	76	T	C	-0.11	.	*	F	2.07	0.76
Ser	77	.	.	B	0.49	*	*	F	0.73	0.50
Phe	78	.	.	B	0.03	*	*	.	0.24	0.46
Leu	79	.	.	B	-0.46	.	.	.	-0.40	0.34
Ala	80	.	.	B	.	.	T	.	-0.77	.	.	.	-0.20	0.22
Pro	81	.	.	B	.	.	T	.	-1.28	.	.	.	-0.20	0.37
Gly	82	T	T	.	-0.98	.	.	.	0.20	0.37
Phe	83	.	.	B	.	.	T	.	-0.28	.	.	.	-0.20	0.63

5

10

15

20

-10-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Thr	84	.	.	B	B	.	.	.	-0.32	.	.	.	-0.60	0.65
Leu	85	.	.	B	B	.	.	.	-0.08	*	*	.	-0.60	0.49
Gln	86	.	.	B	B	.	.	.	0.24	*	.	.	-0.29	0.56
Asn	87	.	.	B	.	.	T	.	0.63	*	.	F	0.87	0.76
Val	88	.	.	B	.	.	T	.	1.03	*	*	F	1.93	1.84
Gly	89	T	C	1.00	*	.	F	2.74	1.42
Arg	90	T	T	.	1.51	*	.	F	3.10	0.87
Lys	91	T	C	1.51	*	.	F	2.74	1.58
Ser	92	T	C	1.20	*	.	F	2.43	2.76
Gly	93	T	C	1.84	.	.	F	2.38	2.04
Ser	94	T	C	1.38	.	.	F	2.33	1.57
Glu	95	C	1.06	.	.	F	1.63	0.97
Thr	96	C	1.01	.	.	F	2.04	1.51
Pro	97	C	1.00	.	.	F	2.60	1.96
Leu	98	C	1.34	.	.	F	2.04	1.63
Pro	99	A	0.83	.	.	F	1.58	1.89
Glu	100	A	A	0.24	.	.	F	1.12	1.01
Thr	101	A	A	0.52	.	.	F	0.86	1.23
Asp	102	A	A	0.07	.	.	F	0.60	1.08
Leu	103	A	A	0.18	.	.	.	0.30	0.34
Ala	104	A	A	0.14	.	.	.	-0.60	0.20

5

10

15

20

-11-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
His	105	.	A	B	-0.16	*	.	.	-0.60	0.19
Cys	106	.	A	B	-0.19	*	.	.	-0.60	0.31
Phe	107	.	A	B	-0.50	*	.	.	-0.60	0.30
Tyr	108	.	.	B	.	.	T	.	-0.54	.	.	.	-0.20	0.32
Ser	109	T	T	.	0.04	.	*	F	0.35	0.44
Gly	110	T	T	.	-0.27	.	*	F	0.35	0.82
Thr	111	T	T	.	0.40	.	*	F	0.59	0.52
Val	112	.	.	B	B	.	.	.	0.89	.	*	F	0.93	0.65
Asn	113	.	.	.	B	T	.	.	0.83	.	*	F	1.72	1.01
Gly	114	.	.	.	B	.	.	C	0.83	.	*	F	1.61	0.94
Asp	115	T	C	0.59	.	*	F	2.40	1.69
Pro	116	T	C	0.31	.	*	F	2.16	1.06
Ser	117	T	C	0.58	.	*	F	1.92	1.08
Ser	118	A	T	.	-0.23	.	.	F	1.33	0.66
Ala	119	A	A	-0.19	.	.	.	-0.06	0.35
Ala	120	A	A	-1.00	.	.	.	-0.30	0.35
Ala	121	A	A	-1.46	.	.	.	-0.60	0.22
Leu	122	A	A	-1.16	.	.	.	-0.60	0.11
Ser	123	A	A	-1.20	.	.	.	-0.30	0.20
Leu	124	A	A	-1.47	*	*	.	-0.30	0.19
Cys	125	.	A	B	-0.77	*	*	.	-0.30	0.17

5

10

15

20

-12-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Glu	126	.	A	B	-0.52	*	*	.	0.30	0.25
Gly	127	A	-0.30	*	*	F	0.65	0.30
Val	128	A	-0.70	*	*	F	0.65	0.57
Arg	129	.	.	B	-0.13	*	*	F	0.65	0.29
Gly	130	.	.	B	B	.	.	.	-0.28	*	*	.	-0.60	0.45
Ala	131	.	.	B	B	.	.	.	-1.09	*	*	.	-0.60	0.50
Phe	132	.	.	B	B	.	.	.	-1.09	*	*	.	-0.60	0.21
Tyr	133	.	.	B	B	.	.	.	-0.23	*	*	.	-0.60	0.21
Leu	134	.	A	B	B	.	.	.	-0.93	*	*	.	-0.60	0.36
Leu	135	.	A	B	B	.	.	.	-0.83	.	*	.	-0.60	0.42
Gly	136	A	A	.	B	.	.	.	-0.94	.	.	.	-0.60	0.42
Glu	137	A	A	-1.13	.	.	.	-0.60	0.44
Ala	138	A	A	.	B	.	.	.	-0.89	.	.	.	-0.60	0.38
Tyr	139	.	.	B	B	.	.	.	-0.29	.	.	.	-0.60	0.66
Phe	140	.	.	B	B	.	.	.	-0.29	.	.	.	-0.60	0.59
Ile	141	.	.	B	B	.	.	.	-0.16	.	.	.	-0.60	0.48
Gln	142	.	.	B	B	.	.	.	-0.74	.	.	.	-0.60	0.48
Pro	143	.	.	B	B	.	.	.	-0.74	.	.	.	-0.60	0.55
Leu	144	.	A	C	-0.80	*	.	.	-0.40	0.80
Pro	145	.	A	C	-0.10	*	.	.	-0.10	0.62
Ala	146	A	A	0.90	*	*	.	0.30	0.69

5

10

15

20

-13-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	147	A	A	0.09	*	.	.	0.75	1.64
Ser	148	A	A	-0.29	*	.	F	0.75	0.88
Glu	149	A	A	0.21	*	.	F	0.45	0.88
Arg	150	A	A	-0.17	*	.	F	0.60	1.25
Leu	151	A	A	-0.17	*	.	.	0.30	0.94
Ala	152	A	A	0.21	*	*	.	0.30	0.55
Thr	153	A	A	0.17	*	*	.	0.04	0.43
Ala	154	A	A	0.17	.	.	.	0.08	0.52
Ala	155	T	C	0.10	.	*	F	2.07	0.89
Pro	156	T	C	0.70	.	.	F	2.86	1.24
Gly	157	T	T	.	1.08	.	.	F	3.40	1.90
Glu	158	T	C	0.80	.	.	F	2.86	2.90
Lys	159	C	1.18	.	.	F	2.32	1.90
Pro	160	C	0.96	.	*	F	1.98	2.97
Pro	161	C	1.17	.	*	F	1.64	1.41
Ala	162	A	A	0.81	.	*	F	0.60	1.22
Pro	163	A	A	0.78	.	*	.	-0.60	0.68
Leu	164	A	A	-0.08	.	*	.	-0.60	0.60
Gln	165	A	A	-0.68	*	*	.	-0.60	0.49
Phe	166	.	A	B	-0.36	*	*	.	-0.60	0.26
His	167	.	A	B	0.34	*	*	.	-0.26	0.62

5

10

15

20

-14-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	168	.	A	B	0.56	*	*	.	0.38	0.70
Leu	169	.	A	B	1.48	*	*	.	0.87	1.31
Arg	170	T	T	.	1.48	*	.	F	3.06	1.88
Arg	171	T	T	.	1.83	*	.	F	3.40	3.96
Asn	172	T	T	.	1.87	*	.	F	3.06	4.75
Arg	173	T	T	.	1.82	*	.	F	2.72	4.05
Gln	174	T	.	.	2.29	.	.	F	2.43	1.53
Gly	175	T	.	.	1.83	.	.	F	2.19	0.94
Asp	176	T	T	.	1.41	.	*	F	2.30	0.48
Val	177	.	.	B	.	.	T	.	0.74	*	.	F	1.85	0.40
Gly	178	T	T	.	0.29	*	.	F	2.50	0.22
Gly	179	.	.	B	.	.	T	.	-0.57	.	*	F	1.85	0.13
Thr	180	.	.	B	B	.	.	.	-1.08	.	*	F	0.30	0.13
Cys	181	.	.	B	B	.	.	.	-1.08	.	.	.	-0.10	0.10
Gly	182	.	.	B	B	.	.	.	-0.22	.	.	.	-0.05	0.16
Val	183	.	.	B	B	.	.	.	0.12	.	.	.	0.30	0.19
Val	184	.	.	B	B	.	.	.	0.26	*	*	.	0.90	0.60
Asp	185	.	.	B	.	.	T	.	0.68	*	*	F	1.75	0.94
Asp	186	.	.	B	.	.	T	.	1.13	*	*	F	2.20	2.49
Glu	187	.	.	B	.	.	T	.	1.17	*	*	F	2.50	5.18
Pro	188	T	C	1.68	*	*	F	3.00	4.48

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Arg	189	T	C	2.58	*	*	F	2.70	2.66
Pro	190	T	C	1.99	*	*	F	2.40	3.07
Thr	191	T	C	1.99	*	*	F	2.10	2.00
Gly	192	T	C	1.68	*	*	F	1.80	1.77
Lys	193	A	A	1.89	*	*	F	0.90	1.65
Ala	194	A	A	1.78	*	*	F	0.90	1.98
Glu	195	A	A	1.99	.	*	F	0.90	3.35
Thr	196	A	A	2.30	.	*	F	0.90	2.90
Glu	197	A	A	2.64	.	*	F	0.90	4.79
Asp	198	A	A	2.26	.	*	F	0.90	4.79
Glu	199	A	A	2.53	.	.	F	0.90	3.29
Asp	200	A	T	.	2.53	.	.	F	1.30	2.74
Glu	201	A	T	.	2.50	.	.	F	1.30	2.84
Gly	202	A	T	.	2.50	.	.	F	1.30	1.62
Thr	203	A	T	.	2.50	.	.	F	1.30	1.68
Glu	204	A	A	2.50	*	.	F	0.90	1.62
Gly	205	A	A	2.16	*	.	F	1.20	2.84
Glu	206	A	A	1.94	*	.	F	1.50	1.95
Asp	207	.	A	.	.	T	.	.	2.29	*	.	F	2.20	1.74
Glu	208	.	A	C	2.31	*	.	F	2.30	3.04
Gly	209	T	C	2.01	*	.	F	3.00	1.85

5

10

15

20

-16-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Pro	210	T	T	.	2.14	.	.	F	2.60	1.48
Gln	211	T	T	.	2.14	.	.	F	2.30	1.32
Trp	212	T	C	2.14	.	.	F	1.44	2.32
Ser	213	C	1.93	.	.	F	1.78	2.50
Pro	214	T	T	.	1.69	.	.	F	2.12	2.23
Gln	215	T	C	1.09	.	.	F	1.56	2.15
Asp	216	T	C	1.09	.	*	F	2.40	1.32
Pro	217	T	C	1.03	.	.	F	2.16	1.48
Ala	218	T	.	.	0.48	.	.	F	1.77	0.85
Leu	219	.	.	B	0.34	*	.	F	0.53	0.38
Gln	220	.	.	B	0.34	*	.	F	-0.01	0.24
Gly	221	.	.	B	.	.	T	.	0.13	*	*	F	-0.05	0.41
Val	222	.	.	B	.	.	T	.	0.03	*	.	F	-0.05	0.77
Gly	223	.	.	B	.	.	T	.	0.28	*	.	F	0.25	0.64
Gln	224	.	.	B	.	.	T	.	0.78	*	*	F	0.25	0.64
Pro	225	.	.	B	0.43	.	.	F	0.20	1.25
Thr	226	T	.	.	0.48	.	*	F	0.60	1.25
Gly	227	T	C	0.44	*	*	F	0.45	0.97
Thr	228	.	.	B	.	.	T	.	0.90	*	*	F	0.25	0.44
Gly	229	.	.	B	.	.	T	.	0.94	.	*	F	0.85	0.60
Ser	230	.	.	B	.	.	T	.	1.20	.	*	F	1.30	1.20

5

10

15

20

-17-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ile	231	.	A	B	1.62	.	*	F	0.90	1.67
Arg	232	.	A	B	1.27	.	*	F	0.90	3.30
Lys	233	.	A	B	0.72	.	.	F	0.90	2.13
Lys	234	.	A	B	B	.	.	.	0.77	.	.	F	0.90	2.26
Arg	235	.	A	B	B	.	.	.	0.77	.	.	F	0.90	1.55
Phe	236	.	.	B	B	.	.	.	1.62	.	*	.	0.75	1.04
Val	237	.	.	B	B	.	.	.	1.62	.	*	.	0.30	0.71
Ser	238	.	.	B	.	.	T	.	1.33	*	*	.	0.70	0.71
Ser	239	T	C	0.43	*	.	.	0.15	1.28
His	240	T	C	0.32	*	*	.	0.45	1.28
Arg	241	T	C	0.71	*	.	.	1.05	1.65
Tyr	242	A	.	.	B	.	.	.	0.97	*	.	.	0.45	1.78
Val	243	A	.	.	B	.	.	.	0.46	*	.	.	0.45	1.29
Glu	244	.	.	B	B	.	.	.	-0.10	*	.	.	-0.30	0.54
Thr	245	.	.	B	B	.	.	.	-0.66	*	.	.	-0.60	0.26
Met	246	A	.	B	B	.	.	.	-0.77	*	.	.	-0.60	0.35
Leu	247	A	.	.	B	.	.	.	-0.52	.	.	.	0.30	0.34
Val	248	A	.	.	B	.	.	.	0.03	.	.	.	-0.30	0.41
Ala	249	A	.	.	B	.	.	.	-0.57	.	.	.	-0.30	0.55
Asp	250	A	T	.	-0.84	.	.	F	0.25	0.66
Gln	251	A	T	.	-0.24	.	.	F	0.25	0.90

5

10

15

20

-18-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	252	A	T	.	-0.13	.	.	F	1.30	1.54
Met	253	A	T	.	0.69	.	*	.	0.70	0.80
Ala	254	A	0.93	.	*	.	-0.10	0.63
Glu	255	A	0.63	.	*	.	-0.10	0.46
Phe	256	A	0.29	.	*	.	-0.10	0.63
His	257	A	T	.	-0.22	*	.	.	0.10	0.61
Gly	258	A	T	.	0.42	*	.	F	0.25	0.29
Ser	259	A	T	.	0.98	*	*	F	0.25	0.68
Gly	260	A	T	.	0.73	*	*	F	0.85	0.68
Leu	261	A	A	0.62	.	.	F	0.00	1.07
Lys	262	A	A	-0.16	.	.	.	-0.60	0.66
His	263	.	A	B	-0.12	*	.	.	-0.60	0.55
Tyr	264	.	A	B	-0.63	*	.	.	-0.60	0.96
Leu	265	.	A	B	-0.99	*	.	.	-0.60	0.40
Leu	266	.	A	B	-0.48	*	.	.	-0.60	0.25
Thr	267	.	A	B	-1.38	*	.	.	-0.60	0.22
Leu	268	.	A	B	-1.93	*	.	.	-0.60	0.19
Phe	269	A	A	-2.28	*	*	.	-0.60	0.24
Ser	270	A	A	-1.36	*	*	.	-0.60	0.17
Val	271	A	A	-1.36	*	*	.	-0.60	0.39
Ala	272	A	A	-1.29	*	*	.	-0.60	0.38

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni Surfa...
Ala	273	A	A	-0.43	*	*	.	-0.60	0.44
Arg	274	A	A	0.23	*	*	.	-0.15	1.18
Leu	275	A	A	0.32	*	*	.	0.45	1.59
Tyr	276	T	.	.	0.88	*	*	.	1.39	2.44
Lys	277	.	.	B	0.58	*	*	F	1.48	1.67
His	278	.	.	B	.	.	T	.	1.28	.	*	F	1.12	1.42
Pro	279	.	.	B	.	.	T	.	1.17	.	*	F	2.36	1.77
Ser	280	T	T	.	1.68	.	*	F	3.40	1.43
Ile	281	.	.	B	.	.	T	.	1.07	.	*	F	2.36	1.41
Arg	282	.	.	B	B	.	.	.	0.72	.	*	F	1.47	0.67
Asn	283	.	.	B	B	.	.	.	-0.06	*	*	F	1.13	0.67
Ser	284	.	.	B	B	.	.	.	-0.70	*	*	F	0.19	0.79
Val	285	.	.	B	B	.	.	.	-1.26	*	*	.	-0.30	0.30
Ser	286	.	.	B	B	.	.	.	-1.22	.	*	.	-0.60	0.14
Leu	287	.	.	B	B	.	.	.	-1.29	.	*	.	-0.60	0.08
Val	288	.	.	B	B	.	.	.	-2.18	*	.	.	-0.60	0.21
Val	289	.	.	B	B	.	.	.	-2.69	.	*	.	-0.60	0.11
Val	290	.	.	B	B	.	.	.	-2.69	.	.	.	-0.60	0.11
Lys	291	.	.	B	B	.	.	.	-3.28	.	.	.	-0.60	0.11
Ile	292	.	.	B	B	.	.	.	-2.50	.	.	.	-0.60	0.10
Leu	293	.	.	B	B	.	.	.	-1.64	.	*	.	-0.60	0.19

5

10

15

20

-20-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni... Surfa...
Val	294	.	.	B	B	.	.	.	-0.79	.	.	.	-0.30	0.16
Ile	295	.	.	B	B	.	.	.	0.07	.	*	.	0.00	0.39
His	296	A	.	.	B	.	.	.	0.07	.	*	.	0.90	0.81
Asp	297	A	.	.	B	.	.	.	0.61	.	.	F	1.80	2.19
Glu	298	A	1.21	*	.	F	2.30	3.09
Gln	299	T	.	.	2.07	*	.	F	3.00	3.51
Lys	300	C	2.10	.	.	F	2.50	3.64
Gly	301	T	C	1.82	.	.	F	2.40	1.56
Pro	302	T	C	1.52	.	.	F	2.10	1.30
Glu	303	.	.	B	.	.	T	.	1.52	*	.	F	1.45	0.87
Val	304	A	T	.	0.93	*	.	F	1.00	1.42
Thr	305	A	T	.	0.30	.	*	F	0.85	0.93
Ser	306	A	T	.	-0.17	.	*	F	0.85	0.54
Asn	307	A	T	.	-0.27	.	*	F	-0.05	0.60
Ala	308	A	T	.	-1.08	*	*	.	-0.20	0.60
Ala	309	A	-0.11	*	*	.	-0.40	0.37
Leu	310	A	0.20	*	*	.	-0.10	0.45
Thr	311	.	.	B	-0.20	*	*	.	-0.10	0.72
Leu	312	.	.	B	-0.87	*	*	.	-0.40	0.61
Arg	313	.	.	B	-0.28	*	*	.	-0.40	0.40
Asn	314	T	.	.	0.02	*	*	.	0.30	0.44

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Phe	315	T	T	.	0.83	*	*	.	0.20	0.57
Cys	316	T	T	.	1.19	*	*	.	0.20	0.50
Asn	317	T	T	.	2.00	*	*	.	0.20	0.62
Trp	318	T	T	.	1.86	*	.	.	0.35	1.25
Gln	319	T	.	.	1.86	.	.	.	0.45	3.16
Lys	320	T	.	.	2.34	*	.	F	0.60	3.16
Gln	321	T	.	.	2.80	.	.	F	0.94	4.65
His	322	C	2.50	*	.	F	1.68	4.15
Asn	323	C	2.79	*	.	F	2.02	2.78
Pro	324	T	C	2.90	.	.	F	2.56	2.68
Pro	325	T	T	.	2.86	*	.	F	3.40	3.86
Ser	326	T	C	2.27	.	.	F	2.86	4.01
Asp	327	T	C	2.30	.	.	F	2.52	2.62
Arg	328	A	A	2.27	.	.	F	1.58	2.94
Asp	329	A	A	2.23	*	.	F	1.24	2.98
Ala	330	A	A	2.44	*	.	.	0.90	2.80
Glu	331	A	A	2.43	*	.	.	0.75	2.38
His	332	A	T	.	1.84	*	.	.	1.15	2.06
Tyr	333	A	T	.	0.84	*	.	.	0.85	2.06
Asp	334	A	T	.	0.03	.	.	.	0.70	0.83
Thr	335	A	T	.	-0.08	.	.	.	-0.20	0.51

5

10

15

20

-22-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	336	A	A	-0.39	*	.	.	-0.60	0.28
Ile	337	A	A	-0.24	*	.	.	-0.60	0.24
Leu	338	.	A	B	0.00	.	.	.	-0.60	0.33
Phe	339	.	A	B	0.00	.	*	.	-0.60	0.56
Thr	340	.	A	B	-0.50	.	.	F	0.00	1.34
Arg	341	.	A	B	-0.58	.	*	F	0.25	1.34
Gln	342	.	A	.	.	T	.	.	-0.03	.	*	F	1.35	0.83
Asp	343	.	A	.	.	T	.	.	0.48	.	*	F	1.60	0.57
Leu	344	.	A	.	.	T	.	.	1.18	*	.	F	2.15	0.39
Cys	345	T	T	.	1.18	.	*	F	2.50	0.39
Gly	346	T	T	.	0.40	.	*	F	2.25	0.34
Ser	347	T	T	.	0.40	.	.	F	1.10	0.22
Gln	348	.	.	B	.	.	T	.	0.09	.	.	F	1.35	0.68
Thr	349	.	.	B	0.09	.	.	F	0.90	0.99
Cys	350	.	.	B	0.41	.	.	F	0.05	0.61
Asp	351	.	.	B	.	.	T	.	0.16	*	.	F	0.25	0.35
Thr	352	.	.	B	.	.	T	.	-0.13	.	.	F	0.25	0.24
Leu	353	.	.	B	.	.	T	.	-0.13	.	.	.	0.10	0.45
Gly	354	.	.	B	.	.	T	.	-0.68	.	.	.	0.70	0.45
Met	355	.	.	B	-0.36	.	.	.	-0.10	0.23
Ala	356	.	.	B	-0.67	.	.	.	-0.10	0.28

5

10

15

20

-23-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asp	357	.	.	B	.	.	T	.	-1.21	.	.	.	0.10	0.41
Val	358	.	.	B	.	.	T	.	-1.07	.	.	.	0.10	0.30
Gly	359	.	.	B	.	.	T	.	-0.72	.	.	.	0.10	0.16
Thr	360	.	.	B	.	.	T	.	-0.33	.	.	.	0.70	0.16
Val	361	.	.	B	-0.04	.	*	.	0.24	0.34
Cys	362	.	.	B	0.07	*	.	.	1.18	0.46
Asp	363	.	.	B	.	.	T	.	0.62	*	.	F	1.87	0.62
Pro	364	T	T	.	0.30	*	.	F	3.06	1.12
Ser	365	T	T	.	0.31	*	.	F	3.40	1.12
Arg	366	T	T	.	0.31	*	.	F	2.91	0.90
Ser	367	.	.	.	B	T	.	.	0.09	*	.	F	1.87	0.43
Cys	368	.	.	B	B	.	.	.	0.09	*	.	.	0.38	0.22
Ser	369	.	.	B	B	.	.	.	0.30	*	.	.	0.64	0.20
Val	370	.	.	B	B	.	.	.	0.60	*	.	.	0.30	0.25
Ile	371	.	.	B	B	.	.	.	0.14	*	.	.	0.60	0.77
Glu	372	.	.	B	B	.	.	.	-0.37	.	.	.	0.60	0.57
Asp	373	A	T	.	0.30	.	.	F	1.15	0.63
Asp	374	A	T	.	0.01	*	.	.	1.30	1.56
Gly	375	A	T	.	0.28	.	.	.	1.00	0.91
Leu	376	A	T	.	0.47	*	.	.	0.70	0.55
Gln	377	A	A	0.16	.	.	.	-0.30	0.29

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	378	A	A	-0.16	*	.	.	-0.60	0.42
Ala	379	A	A	-0.74	*	.	.	-0.60	0.73
Phe	380	A	A	-0.43	*	.	.	-0.60	0.43
Thr	381	A	A	0.38	*	*	.	-0.60	0.57
Thr	382	A	A	-0.43	*	.	.	-0.30	0.98
Ala	383	A	A	-0.19	*	.	.	-0.60	0.94
His	384	A	A	0.37	*	.	.	-0.30	0.64
Glu	385	A	A	0.21	*	.	.	-0.30	0.61
Leu	386	A	A	-0.18	*	.	.	-0.30	0.45
Gly	387	A	.	.	B	.	.	.	0.13	*	.	.	-0.60	0.28
His	388	A	.	.	B	.	.	.	0.12	*	.	.	-0.60	0.26
Val	389	A	.	.	B	.	.	.	-0.06	*	.	.	-0.60	0.32
Phe	390	A	.	.	B	.	.	.	-0.09	*	.	.	-0.60	0.49
Asn	391	.	.	B	B	.	.	.	0.72	*	.	.	-0.60	0.49
Met	392	.	.	B	.	.	T	.	1.07	*	.	.	0.25	1.11
Pro	393	A	T	.	0.51	*	.	.	0.85	2.14
His	394	T	T	.	1.41	*	.	F	1.70	1.34
Asp	395	A	T	.	2.11	*	.	F	1.30	2.72
Asp	396	A	A	1.44	*	.	F	0.90	3.04
Ala	397	A	A	1.46	*	.	F	0.90	1.20
Lys	398	A	A	1.37	*	*	F	0.75	0.73

5

10

15

20

-25-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gln	399	A	A	0.59	.	*	.	0.60	0.58
Cys	400	.	A	B	0.59	.	*	.	-0.30	0.48
Ala	401	.	A	B	0.24	.	*	.	0.30	0.38
Ser	402	.	.	B	.	.	T	.	-0.02	.	*	.	0.10	0.22
Leu	403	.	.	B	.	.	T	.	-0.07	.	.	.	0.04	0.30
Asn	404	T	T	.	-0.07	.	.	.	0.68	0.48
Gly	405	T	T	.	0.60	.	.	F	1.37	0.62
Val	406	C	0.89	.	.	F	1.96	1.26
Asn	407	T	C	1.16	.	.	F	2.40	1.05
Gln	408	A	T	.	1.37	*	.	F	1.96	1.44
Asp	409	A	T	.	0.77	*	.	F	1.72	1.92
Ser	410	A	T	.	0.52	.	.	.	1.33	1.18
His	411	A	A	1.08	.	*	.	-0.06	0.69
Met	412	A	A	0.48	.	.	.	0.30	0.55
Met	413	A	A	-0.33	.	.	.	-0.60	0.41
Ala	414	A	A	-0.63	.	.	.	-0.60	0.25
Ser	415	A	A	-0.33	*	.	.	-0.60	0.34
Met	416	A	A	-1.11	*	*	.	-0.60	0.55
Leu	417	A	T	.	-0.51	*	.	.	-0.20	0.45
Ser	418	A	T	.	0.06	*	.	.	0.38	0.56
Asn	419	A	T	.	0.34	.	.	.	0.66	0.76

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	420	T	C	0.64	.	.	.	1.29	1.24
Asp	421	T	T	.	1.03	.	.	.	2.37	1.60
His	422	T	T	.	1.56	.	.	F	2.80	1.54
Ser	423	T	C	1.56	.	.	F	1.72	1.97
Gln	424	T	C	1.34	.	.	F	1.44	1.58
Pro	425	T	.	.	1.49	.	.	F	0.86	1.79
Trp	426	T	.	.	1.19	.	.	F	0.43	0.72
Ser	427	T	C	0.63	.	.	F	0.15	0.55
Pro	428	T	T	.	0.69	.	.	F	0.35	0.36
Cys	429	T	T	.	0.09	.	.	.	0.20	0.54
Ser	430	.	.	B	.	.	T	.	-0.59	.	.	.	-0.20	0.40
Ala	431	.	.	B	B	.	.	.	-0.61	.	.	.	-0.60	0.18
Tyr	432	.	.	B	B	.	.	.	-0.61	.	.	.	-0.60	0.49
Met	433	.	.	B	B	.	.	.	-1.10	.	.	.	-0.60	0.49
Ile	434	.	.	B	B	.	.	.	-1.24	*	.	.	-0.60	0.42
Thr	435	.	.	B	B	.	.	.	-0.94	*	.	.	-0.60	0.22
Ser	436	.	.	B	B	.	.	.	-0.36	*	.	.	-0.60	0.37
Phe	437	.	.	B	B	.	.	.	-0.46	*	.	.	-0.60	0.85
Leu	438	.	.	B	.	.	T	.	0.11	*	.	F	0.56	0.58
Asp	439	T	T	.	0.66	*	.	F	1.27	0.59
Asn	440	T	C	0.97	.	.	F	1.38	0.68

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni Surfa...
Gly	441	T	T	.	0.60	.	.	F	2.94	1.42
His	442	T	T	.	0.49	.	.	F	3.10	0.46
Gly	443	A	T	.	0.70	.	.	F	1.49	0.23
Glu	444	A	T	.	0.70	.	.	.	1.03	0.23
Cys	445	.	.	B	.	.	T	.	0.74	.	*	.	1.32	0.29
Leu	446	.	A	B	0.88	.	.	.	1.25	0.58
Met	447	.	A	B	0.91	*	.	.	1.28	0.52
Asp	448	.	A	.	.	T	.	.	1.26	*	.	F	2.02	1.67
Lys	449	.	A	C	1.04	*	.	F	2.16	3.26
Pro	450	T	T	.	0.82	*	*	F	3.40	5.10
Gln	451	T	T	.	1.63	*	*	F	3.06	2.14
Asn	452	.	.	B	.	.	T	.	1.42	*	*	F	2.02	1.85
Pro	453	.	.	B	.	.	T	.	1.21	*	*	F	0.63	0.99
Ile	454	.	.	B	0.82	*	*	F	0.09	0.88
Gln	455	.	.	B	1.03	*	*	F	-0.25	0.54
Leu	456	.	.	B	.	.	T	.	0.22	*	*	F	0.25	0.59
Pro	457	.	.	B	.	.	T	.	0.01	*	*	F	0.25	0.69
Gly	458	.	.	B	.	.	T	.	-0.12	.	*	F	0.25	0.62
Asp	459	.	.	B	.	.	T	.	0.46	.	*	F	0.25	0.74
Leu	460	T	C	0.16	.	*	F	1.05	0.69
Pro	461	.	.	B	.	.	T	.	0.72	.	*	F	0.85	0.93

5

10

15

20

-28-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	462	.	.	B	.	.	T	.	0.93	.	.	F	0.25	0.88
Thr	463	.	.	B	.	.	T	.	0.69	.	*	F	0.74	1.78
Ser	464	.	.	B	0.69	*	.	F	1.48	1.16
Tyr	465	T	.	.	1.61	*	.	F	2.22	1.88
Asp	466	T	T	.	1.82	.	.	.	2.61	2.56
Ala	467	T	T	.	1.50	*	.	F	3.40	3.31
Asn	468	T	T	.	1.81	.	*	F	2.76	1.13
Arg	469	.	.	B	.	.	T	.	1.41	.	*	F	2.32	1.17
Gln	470	.	.	B	B	.	.	.	1.34	*	*	.	0.53	1.01
Cys	471	.	.	B	B	.	.	.	0.64	*	*	.	0.04	0.90
Gln	472	.	.	B	B	.	.	.	0.89	.	.	.	-0.60	0.40
Phe	473	.	.	B	B	.	.	.	0.89	.	.	.	-0.26	0.23
Thr	474	.	.	B	B	.	.	.	0.78	.	.	.	0.08	0.74
Phe	475	.	.	.	B	T	.	.	0.48	.	*	.	1.72	0.71
Gly	476	T	T	.	1.19	.	*	F	2.76	1.10
Glu	477	T	T	.	1.16	.	*	F	3.40	1.52
Asp	478	T	T	.	1.19	*	.	F	3.06	2.39
Ser	479	T	T	.	1.29	*	.	F	2.72	1.30
Lys	480	T	.	.	1.99	*	.	F	2.43	1.16
His	481	T	.	.	1.74	*	.	F	2.34	1.16
Cys	482	T	C	1.16	*	.	F	2.10	0.87

5

10

15

20

-29-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Pro	483	A	T	.	0.86	.	.	F	2.15	0.44
Asp	484	T	T	.	0.84	*	.	F	2.50	0.43
Ala	485	A	T	.	0.13	*	.	F	2.00	1.17
Ala	486	A	-0.13	.	.	F	1.40	0.41
Ser	487	.	.	B	.	T	T	.	0.22	.	.	F	1.75	0.33
Thr	488	.	.	B	.	.	T	.	-0.38	*	.	F	0.50	0.46
Cys	489	.	.	B	.	.	T	.	-0.67	*	.	F	-0.05	0.38
Ser	490	.	.	B	.	.	T	.	-0.74	.	.	F	-0.05	0.30
Thr	491	.	.	B	B	.	.	.	-0.47	.	.	.	-0.60	0.11
Leu	492	.	.	B	B	.	.	.	-0.51	.	.	.	-0.60	0.30
Trp	493	.	.	B	B	.	.	.	-0.51	.	.	.	-0.60	0.22
Cys	494	.	.	B	B	.	.	.	-0.14	.	.	.	-0.60	0.22
Thr	495	.	.	B	B	T	.	.	-0.19	.	.	F	-0.05	0.36
Gly	496	.	.	.	B	T	.	.	-0.22	.	.	F	-0.05	0.34
Thr	497	T	T	.	-0.27	.	.	F	0.65	0.62
Ser	498	T	T	.	-0.79	.	.	F	0.65	0.32
Gly	499	T	T	.	-0.98	.	.	F	0.35	0.27
Gly	500	T	T	.	-1.33	.	.	F	0.35	0.14
Val	501	.	.	B	B	.	.	.	-0.99	.	.	.	-0.60	0.05
Leu	502	.	.	B	B	.	.	.	-0.99	.	.	.	-0.60	0.10
Val	503	.	.	B	B	.	.	.	-0.64	.	.	.	-0.60	0.14

5

10

15

20

-30-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Cys	504	.	.	B	.	.	T	.	-0.33	.	.	.	-0.20	0.38
Gln	505	.	.	B	.	.	T	.	-0.69	.	.	.	0.10	0.62
Thr	506	.	.	B	.	.	T	.	-0.04	.	.	F	0.25	0.72
Lys	507	.	.	B	.	.	T	.	0.48	.	.	F	0.40	2.09
His	508	C	0.74	.	.	.	-0.05	1.27
Phe	509	.	.	B	1.41	.	.	.	-0.40	0.89
Pro	510	T	.	.	1.07	.	.	.	0.30	0.74
Trp	511	T	T	.	1.07	.	.	.	0.20	0.54
Ala	512	T	T	.	0.72	.	.	.	0.51	0.90
Asp	513	T	T	.	0.09	.	.	F	1.27	0.78
Gly	514	T	T	.	0.44	.	.	F	1.58	0.40
Thr	515	T	T	.	0.66	.	.	F	2.49	0.39
Ser	516	T	T	.	0.60	.	*	F	3.10	0.40
Cys	517	T	T	.	1.23	.	*	F	2.49	0.40
Gly	518	T	T	.	0.94	.	*	F	2.48	0.56
Glu	519	T	.	.	0.62	.	*	F	1.67	0.44
Gly	520	T	.	.	0.04	.	*	F	1.36	0.44
Lys	521	T	.	.	0.34	.	*	F	0.45	0.31
Trp	522	T	.	.	0.67	.	*	.	0.90	0.29
Cys	523	.	.	B	.	.	T	.	1.06	.	*	.	-0.20	0.29
Ile	524	.	.	B	.	.	T	.	0.39	.	*	.	0.70	0.29

5

10

15

20

-31-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asn	525	T	T	.	-0.12	.	*	.	0.20	0.15
Gly	526	T	T	.	-0.17	*	*	F	0.65	0.20
Lys	527	T	.	.	0.17	*	*	F	0.45	0.47
Cys	528	T	T	.	0.52	.	*	.	1.40	0.58
Val	529	.	.	B	.	.	T	.	1.41	*	*	.	1.04	0.85
Asn	530	.	.	B	.	.	T	.	1.52	*	.	F	1.83	0.71
Lys	531	.	.	B	.	.	T	.	1.91	*	.	F	2.32	2.58
Thr	532	.	.	B	.	.	T	.	1.83	*	.	F	2.66	6.96
Asp	533	T	T	.	1.80	*	.	F	3.40	5.89
Arg	534	T	T	.	2.66	*	.	F	3.06	2.55
Lys	535	.	.	B	.	.	T	.	2.34	*	.	F	2.32	2.95
His	536	.	.	B	2.09	*	.	F	1.78	2.55
Phe	537	.	.	B	1.70	*	.	F	1.44	2.01
Asp	538	.	.	B	1.67	*	.	F	0.65	0.87
Thr	539	.	.	B	1.21	*	.	F	-0.25	0.87
Pro	540	C	0.87	*	*	F	-0.05	1.00
Phe	541	T	.	.	0.61	.	*	F	0.45	0.80
His	542	T	T	.	0.97	.	*	.	0.20	0.58
Gly	543	T	T	.	0.37	.	*	.	0.20	0.37
Ser	544	T	T	.	0.39	.	*	.	0.20	0.43
Trp	545	T	T	.	0.26	.	*	.	0.20	0.33

5

10

15

20

-32-

Res	Pos.	Garnl... Alpha	Chou... Alpha	Garnl... Beta	Chou... Beta	Garnl... Turn	Chou... Turn	Garnl... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	546	C	0.74	.	*	.	-0.20	0.33
Met	547	T	.	.	0.49	.	.	.	0.00	0.38
Trp	548	T	.	.	0.49	.	.	.	0.00	0.38
Gly	549	T	C	0.79	.	.	.	0.00	0.38
Pro	550	T	T	.	0.41	.	.	F	0.35	0.64
Trp	551	T	T	.	0.46	*	.	F	0.66	0.33
Gly	552	T	T	.	1.17	*	.	F	1.27	0.44
Asp	553	T	.	.	1.14	*	.	F	1.98	0.56
Cys	554	T	T	.	0.82	*	.	F	2.49	0.77
Ser	555	T	T	.	0.69	*	.	F	3.10	0.42
Arg	556	T	T	.	0.63	*	.	F	2.79	0.25
Thr	557	T	T	.	0.63	*	.	F	2.18	0.46
Cys	558	T	T	.	-0.22	*	.	F	1.87	0.34
Gly	559	T	T	.	0.44	*	.	F	1.56	0.13
Gly	560	T	T	.	0.50	*	.	F	0.65	0.15
Gly	561	T	T	.	0.08	*	*	F	0.35	0.45
Val	562	.	.	B	B	.	.	.	-0.21	*	*	.	-0.60	0.65
Gln	563	.	.	B	B	.	.	.	0.57	*	*	.	-0.60	0.65
Tyr	564	.	.	B	B	.	.	.	0.91	*	*	.	-0.15	1.29
Thr	565	.	.	B	B	.	.	.	0.59	*	*	.	0.79	3.01
Met	566	.	.	B	B	.	.	.	0.93	*	*	.	0.98	0.93

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emil... Surfa...
Arg	567	.	.	B	B	.	.	.	1.79	*	*	.	1.62	0.99
Glu	568	T	.	.	1.58	*	*	F	2.86	1.11
Cys	569	T	T	.	0.97	*	.	F	3.40	1.73
Asp	570	T	T	.	1.07	*	..	F	2.91	0.66
Asn	571	T	C	1.71	*	.	F	2.37	0.59
Pro	572	T	C	1.60	*	.	F	2.52	2.18
Val	573	C	1.26	*	.	F	2.32	2.10
Pro	574	T	T	.	1.58	*	.	F	2.42	1.29
Lys	575	T	T	.	1.62	*	.	F	2.61	0.83
Asn	576	T	T	.	1.38	*	.	F	3.40	2.23
Gly	577	T	T	.	0.92	*	.	F	3.06	2.26
Gly	578	T	T	.	1.78	*	.	F	2.27	0.61
Lys	579	.	.	B	.	.	T	.	1.64	.	.	F	1.53	0.65
Tyr	580	.	.	B	.	.	T	.	1.64	.	.	F	1.19	0.65
Cys	581	.	.	B	.	.	T	.	1.76	.	.	F	1.30	1.32
Glu	582	.	.	B	1.24	.	*	F	1.10	1.29
Gly	583	.	.	B	B	.	.	.	1.70	.	*	F	0.75	0.61
Lys	584	.	.	B	B	.	.	.	1.41	.	*	F	0.90	2.24
Arg	585	.	.	B	B	.	.	.	1.77	.	*	F	1.15	2.02
Tyr	586	.	.	B	B	.	.	.	2.13	.	*	.	1.25	4.01
Arg	587	.	.	B	B	.	.	.	1.47	*	*	.	1.50	2.68

5

10

15

20

-34-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Tyr	588	.	.	B	.	.	T	.	1.81	*	*	.	2.00	0.73
Arg	589	T	T	.	0.96	*	*	.	2.50	1.59
Ser	590	T	T	.	0.84	*	*	.	2.10	0.67
Cys	591	T	T	.	1.70	.	*	.	1.85	0.74
Asn	592	.	A	.	.	T	.	.	0.92	.	*	.	1.50	0.63
Leu	593	.	A	B	0.96	.	.	.	0.89	0.25
Glu	594	.	A	B	0.84	.	.	F	1.13	0.73
Asp	595	.	A	.	.	T	.	.	1.17	.	.	F	2.17	0.76
Cys	596	.	.	B	.	.	T	.	1.81	.	.	F	2.66	1.48
Pro	597	T	T	.	1.47	*	*	F	3.40	1.37
Asp	598	T	T	.	2.32	*	*	F	2.91	0.81
Asn	599	T	T	.	2.01	*	.	F	3.02	3.03
Asn	600	T	T	.	1.31	*	.	F	2.98	2.83
Gly	601	T	T	.	2.09	*	.	F	2.94	1.47
Lys	602	T	C	2.30	*	*	F	2.70	1.79
Thr	603	T	C	2.30	*	.	F	3.00	1.92
Phe	604	A	A	2.30	*	.	F	2.10	3.37
Arg	605	A	A	1.63	.	.	F	1.80	2.91
Glu	606	A	A	1.98	*	.	F	1.50	1.08
Glu	607	A	A	1.34	*	.	F	1.20	2.17
Gln	608	A	A	1.62	*	.	F	0.90	1.12

5

10

15

20

-35-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Cys	609	A	A	2.32	*	*	.	0.60	0.88
Glu	610	A	A	2.21	.	*	.	0.60	0.81
Ala	611	A	A	1.51	.	*	.	0.60	0.81
His	612	A	A	1.21	*	.	.	0.45	1.32
Asn	613	A	A	1.26	*	*	.	0.45	1.02
Glu	614	A	A	1.33	*	.	.	0.45	2.02
Phe	615	A	A	1.03	*	*	F	0.60	1.50
Ser	616	A	A	0.92	.	.	F	0.90	1.25
Lys	617	A	A	0.61	.	.	F	0.45	0.62
Ala	618	.	A	.	.	T	.	.	0.31	.	.	F	0.25	0.71
Ser	619	.	A	.	.	T	.	.	-0.03	.	.	F	0.85	0.71
Phe	620	T	.	.	0.46	.	.	F	1.26	0.35
Gly	621	T	T	.	0.17	.	.	F	1.07	0.54
Ser	622	T	C	-0.73	.	*	F	1.08	0.41
Gly	623	T	C	-0.14	.	.	F	0.99	0.35
Pro	624	T	C	-0.13	.	.	F	2.10	0.61
Ala	625	.	A	C	-0.32	.	.	F	0.89	0.48
Val	626	.	A	B	-0.19	*	.	.	0.03	0.34
Glu	627	.	A	B	0.16	*	.	.	-0.18	0.34
Trp	628	.	A	B	0.26	*	.	.	-0.09	0.67
Ile	629	.	.	B	-0.12	*	.	.	-0.25	1.42

5

10

15

20

-36-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Pro	630	.	.	B	.	.	T	.	0.12	*	.	.	0.10	0.83
Lys	631	T	T	.	0.12	*	.	.	0.20	0.78
Tyr	632	T	T	.	-0.18	*	.	.	0.20	0.82
Ala	633	T	T	.	-0.10	*	.	.	0.84	0.71
Gly	634	T	.	.	0.83	*	.	.	0.98	0.55
Val	635	.	.	B	1.04	.	*	.	0.92	0.70
Ser	636	.	.	B	.	.	T	.	1.11	.	*	F	2.66	1.17
Pro	637	T	T	.	0.69	.	*	F	3.40	2.31
Lys	638	T	T	.	1.32	.	*	F	3.06	1.67
Asp	639	T	T	.	0.86	.	*	F	2.72	2.49
Arg	640	A	A	0.82	.	*	F	1.58	1.33
Cys	641	A	A	0.46	*	*	F	1.09	0.46
Lys	642	.	A	B	0.67	*	*	.	0.30	0.15
Leu	643	.	A	B	0.03	.	*	.	0.30	0.13
Ile	644	.	A	B	0.08	.	*	.	-0.60	0.25
Cys	645	.	A	B	-0.38	.	*	.	0.30	0.25
Gln	646	.	A	B	-0.60	*	*	.	-0.30	0.30
Ala	647	.	A	B	-0.99	*	*	.	-0.30	0.30
Lys	648	.	A	B	-0.42	*	*	F	-0.15	0.55
Gly	649	T	T	.	-0.23	*	.	F	0.65	0.50
Ile	650	T	T	.	-0.27	.	*	.	0.20	0.43

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	651	.	.	B	.	.	T	.	-1.12	.	*	.	-0.20	0.18
Tyr	652	.	.	B	.	.	T	.	-1.34	.	.	.	-0.20	0.14
Phe	653	.	.	B	B	.	.	.	-1.39	.	.	.	-0.60	0.16
Phe	654	.	.	B	B	.	.	.	-1.26	.	*	.	-0.60	0.29
Val	655	.	.	B	B	.	.	.	-0.32	.	*	.	-0.60	0.28
Leu	656	.	.	B	B	.	.	.	-0.83	.	*	.	-0.60	0.65
Gln	657	.	.	B	.	.	T	.	-1.44	.	.	.	-0.20	0.56
Pro	658	.	.	B	.	.	T	.	-0.74	*	.	F	-0.05	0.56
Lys	659	T	T	.	-0.39	.	*	F	1.40	1.13
Val	660	.	.	B	.	.	T	.	0.16	.	.	F	0.85	0.65
Val	661	.	.	B	.	.	T	.	0.76	.	*	F	0.85	0.60
Asp	662	.	.	B	.	.	T	.	0.09	.	.	F	1.06	0.47
Gly	663	.	.	B	.	.	T	.	0.00	*	.	F	0.67	0.34
Thr	664	.	.	B	.	.	T	.	-0.26	*	.	F	1.48	0.61
Pro	665	.	.	B	0.60	.	.	F	1.49	0.56
Cys	666	T	.	.	1.16	.	.	F	2.10	0.95
Ser	667	T	C	0.84	.	.	F	1.89	0.88
Pro	668	T	T	.	0.89	.	.	F	1.88	0.82
Asp	669	T	T	.	0.34	.	.	F	1.82	2.06
Ser	670	T	T	.	-0.11	.	.	F	1.61	1.14
Thr	671	.	.	.	B	T	.	.	-0.30	.	*	F	0.85	0.39

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni Surfa...
Ser	672	.	.	B	B	.	.	.	0.00	.	*	F	-0.15	0.18
Val	673	.	.	B	B	.	.	.	-0.13	.	*	.	-0.60	0.23
Cys	674	.	.	B	B	.	.	.	-0.13	.	*	.	-0.60	0.16
Val	675	.	.	B	B	.	.	.	-0.50	.	*	.	-0.60	0.20
Gln	676	.	.	B	B	.	.	.	-1.04	.	*	F	-0.45	0.15
Gly	677	.	.	B	B	.	.	.	-0.70	.	*	F	-0.45	0.20
Gln	678	.	.	B	B	.	.	.	-0.43	.	*	F	-0.15	0.54
Cys	679	.	.	B	B	.	.	.	-0.11	.	.	.	0.30	0.32
Val	680	.	.	B	B	.	.	.	0.08	*	*	.	0.30	0.32
Lys	681	.	.	B	.	.	T	.	0.08	*	.	.	0.10	0.10
Ala	682	.	.	B	.	.	T	.	0.53	*	.	.	0.70	0.30
Gly	683	.	.	B	.	.	T	.	-0.36	*	.	.	1.00	0.80
Cys	684	.	.	B	.	.	T	.	-0.58	*	.	.	1.00	0.28
Asp	685	A	.	.	B	.	.	.	0.28	*	.	.	0.30	0.20
Arg	686	A	.	.	B	.	.	.	-0.07	*	.	.	0.60	0.33
Ile	687	A	.	.	B	.	.	.	0.57	*	.	.	0.60	0.82
Ile	688	A	.	.	B	.	.	.	0.96	*	.	F	0.75	0.99
Asp	689	A	T	.	1.67	*	*	F	1.30	1.01
Ser	690	A	T	.	0.97	*	*	F	1.30	2.88
Lys	691	A	T	.	0.86	*	.	F	1.61	3.55
Lys	692	T	T	.	1.79	*	*	F	2.32	3.55

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Lys	693	T	.	.	2.01	*	*	F	2.43	5.30
Phe	694	T	.	.	1.67	*	*	F	2.74	1.42
Asp	695	T	T	.	1.11	*	.	F	3.10	0.70
Lys	696	.	.	B	.	.	T	.	0.40	*	.	F	2.39	0.26
Cys	697	.	.	B	.	.	T	.	0.01	*	.	.	1.63	0.16
Gly	698	.	.	B	.	.	T	.	-0.38	*	.	.	1.32	0.10
Val	699	.	.	B	0.32	*	.	.	0.21	0.05
Cys	700	T	.	.	-0.02	.	.	.	0.00	0.14
Gly	701	T	T	.	-0.37	.	.	F	0.65	0.14
Gly	702	T	T	.	-0.01	.	.	F	0.65	0.26
Asn	703	T	T	.	-0.33	.	.	F	0.65	0.69
Gly	704	T	T	.	0.57	.	.	F	0.65	0.37
Ser	705	T	T	.	1.28	.	.	F	1.25	0.76
Thr	706	.	.	B	.	.	T	.	0.73	.	.	F	1.41	0.94
Cys	707	.	.	B	.	.	T	.	0.78	.	*	F	1.37	0.67
Lys	708	.	.	B	.	.	T	.	0.43	.	*	F	1.63	0.67
Lys	709	.	.	B	0.48	*	*	F	1.69	0.46
Ile	710	.	.	B	.	.	T	.	-0.08	*	*	F	2.60	1.14
Ser	711	.	.	B	.	.	T	.	-0.08	*	*	F	1.89	0.42
Gly	712	.	.	B	.	.	T	.	0.29	*	*	F	1.03	0.31
Ser	713	.	.	B	.	.	T	.	-0.34	*	*	F	0.77	0.58

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Val	714	.	.	B	B	.	.	.	-0.34	.	*	F	0.11	0.44
Thr	715	.	.	B	B	.	.	.	0.33	.	.	F	0.73	0.89
Ser	716	.	.	B	B	.	.	.	0.29	.	.	F	1.16	1.03
Ala	717	.	.	B	0.39	.	.	F	1.64	1.37
Lys	718	T	C	0.66	.	.	F	2.32	1.49
Pro	719	T	T	.	1.51	*	.	F	2.80	1.51
Gly	720	T	T	.	0.93	*	.	F	2.52	2.50
Tyr	721	.	.	B	.	.	T	.	0.34	*	.	.	1.54	0.88
His	722	.	.	B	B	.	.	.	0.62	*	.	.	-0.04	0.40
Asp	723	.	.	B	B	.	.	.	-0.31	*	.	.	-0.32	0.58
Ile	724	.	.	B	B	.	.	.	-0.31	*	.	.	-0.60	0.26
Ile	725	.	.	B	B	.	.	.	-0.28	*	.	.	-0.60	0.29
Thr	726	.	.	B	B	.	.	.	-0.38	*	.	.	-0.60	0.25
Ile	727	.	.	B	.	.	T	.	-0.93	*	.	.	-0.20	0.36
Pro	728	.	.	B	.	.	T	.	-1.24	*	.	F	-0.05	0.52
Thr	729	T	C	-0.36	*	.	F	0.15	0.52
Gly	730	T	C	-0.36	.	*	F	0.30	1.19
Ala	731	.	.	.	B	.	.	C	-0.04	.	*	F	-0.25	0.54
Thr	732	.	.	.	B	.	.	C	-0.01	.	*	F	0.65	0.65
Asn	733	.	.	B	B	.	.	.	0.24	.	*	F	-0.15	0.48
Ile	734	.	.	B	B	.	.	.	0.56	.	*	F	0.45	0.96

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Glu	735	.	.	B	B	.	.	.	1.01	.	*	F	0.60	1.15
Val	736	.	.	B	B	.	.	.	1.60	.	*	F	0.90	1.40
Lys	737	.	.	B	B	.	.	.	1.91	.	*	F	1.24	3.21
Gln	738	.	.	B	2.02	.	*	F	1.78	3.21
Arg	739	.	.	B	2.57	*	*	F	2.12	8.48
Asn	740	.	.	B	.	.	T	.	2.27	*	*	F	2.66	4.20
Gln	741	T	T	.	3.23	*	*	F	3.40	3.25
Arg	742	T	T	.	3.19	*	.	F	3.06	3.25
Gly	743	T	T	.	3.19	*	.	F	3.00	3.25
Ser	744	T	.	.	2.73	*	.	F	2.74	3.02
Arg	745	C	2.43	*	*	F	2.48	1.52
Asn	746	T	T	.	1.73	*	.	F	2.82	2.06
Asn	747	T	T	.	0.81	*	.	F	2.80	1.33
Gly	748	T	C	0.57	.	*	F	1.57	0.56
Ser	749	.	.	B	.	.	T	.	-0.02	.	*	F	0.79	0.35
Phe	750	.	A	B	-0.09	.	*	.	-0.04	0.15
Leu	751	.	A	B	-0.68	.	.	.	-0.32	0.31
Ala	752	.	A	B	-1.27	*	.	.	-0.60	0.23
Ile	753	.	A	B	-0.92	.	.	.	-0.60	0.27
Lys	754	A	A	-0.97	.	.	.	0.30	0.55
Ala	755	A	A	-0.58	.	.	.	0.30	0.54

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	756	A	A	-0.01	.	.	F	0.60	1.12
Asp	757	A	T	.	-0.31	.	.	F	0.85	0.87
Gly	758	.	.	B	.	.	T	.	-0.23	.	*	F	0.25	0.61
Thr	759	.	.	B	.	.	T	.	-0.28	.	.	F	-0.05	0.50
Tyr	760	.	.	B	.	.	T	.	-0.03	.	*	.	-0.20	0.48
Ile	761	.	.	B	0.56	.	*	.	-0.40	0.48
Leu	762	.	.	B	0.31	.	*	.	-0.40	0.55
Asn	763	.	.	B	.	.	T	.	0.34	.	*	F	-0.50	0.55
Gly	764	T	T	.	-0.16	.	*	F	0.50	1.14
Asp	765	T	T	.	-0.21	.	*	F	0.50	1.14
Tyr	766	T	C	0.37	.	*	F	0.45	0.95
Thr	767	.	.	B	B	.	.	.	0.37	.	*	.	-0.15	1.38
Leu	768	.	.	B	B	.	.	.	0.37	*	*	.	-0.60	0.68
Ser	769	.	.	B	B	.	.	.	0.71	*	.	F	-0.45	0.75
Thr	770	.	.	B	B	.	.	.	0.71	*	*	F	-0.15	0.90
Leu	771	A	.	.	B	.	.	.	0.07	*	.	F	0.60	1.83
Glu	772	A	.	.	B	.	.	.	-0.22	*	.	F	0.45	0.96
Gln	773	A	.	.	B	.	.	.	0.34	*	*	F	0.45	0.66
Asp	774	A	.	.	B	.	.	.	0.69	.	*	F	0.00	1.25
Ile	775	A	.	.	B	.	.	.	0.66	.	*	.	0.75	1.44
Met	776	A	.	.	B	.	.	.	0.61	.	*	.	0.30	0.82

5

10

15

20

-43-

Res	Pos.	Garnl... Alpha	Chou... Alpha	Garnl... Beta	Chou... Beta	Garnl... Turn	Chou... Turn	Garnl... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Tyr	777	.	.	B	B	.	.	.	-0.24	.	*	.	-0.30	0.37
Lys	778	.	.	B	B	.	.	.	-1.06	.	*	.	-0.60	0.39
Gly	779	.	.	B	B	.	.	.	-0.94	.	*	.	-0.60	0.32
Val	780	.	.	B	B	.	.	.	-0.30	.	*	.	-0.30	0.40
Val	781	.	.	B	B	.	.	.	0.00	.	*	.	-0.30	0.32
Leu	782	.	.	B	B	.	.	.	-0.10	.	*	.	-0.60	0.43
Arg	783	.	.	B	B	.	.	.	-0.44	.	*	.	-0.60	0.57
Tyr	784	.	.	B	.	.	T	.	-0.40	*	*	.	0.25	1.03
Ser	785	T	T	.	-0.13	.	*	F	0.80	1.68
Gly	786	T	C	0.13	*	*	F	1.05	0.86
Ser	787	T	C	0.13	.	*	F	0.45	0.56
Ser	788	.	A	C	0.02	.	*	F	0.05	0.34
Ala	789	A	A	0.38	*	.	F	0.45	0.60
Ala	790	A	A	-0.21	*	*	.	0.60	0.88
Leu	791	A	A	0.24	*	*	.	0.30	0.46
Glu	792	A	A	0.24	*	*	.	0.60	0.89
Arg	793	.	A	B	B	.	.	.	-0.16	*	*	F	0.90	1.18
Ile	794	A	A	.	B	.	.	.	0.13	*	*	F	0.60	1.24
Arg	795	A	A	.	B	.	.	.	0.51	*	*	F	0.75	0.96
Ser	796	.	A	.	.	T	.	.	0.51	.	*	F	1.13	0.76
Phe	797	C	0.56	.	*	F	0.81	0.89

5

10

15

20

-44-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	798	T	C	0.44	.	*	F	1.89	0.91
Pro	799	T	C	1.12	*	*	F	2.32	1.17
Leu	800	T	T	.	0.20	*	*	F	2.80	2.10
Lys	801	T	C	0.19	*	*	F	2.32	1.29
Glu	802	C	0.00	.	*	F	1.84	1.20
Pro	803	A	.	.	B	.	.	.	0.30	.	*	F	1.16	1.02
Leu	804	A	.	.	B	.	.	.	-0.34	.	*	F	0.73	0.89
Thr	805	.	.	B	B	.	.	.	-0.34	.	*	.	-0.30	0.38
Ile	806	.	.	B	B	.	.	.	-0.70	.	*	.	-0.60	0.20
Gln	807	.	.	B	B	.	.	.	-1.56	.	.	.	-0.60	0.35
Val	808	.	.	B	B	.	.	.	-1.69	.	*	.	-0.60	0.18
Leu	809	.	.	B	B	.	.	.	-0.88	.	*	.	-0.60	0.26
Thr	810	.	.	B	B	.	.	.	-1.16	.	.	.	-0.60	0.24
Val	811	.	.	B	B	.	.	.	-1.08	.	*	.	-0.60	0.33
Gly	812	.	.	B	B	.	.	.	-0.97	*	*	.	-0.60	0.33
Asn	813	A	-0.32	*	*	.	0.12	0.44
Ala	814	A	0.53	*	*	.	0.34	0.92
Leu	815	A	-0.04	*	*	F	1.76	1.86
Arg	816	.	.	B	0.86	*	*	F	1.53	0.81
Pro	817	.	.	B	0.96	*	*	F	2.20	1.61
Lys	818	.	.	B	B	.	.	.	0.64	*	*	F	1.48	3.05

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ile	819	.	.	B	B	.	.	.	0.99	.	*	F	1.56	2.25
Lys	820	.	.	B	B	.	.	.	1.10	*	*	F	0.44	2.28
Tyr	821	.	.	B	B	.	.	.	0.13	*	*	.	-0.38	0.99
Thr	822	.	.	B	B	.	.	.	0.39	.	*	.	-0.45	1.04
Tyr	823	A	.	.	B	.	.	.	0.39	.	*	.	-0.45	1.04
Phe	824	A	.	.	B	.	.	.	1.32	.	*	.	-0.45	1.33
Val	825	A	.	.	B	.	.	.	1.32	.	.	.	0.45	1.85
Lys	826	A	.	.	B	.	.	.	1.57	.	.	F	0.90	2.36
Lys	827	A	A	1.58	*	.	F	0.90	4.71
Lys	828	A	A	1.12	*	.	F	0.90	8.51
Lys	829	A	A	1.82	*	.	F	0.90	3.68
Glu	830	A	A	2.09	*	.	F	0.90	2.96
Ser	831	A	A	1.16	*	.	F	0.90	1.50
Phe	832	A	A	0.90	.	.	.	0.30	0.52
Asn	833	.	A	B	0.54	*	.	.	-0.30	0.47
Ala	834	.	.	B	-0.20	*	*	.	-0.40	0.50
Ile	835	C	-0.50	*	.	.	-0.20	0.50
Pro	836	T	C	-0.79	.	.	.	0.00	0.42
Thr	837	T	T	.	-0.38	*	*	.	0.20	0.42
Phe	838	A	T	.	-1.23	*	.	.	-0.20	0.63
Ser	839	T	C	-1.53	*	.	.	0.00	0.30

5

10

15

20

-46-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	840	.	A	B	B	.	.	.	-0.64	*	.	.	-0.60	0.15
Trp	841	.	A	B	B	.	.	.	-0.43	.	.	.	-0.60	0.29
Val	842	A	A	.	B	.	.	.	-0.41	.	.	.	-0.30	0.38
Ile	843	A	A	.	B	.	.	.	-0.06	*	.	.	-0.60	0.40
Glu	844	A	A	.	B	.	.	.	0.24	*	.	.	-0.60	0.37
Glu	845	A	A	0.17	*	.	.	0.30	0.87
Trp	846	A	A	0.16	*	.	.	0.61	0.66
Gly	847	A	A	1.06	*	.	F	1.37	0.51
Glu	848	.	A	.	.	T	.	.	1.64	*	.	F	2.08	0.59
Cys	849	.	A	.	.	T	.	.	0.98	*	.	F	2.09	0.76
Ser	850	T	T	.	0.98	.	.	F	3.10	0.41
Lys	851	T	T	.	0.46	.	.	F	2.79	0.41
Ser	852	T	T	.	0.46	.	.	F	2.18	0.63
Cys	853	T	T	.	0.17	*	*	.	2.02	0.47
Glu	854	A	A	0.83	*	.	.	0.61	0.24
Leu	855	A	A	1.24	.	.	.	-0.30	0.32
Gly	856	.	A	1.31	.	*	.	0.85	1.16
Trp	857	A	A	0.80	*	*	.	0.75	1.31
Gln	858	A	A	0.61	*	*	.	-0.15	1.31
Arg	859	A	A	0.61	*	*	.	-0.30	0.98
Arg	860	.	A	B	0.76	.	*	.	0.45	1.61

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	861	.	A	B	1.21	*	.	.	0.60	0.50
Val	862	.	A	B	1.50	*	.	.	0.60	0.50
Glu	863	.	A	B	0.61	.	.	.	0.94	0.43
Cys	864	.	A	B	0.50	.	.	.	0.98	0.36
Arg	865	.	A	.	.	T	.	.	0.04	.	.	F	2.17	0.78
Asp	866	T	T	.	0.86	.	.	F	2.91	0.45
Ile	867	T	T	.	1.50	.	.	F	3.40	1.45
Asn	868	T	T	.	0.91	.	.	F	3.06	1.14
Gly	869	T	C	1.28	.	.	F	2.07	0.69
Gln	870	T	C	1.17	.	*	F	1.28	1.32
Pro	871	T	C	0.50	.	*	F	1.54	1.42
Ala	872	T	C	0.80	.	*	F	1.05	0.77
Ser	873	A	T	.	0.84	*	.	F	0.85	0.45
Glu	874	A	A	1.19	*	.	F	0.75	0.58
Cys	875	A	A	0.33	*	.	.	0.60	1.00
Ala	876	A	A	0.59	*	.	.	0.60	0.55
Lys	877	A	A	0.97	*	.	F	0.75	0.64
Glu	878	A	A	0.68	*	.	F	0.90	1.84
Val	879	A	A	0.38	*	.	F	0.90	1.84
Lys	880	A	A	0.73	*	.	F	0.90	1.23
Pro	881	A	T	.	1.43	*	.	F	1.30	1.03

5

10

15

20

-48-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni Surfa...
Ala	882	T	T	.	1.18	*	.	F	2.01	2.71
Ser	883	T	T	.	0.51	.	*	F	2.32	2.10
Thr	884	T	T	.	0.78	.	*	F	2.18	0.73
Arg	885	.	.	B	.	.	T	.	0.73	.	*	F	2.09	0.73
Pro	886	T	T	.	0.91	.	*	F	3.10	0.91
Cys	887	T	T	.	1.29	.	*	.	2.64	0.85
Ala	888	T	T	.	0.92	.	*	.	2.43	0.67
Asp	889	T	.	.	1.02	.	*	.	1.72	0.23
His	890	T	C	0.91	.	*	.	1.51	0.67
Pro	891	T	T	.	0.83	.	.	.	1.65	1.16
Cys	892	T	T	.	1.50	.	*	.	1.00	0.73
Pro	893	T	T	.	1.28	.	*	.	0.60	0.93
Gln	894	.	A	.	.	T	.	.	0.93	.	.	.	0.10	0.49
Trp	895	.	A	B	0.97	.	.	.	-0.40	0.91
Gln	896	.	A	B	0.89	.	.	.	-0.05	1.02
Leu	897	.	A	B	1.26	.	.	.	-0.60	0.62
Gly	898	T	.	.	1.17	.	.	.	0.00	0.79
Glu	899	T	.	.	0.50	.	.	F	0.45	0.61
Trp	900	T	.	.	0.49	.	.	F	0.45	0.40
Ser	901	T	T	.	0.53	.	.	F	0.65	0.54
Ser	902	T	T	.	1.03	.	.	F	1.25	0.62

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Cys	903	T	T	.	0.71	.	*	F	0.65	0.85
Ser	904	T	T	.	0.37	*	*	F	1.25	0.34
Lys	905	T	.	.	0.70	*	*	F	1.05	0.25
Thr	906	T	.	.	0.66	*	*	F	1.69	0.94
Cys	907	T	.	.	0.71	*	.	F	2.03	0.69
Gly	908	T	T	.	1.42	*	*	F	2.27	0.54
Lys	909	T	T	.	1.77	*	*	F	2.61	0.75
Gly	910	T	T	.	1.83	*	*	F	3.40	2.81
Tyr	911	T	T	.	1.84	.	.	F	3.06	5.57
Lys	912	.	A	B	1.70	*	.	F	1.92	3.73
Lys	913	.	A	B	2.09	*	.	F	1.58	3.11
Arg	914	.	A	B	1.38	*	.	F	1.24	3.97
Ser	915	.	A	B	0.91	*	.	F	0.90	1.06
Leu	916	.	A	B	0.86	*	.	F	0.75	0.44
Lys	917	.	A	B	0.78	*	.	.	0.30	0.30
Cys	918	.	A	B	0.73	*	.	.	-0.30	0.30
Leu	919	.	A	B	0.28	*	.	.	0.30	0.62
Ser	920	.	.	B	0.23	.	.	.	0.50	0.31
His	921	.	.	B	.	.	T	.	0.19	*	.	F	0.85	0.56
Asp	922	T	T	.	-0.67	*	.	F	0.65	0.51
Gly	923	T	T	.	-0.30	.	.	F	0.65	0.31

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	924	T	T	.	0.48	.	.	F	0.65	0.31
Val	925	.	.	B	0.78	.	.	.	-0.10	0.25
Leu	926	.	.	B	0.51	.	.	.	-0.10	0.44
Ser	927	.	.	B	-0.16	.	.	.	-0.10	0.59
His	928	.	.	B	.	.	T	.	0.19	.	.	.	0.10	0.43
Glu	929	.	.	B	.	.	T	.	0.32	.	.	F	0.85	0.87
Ser	930	A	T	.	0.37	*	.	F	1.30	1.00
Cys	931	A	T	.	1.22	*	.	F	0.85	0.61
Asp	932	A	T	.	1.57	*	.	F	1.15	0.70
Pro	933	A	T	.	1.39	*	.	F	1.30	1.05
Leu	934	A	T	.	1.43	*	.	F	1.30	3.02
Lys	935	A	T	.	1.70	*	.	F	1.30	3.62
Lys	936	A	A	1.67	*	.	F	0.90	3.18
Pro	937	A	A	0.78	*	.	F	0.90	3.34
Lys	938	A	A	0.99	*	*	F	0.90	1.17
His	939	A	A	1.10	*	*	.	0.60	0.98
Phe	940	.	A	B	0.39	*	*	.	-0.30	0.55
Ile	941	.	A	B	0.03	*	*	.	-0.30	0.15
Asp	942	A	A	-0.36	*	*	.	-0.60	0.16
Phe	943	A	A	-0.99	*	*	.	-0.60	0.18
Cys	944	A	A	-0.96	.	.	.	-0.60	0.26

5

10

15

20

-51-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Thr	945	A	A	-0.92	.	*	.	0.30	0.27
Met	946	A	A	-0.33	.	*	.	-0.60	0.16
Ala	947	A	A	-0.72	.	.	.	-0.30	0.41
Glu	948	A	A	-0.41	.	.	.	0.30	0.36
Cys	949	A	A	-0.13	.	.	.	0.30	0.47
Ser	950	A	A	-0.21	.	.	.	0.30	0.60

Table 2

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Met	1	.	.	B	-0.37	.	.	.	-0.40	0.50
Phe	2	.	.	B	-0.57	.	.	.	-0.40	0.61
Pro	3	.	.	B	-0.77	.	.	.	-0.40	0.48
Ala	4	C	-0.59	.	*	.	-0.20	0.49
Pro	5	C	-0.09	.	*	.	-0.20	0.87
Ala	6	C	0.22	*	*	.	0.85	1.11
Ala	7	T	C	0.11	*	*	.	0.45	1.15
Pro	8	A	T	.	0.11	*	.	.	-0.20	0.61
Arg	9	T	T	.	0.00	*	.	.	0.20	0.94
Trp	10	.	.	B	.	.	T	.	-0.60	*	.	.	-0.20	0.81
Leu	11	.	A	B	-0.82	*	.	.	-0.60	0.43
Pro	12	.	A	B	-1.04	*	.	.	-0.60	0.18
Phe	13	.	A	B	-1.64	*	.	.	-0.60	0.14
Leu	14	A	A	-2.57	*	.	.	-0.60	0.14
Leu	15	A	A	-3.09	.	.	.	-0.60	0.08
Leu	16	A	A	-3.09	.	.	.	-0.60	0.07
Leu	17	A	A	-3.69	.	.	.	-0.60	0.07
Leu	18	A	A	-3.80	.	.	.	-0.60	0.07
Leu	19	A	A	-3.20	.	.	.	-0.60	0.07
Leu	20	A	A	-3.20	.	.	.	-0.60	0.14

5

10

15

20

-53-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	21	A	A	-2.98	*	.	.	-0.60	0.14
Leu	22	.	A	B	-2.06	*	.	.	-0.60	0.17
Pro	23	.	A	B	-1.59	*	.	.	-0.60	0.39
Leu	24	A	A	-1.37	*	.	.	-0.60	0.47
Ala	25	A	A	-0.77	*	.	.	-0.04	0.58
Arg	26	.	A	B	-0.54	*	.	.	0.82	0.58
Gly	27	.	A	B	0.38	.	.	F	0.63	0.71
Ala	28	.	.	B	0.38	.	.	F	2.14	1.37
Pro	29	C	0.60	.	.	F	2.60	1.08
Ala	30	.	.	B	0.60	.	.	F	1.84	1.11
Arg	31	.	.	B	0.14	.	.	F	1.58	1.11
Pro	32	.	.	B	0.14	.	*	F	1.17	0.71
Ala	33	.	.	B	.	.	T	.	0.73	.	*	F	1.11	0.69
Ala	34	A	T	.	0.36	.	*	F	0.85	0.61
Gly	35	T	C	0.64	.	*	F	0.45	0.40
Gly	36	T	C	0.53	.	*	F	0.45	0.53
Gln	37	A	-0.07	.	.	F	0.65	0.91
Ala	38	.	.	B	-0.33	.	.	F	0.65	0.76
Ser	39	.	.	B	B	B	.	.	-0.60	.	.	F	-0.15	0.57
Glu	40	.	.	B	B	B	.	.	-0.47	.	.	F	-0.15	0.24
Leu	41	.	.	B	B	B	.	.	-0.43	.	*	.	-0.30	0.37

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Val	42	.	.	B	B	B	.	.	-0.32	.	*	.	-0.30	0.40
Val	43	.	.	B	B	B	.	.	-0.54	.	*	.	0.30	0.46
Pro	44	.	.	B	B	B	.	.	-0.46	.	*	F	-0.24	0.46
Thr	45	.	.	B	B	B	.	.	-0.80	.	*	F	0.27	0.95
Arg	46	.	.	B	B	B	.	.	-0.29	.	*	F	0.63	1.26
Leu	47	T	C	-0.02	.	*	F	2.04	1.10
Pro	48	T	C	0.49	*	*	F	2.10	0.77
Gly	49	T	C	0.70	*	*	F	1.89	0.39
Ser	50	T	C	0.20	*	*	F	1.68	0.81
Ala	51	A	A	-0.50	*	*	F	0.87	0.43
Gly	52	A	A	-0.50	.	.	F	0.66	0.44
Glu	53	A	A	-0.32	.	*	.	-0.30	0.27
Leu	54	A	A	-0.79	.	*	.	-0.30	0.37
Ala	55	A	A	-0.79	.	*	.	-0.60	0.31
Leu	56	A	A	-0.79	.	*	.	-0.60	0.24
His	57	A	A	-1.14	.	*	.	-0.60	0.29
Leu	58	A	A	-1.49	*	*	.	-0.60	0.25
Ser	59	A	A	-0.63	*	*	.	-0.60	0.30
Ala	60	A	A	-0.39	*	*	.	-0.30	0.44
Phe	61	A	A	-0.28	*	*	.	-0.30	0.53
Gly	62	T	T	.	-1.10	*	.	.	0.50	0.34

5

10

15

20

-55-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Lys	63	A	T	.	-1.10	.	*	F	-0.05	0.25
Gly	64	.	.	B	.	.	T	.	-0.69	.	*	.	-0.20	0.24
Phe	65	.	.	B	.	.	T	.	-0.91	.	*	.	0.70	0.47
Val	66	.	.	B	B	.	.	.	-0.80	*	*	.	-0.30	0.19
Leu	67	.	.	B	B	.	.	.	-0.67	*	*	.	-0.30	0.20
Arg	68	.	.	B	B	.	.	.	-0.71	.	*	.	0.00	0.35
Leu	69	.	.	B	B	.	.	.	-0.37	*	*	.	1.20	0.80
Ala	70	T	C	0.03	.	*	.	2.55	1.61
Pro	71	T	C	0.19	*	*	F	3.00	1.10
Asp	72	T	T	.	0.19	.	*	F	2.60	1.16
Asp	73	A	T	.	-0.51	.	*	F	1.75	0.95
Ser	74	A	A	0.09	.	.	.	0.90	0.62
Phe	75	A	A	0.68	.	.	.	0.60	0.57
Leu	76	A	A	0.19	.	*	.	0.30	0.59
Ala	77	A	A	0.23	.	*	.	-0.60	0.38
Pro	78	A	A	-0.66	.	*	.	-0.30	0.89
Glu	79	A	A	-0.36	*	*	F	-0.15	0.75
Phe	80	A	A	0.46	*	.	F	0.90	1.29
Lys	81	A	A	0.46	*	*	F	0.90	1.63
Ile	82	A	A	0.70	*	.	F	0.75	0.78
Glu	83	A	A	0.57	*	*	F	0.45	0.89

5

10

15

20

-56-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni Surfa...
Arg	84	A	A	0.27	*	*	F	0.75	0.44
Leu	85	.	A	.	.	T	.	.	0.62	*	*	F	0.85	0.84
Gly	86	.	A	.	.	T	.	.	0.69	*	*	F	1.15	0.48
Gly	87	T	C	0.99	*	*	F	1.35	0.48
Ser	88	T	C	0.68	*	*	F	1.05	0.59
Gly	89	T	C	0.22	*	*	F	1.05	0.86
Arg	90	.	.	B	.	.	T	.	0.69	.	*	F	1.19	0.86
Ala	91	T	C	1.03	.	*	F	1.73	0.63
Thr	92	.	.	B	.	.	T	.	1.49	.	*	F	2.32	1.11
Gly	93	.	.	B	.	.	T	.	1.44	.	*	F	2.66	1.11
Gly	94	T	T	.	0.98	*	*	F	3.40	1.09
Glu	95	.	.	B	0.98	*	*	F	2.31	0.62
Arg	96	.	.	B	1.22	*	.	F	2.12	1.23
Gly	97	T	.	.	0.87	*	*	F	2.18	1.23
Leu	98	.	.	B	.	.	T	.	0.51	*	.	F	1.49	0.38
Arg	99	.	.	B	.	.	T	.	0.16	*	.	.	0.70	0.17
Gly	100	.	.	B	.	.	T	.	-0.14	*	.	.	-0.20	0.15
Cys	101	.	.	B	.	.	T	.	-0.60	*	.	.	-0.20	0.24
Phe	102	.	.	B	-0.57	.	*	.	-0.10	0.12
Phe	103	.	.	B	.	.	T	.	-0.61	.	*	.	-0.20	0.18
Ser	104	.	.	B	.	.	T	.	-0.72	.	*	F	-0.05	0.24

5

10

15

20

-57-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	105	T	C	-0.72	.	*	F	0.15	0.45
Thr	106	T	C	-0.06	*	*	F	0.45	0.52
Val	107	.	.	.	B	.	.	C	0.43	.	*	F	1.25	0.67
Asn	108	.	.	.	B	.	.	C	1.13	.	*	F	1.70	1.05
Gly	109	.	.	.	B	.	.	C	1.13	.	*	F	2.30	1.26
Glu	110	T	C	0.67	.	*	F	3.00	2.27
Pro	111	A	T	.	0.39	.	*	F	2.50	1.16
Glu	112	A	T	.	0.66	.	*	F	2.20	1.19
Ser	113	A	T	.	-0.20	.	.	F	1.75	0.69
Leu	114	A	A	.	B	.	.	.	-0.16	.	.	.	0.00	0.33
Ala	115	A	A	.	B	.	.	.	-0.97	.	.	.	-0.30	0.26
Ala	116	A	A	.	B	.	.	.	-1.42	.	.	.	-0.60	0.16
Val	117	A	A	.	B	.	.	.	-1.31	.	.	.	-0.60	0.10
Ser	118	.	A	B	B	.	.	.	-1.36	*	.	.	-0.30	0.20
Leu	119	.	.	B	B	.	.	.	-1.36	*	.	.	-0.30	0.20
Cys	120	.	.	B	.	.	T	.	-1.07	*	.	.	0.10	0.22
Arg	121	.	.	B	.	.	T	.	-0.82	*	.	.	0.10	0.22
Gly	122	T	T	.	-0.27	*	.	F	0.65	0.26
Leu	123	T	T	.	-0.67	*	.	F	1.25	0.65
Ser	124	T	C	-0.67	*	.	F	0.45	0.29
Gly	125	.	.	B	.	.	T	.	-0.81	.	*	F	-0.05	0.24

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	126	.	.	B	.	.	T	.	-0.92	.	*	F	-0.05	0.24
Phe	127	.	.	B	.	.	T	.	-0.92	.	*	.	0.10	0.30
Leu	128	.	A	B	.	.	.	C	-0.11	.	*	.	-0.30	0.30
Leu	129	.	A	0.19	.	*	F	0.65	0.39
Asp	130	A	A	-0.17	.	.	F	0.45	0.77
Gly	131	A	A	-0.18	.	.	F	0.45	0.81
Glu	132	A	A	-0.37	.	*	F	0.90	1.42
Glu	133	A	A	0.44	.	*	F	0.75	0.60
Phe	134	A	A	1.04	.	*	.	0.45	1.04
Thr	135	.	A	B	1.04	.	*	.	0.30	0.93
Ile	136	.	.	B	1.04	.	*	F	0.05	0.93
Gln	137	.	.	B	0.46	.	*	F	-0.10	1.06
Pro	138	C	0.11	.	*	F	0.25	0.75
Gln	139	T	.	.	0.47	.	*	F	0.60	1.05
Gly	140	T	C	0.48	.	*	F	0.45	0.60
Ala	141	T	T	.	0.56	.	*	F	1.25	0.52
Gly	142	T	C	-0.03	.	.	F	0.45	0.25
Gly	143	T	C	0.18	.	.	F	0.65	0.25
Ser	144	C	-0.03	.	.	F	0.65	0.43
Leu	145	.	.	B	0.28	*	.	F	0.65	0.68
Ala	146	.	.	B	0.98	*	.	F	0.85	0.93

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gln	147	.	.	B	.	.	T	.	0.51	.	*	F	2.00	1.36
Pro	148	.	.	B	.	.	T	.	0.86	*	.	.	1.05	1.36
His	149	.	.	B	.	.	T	.	1.27	*	.	.	1.45	2.34
Arg	150	.	.	B	.	.	T	.	1.79	*	.	.	1.55	2.64
Leu	151	.	.	B	2.03	*	.	.	0.85	1.80
Gln	152	.	.	B	1.82	*	.	.	0.65	1.31
Arg	153	T	.	.	1.44	*	.	.	1.05	1.03
Trp	154	T	.	.	1.13	*	.	F	0.84	1.26
Gly	155	T	C	0.43	*	.	F	0.93	0.72
Pro	156	T	C	1.36	*	.	F	1.17	0.37
Ala	157	T	T	.	1.14	*	.	F	1.61	0.69
Gly	158	T	C	0.22	*	.	F	2.40	1.08
Ala	159	C	0.30	*	*	F	1.81	0.58
Arg	160	.	.	B	0.76	*	*	F	1.37	0.89
Pro	161	.	.	B	0.62	*	*	F	1.58	1.75
Leu	162	C	1.00	*	*	F	1.84	1.72
Pro	163	C	1.34	*	*	F	1.90	1.35
Arg	164	C	1.64	*	*	F	2.20	1.52
Gly	165	T	C	1.53	*	*	F	2.40	1.93
Pro	166	T	C	0.89	*	.	F	3.00	2.17
Glu	167	T	C	1.70	*	.	F	2.55	0.82

5

10

15

20

-60-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Trp	168	A	T	.	1.60	*	.	.	2.05	1.44
Glu	169	A	1.14	*	.	.	1.85	1.34
Val	170	A	1.49	.	.	F	1.85	0.77
Glu	171	A	1.36	.	*	F	2.00	1.26
Thr	172	A	1.36	.	*	F	2.15	0.72
Gly	173	T	C	1.76	.	.	F	3.00	1.68
Glu	174	A	T	.	1.76	.	.	F	2.50	1.90
Gly	175	A	T	.	2.61	.	.	F	2.20	2.28
Gln	176	A	T	.	2.72	.	.	F	1.90	4.00
Arg	177	A	A	2.69	.	*	F	1.54	4.52
Gln	178	A	A	3.03	.	*	F	1.58	4.52
Glu	179	.	A	.	.	T	.	.	3.00	*	*	F	2.32	4.36
Arg	180	.	A	.	.	T	.	.	3.34	*	.	F	2.66	3.03
Gly	181	T	T	.	3.34	.	*	F	3.40	3.03
Asp	182	T	C	3.23	.	.	F	2.86	3.03
His	183	T	C	2.93	.	*	F	2.52	2.58
Gln	184	T	C	2.93	.	*	F	2.18	3.50
Glu	185	.	A	C	2.82	.	*	F	1.44	3.63
Asp	186	A	A	3.17	.	.	F	0.90	4.61
Ser	187	A	A	2.87	.	.	F	0.90	4.61
Glu	188	A	A	2.90	.	.	F	0.90	3.57

5

10

15

20

-61-

Res	Pos.	Garni... Alpha	Choi... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	Jams... Antig...	Emni Surfa...
Glu	189	A	A	2.90	.	.	F	0.90	3.70
Glu	190	A	A	2.90	.	.	F	0.90	4.79
Ser	191	A	A	2.90	.	.	F	0.90	4.79
Gln	192	A	A	2.61	.	.	F	0.90	4.79
Glu	193	A	A	2.61	.	.	F	0.90	2.79
Glu	194	A	A	2.27	.	.	F	0.90	3.61
Glu	195	A	A	1.68	.	.	F	0.90	2.06
Ala	196	A	A	1.68	.	.	F	1.16	1.20
Glu	197	A	A	1.68	.	.	F	1.27	0.93
Gly	198	A	A	1.47	.	.	F	1.53	0.93
Ala	199	.	A	.	.	T	.	.	1.26	.	.	F	2.34	1.42
Ser	200	C	1.04	.	.	F	2.60	1.27
Glu	201	C	1.42	*	.	F	2.04	1.99
Pro	202	C	0.61	*	.	F	1.78	3.04
Pro	203	C	0.61	.	.	F	1.52	1.87
Pro	204	T	C	0.61	.	.	F	1.46	1.07
Pro	205	T	C	0.60	.	.	F	0.45	0.70
Leu	206	T	C	0.30	*	*	F	0.45	0.65
Gly	207	.	.	B	.	.	T	.	0.62	.	*	F	0.51	0.57
Ala	208	.	.	B	0.52	.	*	F	1.17	0.72
Thr	209	.	.	B	0.78	*	*	F	1.58	1.25

5

10

15

20

-62-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	210	.	.	B	.	.	T	.	1.10	*	.	F	2.34	2.53
Arg	211	.	.	B	.	.	T	.	1.21	*	.	F	2.60	4.91
Thr	212	.	.	B	.	.	T	.	0.70	*	.	F	2.34	2.95
Lys	213	.	.	B	.	.	T	.	0.99	*	.	F	2.08	1.63
Arg	214	.	.	B	B	.	.	.	1.30	*	.	F	1.42	1.12
Phe	215	.	.	B	B	.	.	.	1.01	*	*	.	1.01	1.34
Val	216	.	.	B	B	.	.	.	1.01	*	*	.	0.60	0.68
Ser	217	A	.	.	B	.	.	.	0.62	*	*	.	0.60	0.68
Glu	218	A	A	-0.28	*	*	.	-0.30	0.68
Ala	219	A	A	.	B	.	.	.	-0.39	*	*	.	0.30	0.68
Arg	220	A	A	.	B	.	.	.	0.00	*	*	.	0.60	0.87
Phe	221	A	A	.	B	.	.	.	0.04	*	.	.	0.60	0.73
Val	222	A	A	.	B	.	.	.	-0.47	*	*	.	-0.30	0.59
Glu	223	A	A	.	B	.	.	.	-1.32	*	*	.	-0.30	0.25
Thr	224	A	A	.	B	.	.	.	-1.32	*	*	.	-0.60	0.21
Leu	225	A	A	.	B	.	.	.	-1.43	*	*	.	-0.60	0.29
Leu	226	A	A	.	B	.	.	.	-1.32	.	.	.	0.30	0.28
Val	227	A	A	.	B	.	.	.	-0.77	.	.	.	-0.60	0.20
Ala	228	A	A	.	B	.	.	.	-1.37	.	.	.	-0.30	0.32
Asp	229	A	A	.	B	.	.	.	-1.64	.	.	.	-0.30	0.38
Ala	230	A	A	-1.42	.	.	.	-0.30	0.52

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	231	A	A	-1.31	.	.	.	0.30	0.52
Met	232	A	A	-0.70	.	.	.	-0.30	0.27
Ala	233	A	A	-0.46	.	.	.	-0.60	0.42
Ala	234	A	A	-1.04	.	.	.	-0.60	0.31
Phe	235	A	A	-0.46	.	.	.	-0.60	0.32
Tyr	236	A	A	-0.97	.	.	.	-0.60	0.52
Gly	237	A	A	-0.37	.	.	.	-0.60	0.43
Ala	238	A	A	0.22	.	.	.	-0.60	0.86
Asp	239	A	A	0.78	*	*	.	-0.30	0.88
Leu	240	A	A	0.59	*	.	.	0.45	1.21
Gln	241	A	A	.	B	.	.	.	0.02	*	*	.	-0.30	0.84
Asn	242	A	A	.	B	.	.	.	0.06	*	.	.	-0.30	0.41
His	243	.	A	B	B	.	.	.	-0.17	*	*	.	-0.60	0.72
Ile	244	.	A	B	B	.	.	.	-0.77	*	.	.	-0.60	0.35
Leu	245	.	A	B	B	.	.	.	-0.26	*	.	.	-0.60	0.21
Thr	246	.	A	B	B	.	.	.	-1.11	*	.	.	-0.60	0.21
Leu	247	.	A	B	B	.	.	.	-1.70	*	.	.	-0.60	0.22
Met	248	A	A	.	B	.	.	.	-2.26	*	*	.	-0.60	0.27
Ser	249	A	A	.	B	.	.	.	-1.26	*	*	.	-0.60	0.19
Val	250	A	A	.	B	.	.	.	-1.33	*	*	.	-0.30	0.45
Ala	251	A	A	.	B	.	.	.	-1.27	*	*	.	-0.30	0.32

5

10

15

20

-64-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni Surfa...
Ala	252	A	A	.	B	.	.	.	-0.41	*	*	.	-0.60	0.37
Arg	253	A	A	.	B	.	.	.	0.16	*	*	.	-0.15	1.01
Ile	254	A	A	.	B	.	.	.	0.24	*	*	.	0.45	1.36
Tyr	255	A	0.80	*	*	.	0.99	2.08
Lys	256	.	.	B	0.50	*	*	.	1.33	1.42
His	257	.	.	B	.	.	T	.	1.13	.	*	F	1.12	1.42
Pro	258	T	C	1.02	.	*	F	2.56	1.81
Ser	259	T	T	.	1.61	.	*	F	3.40	1.46
Ile	260	T	T	.	0.97	.	*	F	2.76	1.44
Lys	261	.	.	B	0.92	.	*	F	1.67	0.65
Asn	262	T	.	.	0.14	*	*	F	1.73	0.78
Ser	263	.	.	B	B	.	.	.	-0.24	*	*	F	0.19	0.92
Ile	264	.	.	B	B	.	.	.	-0.80	*	*	.	-0.30	0.45
Asn	265	.	.	B	B	.	.	.	-0.77	*	*	.	-0.60	0.21
Leu	266	.	.	B	B	.	.	.	-0.77	.	*	.	-0.60	0.12
Met	267	A	.	.	B	.	.	.	-1.62	*	.	.	-0.60	0.33
Val	268	.	.	B	B	.	.	.	-2.13	.	*	.	-0.60	0.15
Val	269	.	.	B	B	.	.	.	-2.13	.	.	.	-0.60	0.15
Lys	270	A	.	.	B	.	.	.	-2.99	.	.	.	-0.60	0.11
Val	271	.	.	B	B	.	.	.	-2.18	.	.	.	-0.60	0.11
Leu	272	.	.	B	B	.	.	.	-1.58	.	.	.	-0.30	0.25

5

10

15

20

-65-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ile	273	A	.	.	B	.	.	.	-0.72	.	.	.	0.30	0.21
Val	274	A	.	.	B	.	.	.	0.18	.	*	.	0.30	0.49
Glu	275	A	.	.	B	.	.	.	-0.16	.	.	.	0.75	1.19
Asp	276	A	A	0.36	.	.	F	0.90	1.79
Glu	277	A	A	0.96	*	.	F	0.90	2.39
Lys	278	.	A	.	.	T	.	.	1.84	*	*	F	1.30	2.13
Trp	279	.	A	C	1.84	.	*	F	1.10	2.21
Gly	280	T	C	1.54	*	.	F	1.35	0.95
Pro	281	T	C	1.54	*	*	F	1.36	0.64
Glu	282	.	.	B	.	.	T	.	1.54	*	*	F	1.62	1.01
Val	283	.	.	B	.	.	T	.	1.16	*	*	F	2.23	1.64
Ser	284	T	C	1.10	.	*	F	2.74	1.05
Asp	285	T	T	.	0.63	.	.	F	3.10	0.60
Asn	286	T	T	.	0.53	.	*	F	2.49	0.67
Gly	287	T	T	.	-0.28	*	*	F	2.18	0.72
Gly	288	T	.	.	0.69	*	*	F	1.07	0.35
Leu	289	.	.	B	0.99	*	*	F	0.36	0.43
Thr	290	.	.	B	0.29	*	*	.	-0.10	0.70
Leu	291	.	.	B	-0.38	*	*	.	-0.40	0.61
Arg	292	.	.	B	-0.03	*	*	.	-0.40	0.40
Asn	293	.	.	B	0.02	*	*	.	-0.10	0.44

5

10

15

20

-66-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Phe	294	T	T	.	0.83	*	*	.	0.20	0.57
Cys	295	T	T	.	1.26	*	*	.	0.20	0.50
Asn	296	T	T	.	2.18	*	*	.	0.20	0.61
Trp	297	T	T	.	1.37	*	*	.	0.65	1.38
Gln	298	T	.	.	1.37	*	.	.	0.45	2.23
Arg	299	T	.	.	2.07	*	.	.	1.05	2.23
Arg	300	T	.	.	2.52	*	*	F	1.20	3.67
Phe	301	T	.	.	2.22	*	*	F	1.84	3.28
Asn	302	T	.	.	2.51	*	*	F	2.18	2.24
Gln	303	T	C	2.62	*	.	F	2.52	1.91
Pro	304	T	C	2.48	*	.	F	2.86	4.33
Ser	305	T	T	.	2.16	*	*	F	3.40	3.66
Asp	306	T	T	.	2.86	*	.	F	3.06	3.27
Arg	307	C	2.82	*	.	F	2.32	3.66
His	308	C	2.58	*	.	F	1.98	3.72
Pro	309	C	2.79	*	.	F	1.64	3.49
Glu	310	T	.	.	2.78	*	.	F	1.50	2.97
His	311	A	T	.	2.19	*	.	F	1.00	3.15
Tyr	312	A	T	.	1.19	*	.	F	1.00	2.06
Asp	313	A	T	.	0.41	.	.	F	0.85	0.83
Thr	314	A	T	.	-0.19	.	.	.	-0.20	0.51

5

10

15

20

-67-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexl...	James... Antig...	Emini Surfa...
Ala	315	A	.	.	B	.	.	.	-0.50	*	.	.	-0.60	0.27
Ile	316	.	.	B	B	.	.	.	-0.36	*	.	.	-0.60	0.23
Leu	317	.	.	B	B	.	.	.	-0.11	.	.	.	-0.60	0.31
Leu	318	.	.	B	B	.	.	.	-0.11	.	*	.	-0.60	0.53
Thr	319	.	.	B	B	.	.	.	-0.50	.	.	F	0.00	1.23
Arg	320	.	.	B	B	.	.	.	-0.58	.	*	F	-0.08	1.29
Gln	321	.	.	.	B	T	.	.	-0.03	.	*	F	0.69	0.84
Asn	322	T	T	.	0.78	.	*	F	1.31	0.57
Phe	323	T	T	.	1.59	.	.	.	1.98	0.51
Cys	324	T	T	.	1.56	.	*	.	2.20	0.51
Gly	325	T	T	.	0.63	.	*	F	1.53	0.31
Gln	326	T	.	.	-0.03	.	.	F	1.11	0.30
Glu	327	T	.	.	-0.03	.	.	F	0.89	0.30
Gly	328	T	.	.	0.36	.	.	F	1.27	0.50
Leu	329	.	.	B	0.21	.	.	F	0.65	0.42
Cys	330	.	.	B	0.21	.	.	.	0.50	0.20
Asp	331	.	.	B	.	.	T	.	-0.64	.	.	.	0.10	0.20
Thr	332	.	.	B	.	.	T	.	-1.23	*	.	.	-0.20	0.18
Leu	333	.	.	B	.	.	T	.	-0.89	.	.	.	0.10	0.34
Gly	334	.	.	B	.	.	T	.	-0.97	.	.	.	0.70	0.34
Val	335	.	.	B	-0.64	.	.	.	-0.40	0.16

5

10

15

20

-68-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni Surfa...
Ala	336	.	.	B	-0.96	.	.	.	-0.10	0.20
Asp	337	.	.	B	.	.	T	.	-1.53	.	.	.	0.10	0.29
Ile	338	.	.	B	.	.	T	.	-1.39	.	.	.	-0.20	0.27
Gly	339	.	.	B	.	.	T	.	-1.04	*	.	.	0.10	0.14
Thr	340	.	.	B	.	.	T	.	-0.40	.	.	.	0.70	0.14
Ile	341	.	.	B	0.19	.	.	.	0.24	0.32
Cys	342	.	.	B	0.23	.	.	.	1.18	0.52
Asp	343	.	.	B	.	.	T	.	0.82	*	.	F	1.87	0.72
Pro	344	T	T	.	0.50	.	.	F	3.06	1.37
Asn	345	T	T	.	0.51	.	.	F	3.40	1.37
Lys	346	T	T	.	0.54	*	.	F	3.06	1.10
Ser	347	.	.	.	B	T	.	.	0.32	.	.	F	1.87	0.53
Cys	348	.	.	B	B	.	.	.	0.32	*	.	.	0.38	0.23
Ser	349	.	.	B	B	.	.	.	0.53	*	.	.	0.64	0.20
Val	350	.	.	B	B	.	.	.	0.53	*	.	.	0.30	0.25
Ile	351	.	.	B	B	.	.	.	0.14	*	.	.	0.60	0.80
Glu	352	A	.	.	B	.	.	.	-0.37	.	.	.	0.60	0.59
Asp	353	A	A	0.30	.	.	F	0.75	0.66
Glu	354	A	A	0.01	*	.	F	0.90	1.62
Gly	355	A	A	0.28	*	.	F	0.75	0.95
Leu	356	A	A	1.13	*	.	.	0.30	0.57

5

10

15

20

-69-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gln	357	A	A	0.82	*	.	.	-0.30	0.45
Ala	358	A	A	0.01	*	.	.	-0.60	0.66
Ala	359	A	A	-0.58	*	.	.	-0.60	0.66
His	360	A	A	-0.27	*	.	.	-0.60	0.38
Thr	361	A	A	0.54	*	.	.	-0.60	0.52
Leu	362	A	A	-0.27	*	.	.	-0.30	0.88
Ala	363	A	A	-0.02	*	.	.	-0.30	0.54
His	364	A	A	0.53	*	.	.	-0.30	0.37
Glu	365	A	A	-0.29	*	.	.	-0.30	0.61
Leu	366	A	A	.	B	.	.	.	-0.79	*	.	.	-0.30	0.45
Gly	367	A	A	.	B	.	.	.	-0.28	*	.	.	-0.60	0.27
His	368	A	A	.	B	.	.	.	-0.29	*	.	.	-0.30	0.21
Val	369	A	A	.	B	.	.	.	-0.47	*	.	.	-0.60	0.25
Leu	370	.	A	B	B	.	.	.	-0.50	*	.	.	-0.26	0.39
Ser	371	.	A	B	B	.	.	.	0.31	*	.	.	0.08	0.39
Met	372	.	.	B	0.66	.	.	.	0.92	0.88
Pro	373	T	.	.	0.39	*	.	.	2.41	1.78
His	374	T	T	.	1.29	*	.	F	3.40	1.78
Asp	375	T	T	.	1.89	.	.	F	3.06	3.61
Asp	376	T	T	.	1.52	.	.	F	2.89	3.61
Ser	377	T	T	.	1.81	*	*	F	2.72	1.42

5

10

15

20

-70-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Lys	378	.	.	B	.	.	T	.	2.13	*	*	F	2.15	1.23
Pro	379	T	T	.	1.36	*	*	F	2.38	1.44
Cys	380	.	.	B	.	.	T	.	0.66	*	*	F	1.70	0.89
Thr	381	.	.	B	.	.	T	.	0.31	*	*	F	1.53	0.38
Arg	382	.	.	B	B	.	.	.	0.40	*	*	F	0.36	0.25
Leu	383	.	.	B	B	.	.	.	-0.24	*	*	.	0.04	0.71
Phe	384	.	.	B	B	.	.	.	-0.38	*	.	.	-0.43	0.49
Gly	385	.	.	.	B	.	.	C	0.33	*	.	F	0.05	0.25
Pro	386	T	C	0.61	*	*	F	0.45	0.59
Met	387	T	T	.	0.47	*	*	F	0.65	0.93
Gly	388	A	T	.	0.42	.	.	F	1.00	1.29
Lys	389	A	T	.	0.52	.	.	.	0.10	0.62
His	390	A	A	0.28	.	.	.	-0.30	0.62
His	391	A	A	0.28	.	*	.	-0.30	0.63
Val	392	.	A	B	0.07	.	.	.	-0.30	0.49
Met	393	A	A	-0.29	.	*	.	-0.60	0.30
Ala	394	A	A	-1.19	.	*	.	-0.60	0.19
Pro	395	A	A	-1.19	.	*	.	-0.60	0.19
Leu	396	A	A	-1.97	.	*	.	-0.60	0.26
Phe	397	A	A	-1.11	*	*	.	-0.60	0.21
Val	398	A	A	-0.51	*	.	.	-0.60	0.22

5

10

15

20

-71-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karph... Flexi...	James... Antig...	Emini Surfa...
His	399	.	A	B	-0.23	*	*	.	-0.60	0.46
Leu	400	.	A	B	-0.83	*	*	.	-0.60	0.77
Asn	401	.	A	.	.	T	.	.	-0.23	*	*	F	-0.05	0.85
Gln	402	.	A	.	.	T	.	.	0.18	.	*	F	-0.05	0.97
Thr	403	.	A	.	.	T	.	.	0.73	.	*	F	0.10	1.24
Leu	404	.	A	C	0.56	.	*	F	-0.10	1.03
Pro	405	T	.	.	0.70	.	.	.	0.00	0.92
Trp	406	T	.	.	0.40	.	.	.	0.00	0.34
Ser	407	T	C	-0.19	.	.	.	0.00	0.55
Pro	408	T	T	.	-0.48	.	.	.	0.20	0.36
Cys	409	T	T	.	0.09	.	.	.	0.20	0.34
Ser	410	.	.	B	.	.	T	.	-0.51	.	.	.	-0.20	0.40
Ala	411	.	A	B	-0.53	.	.	.	-0.60	0.21
Met	412	.	A	B	-0.23	.	.	.	-0.60	0.57
Tyr	413	.	A	B	-0.83	.	.	.	-0.60	0.74
Leu	414	.	A	B	-0.98	*	.	.	-0.60	0.60
Thr	415	.	A	B	-0.68	*	.	.	-0.60	0.50
Glu	416	A	A	-0.43	*	.	.	-0.30	0.54
Leu	417	A	A	-0.18	*	.	F	0.76	0.64
Leu	418	A	T	.	0.03	*	.	F	1.47	0.44
Asp	419	T	T	.	0.50	*	.	F	2.18	0.35

5

10

15

20

-72-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	420	T	T	.	0.81	.	.	F	1.89	0.42
Gly	421	T	T	.	0.14	.	.	F	3.10	0.84
His	422	T	T	.	0.14	.	.	F	2.79	0.27
Gly	423	T	T	.	0.14	.	.	F	1.58	0.23
Asp	424	.	.	B	.	.	T	.	0.14	.	*	.	0.72	0.19
Cys	425	.	.	B	.	.	T	.	-0.10	.	*	.	1.01	0.23
Leu	426	.	.	B	0.03	.	*	.	0.50	0.24
Leu	427	.	.	B	-0.28	.	*	.	0.50	0.22
Asp	428	.	.	B	-0.52	*	*	.	-0.10	0.40
Ala	429	.	.	B	.	.	T	.	-1.11	*	.	F	0.25	0.49
Pro	430	A	T	.	-1.26	.	.	F	0.25	0.60
Gly	431	T	T	.	-0.66	.	.	F	0.65	0.30
Ala	432	.	.	B	.	.	T	.	-0.66	.	.	.	-0.20	0.46
Ala	433	.	.	B	-0.87	.	.	.	-0.40	0.24
Leu	434	.	.	B	-0.59	.	.	.	-0.40	0.38
Pro	435	.	.	B	-0.72	.	.	.	-0.40	0.54
Leu	436	.	.	B	.	.	T	.	-1.19	.	.	.	-0.20	0.53
Pro	437	.	.	B	.	.	T	.	-0.81	.	.	F	0.00	0.53
Thr	438	T	T	.	-0.57	.	*	F	0.45	0.53
Gly	439	T	C	0.36	.	*	F	0.30	0.64
Leu	440	T	C	-0.03	.	*	F	1.25	0.81

5

10

15

20

-73-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Pro	441	.	.	B	.	.	T	.	0.19	.	*	F	0.50	0.55
Gly	442	.	.	B	.	.	T	.	-0.41	.	*	F	0.45	0.57
Arg	443	.	.	B	.	.	T	.	-0.34	.	*	.	0.25	0.57
Met	444	.	A	B	0.00	.	*	.	-0.50	0.57
Ala	445	.	A	B	0.00	*	*	.	-0.10	1.00
Leu	446	.	A	B	0.21	*	.	.	-0.60	0.42
Tyr	447	.	A	B	0.56	*	*	.	-0.60	0.71
Gln	448	.	A	B	0.44	*	*	.	-0.45	1.22
Leu	449	A	A	0.38	*	*	.	-0.15	2.57
Asp	450	A	A	1.08	*	*	F	-0.15	0.88
Gln	451	.	A	B	1.89	*	*	F	0.75	0.99
Gln	452	.	A	B	1.24	*	*	F	0.90	2.09
Cys	453	.	A	B	0.54	*	*	F	0.75	0.88
Arg	454	.	A	B	1.01	*	*	.	-0.30	0.44
Gln	455	.	A	B	0.80	*	*	.	-0.30	0.25
Ile	456	.	A	B	0.80	*	.	.	-0.30	0.72
Phe	457	.	A	.	.	T	.	.	0.10	*	*	.	0.70	0.62
Gly	458	T	C	0.88	*	*	.	0.00	0.31
Pro	459	T	T	.	0.73	*	*	F	0.65	0.86
Asp	460	T	T	.	0.07	*	*	F	1.40	1.35
Phe	461	T	T	.	0.74	*	*	.	1.35	0.73

5

10

15

20

-74-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni Surfa...
Arg	462	T	.	.	1.44	*	*	.	1.40	0.73
His	463	T	.	.	1.48	*	*	.	1.65	0.71
Cys	464	T	C	1.39	*	*	.	1.45	1.18
Pro	465	T	T	.	0.80	*	.	F	2.50	0.80
Asn	466	T	T	.	1.50	*	*	F	1.65	0.60
Thr	467	T	T	.	1.39	*	*	F	1.55	1.93
Ser	468	.	A	.	.	T	.	.	0.57	*	.	F	1.50	2.08
Ala	469	.	A	.	.	T	.	.	0.57	.	.	F	1.10	0.96
Gln	470	.	A	B	0.19	.	.	F	0.45	0.36
Asp	471	.	A	B	0.19	*	*	F	0.45	0.27
Val	472	.	A	B	-0.31	*	.	.	-0.30	0.46
Cys	473	.	A	B	-0.30	*	.	.	-0.30	0.22
Ala	474	.	A	B	-0.38	*	*	.	-0.60	0.14
Gln	475	.	A	B	-0.41	.	*	.	-0.60	0.10
Leu	476	.	A	B	-0.72	*	*	.	-0.60	0.25
Trp	477	.	A	B	0.13	.	*	.	-0.60	0.36
Cys	478	.	A	B	0.46	.	.	.	-0.26	0.35
His	479	T	T	.	0.46	.	.	.	0.88	0.42
Thr	480	T	T	.	0.46	.	*	.	1.52	0.40
Asp	481	T	T	.	1.06	.	.	F	3.06	1.30
Gly	482	T	T	.	0.53	.	.	F	3.40	1.48

5

10

15

20

-75-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	483	T	.	C	0.53	*	.	F	2.41	0.85
Glu	484	A	0.53	*	.	F	1.67	0.27
Pro	485	A	0.53	.	.	F	0.73	0.37
Leu	486	A	0.58	*	.	.	0.24	0.53
Cys	487	A	0.92	.	.	.	0.78	0.62
His	488	.	.	B	1.17	.	.	F	0.61	0.64
Thr	489	T	T	.	0.87	.	.	F	1.49	0.77
Lys	490	T	T	.	0.27	.	.	F	2.52	1.92
Asn	491	T	T	.	0.87	.	.	F	2.80	1.16
Gly	492	T	T	.	1.24	.	.	F	2.52	1.25
Ser	493	C	0.69	.	.	F	1.09	0.66
Leu	494	C	1.00	.	.	.	0.36	0.41
Pro	495	.	.	B	0.61	.	.	.	0.18	0.69
Trp	496	T	T	.	0.30	.	.	.	0.50	0.51
Ala	497	.	.	B	.	.	T	.	0.43	.	.	.	0.05	0.90
Asp	498	T	T	.	0.07	.	.	F	1.15	0.90
Gly	499	T	T	.	0.53	.	.	F	1.40	0.46
Thr	500	T	C	0.53	.	.	F	2.05	0.45
Pro	501	T	T	.	0.48	.	.	F	2.50	0.42
Cys	502	T	T	.	1.03	.	*	F	1.65	0.42
Gly	503	T	C	0.22	.	.	F	1.20	0.39

5

10

15

20

-76-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni Surfa...
Pro	504	T	.	.	-0.10	.	.	F	0.65	0.21
Gly	505	T	.	.	-0.09	.	.	.	0.25	0.21
His	506	.	.	B	0.12	.	.	.	-0.40	0.28
Leu	507	.	.	B	0.44	.	.	.	0.50	0.32
Cys	508	.	.	B	.	.	T	.	0.49	.	*	.	0.91	0.32
Ser	509	T	T	.	0.03	.	.	F	1.67	0.31
Glu	510	T	T	.	-0.43	.	.	F	1.28	0.20
Gly	511	T	T	.	-0.61	*	.	F	1.49	0.31
Ser	512	T	.	.	0.20	*	.	F	2.10	0.36
Cys	513	.	A	C	0.87	.	.	F	1.79	0.36
Leu	514	.	A	C	1.17	.	.	F	1.58	0.63
Pro	515	A	A	0.31	.	.	F	1.17	0.81
Glu	516	A	A	0.66	*	.	F	1.11	1.13
Glu	517	A	A	1.07	*	.	F	0.90	2.37
Glu	518	A	A	1.52	.	.	F	0.90	3.00
Val	519	A	A	2.38	.	.	F	0.90	2.68
Glu	520	A	A	2.38	*	.	F	0.90	3.09
Arg	521	A	T	.	1.52	*	.	F	1.30	2.76
Pro	522	A	T	.	0.67	*	*	F	1.30	2.76
Lys	523	A	T	.	0.67	*	*	F	1.30	1.18
Pro	524	.	.	B	.	.	T	.	1.18	*	*	F	1.30	1.01

5

10

15

20

-77-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Val	525	.	.	B	0.83	*	*	F	0.65	0.65
Val	526	.	.	B	0.43	.	*	F	0.65	0.32
Asp	527	.	.	B	.	.	T	.	0.06	*	.	F	-0.05	0.22
Gly	528	.	.	B	.	.	T	.	-0.20	*	.	F	-0.05	0.30
Gly	529	T	T	.	-0.28	.	.	F	0.65	0.62
Trp	530	T	C	0.23	.	.	.	0.00	0.39
Ala	531	C	0.88	.	.	.	-0.20	0.39
Pro	532	T	.	.	0.59	.	.	.	0.00	0.61
Trp	533	T	.	.	0.59	.	.	.	0.00	0.61
Gly	534	T	C	0.93	.	.	.	0.00	0.59
Pro	535	T	T	.	0.56	.	.	F	0.35	0.66
Trp	536	T	T	.	0.84	*	.	F	0.66	0.34
Gly	537	T	C	1.17	*	.	F	1.07	0.46
Glu	538	T	.	.	1.14	*	..	F	1.98	0.58
Cys	539	T	T	.	0.82	*	.	F	2.49	0.80
Ser	540	T	T	.	0.69	*	.	F	3.10	0.43
Arg	541	T	T	.	0.63	*	.	F	2.79	0.25
Thr	542	T	T	.	0.63	*	.	F	2.18	0.46
Cys	543	T	T	.	-0.22	*	.	F	1.87	0.34
Gly	544	T	T	.	0.44	*	.	F	1.56	0.13
Gly	545	T	T	.	0.04	*	*	F	0.65	0.15

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gly	546	T	T	.	-0.37	*	*	F	0.35	0.25
Val	547	.	.	B	B	.	.	.	-0.09	*	*	.	-0.60	0.33
Gln	548	.	.	B	B	.	.	.	0.69	*	*	.	-0.60	0.46
Phe	549	.	.	B	B	.	.	.	1.03	*	*	.	-0.30	0.91
Ser	550	.	.	B	B	.	.	.	0.71	*	*	.	0.79	2.13
His	551	.	.	B	1.10	*	*	.	1.18	0.66
Arg	552	T	.	.	1.96	*	*	.	2.37	1.52
Glu	553	T	.	.	1.74	*	*	F	2.86	1.89
Cys	554	T	T	.	2.44	*	.	F	3.40	2.15
Lys	555	T	T	.	2.53	*	.	F	3.06	1.90
Asp	556	T	C	2.57	*	.	F	2.52	1.70
Pro	557	T	C	2.46	*	.	F	2.52	5.49
Glu	558	C	2.11	.	.	F	2.32	4.41
Pro	559	T	T	.	2.43	.	*	F	2.72	2.62
Gln	560	T	T	.	2.50	.	*	F	2.76	1.67
Asn	561	T	T	.	2.26	*	*	F	3.40	1.89
Gly	562	T	T	.	1.80	*	*	F	2.76	1.92
Gly	563	T	T	.	0.99	*	*	F	2.27	0.59
Arg	564	.	.	B	.	.	T	.	0.86	*	.	F	0.93	0.30
Tyr	565	.	.	B	.	.	T	.	0.97	.	.	.	0.44	0.30
Cys	566	.	.	B	.	.	T	.	1.08	.	.	.	1.00	0.60

5

10

15

20

-79-

Res	Pos.	Garnl... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	567	.	.	B	0.83	.	*	.	1.40	0.60
Gly	568	.	.	B	1.22	.	*	F	1.55	0.39
Arg	569	.	.	B	0.87	.	*	F	2.30	1.45
Arg	570	T	.	.	1.11	*	*	F	3.00	2.75
Ala	571	T	.	.	1.48	*	*	F	2.70	4.82
Lys	572	T	.	.	1.62	*	*	F	2.40	3.30
Tyr	573	T	T	.	1.93	*	.	F	1.85	0.90
Gln	574	T	T	.	1.51	.	.	F	1.10	1.22
Ser	575	T	T	.	1.40	.	*	.	0.50	0.88
Cys	576	T	T	.	1.99	.	.	.	0.50	0.97
His	577	.	A	B	1.28	.	.	.	0.60	0.97
Thr	578	.	A	.	.	T	.	.	1.31	.	.	F	0.85	0.39
Glu	579	.	A	.	.	T	.	.	1.10	.	.	F	1.00	1.12
Glu	580	.	A	.	.	T	.	.	1.40	.	.	F	1.64	1.27
Cys	581	.	A	B	1.72	.	*	F	1.58	1.47
Pro	582	T	C	1.80	.	*	F	2.37	0.84
Pro	583	T	T	.	1.81	*	.	F	2.91	0.97
Asp	584	T	T	.	1.11	*	.	F	3.40	2.43
Gly	585	T	T	.	1.22	*	.	F	3.06	1.36
Lys	586	.	A	.	.	T	.	.	1.89	*	.	F	2.32	1.72
Ser	587	A	A	2.10	.	.	F	1.58	1.79

5

10

15

20

-80-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Phe	588	A	A	2.31	.	.	F	1.24	3.13
Arg	589	A	A	1.64	.	.	F	0.90	2.71
Glu	590	A	A	1.99	.	.	F	0.60	1.08
Gln	591	A	A	1.99	.	.	F	0.90	2.17
Gln	592	A	A	2.04	.	*	F	0.90	2.21
Cys	593	A	A	2.74	.	*	F	1.15	2.00
Glu	594	.	A	.	.	T	.	.	2.04	.	.	F	1.50	1.86
Lys	595	.	A	.	.	T	.	.	1.80	.	.	F	1.75	1.08
Tyr	596	T	.	.	1.80	.	.	.	2.05	3.17
Asn	597	T	T	.	1.56	.	.	.	2.50	2.94
Ala	598	T	T	.	1.91	.	.	.	1.35	2.30
Tyr	599	.	.	B	.	.	T	.	1.91	.	.	.	0.70	2.12
Asn	600	.	.	B	.	.	T	.	1.27	.	*	.	0.75	2.20
Tyr	601	.	.	B	1.51	.	.	.	0.25	2.16
Thr	602	.	.	B	1.17	.	*	F	0.70	2.30
Asp	603	.	.	B	.	.	T	.	1.76	.	*	F	1.75	1.42
Met	604	.	.	B	.	.	T	.	1.19	.	*	F	2.00	1.45
Asp	605	T	T	.	0.38	*	.	F	2.50	0.83
Gly	606	.	.	B	.	.	T	.	0.62	*	*	F	1.85	0.41
Asn	607	.	.	B	B	.	.	.	0.64	*	*	F	0.60	0.72
Leu	608	A	.	.	B	.	.	.	-0.21	*	*	.	-0.10	0.45

5

10

15

20

-81-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	609	.	.	B	B	.	.	.	0.18	*	*	.	-0.35	0.34
Gln	610	.	.	B	B	.	.	.	0.22	*	.	.	-0.60	0.33
Trp	611	.	.	B	B	.	.	.	0.32	*	.	.	-0.60	0.79
Val	612	.	.	B	B	.	.	.	-0.27	*	.	.	-0.45	1.50
Pro	613	.	.	B	.	.	T	.	0.20	*	.	.	-0.20	0.88
Lys	614	.	.	B	.	.	T	.	0.16	*	*	.	-0.20	0.82
Tyr	615	.	.	B	.	.	T	.	-0.14	.	.	.	0.10	0.82
Ala	616	T	T	.	-0.07	*	*	.	0.50	0.71
Gly	617	T	.	.	0.90	*	.	.	0.64	0.55
Val	618	.	.	B	1.11	.	*	.	0.58	0.69
Ser	619	.	.	B	.	.	T	.	1.18	.	*	F	2.32	1.14
Pro	620	.	.	B	.	.	T	.	0.76	.	*	F	2.66	2.26
Arg	621	T	T	.	1.39	.	*	F	3.40	1.63
Asp	622	T	T	.	0.92	.	*	F	3.06	2.43
Arg	623	.	A	.	.	T	.	.	1.08	.	*	F	2.32	1.30
Cys	624	.	A	B	0.71	*	*	F	1.43	0.57
Lys	625	.	A	B	1.03	*	*	.	0.64	0.18
Leu	626	.	A	B	0.33	*	*	.	0.30	0.18
Phe	627	.	A	B	0.44	.	*	.	0.04	0.35
Cys	628	.	A	B	-0.01	.	*	.	0.98	0.34
Arg	629	.	A	B	0.77	*	*	.	1.32	0.41

5

10

15

20

-82-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	630	A	T	.	0.42	*	*	.	2.36	0.92
Arg	631	T	T	.	1.23	.	*	F	3.40	2.31
Gly	632	T	T	.	1.23	.	*	F	3.06	2.04
Arg	633	T	T	.	1.94	.	*	F	2.72	1.75
Ser	634	A	A	0.98	*	*	F	1.58	1.79
Glu	635	A	A	0.87	*	*	F	1.24	1.34
Phe	636	A	A	0.76	*	*	F	0.45	0.59
Lys	637	A	A	0.51	*	*	.	0.30	0.77
Val	638	A	A	0.44	*	*	.	0.30	0.45
Phe	639	A	A	-0.11	.	.	.	0.45	1.03
Glu	640	A	A	-1.00	*	.	.	0.30	0.38
Ala	641	A	.	.	B	.	.	.	-0.30	*	.	.	-0.30	0.36
Lys	642	A	.	.	B	.	.	.	-0.69	.	.	.	0.30	0.70
Val	643	A	.	.	B	.	.	.	-0.14	.	.	.	0.60	0.40
Ile	644	A	.	.	B	.	.	.	-0.26	.	*	F	0.45	0.57
Asp	645	.	.	B	B	.	.	.	-0.92	.	.	F	0.45	0.23
Gly	646	.	.	B	B	.	.	.	-0.68	*	.	F	-0.45	0.17
Thr	647	.	.	B	B	.	.	.	-0.93	*	.	F	-0.15	0.24
Leu	648	.	.	.	B	.	.	C	-0.08	.	.	F	0.05	0.22
Cys	649	.	.	.	B	T	.	.	0.50	*	*	.	0.10	0.39
Gly	650	T	C	-0.31	.	.	F	0.45	0.39

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Pro	651	T	T	.	-0.56	.	.	F	0.65	0.39
Glu	652	A	T	.	-1.13	.	.	F	0.25	0.73
Thr	653	A	T	.	-0.99	.	.	F	0.25	0.52
Leu	654	A	.	.	B	.	.	.	-1.18	*	*	.	-0.30	0.18
Ala	655	.	.	B	B	.	.	.	-0.72	*	*	.	-0.60	0.08
Ile	656	.	.	B	B	.	.	.	-0.86	.	*	.	-0.60	0.10
Cys	657	.	.	B	B	.	.	.	-0.86	.	*	.	-0.60	0.13
Val	658	A	.	.	B	.	.	.	-1.21	.	*	.	-0.30	0.21
Arg	659	.	.	B	B	.	.	.	-1.26	.	*	.	-0.30	0.16
Gly	660	.	.	.	B	T	T	.	-0.62	.	*	F	0.25	0.23
Gln	661	.	.	B	B	.	.	.	-0.32	.	*	F	0.45	0.61
Cys	662	.	.	B	B	.	.	.	0.00	.	*	.	0.30	0.32
Val	663	.	.	B	B	.	.	.	0.19	.	*	.	0.30	0.32
Lys	664	.	.	B	.	.	T	.	0.08	.	*	.	0.10	0.10
Ala	665	.	.	B	.	.	T	.	0.39	*	.	.	0.70	0.30
Gly	666	.	.	B	.	.	T	.	-0.47	*	.	.	0.70	0.56
Cys	667	.	.	B	.	.	T	.	-0.66	*	*	.	0.70	0.21
Asp	668	.	.	B	B	.	.	.	0.20	*	*	.	-0.30	0.15
His	669	.	.	B	B	.	.	.	-0.14	*	.	.	0.30	0.26
Val	670	.	.	B	B	.	.	.	0.23	*	.	.	0.30	0.64
Val	671	.	.	B	B	.	.	.	0.69	*	.	.	0.64	0.59

5

10

15

20

-84-

Res	Pos.	Garnl... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Asp	672	.	.	B	B	.	.	.	1.40	*	.	F	1.13	0.86
Ser	673	.	.	B	.	.	T	.	0.59	*	.	F	2.32	2.31
Pro	674	A	T	.	0.62	*	.	F	2.66	2.56
Arg	675	T	T	.	1.52	*	.	F	3.40	2.56
Lys	676	T	T	.	1.71	*	.	F	3.06	3.82
Leu	677	T	.	.	1.37	*	.	F	2.52	1.33
Asp	678	T	T	.	0.81	*	.	F	2.23	0.67
Lys	679	.	.	B	.	.	T	.	0.36	*	.	F	1.49	0.25
Cys	680	.	.	B	.	.	T	.	-0.10	*	.	.	0.70	0.16
Gly	681	.	.	B	.	.	T	.	-0.49	*	.	.	0.70	0.10
Val	682	.	.	B	0.37	*	.	.	-0.10	0.05
Cys	683	.	.	B	.	.	T	.	0.02	.	.	.	0.10	0.18
Gly	684	T	T	.	-0.02	.	.	F	1.59	0.18
Gly	685	T	T	.	0.34	.	.	F	1.93	0.38
Lys	686	T	T	.	0.02	.	.	F	2.27	0.96
Gly	687	T	.	.	0.99	.	.	F	2.41	0.52
Asn	688	T	T	.	1.70	.	.	F	3.40	1.03
Ser	689	.	.	B	.	.	T	.	1.19	.	.	F	2.66	1.03
Cys	690	.	.	B	.	.	T	.	1.23	.	.	F	2.34	0.77
Arg	691	.	.	B	.	.	T	.	0.84	.	.	F	2.17	0.64
Lys	692	.	.	B	0.89	*	.	F	1.80	0.47

5

10

15

20

-85-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Val	693	.	.	B	.	.	T	.	0.08	*	.	F	1.98	1.18
Ser	694	.	.	B	.	.	T	.	0.07	*	.	F	1.70	0.50
Gly	695	.	.	B	.	.	T	.	0.52	*	.	F	0.93	0.36
Ser	696	.	.	B	.	.	T	.	0.10	*	.	F	0.46	0.75
Leu	697	.	.	B	0.06	.	*	F	0.39	0.81
Thr	698	.	.	B	0.67	.	.	F	0.37	1.31
Pro	699	.	.	B	.	.	T	.	0.62	.	.	F	0.10	1.53
Thr	700	T	T	.	0.72	.	.	F	0.50	1.84
Asn	701	.	.	B	.	.	T	.	1.02	.	.	F	0.10	2.00
Tyr	702	T	T	.	1.83	*	.	.	0.35	2.08
Gly	703	T	T	.	1.26	*	.	.	0.65	2.41
Tyr	704	T	T	.	0.61	*	.	.	0.35	1.05
Asn	705	.	.	B	.	.	T	.	0.61	*	.	.	-0.20	0.50
Asp	706	.	.	B	.	.	T	.	-0.28	*	.	.	0.10	0.72
Ile	707	.	.	B	B	.	.	.	-0.24	*	.	.	-0.60	0.32
Val	708	.	.	B	B	.	.	.	-0.49	.	.	.	-0.30	0.31
Thr	709	.	.	B	B	.	.	.	-0.59	*	.	.	-0.60	0.19
Ile	710	.	.	B	B	.	.	.	-1.18	.	.	.	-0.60	0.27
Pro	711	.	.	B	.	.	T	.	-1.49	*	.	.	-0.20	0.36
Ala	712	.	.	B	.	.	T	.	-0.60	*	.	.	-0.20	0.36
Gly	713	T	C	-0.63	.	*	.	0.00	0.83

5

10

15

20

-86-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	714	T	C	-0.32	.	*	F	0.15	0.38
Thr	715	.	.	B	B	.	.	.	-0.29	.	*	F	0.45	0.62
Asn	716	.	.	B	B	.	.	.	-0.03	.	*	F	-0.15	0.47
Ile	717	.	.	B	B	.	.	.	0.56	.	*	F	0.45	0.92
Asp	718	.	.	B	B	.	.	.	1.01	.	*	F	0.60	1.11
Val	719	.	.	B	B	.	.	.	1.30	.	*	F	0.90	1.35
Lys	720	.	.	B	B	.	.	.	1.58	.	*	F	0.90	2.58
Gln	721	.	.	B	1.37	.	*	F	1.10	2.10
Arg	722	.	.	B	1.91	.	*	F	1.10	4.38
Ser	723	C	1.06	*	*	F	1.30	2.17
His	724	T	C	1.91	*	*	F	1.05	0.93
Pro	725	T	C	1.87	.	*	F	1.33	0.82
Gly	726	T	T	.	1.87	*	*	F	1.21	0.99
Val	727	.	.	B	.	.	T	.	1.41	*	*	F	1.84	1.21
Gln	728	.	.	B	1.71	.	*	F	1.77	0.77
Asn	729	.	.	B	.	T	T	.	1.50	*	.	F	2.80	1.26
Asp	730	T	T	.	0.90	*	.	F	1.92	2.66
Gly	731	T	T	.	0.66	.	.	F	1.64	1.27
Asn	732	.	.	B	.	.	T	.	0.70	.	*	F	0.81	0.80
Tyr	733	.	A	B	0.74	.	.	.	-0.32	0.39
Leu	734	.	A	B	0.43	*	.	.	-0.60	0.79

5

10

15

20

-87-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ala	735	.	A	B	-0.16	*	.	.	-0.60	0.71
Leu	736	.	A	B	0.19	.	.	.	-0.40	0.46
Lys	737	.	A	B	-0.16	.	.	F	0.85	0.93
Thr	738	.	.	B	.	.	T	.	0.09	.	.	F	1.45	0.91
Ala	739	A	T	.	0.66	.	.	F	2.10	1.91
Asp	740	.	.	B	.	.	T	.	0.43	.	.	F	2.00	1.50
Gly	741	.	.	B	.	.	T	.	0.43	.	*	F	1.05	0.86
Gln	742	.	.	B	0.39	.	*	F	0.35	0.70
Tyr	743	.	.	B	0.36	.	*	.	0.30	0.67
Leu	744	.	.	B	0.94	.	*	.	-0.20	0.67
Leu	745	.	.	B	0.13	.	*	.	-0.40	0.63
Asn	746	.	.	B	.	.	T	.	-0.11	.	*	F	-0.05	0.33
Gly	747	T	T	.	-1.00	.	*	F	0.35	0.40
Asn	748	T	C	-1.06	.	*	.	0.00	0.34
Leu	749	T	C	-0.83	.	*	.	0.00	0.29
Ala	750	A	A	B	-0.91	.	*	.	-0.60	0.29
Ile	751	.	A	B	-0.91	*	*	.	-0.60	0.13
Ser	752	.	A	B	-0.57	*	.	.	-0.60	0.27
Ala	753	A	A	-0.57	*	*	.	-0.30	0.46
Ile	754	A	A	-0.64	*	.	.	0.45	1.09
Glu	755	A	A	-0.87	*	.	F	0.45	0.57

5

10

15

20

-88-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Gln	756	A	.	.	B	.	.	.	-0.83	.	*	F	0.45	0.47
Asp	757	A	.	.	B	.	.	.	-0.49	.	*	F	-0.15	0.49
Ile	758	A	.	.	B	.	.	.	-0.24	.	*	.	0.60	0.57
Leu	759	A	.	.	B	.	.	.	0.33	.	*	.	0.30	0.33
Val	760	A	.	.	B	.	.	.	-0.56	.	*	.	0.30	0.28
Lys	761	A	.	.	B	.	.	.	-1.37	.	*	F	-0.45	0.28
Gly	762	.	.	B	B	.	.	.	-1.32	.	*	F	-0.45	0.28
Thr	763	.	.	B	B	.	.	.	-0.68	.	*	F	0.45	0.76
Ile	764	.	.	B	B	.	.	.	-0.17	.	.	F	-0.15	0.59
Leu	765	.	.	B	B	.	.	.	0.34	.	*	.	-0.60	0.80
Lys	766	.	.	B	B	.	.	.	0.00	.	*	F	-0.45	0.55
Tyr	767	.	.	B	.	.	T	.	-0.54	*	*	F	0.40	1.05
Ser	768	T	C	-0.82	*	*	F	0.45	0.89
Gly	769	T	C	-0.24	*	.	F	0.45	0.45
Ser	770	T	C	-0.24	.	*	F	0.15	0.42
Ile	771	.	A	B	-0.29	*	*	.	-0.60	0.26
Ala	772	.	A	B	0.07	*	.	.	-0.30	0.45
Thr	773	.	A	B	-0.44	*	*	.	0.30	0.66
Leu	774	.	A	B	-0.10	*	.	.	-0.30	0.77
Glu	775	A	A	-0.10	*	.	.	0.45	1.32
Arg	776	.	A	B	0.09	.	.	F	0.60	1.23

5

10

15

20

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Leu	777	.	A	.	.	T	.	.	0.79	.	.	F	1.00	1.29
Gln	778	.	A	.	.	T	.	.	0.89	.	.	F	1.30	1.46
Ser	779	.	A	.	.	T	.	.	0.89	.	.	F	1.00	1.15
Phe	780	.	.	B	0.68	*	.	F	0.41	1.15
Arg	781	C	0.57	.	*	F	0.82	1.03
Pro	782	C	1.17	*	.	F	1.63	1.33
Leu	783	T	C	0.36	*	.	F	2.04	2.37
Pro	784	T	C	0.34	*	*	F	2.10	1.00
Glu	785	T	C	0.19	*	*	F	1.29	0.93
Pro	786	.	.	B	.	.	T	.	0.08	*	*	F	0.88	0.84
Leu	787	.	.	B	B	.	.	.	-0.52	.	*	F	0.27	0.94
Thr	788	.	.	B	B	.	.	.	-0.52	.	*	.	-0.09	0.45
Val	789	.	.	B	B	.	.	.	-0.62	.	.	.	-0.60	0.24
Gln	790	.	.	B	B	.	.	.	-1.48	.	.	.	-0.60	0.42
Leu	791	.	.	B	B	.	.	.	-1.48	.	.	.	-0.60	0.21
Leu	792	.	.	B	B	.	.	.	-1.01	.	*	.	-0.60	0.45
Thr	793	.	.	B	B	.	.	.	-0.70	.	*	.	-0.60	0.26
Val	794	.	.	B	.	.	T	.	-0.70	*	.	F	0.25	0.54
Pro	795	.	.	B	.	.	T	.	-1.40	*	.	F	0.25	0.48
Gly	796	.	.	B	.	.	T	.	-0.80	*	.	F	-0.05	0.29
Glu	797	.	.	B	.	.	T	.	-0.20	.	*	F	0.25	0.60

5

10

15

20

-90-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Val	798	.	.	B	0.16	.	*	F	0.05	0.60
Phe	799	.	.	B	0.16	.	*	F	1.00	1.22
Pro	800	.	.	B	.	.	T	.	0.41	*	*	F	1.25	0.52
Pro	801	T	T	.	0.51	*	*	F	2.00	1.41
Lys	802	T	T	.	0.20	*	*	F	1.60	2.55
Val	803	.	.	B	.	.	T	.	0.36	.	*	F	2.00	2.38
Lys	804	.	.	B	B	.	.	.	0.36	.	*	F	0.80	1.33
Tyr	805	.	.	B	B	.	.	.	-0.29	.	*	.	0.00	0.58
Thr	806	.	.	B	B	.	.	.	-0.29	.	*	.	-0.20	0.58
Phe	807	.	.	B	B	.	.	.	-0.33	.	*	.	-0.40	0.45
Phe	808	.	.	B	B	.	.	.	0.52	*	*	.	-0.60	0.46
Val	809	.	.	B	.	.	T	.	-0.38	*	*	.	-0.20	0.53
Pro	810	.	.	B	.	.	T	.	-0.13	.	*	F	-0.05	0.45
Asn	811	T	T	.	-0.52	.	*	F	1.25	0.88
Asp	812	T	T	.	-0.12	.	*	F	1.40	1.02
Val	813	A	-0.02	*	*	F	0.65	0.89
Asp	814	A	0.83	*	*	.	0.50	0.54
Phe	815	A	0.74	.	*	.	0.80	0.57
Ser	816	A	0.44	.	*	.	0.65	1.02
Met	817	A	0.49	.	*	.	1.40	0.82
Gln	818	A	T	.	1.34	.	*	F	2.20	1.89

5

10

15

20

-91-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Ser	819	T	C	1.46	.	*	F	3.00	2.44
Ser	820	T	C	1.57	.	*	F	2.70	4.84
Lys	821	A	T	.	1.56	.	*	F	2.20	2.82
Glu	822	A	1.84	.	*	F	1.70	3.04
Arg	823	A	.	.	B	.	.	.	1.84	*	*	F	1.20	3.27
Ala	824	A	.	.	B	.	.	.	1.26	*	*	F	0.90	2.63
Thr	825	.	.	B	B	.	.	.	0.67	*	*	F	0.60	1.06
Thr	826	.	.	B	B	.	.	.	0.62	*	*	F	-0.15	0.38
Asn	827	.	.	B	B	.	.	.	0.41	*	*	.	-0.60	0.65
Ile	828	.	.	B	B	.	.	.	-0.51	*	*	.	-0.60	0.70
Ile	829	.	.	B	B	.	.	.	-0.73	*	.	.	-0.60	0.40
Gln	830	.	A	B	-0.46	*	.	.	-0.60	0.21
Pro	831	.	A	B	-0.73	*	.	.	-0.60	0.40
Leu	832	.	A	B	-0.73	*	*	.	-0.60	0.57
Leu	833	.	A	B	-0.13	.	.	.	-0.60	0.57
His	834	.	A	B	-0.10	.	*	.	-0.60	0.39
Ala	835	.	A	B	B	.	.	.	-0.91	.	*	.	-0.60	0.35
Gln	836	.	A	B	B	.	.	.	-1.04	.	.	.	-0.60	0.35
Trp	837	.	A	B	B	.	.	.	-0.23	.	.	.	-0.60	0.26
Val	838	.	A	B	B	.	.	.	0.29	.	*	.	-0.60	0.42
Leu	839	.	.	B	.	.	T	.	0.02	*	.	.	-0.20	0.26

5

10

15

20

-92-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emni Surfa...
Gly	840	T	T	.	0.61	*	.	.	0.45	0.33
Asp	841	T	T	.	-0.06	.	.	F	1.15	0.76
Trp	842	T	T	.	-0.07	.	.	F	2.00	0.50
Ser	843	T	C	0.49	*	.	F	2.05	0.67
Glu	844	T	T	.	0.99	.	.	F	2.50	0.54
Cys	845	T	T	.	0.67	.	.	F	1.65	0.74
Ser	846	T	T	.	0.32	.	.	F	2.00	0.30
Ser	847	T	.	.	0.02	.	.	F	1.55	0.17
Thr	848	T	.	.	-0.02	.	.	F	0.70	0.32
Cys	849	T	.	.	-0.31	.	.	F	0.45	0.24
Gly	850	T	T	.	0.36	*	.	.	0.20	0.18
Ala	851	T	T	.	0.77	.	.	.	0.20	0.22
Gly	852	T	T	.	1.18	.	.	.	0.50	0.81
Trp	853	T	T	.	1.18	*	.	.	1.25	1.60
Gln	854	.	.	B	B	.	.	.	0.99	*	.	F	0.60	2.29
Arg	855	.	.	B	B	.	.	.	1.33	*	.	F	0.60	1.72
Arg	856	.	.	B	B	.	.	.	1.26	.	*	F	0.90	2.83
Thr	857	.	.	B	B	.	.	.	1.71	.	.	F	1.05	0.87
Val	858	.	.	B	B	.	.	.	2.00	.	.	.	1.20	0.87
Glu	859	.	.	B	B	.	.	.	1.79	.	.	.	1.50	0.75
Cys	860	T	.	.	1.38	.	*	.	2.40	0.80

5

10

15

20

-93-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Arg	861	T	.	.	0.92	.	.	F	3.00	1.44
Asp	862	T	C	1.23	.	*	F	2.55	0.82
Pro	863	T	T	.	1.50	.	*	F	2.60	2.66
Ser	864	T	T	.	1.20	.	*	F	2.30	1.37
Gly	865	T	T	.	1.28	.	.	F	1.70	1.10
Gln	866	A	0.86	.	*	F	0.05	0.72
Ala	867	.	.	B	0.19	.	*	F	0.05	0.78
Ser	868	.	.	B	0.40	.	*	.	-0.10	0.42
Ala	869	A	0.74	.	*	.	-0.10	0.39
Thr	870	A	T	.	0.50	*	.	.	0.70	0.77
Cys	871	A	T	.	-0.31	*	.	.	0.70	0.58
Asn	872	A	T	.	0.32	*	.	.	0.10	0.48
Lys	873	A	T	.	0.41	.	.	F	0.85	0.66
Ala	874	A	1.00	*	.	F	0.80	1.90
Leu	875	A	1.31	*	.	F	1.10	2.05
Lys	876	A	T	.	1.39	.	.	F	1.30	1.71
Pro	877	A	T	.	1.43	.	.	F	1.30	1.71
Glu	878	A	T	.	1.18	.	.	F	1.30	4.14
Asp	879	A	T	.	1.10	.	.	F	1.30	3.20
Ala	880	A	1.91	.	.	F	1.10	1.11
Lys	881	A	T	.	1.57	.	.	F	1.30	1.11

5

10

15

20

-94-

Res	Pos.	Garni... Alpha	Chou... Alpha	Garni... Beta	Chou... Beta	Garni... Turn	Chou... Turn	Garni... Coil	Kyte... Hydro...	Eisen... Alpha	Eisen... Beta	Karpl... Flexi...	James... Antig...	Emini Surfa...
Pro	882	A	T	.	1.78	*	.	F	1.15	0.89
Cys	883	A	T	.	0.97	*	.	F	1.30	1.53
Glu	884	A	T	.	0.30	.	.	F	1.15	0.63
Ser	885	A	A	0.68	*	.	F	-0.15	0.22
Gln	886	.	A	B	-0.18	*	.	F	-0.15	0.63
Leu	887	.	A	B	-0.36	.	.	.	-0.30	0.30
Cys	888	.	A	B	-0.08	.	.	.	-0.60	0.29
Pro	889	.	A	B	-0.47	.	.	.	-0.60	0.21
Leu	890	.	.	B	-0.56	.	.	.	-0.40	0.33

Detailed Description of the Preferred Embodiments

By screening cDNA libraries with cDNA encoding the anti-angiogenic domain of TSP-1, the present inventors have identified two novel proteins, METH1 and METH2 (also called VEGA-1 and VEGA-2, respectively, for vascular endothelial growth antagonist) which contain the anti-angiogenic domain of TSP-1, a metalloproteinase domain, and a disintegrin-like domain. The present inventors have demonstrated that both METH1 and METH2 have anti-angiogenic activity.

Thus, the present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding a METH1 polypeptide having the amino acid sequence shown in SEQ ID NO:2, which was determined by sequencing a cloned cDNA. The METH1 protein of the present invention shares sequence homology with thrombospondin-1 and pNPI. The nucleotide sequence shown in SEQ ID NO:1 was obtained by sequencing a cDNA clone, which was deposited on January 15, 1998 at the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, and given accession number 209581. The cDNA clone contained in ATCC Deposit No. 209581 contains a METH1 sequence, encoding amino acids 1 to 950 of SEQ ID NO:2.

The present invention also provides isolated nucleic acid molecules comprising a polynucleotide encoding a METH2 polypeptide having the amino acid sequence shown in SEQ ID NO:4, which was partially determined by sequencing a cloned cDNA. The METH2 protein of the present invention shares sequence homology with thrombospondin-1 and pNPI. The nucleotide sequence shown in SEQ ID NO:3 was partially obtained by sequencing a cDNA clone, which was deposited on January 15, 1998 at the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, and given accession number 209582. The cDNA clone contained in ATCC Deposit No. 209582 contains a partial METH2 sequence, encoding amino acids 112-890 of SEQ ID NO:4. A cDNA clone containing the entire METH2 sequence was deposited on March 14, 2000 at the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, and given accession number PTA 1478.

Nucleic Acid Molecules

Some of the nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer (such as the Model 373 from Applied Biosystems, Inc.), and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

Using the information provided herein, such as the nucleotide sequence in SEQ ID NO: 1 or SEQ ID NO:3, a nucleic acid molecule of the present invention encoding a METH1 or METH2 polypeptide may be obtained using standard cloning and screening procedures, such as those for cloning cDNAs using mRNA as starting material. Illustrative of the invention, the nucleic acid molecule described in SEQ ID NO:1 was discovered in a cDNA library derived from human heart and the nucleic acid molecule described in SEQ ID NO:3 was discovered in a cDNA library derived from human lung. The determined nucleotide sequence of the METH1 cDNA of SEQ ID NO:1 contains an open reading frame encoding a protein of about 950 amino acid residues, including a predicted leader sequence of about 28 amino acid residues. The present inventors have determined that the nucleotide sequence of the METH2 cDNA of SEQ ID NO:3 contains an open reading frame encoding a protein of about 890 amino acid residues, including a predicted leader sequence of about 23 amino acid residues.

-97-

The present invention also provides the mature form(s) of the METH1 and METH2 proteins of the present invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species on the protein. Further, it has long been known that the cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide. Therefore, the present invention provides a nucleotide sequence encoding the mature METH1 polypeptide having the amino acid sequence encoded by the cDNA clone contained in the host identified as ATCC Deposit No. 209581 and as shown in SEQ ID NO:2. The present invention also provides a nucleotide sequence encoding the mature METH2 polypeptide having the amino acid sequence as shown in SEQ ID NO:4. By the mature METH1 protein having the amino acid sequence encoded by the cDNA clone contained in the host identified as ATCC Deposit No. 209581 is meant the mature form(s) of the METH1 protein produced by expression in a mammalian cell (e.g., COS cells, as described below) of the complete open reading frame encoded by the human DNA sequence of the clone contained in the vector in the deposited host. As indicated below, the mature METH1 having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581 may or may not differ from the predicted "mature" METH1 protein shown in SEQ ID NO:2 (amino acids from about 29 to about 950) depending on the accuracy of the predicted cleavage site based on computer analysis; and the mature METH2 may or may not differ from the predicted "mature" METH2 protein shown in SEQ ID NO: 4 (amino acids from about 24 to about 890) depending on the accuracy of the predicted cleavage site based on computer analysis. Additionally, the mature form of the protein may then undergo even more processing after the prodomain has been cleaved (e.g., a second cleavage distal to the prodomain, located in the metalloprotease domain/cysteine-rich region). Thus, "mature" forms of the proteins encompass not only those forms produced by cleavage of the prodomain, but also other processed forms of the protein.

Methods for predicting whether a protein has a secretory leader as well as the cleavage point for that leader sequence are available. For instance, the methods of McGeoch (*Virus Res.* 3:271-286 (1985)) and von Heinje (*Nucleic Acids Res.* 14:4683-4690 (1986)) can be used. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. von Heinje, *supra*. However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the predicted amino acid sequence of the complete METH1 and METH2 polypeptides of the present invention were analyzed by a computer program ("PSORT") (K. Nakai and M. Kanehisa, *Genomics* 14:897-911 (1992)), which is an expert system for predicting the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis by the PSORT program predicted the cleavage site between amino acids 28 and 29 in SEQ ID NO:2 and amino acids 23 and 24 in SEQ ID NO:4. Thereafter, the complete amino acid sequences were further analyzed by visual inspection, applying a simple form of the (-1,-3) rule of von Heinje. von Heinje, *supra*. Thus, the leader sequence for the METH1 protein is predicted to consist of amino acid residues from about 1 to about 28 in SEQ ID NO:2, while the mature METH1 protein is predicted to consist of residues from about 29 to about 950; and the leader sequence for the METH2 protein is predicted to consist of amino acid residues from about 1 to about 23 in SEQ ID NO:4, while the mature METH2 protein is predicted to consist of residues from about 24 to about 890. An alternative predicted mature METH1 protein consists of residues 30 to 950 in SEQ ID NO:2. Another alternative predicted mature METH1 protein consists of residues 35 to 950 of SEQ ID NO:2. An alternative predicted mature METH2 protein consists of residues 31 to 890 of SEQ ID NO:4.

As one of ordinary skill would appreciate, due to the possibilities of sequencing errors, as well as the variability of cleavage sites for leaders in different known proteins, the predicted METH1 polypeptide encoded by the deposited cDNA comprises about 950 amino acids, but may be anywhere in the range of 910-990 amino acids; and the predicted leader sequence of this protein is about 28 amino acids, but may be anywhere in the range

-99-

of about 18 to about 38 amino acids. An alternative predicted METH1 polypeptide is shown in SEQ ID NO:125, and comprises an additional 18 amino acid residues on the N-terminus. Also, the predicted METH2 polypeptide comprises about 890 amino acids, but may be anywhere in the range of 850 to about 930 amino acids; and the predicted leader sequence of this protein is about 23 amino acids, but may be anywhere in the range of about 13 to about 33 amino acids.

As indicated, nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA may be double-stranded or single-stranded. Single-stranded DNA or RNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

By "isolated" nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Isolated nucleic acid molecules of the present invention include DNA molecules comprising an open reading frame (ORF) shown in SEQ ID NO:1; DNA molecules comprising the coding sequence for the mature METH1 protein; and DNA molecules which comprise a sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode the METH1 protein. Also included are DNA molecules comprising an open reading frame (ORF) shown in SEQ ID NO:3; DNA molecules comprising the coding sequence for the mature METH2 protein; and DNA molecules which comprise a sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode the METH2

-100-

protein. Of course, the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate such degenerate variants.

Polynucleotides of the present invention encompass not only polynucleotides encoding the full length sequence, but polynucleotides encoding the mature, proprotein, processed forms of the protein, deletion mutants, substitution variants, allelic variants, analogs, derivatives, etc.

In another aspect, the invention provides isolated nucleic acid molecules encoding the METH1 or METH2 polypeptides having an amino acid sequence as encoded by the cDNA clones contained in the plasmids deposited as ATCC Deposit No. 209581 on January 15, 1998 or ATCC Deposit No. 209582 on January 15, 1998, respectively; or METH2 polypeptides having the amino acid sequence as encoded by the cDNA clone contained in the plasmid deposited as ATCC Deposit No. PTA 1478 on March 14, 2000. In a further embodiment, nucleic acid molecules are provided encoding the mature METH1 or METH2 polypeptide or the full-length METH1 or METH2 polypeptide lacking the N-terminal methionine. The invention also provides an isolated nucleic acid molecule having the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3 or the nucleotide sequence of the METH1 or METH2 cDNA contained in the above-described deposited clones, or a nucleic acid molecule having a sequence complementary to one of the above sequences. Such isolated molecules, particularly DNA molecules, are useful as probes for gene mapping, by *in situ* hybridization with chromosomes, and for detecting expression of the METH1 or METH2 gene in human tissue, for instance, by Northern blot analysis.

The present invention is further directed to fragments of the isolated nucleic acid molecules described herein. By a fragment of an isolated nucleic acid molecule having the nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3 is intended fragments at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length which are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800,

-101-

2900, or 3000 nt in length are also useful according to the present invention as are fragments corresponding to most, if not all, of the nucleotide sequence of the deposited cDNA or as shown in SEQ ID NO:1 or SEQ ID NO:3. By a fragment at least 20 nt in length, for example, is intended fragments which include 20 or more contiguous bases from the nucleotide sequence of the deposited cDNA or the nucleotide sequence as shown in SEQ ID NO:1 or SEQ ID NO:3.

Preferred nucleic acid fragments of the present invention include nucleic acid molecules encoding epitope-bearing portions of the METH1 or METH2 protein. Methods for determining epitope-bearing portions of the METH1 and METH2 proteins are described in detail below.

Other preferred nucleic acid fragments of the present invention include nucleic acid molecules encoding: the metalloprotease domain of METH1, amino acids 235 to 459 in SEQ ID NO:2; the disintegrin domain of METH1, amino acids 460 to 544 in SEQ ID NO:2; the first TSP-like domain of METH1, amino acids 545 to 598 in SEQ ID NO:2; the second TSP-like domain of METH1, amino acids 841 to 894 in SEQ ID NO:2; the third TSP-like domain of METH1, amino acids 895 to 934 in SEQ ID NO:2; amino acids 536 to 613 in SEQ ID NO:2; amino acids 549 to 563 in SEQ ID NO:2; the metalloprotease domain of METH2, amino acids 214 to 439 in SEQ ID NO:4; the disintegrin domain of METH2, amino acids 440 to 529 in SEQ ID NO:4; the first TSP-like domain of METH2, amino acids 530 to 583 in SEQ ID NO:4; the second TSP-like domain of METH2, amino acids 837 to 890 in SEQ ID NO:4; amino acids 280 to 606 in SEQ ID NO:4; and amino acids 529 to 548 in SEQ ID NO:4; and nucleic acid molecules encoding combinations of these domains.

Thus, preferred embodiments include a nucleic acid molecule encoding a METH1 or METH2 protein lacking the signal sequence (cleavage occurs for METH1 somewhere about 1-24 to about 1-34 and about 1-23 to about 1-30 for METH2); a METH1 or METH2 protein lacking the signal sequence and the prodomain (cleavage for the prodomain can occur in METH1 between amino acids about 232 to 236 and in METH2 between amino acids about 211 to 215); a METH1 or METH2 protein lacking the signal sequence, the prodomain, and the metalloprotease domain; a METH1 or METH2 protein lacking the signal sequence, the prodomain, the metalloprotease domain, and the cysteine

rich domain; a METH1 or METH2 protein lacking the signal sequence, the prodomain, the metalloprotease domain, cysteine rich domain and TSP1; a METH1 or METH2 protein lacking the signal sequence, the prodomain, the metalloprotease domain, cysteine rich domain, TSP1 and TSP2. Also preferred are polypeptides encoded by such nucleic acids.

Similarly, preferred embodiments include a nucleic acid encoding a METH1 protein lacking TSP3; a METH1 protein lacking TSP2 and TSP3; a METH1 protein lacking TSP3, TSP2, and TSP1; a METH1 protein lacking the cysteine-rich domain, TSP1, TSP2, and TSP3; a METH1 protein lacking the metalloprotease domain, the cysteine-rich domain, TSP1, TSP2 and TSP3; and a METH1 protein lacking the prodomain, the metalloprotease domain, the cysteine-rich domain, TSP1, TSP2, and TSP3; a METH2 protein lacking TSP2; a METH2 protein lacking TSP1 and TSP2; a METH2 protein lacking the cysteine-rich domain, TSP1 and TSP2; a METH2 protein lacking the metalloprotease domain, the cysteine-rich domain, TSP1 and TSP2; and a METH2 protein lacking the prodomain, the metalloprotease domain, the cysteine-rich domain, TSP1 and TSP2. Also preferred are polypeptide encoded by such nucleic acids.

Also preferred are nucleic acids encoding any combination of METH1 domains. For example, nucleic acid molecule encoding polypeptides comprising the following domains of METH1 are preferred: signal sequence and prodomain; signal sequence, prodomain and metalloprotease domain; signal sequence and metalloprotease domain; signal sequence, prodomain, metalloprotease domain, and cysteine rich domain; signal sequence and cysteine rich domain; signal sequence, metalloprotease domain and cysteine rich domain; signal sequence, prodomain, and cysteine rich domain; signal sequence, prodomain, metalloprotease domain, cysteine rich domain, and TSP1; signal sequence and TSP1; signal sequence, prodomain and TSP1; signal sequence, prodomain, metalloprotease domain and TSP1; signal sequence, metalloprotease domain, and TSP1; signal sequence, prodomain, cysteine rich domain and TSP1; signal sequence, cysteine rich domain and TSP1; signal sequence, metalloprotease domain, cysteine rich domain and TSP1; signal sequence, prodomain, metalloprotease domain, cysteine rich domain, TSP1 and TSP2; signal sequence and TSP2; signal sequence, prodomain and TSP2; signal sequence, metalloprotease domain and TSP2; signal sequence, cysteine rich

domain and TSP2; signal sequence, TSP1 and TSP2; signal sequence, prodomain,
metalloprotease domain and TSP2; signal sequence, prodomain, cysteine rich domain and
TSP2; signal sequence, prodomain, TSP1 and TSP2; signal sequence, metalloprotease
domain, cysteine rich domain and TSP2; signal sequence, metalloprotease domain, TSP1
5 and TSP2; signal sequence, metalloprotease domain, cysteine rich domain, TSP1 and
TSP2; signal sequence, prodomain, cysteine rich domain, TSP1 and TSP2; signal
sequence and TSP3; signal sequence, prodomain and TSP3; signal sequence, prodomain,
metalloprotease domain and TSP3; signal sequence, metalloprotease domain and TSP3;
signal sequence, prodomain, metalloprotease domain, cysteine rich domain and TSP3;
10 signal sequence, cysteine rich domain and TSP3; signal sequence, prodomain, cysteine
rich domain and TSP3; signal sequence, prodomain, metalloprotease domain, cysteine
rich domain, TSP1 and TSP3; signal sequence, TSP1 and TSP3; signal sequence,
prodomain, TSP1 and TSP3; signal sequence, prodomain, metalloprotease domain, TSP1
and TSP3; signal sequence, prodomain, cysteine rich domain, TSP1 and TSP3; signal
15 sequence, TSP2 and TSP3; signal sequence, prodomain, cysteine rich domain, TSP1,
TSP2 and TSP3; signal sequence, prodomain, metalloprotease domain, TSP1, TSP2 and
TSP3; signal sequence, metalloprotease domain, TSP1, TSP2 and TSP3; signal sequence,
TSP1, TSP2 and TSP3; signal sequence, metalloprotease domain, cysteine rich domain,
TSP1, TSP2 and TSP3; signal sequence, prodomain, metalloprotease domain, TSP1 and
20 TSP2; signal sequence, prodomain, metalloprotease domain, cysteine rich domain, and
TSP2; signal sequence, prodomain, metalloprotease domain, cysteine rich domain, TSP2
and TSP3; signal sequence, TSP1, TSP2 and TSP3; signal sequence, cysteine rich
domain, TSP1 and TSP2; signal sequence, cysteine rich domain, TSP1 and TSP3; signal
sequence, cysteine rich domain, TSP2 and TSP3; signal sequence, cysteine rich domain,
25 TSP1, TSP2, and TSP3; signal sequence, metalloprotease domain, cysteine rich domain,
and TSP3; signal sequence, metalloprotease domain, cysteine rich domain, TSP1 and
TSP3; signal sequence, metalloprotease domain, cysteine rich domain, TSP2 and TSP3;
signal sequence, metalloprotease domain, TSP1 and TSP3; signal sequence,
metalloprotease domain, TSP2 and TSP3; signal sequence, prodomain, metalloprotease
30 domain, TSP1 and TSP3; signal sequence, prodomain, metalloprotease domain, TSP2
and TSP3; prodomain and metalloprotease domain; prodomain and cysteine rich domain;

-104-

prodomain and TSP1; prodomain and TSP2; prodomain and TSP3; prodomain,
metalloprotease domain and cysteine rich domain; prodomain, metalloprotease domain
and TSP1; prodomain, metalloprotease domain and TSP2; prodomain, metalloprotease
domain and TSP3; prodomain, metalloprotease domain, cysteine rich domain and TSP1;
5 prodomain, metalloprotease domain, cysteine rich domain and TSP2; prodomain,
metalloprotease domain, cysteine rich domain and TSP3; prodomain, cysteine rich
domain and TSP1; prodomain, cysteine rich domain and TSP2; prodomain, cysteine rich
domain and TSP3; prodomain, metalloprotease domain, cysteine rich domain, TSP1 and
TSP2; prodomain, metalloprotease domain, cysteine rich domain, TSP1, TSP2 and TSP3;
10 prodomain, cysteine rich domain, TSP1 and TSP2; prodomain, metalloprotease domain,
TSP1 and TSP2; prodomain, metalloprotease domain, cysteine rich domain, TSP2 and
TSP3; prodomain, cysteine rich domain, TSP1 and TSP3; prodomain, cysteine rich
domain, TSP2 and TSP3; prodomain, TSP1 and TSP2; prodomain, TSP1 and TSP3;
prodomain, TSP2 and TSP3; prodomain, metalloprotease domain, TSP1 and TSP2;
15 prodomain, metalloprotease domain, TSP1 and TSP3; prodomain, metalloprotease
domain, TSP2 and TSP3; prodomain, metalloprotease domain, cysteine rich domain,
TSP2 and TSP3; prodomain, TSP1 and TSP2; prodomain, TSP1 and TSP3; prodomain,
TSP2 and TSP3; prodomain, metalloprotease domain, TSP1 and TSP2; prodomain,
metalloprotease domain, TSP1 and TSP3; prodomain, metalloprotease domain, TSP2 and
20 TSP3; prodomain, metalloprotease domain, cysteine domain, TSP1 and TSP3;
prodomain, cysteine rich domain, TSP1, TSP2 and TSP3; prodomain, metalloprotease
domain, TSP1, TSP2, and TSP3; metalloprotease domain and cysteine rich domain;
metalloprotease domain and TSP1; metalloprotease domain and TSP2; metalloprotease
domain and TSP3; metalloprotease domain, cysteine rich domain and TSP1;
25 metalloprotease domain, cysteine rich domain and TSP2; metalloprotease domain,
cysteine rich domain and TSP3; metalloprotease domain, cysteine rich domain, TSP1 and
TSP2; metalloprotease domain, cysteine rich domain, TSP1, TSP2 and TSP3;
metalloprotease domain, cysteine rich domain, TSP1 and TSP3; metalloprotease domain,
cysteine rich domain, TSP2 and TSP3; metalloprotease domain, TSP1 and TSP2;
30 metalloprotease domain, TSP1 and TSP3; metalloprotease domain, TSP2 and TSP3;
metalloprotease domain, TSP1, TSP2 and TSP3; cysteine rich domain and TSP1; cysteine

rich domain and TSP2; cysteine rich domain and TSP3; cysteine rich domain, TSP1 and TSP2; cysteine rich domain, TSP1 and TSP3; cysteine rich domain, TSP2 and TSP3; cysteine rich domain, TSP1, TSP2 and TSP3; TSP1 and TSP2; TSP1 and TSP3; TSP2 and TSP3; and/or TSP1, TSP2 and TSP3. These domains may be present in the METH1 molecule in the same order or a different order than in the naturally occurring molecule. Also preferred are polypeptides encoded by such nucleic acids.

Also preferred are nucleic acids encoding any combination of METH2 domains. For example, nucleic acid molecule encoding polypeptides comprising the following domains of METH2 are preferred: signal sequence and prodomain; signal sequence, prodomain and metalloprotease domain; signal sequence and metalloprotease domain; signal sequence, prodomain, metalloprotease domain, and cysteine rich domain; signal sequence and cysteine rich domain; signal sequence, metalloprotease domain and cysteine rich domain; signal sequence, prodomain, and cysteine rich domain; signal sequence, prodomain, metalloprotease domain, cysteine rich domain, and TSP1; signal sequence and TSP1; signal sequence, prodomain and TSP1; signal sequence, prodomain, metalloprotease domain and TSP1; signal sequence, metalloprotease domain, and TSP1; signal sequence, prodomain, cysteine rich domain and TSP1; signal sequence, cysteine rich domain and TSP1; signal sequence, metalloprotease domain, cysteine rich domain and TSP1; signal sequence, prodomain, metalloprotease domain, cysteine rich domain, TSP1 and TSP2; signal sequence and TSP2; signal sequence, prodomain and TSP2; signal sequence, metalloprotease domain and TSP2; signal sequence, cysteine rich domain and TSP2; signal sequence, TSP1 and TSP2; signal sequence, prodomain, metalloprotease domain and TSP2; signal sequence, prodomain, cysteine rich domain and TSP2; signal sequence, prodomain, TSP1 and TSP2; signal sequence, metalloprotease domain, cysteine rich domain and TSP2; signal sequence, metalloprotease domain, TSP1 and TSP2; signal sequence, metalloprotease domain, cysteine rich domain, TSP1 and TSP2; signal sequence, prodomain, cysteine rich domain, TSP1 and TSP2; signal sequence, prodomain, metalloprotease domain, TSP1 and TSP2; signal sequence, prodomain, metalloprotease domain, cysteine rich domain, and TSP2; signal sequence, cysteine rich domain, TSP1 and TSP2; prodomain and metalloprotease domain; prodomain and cysteine rich domain; prodomain and TSP1; prodomain and TSP2;

-106-

prodomain, metalloprotease domain and cysteine rich domain; prodomain, metalloprotease domain and TSP1; prodomain, metalloprotease domain and TSP2; prodomain, metalloprotease domain, cysteine rich domain and TSP1; prodomain, metalloprotease domain, cysteine rich domain and TSP2; prodomain, cysteine rich domain and TSP1; prodomain, cysteine rich domain and TSP2; prodomain, metalloprotease domain, cysteine rich domain, TSP1 and TSP2; prodomain, cysteine rich domain, TSP1 and TSP2; prodomain, metalloprotease domain, TSP1 and TSP2; prodomain, metalloprotease domain, TSP1 and TSP2; prodomain, TSP1 and TSP2; prodomain, metalloprotease domain, TSP1 and TSP2; metalloprotease domain and cysteine rich domain; metalloprotease domain and TSP1; metalloprotease domain and TSP2; metalloprotease domain, cysteine rich domain and TSP1; metalloprotease domain, cysteine rich domain and TSP2; metalloprotease domain, cysteine rich domain, TSP1 and TSP2; metalloprotease domain, TSP1 and TSP2; cysteine rich domain and TSP1; cysteine rich domain and TSP2; cysteine rich domain, TSP1 and TSP2. These domains may be present in the METH2 molecule in the same order or a different order than in the naturally occurring molecule. Also preferred are polypeptides encoded by such nucleic acids.

Additionally, METH1 and METH2 domains may be combined to form hybrid molecules. Any domain of METH1 may be combined with any domain of METH2 to form a hybrid molecule. For example, the TSP1 domain of METH1 may be replaced with the TSP1 domain of METH2 to form a hybrid molecule, leaving the remainder of the METH1 molecule intact. Also, the TSP1 domain of METH1 may be replaced with the TSP2 domain of METH2 to form a hybrid molecule, leaving the remainder of the METH1 molecule intact. Additionally, the TSP1 domain of METH1 may be combined with the TSP2 domain of METH2 to form a hybrid molecule, without any additional METH1 and/or METH2 sequences. These domains may be present in the same or a different order as occurs in the naturally occurring molecules. Also preferred are polypeptides encoded by such nucleic acids.

Further embodiments include nucleic acids encoding a METH1 or METH2 polypeptide in which: one or more TSP domains have been replaced with other known TSP domains; the metalloprotease domain has been replaced with another known

-107-

metalloprotease domain; the disintegrin domain has been replaced with another known disintegrin domain. One or more domains may be replaced in this manner. For example, the both the metalloprotease and disintegrin domains may be replaced. Alternatively, all three TSP domains may be replaced. Also preferred are polypeptides encoded by such nucleic acids.

Preferred embodiments are polynucleotides encoding the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 except for several, 5-10, 1-5, 1-3, 1-2 or 1 amino acid residues are substituted, deleted or added, in any combination.

In addition, the present inventors have identified the following cDNA clones related to portions of the sequence shown in SEQ ID NO:1: HOUQC17RA (SEQ ID NO:14), HPLBM11R (SEQ ID NO:15), HGBI07R (SEQ ID NO:16), HNTMA49R (SEQ ID NO:17), HNALE27R (SEQ ID NO:18), and HIBDB45R (SEQ ID NO:19).

The following public ESTs, which relate to portions of SEQ ID NO:1, have also been identified: D67076 (SEQ ID NO:20), AB001735 (SEQ ID NO:21), X14787 (SEQ ID NO:22), U64857 (SEQ ID NO:23), X04665 (SEQ ID NO:24), M64866 (SEQ ID NO:25), L07803 (SEQ ID NO:26), U08006 (SEQ ID NO:27), M16974 (SEQ ID NO:28), L13855 (SEQ ID NO:29), AL021529 (SEQ ID NO:30), D86074 (SEQ ID NO:31), L05390 (SEQ ID NO:32), Z69361 (SEQ ID NO:33), X99599 (SEQ ID NO:34), AF018073 (SEQ ID NO:35), L23760 (SEQ ID NO:36), Z46970 (SEQ ID NO:37), AC004449 (SEQ ID NO:38), Z69589 (SEQ ID NO:39), Z22279 (SEQ ID NO:40), X17524 (SEQ ID NO:41), AI126019 (SEQ ID NO:103), AI571069 (SEQ ID NO:104), AI148739 (SEQ ID NO:105), AI335849 (SEQ ID NO:106), AA677116 (SEQ ID NO:107), H27128 (SEQ ID NO:108), AA368429 (SEQ ID NO:109), AA345812 (SEQ ID NO:110), AA373718 (SEQ ID NO:111), AI537518 (SEQ ID NO:112), N88341 (SEQ ID NO:113), C03600 (SEQ ID NO:114), AA066142 (SEQ ID NO:115), AI40095 (SEQ ID NO:94), AA288689 (SEQ ID NO:116), AI464076 (SEQ ID NO:97), R13547 (SEQ ID NO:117), R19976 (SEQ ID NO:118), Z43925 (SEQ ID NO:119), AA670987 (SEQ ID NO:120), AA635657 (SEQ ID NO:96), W24878 (SEQ ID NO:121), W47316 (SEQ ID NO:122), W35345 (SEQ ID NO:123), and N27243 (SEQ ID NO:124).

The present inventors have also identified the following cDNA clones related to portions of SEQ ID NO:3: HCE4D69FP02 (SEQ ID NO:42), HIBDB45F (SEQ ID

NO:43), HKIXH64R (SEQ ID NO:44), HIBDB45R (SEQ ID NO:19), HCE3Z95R (SEQ ID NO:45), HTLEQ90R (SEQ ID NO:46), HMWEF45R (SEQ ID NO:47), HTOFC34RA (SEQ ID NO:48), HHFDI20R (SEQ ID NO:49), HMSHY47R (SEQ ID NO:50), HCESF90R (SEQ ID NO:51), HMCAO46R (SEQ ID NO:52), HTTAQ67R (SEQ ID NO:53), HFKCF19F (SEQ ID NO:54), HMCAS31R (SEQ ID NO:55), HMWGP26R (SEQ ID NO:56), HLHTP36R (SEQ ID NO:57), HE8AN11R (SEQ ID NO:58), HEONN73R (SEQ ID NO:59), HBNBG53R (SEQ ID NO:60), and HMSCH94R (SEQ ID NO:61).

The following public ESTs, which relate to portions of the sequence shown in SEQ ID NO:3, have also been identified: D67076 (SEQ ID NO:20), AB001735 (SEQ ID NO:21), AB005287 (SEQ ID NO:62), X87619 (SEQ ID NO:63), X14787 (SEQ ID NO:22), X04665 (SEQ ID NO:24), M87276 (SEQ ID NO:64), M62458 (SEQ ID NO:65), AB002364 (SEQ ID NO:66), AB005297 (SEQ ID NO:67), X69161 (SEQ ID NO:68), X16619 (SEQ ID NO:69), I36448 (SEQ ID NO:70), L12260 (SEQ ID NO:71), I36352 (SEQ ID NO:72), X15898 (SEQ ID NO:73), I07789 (SEQ ID NO:74), I08144 (SEQ ID NO:75), U31814 (SEQ ID NO:76), AF001444 (SEQ ID NO:77), AI400905 (SEQ ID NO:94), AI378857 (SEQ ID NO:95), AA635657 (SEQ ID NO:96), AI464076 (SEQ ID NO:97), CO6578 (SEQ ID NO:98), AA855532 (SEQ ID NO:99), H11881 (SEQ ID NO:100), AA350801 (SEQ ID NO:101), and AA350802 (SEQ ID NO:102).

In specific embodiments, the polynucleotides of the invention are less than 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, or 7.5 kb in length. In a further embodiment, polynucleotides of the invention comprise at least 15 contiguous nucleotides of METH1 or METH2 coding sequence, but do not comprise all or a portion of any METH1 or METH2 intron. In another embodiment, the nucleic acid comprising METH1 or METH2 coding sequence does not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the METH1 or METH2 gene in the genome).

In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a portion of the polynucleotide in a nucleic acid molecule of the invention described above, for instance, the cDNA clones contained in ATCC Deposit No. 209581; ATCC Deposit No. 209582; or ATCC Deposit No. PTA 1478. By "stringent hybridization

conditions" is intended overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (750 mM NaCl, 75mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

5 By a polynucleotide which hybridizes to a "portion" of a polynucleotide is intended a polynucleotide (either DNA or RNA) hybridizing to at least about 15 nucleotides (nt), and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably about 30, 40, 50, 60 or 70 nt of the reference polynucleotide. These are useful as diagnostic probes and primers as discussed above
10 and in more detail below.

By a portion of a polynucleotide of "at least 20 nt in length," for example, is intended 20 or more contiguous nucleotides from the nucleotide sequence of the reference polynucleotide (e.g., the deposited cDNAs or the nucleotide sequence as shown in SEQ ID NO:1 or SEQ ID NO:3). Of course, a polynucleotide which hybridizes only to a poly
15 A sequence (such as the 3' terminal poly(A) tract of the METH1 or METH2 cDNA shown in SEQ ID NO:1 and SEQ ID NO:3, respectively) or to a complementary stretch of T (or U) residues, would not be included in a polynucleotide of the invention used to hybridize to a portion of a nucleic acid of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the
20 complement thereof (e.g., practically any double-stranded cDNA clone).

Also contemplated are nucleic acid molecules that hybridize to the METH1 or METH2 polynucleotides at moderately high stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages
25 of formamide result in lowered stringency); salt conditions, or temperature. For example, moderately high stringency conditions include an overnight incubation at 3° C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower
30 stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

-110-

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

The METH1 or METH2 polynucleotide can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, METH1 or METH2 polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the METH1 or METH2 polynucleotides can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. METH1 or METH2 polynucleotides may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

"SEQ ID NO:1" refers to a METH1 polynucleotide sequence while "SEQ ID NO:2" refers to a METH1 polypeptide sequence. "SEQ ID NO:3" refers to a METH2 polynucleotide sequence while "SEQ ID NO:4" refers to a METH2 polypeptide sequence.

-111-

As indicated, nucleic acid molecules of the present invention which encode a METH1 or METH2 polypeptide may include, but are not limited to, those encoding the amino acid sequence of the mature polypeptide, by itself; the coding sequence for the mature polypeptide and additional sequences, such as those encoding the leader or secretory sequence, such as a pre-, or pro- or prepro- protein sequence; the coding sequence of the mature polypeptide, with or without the aforementioned additional coding sequences, together with additional, non-coding sequences, including for example, but not limited to introns and non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences that play a role in transcription, mRNA processing, including splicing and polyadenylation signals, for example - ribosome binding and stability of mRNA; an additional coding sequence which codes for additional amino acids, such as those which provide additional functionalities. Thus, the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused polypeptide. In certain preferred embodiments of this aspect of the invention, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described in Gentz *et al.*, *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. The "HA" tag is another peptide useful for purification which corresponds to an epitope derived from the influenza hemagglutinin protein, which has been described by Wilson *et al.*, *Cell* 37:767-778 (1984). As discussed below, other such fusion proteins include the METH1 or METH2 fused to Fc at the - or C-terminus. Other fusion proteins include METH1 or METH2 fused to Flag at the - or C-terminus. Other fusion proteins include METH1 fragments or METH2 fragments fused to Flag or Fc at the - or C-terminus. Particularly preferred are fragments of METH1 or METH2, such as H541-Q894, M1-P799, F236-E614, or K801-Q950 of SEQ ID NO:2, fused to Fc or Flag at the - or C-terminus.

As stated above, METH1 or METH 2 may be fused with the FLAG polypeptide sequence (see U.S. Pat. No. 4,851,341; see also Hopp *et al.*, *Bio/Technology* 6:1204, 1988). The FLAG polypeptide sequence is highly antigenic and provides an epitope for binding by a specific monoclonal antibody, enabling rapid purification of the expressed

-112-

recombinant protein. This sequence is also specifically cleaved by bovine mucosal enterokinase at the residue immediately following the Asp-Lys pairing.

The present invention further relates to variants of the nucleic acid molecules of the present invention, which encode portions, analogs or derivatives of the METH1 or METH2 protein. Variants may occur naturally, such as a natural allelic variant. By an "allelic variant" is intended one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. Lewin, B., ed., *Genes II*, John Wiley & Sons, New York (1985). Non-naturally occurring variants may be produced using art-known mutagenesis techniques.

Such variants include those produced by nucleotide substitutions, deletions or additions, which may involve one or more nucleotides. The variants may be altered in coding regions, non-coding regions, or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the METH1 or METH2 protein or portions thereof. Also especially preferred in this regard are conservative substitutions.

Further embodiments of the invention include isolated nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 80% identical, and more preferably at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to: a nucleotide sequence encoding the polypeptide having the amino acid sequence in SEQ ID NO:2; a nucleotide sequence encoding the polypeptide having the amino acid sequence in SEQ ID NO:2, but lacking the N-terminal methionine; a nucleotide sequence encoding the polypeptide having the amino acid sequence at positions from about 29 to about 950 in SEQ ID NO:2; a nucleotide sequence encoding the polypeptide having the amino acid sequence at position from about 30 to about 950 in SEQ ID NO:2; a nucleotide sequence encoding the polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581; a nucleotide sequence encoding the mature METH1 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581; a nucleotide sequence encoding amino acids 235 to 459 in SEQ ID NO:2 (the

metalloprotease domain of METH1); a nucleotide sequence encoding amino acids 460 to 544 in SEQ ID NO:2 (the disintegrin domain of METH1); a nucleotide sequence encoding amino acids 545 to 598 in SEQ ID NO:2 (the first TSP-like domain of METH1); a nucleotide sequence encoding amino acids 841 to 894 in SEQ ID NO:2 (the second TSP-like domain of METH1); a nucleotide sequence encoding amino acids 895 to 934 in SEQ ID NO:2 (the third TSP-like domain of METH1); a nucleotide sequence encoding amino acids 536 to 613 in SEQ ID NO:2; a nucleotide sequence encoding amino acids 549 to 563 in SEQ ID NO:2; a nucleotide sequence encoding the polypeptide having the amino acid sequence in SEQ ID NO:4; a nucleotide sequence encoding the polypeptide having the amino acid sequence in SEQ ID NO:4, but lacking the N-terminal methionine; a nucleotide sequence encoding the polypeptide having the amino acid sequence at positions from about 24 to about 890 in SEQ ID NO:4; a nucleotide sequence encoding the polypeptide having the amino acid sequence at positions from about 112 to about 890 in SEQ ID NO:4; a nucleotide sequence encoding the polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209582 or PTA 1478; a nucleotide sequence encoding the mature METH2 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209582 or PTA 1478; a nucleotide sequence encoding amino acids 214 to 439 in SEQ ID NO:4 (the metalloprotease domain of METH2); a nucleotide sequence encoding amino acids 440 to 529 in SEQ ID NO:4 (the disintegrin domain of METH2); a nucleotide sequence encoding amino acids 530 to 583 in SEQ ID NO:4 (the first TSP-like domain of METH2); a nucleotide sequence encoding amino acids 837 to 890 in SEQ ID NO:4 (the second TSP-like domain of METH2); a nucleotide sequence encoding amino acids 280 to 606 in SEQ ID NO:4; a nucleotide sequence encoding amino acids 529 to 548 in SEQ ID NO:4; or a nucleotide sequence complementary to any of the above nucleotide sequences.

By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence encoding a METH1 or METH2 polypeptide is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the METH1 or

METH2 polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular nucleic acid molecule is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3 or to the nucleotide sequence of the deposited cDNA clones can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). Bestfit uses the local homology algorithm of Smith and Waterman, *Advances in Applied Mathematics* 2: 482-489 (1981), to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference nucleotide sequence and that gaps in homology of up to 5% of the total number of nucleotides in the reference sequence are allowed.

A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag *et al.*, *Comp. Appl. Biosci.* 6:237-245 (1990). In a sequence alignment, the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch

-115-

Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

5 If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of
10 the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by the results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the
15 purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence are calculated for the purposes of manually adjusting the percent identity score.

20 For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and, therefore, the FASTDB alignment does not show a match/alignment of the first 10 bases at the 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence), so 10% is subtracted from the percent identity score calculated by the FASTDB program.
25 If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal, so that there are no bases on the 5' or 3' ends of the subject sequence which are not matched/aligned with the query. In this case, the percent identity calculated by FASTDB is not manually corrected. Once again, only
30 bases 5' and 3' of the subject sequence which are not matched/aligned with the query

sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The present application is directed to nucleic acid molecules at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence shown in SEQ ID NO:1 or SEQ ID NO:3 or to the nucleic acid sequence of the deposited cDNAs, irrespective of whether they encode a polypeptide having METH1 or METH2 activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having METH1 or METH2 activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase chain reaction (PCR) primer. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having METH1 or METH2 activity include, *inter alia*, (1) isolating the METH1 or METH2 gene or allelic variants thereof in a cDNA library; (2) *in situ* hybridization (e.g., "FISH") to metaphase chromosomal spreads to provide precise chromosomal location of the METH1 or METH2 gene, as described in Verma *et al.*, *Human Chromosomes: A Manual of Basic Techniques*, Pergamon Press, New York (1988); and (3) Northern Blot analysis for detecting METH1 or METH2 mRNA expression in specific tissues.

Preferred, however, are nucleic acid molecules having sequences at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence shown in SEQ ID NO:1 or SEQ ID NO:3 or to a nucleic acid sequence of the deposited cDNAs which do, in fact, encode a polypeptide having METH1 or METH2 protein activity. By "a polypeptide having METH1 activity" is intended polypeptides exhibiting METH1 activity in a particular biological assay. For example, METH1 protein activity can be measured using the chorioallantoic membrane assay (Iruela-Arispe *et al.*, *Thrombosis and Haemostasis* 78(1):672-677 (1997)) or the cornea pocket assay (Tolsma *et al.*, *J. Cell. Biol.* 122:497-511 (1993)), both described in Example 4, below. By "a polypeptide having METH2 activity" is intended polypeptides exhibiting METH2 activity in a particular biological assay. For example, METH2 protein activity can also be measured using the chorioallantoic membrane assay (Iruela-Arispe *et al.*, *Thrombosis and Haemostasis* 78(1):672-677 (1997)) or the cornea pocket assay (Tolsma *et al.*, *J. Cell. Biol.* 122:497-511 (1993)), both described in Example 4, below.

Briefly, in the chorioallantoic assay, the potentially anti-angiogenic compound of interest is added to type I collagen pellets (Vitrogen), along with an angiogenic growth factor, such as bFGF. The samples are mixed and placed onto nylon meshes, and allowed to polymerize. After polymerization is complete, the meshes are placed onto the chorioallantoic membrane of 12 day old chick embryos and placed at 37°C for 24 hours. The embryos are then injected with a fluorescent agent, such as FITC-dextran, and the meshes are fixed and mounted for observation under a fluorescent microscope.

In the cornea pocket assay, hydron pellets containing the compound of interest and an angiogenic growth factor, such as bFGF, are implanted 1 to 2mm from the limbus of the cornea of rats or mice. Response is examined after a period of time, for example 5 days. The extent of angiogenesis is evaluated by measuring the capillaries migrating from the limb of the cornea.

Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a nucleic acid sequence of the deposited cDNAs or a nucleic acid sequence shown in SEQ ID NO:1 or SEQ ID NO:3 will encode a polypeptide "having METH1 or METH2 protein activity." In fact, since degenerate variants of these nucleotide sequences all encode the same polypeptide, this will be clear to the skilled artisan even without performing the above described comparison assay. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having METH1 or METH2 protein activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid).

In particular, there are provided METH2 nucleic acids with one or more of the following nucleic acid substitutions and/or deletions: "C" substituted for "T" at position 3; "C" substituted for "T" at position 32; "C" substituted for "T" at position 37; "TGC" at positions 65-67 deleted; "C" substituted for "T" at position 199; "C" substituted for "T" at position 303; "C" substituted for "T" at position 306; "C" substituted for "T" at position 309; "C" substituted for "T" at position 950; "C" substituted for "G" at position

-118-

1292; "C" substituted for "T" at position 1577; and/or "G" substituted for "A" at position 2377. Likewise, there are provided METH2 polypeptides with one or more of the following amino acid substitutions and/or deletions: "L" substituted for "F" at position 2; "P" substituted for "L" at position 12; "L" substituted for "F" at position 14; "L" at position 23 deleted; "P" substituted for "L" at position 318; "A" substituted for "G" at position 432; "A" substituted for "V" at position 527; and/or "A" substituted for "T" at position 794.

For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990), wherein the authors indicate that proteins are surprisingly tolerant of amino acid substitutions.

Vectors and Host Cells

The present invention also relates to vectors which include the isolated DNA molecules of the present invention, host cells which are genetically engineered with the recombinant vectors, and the production of METH1 or METH2 polypeptides or fragments thereof by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged *in vitro* using an appropriate packaging cell line and then transduced into host cells.

The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli lac*, *trp* and *tac* promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a

-119-

ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will preferably include a translation initiating at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

5 As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and
10 *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

15 Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG
20 available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled
25 artisan.

In addition to the use of expression vectors in the practice of the present invention, the present invention further includes novel expression vectors comprising operator and promoter elements operatively linked to nucleotide sequences encoding a protein of interest. One example of such a vector is pHE4-5 which is described in detail
30 below.

-120-

As summarized in Figures 8 and 9, components of the pHE4-5 vector (SEQ ID NO:12) include: 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two *lac* operator sequences, 5) a Shine-Delgarno sequence, 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences were made synthetically. Synthetic production of nucleic acid sequences is well known in the art. CLONTECH 95/96 Catalog, pages 215-216, CLONTECH, 1020 East Meadow Circle, Palo Alto, CA 94303. A nucleotide sequence encoding METH1 (SEQ ID NO:2) or METH2 (SEQ ID NO:4), is operatively linked to the promoter and operator by inserting the nucleotide sequence between the NdeI and Asp718 sites of the pHE4-5 vector.

As noted above, the pHE4-5 vector contains a *lacIq* gene. *LacIq* is an allele of the *lacI* gene which confers tight regulation of the *lac* operator. Amann, E. *et al.*, *Gene* 69:301-315 (1988); Stark, M., *Gene* 51:255-267 (1987). The *lacIq* gene encodes a repressor protein which binds to *lac* operator sequences and blocks transcription of downstream (*i.e.*, 3') sequences. However, the *lacIq* gene product dissociates from the *lac* operator in the presence of either lactose or certain lactose analogs, *e.g.*, isopropyl B-D-thiogalactopyranoside (IPTG). METH1 or METH2 thus is not produced in appreciable quantities in uninduced host cells containing the pHE4-5 vector. Induction of these host cells by the addition of an agent such as IPTG, however, results in the expression of the METH1 or METH2 coding sequence.

The promoter/operator sequences of the pHE4-5 vector (SEQ ID NO:13) comprise a T5 phage promoter and two *lac* operator sequences. One operator is located 5' to the transcriptional start site and the other is located 3' to the same site. These operators, when present in combination with the *lacIq* gene product, confer tight repression of down-stream sequences in the absence of a *lac* operon inducer, *e.g.*, IPTG. Expression of operatively linked sequences located down-stream from the *lac* operators may be induced by the addition of a *lac* operon inducer, such as IPTG. Binding of a *lac* inducer to the *lacIq* proteins results in their release from the *lac* operator sequences and the initiation of transcription of operatively linked sequences. *Lac* operon regulation of

gene expression is reviewed in Devlin, T., TEXTBOOK OF BIOCHEMISTRY WITH CLINICAL CORRELATIONS, 4th Edition (1997), pages 802-807.

The pHE4 series of vectors contain all of the components of the pHE4-5 vector except for the METH1 or METH2 coding sequence. Features of the pHE4 vectors include optimized synthetic T5 phage promoter, *lac* operator, and Shine-Delgarno sequences. Further, these sequences are also optimally spaced so that expression of an inserted gene may be tightly regulated and high level of expression occurs upon induction.

Among known bacterial promoters suitable for use in the production of proteins of the present invention include the *E. coli lacI* and *lacZ* promoters, the T3 and T7 promoters, the *gpt* promoter, the lambda PR and PL promoters and the *trp* promoter. Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous Sarcoma Virus (RSV), and metallothionein promoters, such as the mouse metallothionein-I promoter.

The pHE4-5 vector also contains a Shine-Delgarno sequence 5' to the AUG initiation codon. Shine-Delgarno sequences are short sequences generally located about 10 nucleotides up-stream (*i.e.*, 5') from the AUG initiation codon. These sequences essentially direct prokaryotic ribosomes to the AUG initiation codon.

Thus, the present invention is also directed to expression vectors useful for the production of the proteins of the present invention. This aspect of the invention is exemplified by the pHE4-5 vector (SEQ ID NO:12).

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis *et al.*, *Basic Methods In Molecular Biology* (1986). It is specifically contemplated that METH1 and/or METH2 polypeptides may in fact be expressed by a host cell lacking a recombinant vector.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino

acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to solubilize proteins. For example, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is thoroughly advantageous for use in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232 262). On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified in the advantageous manner described. This is the case when the Fc portion proves to be a hindrance to use in therapy and diagnosis, for example when the fusion protein is to be used as an antigen for immunizations. In drug discovery, for example, human proteins, such as the hIL-5-receptor, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. See, D. Bennett *et al.*, *J. Mol. Recognition* 8:52-58 (1995) and K. Johanson *et al.*, *J. of Biol. Chem.* 270(16):9459-9471 (1995).

The METH1 or METH2 protein can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

METH1 and/or METH2 polypeptides, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic

procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the METH1 and/or METH2 polypeptides may be glycosylated or may be non-glycosylated. In addition, METH1 and/or METH2 polypeptides may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express METH1 and/or METH2 protein in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O₂. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O₂. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., *et al.*, *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., *et al.*, *Yeast* 5:167-77 (1989); Tschopp, J.F., *et al.*, *Nucl. Acids Res.* 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a METH1 and/or METH2 polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding a METH1 and/or METH2 polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular

Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a METH1 and/or METH2 protein of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a METH1 and/or METH2 polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., METH1 and/or METH2 coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with METH1 and/or METH2 polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous METH1 and/or METH2 polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous METH1 and/or METH2 polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (*see, e.g.*, U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller *et al.*, *Proc. Natl. Acad.*

Sci. USA 86:8932-8935 (1989); and Zijlstra *et al.*, *Nature* 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (*e.g.*, see Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H. Freeman & Co., N.Y., and Hunkapiller, M., *et al.*, 1984, *Nature* 310:105-111). For example, a peptide corresponding to a fragment of the METH1 and/or METH2 polypeptides of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the METH1 and/or METH2 polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, α -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, γ -Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoro-amino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

Non-naturally occurring variants may be produced using art-known mutagenesis techniques, which include, but are not limited to oligonucleotide mediated mutagenesis, alanine scanning, PCR mutagenesis, site directed mutagenesis (*see, e.g.*, Carter *et al.*, *Nucl. Acids Res.* 13:4331 (1986); and Zoller *et al.*, *Nucl. Acids Res.* 10:6487 (1982)), cassette mutagenesis (*see, e.g.*, Wells *et al.*, *Gene* 34:315 (1985)), restriction selection mutagenesis (*see, e.g.*, Wells *et al.*, *Philos. Trans. R. Soc. London SerA* 317:415 (1986)).

The invention encompasses METH1 and/or METH2 polypeptides which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any
5 of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH_4 ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include,
10 for example, e.g., N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic,
15 fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of METH1 and/or METH2 which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U. S. Patent No. 4,179,337). The chemical moieties for derivitization may be selected from
20 water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired
25 therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other
30

known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.

As noted above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Patent No. 5,643,575; Morpurgo *et al.*, *Appl. Biochem. Biotechnol.* 56:59-72 (1996); Vorobjev *et al.*, *Nucleosides Nucleotides* 18:2745-2750 (1999); and Caliceti *et al.*, *Bioconjug. Chem.* 10:638-646 (1999), the disclosures of each of which are incorporated herein by reference.

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik *et al.*, *Exp. Hematol.* 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to a proteins via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid,

-128-

glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (or peptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be attached to the protein either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins are described in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992); Francis *et al.*, *Intern. J. of Hematol.* 68:1-18 (1998); U.S. Patent No. 4,002,531; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.

One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride ($\text{ClSO}_2\text{CH}_2\text{CF}_3$). Upon reaction of protein with tresylated MPEG, polyethylene glycol is directly attached to amine groups of the protein. Thus, the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoroethane sulphonyl group.

-129-

Polyethylene glycol can also be attached to proteins using a number of different intervening linkers. For example, U.S. Patent No. 5,612,460, the entire disclosure of which is incorporated herein by reference, discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives. A number additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in WO 98/32466, the entire disclosure of which is incorporated herein by reference. Pegylated protein products produced using the reaction chemistries set out herein are included within the scope of the invention.

The number of polyethylene glycol moieties attached to each protein of the invention (*i.e.*, the degree of substitution) may also vary. For example, the pegylated proteins of the invention may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, or more polyethylene glycol molecules. Similarly, the average degree of substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein molecule. Methods for determining the degree of substitution are discussed, for example, in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992).

The METH1 and/or METH2 polypeptides of the invention may be in monomers or multimers (*i.e.*, dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the METH1 and/or METH2 polypeptides of the invention, their preparation, and compositions (preferably, pharmaceutical compositions) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only METH1 and/or METH2 polypeptides of the invention (including METH1 and/or METH2 fragments,

-130-

variants, splice variants, and fusion proteins, as described herein). These homomers may contain METH1 and/or METH2 polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only METH1 and/or METH2 polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing METH1 and/or METH2 polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (e.g., containing METH1 and/or METH2 polypeptides having identical or different amino acid sequences) or a homotrimer (e.g., containing METH1 and/or METH2 polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (i.e., polypeptides of different proteins) in addition to the METH1 and/or METH2 polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked by, for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the METH1 and/or METH2 polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in SEQ ID NO:2 or 4, or contained in the polypeptide encoded by either the clone HATCK89 or the clones deposited as ATCC

Deposit No. 209581 or 209582 or PTA 1478). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation.

5 Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a METH1 and/or METH2 fusion protein. In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence

10 contained in a METH1 and/or METH2-Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another Fibroblast Growth Factor family member that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication No. WO

15 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional

20 recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers

25 were originally identified in several DNA-binding proteins (Landschulz *et al.*, *Science* 240:1759, (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO

30 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or

-132-

trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe *et al.* (*FEBS Letters* 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the

multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

METH1 and METH2 Polypeptides and Fragments

The invention further provides an isolated METH1 polypeptide having the amino acid sequence encoded by the deposited cDNA, or the amino acid sequence in SEQ ID NO:2, or a peptide or polypeptide comprising a portion of the above polypeptides. The invention also provides an isolated METH2 polypeptide having the amino acid sequence encoded by the deposited cDNA, or the amino acid sequence in SEQ ID NO:4, or a peptide or polypeptide comprising a portion of the above polypeptides.

Polypeptides of the present invention encompass not only full length polypeptides, but the mature, proprotein, processed forms of the protein, deletion mutants, substitution variants, allelic variants, analogs, derivatives, etc.

METH1 or METH2 polypeptides can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The METH1 or METH2 polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in the METH1 or METH2 polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given METH1 or METH2 polypeptide. Also, a given METH1 or METH2 polypeptide may contain many types of modifications. METH1 or METH2 polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic METH1 or METH2 polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter *et al.*, *Meth Enzymol* 182:626-646 (1990); Rattan *et al.*, *Ann NY Acad Sci* 663:48-62 (1992).)

-135-

It will be recognized in the art that some amino acid sequences of the METH1 and METH2 polypeptides can be varied without significant effect of the structure or function of the protein. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the protein which determine activity.

5 The present inventors have shown that METH1 and METH2 inhibit angiogenesis *in vitro* and *in vivo*. METH1 and METH2 each contain a metalloprotease domain, a disintegrin domain, and TSP-like domains. The metalloprotease domain may be catalytically active. The disintegrin domain may play a role in inhibiting angiogenesis by interacting with integrins, since integrins are essential for the mediation of both
10 proliferative and migratory signals. The present inventors have shown that peptides derived from the TSP-like domains of METH1 and METH2 inhibit angiogenesis *in vitro* and *in vivo*.

 Thus, the invention further includes variations of the METH1 polypeptide which show substantial METH1 polypeptide activity or which include regions of METH1
15 protein such as the protein portions discussed below; and variations of the METH2 polypeptide which show substantial METH2 polypeptide activity or which include regions of METH2 protein such as the protein portions discussed below. Such mutants include deletions, insertions, inversions, repeats, and type substitutions. As indicated above, guidance concerning which amino acid changes are likely to be phenotypically
20 silent can be found in Bowie, J.U., *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990).

 Thus, the fragment, derivative or analog of the polypeptide of SEQ ID NO:2 or SEQ ID NO:4, or that encoded by the deposited cDNA, may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino
25 acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the
30 additional amino acids are fused to the mature polypeptide, such as an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for

purification of the mature polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

Of particular interest are substitutions of charged amino acids with another charged amino acid and with neutral or negatively charged amino acids. The latter results in proteins with reduced positive charge to improve the characteristics of the METH1 or METH2 proteins. The prevention of aggregation is highly desirable. Aggregation of proteins not only results in a loss of activity but can also be problematic when preparing pharmaceutical formulations, because they can be immunogenic. (Pinckard *et al.*, *Clin. Exp. Immunol.* 2:331-340 (1967); Robbins *et al.*, *Diabetes* 36:838-845 (1987); Cleland *et al.*, *Crit. Rev. Therapeutic Drug Carrier Systems* 10:307-377 (1993)).

As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein (see Table 3).

TABLE 3. Conservative Amino Acid Substitutions.

Aromatic	Phenylalanine Tryptophan Tyrosine
Hydrophobic	Leucine Isoleucine Valine
Polar	Glutamine Asparagine
Basic	Arginine Lysine Histidine
Acidic	Aspartic Acid Glutamic Acid
Small	Alanine Serine Threonine Methionine Glycine

-137-

Of course, the number of amino acid substitutions a skilled artisan would make depends on many factors, including those described above. Generally speaking, the number of amino acid substitutions for any given METH1 or METH2 polypeptide will not be more than 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1.

5 In particular, preferred METH1 molecules contain one or more of the following conservative substitutions: M1 replaced with A, G, I, L, S, T, or V; G2 replaced with A, I, L, S, T, M, or V; N3 replaced with Q; A4 replaced with G, I, L, S, T, M, or V; E5 replaced with D; R6 replaced with H, or K; A7 replaced with G, I, L, S, T, M, or V; G9 replaced with A, I, L, S, T, M, or V; S10 replaced with A, G, I, L, T, M, or V; R11 replaced with H, or K; S12 replaced with A, G, I, L, T, M, or V; F13 replaced with W, or Y; G14 replaced with A, I, L, S, T, M, or V; V16 replaced with A, G, I, L, S, T, or M; T18 replaced with A, G, I, L, S, M, or V; L19 replaced with A, G, I, S, T, M, or V; L20 replaced with A, G, I, S, T, M, or V; L21 replaced with A, G, I, S, T, M, or V; L22 replaced with A, G, I, S, T, M, or V; A23 replaced with G, I, L, S, T, M, or V; A24 replaced with G, I, L, S, T, M, or V; A25 replaced with G, I, L, S, T, M, or V; L26 replaced with A, G, I, S, T, M, or V; L27 replaced with A, G, I, S, T, M, or V; A28 replaced with G, I, L, S, T, M, or V; V29 replaced with A, G, I, L, S, T, or M; S30 replaced with A, G, I, L, T, M, or V; D31 replaced with E; A32 replaced with G, I, L, S, T, M, or V; L33 replaced with A, G, I, S, T, M, or V; G34 replaced with A, I, L, S, T, M, or V; R35 replaced with H, or K; S37 replaced with A, G, I, L, T, M, or V; E38 replaced with D; E39 replaced with D; D40 replaced with E; E41 replaced with D; E42 replaced with D; L43 replaced with A, G, I, S, T, M, or V; V44 replaced with A, G, I, L, S, T, or M; V45 replaced with A, G, I, L, S, T, or M; E47 replaced with D; L48 replaced with A, G, I, S, T, M, or V; E49 replaced with D; R50 replaced with H, or K; A51 replaced with G, I, L, S, T, M, or V; G53 replaced with A, I, L, S, T, M, or V; H54 replaced with K, or R; G55 replaced with A, I, L, S, T, M, or V; T56 replaced with A, G, I, L, S, M, or V; T57 replaced with A, G, I, L, S, M, or V; R58 replaced with H, or K; L59 replaced with A, G, I, S, T, M, or V; R60 replaced with H, or K; L61 replaced with A, G, I, S, T, M, or V; H62 replaced with K, or R; A63 replaced with G, I, L, S, T, M, or V; F64 replaced with W, or Y; D65 replaced with E; Q66 replaced with N; Q67 replaced with N; L68 replaced with A, G, I, S, T, M, or V; D69 replaced with E; L70 replaced with A, G, I, S,

-138-

T, M, or V; E71 replaced with D; L72 replaced with A, G, I, S, T, M, or V; R73 replaced with H, or K; D75 replaced with E; S76 replaced with A, G, I, L, T, M, or V; S77 replaced with A, G, I, L, T, M, or V; F78 replaced with W, or Y; L79 replaced with A, G, I, S, T, M, or V; A80 replaced with G, I, L, S, T, M, or V; G82 replaced with A, I, L, S, T, M, or V; F83 replaced with W, or Y; T84 replaced with A, G, I, L, S, M, or V; L85 replaced with A, G, I, S, T, M, or V; Q86 replaced with N; N87 replaced with Q; V88 replaced with A, G, I, L, S, T, or M; G89 replaced with A, I, L, S, T, M, or V; R90 replaced with H, or K; K91 replaced with H, or R; S92 replaced with A, G, I, L, T, M, or V; G93 replaced with A, I, L, S, T, M, or V; S94 replaced with A, G, I, L, T, M, or V; E95 replaced with D; T96 replaced with A, G, I, L, S, M, or V; L98 replaced with A, G, I, S, T, M, or V; E100 replaced with D; T101 replaced with A, G, I, L, S, M, or V; D102 replaced with E; L103 replaced with A, G, I, S, T, M, or V; A104 replaced with G, I, L, S, T, M, or V; H105 replaced with K, or R; F107 replaced with W, or Y; Y108 replaced with F, or W; S109 replaced with A, G, I, L, T, M, or V; G110 replaced with A, I, L, S, T, M, or V; T111 replaced with A, G, I, L, S, M, or V; V112 replaced with A, G, I, L, S, T, or M; N113 replaced with Q; G114 replaced with A, I, L, S, T, M, or V; D115 replaced with E; S117 replaced with A, G, I, L, T, M, or V; S118 replaced with A, G, I, L, T, M, or V; A119 replaced with G, I, L, S, T, M, or V; A120 replaced with G, I, L, S, T, M, or V; A121 replaced with G, I, L, S, T, M, or V; L122 replaced with A, G, I, S, T, M, or V; S123 replaced with A, G, I, L, T, M, or V; L124 replaced with A, G, I, S, T, M, or V; E126 replaced with D; G127 replaced with A, I, L, S, T, M, or V; V128 replaced with A, G, I, L, S, T, or M; R129 replaced with H, or K; G130 replaced with A, I, L, S, T, M, or V; A131 replaced with G, I, L, S, T, M, or V; F132 replaced with W, or Y; Y133 replaced with F, or W; L134 replaced with A, G, I, S, T, M, or V; L135 replaced with A, G, I, S, T, M, or V; G136 replaced with A, I, L, S, T, M, or V; E137 replaced with D; A138 replaced with G, I, L, S, T, M, or V; Y139 replaced with F, or W; F140 replaced with W, or Y; I141 replaced with A, G, L, S, T, M, or V; Q142 replaced with N; L144 replaced with A, G, I, S, T, M, or V; A146 replaced with G, I, L, S, T, M, or V; A147 replaced with G, I, L, S, T, M, or V; S148 replaced with A, G, I, L, T, M, or V; E149 replaced with D; R150 replaced with H, or K; L151 replaced with A, G, I, S, T, M, or V; A152 replaced with G, I, L, S, T, M, or V; T153 replaced with A, G, I, L, S, M, or V; A154 replaced

-139-

with G, I, L, S, T, M, or V; A155 replaced with G, I, L, S, T, M, or V; G157 replaced
with A, I, L, S, T, M, or V; E158 replaced with D; K159 replaced with H, or R; A162
replaced with G, I, L, S, T, M, or V; L164 replaced with A, G, I, S, T, M, or V; Q165
replaced with N; F166 replaced with W, or Y; H167 replaced with K, or R; L168 replaced
5 with A, G, I, S, T, M, or V; L169 replaced with A, G, I, S, T, M, or V; R170 replaced
with H, or K; R171 replaced with H, or K; N172 replaced with Q; R173 replaced with
H, or K; Q174 replaced with N; G175 replaced with A, I, L, S, T, M, or V; D176 replaced
with E; V177 replaced with A, G, I, L, S, T, or M; G178 replaced with A, I, L, S, T, M,
or V; G179 replaced with A, I, L, S, T, M, or V; T180 replaced with A, G, I, L, S, M, or
10 V; G182 replaced with A, I, L, S, T, M, or V; V183 replaced with A, G, I, L, S, T, or M;
V184 replaced with A, G, I, L, S, T, or M; D185 replaced with E; D186 replaced with E;
E187 replaced with D; R189 replaced with H, or K; T191 replaced with A, G, I, L, S, M,
or V; G192 replaced with A, I, L, S, T, M, or V; K193 replaced with H, or R; A194
replaced with G, I, L, S, T, M, or V; E195 replaced with D; T196 replaced with A, G, I,
15 L, S, M, or V; E197 replaced with D; D198 replaced with E; E199 replaced with D; D200
replaced with E; E201 replaced with D; G202 replaced with A, I, L, S, T, M, or V; T203
replaced with A, G, I, L, S, M, or V; E204 replaced with D; G205 replaced with A, I, L,
S, T, M, or V; E206 replaced with D; D207 replaced with E; E208 replaced with D; G209
replaced with A, I, L, S, T, M, or V; Q211 replaced with N; W212 replaced with F, or Y;
20 S213 replaced with A, G, I, L, T, M, or V; Q215 replaced with N; D216 replaced with E;
A218 replaced with G, I, L, S, T, M, or V; L219 replaced with A, G, I, S, T, M, or V;
Q220 replaced with N; G221 replaced with A, I, L, S, T, M, or V; V222 replaced with A,
G, I, L, S, T, or M; G223 replaced with A, I, L, S, T, M, or V; Q224 replaced with N;
T226 replaced with A, G, I, L, S, M, or V; G227 replaced with A, I, L, S, T, M, or V;
25 T228 replaced with A, G, I, L, S, M, or V; G229 replaced with A, I, L, S, T, M, or V;
S230 replaced with A, G, I, L, T, M, or V; I231 replaced with A, G, L, S, T, M, or V;
R232 replaced with H, or K; K233 replaced with H, or R; K234 replaced with H, or R;
R235 replaced with H, or K; F236 replaced with W, or Y; V237 replaced with A, G, I,
L, S, T, or M; S238 replaced with A, G, I, L, T, M, or V; S239 replaced with A, G, I, L,
30 T, M, or V; H240 replaced with K, or R; R241 replaced with H, or K; Y242 replaced with
F, or W; V243 replaced with A, G, I, L, S, T, or M; E244 replaced with D; T245 replaced

-140-

with A, G, I, L, S, M, or V; M246 replaced with A, G, I, L, S, T, or V; L247 replaced
with A, G, I, S, T, M, or V; V248 replaced with A, G, I, L, S, T, or M; A249 replaced
with G, I, L, S, T, M, or V; D250 replaced with E; Q251 replaced with N; S252 replaced
with A, G, I, L, T, M, or V; M253 replaced with A, G, I, L, S, T, or V; A254 replaced
5 with G, I, L, S, T, M, or V; E255 replaced with D; F256 replaced with W, or Y; H257
replaced with K, or R; G258 replaced with A, I, L, S, T, M, or V; S259 replaced with A,
G, I, L, T, M, or V; G260 replaced with A, I, L, S, T, M, or V; L261 replaced with A, G,
I, S, T, M, or V; K262 replaced with H, or R; H263 replaced with K, or R; Y264 replaced
with F, or W; L265 replaced with A, G, I, S, T, M, or V; L266 replaced with A, G, I, S,
10 T, M, or V; T267 replaced with A, G, I, L, S, M, or V; L268 replaced with A, G, I, S, T,
M, or V; F269 replaced with W, or Y; S270 replaced with A, G, I, L, T, M, or V; V271
replaced with A, G, I, L, S, T, or M; A272 replaced with G, I, L, S, T, M, or V; A273
replaced with G, I, L, S, T, M, or V; R274 replaced with H, or K; L275 replaced with A,
G, I, S, T, M, or V; Y276 replaced with F, or W; K277 replaced with H, or R; H278
15 replaced with K, or R; S280 replaced with A, G, I, L, T, M, or V; I281 replaced with A,
G, L, S, T, M, or V; R282 replaced with H, or K; N283 replaced with Q; S284 replaced
with A, G, I, L, T, M, or V; V285 replaced with A, G, I, L, S, T, or M; S286 replaced
with A, G, I, L, T, M, or V; L287 replaced with A, G, I, S, T, M, or V; V288 replaced
with A, G, I, L, S, T, or M; V289 replaced with A, G, I, L, S, T, or M; V290 replaced
20 with A, G, I, L, S, T, or M; K291 replaced with H, or R; I292 replaced with A, G, L, S,
T, M, or V; L293 replaced with A, G, I, S, T, M, or V; V294 replaced with A, G, I, L, S,
T, or M; I295 replaced with A, G, L, S, T, M, or V; H296 replaced with K, or R; D297
replaced with E; E298 replaced with D; Q299 replaced with N; K300 replaced with H,
or R; G301 replaced with A, I, L, S, T, M, or V; E303 replaced with D; V304 replaced
25 with A, G, I, L, S, T, or M; T305 replaced with A, G, I, L, S, M, or V; S306 replaced with
A, G, I, L, T, M, or V; N307 replaced with Q; A308 replaced with G, I, L, S, T, M, or V;
A309 replaced with G, I, L, S, T, M, or V; L310 replaced with A, G, I, S, T, M, or V;
T311 replaced with A, G, I, L, S, M, or V; L312 replaced with A, G, I, S, T, M, or V;
R313 replaced with H, or K; N314 replaced with Q; F315 replaced with W, or Y; N317
30 replaced with Q; W318 replaced with F, or Y; Q319 replaced with N; K320 replaced with
H, or R; Q321 replaced with N; H322 replaced with K, or R; N323 replaced with Q; S326

-141-

replaced with A, G, I, L, T, M, or V; D327 replaced with E; R328 replaced with H, or K;
D329 replaced with E; A330 replaced with G, I, L, S, T, M, or V; E331 replaced with D;
H332 replaced with K, or R; Y333 replaced with F, or W; D334 replaced with E; T335
replaced with A, G, I, L, S, M, or V; A336 replaced with G, I, L, S, T, M, or V; I337
5 replaced with A, G, L, S, T, M, or V; L338 replaced with A, G, I, S, T, M, or V; F339
replaced with W, or Y; T340 replaced with A, G, I, L, S, M, or V; R341 replaced with H,
or K; Q342 replaced with N; D343 replaced with E; L344 replaced with A, G, I, S, T, M,
or V; G346 replaced with A, I, L, S, T, M, or V; S347 replaced with A, G, I, L, T, M, or
V; Q348 replaced with N; T349 replaced with A, G, I, L, S, M, or V; D351 replaced with
10 E; T352 replaced with A, G, I, L, S, M, or V; L353 replaced with A, G, I, S, T, M, or V;
G354 replaced with A, I, L, S, T, M, or V; M355 replaced with A, G, I, L, S, T, or V;
A356 replaced with G, I, L, S, T, M, or V; D357 replaced with E; V358 replaced with A,
G, I, L, S, T, or M; G359 replaced with A, I, L, S, T, M, or V; T360 replaced with A, G,
I, L, S, M, or V; V361 replaced with A, G, I, L, S, T, or M; D363 replaced with E; S365
15 replaced with A, G, I, L, T, M, or V; R366 replaced with H, or K; S367 replaced with A,
G, I, L, T, M, or V; S369 replaced with A, G, I, L, T, M, or V; V370 replaced with A, G,
I, L, S, T, or M; I371 replaced with A, G, L, S, T, M, or V; E372 replaced with D; D373
replaced with E; D374 replaced with E; G375 replaced with A, I, L, S, T, M, or V; L376
replaced with A, G, I, S, T, M, or V; Q377 replaced with N; A378 replaced with G, I, L,
20 S, T, M, or V; A379 replaced with G, I, L, S, T, M, or V; F380 replaced with W, or Y;
T381 replaced with A, G, I, L, S, M, or V; T382 replaced with A, G, I, L, S, M, or V;
A383 replaced with G, I, L, S, T, M, or V; H384 replaced with K, or R; E385 replaced
with D; L386 replaced with A, G, I, S, T, M, or V; G387 replaced with A, I, L, S, T, M,
or V; H388 replaced with K, or R; V389 replaced with A, G, I, L, S, T, or M; F390
25 replaced with W, or Y; N391 replaced with Q; M392 replaced with A, G, I, L, S, T, or
V; H394 replaced with K, or R; D395 replaced with E; D396 replaced with E; A397
replaced with G, I, L, S, T, M, or V; K398 replaced with H, or R; Q399 replaced with N;
A401 replaced with G, I, L, S, T, M, or V; S402 replaced with A, G, I, L, T, M, or V;
L403 replaced with A, G, I, S, T, M, or V; N404 replaced with Q; G405 replaced with A,
30 I, L, S, T, M, or V; V406 replaced with A, G, I, L, S, T, or M; N407 replaced with Q;
Q408 replaced with N; D409 replaced with E; S410 replaced with A, G, I, L, T, M, or V;

H411 replaced with K, or R; M412 replaced with A, G, I, L, S, T, or V; M413 replaced with A, G, I, L, S, T, or V; A414 replaced with G, I, L, S, T, M, or V; S415 replaced with A, G, I, L, T, M, or V; M416 replaced with A, G, I, L, S, T, or V; L417 replaced with A, G, I, S, T, M, or V; S418 replaced with A, G, I, L, T, M, or V; N419 replaced with Q;
5 L420 replaced with A, G, I, S, T, M, or V; D421 replaced with E; H422 replaced with K, or R; S423 replaced with A, G, I, L, T, M, or V; Q424 replaced with N; W426 replaced with F, or Y; S427 replaced with A, G, I, L, T, M, or V; S430 replaced with A, G, I, L, T, M, or V; A431 replaced with G, I, L, S, T, M, or V; Y432 replaced with F, or W; M433 replaced with A, G, I, L, S, T, or V; I434 replaced with A, G, L, S, T, M, or V;
10 T435 replaced with A, G, I, L, S, M, or V; S436 replaced with A, G, I, L, T, M, or V; F437 replaced with W, or Y; L438 replaced with A, G, I, S, T, M, or V; D439 replaced with E; N440 replaced with Q; G441 replaced with A, I, L, S, T, M, or V; H442 replaced with K, or R; G443 replaced with A, I, L, S, T, M, or V; E444 replaced with D; L446 replaced with A, G, I, S, T, M, or V; M447 replaced with A, G, I, L, S, T, or V; D448
15 replaced with E; K449 replaced with H, or R; Q451 replaced with N; N452 replaced with Q; I454 replaced with A, G, L, S, T, M, or V; Q455 replaced with N; L456 replaced with A, G, I, S, T, M, or V; G458 replaced with A, I, L, S, T, M, or V; D459 replaced with E; L460 replaced with A, G, I, S, T, M, or V; G462 replaced with A, I, L, S, T, M, or V; T463 replaced with A, G, I, L, S, M, or V; S464 replaced with A, G, I, L, T, M, or V;
20 Y465 replaced with F, or W; D466 replaced with E; A467 replaced with G, I, L, S, T, M, or V; N468 replaced with Q; R469 replaced with H, or K; Q470 replaced with N; Q472 replaced with N; F473 replaced with W, or Y; T474 replaced with A, G, I, L, S, M, or V; F475 replaced with W, or Y; G476 replaced with A, I, L, S, T, M, or V; E477 replaced with D; D478 replaced with E; S479 replaced with A, G, I, L, T, M, or V; K480 replaced
25 with H, or R; H481 replaced with K, or R; D484 replaced with E; A485 replaced with G, I, L, S, T, M, or V; A486 replaced with G, I, L, S, T, M, or V; S487 replaced with A, G, I, L, T, M, or V; T488 replaced with A, G, I, L, S, M, or V; S490 replaced with A, G, I, L, T, M, or V; T491 replaced with A, G, I, L, S, M, or V; L492 replaced with A, G, I, S, T, M, or V; W493 replaced with F, or Y; T495 replaced with A, G, I, L, S, M, or V; G496
30 replaced with A, I, L, S, T, M, or V; T497 replaced with A, G, I, L, S, M, or V; S498 replaced with A, G, I, L, T, M, or V; G499 replaced with A, I, L, S, T, M, or V; G500

-143-

replaced with A, I, L, S, T, M, or V; V501 replaced with A, G, I, L, S, T, or M; L502 replaced with A, G, I, S, T, M, or V; V503 replaced with A, G, I, L, S, T, or M; Q505 replaced with N; T506 replaced with A, G, I, L, S, M, or V; K507 replaced with H, or R; H508 replaced with K, or R; F509 replaced with W, or Y; W511 replaced with F, or Y;

5 A512 replaced with G, I, L, S, T, M, or V; D513 replaced with E; G514 replaced with A, I, L, S, T, M, or V; T515 replaced with A, G, I, L, S, M, or V; S516 replaced with A, G, I, L, T, M, or V; G518 replaced with A, I, L, S, T, M, or V; E519 replaced with D; G520 replaced with A, I, L, S, T, M, or V; K521 replaced with H, or R; W522 replaced with F, or Y; I524 replaced with A, G, L, S, T, M, or V; N525 replaced with Q; G526 replaced

10 with A, I, L, S, T, M, or V; K527 replaced with H, or R; V529 replaced with A, G, I, L, S, T, or M; N530 replaced with Q; K531 replaced with H, or R; T532 replaced with A, G, I, L, S, M, or V; D533 replaced with E; R534 replaced with H, or K; K535 replaced with H, or R; H536 replaced with K, or R; F537 replaced with W, or Y; D538 replaced with E; T539 replaced with A, G, I, L, S, M, or V; F541 replaced with W, or Y; H542

15 replaced with K, or R; G543 replaced with A, I, L, S, T, M, or V; S544 replaced with A, G, I, L, T, M, or V; W545 replaced with F, or Y; G546 replaced with A, I, L, S, T, M, or V; M547 replaced with A, G, I, L, S, T, or V; W548 replaced with F, or Y; G549 replaced with A, I, L, S, T, M, or V; W551 replaced with F, or Y; G552 replaced with A, I, L, S, T, M, or V; D553 replaced with E; S555 replaced with A, G, I, L, T, M, or V; R556

20 replaced with H, or K; T557 replaced with A, G, I, L, S, M, or V; G559 replaced with A, I, L, S, T, M, or V; G560 replaced with A, I, L, S, T, M, or V; G561 replaced with A, I, L, S, T, M, or V; V562 replaced with A, G, I, L, S, T, or M; Q563 replaced with N; Y564 replaced with F, or W; T565 replaced with A, G, I, L, S, M, or V; M566 replaced with A, G, I, L, S, T, or V; R567 replaced with H, or K; E568 replaced with D; D570 replaced

25 with E; N571 replaced with Q; V573 replaced with A, G, I, L, S, T, or M; K575 replaced with H, or R; N576 replaced with Q; G577 replaced with A, I, L, S, T, M, or V; G578 replaced with A, I, L, S, T, M, or V; K579 replaced with H, or R; Y580 replaced with F, or W; E582 replaced with D; G583 replaced with A, I, L, S, T, M, or V; K584 replaced with H, or R; R585 replaced with H, or K; V586 replaced with A, G, I, L, S, T, or M;

30 R587 replaced with H, or K; Y588 replaced with F, or W; R589 replaced with H, or K; S590 replaced with A, G, I, L, T, M, or V; N592 replaced with Q; L593 replaced with A,

-144-

G, I, S, T, M, or V; E594 replaced with D; D595 replaced with E; D598 replaced with E; N599 replaced with Q; N600 replaced with Q; G601 replaced with A, I, L, S, T, M, or V; K602 replaced with H, or R; T603 replaced with A, G, I, L, S, M, or V; F604 replaced with W, or Y; R605 replaced with H, or K; E606 replaced with D; E607 replaced with D; Q608 replaced with N; E610 replaced with D; A611 replaced with G, I, L, S, T, M, or V; H612 replaced with K, or R; N613 replaced with Q; E614 replaced with D; F615 replaced with W, or Y; S616 replaced with A, G, I, L, T, M, or V; K617 replaced with H, or R; A618 replaced with G, I, L, S, T, M, or V; S619 replaced with A, G, I, L, T, M, or V; F620 replaced with W, or Y; G621 replaced with A, I, L, S, T, M, or V; S622 replaced with A, G, I, L, T, M, or V; G623 replaced with A, I, L, S, T, M, or V; A625 replaced with G, I, L, S, T, M, or V; V626 replaced with A, G, I, L, S, T, or M; E627 replaced with D; W628 replaced with F, or Y; I629 replaced with A, G, L, S, T, M, or V; K631 replaced with H, or R; Y632 replaced with F, or W; A633 replaced with G, I, L, S, T, M, or V; G634 replaced with A, I, L, S, T, M, or V; V635 replaced with A, G, I, L, S, T, or M; S636 replaced with A, G, I, L, T, M, or V; K638 replaced with H, or R; D639 replaced with E; R640 replaced with H, or K; K642 replaced with H, or R; L643 replaced with A, G, I, S, T, M, or V; I644 replaced with A, G, L, S, T, M, or V; Q646 replaced with N; A647 replaced with G, I, L, S, T, M, or V; K648 replaced with H, or R; G649 replaced with A, I, L, S, T, M, or V; I650 replaced with A, G, L, S, T, M, or V; G651 replaced with A, I, L, S, T, M, or V; Y652 replaced with F, or W; F653 replaced with W, or Y; F654 replaced with W, or Y; V655 replaced with A, G, I, L, S, T, or M; L656 replaced with A, G, I, S, T, M, or V; Q657 replaced with N; K659 replaced with H, or R; V660 replaced with A, G, I, L, S, T, or M; V661 replaced with A, G, I, L, S, T, or M; D662 replaced with E; G663 replaced with A, I, L, S, T, M, or V; T664 replaced with A, G, I, L, S, M, or V; S667 replaced with A, G, I, L, T, M, or V; D669 replaced with E; S670 replaced with A, G, I, L, T, M, or V; T671 replaced with A, G, I, L, S, M, or V; S672 replaced with A, G, I, L, T, M, or V; V673 replaced with A, G, I, L, S, T, or M; V675 replaced with A, G, I, L, S, T, or M; Q676 replaced with N; G677 replaced with A, I, L, S, T, M, or V; Q678 replaced with N; V680 replaced with A, G, I, L, S, T, or M; K681 replaced with H, or R; A682 replaced with G, I, L, S, T, M, or V; G683 replaced with A, I, L, S, T, M, or V; D685 replaced with E; R686 replaced with H, or K; I687

-145-

replaced with A, G, L, S, T, M, or V; I688 replaced with A, G, L, S, T, M, or V; D689 replaced with E; S690 replaced with A, G, I, L, T, M, or V; K691 replaced with H, or R; K692 replaced with H, or R; K693 replaced with H, or R; F694 replaced with W, or Y; D695 replaced with E; K696 replaced with H, or R; G698 replaced with A, I, L, S, T, M, or V; V699 replaced with A, G, I, L, S, T, or M; G701 replaced with A, I, L, S, T, M, or V; G702 replaced with A, I, L, S, T, M, or V; N703 replaced with Q; G704 replaced with A, I, L, S, T, M, or V; S705 replaced with A, G, I, L, T, M, or V; T706 replaced with A, G, I, L, S, M, or V; K708 replaced with H, or R; K709 replaced with H, or R; I710 replaced with A, G, L, S, T, M, or V; S711 replaced with A, G, I, L, T, M, or V; G712 replaced with A, I, L, S, T, M, or V; S713 replaced with A, G, I, L, T, M, or V; V714 replaced with A, G, I, L, S, T, or M; T715 replaced with A, G, I, L, S, M, or V; S716 replaced with A, G, I, L, T, M, or V; A717 replaced with G, I, L, S, T, M, or V; K718 replaced with H, or R; G720 replaced with A, I, L, S, T, M, or V; Y721 replaced with F, or W; H722 replaced with K, or R; D723 replaced with E; I724 replaced with A, G, L, S, T, M, or V; I725 replaced with A, G, L, S, T, M, or V; T726 replaced with A, G, I, L, S, M, or V; I727 replaced with A, G, L, S, T, M, or V; T729 replaced with A, G, I, L, S, M, or V; G730 replaced with A, I, L, S, T, M, or V; A731 replaced with G, I, L, S, T, M, or V; T732 replaced with A, G, I, L, S, M, or V; N733 replaced with Q; I734 replaced with A, G, L, S, T, M, or V; E735 replaced with D; V736 replaced with A, G, I, L, S, T, or M; K737 replaced with H, or R; Q738 replaced with N; R739 replaced with H, or K; N740 replaced with Q; Q741 replaced with N; R742 replaced with H, or K; G743 replaced with A, I, L, S, T, M, or V; S744 replaced with A, G, I, L, T, M, or V; R745 replaced with H, or K; N746 replaced with Q; N747 replaced with Q; G748 replaced with A, I, L, S, T, M, or V; S749 replaced with A, G, I, L, T, M, or V; F750 replaced with W, or Y; L751 replaced with A, G, I, S, T, M, or V; A752 replaced with G, I, L, S, T, M, or V; I753 replaced with A, G, L, S, T, M, or V; K754 replaced with H, or R; A755 replaced with G, I, L, S, T, M, or V; A756 replaced with G, I, L, S, T, M, or V; D757 replaced with E; G758 replaced with A, I, L, S, T, M, or V; T759 replaced with A, G, I, L, S, M, or V; Y760 replaced with F, or W; I761 replaced with A, G, L, S, T, M, or V; L762 replaced with A, G, I, S, T, M, or V; N763 replaced with Q; G764 replaced with A, I, L, S, T, M, or V; D765 replaced with E; Y766 replaced with F, or W; T767 replaced with

-146-

A, G, I, L, S, M, or V; L768 replaced with A, G, I, S, T, M, or V; S769 replaced with A, G, I, L, T, M, or V; T770 replaced with A, G, I, L, S, M, or V; L771 replaced with A, G, I, S, T, M, or V; E772 replaced with D; Q773 replaced with N; D774 replaced with E; I775 replaced with A, G, L, S, T, M, or V; M776 replaced with A, G, I, L, S, T, or V;

5 Y777 replaced with F, or W; K778 replaced with H, or R; G779 replaced with A, I, L, S, T, M, or V; V780 replaced with A, G, I, L, S, T, or M; V781 replaced with A, G, I, L, S, T, or M; L782 replaced with A, G, I, S, T, M, or V; R783 replaced with H, or K; Y784 replaced with F, or W; S785 replaced with A, G, I, L, T, M, or V; G786 replaced with A, I, L, S, T, M, or V; S787 replaced with A, G, I, L, T, M, or V; S788 replaced with A, G,

10 I, L, T, M, or V; A789 replaced with G, I, L, S, T, M, or V; A790 replaced with G, I, L, S, T, M, or V; L791 replaced with A, G, I, S, T, M, or V; E792 replaced with D; R793 replaced with H, or K; I794 replaced with A, G, L, S, T, M, or V; R795 replaced with H, or K; S796 replaced with A, G, I, L, T, M, or V; F797 replaced with W, or Y; S798 replaced with A, G, I, L, T, M, or V; L800 replaced with A, G, I, S, T, M, or V; K801

15 replaced with H, or R; E802 replaced with D; L804 replaced with A, G, I, S, T, M, or V; T805 replaced with A, G, I, L, S, M, or V; I806 replaced with A, G, L, S, T, M, or V; Q807 replaced with N; V808 replaced with A, G, I, L, S, T, or M; L809 replaced with A, G, I, S, T, M, or V; T810 replaced with A, G, I, L, S, M, or V; V811 replaced with A, G, I, L, S, T, or M; G812 replaced with A, I, L, S, T, M, or V; N813 replaced with Q; A814

20 replaced with G, I, L, S, T, M, or V; L815 replaced with A, G, I, S, T, M, or V; R816 replaced with H, or K; K818 replaced with H, or R; I819 replaced with A, G, L, S, T, M, or V; K820 replaced with H, or R; Y821 replaced with F, or W; T822 replaced with A, G, I, L, S, M, or V; Y823 replaced with F, or W; F824 replaced with W, or Y; V825 replaced with A, G, I, L, S, T, or M; K826 replaced with H, or R; K827 replaced with H,

25 or R; K828 replaced with H, or R; K829 replaced with H, or R; E830 replaced with D; S831 replaced with A, G, I, L, T, M, or V; F832 replaced with W, or Y; N833 replaced with Q; A834 replaced with G, I, L, S, T, M, or V; I835 replaced with A, G, L, S, T, M, or V; T837 replaced with A, G, I, L, S, M, or V; F838 replaced with W, or Y; S839 replaced with A, G, I, L, T, M, or V; A840 replaced with G, I, L, S, T, M, or V; W841

30 replaced with F, or Y; V842 replaced with A, G, I, L, S, T, or M; I843 replaced with A, G, L, S, T, M, or V; E844 replaced with D; E845 replaced with D; W846 replaced with

-147-

F, or Y; G847 replaced with A, I, L, S, T, M, or V; E848 replaced with D; S850 replaced with A, G, I, L, T, M, or V; K851 replaced with H, or R; S852 replaced with A, G, I, L, T, M, or V; E854 replaced with D; L855 replaced with A, G, I, S, T, M, or V; G856 replaced with A, I, L, S, T, M, or V; W857 replaced with F, or Y; Q858 replaced with N;

5 R859 replaced with H, or K; R860 replaced with H, or K; L861 replaced with A, G, I, S, T, M, or V; V862 replaced with A, G, I, L, S, T, or M; E863 replaced with D; R865 replaced with H, or K; D866 replaced with E; I867 replaced with A, G, L, S, T, M, or V; N868 replaced with Q; G869 replaced with A, I, L, S, T, M, or V; Q870 replaced with N; A872 replaced with G, I, L, S, T, M, or V; S873 replaced with A, G, I, L, T, M, or V;

10 E874 replaced with D; A876 replaced with G, I, L, S, T, M, or V; K877 replaced with H, or R; E878 replaced with D; V879 replaced with A, G, I, L, S, T, or M; K880 replaced with H, or R; A882 replaced with G, I, L, S, T, M, or V; S883 replaced with A, G, I, L, T, M, or V; T884 replaced with A, G, I, L, S, M, or V; R885 replaced with H, or K; A888 replaced with G, I, L, S, T, M, or V; D889 replaced with E; H890 replaced with K, or R;

15 Q894 replaced with N; W895 replaced with F, or Y; Q896 replaced with N; L897 replaced with A, G, I, S, T, M, or V; G898 replaced with A, I, L, S, T, M, or V; E899 replaced with D; W900 replaced with F, or Y; S901 replaced with A, G, I, L, T, M, or V; S902 replaced with A, G, I, L, T, M, or V; S904 replaced with A, G, I, L, T, M, or V; K905 replaced with H, or R; T906 replaced with A, G, I, L, S, M, or V; G908 replaced with A, I, L, S, T, M, or V; K909 replaced with H, or R; G910 replaced with A, I, L, S, T, M, or V; Y911 replaced with F, or W; K912 replaced with H, or R; K913 replaced with H, or R; R914 replaced with H, or K; S915 replaced with A, G, I, L, T, M, or V; L916 replaced with A, G, I, S, T, M, or V; K917 replaced with H, or R; L919 replaced with A, G, I, S, T, M, or V; S920 replaced with A, G, I, L, T, M, or V; H921 replaced with K, or R; D922 replaced with E; G923 replaced with A, I, L, S, T, M, or V; G924 replaced with A, I, L, S, T, M, or V; V925 replaced with A, G, I, L, S, T, or M; L926 replaced with A, G, I, S, T, M, or V; S927 replaced with A, G, I, L, T, M, or V; H928 replaced with K, or R; E929 replaced with D; S930 replaced with A, G, I, L, T, M, or V; D932 replaced with E; L934 replaced with A, G, I, S, T, M, or V; K935 replaced with H, or R; K936 replaced with H, or R; K938 replaced with H, or R; H939 replaced with K, or R; F940 replaced with W, or Y; I941 replaced with A, G, L, S, T, M, or V; D942

20

25

30

-148-

replaced with E; F943 replaced with W, or Y; T945 replaced with A, G, I, L, S, M, or V; M946 replaced with A, G, I, L, S, T, or V; A947 replaced with G, I, L, S, T, M, or V; E948 replaced with D; S950 replaced with A, G, I, L, T, M, or V.

Also preferred are METH1 polypeptides with one or more of the following non-conservative substitutions: M1 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G2 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N3 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; A4 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E5 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R6 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A7 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P8 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G9 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S10 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R11 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S12 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F13 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G14 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P15 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; V16 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P17 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; T18 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L19 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L20 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L21 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L22 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A23 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A24 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A25 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L26 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L27 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A28 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V29 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S30 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D31 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A32 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L33 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G34 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R35 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P36 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; S37 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E38 replaced with H,

-149-

K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E39 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D40 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E41 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E42 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L43 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V44 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V45 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P46 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E47 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L48 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E49 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R50 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A51 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P52 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G53 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H54 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G55 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T56 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T57 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R58 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L59 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R60 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L61 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H62 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A63 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F64 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; D65 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q66 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Q67 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L68 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D69 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L70 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E71 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L72 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R73 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P74 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; D75 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S76 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S77 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F78 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; L79

-150-

replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A80 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P81 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G82 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F83 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; T84 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L85 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q86 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N87 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; V88 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G89 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R90 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K91 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S92 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G93 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S94 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E95 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T96 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P97 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L98 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P99 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E100 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T101 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D102 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L103 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A104 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H105 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C106 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; F107 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Y108 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S109 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G110 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T111 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V112 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N113 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G114 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D115 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P116 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; S117 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S118 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A119 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A120 replaced with D, E, H,

-151-

K, R, N, Q, F, W, Y, P, or C; A121 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C;
L122 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S123 replaced with D, E, H,
K, R, N, Q, F, W, Y, P, or C; L124 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C;
C125 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; E126
5 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G127 replaced with
D, E, H, K, R, N, Q, F, W, Y, P, or C; V128 replaced with D, E, H, K, R, N, Q, F, W, Y,
P, or C; R129 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G130
replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A131 replaced with D, E, H, K, R,
N, Q, F, W, Y, P, or C; F132 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V,
10 P, or C; Y133 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; L134
replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L135 replaced with D, E, H, K, R,
N, Q, F, W, Y, P, or C; G136 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E137
replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A138 replaced with
D, E, H, K, R, N, Q, F, W, Y, P, or C; Y139 replaced with D, E, H, K, R, N, Q, A, G, I,
15 L, S, T, M, V, P, or C; F140 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V,
P, or C; I141 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q142 replaced with D,
E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; P143 replaced with D, E, H, K, R,
A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L144 replaced with D, E, H, K, R, N, Q, F,
W, Y, P, or C; P145 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y,
20 or C; A146 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A147 replaced with D,
E, H, K, R, N, Q, F, W, Y, P, or C; S148 replaced with D, E, H, K, R, N, Q, F, W, Y, P,
or C; E149 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R150
replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L151 replaced with D,
E, H, K, R, N, Q, F, W, Y, P, or C; A152 replaced with D, E, H, K, R, N, Q, F, W, Y, P,
25 or C; T153 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A154 replaced with D,
E, H, K, R, N, Q, F, W, Y, P, or C; A155 replaced with D, E, H, K, R, N, Q, F, W, Y, P,
or C; P156 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G157
replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E158 replaced with H, K, R, A, G,
I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K159 replaced with D, E, A, G, I, L, S, T, M, V,
30 N, Q, F, W, Y, P, or C; P160 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q,
F, W, Y, or C; P161 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y,

-152-

or C; A162 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P163 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L164 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q165 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; F166 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C;

5 H167 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L168 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L169 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R170 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R171 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N172 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; R173 replaced with D, E, A,

10 G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q174 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G175 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D176 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V177 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G178 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G179 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T180

15 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C181 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G182 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V183 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V184 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D185 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D186 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q,

20 F, W, Y, P, or C; E187 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P188 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; R189 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P190 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; T191 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G192 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C;

25 K193 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A194 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E195 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T196 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E197 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D198 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E199 replaced with

30 H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D200 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E201 replaced with H, K, R, A, G, I, L, S, T,

M, V, N, Q, F, W, Y, P, or C; G202 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T203 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E204 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G205 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E206 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D207 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E208 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G209 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P210 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; Q211 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; W212 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S213 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P214 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; Q215 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; D216 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P217 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A218 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L219 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q220 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G221 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V222 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G223 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q224 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; P225 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; T226 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G227 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T228 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G229 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S230 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I231 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R232 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K233 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K234 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R235 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F236 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; V237 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S238 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S239 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H240 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R241 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y,

P, or C; Y242 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; V243 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E244 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T245 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M246 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L247 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V248 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A249 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D250 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q251 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; S252 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M253 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A254 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E255 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F256 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; H257 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G258 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S259 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G260 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L261 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K262 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H263 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y264 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; L265 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L266 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T267 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L268 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F269 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S270 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V271 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A272 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A273 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R274 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L275 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y276 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; K277 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H278 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P279 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; S280 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I281 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R282 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N283 replaced with D, E, H, K, R, A, G, I, L, S,

-155-

T, M, V, F, W, Y, P, or C; S284 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C;
V285 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S286 replaced with D, E, H,
K, R, N, Q, F, W, Y, P, or C; L287 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C;
V288 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V289 replaced with D, E, H,
5 K, R, N, Q, F, W, Y, P, or C; V290 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C;
K291 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I292 replaced
with D, E, H, K, R, N, Q, F, W, Y, P, or C; L293 replaced with D, E, H, K, R, N, Q, F,
W, Y, P, or C; V294 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I295 replaced
with D, E, H, K, R, N, Q, F, W, Y, P, or C; H296 replaced with D, E, A, G, I, L, S, T, M,
10 V, N, Q, F, W, Y, P, or C; D297 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F,
W, Y, P, or C; E298 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or
C; Q299 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; K300
replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G301 replaced with
D, E, H, K, R, N, Q, F, W, Y, P, or C; P302 replaced with D, E, H, K, R, A, G, I, L, S,
15 T, M, V, N, Q, F, W, Y, or C; E303 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q,
F, W, Y, P, or C; V304 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T305
replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S306 replaced with D, E, H, K, R,
N, Q, F, W, Y, P, or C; N307 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W,
Y, P, or C; A308 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A309 replaced
20 with D, E, H, K, R, N, Q, F, W, Y, P, or C; L310 replaced with D, E, H, K, R, N, Q, F,
W, Y, P, or C; T311 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L312 replaced
with D, E, H, K, R, N, Q, F, W, Y, P, or C; R313 replaced with D, E, A, G, I, L, S, T, M,
V, N, Q, F, W, Y, P, or C; N314 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F,
W, Y, P, or C; F315 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C;
25 C316 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; N317
replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; W318 replaced with
D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Q319 replaced with D, E, H, K, R,
A, G, I, L, S, T, M, V, F, W, Y, P, or C; K320 replaced with D, E, A, G, I, L, S, T, M, V,
N, Q, F, W, Y, P, or C; Q321 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W,
30 Y, P, or C; H322 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N323
replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; P324 replaced with

-156-

D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; P325 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; S326 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D327 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R328 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D329 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A330 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E331 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H332 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y333 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; D334 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T335 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A336 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I337 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L338 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F339 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; T340 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R341 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q342 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; D343 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L344 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C345 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G346 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S347 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q348 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; T349 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C350 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; D351 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T352 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L353 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G354 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M355 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A356 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D357 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V358 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G359 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T360 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V361 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C362 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; D363 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P364 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V,

-157-

N, Q, F, W, Y, or C; S365 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R366 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S367 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C368 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; S369 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; 5 V370 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I371 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E372 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D373 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D374 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G375 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L376 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q377 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; A378 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A379 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F380 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; T381 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T382 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A383 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H384 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E385 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L386 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G387 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H388 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V389 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F390 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; N391 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; M392 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P393 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; H394 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D395 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D396 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A397 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K398 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q399 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; C400 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; A401 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S402 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L403 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N404 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G405

-158-

replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V406 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N407 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Q408 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; D409 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S410 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H411 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; M412 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M413 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A414 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S415 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M416 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L417 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S418 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N419 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L420 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D421 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H422 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S423 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q424 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; P425 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; W426 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S427 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P428 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; C429 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; S430 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A431 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y432 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; M433 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I434 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T435 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S436 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F437 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; L438 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D439 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N440 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G441 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H442 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G443 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E444 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C445 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; L446

-159-

replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M447 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D448 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K449 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P450 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; Q451 replaced
5 with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N452 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; P453 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; I454 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q455 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L456 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P457 replaced with D, E, H, K, R,
10 A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G458 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D459 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L460 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P461 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G462 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T463 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S464
15 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y465 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; D466 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A467 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N468 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; R469 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q470 replaced with D, E, H, K, R,
20 A, G, I, L, S, T, M, V, F, W, Y, P, or C; C471 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; Q472 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; F473 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; T474 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F475 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G476 replaced with D, E, H, K, R, N, Q,
25 F, W, Y, P, or C; E477 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D478 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S479 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K480 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H481 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C482 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q,
30 F, W, Y, or P; P483 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; D484 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A485

-160-

replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A486 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S487 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T488 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C489 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; S490 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T491 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L492 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; W493 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; C494 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; T495 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G496 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T497 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S498 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G499 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G500 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V501 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L502 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V503 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C504 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; Q505 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; T506 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K507 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H508 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F509 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; P510 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; W511 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; A512 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D513 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G514 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T515 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S516 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C517 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G518 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E519 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G520 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K521 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; W522 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; C523 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; I524 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N525 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G526 replaced with D, E, H,

-161-

K, R, N, Q, F, W, Y, P, or C; K527 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C528 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; V529 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N530 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; K531 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T532 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D533 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R534 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K535 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H536 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F537 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; D538 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T539 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P540 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; F541 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; H542 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G543 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S544 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; W545 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G546 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M547 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; W548 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G549 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P550 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; W551 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G552 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D553 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C554 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; S555 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R556 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T557 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C558 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G559 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G560 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G561 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V562 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q563 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Y564 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; T565 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M566 replaced with D, E, H, K, R, N, Q, F,

-162-

W, Y, P, or C; R567 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E568 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C569 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; D570 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N571 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; P572 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; V573 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P574 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; K575 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N576 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G577 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G578 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K579 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y580 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; C581 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; E582 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G583 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K584 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R585 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V586 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R587 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y588 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; R589 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S590 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C591 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; N592 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L593 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E594 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D595 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C596 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; P597 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; D598 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N599 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N600 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G601 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K602 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T603 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F604 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M,

-163-

V, P, or C; R605 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E606 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E607 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q608 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; C609 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; E610 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A611 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H612 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N613 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; E614 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F615 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S616 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K617 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A618 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S619 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F620 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G621 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S622 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G623 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P624 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A625 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V626 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E627 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; W628 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; I629 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P630 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; K631 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y632 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; A633 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G634 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V635 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S636 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P637 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; K638 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D639 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R640 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C641 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; K642 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L643 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I644 replaced with D, E, H,

-164-

K, R, N, Q, F, W, Y, P, or C; C645 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; Q646 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; A647 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K648 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G649 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I650 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G651 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y652 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; F653 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; F654 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; V655 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L656 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q657 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; P658 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; K659 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V660 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V661 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D662 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G663 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T664 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P665 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; C666 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; S667 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P668 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; D669 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S670 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T671 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S672 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V673 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C674 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; V675 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q676 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G677 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q678 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; C679 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; V680 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K681 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A682 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G683 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C684 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y,

-165-

or P; D685 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R686 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I687 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I688 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D689 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S690 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K691 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K692 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K693 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F694 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; D695 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K696 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C697 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G698 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V699 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C700 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G701 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G702 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N703 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G704 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S705 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T706 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C707 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; K708 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K709 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I710 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S711 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G712 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S713 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V714 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T715 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S716 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A717 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K718 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P719 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G720 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y721 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; H722 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D723 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I724 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I725 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C;

-166-

T726 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I727 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P728 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; T729 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G730 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A731 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T732 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N733 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; I734 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E735 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V736 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K737 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q738 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; R739 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N740 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Q741 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; R742 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G743 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S744 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R745 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N746 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N747 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G748 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S749 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F750 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; L751 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A752 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I753 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K754 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A755 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A756 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D757 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G758 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T759 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y760 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; I761 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L762 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N763 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G764 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D765 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y766 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; T767 replaced

-167-

with D, E, H, K, R, N, Q, F, W, Y, P, or C; L768 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S769 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T770 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L771 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E772 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q773 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; D774 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I775 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M776 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y777 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; K778 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G779 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V780 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V781 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L782 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R783 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y784 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S785 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G786 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S787 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S788 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A789 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A790 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L791 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E792 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R793 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I794 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R795 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S796 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F797 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S798 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P799 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L800 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K801 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E802 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P803 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L804 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T805 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I806 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q807 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; V808 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L809 replaced with

-168-

D, E, H, K, R, N, Q, F, W, Y, P, or C; T810 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V811 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G812 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N813 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; A814 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C;

5 L815 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R816 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P817 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; K818 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I819 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K820 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y821 replaced with

10 D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; T822 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y823 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; F824 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; V825 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K826 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K827 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K828 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K829 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E830 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S831 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F832 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; N833 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; A834 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I835 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P836 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; T837 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F838 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S839 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A840 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; W841 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; V842 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I843 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E844 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E845 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; W846 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G847 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E848 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C849 replaced with D, E, H, K, R, A, G, I, L, S,

30

-169-

T, M, V, N, Q, F, W, Y, or P; S850 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K851 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S852 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C853 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; E854 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L855 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G856 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; W857 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Q858 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; R859 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R860 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L861 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V862 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E863 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C864 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; R865 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D866 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I867 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N868 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G869 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q870 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; P871 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A872 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S873 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E874 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C875 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; A876 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K877 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E878 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V879 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K880 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P881 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A882 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S883 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T884 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R885 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P886 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; C887 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; A888 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D889

-170-

replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H890 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P891 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; C892 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; P893 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; Q894 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; W895 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Q896 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L897 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G898 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E899 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; W900 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S901 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S902 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C903 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; S904 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K905 replaced with D, E, A, G, I, L, S, T, M; V, N, Q, F, W, Y, P, or C; T906 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C907 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G908 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K909 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G910 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y911 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; K912 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K913 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R914 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S915 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L916 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K917 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C918 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; L919 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S920 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H921 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D922 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G923 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G924 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V925 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L926 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S927 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H928 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E929

-171-

replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S930 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C931 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; D932 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P933 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L934 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K935 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K936 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P937 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; K938 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H939 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F940 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; I941 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D942 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F943 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; C944 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; T945 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M946 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A947 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E948 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C949 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; S950 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C.

Also preferred are METH2 polypeptides with one or more of the following conservative amino acid substitutions: M1 replaced with A, G, I, L, S, T, or V; F2 replaced with W, or Y; A4 replaced with G, I, L, S, T, M, or V; A6 replaced with G, I, L, S, T, M, or V; A7 replaced with G, I, L, S, T, M, or V; R9 replaced with H, or K; W10 replaced with F, or Y; L11 replaced with A, G, I, S, T, M, or V; F13 replaced with W, or Y; L14 replaced with A, G, I, S, T, M, or V; L15 replaced with A, G, I, S, T, M, or V; L16 replaced with A, G, I, S, T, M, or V; L17 replaced with A, G, I, S, T, M, or V; L18 replaced with A, G, I, S, T, M, or V; L19 replaced with A, G, I, S, T, M, or V; L20 replaced with A, G, I, S, T, M, or V; L21 replaced with A, G, I, S, T, M, or V; L22 replaced with A, G, I, S, T, M, or V; L24 replaced with A, G, I, S, T, M, or V; A25 replaced with G, I, L, S, T, M, or V; R26 replaced with H, or K; G27 replaced with A, I, L, S, T, M, or V; A28 replaced with G, I, L, S, T, M, or V; A30 replaced with G, I, L, S, T, M, or V; R31 replaced with H, or K; A33 replaced with G, I, L, S, T, M, or V; A34

-172-

replaced with G, I, L, S, T, M, or V; G35 replaced with A, I, L, S, T, M, or V; G36 replaced with A, I, L, S, T, M, or V; Q37 replaced with N; A38 replaced with G, I, L, S, T, M, or V; S39 replaced with A, G, I, L, T, M, or V; E40 replaced with D; L41 replaced with A, G, I, S, T, M, or V; V42 replaced with A, G, I, L, S, T, or M; V43 replaced with A, G, I, L, S, T, or M; T45 replaced with A, G, I, L, S, M, or V; R46 replaced with H, or K; L47 replaced with A, G, I, S, T, M, or V; G49 replaced with A, I, L, S, T, M, or V; S50 replaced with A, G, I, L, T, M, or V; A51 replaced with G, I, L, S, T, M, or V; G52 replaced with A, I, L, S, T, M, or V; E53 replaced with D; L54 replaced with A, G, I, S, T, M, or V; A55 replaced with G, I, L, S, T, M, or V; L56 replaced with A, G, I, S, T, M, or V; H57 replaced with K, or R; L58 replaced with A, G, I, S, T, M, or V; S59 replaced with A, G, I, L, T, M, or V; A60 replaced with G, I, L, S, T, M, or V; F61 replaced with W, or Y; G62 replaced with A, I, L, S, T, M, or V; K63 replaced with H, or R; G64 replaced with A, I, L, S, T, M, or V; F65 replaced with W, or Y; V66 replaced with A, G, I, L, S, T, or M; L67 replaced with A, G, I, S, T, M, or V; R68 replaced with H, or K; L69 replaced with A, G, I, S, T, M, or V; A70 replaced with G, I, L, S, T, M, or V; D72 replaced with E; D73 replaced with E; S74 replaced with A, G, I, L, T, M, or V; F75 replaced with W, or Y; L76 replaced with A, G, I, S, T, M, or V; A77 replaced with G, I, L, S, T, M, or V; E79 replaced with D; F80 replaced with W, or Y; K81 replaced with H, or R; I82 replaced with A, G, L, S, T, M, or V; E83 replaced with D; R84 replaced with H, or K; L85 replaced with A, G, I, S, T, M, or V; G86 replaced with A, I, L, S, T, M, or V; G87 replaced with A, I, L, S, T, M, or V; S88 replaced with A, G, I, L, T, M, or V; G89 replaced with A, I, L, S, T, M, or V; R90 replaced with H, or K; A91 replaced with G, I, L, S, T, M, or V; T92 replaced with A, G, I, L, S, M, or V; G93 replaced with A, I, L, S, T, M, or V; G94 replaced with A, I, L, S, T, M, or V; E95 replaced with D; R96 replaced with H, or K; G97 replaced with A, I, L, S, T, M, or V; L98 replaced with A, G, I, S, T, M, or V; R99 replaced with H, or K; G100 replaced with A, I, L, S, T, M, or V; F102 replaced with W, or Y; F103 replaced with W, or Y; S104 replaced with A, G, I, L, T, M, or V; G105 replaced with A, I, L, S, T, M, or V; T106 replaced with A, G, I, L, S, M, or V; V107 replaced with A, G, I, L, S, T, or M; N108 replaced with Q; G109 replaced with A, I, L, S, T, M, or V; E110 replaced with D; E112 replaced with D; S113 replaced with A, G, I, L, T, M, or V; L114 replaced with A, G, I, S, T, M, or V; A115

-173-

replaced with G, I, L, S, T, M, or V; A116 replaced with G, I, L, S, T, M, or V; V117 replaced with A, G, I, L, S, T, or M; S118 replaced with A, G, I, L, T, M, or V; L119 replaced with A, G, I, S, T, M, or V; R121 replaced with H, or K; G122 replaced with A, I, L, S, T, M, or V; L123 replaced with A, G, I, S, T, M, or V; S124 replaced with A, G, I, L, T, M, or V; G125 replaced with A, I, L, S, T, M, or V; S126 replaced with A, G, I, L, T, M, or V; F127 replaced with W, or Y; L128 replaced with A, G, I, S, T, M, or V; L129 replaced with A, G, I, S, T, M, or V; D130 replaced with E; G131 replaced with A, I, L, S, T, M, or V; E132 replaced with D; E133 replaced with D; F134 replaced with W, or Y; T135 replaced with A, G, I, L, S, M, or V; I136 replaced with A, G, L, S, T, M, or V; Q137 replaced with N; Q139 replaced with N; G140 replaced with A, I, L, S, T, M, or V; A141 replaced with G, I, L, S, T, M, or V; G142 replaced with A, I, L, S, T, M, or V; G143 replaced with A, I, L, S, T, M, or V; S144 replaced with A, G, I, L, T, M, or V; L145 replaced with A, G, I, S, T, M, or V; A146 replaced with G, I, L, S, T, M, or V; Q147 replaced with N; H149 replaced with K, or R; R150 replaced with H, or K; L151 replaced with A, G, I, S, T, M, or V; Q152 replaced with N; R153 replaced with H, or K; W154 replaced with F, or Y; G155 replaced with A, I, L, S, T, M, or V; A157 replaced with G, I, L, S, T, M, or V; G158 replaced with A, I, L, S, T, M, or V; A159 replaced with G, I, L, S, T, M, or V; R160 replaced with H, or K; L162 replaced with A, G, I, S, T, M, or V; R164 replaced with H, or K; G165 replaced with A, I, L, S, T, M, or V; E167 replaced with D; W168 replaced with F, or Y; E169 replaced with D; V170 replaced with A, G, I, L, S, T, or M; E171 replaced with D; T172 replaced with A, G, I, L, S, M, or V; G173 replaced with A, I, L, S, T, M, or V; E174 replaced with D; G175 replaced with A, I, L, S, T, M, or V; Q176 replaced with N; R177 replaced with H, or K; Q178 replaced with N; E179 replaced with D; R180 replaced with H, or K; G181 replaced with A, I, L, S, T, M, or V; D182 replaced with E; H183 replaced with K, or R; Q184 replaced with N; E185 replaced with D; D186 replaced with E; S187 replaced with A, G, I, L, T, M, or V; E188 replaced with D; E189 replaced with D; E190 replaced with D; S191 replaced with A, G, I, L, T, M, or V; Q192 replaced with N; E193 replaced with D; E194 replaced with D; E195 replaced with D; A196 replaced with G, I, L, S, T, M, or V; E197 replaced with D; G198 replaced with A, I, L, S, T, M, or V; A199 replaced with G, I, L, S, T, M, or V; S200 replaced with A, G, I, L, T, M, or V; E201 replaced with D; L206 replaced

-174-

with A, G, I, S, T, M, or V; G207 replaced with A, I, L, S, T, M, or V; A208 replaced
with G, I, L, S, T, M, or V; T209 replaced with A, G, I, L, S, M, or V; S210 replaced with
A, G, I, L, T, M, or V; R211 replaced with H, or K; T212 replaced with A, G, I, L, S, M,
or V; K213 replaced with H, or R; R214 replaced with H, or K; F215 replaced with W,
5 or Y; V216 replaced with A, G, I, L, S, T, or M; S217 replaced with A, G, I, L, T, M, or
V; E218 replaced with D; A219 replaced with G, I, L, S, T, M, or V; R220 replaced with
H, or K; F221 replaced with W, or Y; V222 replaced with A, G, I, L, S, T, or M; E223
replaced with D; T224 replaced with A, G, I, L, S, M, or V; L225 replaced with A, G, I,
S, T, M, or V; L226 replaced with A, G, I, S, T, M, or V; V227 replaced with A, G, I, L,
10 S, T, or M; A228 replaced with G, I, L, S, T, M, or V; D229 replaced with E; A230
replaced with G, I, L, S, T, M, or V; S231 replaced with A, G, I, L, T, M, or V; M232
replaced with A, G, I, L, S, T, or V; A233 replaced with G, I, L, S, T, M, or V; A234
replaced with G, I, L, S, T, M, or V; F235 replaced with W, or Y; Y236 replaced with F,
or W; G237 replaced with A, I, L, S, T, M, or V; A238 replaced with G, I, L, S, T, M, or
15 V; D239 replaced with E; L240 replaced with A, G, I, S, T, M, or V; Q241 replaced with
N; N242 replaced with Q; H243 replaced with K, or R; I244 replaced with A, G, L, S, T,
M, or V; L245 replaced with A, G, I, S, T, M, or V; T246 replaced with A, G, I, L, S, M,
or V; L247 replaced with A, G, I, S, T, M, or V; M248 replaced with A, G, I, L, S, T, or
V; S249 replaced with A, G, I, L, T, M, or V; V250 replaced with A, G, I, L, S, T, or M;
20 A251 replaced with G, I, L, S, T, M, or V; A252 replaced with G, I, L, S, T, M, or V;
R253 replaced with H, or K; I254 replaced with A, G, L, S, T, M, or V; Y255 replaced
with F, or W; K256 replaced with H, or R; H257 replaced with K, or R; S259 replaced
with A, G, I, L, T, M, or V; I260 replaced with A, G, L, S, T, M, or V; K261 replaced
with H, or R; N262 replaced with Q; S263 replaced with A, G, I, L, T, M, or V; I264
25 replaced with A, G, L, S, T, M, or V; N265 replaced with Q; L266 replaced with A, G,
I, S, T, M, or V; M267 replaced with A, G, I, L, S, T, or V; V268 replaced with A, G, I,
L, S, T, or M; V269 replaced with A, G, I, L, S, T, or M; K270 replaced with H, or R;
V271 replaced with A, G, I, L, S, T, or M; L272 replaced with A, G, I, S, T, M, or V;
I273 replaced with A, G, L, S, T, M, or V; V274 replaced with A, G, I, L, S, T, or M;
30 E275 replaced with D; D276 replaced with E; E277 replaced with D; K278 replaced with
H, or R; W279 replaced with F, or Y; G280 replaced with A, I, L, S, T, M, or V; E282

-175-

replaced with D; V283 replaced with A, G, I, L, S, T, or M; S284 replaced with A, G, I, L, T, M, or V; D285 replaced with E; N286 replaced with Q; G287 replaced with A, I, L, S, T, M, or V; G288 replaced with A, I, L, S, T, M, or V; L289 replaced with A, G, I, S, T, M, or V; T290 replaced with A, G, I, L, S, M, or V; L291 replaced with A, G, I, S, T, M, or V; R292 replaced with H, or K; N293 replaced with Q; F294 replaced with W, or Y; N296 replaced with Q; W297 replaced with F, or Y; Q298 replaced with N; R299 replaced with H, or K; R300 replaced with H, or K; F301 replaced with W, or Y; N302 replaced with Q; Q303 replaced with N; S305 replaced with A, G, I, L, T, M, or V; D306 replaced with E; R307 replaced with H, or K; H308 replaced with K, or R; E310 replaced with D; H311 replaced with K, or R; Y312 replaced with F, or W; D313 replaced with E; T314 replaced with A, G, I, L, S, M, or V; A315 replaced with G, I, L, S, T, M, or V; I316 replaced with A, G, L, S, T, M, or V; L317 replaced with A, G, I, S, T, M, or V; L318 replaced with A, G, I, S, T, M, or V; T319 replaced with A, G, I, L, S, M, or V; R320 replaced with H, or K; Q321 replaced with N; N322 replaced with Q; F323 replaced with W, or Y; G325 replaced with A, I, L, S, T, M, or V; Q326 replaced with N; E327 replaced with D; G328 replaced with A, I, L, S, T, M, or V; L329 replaced with A, G, I, S, T, M, or V; D331 replaced with E; T332 replaced with A, G, I, L, S, M, or V; L333 replaced with A, G, I, S, T, M, or V; G334 replaced with A, I, L, S, T, M, or V; V335 replaced with A, G, I, L, S, T, or M; A336 replaced with G, I, L, S, T, M, or V; D337 replaced with E; I338 replaced with A, G, L, S, T, M, or V; G339 replaced with A, I, L, S, T, M, or V; T340 replaced with A, G, I, L, S, M, or V; I341 replaced with A, G, L, S, T, M, or V; D343 replaced with E; N345 replaced with Q; K346 replaced with H, or R; S347 replaced with A, G, I, L, T, M, or V; S349 replaced with A, G, I, L, T, M, or V; V350 replaced with A, G, I, L, S, T, or M; I351 replaced with A, G, L, S, T, M, or V; E352 replaced with D; D353 replaced with E; E354 replaced with D; G355 replaced with A, I, L, S, T, M, or V; L356 replaced with A, G, I, S, T, M, or V; Q357 replaced with N; A358 replaced with G, I, L, S, T, M, or V; A359 replaced with G, I, L, S, T, M, or V; H360 replaced with K, or R; T361 replaced with A, G, I, L, S, M, or V; L362 replaced with A, G, I, S, T, M, or V; A363 replaced with G, I, L, S, T, M, or V; H364 replaced with K, or R; E365 replaced with D; L366 replaced with A, G, I, S, T, M, or V; G367 replaced with A, I, L, S, T, M, or V; H368 replaced with K, or R; V369 replaced with A,

-176-

G, I, L, S, T, or M; L370 replaced with A, G, I, S, T, M, or V; S371 replaced with A, G, I, L, T, M, or V; M372 replaced with A, G, I, L, S, T, or V; H374 replaced with K, or R; D375 replaced with E; D376 replaced with E; S377 replaced with A, G, I, L, T, M, or V; K378 replaced with H, or R; T381 replaced with A, G, I, L, S, M, or V; R382 replaced
5 with H, or K; L383 replaced with A, G, I, S, T, M, or V; F384 replaced with W, or Y; G385 replaced with A, I, L, S, T, M, or V; M387 replaced with A, G, I, L, S, T, or V; G388 replaced with A, I, L, S, T, M, or V; K389 replaced with H, or R; H390 replaced with K, or R; H391 replaced with K, or R; V392 replaced with A, G, I, L, S, T, or M; M393 replaced with A, G, I, L, S, T, or V; A394 replaced with G, I, L, S, T, M, or V;
10 L396 replaced with A, G, I, S, T, M, or V; F397 replaced with W, or Y; V398 replaced with A, G, I, L, S, T, or M; H399 replaced with K, or R; L400 replaced with A, G, I, S, T, M, or V; N401 replaced with Q; Q402 replaced with N; T403 replaced with A, G, I, L, S, M, or V; L404 replaced with A, G, I, S, T, M, or V; W406 replaced with F, or Y; S407 replaced with A, G, I, L, T, M, or V; S410 replaced with A, G, I, L, T, M, or V;
15 A411 replaced with G, I, L, S, T, M, or V; M412 replaced with A, G, I, L, S, T, or V; Y413 replaced with F, or W; L414 replaced with A, G, I, S, T, M, or V; T415 replaced with A, G, I, L, S, M, or V; E416 replaced with D; L417 replaced with A, G, I, S, T, M, or V; L418 replaced with A, G, I, S, T, M, or V; D419 replaced with E; G420 replaced with A, I, L, S, T, M, or V; G421 replaced with A, I, L, S, T, M, or V; H422 replaced
20 with K, or R; G423 replaced with A, I, L, S, T, M, or V; D424 replaced with E; L426 replaced with A, G, I, S, T, M, or V; L427 replaced with A, G, I, S, T, M, or V; D428 replaced with E; A429 replaced with G, I, L, S, T, M, or V; G431 replaced with A, I, L, S, T, M, or V; A432 replaced with G, I, L, S, T, M, or V; A433 replaced with G, I, L, S, T, M, or V; L434 replaced with A, G, I, S, T, M, or V; L436 replaced with A, G, I, S, T, M, or V; T438 replaced with A, G, I, L, S, M, or V; G439 replaced with A, I, L, S, T, M,
25 or V; L440 replaced with A, G, I, S, T, M, or V; G442 replaced with A, I, L, S, T, M, or V; R443 replaced with H, or K; M444 replaced with A, G, I, L, S, T, or V; A445 replaced with G, I, L, S, T, M, or V; L446 replaced with A, G, I, S, T, M, or V; Y447 replaced with F, or W; Q448 replaced with N; L449 replaced with A, G, I, S, T, M, or V; D450
30 replaced with E; Q451 replaced with N; Q452 replaced with N; R454 replaced with H, or K; Q455 replaced with N; I456 replaced with A, G, L, S, T, M, or V; F457 replaced

-177-

with W, or Y; G458 replaced with A, I, L, S, T, M, or V; D460 replaced with E; F461 replaced with W, or Y; R462 replaced with H, or K; H463 replaced with K, or R; N466 replaced with Q; T467 replaced with A, G, I, L, S, M, or V; S468 replaced with A, G, I, L, T, M, or V; A469 replaced with G, I, L, S, T, M, or V; Q470 replaced with N; D471 replaced with E; V472 replaced with A, G, I, L, S, T, or M; A474 replaced with G, I, L, S, T, M, or V; Q475 replaced with N; L476 replaced with A, G, I, S, T, M, or V; W477 replaced with F, or Y; H479 replaced with K, or R; T480 replaced with A, G, I, L, S, M, or V; D481 replaced with E; G482 replaced with A, I, L, S, T, M, or V; A483 replaced with G, I, L, S, T, M, or V; E484 replaced with D; L486 replaced with A, G, I, S, T, M, or V; H488 replaced with K, or R; T489 replaced with A, G, I, L, S, M, or V; K490 replaced with H, or R; N491 replaced with Q; G492 replaced with A, I, L, S, T, M, or V; S493 replaced with A, G, I, L, T, M, or V; L494 replaced with A, G, I, S, T, M, or V; W496 replaced with F, or Y; A497 replaced with G, I, L, S, T, M, or V; D498 replaced with E; G499 replaced with A, I, L, S, T, M, or V; T500 replaced with A, G, I, L, S, M, or V; G503 replaced with A, I, L, S, T, M, or V; G505 replaced with A, I, L, S, T, M, or V; H506 replaced with K, or R; L507 replaced with A, G, I, S, T, M, or V; S509 replaced with A, G, I, L, T, M, or V; E510 replaced with D; G511 replaced with A, I, L, S, T, M, or V; S512 replaced with A, G, I, L, T, M, or V; L514 replaced with A, G, I, S, T, M, or V; E516 replaced with D; E517 replaced with D; E518 replaced with D; V519 replaced with A, G, I, L, S, T, or M; E520 replaced with D; R521 replaced with H, or K; K523 replaced with H, or R; V525 replaced with A, G, I, L, S, T, or M; V526 replaced with A, G, I, L, S, T, or M; D527 replaced with E; G528 replaced with A, I, L, S, T, M, or V; G529 replaced with A, I, L, S, T, M, or V; W530 replaced with F, or Y; A531 replaced with G, I, L, S, T, M, or V; W533 replaced with F, or Y; G534 replaced with A, I, L, S, T, M, or V; W536 replaced with F, or Y; G537 replaced with A, I, L, S, T, M, or V; E538 replaced with D; S540 replaced with A, G, I, L, T, M, or V; R541 replaced with H, or K; T542 replaced with A, G, I, L, S, M, or V; G544 replaced with A, I, L, S, T, M, or V; G545 replaced with A, I, L, S, T, M, or V; G546 replaced with A, I, L, S, T, M, or V; V547 replaced with A, G, I, L, S, T, or M; Q548 replaced with N; F549 replaced with W, or Y; S550 replaced with A, G, I, L, T, M, or V; H551 replaced with K, or R; R552 replaced with H, or K; E553 replaced with D; K555 replaced with H, or R; D556 replaced

-178-

with E; E558 replaced with D; Q560 replaced with N; N561 replaced with Q; G562 replaced with A, I, L, S, T, M, or V; G563 replaced with A, I, L, S, T, M, or V; R564 replaced with H, or K; Y565 replaced with F, or W; L567 replaced with A, G, I, S, T, M, or V; G568 replaced with A, I, L, S, T, M, or V; R569 replaced with H, or K; R570 replaced with H, or K; A571 replaced with G, I, L, S, T, M, or V; K572 replaced with H, or R; Y573 replaced with F, or W; Q574 replaced with N; S575 replaced with A, G, I, L, T, M, or V; H577 replaced with K, or R; T578 replaced with A, G, I, L, S, M, or V; E579 replaced with D; E580 replaced with D; D584 replaced with E; G585 replaced with A, I, L, S, T, M, or V; K586 replaced with H, or R; S587 replaced with A, G, I, L, T, M, or V; F588 replaced with W, or Y; R589 replaced with H, or K; E590 replaced with D; Q591 replaced with N; Q592 replaced with N; E594 replaced with D; K595 replaced with H, or R; Y596 replaced with F, or W; N597 replaced with Q; A598 replaced with G, I, L, S, T, M, or V; Y599 replaced with F, or W; N600 replaced with Q; Y601 replaced with F, or W; T602 replaced with A, G, I, L, S, M, or V; D603 replaced with E; M604 replaced with A, G, I, L, S, T, or V; D605 replaced with E; G606 replaced with A, I, L, S, T, M, or V; N607 replaced with Q; L608 replaced with A, G, I, S, T, M, or V; L609 replaced with A, G, I, S, T, M, or V; Q610 replaced with N; W611 replaced with F, or Y; V612 replaced with A, G, I, L, S, T, or M; K614 replaced with H, or R; Y615 replaced with F, or W; A616 replaced with G, I, L, S, T, M, or V; G617 replaced with A, I, L, S, T, M, or V; V618 replaced with A, G, I, L, S, T, or M; S619 replaced with A, G, I, L, T, M, or V; R621 replaced with H, or K; D622 replaced with E; R623 replaced with H, or K; K625 replaced with H, or R; L626 replaced with A, G, I, S, T, M, or V; F627 replaced with W, or Y; R629 replaced with H, or K; A630 replaced with G, I, L, S, T, M, or V; R631 replaced with H, or K; G632 replaced with A, I, L, S, T, M, or V; R633 replaced with H, or K; S634 replaced with A, G, I, L, T, M, or V; E635 replaced with D; F636 replaced with W, or Y; K637 replaced with H, or R; V638 replaced with A, G, I, L, S, T, or M; F639 replaced with W, or Y; E640 replaced with D; A641 replaced with G, I, L, S, T, M, or V; K642 replaced with H, or R; V643 replaced with A, G, I, L, S, T, or M; I644 replaced with A, G, L, S, T, M, or V; D645 replaced with E; G646 replaced with A, I, L, S, T, M, or V; T647 replaced with A, G, I, L, S, M, or V; L648 replaced with A, G, I, S, T, M, or V; G650 replaced with A, I, L, S, T, M, or V; E652 replaced with D; T653

-179-

replaced with A, G, I, L, S, M, or V; L654 replaced with A, G, I, S, T, M, or V; A655 replaced with G, I, L, S, T, M, or V; I656 replaced with A, G, L, S, T, M, or V; V658 replaced with A, G, I, L, S, T, or M; R659 replaced with H, or K; G660 replaced with A, I, L, S, T, M, or V; Q661 replaced with N; V663 replaced with A, G, I, L, S, T, or M; K664 replaced with H, or R; A665 replaced with G, I, L, S, T, M, or V; G666 replaced with A, I, L, S, T, M, or V; D668 replaced with E; H669 replaced with K, or R; V670 replaced with A, G, I, L, S, T, or M; V671 replaced with A, G, I, L, S, T, or M; D672 replaced with E; S673 replaced with A, G, I, L, T, M, or V; R675 replaced with H, or K; K676 replaced with H, or R; L677 replaced with A, G, I, S, T, M, or V; D678 replaced with E; K679 replaced with H, or R; G681 replaced with A, I, L, S, T, M, or V; V682 replaced with A, G, I, L, S, T, or M; G684 replaced with A, I, L, S, T, M, or V; G685 replaced with A, I, L, S, T, M, or V; K686 replaced with H, or R; G687 replaced with A, I, L, S, T, M, or V; N688 replaced with Q; S689 replaced with A, G, I, L, T, M, or V; R691 replaced with H, or K; K692 replaced with H, or R; V693 replaced with A, G, I, L, S, T, or M; S694 replaced with A, G, I, L, T, M, or V; G695 replaced with A, I, L, S, T, M, or V; S696 replaced with A, G, I, L, T, M, or V; L697 replaced with A, G, I, S, T, M, or V; T698 replaced with A, G, I, L, S, M, or V; T700 replaced with A, G, I, L, S, M, or V; N701 replaced with Q; Y702 replaced with F, or W; G703 replaced with A, I, L, S, T, M, or V; Y704 replaced with F, or W; N705 replaced with Q; D706 replaced with E; I707 replaced with A, G, L, S, T, M, or V; V708 replaced with A, G, I, L, S, T, or M; T709 replaced with A, G, I, L, S, M, or V; I710 replaced with A, G, L, S, T, M, or V; A712 replaced with G, I, L, S, T, M, or V; G713 replaced with A, I, L, S, T, M, or V; A714 replaced with G, I, L, S, T, M, or V; T715 replaced with A, G, I, L, S, M, or V; N716 replaced with Q; I717 replaced with A, G, L, S, T, M, or V; D718 replaced with E; V719 replaced with A, G, I, L, S, T, or M; K720 replaced with H, or R; Q721 replaced with N; R722 replaced with H, or K; S723 replaced with A, G, I, L, T, M, or V; H724 replaced with K, or R; G726 replaced with A, I, L, S, T, M, or V; V727 replaced with A, G, I, L, S, T, or M; Q728 replaced with N; N729 replaced with Q; D730 replaced with E; G731 replaced with A, I, L, S, T, M, or V; N732 replaced with Q; Y733 replaced with F, or W; L734 replaced with A, G, I, S, T, M, or V; A735 replaced with G, I, L, S, T, M, or V; L736 replaced with A, G, I, S, T, M, or V; K737 replaced with H, or R; T738

-180-

replaced with A, G, I, L, S, M, or V; A739 replaced with G, I, L, S, T, M, or V; D740 replaced with E; G741 replaced with A, I, L, S, T, M, or V; Q742 replaced with N; Y743 replaced with F, or W; L744 replaced with A, G, I, S, T, M, or V; L745 replaced with A, G, I, S, T, M, or V; N746 replaced with Q; G747 replaced with A, I, L, S, T, M, or V; 5 N748 replaced with Q; L749 replaced with A, G, I, S, T, M, or V; A750 replaced with G, I, L, S, T, M, or V; I751 replaced with A, G, L, S, T, M, or V; S752 replaced with A, G, I, L, T, M, or V; A753 replaced with G, I, L, S, T, M, or V; I754 replaced with A, G, L, S, T, M, or V; E755 replaced with D; Q756 replaced with N; D757 replaced with E; I758 replaced with A, G, L, S, T, M, or V; L759 replaced with A, G, I, S, T, M, or V; V760 replaced with A, G, I, L, S, T, or M; K761 replaced with H, or R; G762 replaced with A, 10 I, L, S, T, M, or V; T763 replaced with A, G, I, L, S, M, or V; I764 replaced with A, G, L, S, T, M, or V; L765 replaced with A, G, I, S, T, M, or V; K766 replaced with H, or R; Y767 replaced with F, or W; S768 replaced with A, G, I, L, T, M, or V; G769 replaced with A, I, L, S, T, M, or V; S770 replaced with A, G, I, L, T, M, or V; I771 replaced with A, G, L, S, T, M, or V; A772 replaced with G, I, L, S, T, M, or V; T773 replaced with A, 15 G, I, L, S, M, or V; L774 replaced with A, G, I, S, T, M, or V; E775 replaced with D; R776 replaced with H, or K; L777 replaced with A, G, I, S, T, M, or V; Q778 replaced with N; S779 replaced with A, G, I, L, T, M, or V; F780 replaced with W, or Y; R781 replaced with H, or K; L783 replaced with A, G, I, S, T, M, or V; E785 replaced with D; 20 L787 replaced with A, G, I, S, T, M, or V; T788 replaced with A, G, I, L, S, M, or V; V789 replaced with A, G, I, L, S, T, or M; Q790 replaced with N; L791 replaced with A, G, I, S, T, M, or V; L792 replaced with A, G, I, S, T, M, or V; T793 replaced with A, G, I, L, S, M, or V; V794 replaced with A, G, I, L, S, T, or M; G796 replaced with A, I, L, S, T, M, or V; E797 replaced with D; V798 replaced with A, G, I, L, S, T, or M; F799 replaced with W, or Y; K802 replaced with H, or R; V803 replaced with A, G, I, L, S, T, 25 or M; K804 replaced with H, or R; Y805 replaced with F, or W; T806 replaced with A, G, I, L, S, M, or V; F807 replaced with W, or Y; F808 replaced with W, or Y; V809 replaced with A, G, I, L, S, T, or M; N811 replaced with Q; D812 replaced with E; V813 replaced with A, G, I, L, S, T, or M; D814 replaced with E; F815 replaced with W, or Y; 30 S816 replaced with A, G, I, L, T, M, or V; M817 replaced with A, G, I, L, S, T, or V; Q818 replaced with N; S819 replaced with A, G, I, L, T, M, or V; S820 replaced with A,

-181-

G, I, L, T, M, or V; K821 replaced with H, or R; E822 replaced with D; R823 replaced with H, or K; A824 replaced with G, I, L, S, T, M, or V; T825 replaced with A, G, I, L, S, M, or V; T826 replaced with A, G, I, L, S, M, or V; N827 replaced with Q; I828 replaced with A, G, L, S, T, M, or V; I829 replaced with A, G, L, S, T, M, or V; Q830 replaced with N; L832 replaced with A, G, I, S, T, M, or V; L833 replaced with A, G, I, S, T, M, or V; H834 replaced with K, or R; A835 replaced with G, I, L, S, T, M, or V; Q836 replaced with N; W837 replaced with F, or Y; V838 replaced with A, G, I, L, S, T, or M; L839 replaced with A, G, I, S, T, M, or V; G840 replaced with A, I, L, S, T, M, or V; D841 replaced with E; W842 replaced with F, or Y; S843 replaced with A, G, I, L, T, M, or V; E844 replaced with D; S846 replaced with A, G, I, L, T, M, or V; S847 replaced with A, G, I, L, T, M, or V; T848 replaced with A, G, I, L, S, M, or V; G850 replaced with A, I, L, S, T, M, or V; A851 replaced with G, I, L, S, T, M, or V; G852 replaced with A, I, L, S, T, M, or V; W853 replaced with F, or Y; Q854 replaced with N; R855 replaced with H, or K; R856 replaced with H, or K; T857 replaced with A, G, I, L, S, M, or V; V858 replaced with A, G, I, L, S, T, or M; E859 replaced with D; R861 replaced with H, or K; D862 replaced with E; S864 replaced with A, G, I, L, T, M, or V; G865 replaced with A, I, L, S, T, M, or V; Q866 replaced with N; A867 replaced with G, I, L, S, T, M, or V; S868 replaced with A, G, I, L, T, M, or V; A869 replaced with G, I, L, S, T, M, or V; T870 replaced with A, G, I, L, S, M, or V; N872 replaced with Q; K873 replaced with H, or R; A874 replaced with G, I, L, S, T, M, or V; L875 replaced with A, G, I, S, T, M, or V; K876 replaced with H, or R; E878 replaced with D; D879 replaced with E; A880 replaced with G, I, L, S, T, M, or V; K881 replaced with H, or R; E884 replaced with D; S885 replaced with A, G, I, L, T, M, or V; Q886 replaced with N; L887 replaced with A, G, I, S, T, M, or V; L890 replaced with A, G, I, S, T, M, or V.

Also preferred are METH2 polypeptides with one or more of the following conservative amino acid substitutions: M1 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F2 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; P3 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A4 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P5 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A6 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A7 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P8 replaced with D, E, H, K, R, A, G, I, L,

-182-

S, T, M, V, N, Q, F, W, Y, or C; R9 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; W10 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; L11 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P12 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; F13 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; L14 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L15 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L16 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L17 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L18 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L19 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L20 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L21 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L22 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P23 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L24 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A25 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R26 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G27 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A28 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P29 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A30 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R31 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P32 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A33 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A34 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G35 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G36 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q37 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; A38 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S39 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E40 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L41 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V42 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V43 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P44 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; T45 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R46 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L47 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P48 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G49 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S50 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A51 replaced with D, E, H, K, R, N, Q, F, W,

Y, P, or C; G52 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E53 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L54 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A55 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L56 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H57 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L58 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S59 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A60 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F61 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G62 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K63 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G64 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F65 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; V66 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L67 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R68 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L69 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A70 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P71 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; D72 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D73 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S74 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F75 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; L76 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A77 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P78 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E79 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F80 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; K81 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I82 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E83 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R84 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L85 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G86 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G87 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S88 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G89 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R90 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A91 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T92 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G93 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G94 replaced with D, E, H, K, R, N, Q, F, W,

-184-

Y, P, or C; E95 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R96 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G97 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L98 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R99 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G100 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C101 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; F102 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; F103 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S104 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G105 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T106 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V107 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N108 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G109 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E110 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P111 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E112 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S113 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L114 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A115 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A116 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V117 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S118 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L119 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C120 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; R121 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G122 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L123 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S124 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G125 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S126 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F127 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; L128 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L129 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D130 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G131 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E132 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E133 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F134 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; T135 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I136 replaced with D, E, H, K, R,

-185-

N, Q, F, W, Y, P, or C; Q137 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; P138 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; Q139 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G140 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A141 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G142 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G143 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S144 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L145 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A146 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q147 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; P148 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; H149 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R150 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L151 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q152 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; R153 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; W154 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G155 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P156 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A157 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G158 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A159 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R160 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P161 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L162 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P163 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; R164 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G165 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P166 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E167 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; W168 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; E169 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V170 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E171 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T172 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G173 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E174 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G175 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q176 replaced with D, E, H, K, R, A, G, I, L, S,

T, M, V, F, W, Y, P, or C; R177 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q178 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; E179 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R180 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G181 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D182 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H183 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q184 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; E185 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D186 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S187 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E188 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E189 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E190 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S191 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q192 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; E193 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E194 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E195 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A196 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E197 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G198 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A199 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S200 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E201 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P202 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; P203 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; P204 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; P205 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L206 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G207 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A208 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T209 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S210 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R211 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T212 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K213 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R214 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F215 replaced with D, E, H, K,

-187-

R, N, Q, A, G, I, L, S, T, M, V, P, or C; V216 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S217 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E218 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A219 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R220 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F221 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; V222 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E223 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T224 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L225 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L226 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V227 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A228 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D229 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A230 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S231 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M232 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A233 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A234 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F235 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Y236 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G237 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A238 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D239 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L240 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q241 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N242 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; H243 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I244 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L245 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T246 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L247 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M248 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S249 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V250 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A251 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A252 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R253 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I254 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y255 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; K256 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H257 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P,

or C; P258 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; S259 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I260 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K261 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N262 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; S263 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I264 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N265 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L266 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M267 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V268 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V269 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K270 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V271 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L272 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I273 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V274 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E275 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D276 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E277 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K278 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; W279 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G280 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P281 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E282 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V283 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S284 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D285 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N286 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G287 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G288 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L289 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T290 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L291 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R292 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N293 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; F294 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; C295 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; N296 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; W297 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Q298 replaced with D, E, H, K, R, A, G,

-189-

I, L, S, T, M, V, F, W, Y, P, or C; R299 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R300 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F301 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; N302 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Q303 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; P304 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; S305 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D306 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R307 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H308 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P309 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E310 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H311 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y312 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; D313 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T314 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A315 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I316 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L317 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L318 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T319 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R320 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q321 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N322 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; F323 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; C324 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G325 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q326 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; E327 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G328 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L329 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C330 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; D331 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T332 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L333 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G334 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V335 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A336 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D337 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I338

-190-

replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G339 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T340 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I341 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C342 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; D343 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P344 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; N345 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; K346 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S347 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C348 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; S349 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V350 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I351 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E352 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D353 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E354 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G355 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L356 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q357 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; A358 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A359 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H360 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T361 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L362 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A363 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H364 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E365 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L366 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G367 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H368 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V369 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L370 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S371 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M372 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P373 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; H374 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D375 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D376 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S377 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K378 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P379

-191-

replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; C380 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; T381 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R382 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L383 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F384 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G385 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P386 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; M387 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G388 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K389 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H390 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H391 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V392 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M393 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A394 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P395 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L396 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F397 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; V398 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H399 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L400 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N401 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Q402 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; T403 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L404 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P405 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; W406 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S407 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P408 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; C409 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; S410 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A411 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M412 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y413 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; L414 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T415 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E416 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L417 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L418 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D419 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W,

-192-

Y, P, or C; G420 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G421 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H422 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G423 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D424 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C425 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; L426 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L427 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D428 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A429 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P430 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G431 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A432 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A433 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L434 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P435 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L436 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P437 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; T438 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G439 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L440 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P441 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G442 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R443 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; M444 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A445 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L446 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y447 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Q448 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L449 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D450 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q451 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Q452 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; C453 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; R454 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q455 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; I456 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F457 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G458 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P459 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; D460 replaced with H, K, R,

-193-

A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F461 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; R462 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H463 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C464 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; P465 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; N466 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; T467 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S468 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A469 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q470 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; D471 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V472 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C473 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; A474 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q475 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L476 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; W477 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; C478 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; H479 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T480 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D481 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G482 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A483 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E484 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P485 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L486 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C487 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; H488 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T489 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K490 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; N491 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G492 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S493 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L494 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P495 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; W496 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; A497 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D498 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G499 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T500

replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P501 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; C502 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G503 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P504 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G505 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H506 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L507 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C508 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; S509 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E510 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G511 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S512 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C513 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; L514 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P515 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E516 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E517 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E518 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V519 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E520 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R521 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P522 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; K523 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P524 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; V525 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V526 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D527 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G528 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G529 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; W530 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; A531 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P532 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; W533 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G534 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P535 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; W536 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G537 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E538 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C539 replaced with D, E, H, K,

-195-

R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; S540 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R541 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T542 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C543 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G544 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G545 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G546 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V547 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q548 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; F549 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S550 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H551 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R552 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E553 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C554 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; K555 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D556 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P557 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E558 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P559 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; Q560 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N561 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G562 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G563 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R564 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y565 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; C566 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; L567 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G568 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R569 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R570 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A571 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K572 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y573 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Q574 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; S575 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C576 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; H577 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T578 replaced with D, E, H, K,

-196-

R, N, Q, F, W, Y, P, or C; E579 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E580 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C581 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; P582 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; P583 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; D584 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G585 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K586 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S587 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F588 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; R589 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E590 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q591 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Q592 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; C593 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; E594 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K595 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y596 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; N597 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; A598 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y599 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; N600 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Y601 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; T602 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D603 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; M604 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D605 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G606 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N607 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L608 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L609 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q610 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; W611 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; V612 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P613 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; K614 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y615 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; A616 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C;

-197-

G617 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V618 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S619 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P620 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; R621 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D622 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R623 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C624 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; K625 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L626 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F627 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; C628 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; R629 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A630 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R631 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G632 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R633 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S634 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E635 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F636 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; K637 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V638 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F639 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; E640 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A641 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K642 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V643 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I644 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D645 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G646 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T647 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L648 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C649 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G650 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P651 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E652 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T653 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L654 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A655 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I656 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C657 replaced with D, E, H, K, R, A, G, I, L, S, T,

-198-

M, V, N, Q, F, W, Y, or P; V658 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R659 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G660 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q661 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; C662 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; V663 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K664 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A665 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G666 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C667 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; D668 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; H669 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V670 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V671 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D672 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S673 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P674 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; R675 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K676 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L677 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D678 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K679 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C680 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G681 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V682 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C683 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G684 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G685 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K686 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G687 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N688 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; S689 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C690 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; R691 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; K692 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V693 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S694 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G695 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S696 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L697 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T698

-199-

replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P699 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; T700 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N701 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Y702 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; G703 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Y704 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; N705 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; D706 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I707 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V708 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T709 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I710 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P711 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; A712 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G713 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A714 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T715 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N716 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; I717 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D718 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V719 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K720 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q721 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; R722 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S723 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H724 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P725 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G726 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V727 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q728 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; N729 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; D730 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G731 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N732 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Y733 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; L734 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A735 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L736 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K737 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T738 replaced with D, E, H, K, R, N, Q, F, W, Y,

-200-

P, or C; A739 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D740 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G741 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q742 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Y743 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C;

5 L744 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L745 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N746 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; G747 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N748 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L749 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A750 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I751 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S752 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A753 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I754 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E755 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Q756 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; D757 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I758 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L759 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V760 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K761 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; G762 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T763 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I764 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L765 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K766 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y767 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S768 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G769 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S770 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I771 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A772 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T773 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L774 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E775 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R776 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; L777 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q778 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; S779 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F780 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; R781 replaced with D,

10
15
20
25
30

-201-

E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P782 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L783 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P784 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E785 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P786 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L787 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T788 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V789 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q790 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L791 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L792 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T793 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V794 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P795 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; G796 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E797 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V798 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F799 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; P800 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; P801 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; K802 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V803 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K804 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y805 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; T806 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; F807 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; F808 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; V809 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P810 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; N811 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; D812 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V813 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D814 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F815 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S816 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M817 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q818 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; S819 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S820 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K821 replaced with

-202-

D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E822 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R823 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A824 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T825 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T826 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; N827 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; I828 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; I829 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q830 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; P831 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L832 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L833 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; H834 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A835 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q836 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; W837 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; V838 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L839 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G840 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; D841 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; W842 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S843 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E844 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C845 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; S846 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S847 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T848 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C849 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; G850 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A851 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G852 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; W853 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; Q854 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; R855 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R856 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; T857 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V858 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E859 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; C860 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; R861 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or

-203-

C; D862 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P863 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; S864 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G865 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q866 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; A867 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; S868 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A869 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; T870 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C871 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; N872 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; K873 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A874 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L875 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K876 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P877 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; E878 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D879 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A880 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K881 replaced with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P882 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; C883 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; E884 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S885 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; Q886 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; L887 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; C888 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or P; P889 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; L890 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C.

METH1 or METH2 polypeptides may contain 50, 40, 30, 10, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 conservative or non-conservative amino acid substitutions. Additionally, METH1 or METH2 polypeptides may contain both conservative or non-conservative substitutions, in any combination. A METH1 or METH2 polypeptide may contain 50, 40, 30, 10, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 conservative amino acids substitutions, and 50, 40, 30, 10, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 non-conservative amino acid substitutions in the same polypeptide. For example, a particular polypeptide may

contain 10 conservative amino acid substitutions and 10 non-conservative amino acid substitutions. Polynucleotides encoding such METH1 or METH2 polypeptides with substitutions are also encompassed within the present invention.

The substitutions may be made in full-length METH1 or METH2, mature
5 METH1 or METH2, and any other METH1 or METH2 variant disclosed herein, including METH1 or METH2 polypeptides with N- and/or C-terminal amino acid deletions; METH1 or METH2 polypeptides which lack one or more domains; or hybrid METH1/METH2 molecules.

Amino acids in the METH1 and METH2 proteins of the present invention that are
10 essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, *Science* 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as *in vitro* or *in vivo* inhibition of angiogenesis. Sites that are critical for
15 inhibition of angiogenesis can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992) and de Vos *et al.*, *Science* 255:306-312 (1992)).

Particularly preferred are polypeptides with amino acid substitutions at the boundaries of each domain (for example, at the boundary of the metalloprotease domain).
20 Amino acid substitutions at these boundaries may be made to change the activity of the protein, for example, to prevent cleavage. Amino acid substitutions may also be made which do not affect the activity of the protein. For example, the following amino acids may be replaced in METH1, with the following amino acids: L-19 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; L-20 may be replaced with A,
25 C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; L-21 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; L-22 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; A-23 may be replaced with may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; A-24 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; A-25 may be
30 replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; L-26 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; L-27 may be

-205-

replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; A-28 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; V-29 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W or Y; S-30 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; D-31 may be replaced with A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; A-32 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; L-33 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; G-34 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; R-35 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; P-36 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; S-37 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; E-38 may be replaced with A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; E-39 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; P-225 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; T-226 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W or Y; G-227 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; T-228 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W or Y; G-229 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; S-230 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; I-231 may be replaced with A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W or Y; R-232 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; K-233 may be replaced with A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W or Y; K-234 may be replaced with A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W or Y; R-235 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; F-236 may be replaced with A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; V-237 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W or Y; S-238 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; S-239 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; H-240 may be replaced with A, C, D, E, F, G, I, K, L, M, N, P, Q, R, S, T, V, W or Y; R-241 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; Y-242 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; V-243 may be

-206-

replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W or Y; E-244 may be replaced with A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; T-245 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W or Y; K-449 may be replaced with A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W or Y; P-450 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; Q-451 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W or Y; N-452 may be replaced with A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; P-453 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; I-454 may be replaced with A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W or Y; Q-455 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W or Y; L-456 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; P-457 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; G-458 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; D-459 may be replaced with A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; L-460 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; P-461 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; G-462 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; T-463 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W or Y; S-464 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; Y-465 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; D-466 may be replaced with A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; A-467 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; N-468 may be replaced with A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; R-469 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; R-534 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; K-535 may be replaced with A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W or Y; H-536 may be replaced with A, C, D, E, F, G, I, K, L, M, N, P, Q, R, S, T, V, W or Y; F-537 may be replaced with A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; D-538 may be replaced with A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; T-539 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W or Y; P-540 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; F-541 may be

-207-

replaced with A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; H-542 may be replaced with A, C, D, E, F, G, I, K, L, M, N, P, Q, R, S, T, V, W or Y; G-543 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; S-544 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; W-545 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y; G-546 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; M-547 may be replaced with A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W or Y; W-548 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y; G-549 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; P-550 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; W-551 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y; G-552 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; D-553 may be replaced with A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; G-554 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; S-831 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; F-832 may be replaced with A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; N-833 may be replaced with A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; A-834 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; I-835 may be replaced with A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W or Y; P-836 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; T-837 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W or Y; F-838 may be replaced with A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; S-839 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; A-840 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; W-841 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V or Y; V-842 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W or Y; I-843 may be replaced with A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W or Y; E-844 may be replaced with A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; E-845 may be replaced with A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; W-846 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y; G-847 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; E-848 may be

-208-

replaced with A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; C-849 may be replaced with A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; S-850 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; K-851 may be replaced with A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W or Y; R-885 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; P-886 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; C-887 may be replaced with A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; A-888 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; D-889 may be replaced with A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; H-890 may be replaced with A, C, D, E, F, G, I, K, L, M, N, P, Q, R, S, T, V, W or Y; P-891 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; C-892 may be replaced with A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; P-893 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; Q-894 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W or Y; W-895 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y; Q-896 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W or Y; L-897 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; G-898 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; E-899 may be replaced with A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; W-900 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y; S-901 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; S-902 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; C-903 may be replaced with A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; S-904 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; and/or K-905 may be replaced with A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W or Y.

In addition, the following amino acids may be replaced in METH2 with the following amino acids: L-14 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; L-15 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; L-16 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; L-17 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; L-18 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V,

-209-

W or Y; L-19 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; L-20 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; L-21 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; L-22 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; P-23 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; L-24 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; A-25 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; R-26 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; G-27 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; A-28 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; P-29 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; A-30 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; R-31 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; P-32 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; A-33 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; A-34 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; P-204 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; P-205 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; L-206 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; G-207 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; A-208 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; T-209 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W or Y; S-210 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; R-211 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; T-212 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W or Y; K-213 may be replaced with A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W or Y; R-214 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; F-215 may be replaced with A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; V-216 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W or Y; S-217 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; E-218 may be replaced with A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; A-219 may be

-210-

replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; R-220 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; F-221 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; V-222 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W or Y; E-223 may be replaced with A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; T-224 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W or Y; P-430 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; G-431 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; A-432 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; A-433 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; L-434 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; P-435 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; L-436 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; P-437 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; T-438 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W or Y; G-439 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; L-440 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; P-441 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; G-442 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; R-443 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; M-444 may be replaced with A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W or Y; A-445 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; L-446 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; Y-447 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V or W; Q-448 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W or Y; L-449 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; D-450 may be replaced with A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; E-520 may be replaced with A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; R-521 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; P-522 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; K-523 may be replaced with A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W or Y; P-524 may be

-211-

replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; V-525 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W or Y; V-526 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W or Y; D-527 may be replaced with A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; G-528 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; G-529 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; W-530 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y; A-531 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; P-532 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; W-533 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y; G-534 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; P-535 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; W-536 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V or Y; G-537 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; E-538 may be replaced with A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; C-539 may be replaced with A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; S-540 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; N-827 may be replaced with A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; I-828 may be replaced with A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W or Y; I-829 may be replaced with A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W or Y; Q-830 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W or Y; P-831 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; L-832 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; L-833 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; H-834 may be replaced with A, C, D, E, F, G, I, K, L, M, N, P, Q, R, S, T, V, W or Y; A-835 may be replaced with C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; Q-836 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W or Y; W-837 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y; V-838 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W or Y; L-839 may be replaced with A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; G-840 may be replaced with A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; D-841 may be

replaced with A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; W-842 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V or Y; S-843 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; E-844 may be replaced with A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; C-845 may be replaced with A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; S-846 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; and/or S-847 may be replaced with A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y.

METH1 or METH2 polypeptide variants, including substitution, deletion and/or addition variants, which contain amino acid substitutions can be tested for activity in any of the assays described herein, for example, the chorioallantoic assay or the cornea pocket assay. Preferred are METH1 or METH2 polypeptides with conservative substitutions that: maintain all the activities and/or properties of the wild type protein; or have one or more enhanced activities and/or properties compared to the wild type protein. Also preferred are METH1 or METH2 polypeptides with nonconservative substitutions which: lack an activity and/or property of the wild type protein, while maintaining all other activities and/or properties; or lack more than one activity and/or property of the wild type protein.

For example, activities or properties of METH1 or METH2 that may be altered in METH1 or METH2 polypeptides with conservative or nonconservative substitutions include, but are not limited to: stimulation of angiogenesis; stimulation of epithelial cell proliferation; antibody binding; ligand binding; stability; solubility; and/or properties which affect purification.

The polypeptides of the present invention are preferably provided in an isolated form. By "isolated polypeptide" is intended a polypeptide removed from its native environment. Thus, a polypeptide produced and/or contained within a recombinant host cell is considered isolated for purposes of the present invention. Also intended as an "isolated polypeptide" are polypeptides that have been purified, partially or substantially, from a recombinant host cell or from a native source. For example, a recombinantly produced version of the METH1 or METH2 polypeptide can be substantially purified by the one-step method described in Smith and Johnson, *Gene* 67:31-40 (1988).

The polypeptides of the present invention include the METH1 polypeptide encoded by the deposited cDNA including the leader; the mature METH1 polypeptide encoded by the deposited the cDNA minus the leader (i.e., the mature protein); a polypeptide comprising amino acids about 1 to about 950 in SEQ ID NO:2; a polypeptide comprising amino acids about 2 to about 950 in SEQ ID NO:2; a polypeptide comprising amino acids about 29 to about 950 in SEQ ID NO:2; a polypeptide comprising amino acids about 30 to about 950 in SEQ ID NO:2; a polypeptide comprising the metalloprotease domain of METH1, amino acids 235 to 459 in SEQ ID NO:2; a polypeptide comprising the disintegrin domain of METH1, amino acids 460 to 544 in SEQ ID NO:2; a polypeptide comprising the first TSP-like domain of METH1, amino acids 545 to 598 in SEQ ID NO:2; a polypeptide comprising the second TSP-like domain of METH1, amino acids 841 to 894 in SEQ ID NO:2; a polypeptide comprising the third TSP-like domain of METH1, amino acids 895 to 934 in SEQ ID NO:2; a polypeptide comprising amino acids 536 to 613 in SEQ ID NO:2; a polypeptide comprising amino acids 549 to 563 in SEQ ID NO:2; the METH2 polypeptide encoded by the deposited cDNA including the leader; the mature METH2 polypeptide encoded by the deposited the cDNA minus the leader (i.e., the mature protein); a polypeptide comprising amino acids about 1 to about 890 in SEQ ID NO:4; a polypeptide comprising amino acids about 2 to about 890 in SEQ ID NO:4; a polypeptide comprising amino acids about 24 to about 890 in SEQ ID NO:4; a polypeptide comprising amino acids about 112 to about 890 in SEQ ID NO:4; a polypeptide comprising the metalloprotease domain of METH2, amino acids 214 to 439 in SEQ ID NO:4; a polypeptide comprising the disintegrin domain of METH2, amino acids 440 to 529 in SEQ ID NO:4; a polypeptide comprising the first TSP-like domain of METH2, amino acids 530 to 583 in SEQ ID NO:4; a polypeptide comprising the second TSP-like domain of METH2, amino acids 837 to 890 in SEQ ID NO:4; a polypeptide comprising amino acids 280 to 606 in SEQ ID NO:4; a polypeptide comprising amino acids 529 to 548 in SEQ ID NO:4; as well as polypeptides which are at least 80% identical, and more preferably at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polypeptides described above and also include portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a reference amino acid sequence of a METH1 or METH2 polypeptide is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of the METH1 or METH2 polypeptide. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4 or to the amino acid sequence encoded by deposited cDNA clones can be determined conventionally using known computer programs such the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed.

A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag *et al.*, *Comp. App. Biosci.* 6:237-245 (1990). In a sequence alignment, the query and subject sequences are either both nucleotide sequences

-215-

or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total residues of the query sequence. Whether a residue is matched/aligned is determined by the results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a match/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched, the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time, the deletions are internal, so there are no residues at the – or C-termini of the subject

-216-

sequence which are not matched/aligned with the query. In this case, the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the – and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are made for the purposes of the present invention.

The polypeptides of the present invention are useful as a molecular weight marker on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art.

In another aspect, the invention provides a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide of the invention. The epitope of this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide described herein. An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein is the immunogen. On the other hand, a region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, for instance, Geysen *et al.*, *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1983).

As to the selection of peptides or polypeptides bearing an antigenic epitope (i.e., that contain a region of a protein molecule to which an antibody can bind), it is well known in the art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, for instance, Sutcliffe, J. G. *et al.*, "Antibodies that react with predetermined sites on proteins", *Science* 219:660-666 (1983). Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals.

Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a

-217-

polypeptide of the invention. See, for instance, Wilson *et al.*, *Cell* 37:767-778 (1984) at 777.

Antigenic epitope-bearing peptides and polypeptides of the invention preferably contain a sequence of at least seven, more preferably at least nine and most preferably between about at least about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention.

The epitope-bearing peptides and polypeptides of the invention may be produced by any conventional means. Houghten, R. A., "General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids", *Proc. Natl. Acad. Sci. USA* 82:5131-5135 (1985). This "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further described in U.S. Patent No. 4,631,211 to Houghten *et al.* (1986).

As one of skill in the art will appreciate, METH1 or METH2 polypeptides of the present invention and the epitope-bearing fragments thereof described above can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life *in vivo*. This has been shown, e.g., for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins (EPA 394,827; Traunecker *et al.*, *Nature* 331:84- 86 (1988)). Fusion proteins that have a disulfide-linked dimeric structure due to the IgG part can also be more efficient in binding and neutralizing other molecules than the monomeric METH1 or METH2 protein or protein fragment alone (Fountoulakis *et al.*, *J. Biochem.* 270:3958-3964 (1995)).

METH1 and METH2 Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clones or shown in SEQ ID NO:1 or SEQ ID NO:3. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20

-218-

nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clones or the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of METH1 or METH2 polynucleotide fragments include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:1 or SEQ ID NO:3 or the cDNA contained in the deposited clones. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:2 or SEQ ID NO:4 or encoded by the cDNA contained in the deposited clones. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, or 281 to the end of the coding region of SEQ ID NO:2 or SEQ ID NO:4. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted METH1 or METH2 protein as well as the mature form. Further preferred polypeptide fragments include the secreted

METH1 or METH2 protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted METH1 or METH2 polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted METH1 or METH2 protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these METH1 or METH2 polypeptide fragments are also preferred.

Particularly, N-terminal deletions of the METH1 polypeptide can be described by the general formula m-950, where m is an integer from 2 to 949, where m corresponds to the position of the amino acid residue identified in SEQ ID NO:2. Preferably, N-terminal deletions of the METH1 polypeptide of the invention shown as SEQ ID NO:2 include polypeptides comprising the amino acid sequence of residues: G-2 to S-950; N-3 to S-950; A-4 to S-950; E-5 to S-950; R-6 to S-950; A-7 to S-950; P-8 to S-950; G-9 to S-950; S-10 to S-950; R-11 to S-950; S-12 to S-950; F-13 to S-950; G-14 to S-950; P-15 to S-950; V-16 to S-950; P-17 to S-950; T-18 to S-950; L-19 to S-950; L-20 to S-950; L-21 to S-950; L-22 to S-950; A-23 to S-950; A-24 to S-950; A-25 to S-950; L-26 to S-950; L-27 to S-950; A-28 to S-950; V-29 to S-950; S-30 to S-950; D-31 to S-950; A-32 to S-950; L-33 to S-950; G-34 to S-950; R-35 to S-950; P-36 to S-950; S-37 to S-950; E-38 to S-950; E-39 to S-950; D-40 to S-950; E-41 to S-950; E-42 to S-950; L-43 to S-950; V-44 to S-950; V-45 to S-950; P-46 to S-950; E-47 to S-950; L-48 to S-950; E-49 to S-950; R-50 to S-950; A-51 to S-950; P-52 to S-950; G-53 to S-950; H-54 to S-950; G-55 to S-950; T-56 to S-950; T-57 to S-950; R-58 to S-950; L-59 to S-950; R-60 to S-950; L-61 to S-950; H-62 to S-950; A-63 to S-950; F-64 to S-950; D-65 to S-950; Q-66 to S-950; Q-67 to S-950; L-68 to S-950; D-69 to S-950; L-70 to S-950; E-71 to S-950; L-72 to S-950; R-73 to S-950; P-74 to S-950; D-75 to S-950; S-76 to S-950; S-77 to S-950; F-78 to S-950; L-79 to S-950; A-80 to S-950; P-81 to S-950; G-82 to S-950; F-83 to S-950; T-84 to S-950; L-85 to S-950; Q-86 to S-950; N-87 to S-950; V-88 to S-950; G-89 to S-950; R-90 to S-950; K-91 to S-950; S-92 to S-950; G-93 to S-950; S-94 to S-950; E-95 to S-950; T-96 to S-950; P-97 to S-950; L-98 to S-950; P-99 to S-950; E-100 to S-950; T-101 to S-950; D-102 to S-950; L-103 to S-950; A-104 to S-950; H-105 to S-

-220-

950; C-106 to S-950; F-107 to S-950; Y-108 to S-950; S-109 to S-950; G-110 to S-950;
T-111 to S-950; V-112 to S-950; N-113 to S-950; G-114 to S-950; D-115 to S-950; P-
116 to S-950; S-117 to S-950; S-118 to S-950; A-119 to S-950; A-120 to S-950; A-121
to S-950; L-122 to S-950; S-123 to S-950; L-124 to S-950; C-125 to S-950; E-126 to S-
5 950; G-127 to S-950; V-128 to S-950; R-129 to S-950; G-130 to S-950; A-131 to S-950;
F-132 to S-950; Y-133 to S-950; L-134 to S-950; L-135 to S-950; G-136 to S-950; E-137
to S-950; A-138 to S-950; Y-139 to S-950; F-140 to S-950; I-141 to S-950; Q-142 to S-
950; P-143 to S-950; L-144 to S-950; P-145 to S-950; A-146 to S-950; A-147 to S-950;
S-148 to S-950; E-149 to S-950; R-150 to S-950; L-151 to S-950; A-152 to S-950; T-153
10 to S-950; A-154 to S-950; A-155 to S-950; P-156 to S-950; G-157 to S-950; E-158 to S-
950; K-159 to S-950; P-160 to S-950; P-161 to S-950; A-162 to S-950; P-163 to S-950;
L-164 to S-950; Q-165 to S-950; F-166 to S-950; H-167 to S-950; L-168 to S-950; L-169
to S-950; R-170 to S-950; R-171 to S-950; N-172 to S-950; R-173 to S-950; Q-174 to S-
950; G-175 to S-950; D-176 to S-950; V-177 to S-950; G-178 to S-950; G-179 to S-950;
15 T-180 to S-950; C-181 to S-950; G-182 to S-950; V-183 to S-950; V-184 to S-950; D-
185 to S-950; D-186 to S-950; E-187 to S-950; P-188 to S-950; R-189 to S-950; P-190
to S-950; T-191 to S-950; G-192 to S-950; K-193 to S-950; A-194 to S-950; E-195 to S-
950; T-196 to S-950; E-197 to S-950; D-198 to S-950; E-199 to S-950; D-200 to S-950;
E-201 to S-950; G-202 to S-950; T-203 to S-950; E-204 to S-950; G-205 to S-950; E-206
20 to S-950; D-207 to S-950; E-208 to S-950; G-209 to S-950; P-210 to S-950; Q-211 to S-
950; W-212 to S-950; S-213 to S-950; P-214 to S-950; Q-215 to S-950; D-216 to S-950;
P-217 to S-950; A-218 to S-950; L-219 to S-950; Q-220 to S-950; G-221 to S-950; V-
222 to S-950; G-223 to S-950; Q-224 to S-950; P-225 to S-950; T-226 to S-950; G-227
to S-950; T-228 to S-950; G-229 to S-950; S-230 to S-950; I-231 to S-950; R-232 to S-
25 950; K-233 to S-950; K-234 to S-950; R-235 to S-950; F-236 to S-950; V-237 to S-950;
S-238 to S-950; S-239 to S-950; H-240 to S-950; R-241 to S-950; Y-242 to S-950; V-243
to S-950; E-244 to S-950; T-245 to S-950; M-246 to S-950; L-247 to S-950; V-248 to S-
950; A-249 to S-950; D-250 to S-950; Q-251 to S-950; S-252 to S-950; M-253 to S-950;
A-254 to S-950; E-255 to S-950; F-256 to S-950; H-257 to S-950; G-258 to S-950; S-259
30 to S-950; G-260 to S-950; L-261 to S-950; K-262 to S-950; H-263 to S-950; Y-264 to
S-950; L-265 to S-950; L-266 to S-950; T-267 to S-950; L-268 to S-950; F-269 to S-950;

-221-

S-270 to S-950; V-271 to S-950; A-272 to S-950; A-273 to S-950; R-274 to S-950; L-275 to S-950; Y-276 to S-950; K-277 to S-950; H-278 to S-950; P-279 to S-950; S-280 to S-950; I-281 to S-950; R-282 to S-950; N-283 to S-950; S-284 to S-950; V-285 to S-950; S-286 to S-950; L-287 to S-950; V-288 to S-950; V-289 to S-950; V-290 to S-950; K-291 to S-950; I-292 to S-950; L-293 to S-950; V-294 to S-950; I-295 to S-950; H-296 to S-950; D-297 to S-950; E-298 to S-950; Q-299 to S-950; K-300 to S-950; G-301 to S-950; P-302 to S-950; E-303 to S-950; V-304 to S-950; T-305 to S-950; S-306 to S-950; N-307 to S-950; A-308 to S-950; A-309 to S-950; L-310 to S-950; T-311 to S-950; L-312 to S-950; R-313 to S-950; N-314 to S-950; F-315 to S-950; C-316 to S-950; N-317 to S-950; W-318 to S-950; Q-319 to S-950; K-320 to S-950; Q-321 to S-950; H-322 to S-950; N-323 to S-950; P-324 to S-950; P-325 to S-950; S-326 to S-950; D-327 to S-950; R-328 to S-950; D-329 to S-950; A-330 to S-950; E-331 to S-950; H-332 to S-950; Y-333 to S-950; D-334 to S-950; T-335 to S-950; A-336 to S-950; I-337 to S-950; L-338 to S-950; F-339 to S-950; T-340 to S-950; R-341 to S-950; Q-342 to S-950; D-343 to S-950; L-344 to S-950; C-345 to S-950; G-346 to S-950; S-347 to S-950; Q-348 to S-950; T-349 to S-950; C-350 to S-950; D-351 to S-950; T-352 to S-950; L-353 to S-950; G-354 to S-950; M-355 to S-950; A-356 to S-950; D-357 to S-950; V-358 to S-950; G-359 to S-950; T-360 to S-950; V-361 to S-950; C-362 to S-950; D-363 to S-950; P-364 to S-950; S-365 to S-950; R-366 to S-950; S-367 to S-950; C-368 to S-950; S-369 to S-950; V-370 to S-950; I-371 to S-950; E-372 to S-950; D-373 to S-950; D-374 to S-950; G-375 to S-950; L-376 to S-950; Q-377 to S-950; A-378 to S-950; A-379 to S-950; F-380 to S-950; T-381 to S-950; T-382 to S-950; A-383 to S-950; H-384 to S-950; E-385 to S-950; L-386 to S-950; G-387 to S-950; H-388 to S-950; V-389 to S-950; F-390 to S-950; N-391 to S-950; M-392 to S-950; P-393 to S-950; H-394 to S-950; D-395 to S-950; D-396 to S-950; A-397 to S-950; K-398 to S-950; Q-399 to S-950; C-400 to S-950; A-401 to S-950; S-402 to S-950; L-403 to S-950; N-404 to S-950; G-405 to S-950; V-406 to S-950; N-407 to S-950; Q-408 to S-950; D-409 to S-950; S-410 to S-950; H-411 to S-950; M-412 to S-950; M-413 to S-950; A-414 to S-950; S-415 to S-950; M-416 to S-950; L-417 to S-950; S-418 to S-950; N-419 to S-950; L-420 to S-950; D-421 to S-950; H-422 to S-950; S-423 to S-950; Q-424 to S-950; P-425 to S-950; W-426 to S-950; S-427 to S-950; P-428 to S-950; C-429 to S-950; S-430 to S-950; A-431 to S-950; Y-432 to S-950; M-433 to S-950;

-222-

I-434 to S-950; T-435 to S-950; S-436 to S-950; F-437 to S-950; L-438 to S-950; D-439 to S-950; N-440 to S-950; G-441 to S-950; H-442 to S-950; G-443 to S-950; E-444 to S-950; C-445 to S-950; L-446 to S-950; M-447 to S-950; D-448 to S-950; K-449 to S-950; P-450 to S-950; Q-451 to S-950; N-452 to S-950; P-453 to S-950; I-454 to S-950; Q-455 to S-950; L-456 to S-950; P-457 to S-950; G-458 to S-950; D-459 to S-950; L-460 to S-950; P-461 to S-950; G-462 to S-950; T-463 to S-950; S-464 to S-950; Y-465 to S-950; D-466 to S-950; A-467 to S-950; N-468 to S-950; R-469 to S-950; Q-470 to S-950; C-471 to S-950; Q-472 to S-950; F-473 to S-950; T-474 to S-950; F-475 to S-950; G-476 to S-950; E-477 to S-950; D-478 to S-950; S-479 to S-950; K-480 to S-950; H-481 to S-950; C-482 to S-950; P-483 to S-950; D-484 to S-950; A-485 to S-950; A-486 to S-950; S-487 to S-950; T-488 to S-950; C-489 to S-950; S-490 to S-950; T-491 to S-950; L-492 to S-950; W-493 to S-950; C-494 to S-950; T-495 to S-950; G-496 to S-950; T-497 to S-950; S-498 to S-950; G-499 to S-950; G-500 to S-950; V-501 to S-950; L-502 to S-950; V-503 to S-950; C-504 to S-950; Q-505 to S-950; T-506 to S-950; K-507 to S-950; H-508 to S-950; F-509 to S-950; P-510 to S-950; W-511 to S-950; A-512 to S-950; D-513 to S-950; G-514 to S-950; T-515 to S-950; S-516 to S-950; C-517 to S-950; G-518 to S-950; E-519 to S-950; G-520 to S-950; K-521 to S-950; W-522 to S-950; C-523 to S-950; I-524 to S-950; N-525 to S-950; G-526 to S-950; K-527 to S-950; C-528 to S-950; V-529 to S-950; N-530 to S-950; K-531 to S-950; T-532 to S-950; D-533 to S-950; R-534 to S-950; K-535 to S-950; H-536 to S-950; F-537 to S-950; D-538 to S-950; T-539 to S-950; P-540 to S-950; F-541 to S-950; H-542 to S-950; G-543 to S-950; S-544 to S-950; W-545 to S-950; G-546 to S-950; M-547 to S-950; W-548 to S-950; G-549 to S-950; P-550 to S-950; W-551 to S-950; G-552 to S-950; D-553 to S-950; C-554 to S-950; S-555 to S-950; R-556 to S-950; T-557 to S-950; C-558 to S-950; G-559 to S-950; G-560 to S-950; G-561 to S-950; V-562 to S-950; Q-563 to S-950; Y-564 to S-950; T-565 to S-950; M-566 to S-950; R-567 to S-950; E-568 to S-950; C-569 to S-950; D-570 to S-950; N-571 to S-950; P-572 to S-950; V-573 to S-950; P-574 to S-950; K-575 to S-950; N-576 to S-950; G-577 to S-950; G-578 to S-950; K-579 to S-950; Y-580 to S-950; C-581 to S-950; E-582 to S-950; G-583 to S-950; K-584 to S-950; R-585 to S-950; V-586 to S-950; R-587 to S-950; Y-588 to S-950; R-589 to S-950; S-590 to S-950; C-591 to S-950; N-592 to S-950; L-593 to S-950; E-594 to S-950; D-595 to S-950; C-596 to S-950;

-223-

P-597 to S-950; D-598 to S-950; N-599 to S-950; N-600 to S-950; G-601 to S-950; K-602 to S-950; T-603 to S-950; F-604 to S-950; R-605 to S-950; E-606 to S-950; E-607 to S-950; Q-608 to S-950; C-609 to S-950; E-610 to S-950; A-611 to S-950; H-612 to S-950; N-613 to S-950; E-614 to S-950; F-615 to S-950; S-616 to S-950; K-617 to S-950; 5 A-618 to S-950; S-619 to S-950; F-620 to S-950; G-621 to S-950; S-622 to S-950; G-623 to S-950; P-624 to S-950; A-625 to S-950; V-626 to S-950; E-627 to S-950; W-628 to S-950; I-629 to S-950; P-630 to S-950; K-631 to S-950; Y-632 to S-950; A-633 to S-950; G-634 to S-950; V-635 to S-950; S-636 to S-950; P-637 to S-950; K-638 to S-950; D-639 to S-950; R-640 to S-950; C-641 to S-950; K-642 to S-950; L-643 to S-950; I-644 to S-950; 10 C-645 to S-950; Q-646 to S-950; A-647 to S-950; K-648 to S-950; G-649 to S-950; I-650 to S-950; G-651 to S-950; Y-652 to S-950; F-653 to S-950; F-654 to S-950; V-655 to S-950; L-656 to S-950; Q-657 to S-950; P-658 to S-950; K-659 to S-950; V-660 to S-950; V-661 to S-950; D-662 to S-950; G-663 to S-950; T-664 to S-950; P-665 to S-950; C-666 to S-950; S-667 to S-950; P-668 to S-950; D-669 to S-950; S-670 to S-950; T-671 to S-950; 15 S-672 to S-950; V-673 to S-950; C-674 to S-950; V-675 to S-950; Q-676 to S-950; G-677 to S-950; Q-678 to S-950; C-679 to S-950; V-680 to S-950; K-681 to S-950; A-682 to S-950; G-683 to S-950; C-684 to S-950; D-685 to S-950; R-686 to S-950; I-687 to S-950; I-688 to S-950; D-689 to S-950; S-690 to S-950; K-691 to S-950; K-692 to S-950; K-693 to S-950; F-694 to S-950; D-695 to S-950; K-696 to S-950; C-697 to S-950; 20 G-698 to S-950; V-699 to S-950; C-700 to S-950; G-701 to S-950; G-702 to S-950; N-703 to S-950; G-704 to S-950; S-705 to S-950; T-706 to S-950; C-707 to S-950; K-708 to S-950; K-709 to S-950; I-710 to S-950; S-711 to S-950; G-712 to S-950; S-713 to S-950; V-714 to S-950; T-715 to S-950; S-716 to S-950; A-717 to S-950; K-718 to S-950; P-719 to S-950; G-720 to S-950; Y-721 to S-950; H-722 to S-950; D-723 to S-950; I-724 to S-950; 25 I-725 to S-950; T-726 to S-950; I-727 to S-950; P-728 to S-950; T-729 to S-950; G-730 to S-950; A-731 to S-950; T-732 to S-950; N-733 to S-950; I-734 to S-950; E-735 to S-950; V-736 to S-950; K-737 to S-950; Q-738 to S-950; R-739 to S-950; N-740 to S-950; Q-741 to S-950; R-742 to S-950; G-743 to S-950; S-744 to S-950; R-745 to S-950; N-746 to S-950; N-747 to S-950; G-748 to S-950; S-749 to S-950; F-750 to S-950; 30 L-751 to S-950; A-752 to S-950; I-753 to S-950; K-754 to S-950; A-755 to S-950; A-756 to S-950; D-757 to S-950; G-758 to S-950; T-759 to S-950; Y-760 to S-950; I-761

-224-

to S-950; L-762 to S-950; N-763 to S-950; G-764 to S-950; D-765 to S-950; Y-766 to S-950; T-767 to S-950; L-768 to S-950; S-769 to S-950; T-770 to S-950; L-771 to S-950; E-772 to S-950; Q-773 to S-950; D-774 to S-950; I-775 to S-950; M-776 to S-950; Y-777 to S-950; K-778 to S-950; G-779 to S-950; V-780 to S-950; V-781 to S-950; L-782 to S-950; R-783 to S-950; Y-784 to S-950; S-785 to S-950; G-786 to S-950; S-787 to S-950; S-788 to S-950; A-789 to S-950; A-790 to S-950; L-791 to S-950; E-792 to S-950; R-793 to S-950; I-794 to S-950; R-795 to S-950; S-796 to S-950; F-797 to S-950; S-798 to S-950; P-799 to S-950; L-800 to S-950; K-801 to S-950; E-802 to S-950; P-803 to S-950; L-804 to S-950; T-805 to S-950; I-806 to S-950; Q-807 to S-950; V-808 to S-950; L-809 to S-950; T-810 to S-950; V-811 to S-950; G-812 to S-950; N-813 to S-950; A-814 to S-950; L-815 to S-950; R-816 to S-950; P-817 to S-950; K-818 to S-950; I-819 to S-950; K-820 to S-950; Y-821 to S-950; T-822 to S-950; Y-823 to S-950; F-824 to S-950; V-825 to S-950; K-826 to S-950; K-827 to S-950; K-828 to S-950; K-829 to S-950; E-830 to S-950; S-831 to S-950; F-832 to S-950; N-833 to S-950; A-834 to S-950; I-835 to S-950; P-836 to S-950; T-837 to S-950; F-838 to S-950; S-839 to S-950; A-840 to S-950; W-841 to S-950; V-842 to S-950; I-843 to S-950; E-844 to S-950; E-845 to S-950; W-846 to S-950; G-847 to S-950; E-848 to S-950; C-849 to S-950; S-850 to S-950; K-851 to S-950; S-852 to S-950; C-853 to S-950; E-854 to S-950; L-855 to S-950; G-856 to S-950; W-857 to S-950; Q-858 to S-950; R-859 to S-950; R-860 to S-950; L-861 to S-950; V-862 to S-950; E-863 to S-950; C-864 to S-950; R-865 to S-950; D-866 to S-950; I-867 to S-950; N-868 to S-950; G-869 to S-950; Q-870 to S-950; P-871 to S-950; A-872 to S-950; S-873 to S-950; E-874 to S-950; C-875 to S-950; A-876 to S-950; K-877 to S-950; E-878 to S-950; V-879 to S-950; K-880 to S-950; P-881 to S-950; A-882 to S-950; S-883 to S-950; T-884 to S-950; R-885 to S-950; P-886 to S-950; C-887 to S-950; A-888 to S-950; D-889 to S-950; H-890 to S-950; P-891 to S-950; C-892 to S-950; P-893 to S-950; Q-894 to S-950; W-895 to S-950; Q-896 to S-950; L-897 to S-950; G-898 to S-950; E-899 to S-950; W-900 to S-950; S-901 to S-950; S-902 to S-950; C-903 to S-950; S-904 to S-950; K-905 to S-950; T-906 to S-950; C-907 to S-950; G-908 to S-950; K-909 to S-950; G-910 to S-950; Y-911 to S-950; K-912 to S-950; K-913 to S-950; R-914 to S-950; S-915 to S-950; L-916 to S-950; K-917 to S-950; C-918 to S-950; L-919 to S-950; S-920 to S-950; H-921 to S-950; D-922 to S-950; G-923 to S-950; G-924 to S-

950; V-925 to S-950; L-926 to S-950; S-927 to S-950; H-928 to S-950; E-929 to S-950; S-930 to S-950; C-931 to S-950; D-932 to S-950; P-933 to S-950; L-934 to S-950; K-935 to S-950; K-936 to S-950; P-937 to S-950; K-938 to S-950; H-939 to S-950; F-940 to S-950; I-941 to S-950; D-942 to S-950; F-943 to S-950; C-944 to S-950; T-945 to S-950; of SEQ ID NO:2.

Moreover, C-terminal deletions of the METH1 polypeptide can also be described by the general formula $1-n_i$, where n_i is an integer from 2 to 950, where n corresponds to the position of amino acid residue identified in SEQ ID NO:2. Preferably, C-terminal deletions of the METH1 polypeptide of the invention shown as SEQ ID NO:2 include polypeptides comprising the amino acid sequence of residues: M-1 to C-949; M-1 to E-948; M-1 to A-947; M-1 to M-946; M-1 to T-945; M-1 to C-944; M-1 to F-943; M-1 to D-942; M-1 to I-941; M-1 to F-940; M-1 to H-939; M-1 to K-938; M-1 to P-937; M-1 to K-936; M-1 to K-935; M-1 to L-934; M-1 to P-933; M-1 to D-932; M-1 to C-931; M-1 to S-930; M-1 to E-929; M-1 to H-928; M-1 to S-927; M-1 to L-926; M-1 to V-925; M-1 to G-924; M-1 to G-923; M-1 to D-922; M-1 to H-921; M-1 to S-920; M-1 to L-919; M-1 to C-918; M-1 to K-917; M-1 to L-916; M-1 to S-915; M-1 to R-914; M-1 to K-913; M-1 to K-912; M-1 to Y-911; M-1 to G-910; M-1 to K-909; M-1 to G-908; M-1 to C-907; M-1 to T-906; M-1 to K-905; M-1 to S-904; M-1 to C-903; M-1 to S-902; M-1 to S-901; M-1 to W-900; M-1 to E-899; M-1 to G-898; M-1 to L-897; M-1 to Q-896; M-1 to W-895; M-1 to Q-894; M-1 to P-893; M-1 to C-892; M-1 to P-891; M-1 to H-890; M-1 to D-889; M-1 to A-888; M-1 to C-887; M-1 to P-886; M-1 to R-885; M-1 to T-884; M-1 to S-883; M-1 to A-882; M-1 to P-881; M-1 to K-880; M-1 to V-879; M-1 to E-878; M-1 to K-877; M-1 to A-876; M-1 to C-875; M-1 to E-874; M-1 to S-873; M-1 to A-872; M-1 to P-871; M-1 to Q-870; M-1 to G-869; M-1 to N-868; M-1 to I-867; M-1 to D-866; M-1 to R-865; M-1 to C-864; M-1 to E-863; M-1 to V-862; M-1 to L-861; M-1 to R-860; M-1 to R-859; M-1 to Q-858; M-1 to W-857; M-1 to G-856; M-1 to L-855; M-1 to E-854; M-1 to C-853; M-1 to S-852; M-1 to K-851; M-1 to S-850; M-1 to C-849; M-1 to E-848; M-1 to G-847; M-1 to W-846; M-1 to E-845; M-1 to E-844; M-1 to I-843; M-1 to V-842; M-1 to W-841; M-1 to A-840; M-1 to S-839; M-1 to F-838; M-1 to T-837; M-1 to P-836; M-1 to I-835; M-1 to A-834; M-1 to N-833; M-1 to F-832; M-1 to S-831; M-1 to E-830; M-1 to K-829; M-1 to K-828; M-1 to K-827; M-1 to K-826; M-1 to V-825; M-1 to F-824; M-

-226-

1 to Y-823; M-1 to T-822; M-1 to Y-821; M-1 to K-820; M-1 to I-819; M-1 to K-818;
M-1 to P-817; M-1 to R-816; M-1 to L-815; M-1 to A-814; M-1 to N-813; M-1 to G-812;
M-1 to V-811; M-1 to T-810; M-1 to L-809; M-1 to V-808; M-1 to Q-807; M-1 to I-806;
M-1 to T-805; M-1 to L-804; M-1 to P-803; M-1 to E-802; M-1 to K-801; M-1 to L-800;
5 M-1 to P-799; M-1 to S-798; M-1 to F-797; M-1 to S-796; M-1 to R-795; M-1 to I-794;
M-1 to R-793; M-1 to E-792; M-1 to L-791; M-1 to A-790; M-1 to A-789; M-1 to S-788;
M-1 to S-787; M-1 to G-786; M-1 to S-785; M-1 to Y-784; M-1 to R-783; M-1 to L-782;
M-1 to V-781; M-1 to V-780; M-1 to G-779; M-1 to K-778; M-1 to Y-777; M-1 to M-
776; M-1 to I-775; M-1 to D-774; M-1 to Q-773; M-1 to E-772; M-1 to L-771; M-1 to
10 T-770; M-1 to S-769; M-1 to L-768; M-1 to T-767; M-1 to Y-766; M-1 to D-765; M-1
to G-764; M-1 to N-763; M-1 to L-762; M-1 to I-761; M-1 to Y-760; M-1 to T-759; M-1
to G-758; M-1 to D-757; M-1 to A-756; M-1 to A-755; M-1 to K-754; M-1 to I-753; M-1
to A-752; M-1 to L-751; M-1 to F-750; M-1 to S-749; M-1 to G-748; M-1 to N-747; M-1
to N-746; M-1 to R-745; M-1 to S-744; M-1 to G-743; M-1 to R-742; M-1 to Q-741; M-1
15 to N-740; M-1 to R-739; M-1 to Q-738; M-1 to K-737; M-1 to V-736; M-1 to E-735; M-
1 to I-734; M-1 to N-733; M-1 to T-732; M-1 to A-731; M-1 to G-730; M-1 to T-729; M-
1 to P-728; M-1 to I-727; M-1 to T-726; M-1 to I-725; M-1 to I-724; M-1 to D-723; M-1
to H-722; M-1 to Y-721; M-1 to G-720; M-1 to P-719; M-1 to K-718; M-1 to A-717; M-
1 to S-716; M-1 to T-715; M-1 to V-714; M-1 to S-713; M-1 to G-712; M-1 to S-711;
20 M-1 to I-710; M-1 to K-709; M-1 to K-708; M-1 to C-707; M-1 to T-706; M-1 to S-705;
M-1 to G-704; M-1 to N-703; M-1 to G-702; M-1 to G-701; M-1 to C-700; M-1 to V-
699; M-1 to G-698; M-1 to C-697; M-1 to K-696; M-1 to D-695; M-1 to F-694; M-1 to
K-693; M-1 to K-692; M-1 to K-691; M-1 to S-690; M-1 to D-689; M-1 to I-688; M-1
to I-687; M-1 to R-686; M-1 to D-685; M-1 to C-684; M-1 to G-683; M-1 to A-682; M-1
25 to K-681; M-1 to V-680; M-1 to C-679; M-1 to Q-678; M-1 to G-677; M-1 to Q-676; M-
1 to V-675; M-1 to C-674; M-1 to V-673; M-1 to S-672; M-1 to T-671; M-1 to S-670;
M-1 to D-669; M-1 to P-668; M-1 to S-667; M-1 to C-666; M-1 to P-665; M-1 to T-664;
M-1 to G-663; M-1 to D-662; M-1 to V-661; M-1 to V-660; M-1 to K-659; M-1 to P-
658; M-1 to Q-657; M-1 to L-656; M-1 to V-655; M-1 to F-654; M-1 to F-653; M-1 to
30 Y-652; M-1 to G-651; M-1 to I-650; M-1 to G-649; M-1 to K-648; M-1 to A-647; M-1
to Q-646; M-1 to C-645; M-1 to I-644; M-1 to L-643; M-1 to K-642; M-1 to C-641; M-1

-227-

to R-640; M-1 to D-639; M-1 to K-638; M-1 to P-637; M-1 to S-636; M-1 to V-635; M-1
to G-634; M-1 to A-633; M-1 to Y-632; M-1 to K-631; M-1 to P-630; M-1 to I-629; M-1
to W-628; M-1 to E-627; M-1 to V-626; M-1 to A-625; M-1 to P-624; M-1 to G-623; M-
1 to S-622; M-1 to G-621; M-1 to F-620; M-1 to S-619; M-1 to A-618; M-1 to K-617;
5 M-1 to S-616; M-1 to F-615; M-1 to E-614; M-1 to N-613; M-1 to H-612; M-1 to A-611;
M-1 to E-610; M-1 to C-609; M-1 to Q-608; M-1 to E-607; M-1 to E-606; M-1 to R-605;
M-1 to F-604; M-1 to T-603; M-1 to K-602; M-1 to G-601; M-1 to N-600; M-1 to N-599;
M-1 to D-598; M-1 to P-597; M-1 to C-596; M-1 to D-595; M-1 to E-594; M-1 to L-593;
M-1 to N-592; M-1 to C-591; M-1 to S-590; M-1 to R-589; M-1 to Y-588; M-1 to R-587;
10 M-1 to V-586; M-1 to R-585; M-1 to K-584; M-1 to G-583; M-1 to E-582; M-1 to C-
581; M-1 to Y-580; M-1 to K-579; M-1 to G-578; M-1 to G-577; M-1 to N-576; M-1 to
K-575; M-1 to P-574; M-1 to V-573; M-1 to P-572; M-1 to N-571; M-1 to D-570; M-1
to C-569; M-1 to E-568; M-1 to R-567; M-1 to M-566; M-1 to T-565; M-1 to Y-564; M-
1 to Q-563; M-1 to V-562; M-1 to G-561; M-1 to G-560; M-1 to G-559; M-1 to C-558;
15 M-1 to T-557; M-1 to R-556; M-1 to S-555; M-1 to C-554; M-1 to D-553; M-1 to G-552;
M-1 to W-551; M-1 to P-550; M-1 to G-549; M-1 to W-548; M-1 to M-547; M-1 to G-
546; M-1 to W-545; M-1 to S-544; M-1 to G-543; M-1 to H-542; M-1 to F-541; M-1 to
P-540; M-1 to T-539; M-1 to D-538; M-1 to F-537; M-1 to H-536; M-1 to K-535; M-1
to R-534; M-1 to D-533; M-1 to T-532; M-1 to K-531; M-1 to N-530; M-1 to V-529; M-
20 1 to C-528; M-1 to K-527; M-1 to G-526; M-1 to N-525; M-1 to I-524; M-1 to C-523;
M-1 to W-522; M-1 to K-521; M-1 to G-520; M-1 to E-519; M-1 to G-518; M-1 to C-
517; M-1 to S-516; M-1 to T-515; M-1 to G-514; M-1 to D-513; M-1 to A-512; M-1 to
W-511; M-1 to P-510; M-1 to F-509; M-1 to H-508; M-1 to K-507; M-1 to T-506; M-1
to Q-505; M-1 to C-504; M-1 to V-503; M-1 to L-502; M-1 to V-501; M-1 to G-500; M-
25 1 to G-499; M-1 to S-498; M-1 to T-497; M-1 to G-496; M-1 to T-495; M-1 to C-494;
M-1 to W-493; M-1 to L-492; M-1 to T-491; M-1 to S-490; M-1 to C-489; M-1 to T-488;
M-1 to S-487; M-1 to A-486; M-1 to A-485; M-1 to D-484; M-1 to P-483; M-1 to C-482;
M-1 to H-481; M-1 to K-480; M-1 to S-479; M-1 to D-478; M-1 to E-477; M-1 to G-476;
M-1 to F-475; M-1 to T-474; M-1 to F-473; M-1 to Q-472; M-1 to C-471; M-1 to Q-470;
30 M-1 to R-469; M-1 to N-468; M-1 to A-467; M-1 to D-466; M-1 to Y-465; M-1 to S-
464; M-1 to T-463; M-1 to G-462; M-1 to P-461; M-1 to L-460; M-1 to D-459; M-1 to

-228-

G-458; M-1 to P-457; M-1 to L-456; M-1 to Q-455; M-1 to I-454; M-1 to P-453; M-1 to N-452; M-1 to Q-451; M-1 to P-450; M-1 to K-449; M-1 to D-448; M-1 to M-447; M-1 to L-446; M-1 to C-445; M-1 to E-444; M-1 to G-443; M-1 to H-442; M-1 to G-441; M-1 to N-440; M-1 to D-439; M-1 to L-438; M-1 to F-437; M-1 to S-436; M-1 to T-435; M-1 to I-434; M-1 to M-433; M-1 to Y-432; M-1 to A-431; M-1 to S-430; M-1 to C-429; M-1 to P-428; M-1 to S-427; M-1 to W-426; M-1 to P-425; M-1 to Q-424; M-1 to S-423; M-1 to H-422; M-1 to D-421; M-1 to L-420; M-1 to N-419; M-1 to S-418; M-1 to L-417; M-1 to M-416; M-1 to S-415; M-1 to A-414; M-1 to M-413; M-1 to M-412; M-1 to H-411; M-1 to S-410; M-1 to D-409; M-1 to Q-408; M-1 to N-407; M-1 to V-406; M-1 to G-405; M-1 to N-404; M-1 to L-403; M-1 to S-402; M-1 to A-401; M-1 to C-400; M-1 to Q-399; M-1 to K-398; M-1 to A-397; M-1 to D-396; M-1 to D-395; M-1 to H-394; M-1 to P-393; M-1 to M-392; M-1 to N-391; M-1 to F-390; M-1 to V-389; M-1 to H-388; M-1 to G-387; M-1 to L-386; M-1 to E-385; M-1 to H-384; M-1 to A-383; M-1 to T-382; M-1 to T-381; M-1 to F-380; M-1 to A-379; M-1 to A-378; M-1 to Q-377; M-1 to L-376; M-1 to G-375; M-1 to D-374; M-1 to D-373; M-1 to E-372; M-1 to I-371; M-1 to V-370; M-1 to S-369; M-1 to C-368; M-1 to S-367; M-1 to R-366; M-1 to S-365; M-1 to P-364; M-1 to D-363; M-1 to C-362; M-1 to V-361; M-1 to T-360; M-1 to G-359; M-1 to V-358; M-1 to D-357; M-1 to A-356; M-1 to M-355; M-1 to G-354; M-1 to L-353; M-1 to T-352; M-1 to D-351; M-1 to C-350; M-1 to T-349; M-1 to Q-348; M-1 to S-347; M-1 to G-346; M-1 to C-345; M-1 to L-344; M-1 to D-343; M-1 to Q-342; M-1 to R-341; M-1 to T-340; M-1 to F-339; M-1 to L-338; M-1 to I-337; M-1 to A-336; M-1 to T-335; M-1 to D-334; M-1 to Y-333; M-1 to H-332; M-1 to E-331; M-1 to A-330; M-1 to D-329; M-1 to R-328; M-1 to D-327; M-1 to S-326; M-1 to P-325; M-1 to P-324; M-1 to N-323; M-1 to H-322; M-1 to Q-321; M-1 to K-320; M-1 to Q-319; M-1 to W-318; M-1 to N-317; M-1 to C-316; M-1 to F-315; M-1 to N-314; M-1 to R-313; M-1 to L-312; M-1 to T-311; M-1 to L-310; M-1 to A-309; M-1 to A-308; M-1 to N-307; M-1 to S-306; M-1 to T-305; M-1 to V-304; M-1 to E-303; M-1 to P-302; M-1 to G-301; M-1 to K-300; M-1 to Q-299; M-1 to E-298; M-1 to D-297; M-1 to H-296; M-1 to I-295; M-1 to V-294; M-1 to L-293; M-1 to I-292; M-1 to K-291; M-1 to V-290; M-1 to V-289; M-1 to V-288; M-1 to L-287; M-1 to S-286; M-1 to V-285; M-1 to S-284; M-1 to N-283; M-1 to R-282; M-1 to I-281; M-1 to S-280; M-1 to P-279; M-1 to H-278; M-1 to K-277; M-1 to Y-276; M-1

-229-

to L-275; M-1 to R-274; M-1 to A-273; M-1 to A-272; M-1 to V-271; M-1 to S-270; M-1
to F-269; M-1 to L-268; M-1 to T-267; M-1 to L-266; M-1 to L-265; M-1 to Y-264; M-1
to H-263; M-1 to K-262; M-1 to L-261; M-1 to G-260; M-1 to S-259; M-1 to G-258; M-1
to H-257; M-1 to F-256; M-1 to E-255; M-1 to A-254; M-1 to M-253; M-1 to S-252; M-1
5 to Q-251; M-1 to D-250; M-1 to A-249; M-1 to V-248; M-1 to L-247; M-1 to M-246; M-
1 to T-245; M-1 to E-244; M-1 to V-243; M-1 to Y-242; M-1 to R-241; M-1 to H-240;
M-1 to S-239; M-1 to S-238; M-1 to V-237; M-1 to F-236; M-1 to R-235; M-1 to K-234;
M-1 to K-233; M-1 to R-232; M-1 to I-231; M-1 to S-230; M-1 to G-229; M-1 to T-228;
M-1 to G-227; M-1 to T-226; M-1 to P-225; M-1 to Q-224; M-1 to G-223; M-1 to V-222;
10 M-1 to G-221; M-1 to Q-220; M-1 to L-219; M-1 to A-218; M-1 to P-217; M-1 to D-216;
M-1 to Q-215; M-1 to P-214; M-1 to S-213; M-1 to W-212; M-1 to Q-211; M-1 to P-210;
M-1 to G-209; M-1 to E-208; M-1 to D-207; M-1 to E-206; M-1 to G-205; M-1 to E-204;
M-1 to T-203; M-1 to G-202; M-1 to E-201; M-1 to D-200; M-1 to E-199; M-1 to D-198;
M-1 to E-197; M-1 to T-196; M-1 to E-195; M-1 to A-194; M-1 to K-193; M-1 to G-192;
15 M-1 to T-191; M-1 to P-190; M-1 to R-189; M-1 to P-188; M-1 to E-187; M-1 to D-186;
M-1 to D-185; M-1 to V-184; M-1 to V-183; M-1 to G-182; M-1 to C-181; M-1 to T-
180; M-1 to G-179; M-1 to G-178; M-1 to V-177; M-1 to D-176; M-1 to G-175; M-1 to
Q-174; M-1 to R-173; M-1 to N-172; M-1 to R-171; M-1 to R-170; M-1 to L-169; M-1
to L-168; M-1 to H-167; M-1 to F-166; M-1 to Q-165; M-1 to L-164; M-1 to P-163; M-1
20 to A-162; M-1 to P-161; M-1 to P-160; M-1 to K-159; M-1 to E-158; M-1 to G-157; M-1
to P-156; M-1 to A-155; M-1 to A-154; M-1 to T-153; M-1 to A-152; M-1 to L-151; M-1
to R-150; M-1 to E-149; M-1 to S-148; M-1 to A-147; M-1 to A-146; M-1 to P-145; M-1
to L-144; M-1 to P-143; M-1 to Q-142; M-1 to I-141; M-1 to F-140; M-1 to Y-139; M-1
to A-138; M-1 to E-137; M-1 to G-136; M-1 to L-135; M-1 to L-134; M-1 to Y-133; M-1
25 to F-132; M-1 to A-131; M-1 to G-130; M-1 to R-129; M-1 to V-128; M-1 to G-127; M-
1 to E-126; M-1 to C-125; M-1 to L-124; M-1 to S-123; M-1 to L-122; M-1 to A-121;
M-1 to A-120; M-1 to A-119; M-1 to S-118; M-1 to S-117; M-1 to P-116; M-1 to D-115;
M-1 to G-114; M-1 to N-113; M-1 to V-112; M-1 to T-111; M-1 to G-110; M-1 to S-109;
M-1 to Y-108; M-1 to F-107; M-1 to C-106; M-1 to H-105; M-1 to A-104; M-1 to L-103;
30 M-1 to D-102; M-1 to T-101; M-1 to E-100; M-1 to P-99; M-1 to L-98; M-1 to P-97; M-
1 to T-96; M-1 to E-95; M-1 to S-94; M-1 to G-93; M-1 to S-92; M-1 to K-91; M-1 to

-230-

R-90; M-1 to G-89; M-1 to V-88; M-1 to N-87; M-1 to Q-86; M-1 to L-85; M-1 to T-84; M-1 to F-83; M-1 to G-82; M-1 to P-81; M-1 to A-80; M-1 to L-79; M-1 to F-78; M-1 to S-77; M-1 to S-76; M-1 to D-75; M-1 to P-74; M-1 to R-73; M-1 to L-72; M-1 to E-71; M-1 to L-70; M-1 to D-69; M-1 to L-68; M-1 to Q-67; M-1 to Q-66; M-1 to D-65; M-1 to F-64; M-1 to A-63; M-1 to H-62; M-1 to L-61; M-1 to R-60; M-1 to L-59; M-1 to R-58; M-1 to T-57; M-1 to T-56; M-1 to G-55; M-1 to H-54; M-1 to G-53; M-1 to P-52; M-1 to A-51; M-1 to R-50; M-1 to E-49; M-1 to L-48; M-1 to E-47; M-1 to P-46; M-1 to V-45; M-1 to V-44; M-1 to L-43; M-1 to E-42; M-1 to E-41; M-1 to D-40; M-1 to E-39; M-1 to E-38; M-1 to S-37; M-1 to P-36; M-1 to R-35; M-1 to G-34; M-1 to L-33; M-1 to A-32; M-1 to D-31; M-1 to S-30; M-1 to V-29; M-1 to A-28; M-1 to L-27; M-1 to L-26; M-1 to A-25; M-1 to A-24; M-1 to A-23; M-1 to L-22; M-1 to L-21; M-1 to L-20; M-1 to L-19; M-1 to T-18; M-1 to P-17; M-1 to V-16; M-1 to P-15; M-1 to G-14; M-1 to F-13; M-1 to S-12; M-1 to R-11; M-1 to S-10; M-1 to G-9; M-1 to P-8; M-1 to A-7; of SEQ ID NO:2. For example, any of the above listed N- or C-terminal deletions can be combined to produce a N- and C-terminal deleted METH1 polypeptide. Particularly preferred fragment of SEQ ID NO2 are H542-Q894 and K801-S950.

Likewise, C-terminal deletions of the polypeptide of the invention shown as SEQ ID NO:2 include polypeptides comprising the amino acid sequence of residues: F-236 to S-950; F-236 to C-949; F-236 to E-948; F-236 to A-947; F-236 to M-946; F-236 to T-945; F-236 to C-944; F-236 to F-943; F-236 to D-942; F-236 to I-941; F-236 to F-940; F-236 to H-939; F-236 to K-938; F-236 to P-937; F-236 to K-936; F-236 to K-935; F-236 to L-934; F-236 to P-933; F-236 to D-932; F-236 to C-931; F-236 to S-930; F-236 to E-929; F-236 to H-928; F-236 to S-927; F-236 to L-926; F-236 to V-925; F-236 to G-924; F-236 to G-923; F-236 to D-922; F-236 to H-921; F-236 to S-920; F-236 to L-919; F-236 to C-918; F-236 to K-917; F-236 to L-916; F-236 to S-915; F-236 to R-914; F-236 to K-913; F-236 to K-912; F-236 to Y-911; F-236 to G-910; F-236 to K-909; F-236 to G-908; F-236 to C-907; F-236 to T-906; F-236 to K-905; F-236 to S-904; F-236 to C-903; F-236 to S-902; F-236 to S-901; F-236 to W-900; F-236 to E-899; F-236 to G-898; F-236 to L-897; F-236 to Q-896; F-236 to W-895; F-236 to Q-894; F-236 to P-893; F-236 to C-892; F-236 to P-891; F-236 to H-890; F-236 to D-889; F-236 to A-888; F-236 to C-887; F-236 to P-886; F-236 to R-885; F-236 to T-884; F-236 to S-883; F-236 to A-882; F-236 to P-

-231-

881; F-236 to K-880; F-236 to V-879; F-236to E-878; F-236 to K-877; F-236 to A-876;
F-236 to C-875; F-236 to E-874; F-236 to S-873; F-236 to A-872; F-236 to P-871; F-236
to Q-870; F-236to G-869; F-236 to N-868; F-236 to I-867; F-236 to D-866; F-236 to R-
865; F-236 to C-864; F-236 to E-863; F-236 to V-862; F-236 to L-861; F-236to R-860;
5 F-236 to R-859; F-236 to Q-858; F-236 to W-857; F-236 to G-856; F-236 to L-855; F-
236 to E-854; F-236 to C-853; F-236 to S-852; F-236to K-851; F-236 to S-850; F-236
to C-849; F-236 to E-848; F-236 to G-847; F-236 to W-846; F-236 to E-845; F-236 to
E-844; F-236 to I-843; F-236to V-842; F-236 to W-841; F-236 to A-840; F-236 to S-839;
F-236 to F-838; F-236 to T-837; F-236 to P-836; F-236 to I-835; F-236 to A-834; F-
10 236to N-833; F-236 to F-832; F-236 to S-831; F-236 to E-830; F-236 to K-829; F-236
to K-828; F-236 to K-827; F-236 to K-826; F-236 to V-825; F-236to F-824; F-236 to Y-
823; F-236 to T-822; F-236 to Y-821; F-236 to K-820; F-236 to I-819; F-236 to K-818;
F-236 to P-817; F-236 to R-816; F-236to L-815; F-236 to A-814; F-236 to N-813; F-236
to G-812; F-236 to V-811; F-236 to T-810; F-236 to L-809; F-236 to V-808; F-236 to Q-
15 807; F-236to I-806; F-236 to T-805; F-236 to L-804; F-236 to P-803; F-236 to E-802; F-
236 to K-801; F-236 to L-800; F-236 to P-799; F-236 to S-798; F-236 toF-797; F-236 to
S-796; F-236 to R-795; F-236 to I-794; F-236 to R-793; F-236 to E-792; F-236 to L-791;
F-236 to A-790; F-236 to A-789; F-236 toS-788; F-236 to S-787; F-236 to G-786; F-236
to S-785; F-236 to Y-784; F-236 to R-783; F-236 to L-782; F-236 to V-781; F-236 to V-
20 780; F-236 toG-779; F-236 to K-778; F-236 to Y-777; F-236 to M-776; F-236 to I-775;
F-236 to D-774; F-236 to Q-773; F-236 to E-772; F-236 to L-771; F-236 toT-770; F-236
to S-769; F-236 to L-768; F-236 to T-767; F-236 to Y-766; F-236 to D-765; F-236 to G-
764; F-236 to N-763; F-236 to L-762; F-236 toI-761; F-236 to Y-760; F-236 to T-759;
F-236 to G-758; F-236 to D-757; F-236 to A-756; F-236 to A-755; F-236 to K-754; F-
25 236 to I-753; F-236 toA-752; F-236 to L-751; F-236 to F-750; F-236 to S-749; F-236 to
G-748; F-236 to N-747; F-236 to N-746; F-236 to R-745; F-236 to S-744; F-236 toG-
743; F-236 to R-742; F-236 to Q-741; F-236 to N-740; F-236 to R-739; F-236 to Q-738;
F-236 to K-737; F-236 to V-736; F-236 to E-735; F-236 toI-734; F-236 to N-733; F-236
to T-732; F-236 to A-731; F-236 to G-730; F-236 to T-729; F-236 to P-728; F-236 to I-
30 727; F-236 to T-726; F-236 toI-725; F-236 to I-724; F-236 to D-723; F-236 to H-722; F-
236 to Y-721; F-236 to G-720; F-236 to P-719; F-236 to K-718; F-236 to A-717; F-236

-232-

toS-716; F-236 to T-715; F-236 to V-714; F-236 to S-713; F-236 to G-712; F-236 to S-711; F-236 to I-710; F-236 to K-709; F-236 to K-708; F-236 to C-707; F-236 to T-706; F-236 to S-705; F-236 to G-704; F-236 to N-703; F-236 to G-702; F-236 to G-701; F-236 to C-700; F-236 to V-699; F-236 to G-698; F-236 to C-697; F-236 to K-696; F-236 to D-695; F-236 to F-694; F-236 to K-693; F-236 to K-692; F-236 to K-691; F-236 to S-690; F-236 to D-689; F-236 to I-688; F-236 to I-687; F-236 to R-686; F-236 to D-685; F-236 to C-684; F-236 to G-683; F-236 to A-682; F-236 to K-681; F-236 to V-680; F-236 to C-679; F-236 to Q-678; F-236 to G-677; F-236 to Q-676; F-236 to V-675; F-236 to C-674; F-236 to V-673; F-236 to S-672; F-236 to T-671; F-236 to S-670; F-236 to D-669; F-236 to P-668; F-236 to S-667; F-236 to C-666; F-236 to P-665; F-236 to T-664; F-236 to G-663; F-236 to D-662; F-236 to V-661; F-236 to V-660; F-236 to K-659; F-236 to P-658; F-236 to Q-657; F-236 to L-656; F-236 to V-655; F-236 to F-654; F-236 to F-653; F-236 to Y-652; F-236 to G-651; F-236 to I-650; F-236 to G-649; F-236 to K-648; F-236 to A-647; F-236 to Q-646; F-236 to C-645; F-236 to I-644; F-236 to L-643; F-236 to K-642; F-236 to C-641; F-236 to R-640; F-236 to D-639; F-236 to K-638; F-236 to P-637; F-236 to S-636; F-236 to V-635; F-236 to G-634; F-236 to A-633; F-236 to Y-632; F-236 to K-631; F-236 to P-630; F-236 to I-629; F-236 to W-628; F-236 to E-627; F-236 to V-626; F-236 to A-625; F-236 to P-624; F-236 to G-623; F-236 to S-622; F-236 to G-621; F-236 to F-620; F-236 to S-619; F-236 to A-618; F-236 to K-617; F-236 to S-616; F-236 to F-615; F-236 to E-614; F-236 to N-613; F-236 to H-612; F-236 to A-611; F-236 to E-610; F-236 to C-609; F-236 to Q-608; F-236 to E-607; F-236 to E-606; F-236 to R-605; F-236 to F-604; F-236 to T-603; F-236 to K-602; F-236 to G-601; F-236 to N-600; F-236 to N-599; F-236 to D-598; F-236 to P-597; F-236 to C-596; F-236 to D-595; F-236 to E-594; F-236 to L-593; F-236 to N-592; F-236 to C-591; F-236 to S-590; F-236 to R-589; F-236 to Y-588; F-236 to R-587; F-236 to V-586; F-236 to R-585; F-236 to K-584; F-236 to G-583; F-236 to E-582; F-236 to C-581; F-236 to Y-580; F-236 to K-579; F-236 to G-578; F-236 to G-577; F-236 to N-576; F-236 to K-575; F-236 to P-574; F-236 to V-573; F-236 to P-572; F-236 to N-571; F-236 to D-570; F-236 to C-569; F-236 to E-568; F-236 to R-567; F-236 to M-566; F-236 to T-565; F-236 to Y-564; F-236 to Q-563; F-236 to V-562; F-236 to G-561; F-236 to G-560; F-236 to G-559; F-236 to C-558; F-236 to T-557; F-236 to R-556; F-236 to S-555; F-236 to C-554; F-236 to D-553; F-236 to G-552; F-236 to W-

-233-

551; F-236 to P-550; F-236 to G-549; F-236 to W-548; F-236 to M-547; F-236 to G-546;
F-236to W-545; F-236 to S-544; F-236 to G-543; F-236 to H-542; F-236 to F-541; F-236
to P-540; F-236 to T-539; F-236 to D-538; F-236 to F-537; F-236to H-536; F-236 to K-
535; F-236 to R-534; F-236 to D-533; F-236 to T-532; F-236 to K-531; F-236 to N-530;
5 F-236 to V-529; F-236 to C-528; F-236to K-527; F-236 to G-526; F-236 to N-525; F-236
to I-524; F-236 to C-523; F-236 to W-522; F-236 to K-521; F-236 to G-520; F-236 to E-
519; F-236to G-518; F-236 to C-517; F-236 to S-516; F-236 to T-515; F-236 to G-514;
F-236 to D-513; F-236 to A-512; F-236 to W-511; F-236 to P-510; F-236to F-509; F-236
to H-508; F-236 to K-507; F-236 to T-506; F-236 to Q-505; F-236 to C-504; F-236 to V-
10 503; F-236 to L-502; F-236 to V-501; F-236to G-500; F-236 to G-499; F-236 to S-498;
F-236 to T-497; F-236 to G-496; F-236 to T-495; F-236 to C-494; F-236 to W-493; F-
236 to L-492; F-236to T-491; F-236 to S-490; F-236 to C-489; F-236 to T-488; F-236
to S-487; F-236 to A-486; F-236 to A-485; F-236 to D-484; F-236 to P-483; F-236to C-
482; F-236 to H-481; F-236 to K-480; F-236 to S-479; F-236 to D-478; F-236 to E-477;
15 F-236 to G-476; F-236 to F-475; F-236 to T-474; F-236to F-473; F-236 to Q-472; F-236
to C-471; F-236 to Q-470; F-236 to R-469; F-236 to N-468; F-236 to A-467; F-236 to D-
466; F-236 to Y-465; F-236to S-464; F-236 to T-463; F-236 to G-462; F-236 to P-461;
F-236 to L-460; F-236 to D-459; F-236 to G-458; F-236 to P-457; F-236 to L-456; F-
236to Q-455; F-236 to I-454; F-236 to P-453; F-236 to N-452; F-236 to Q-451; F-236 to
20 P-450; F-236 to K-449; F-236 to D-448; F-236 to M-447; F-236to L-446; F-236 to C-
445; F-236 to E-444; F-236 to G-443; F-236 to H-442; F-236 to G-441; F-236 to N-440;
F-236 to D-439; F-236 to L-438; F-236to F-437; F-236 to S-436; F-236 to T-435; F-236
to I-434; F-236 to M-433; F-236 to Y-432; F-236 to A-431; F-236 to S-430; F-236 to C-
429; F-236to P-428; F-236 to S-427; F-236 to W-426; F-236 to P-425; F-236 to Q-424;
25 F-236 to S-423; F-236 to H-422; F-236 to D-421; F-236 to L-420; F-236to N-419; F-236
to S-418; F-236 to L-417; F-236 to M-416; F-236 to S-415; F-236 to A-414; F-236 to M-
413; F-236 to M-412; F-236 to H-411; F-236 to S-410; F-236 to D-409; F-236 to Q-408;
F-236 to N-407; F-236 to V-406; F-236 to G-405; F-236 to N-404; F-236 to L-403; F-236
to S-402; F-236 to A-401; F-236 to C-400; F-236 to Q-399; F-236 to K-398; F-236 to A-
30 397; F-236 to D-396; F-236 to D-395; F-236 to H-394; F-236 to P-393; F-236 to M-392;
F-236 to N-391; F-236 to F-390; F-236 to V-389; F-236 to H-388; F-236 to G-387; F-236

-234-

to L-386; F-236 to E-385; F-236 to H-384; F-236 to A-383; F-236 to T-382; F-236 to T-381; F-236 to F-380; F-236 to A-379; F-236 to A-378; F-236 to Q-377; F-236 to L-376; F-236 to G-375; F-236 to D-374; F-236 to D-373; F-236 to E-372; F-236 to I-371; F-236 to V-370; F-236 to S-369; F-236 to C-368; F-236 to S-367; F-236 to R-366; F-236 to S-365; F-236 to P-364; F-236 to D-363; F-236 to C-362; F-236 to V-361; F-236 to T-360; F-236 to G-359; F-236 to V-358; F-236 to D-357; F-236 to A-356; F-236 to M-355; F-236 to G-354; F-236 to L-353; F-236 to T-352; F-236 to D-351; F-236 to C-350; F-236 to T-349; F-236 to Q-348; F-236 to S-347; F-236 to G-346; F-236 to C-345; F-236 to L-344; F-236 to D-343; F-236 to Q-342; F-236 to R-341; F-236 to T-340; F-236 to F-339; F-236 to L-338; F-236 to I-337; F-236 to A-336; F-236 to T-335; F-236 to D-334; F-236 to Y-333; F-236 to H-332; F-236 to E-331; F-236 to A-330; F-236 to D-329; F-236 to R-328; F-236 to D-327; F-236 to S-326; F-236 to P-325; F-236 to P-324; F-236 to N-323; F-236 to H-322; F-236 to Q-321; F-236 to K-320; F-236 to Q-319; F-236 to W-318; F-236 to N-317; F-236 to C-316; F-236 to F-315; F-236 to N-314; F-236 to R-313; F-236 to L-312; F-236 to T-311; F-236 to L-310; F-236 to A-309; F-236 to A-308; F-236 to N-307; F-236 to S-306; F-236 to T-305; F-236 to V-304; F-236 to E-303; F-236 to P-302; F-236 to G-301; F-236 to K-300; F-236 to Q-299; F-236 to E-298; F-236 to D-297; F-236 to H-296; F-236 to I-295; F-236 to V-294; F-236 to L-293; F-236 to I-292; F-236 to K-291; F-236 to V-290; F-236 to V-289; F-236 to V-288; F-236 to L-287; F-236 to S-286; F-236 to V-285; F-236 to S-284; F-236 to N-283; F-236 to R-282; F-236 to I-281; F-236 to S-280; F-236 to P-279; F-236 to H-278; F-236 to K-277; F-236 to Y-276; F-236 to L-275; F-236 to R-274; F-236 to A-273; F-236 to A-272; F-236 to V-271; F-236 to S-270; F-236 to F-269; F-236 to L-268; F-236 to T-267; F-236 to L-266; F-236 to L-265; F-236 to Y-264; F-236 to H-263; F-236 to K-262; F-236 to L-261; F-236 to G-260; F-236 to S-259; F-236 to G-258; F-236 to H-257; F-236 to F-256; F-236 to E-255; F-236 to A-254; F-236 to M-253; F-236 to S-252; F-236 to Q-251; F-236 to D-250; F-236 to A-249; F-236 to V-248; F-236 to L-247; F-236 to M-246; F-236 to T-245; F-236 to E-244; F-236 to V-243; and/or F-236 to Y-242 of SEQ ID NO:2.

Likewise, C-terminal deletions of the polypeptide of the invention shown as SEQ ID NO:2 include polypeptides comprising the amino acid sequence of residues: L-33 to S-950; L-33 to C-949; L-33 to E-948; L-33 to A-947; L-33 to M-946; L-33 to T-945; L-

-235-

33 to C-944; L-33 to F-943; L-33 to D-942; L-33 to I-941; L-33 to F-940; L-33 to H-939;
L-33 to K-938; L-33 to P-937; L-33 to K-936; L-33 to K-935; L-33 to L-934; L-33 to P-
933; L-33 to D-932; L-33 to C-931; L-33 to S-930; L-33 to E-929; L-33 to H-928; L-33
to S-927; L-33 to L-926; L-33 to V-925; L-33 to G-924; L-33 to G-923; L-33 to D-922;
5 L-33 to H-921; L-33 to S-920; L-33 to L-919; L-33 to C-918; L-33 to K-917; L-33 to L-
916; L-33 to S-915; L-33 to R-914; L-33 to K-913; L-33 to K-912; L-33 to Y-911; L-33
to G-910; L-33 to K-909; L-33 to G-908; L-33 to C-907; L-33 to T-906; L-33 to K-905;
L-33 to S-904; L-33 to C-903; L-33 to S-902; L-33 to S-901; L-33 to W-900; L-33 to E-
899; L-33 to G-898; L-33 to L-897; L-33 to Q-896; L-33 to W-895; L-33 to Q-894; L-33
10 to P-893; L-33 to C-892; L-33 to P-891; L-33 to H-890; L-33 to D-889; L-33 to A-888;
L-33 to C-887; L-33 to P-886; L-33 to R-885; L-33 to T-884; L-33 to S-883; L-33 to A-
882; L-33 to P-881; L-33 to K-880; L-33 to V-879; L-33 to E-878; L-33 to K-877; L-33
to A-876; L-33 to C-875; L-33 to E-874; L-33 to S-873; L-33 to A-872; L-33 to P-871;
L-33 to Q-870; L-33 to G-869; L-33 to N-868; L-33 to I-867; L-33 to D-866; L-33 to R-
15 865; L-33 to C-864; L-33 to E-863; L-33 to V-862; L-33 to L-861; L-33 to R-860; L-33
to R-859; L-33 to Q-858; L-33 to W-857; L-33 to G-856; L-33 to L-855; L-33 to E-854;
L-33 to C-853; L-33 to S-852; L-33 to K-851; L-33 to S-850; L-33 to C-849; L-33 to E-
848; L-33 to G-847; L-33 to W-846; L-33 to E-845; L-33 to E-844; L-33 to I-843; L-33
to V-842; L-33 to W-841; L-33 to A-840; L-33 to S-839; L-33 to F-838; L-33 to T-837;
20 L-33 to P-836; L-33 to I-835; L-33 to A-834; L-33 to N-833; L-33 to F-832; L-33 to S-
831; L-33 to E-830; L-33 to K-829; L-33 to K-828; L-33 to K-827; L-33 to K-826; L-33
to V-825; L-33 to F-824; L-33 to Y-823; L-33 to T-822; L-33 to Y-821; L-33 to K-820;
L-33 to I-819; L-33 to K-818; L-33 to P-817; L-33 to R-816; L-33 to L-815; L-33 to A-
814; L-33 to N-813; L-33 to G-812; L-33 to V-811; L-33 to T-810; L-33 to L-809; L-33
25 to V-808; L-33 to Q-807; L-33 to I-806; L-33 to T-805; L-33 to L-804; L-33 to P-803;
L-33 to E-802; L-33 to K-801; L-33 to L-800; L-33 to P-799; L-33 to S-798; L-33 to F-
797; L-33 to S-796; L-33 to R-795; L-33 to I-794; L-33 to R-793; L-33 to E-792; L-33
to L-791; L-33 to A-790; L-33 to A-789; L-33 to S-788; L-33 to S-787; L-33 to G-786;
L-33 to S-785; L-33 to Y-784; L-33 to R-783; L-33 to L-782; L-33 to V-781; L-33 to V-
30 780; L-33 to G-779; L-33 to K-778; L-33 to Y-777; L-33 to M-776; L-33 to I-775; L-33
to D-774; L-33 to Q-773; L-33 to E-772; L-33 to L-771; L-33 to T-770; L-33 to S-769;

-236-

L-33 to L-768; L-33 to T-767; L-33 to Y-766; L-33 to D-765; L-33 to G-764; L-33 to N-763; L-33 to L-762; L-33 to I-761; L-33 to Y-760; L-33 to T-759; L-33 to G-758; L-33 to D-757; L-33 to A-756; L-33 to A-755; L-33 to K-754; L-33 to I-753; L-33 to A-752; L-33 to L-751; L-33 to F-750; L-33 to S-749; L-33 to G-748; L-33 to N-747; L-33 to N-746; L-33 to R-745; L-33 to S-744; L-33 to G-743; L-33 to R-742; L-33 to Q-741; L-33 to N-740; L-33 to R-739; L-33 to Q-738; L-33 to K-737; L-33 to V-736; L-33 to E-735; L-33 to I-734; L-33 to N-733; L-33 to T-732; L-33 to A-731; L-33 to G-730; L-33 to T-729; L-33 to P-728; L-33 to I-727; L-33 to T-726; L-33 to I-725; L-33 to I-724; L-33 to D-723; L-33 to H-722; L-33 to Y-721; L-33 to G-720; L-33 to P-719; L-33 to K-718; L-33 to A-717; L-33 to S-716; L-33 to T-715; L-33 to V-714; L-33 to S-713; L-33 to G-712; L-33 to S-711; L-33 to I-710; L-33 to K-709; L-33 to K-708; L-33 to C-707; L-33 to T-706; L-33 to S-705; L-33 to G-704; L-33 to N-703; L-33 to G-702; L-33 to G-701; L-33 to C-700; L-33 to V-699; L-33 to G-698; L-33 to C-697; L-33 to K-696; L-33 to D-695; L-33 to F-694; L-33 to K-693; L-33 to K-692; L-33 to K-691; L-33 to S-690; L-33 to D-689; L-33 to I-688; L-33 to I-687; L-33 to R-686; L-33 to D-685; L-33 to C-684; L-33 to G-683; L-33 to A-682; L-33 to K-681; L-33 to V-680; L-33 to C-679; L-33 to Q-678; L-33 to G-677; L-33 to Q-676; L-33 to V-675; L-33 to C-674; L-33 to V-673; L-33 to S-672; L-33 to T-671; L-33 to S-670; L-33 to D-669; L-33 to P-668; L-33 to S-667; L-33 to C-666; L-33 to P-665; L-33 to T-664; L-33 to G-663; L-33 to D-662; L-33 to V-661; L-33 to V-660; L-33 to K-659; L-33 to P-658; L-33 to Q-657; L-33 to L-656; L-33 to V-655; L-33 to F-654; L-33 to F-653; L-33 to Y-652; L-33 to G-651; L-33 to I-650; L-33 to G-649; L-33 to K-648; L-33 to A-647; L-33 to Q-646; L-33 to C-645; L-33 to I-644; L-33 to L-643; L-33 to K-642; L-33 to C-641; L-33 to R-640; L-33 to D-639; L-33 to K-638; L-33 to P-637; L-33 to S-636; L-33 to V-635; L-33 to G-634; L-33 to A-633; L-33 to Y-632; L-33 to K-631; L-33 to P-630; L-33 to I-629; L-33 to W-628; L-33 to E-627; L-33 to V-626; L-33 to A-625; L-33 to P-624; L-33 to G-623; L-33 to S-622; L-33 to G-621; L-33 to F-620; L-33 to S-619; L-33 to A-618; L-33 to K-617; L-33 to S-616; L-33 to F-615; L-33 to E-614; L-33 to N-613; L-33 to H-612; L-33 to A-611; L-33 to E-610; L-33 to C-609; L-33 to Q-608; L-33 to E-607; L-33 to E-606; L-33 to R-605; L-33 to F-604; L-33 to T-603; L-33 to K-602; L-33 to G-601; L-33 to N-600; L-33 to N-599; L-33 to D-598; L-33 to P-597; L-33 to C-596; L-33 to D-595; L-33 to E-594; L-33 to L-

-237-

593; L-33 to N-592; L-33 to C-591; L-33 to S-590; L-33 to R-589; L-33 to Y-588; L-33 to R-587; L-33 to V-586; L-33 to R-585; L-33 to K-584; L-33 to G-583; L-33 to E-582; L-33 to C-581; L-33 to Y-580; L-33 to K-579; L-33 to G-578; L-33 to G-577; L-33 to N-576; L-33 to K-575; L-33 to P-574; L-33 to V-573; L-33 to P-572; L-33 to N-571; L-33 to D-570; L-33 to C-569; L-33 to E-568; L-33 to R-567; L-33 to M-566; L-33 to T-565; L-33 to Y-564; L-33 to Q-563; L-33 to V-562; L-33 to G-561; L-33 to G-560; L-33 to G-559; L-33 to C-558; L-33 to T-557; L-33 to R-556; L-33 to S-555; L-33 to C-554; L-33 to D-553; L-33 to G-552; L-33 to W-551; L-33 to P-550; L-33 to G-549; L-33 to W-548; L-33 to M-547; L-33 to G-546; L-33 to W-545; L-33 to S-544; L-33 to G-543; L-33 to H-542; L-33 to F-541; L-33 to P-540; L-33 to T-539; L-33 to D-538; L-33 to F-537; L-33 to H-536; L-33 to K-535; L-33 to R-534; L-33 to D-533; L-33 to T-532; L-33 to K-531; L-33 to N-530; L-33 to V-529; L-33 to C-528; L-33 to K-527; L-33 to G-526; L-33 to N-525; L-33 to I-524; L-33 to C-523; L-33 to W-522; L-33 to K-521; L-33 to G-520; L-33 to E-519; L-33 to G-518; L-33 to C-517; L-33 to S-516; L-33 to T-515; L-33 to G-514; L-33 to D-513; L-33 to A-512; L-33 to W-511; L-33 to P-510; L-33 to F-509; L-33 to H-508; L-33 to K-507; L-33 to T-506; L-33 to Q-505; L-33 to C-504; L-33 to V-503; L-33 to L-502; L-33 to V-501; L-33 to G-500; L-33 to G-499; L-33 to S-498; L-33 to T-497; L-33 to G-496; L-33 to T-495; L-33 to C-494; L-33 to W-493; L-33 to L-492; L-33 to T-491; L-33 to S-490; L-33 to C-489; L-33 to T-488; L-33 to S-487; L-33 to A-486; L-33 to A-485; L-33 to D-484; L-33 to P-483; L-33 to C-482; L-33 to H-481; L-33 to K-480; L-33 to S-479; L-33 to D-478; L-33 to E-477; L-33 to G-476; L-33 to F-475; L-33 to T-474; L-33 to F-473; L-33 to Q-472; L-33 to C-471; L-33 to Q-470; L-33 to R-469; L-33 to N-468; L-33 to A-467; L-33 to D-466; L-33 to Y-465; L-33 to S-464; L-33 to T-463; L-33 to G-462; L-33 to P-461; L-33 to L-460; L-33 to D-459; L-33 to G-458; L-33 to P-457; L-33 to L-456; L-33 to Q-455; L-33 to I-454; L-33 to P-453; L-33 to N-452; L-33 to Q-451; L-33 to P-450; L-33 to K-449; L-33 to D-448; L-33 to M-447; L-33 to L-446; L-33 to C-445; L-33 to E-444; L-33 to G-443; L-33 to H-442; L-33 to G-441; L-33 to N-440; L-33 to D-439; L-33 to L-438; L-33 to F-437; L-33 to S-436; L-33 to T-435; L-33 to I-434; L-33 to M-433; L-33 to Y-432; L-33 to A-431; L-33 to S-430; L-33 to C-429; L-33 to P-428; L-33 to S-427; L-33 to W-426; L-33 to P-425; L-33 to Q-424; L-33 to S-423; L-33 to H-422; L-33 to D-421; L-33 to L-420; L-33 to N-419; L-33 to S-418; L-33

-238-

to L-417; L-33 to M-416; L-33 to S-415; L-33 to A-414; L-33 to M-413; L-33 to M-412;
L-33 to H-411; L-33 to S-410; L-33 to D-409; L-33 to Q-408; L-33 to N-407; L-33 to V-
406; L-33 to G-405; L-33 to N-404; L-33 to L-403; L-33 to S-402; L-33 to A-401; L-33
to C-400; L-33 to Q-399; L-33 to K-398; L-33 to A-397; L-33 to D-396; L-33 to D-395;
5 L-33 to H-394; L-33 to P-393; L-33 to M-392; L-33 to N-391; L-33 to F-390; L-33 to V-
389; L-33 to H-388; L-33 to G-387; L-33 to L-386; L-33 to E-385; L-33 to H-384; L-33
to A-383; L-33 to T-382; L-33 to T-381; L-33 to F-380; L-33 to A-379; L-33 to A-378;
L-33 to Q-377; L-33 to L-376; L-33 to G-375; L-33 to D-374; L-33 to D-373; L-33 to E-
372; L-33 to I-371; L-33 to V-370; L-33 to S-369; L-33 to C-368; L-33 to S-367; L-33 to
10 R-366; L-33 to S-365; L-33 to P-364; L-33 to D-363; L-33 to C-362; L-33 to V-361; L-33
to T-360; L-33 to G-359; L-33 to V-358; L-33 to D-357; L-33 to A-356; L-33 to M-355;
L-33 to G-354; L-33 to L-353; L-33 to T-352; L-33 to D-351; L-33 to C-350; L-33 to T-
349; L-33 to Q-348; L-33 to S-347; L-33 to G-346; L-33 to C-345; L-33 to L-344; L-33
to D-343; L-33 to Q-342; L-33 to R-341; L-33 to T-340; L-33 to F-339; L-33 to L-338;
15 L-33 to I-337; L-33 to A-336; L-33 to T-335; L-33 to D-334; L-33 to Y-333; L-33 to H-
332; L-33 to E-331; L-33 to A-330; L-33 to D-329; L-33 to R-328; L-33 to D-327; L-33
to S-326; L-33 to P-325; L-33 to P-324; L-33 to N-323; L-33 to H-322; L-33 to Q-321;
L-33 to K-320; L-33 to Q-319; L-33 to W-318; L-33 to N-317; L-33 to C-316; L-33 to F-
315; L-33 to N-314; L-33 to R-313; L-33 to L-312; L-33 to T-311; L-33 to L-310; L-33
20 to A-309; L-33 to A-308; L-33 to N-307; L-33 to S-306; L-33 to T-305; L-33 to V-304;
L-33 to E-303; L-33 to P-302; L-33 to G-301; L-33 to K-300; L-33 to Q-299; L-33 to E-
298; L-33 to D-297; L-33 to H-296; L-33 to I-295; L-33 to V-294; L-33 to L-293; L-33
to I-292; L-33 to K-291; L-33 to V-290; L-33 to V-289; L-33 to V-288; L-33 to L-287;
L-33 to S-286; L-33 to V-285; L-33 to S-284; L-33 to N-283; L-33 to R-282; L-33 to I-
25 281; L-33 to S-280; L-33 to P-279; L-33 to H-278; L-33 to K-277; L-33 to Y-276; L-33
to L-275; L-33 to R-274; L-33 to A-273; L-33 to A-272; L-33 to V-271; L-33 to S-270;
L-33 to F-269; L-33 to L-268; L-33 to T-267; L-33 to L-266; L-33 to L-265; L-33 to Y-
264; L-33 to H-263; L-33 to K-262; L-33 to L-261; L-33 to G-260; L-33 to S-259; L-33
to G-258; L-33 to H-257; L-33 to F-256; L-33 to E-255; L-33 to A-254; L-33 to M-253;
30 L-33 to S-252; L-33 to Q-251; L-33 to D-250; L-33 to A-249; L-33 to V-248; L-33 to L-
247; L-33 to M-246; L-33 to T-245; L-33 to E-244; L-33 to V-243; L-33 to Y-242; L-33

-239-

to R-241; L-33 to H-240; L-33 to S-239; L-33 to S-238; L-33 to V-237; L-33 to F-236;
L-33 to R-235; L-33 to K-234; L-33 to K-233; L-33 to R-232; L-33 to I-231; L-33 to S-
230; L-33 to G-229; L-33 to T-228; L-33 to G-227; L-33 to T-226; L-33 to P-225; L-33
to Q-224; L-33 to G-223; L-33 to V-222; L-33 to G-221; L-33 to Q-220; L-33 to L-219;
5 L-33 to A-218; L-33 to P-217; L-33 to D-216; L-33 to Q-215; L-33 to P-214; L-33 to S-
213; L-33 to W-212; L-33 to Q-211; L-33 to P-210; L-33 to G-209; L-33 to E-208; L-33
to D-207; L-33 to E-206; L-33 to G-205; L-33 to E-204; L-33 to T-203; L-33 to G-202;
L-33 to E-201; L-33 to D-200; L-33 to E-199; L-33 to D-198; L-33 to E-197; L-33 to T-
196; L-33 to E-195; L-33 to A-194; L-33 to K-193; L-33 to G-192; L-33 to T-191; L-33
10 to P-190; L-33 to R-189; L-33 to P-188; L-33 to E-187; L-33 to D-186; L-33 to D-185;
L-33 to V-184; L-33 to V-183; L-33 to G-182; L-33 to C-181; L-33 to T-180; L-33 to G-
179; L-33 to G-178; L-33 to V-177; L-33 to D-176; L-33 to G-175; L-33 to Q-174; L-33
to R-173; L-33 to N-172; L-33 to R-171; L-33 to R-170; L-33 to L-169; L-33 to L-168;
L-33 to H-167; L-33 to F-166; L-33 to Q-165; L-33 to L-164; L-33 to P-163; L-33 to A-
15 162; L-33 to P-161; L-33 to P-160; L-33 to K-159; L-33 to E-158; L-33 to G-157; L-33
to P-156; L-33 to A-155; L-33 to A-154; L-33 to T-153; L-33 to A-152; L-33 to L-151;
L-33 to R-150; L-33 to E-149; L-33 to S-148; L-33 to A-147; L-33 to A-146; L-33 to P-
145; L-33 to L-144; L-33 to P-143; L-33 to Q-142; L-33 to I-141; L-33 to F-140; L-33
to Y-139; L-33 to A-138; L-33 to E-137; L-33 to G-136; L-33 to L-135; L-33 to L-134;
20 L-33 to Y-133; L-33 to F-132; L-33 to A-131; L-33 to G-130; L-33 to R-129; L-33 to V-
128; L-33 to G-127; L-33 to E-126; L-33 to C-125; L-33 to L-124; L-33 to S-123; L-33
to L-122; L-33 to A-121; L-33 to A-120; L-33 to A-119; L-33 to S-118; L-33 to S-117;
L-33 to P-116; L-33 to D-115; L-33 to G-114; L-33 to N-113; L-33 to V-112; L-33 to T-
111; L-33 to G-110; L-33 to S-109; L-33 to Y-108; L-33 to F-107; L-33 to C-106; L-33
25 to H-105; L-33 to A-104; L-33 to L-103; L-33 to D-102; L-33 to T-101; L-33 to E-100;
L-33 to P-99; L-33 to L-98; L-33 to P-97; L-33 to T-96; L-33 to E-95; L-33 to S-94; L-33
to G-93; L-33 to S-92; L-33 to K-91; L-33 to R-90; L-33 to G-89; L-33 to V-88; L-33 to
N-87; L-33 to Q-86; L-33 to L-85; L-33 to T-84; L-33 to F-83; L-33 to G-82; L-33 to P-
81; L-33 to A-80; L-33 to L-79; L-33 to F-78; L-33 to S-77; L-33 to S-76; L-33 to D-75;
30 L-33 to P-74; L-33 to R-73; L-33 to L-72; L-33 to E-71; L-33 to L-70; L-33 to D-69; L-
33 to L-68; L-33 to Q-67; L-33 to Q-66; L-33 to D-65; L-33 to F-64; L-33 to A-63; L-33

-240-

to H-62; L-33 to L-61; L-33 to R-60; L-33 to L-59; L-33 to R-58; L-33 to T-57; L-33 to T-56; L-33 to G-55; L-33 to H-54; L-33 to G-53; L-33 to P-52; L-33 to A-51; L-33 to R-50; L-33 to E-49; L-33 to L-48; L-33 to E-47; L-33 to P-46; L-33 to V-45; L-33 to V-44; L-33 to L-43; L-33 to E-42; L-33 to E-41; L-33 to D-40; and/or L-33 to E-39 of SEQ ID NO:2.

Deletion mutants of METH1 may also be made which comprise all or part of the additional sequence described in SEQ ID NO:125. For example, exemplary deletion mutants include: Q-2 to S-967; R-3 to S-967; A-4 to S-967; V-5 to S-967; P-6 to S-967; E-7 to S-967; G-8 to S-967; F-9 to S-967; G-10 to S-967; R-11 to S-976; R-12 to S-967; K-13 to S-967; L-14 to S-967; G-15 to S-967; S-16 to S-967; D-17 to S-967; and M-18 to S-967.

Moreover, N-terminal deletions of the METH2 polypeptide can be described by the general formula m_2 -890, where m_2 is an integer from 2 to 889, where m corresponds to the position of the amino acid residue identified in SEQ ID NO:4. Preferably, N-terminal deletions of the METH2 polypeptide of the invention shown as SEQ ID NO:4 include polypeptides comprising the amino acid sequence of residues: F-2 to L-890; P-3 to L-890; A-4 to L-890; P-5 to L-890; A-6 to L-890; A-7 to L-890; P-8 to L-890; R-9 to L-890; W-10 to L-890; L-11 to L-890; P-12 to L-890; F-13 to L-890; L-14 to L-890; L-15 to L-890; L-16 to L-890; L-17 to L-890; L-18 to L-890; L-19 to L-890; L-20 to L-890; L-21 to L-890; L-22 to L-890; P-23 to L-890; L-24 to L-890; A-25 to L-890; R-26 to L-890; G-27 to L-890; A-28 to L-890; P-29 to L-890; A-30 to L-890; R-31 to L-890; P-32 to L-890; A-33 to L-890; A-34 to L-890; G-35 to L-890; G-36 to L-890; Q-37 to L-890; A-38 to L-890; S-39 to L-890; E-40 to L-890; L-41 to L-890; V-42 to L-890; V-43 to L-890; P-44 to L-890; T-45 to L-890; R-46 to L-890; L-47 to L-890; P-48 to L-890; G-49 to L-890; S-50 to L-890; A-51 to L-890; G-52 to L-890; E-53 to L-890; L-54 to L-890; A-55 to L-890; L-56 to L-890; H-57 to L-890; L-58 to L-890; S-59 to L-890; A-60 to L-890; F-61 to L-890; G-62 to L-890; K-63 to L-890; G-64 to L-890; F-65 to L-890; V-66 to L-890; L-67 to L-890; R-68 to L-890; L-69 to L-890; A-70 to L-890; P-71 to L-890; D-72 to L-890; D-73 to L-890; S-74 to L-890; F-75 to L-890; L-76 to L-890; A-77 to L-890; P-78 to L-890; E-79 to L-890; F-80 to L-890; K-81 to L-890; I-82 to L-890; E-83 to L-890; R-84 to L-890; L-85 to L-890; G-86 to L-890; G-87 to L-890; S-88 to L-890;

-241-

G-89 to L-890; R-90 to L-890; A-91 to L-890; T-92 to L-890; G-93 to L-890; G-94 to L-890; E-95 to L-890; R-96 to L-890; G-97 to L-890; L-98 to L-890; R-99 to L-890; G-100 to L-890; C-101 to L-890; F-102 to L-890; F-103 to L-890; S-104 to L-890; G-105 to L-890; T-106 to L-890; V-107 to L-890; N-108 to L-890; G-109 to L-890; E-110 to L-890;
5 P-111 to L-890; E-112 to L-890; S-113 to L-890; L-114 to L-890; A-115 to L-890; A-116 to L-890; V-117 to L-890; S-118 to L-890; L-119 to L-890; C-120 to L-890; R-121 to L-890; G-122 to L-890; L-123 to L-890; S-124 to L-890; G-125 to L-890; S-126 to L-890; F-127 to L-890; L-128 to L-890; L-129 to L-890; D-130 to L-890; G-131 to L-890; E-132 to L-890; E-133 to L-890; F-134 to L-890; T-135 to L-890; I-136 to L-890; Q-137 to L-890;
10 P-138 to L-890; Q-139 to L-890; G-140 to L-890; A-141 to L-890; G-142 to L-890; G-143 to L-890; S-144 to L-890; L-145 to L-890; A-146 to L-890; Q-147 to L-890; P-148 to L-890; H-149 to L-890; R-150 to L-890; L-151 to L-890; Q-152 to L-890; R-153 to L-890; W-154 to L-890; G-155 to L-890; P-156 to L-890; A-157 to L-890; G-158 to L-890; A-159 to L-890; R-160 to L-890; P-161 to L-890; L-162 to L-890; P-163 to L-890;
15 R-164 to L-890; G-165 to L-890; P-166 to L-890; E-167 to L-890; W-168 to L-890; E-169 to L-890; V-170 to L-890; E-171 to L-890; T-172 to L-890; G-173 to L-890; E-174 to L-890; G-175 to L-890; Q-176 to L-890; R-177 to L-890; Q-178 to L-890; E-179 to L-890; R-180 to L-890; G-181 to L-890; D-182 to L-890; H-183 to L-890; Q-184 to L-890; E-185 to L-890; D-186 to L-890; S-187 to L-890; E-188 to L-890; E-189 to L-890;
20 E-190 to L-890; S-191 to L-890; Q-192 to L-890; E-193 to L-890; E-194 to L-890; E-195 to L-890; A-196 to L-890; E-197 to L-890; G-198 to L-890; A-199 to L-890; S-200 to L-890; E-201 to L-890; P-202 to L-890; P-203 to L-890; P-204 to L-890; P-205 to L-890; L-206 to L-890; G-207 to L-890; A-208 to L-890; T-209 to L-890; S-210 to L-890; R-211 to L-890; T-212 to L-890; K-213 to L-890; R-214 to L-890; F-215 to L-890;
25 V-216 to L-890; S-217 to L-890; E-218 to L-890; A-219 to L-890; R-220 to L-890; F-221 to L-890; V-222 to L-890; E-223 to L-890; T-224 to L-890; L-225 to L-890; L-226 to L-890; V-227 to L-890; A-228 to L-890; D-229 to L-890; A-230 to L-890; S-231 to L-890; M-232 to L-890; A-233 to L-890; A-234 to L-890; F-235 to L-890; Y-236 to L-890; G-237 to L-890; A-238 to L-890; D-239 to L-890; L-240 to L-890; Q-241 to L-890; N-242 to L-890; H-243 to L-890; I-244 to L-890; L-245 to L-890; T-246 to L-890; L-247 to L-890;
30 E-248 to L-890; M-248 to L-890; S-249 to L-890; V-250 to L-890; A-251 to L-890; A-252 to L-890;

-242-

R-253 to L-890; I-254 to L-890; Y-255 to L-890; K-256 to L-890; H-257 to L-890; P-258 to L-890; S-259 to L-890; I-260 to L-890; K-261 to L-890; N-262 to L-890; S-263 to L-890; I-264 to L-890; N-265 to L-890; L-266 to L-890; M-267 to L-890; V-268 to L-890; V-269 to L-890; K-270 to L-890; V-271 to L-890; L-272 to L-890; I-273 to L-890; V-274 to L-890; E-275 to L-890; D-276 to L-890; E-277 to L-890; K-278 to L-890; W-279 to L-890; G-280 to L-890; P-281 to L-890; E-282 to L-890; V-283 to L-890; S-284 to L-890; D-285 to L-890; N-286 to L-890; G-287 to L-890; G-288 to L-890; L-289 to L-890; T-290 to L-890; L-291 to L-890; R-292 to L-890; N-293 to L-890; F-294 to L-890; C-295 to L-890; N-296 to L-890; W-297 to L-890; Q-298 to L-890; R-299 to L-890; R-300 to L-890; F-301 to L-890; N-302 to L-890; Q-303 to L-890; P-304 to L-890; S-305 to L-890; D-306 to L-890; R-307 to L-890; H-308 to L-890; P-309 to L-890; E-310 to L-890; H-311 to L-890; Y-312 to L-890; D-313 to L-890; T-314 to L-890; A-315 to L-890; I-316 to L-890; L-317 to L-890; L-318 to L-890; T-319 to L-890; R-320 to L-890; Q-321 to L-890; N-322 to L-890; F-323 to L-890; C-324 to L-890; G-325 to L-890; Q-326 to L-890; E-327 to L-890; G-328 to L-890; L-329 to L-890; C-330 to L-890; D-331 to L-890; T-332 to L-890; L-333 to L-890; G-334 to L-890; V-335 to L-890; A-336 to L-890; D-337 to L-890; I-338 to L-890; G-339 to L-890; T-340 to L-890; I-341 to L-890; C-342 to L-890; D-343 to L-890; P-344 to L-890; N-345 to L-890; K-346 to L-890; S-347 to L-890; C-348 to L-890; S-349 to L-890; V-350 to L-890; I-351 to L-890; E-352 to L-890; D-353 to L-890; E-354 to L-890; G-355 to L-890; L-356 to L-890; Q-357 to L-890; A-358 to L-890; A-359 to L-890; H-360 to L-890; T-361 to L-890; L-362 to L-890; A-363 to L-890; H-364 to L-890; E-365 to L-890; L-366 to L-890; G-367 to L-890; H-368 to L-890; V-369 to L-890; L-370 to L-890; S-371 to L-890; M-372 to L-890; P-373 to L-890; H-374 to L-890; D-375 to L-890; D-376 to L-890; S-377 to L-890; K-378 to L-890; P-379 to L-890; C-380 to L-890; T-381 to L-890; R-382 to L-890; L-383 to L-890; F-384 to L-890; G-385 to L-890; P-386 to L-890; M-387 to L-890; G-388 to L-890; K-389 to L-890; H-390 to L-890; H-391 to L-890; V-392 to L-890; M-393 to L-890; A-394 to L-890; P-395 to L-890; L-396 to L-890; F-397 to L-890; V-398 to L-890; H-399 to L-890; L-400 to L-890; N-401 to L-890; Q-402 to L-890; T-403 to L-890; L-404 to L-890; P-405 to L-890; W-406 to L-890; S-407 to L-890; P-408 to L-890; C-409 to L-890; S-410 to L-890; A-411 to L-890; M-412 to L-890; Y-413 to L-890; L-414 to L-890; T-415 to L-890; E-

-243-

416 to L-890; L-417 to L-890; L-418 to L-890; D-419 to L-890; G-420 to L-890; G-421 to L-890; H-422 to L-890; G-423 to L-890; D-424 to L-890; C-425 to L-890; L-426 to L-890; L-427 to L-890; D-428 to L-890; A-429 to L-890; P-430 to L-890; G-431 to L-890; A-432 to L-890; A-433 to L-890; L-434 to L-890; P-435 to L-890; L-436 to L-890; 5 P-437 to L-890; T-438 to L-890; G-439 to L-890; L-440 to L-890; P-441 to L-890; G-442 to L-890; R-443 to L-890; M-444 to L-890; A-445 to L-890; L-446 to L-890; Y-447 to L-890; Q-448 to L-890; L-449 to L-890; D-450 to L-890; Q-451 to L-890; Q-452 to L-890; C-453 to L-890; R-454 to L-890; Q-455 to L-890; I-456 to L-890; F-457 to L-890; G-458 to L-890; P-459 to L-890; D-460 to L-890; F-461 to L-890; R-462 to L-890; H- 10 463 to L-890; C-464 to L-890; P-465 to L-890; N-466 to L-890; T-467 to L-890; S-468 to L-890; A-469 to L-890; Q-470 to L-890; D-471 to L-890; V-472 to L-890; C-473 to L-890; A-474 to L-890; Q-475 to L-890; L-476 to L-890; W-477 to L-890; C-478 to L-890; H-479 to L-890; T-480 to L-890; D-481 to L-890; G-482 to L-890; A-483 to L-890; E-484 to L-890; P-485 to L-890; L-486 to L-890; C-487 to L-890; H-488 to L-890; T-489 15 to L-890; K-490 to L-890; N-491 to L-890; G-492 to L-890; S-493 to L-890; L-494 to L-890; P-495 to L-890; W-496 to L-890; A-497 to L-890; D-498 to L-890; G-499 to L-890; T-500 to L-890; P-501 to L-890; C-502 to L-890; G-503 to L-890; P-504 to L-890; G-505 to L-890; H-506 to L-890; L-507 to L-890; C-508 to L-890; S-509 to L-890; E-510 to L-890; G-511 to L-890; S-512 to L-890; C-513 to L-890; L-514 to L-890; P-515 20 to L-890; E-516 to L-890; E-517 to L-890; E-518 to L-890; V-519 to L-890; E-520 to L-890; R-521 to L-890; P-522 to L-890; K-523 to L-890; P-524 to L-890; V-525 to L-890; V-526 to L-890; D-527 to L-890; G-528 to L-890; G-529 to L-890; W-530 to L-890; A-531 to L-890; P-532 to L-890; W-533 to L-890; G-534 to L-890; P-535 to L-890; W-536 to L-890; G-537 to L-890; E-538 to L-890; C-539 to L-890; S-540 to L-890; R-541 to L- 25 890; T-542 to L-890; C-543 to L-890; G-544 to L-890; G-545 to L-890; G-546 to L-890; V-547 to L-890; Q-548 to L-890; F-549 to L-890; S-550 to L-890; H-551 to L-890; R-552 to L-890; E-553 to L-890; C-554 to L-890; K-555 to L-890; D-556 to L-890; P-557 to L-890; E-558 to L-890; P-559 to L-890; Q-560 to L-890; N-561 to L-890; G-562 to L-890; G-563 to L-890; R-564 to L-890; Y-565 to L-890; C-566 to L-890; L-567 to L- 30 890; G-568 to L-890; R-569 to L-890; R-570 to L-890; A-571 to L-890; K-572 to L-890; Y-573 to L-890; Q-574 to L-890; S-575 to L-890; C-576 to L-890; H-577 to L-890; T-

-244-

578 to L-890; E-579 to L-890; E-580 to L-890; C-581 to L-890; P-582 to L-890; P-583 to L-890; D-584 to L-890; G-585 to L-890; K-586 to L-890; S-587 to L-890; F-588 to L-890; R-589 to L-890; E-590 to L-890; Q-591 to L-890; Q-592 to L-890; C-593 to L-890; E-594 to L-890; K-595 to L-890; Y-596 to L-890; N-597 to L-890; A-598 to L-890; Y-599 to L-890; N-600 to L-890; Y-601 to L-890; T-602 to L-890; D-603 to L-890; M-604 to L-890; D-605 to L-890; G-606 to L-890; N-607 to L-890; L-608 to L-890; L-609 to L-890; Q-610 to L-890; W-611 to L-890; V-612 to L-890; P-613 to L-890; K-614 to L-890; Y-615 to L-890; A-616 to L-890; G-617 to L-890; V-618 to L-890; S-619 to L-890; P-620 to L-890; R-621 to L-890; D-622 to L-890; R-623 to L-890; C-624 to L-890; K-625 to L-890; L-626 to L-890; F-627 to L-890; C-628 to L-890; R-629 to L-890; A-630 to L-890; R-631 to L-890; G-632 to L-890; R-633 to L-890; S-634 to L-890; E-635 to L-890; F-636 to L-890; K-637 to L-890; V-638 to L-890; F-639 to L-890; E-640 to L-890; A-641 to L-890; K-642 to L-890; V-643 to L-890; I-644 to L-890; D-645 to L-890; G-646 to L-890; T-647 to L-890; L-648 to L-890; C-649 to L-890; G-650 to L-890; P-651 to L-890; E-652 to L-890; T-653 to L-890; L-654 to L-890; A-655 to L-890; I-656 to L-890; C-657 to L-890; V-658 to L-890; R-659 to L-890; G-660 to L-890; Q-661 to L-890; C-662 to L-890; V-663 to L-890; K-664 to L-890; A-665 to L-890; G-666 to L-890; C-667 to L-890; D-668 to L-890; H-669 to L-890; V-670 to L-890; V-671 to L-890; D-672 to L-890; S-673 to L-890; P-674 to L-890; R-675 to L-890; K-676 to L-890; L-677 to L-890; D-678 to L-890; K-679 to L-890; C-680 to L-890; G-681 to L-890; V-682 to L-890; C-683 to L-890; G-684 to L-890; G-685 to L-890; K-686 to L-890; G-687 to L-890; N-688 to L-890; S-689 to L-890; C-690 to L-890; R-691 to L-890; K-692 to L-890; V-693 to L-890; S-694 to L-890; G-695 to L-890; S-696 to L-890; L-697 to L-890; T-698 to L-890; P-699 to L-890; T-700 to L-890; N-701 to L-890; Y-702 to L-890; G-703 to L-890; Y-704 to L-890; N-705 to L-890; D-706 to L-890; I-707 to L-890; V-708 to L-890; T-709 to L-890; I-710 to L-890; P-711 to L-890; A-712 to L-890; G-713 to L-890; A-714 to L-890; T-715 to L-890; N-716 to L-890; I-717 to L-890; D-718 to L-890; V-719 to L-890; K-720 to L-890; Q-721 to L-890; R-722 to L-890; S-723 to L-890; H-724 to L-890; P-725 to L-890; G-726 to L-890; V-727 to L-890; Q-728 to L-890; N-729 to L-890; D-730 to L-890; G-731 to L-890; N-732 to L-890; Y-733 to L-890; L-734 to L-890; A-735 to L-890; L-736 to L-890; K-737 to L-890; T-738 to L-890; A-739 to L-890; D-740 to L-

890; G-741 to L-890; Q-742 to L-890; Y-743 to L-890; L-744 to L-890; L-745 to L-890;
N-746 to L-890; G-747 to L-890; N-748 to L-890; L-749 to L-890; A-750 to L-890; I-751
to L-890; S-752 to L-890; A-753 to L-890; I-754 to L-890; E-755 to L-890; Q-756 to L-
890; D-757 to L-890; I-758 to L-890; L-759 to L-890; V-760 to L-890; K-761 to L-890;
5 G-762 to L-890; T-763 to L-890; I-764 to L-890; L-765 to L-890; K-766 to L-890; Y-767
to L-890; S-768 to L-890; G-769 to L-890; S-770 to L-890; I-771 to L-890; A-772 to L-
890; T-773 to L-890; L-774 to L-890; E-775 to L-890; R-776 to L-890; L-777 to L-890;
Q-778 to L-890; S-779 to L-890; F-780 to L-890; R-781 to L-890; P-782 to L-890; L-783
to L-890; P-784 to L-890; E-785 to L-890; P-786 to L-890; L-787 to L-890; T-788 to L-
10 890; V-789 to L-890; Q-790 to L-890; L-791 to L-890; L-792 to L-890; T-793 to L-890;
V-794 to L-890; P-795 to L-890; G-796 to L-890; E-797 to L-890; V-798 to L-890; F-
799 to L-890; P-800 to L-890; P-801 to L-890; K-802 to L-890; V-803 to L-890; K-804
to L-890; Y-805 to L-890; T-806 to L-890; F-807 to L-890; F-808 to L-890; V-809 to L-
890; P-810 to L-890; N-811 to L-890; D-812 to L-890; V-813 to L-890; D-814 to L-890;
15 F-815 to L-890; S-816 to L-890; M-817 to L-890; Q-818 to L-890; S-819 to L-890; S-820
to L-890; K-821 to L-890; E-822 to L-890; R-823 to L-890; A-824 to L-890; T-825 to
L-890; T-826 to L-890; N-827 to L-890; I-828 to L-890; I-829 to L-890; Q-830 to L-890;
P-831 to L-890; L-832 to L-890; L-833 to L-890; H-834 to L-890; A-835 to L-890; Q-
836 to L-890; W-837 to L-890; V-838 to L-890; L-839 to L-890; G-840 to L-890; D-841
20 to L-890; W-842 to L-890; S-843 to L-890; E-844 to L-890; C-845 to L-890; S-846 to
L-890; S-847 to L-890; T-848 to L-890; C-849 to L-890; G-850 to L-890; A-851 to L-
890; G-852 to L-890; W-853 to L-890; Q-854 to L-890; R-855 to L-890; R-856 to L-890;
T-857 to L-890; V-858 to L-890; E-859 to L-890; C-860 to L-890; R-861 to L-890; D-
862 to L-890; P-863 to L-890; S-864 to L-890; G-865 to L-890; Q-866 to L-890; A-867
25 to L-890; S-868 to L-890; A-869 to L-890; T-870 to L-890; C-871 to L-890; N-872 to L-
890; K-873 to L-890; A-874 to L-890; L-875 to L-890; K-876 to L-890; P-877 to L-890;
E-878 to L-890; D-879 to L-890; A-880 to L-890; K-881 to L-890; P-882 to L-890; C-
883 to L-890; E-884 to L-890; S-885 to L-890; of SEQ ID NO:4.

Moreover, C-terminal deletions of the METH2 polypeptide can also be described
30 by the general formula $1-n_2$, where n_2 is an integer from 2 to 890 where n corresponds to
the position of amino acid residue identified in SEQ ID NO:4. Preferably, C-terminal

deletions of the METH2 polypeptide of the invention shown as SEQ ID NO:4 include polypeptides comprising the amino acid sequence of residues: M-1 to P-889; M-1 to C-888; M-1 to L-887; M-1 to Q-886; M-1 to S-885; M-1 to E-884; M-1 to C-883; M-1 to P-882; M-1 to K-881; M-1 to A-880; M-1 to D-879; M-1 to E-878; M-1 to P-877; M-1 to K-876; M-1 to L-875; M-1 to A-874; M-1 to K-873; M-1 to N-872; M-1 to C-871; M-1 to T-870; M-1 to A-869; M-1 to S-868; M-1 to A-867; M-1 to Q-866; M-1 to G-865; M-1 to S-864; M-1 to P-863; M-1 to D-862; M-1 to R-861; M-1 to C-860; M-1 to E-859; M-1 to V-858; M-1 to T-857; M-1 to R-856; M-1 to R-855; M-1 to Q-854; M-1 to W-853; M-1 to G-852; M-1 to A-851; M-1 to G-850; M-1 to C-849; M-1 to T-848; M-1 to S-847; M-1 to S-846; M-1 to C-845; M-1 to E-844; M-1 to S-843; M-1 to W-842; M-1 to D-841; M-1 to G-840; M-1 to L-839; M-1 to V-838; M-1 to W-837; M-1 to Q-836; M-1 to A-835; M-1 to H-834; M-1 to L-833; M-1 to L-832; M-1 to P-831; M-1 to Q-830; M-1 to I-829; M-1 to I-828; M-1 to N-827; M-1 to T-826; M-1 to T-825; M-1 to A-824; M-1 to R-823; M-1 to E-822; M-1 to K-821; M-1 to S-820; M-1 to S-819; M-1 to Q-818; M-1 to M-817; M-1 to S-816; M-1 to F-815; M-1 to D-814; M-1 to V-813; M-1 to D-812; M-1 to N-811; M-1 to P-810; M-1 to V-809; M-1 to F-808; M-1 to F-807; M-1 to T-806; M-1 to Y-805; M-1 to K-804; M-1 to V-803; M-1 to K-802; M-1 to P-801; M-1 to P-800; M-1 to F-799; M-1 to V-798; M-1 to E-797; M-1 to G-796; M-1 to P-795; M-1 to V-794; M-1 to T-793; M-1 to L-792; M-1 to L-791; M-1 to Q-790; M-1 to V-789; M-1 to T-788; M-1 to L-787; M-1 to P-786; M-1 to E-785; M-1 to P-784; M-1 to L-783; M-1 to P-782; M-1 to R-781; M-1 to F-780; M-1 to S-779; M-1 to Q-778; M-1 to L-777; M-1 to R-776; M-1 to E-775; M-1 to L-774; M-1 to T-773; M-1 to A-772; M-1 to I-771; M-1 to S-770; M-1 to G-769; M-1 to S-768; M-1 to Y-767; M-1 to K-766; M-1 to L-765; M-1 to I-764; M-1 to T-763; M-1 to G-762; M-1 to K-761; M-1 to V-760; M-1 to L-759; M-1 to I-758; M-1 to D-757; M-1 to Q-756; M-1 to E-755; M-1 to I-754; M-1 to A-753; M-1 to S-752; M-1 to I-751; M-1 to A-750; M-1 to L-749; M-1 to N-748; M-1 to G-747; M-1 to N-746; M-1 to L-745; M-1 to L-744; M-1 to Y-743; M-1 to Q-742; M-1 to G-741; M-1 to D-740; M-1 to A-739; M-1 to T-738; M-1 to K-737; M-1 to L-736; M-1 to A-735; M-1 to L-734; M-1 to Y-733; M-1 to N-732; M-1 to G-731; M-1 to D-730; M-1 to N-729; M-1 to Q-728; M-1 to V-727; M-1 to G-726; M-1 to P-725; M-1 to H-724; M-1 to S-723; M-1 to R-722; M-1 to Q-721; M-1 to K-720; M-1 to V-719; M-1 to D-718; M-1 to I-717;

-247-

M-1 to N-716; M-1 to T-715; M-1 to A-714; M-1 to G-713; M-1 to A-712; M-1 to P-711;
M-1 to I-710; M-1 to T-709; M-1 to V-708; M-1 to I-707; M-1 to D-706; M-1 to N-705;
M-1 to Y-704; M-1 to G-703; M-1 to Y-702; M-1 to N-701; M-1 to T-700; M-1 to P-699;
M-1 to T-698; M-1 to L-697; M-1 to S-696; M-1 to G-695; M-1 to S-694; M-1 to V-693;
5 M-1 to K-692; M-1 to R-691; M-1 to C-690; M-1 to S-689; M-1 to N-688; M-1 to G-687;
M-1 to K-686; M-1 to G-685; M-1 to G-684; M-1 to C-683; M-1 to V-682; M-1 to G-
681; M-1 to C-680; M-1 to K-679; M-1 to D-678; M-1 to L-677; M-1 to K-676; M-1 to
R-675; M-1 to P-674; M-1 to S-673; M-1 to D-672; M-1 to V-671; M-1 to V-670; M-1
to H-669; M-1 to D-668; M-1 to C-667; M-1 to G-666; M-1 to A-665; M-1 to K-664; M-
10 M-1 to V-663; M-1 to C-662; M-1 to Q-661; M-1 to G-660; M-1 to R-659; M-1 to V-658;
M-1 to C-657; M-1 to I-656; M-1 to A-655; M-1 to L-654; M-1 to T-653; M-1 to E-652;
M-1 to P-651; M-1 to G-650; M-1 to C-649; M-1 to L-648; M-1 to T-647; M-1 to G-646;
M-1 to D-645; M-1 to I-644; M-1 to V-643; M-1 to K-642; M-1 to A-641; M-1 to E-640;
M-1 to F-639; M-1 to V-638; M-1 to K-637; M-1 to F-636; M-1 to E-635; M-1 to S-634;
15 M-1 to R-633; M-1 to G-632; M-1 to R-631; M-1 to A-630; M-1 to R-629; M-1 to C-
628; M-1 to F-627; M-1 to L-626; M-1 to K-625; M-1 to C-624; M-1 to R-623; M-1 to
D-622; M-1 to R-621; M-1 to P-620; M-1 to S-619; M-1 to V-618; M-1 to G-617; M-1
to A-616; M-1 to Y-615; M-1 to K-614; M-1 to P-613; M-1 to V-612; M-1 to W-611; M-
1 to Q-610; M-1 to L-609; M-1 to L-608; M-1 to N-607; M-1 to G-606; M-1 to D-605;
20 M-1 to M-604; M-1 to D-603; M-1 to T-602; M-1 to Y-601; M-1 to N-600; M-1 to Y-
599; M-1 to A-598; M-1 to N-597; M-1 to Y-596; M-1 to K-595; M-1 to E-594; M-1 to
C-593; M-1 to Q-592; M-1 to Q-591; M-1 to E-590; M-1 to R-589; M-1 to F-588; M-1
to S-587; M-1 to K-586; M-1 to G-585; M-1 to D-584; M-1 to P-583; M-1 to P-582; M-1
to C-581; M-1 to E-580; M-1 to E-579; M-1 to T-578; M-1 to H-577; M-1 to C-576; M-1
25 to S-575; M-1 to Q-574; M-1 to Y-573; M-1 to K-572; M-1 to A-571; M-1 to R-570; M-
1 to R-569; M-1 to G-568; M-1 to L-567; M-1 to C-566; M-1 to Y-565; M-1 to R-564;
M-1 to G-563; M-1 to G-562; M-1 to N-561; M-1 to Q-560; M-1 to P-559; M-1 to E-558;
M-1 to P-557; M-1 to D-556; M-1 to K-555; M-1 to C-554; M-1 to E-553; M-1 to R-552;
M-1 to H-551; M-1 to S-550; M-1 to F-549; M-1 to Q-548; M-1 to V-547; M-1 to G-546;
30 M-1 to G-545; M-1 to G-544; M-1 to C-543; M-1 to T-542; M-1 to R-541; M-1 to S-540;
M-1 to C-539; M-1 to E-538; M-1 to G-537; M-1 to W-536; M-1 to P-535; M-1 to G-

-248-

534; M-1 to W-533; M-1 to P-532; M-1 to A-531; M-1 to W-530; M-1 to G-529; M-1 to G-528; M-1 to D-527; M-1 to V-526; M-1 to V-525; M-1 to P-524; M-1 to K-523; M-1 to P-522; M-1 to R-521; M-1 to E-520; M-1 to V-519; M-1 to E-518; M-1 to E-517; M-1 to E-516; M-1 to P-515; M-1 to L-514; M-1 to C-513; M-1 to S-512; M-1 to G-511; M-1 to E-510; M-1 to S-509; M-1 to C-508; M-1 to L-507; M-1 to H-506; M-1 to G-505; M-1 to P-504; M-1 to G-503; M-1 to C-502; M-1 to P-501; M-1 to T-500; M-1 to G-499; M-1 to D-498; M-1 to A-497; M-1 to W-496; M-1 to P-495; M-1 to L-494; M-1 to S-493; M-1 to G-492; M-1 to N-491; M-1 to K-490; M-1 to T-489; M-1 to H-488; M-1 to C-487; M-1 to L-486; M-1 to P-485; M-1 to E-484; M-1 to A-483; M-1 to G-482; M-1 to D-481; M-1 to T-480; M-1 to H-479; M-1 to C-478; M-1 to W-477; M-1 to L-476; M-1 to Q-475; M-1 to A-474; M-1 to C-473; M-1 to V-472; M-1 to D-471; M-1 to Q-470; M-1 to A-469; M-1 to S-468; M-1 to T-467; M-1 to N-466; M-1 to P-465; M-1 to C-464; M-1 to H-463; M-1 to R-462; M-1 to F-461; M-1 to D-460; M-1 to P-459; M-1 to G-458; M-1 to F-457; M-1 to I-456; M-1 to Q-455; M-1 to R-454; M-1 to C-453; M-1 to Q-452; M-1 to Q-451; M-1 to D-450; M-1 to L-449; M-1 to Q-448; M-1 to Y-447; M-1 to L-446; M-1 to A-445; M-1 to M-444; M-1 to R-443; M-1 to G-442; M-1 to P-441; M-1 to L-440; M-1 to G-439; M-1 to T-438; M-1 to P-437; M-1 to L-436; M-1 to P-435; M-1 to L-434; M-1 to A-433; M-1 to A-432; M-1 to G-431; M-1 to P-430; M-1 to A-429; M-1 to D-428; M-1 to L-427; M-1 to L-426; M-1 to C-425; M-1 to D-424; M-1 to G-423; M-1 to H-422; M-1 to G-421; M-1 to G-420; M-1 to D-419; M-1 to L-418; M-1 to L-417; M-1 to E-416; M-1 to T-415; M-1 to L-414; M-1 to Y-413; M-1 to M-412; M-1 to A-411; M-1 to S-410; M-1 to C-409; M-1 to P-408; M-1 to S-407; M-1 to W-406; M-1 to P-405; M-1 to L-404; M-1 to T-403; M-1 to Q-402; M-1 to N-401; M-1 to L-400; M-1 to H-399; M-1 to V-398; M-1 to F-397; M-1 to L-396; M-1 to P-395; M-1 to A-394; M-1 to M-393; M-1 to V-392; M-1 to H-391; M-1 to H-390; M-1 to K-389; M-1 to G-388; M-1 to M-387; M-1 to P-386; M-1 to G-385; M-1 to F-384; M-1 to L-383; M-1 to R-382; M-1 to T-381; M-1 to C-380; M-1 to P-379; M-1 to K-378; M-1 to S-377; M-1 to D-376; M-1 to D-375; M-1 to H-374; M-1 to P-373; M-1 to M-372; M-1 to S-371; M-1 to L-370; M-1 to V-369; M-1 to H-368; M-1 to G-367; M-1 to L-366; M-1 to E-365; M-1 to H-364; M-1 to A-363; M-1 to L-362; M-1 to T-361; M-1 to H-360; M-1 to A-359; M-1 to A-358; M-1 to Q-357; M-1 to L-356; M-1 to G-355; M-1 to E-354; M-1 to D-353; M-1 to E-352;

-249-

M-1 to I-351; M-1 to V-350; M-1 to S-349; M-1 to C-348; M-1 to S-347; M-1 to K-346;
M-1 to N-345; M-1 to P-344; M-1 to D-343; M-1 to C-342; M-1 to I-341; M-1 to T-340;
M-1 to G-339; M-1 to I-338; M-1 to D-337; M-1 to A-336; M-1 to V-335; M-1 to G-334;
M-1 to L-333; M-1 to T-332; M-1 to D-331; M-1 to C-330; M-1 to L-329; M-1 to G-328;
5 M-1 to E-327; M-1 to Q-326; M-1 to G-325; M-1 to C-324; M-1 to F-323; M-1 to N-322;
M-1 to Q-321; M-1 to R-320; M-1 to T-319; M-1 to L-318; M-1 to L-317; M-1 to I-316;
M-1 to A-315; M-1 to T-314; M-1 to D-313; M-1 to Y-312; M-1 to H-311; M-1 to E-
310; M-1 to P-309; M-1 to H-308; M-1 to R-307; M-1 to D-306; M-1 to S-305; M-1 to
P-304; M-1 to Q-303; M-1 to N-302; M-1 to F-301; M-1 to R-300; M-1 to R-299; M-1
10 to Q-298; M-1 to W-297; M-1 to N-296; M-1 to C-295; M-1 to F-294; M-1 to N-293; M-
1 to R-292; M-1 to L-291; M-1 to T-290; M-1 to L-289; M-1 to G-288; M-1 to G-287;
M-1 to N-286; M-1 to D-285; M-1 to S-284; M-1 to V-283; M-1 to E-282; M-1 to P-281;
M-1 to G-280; M-1 to W-279; M-1 to K-278; M-1 to E-277; M-1 to D-276; M-1 to E-
275; M-1 to V-274; M-1 to I-273; M-1 to L-272; M-1 to V-271; M-1 to K-270; M-1 to
15 V-269; M-1 to V-268; M-1 to M-267; M-1 to L-266; M-1 to N-265; M-1 to I-264; M-1
to S-263; M-1 to N-262; M-1 to K-261; M-1 to I-260; M-1 to S-259; M-1 to P-258; M-1
to H-257; M-1 to K-256; M-1 to Y-255; M-1 to I-254; M-1 to R-253; M-1 to A-252; M-1
to A-251; M-1 to V-250; M-1 to S-249; M-1 to M-248; M-1 to L-247; M-1 to T-246; M-
1 to L-245; M-1 to I-244; M-1 to H-243; M-1 to N-242; M-1 to Q-241; M-1 to L-240; M-
20 1 to D-239; M-1 to A-238; M-1 to G-237; M-1 to Y-236; M-1 to F-235; M-1 to A-234;
M-1 to A-233; M-1 to M-232; M-1 to S-231; M-1 to A-230; M-1 to D-229; M-1 to A-
228; M-1 to V-227; M-1 to L-226; M-1 to L-225; M-1 to T-224; M-1 to E-223; M-1 to
V-222; M-1 to F-221; M-1 to R-220; M-1 to A-219; M-1 to E-218; M-1 to S-217; M-1
to V-216; M-1 to F-215; M-1 to R-214; M-1 to K-213; M-1 to T-212; M-1 to R-211; M-1
25 to S-210; M-1 to T-209; M-1 to A-208; M-1 to G-207; M-1 to L-206; M-1 to P-205; M-1
to P-204; M-1 to P-203; M-1 to P-202; M-1 to E-201; M-1 to S-200; M-1 to A-199; M-1
to G-198; M-1 to E-197; M-1 to A-196; M-1 to E-195; M-1 to E-194; M-1 to E-193; M-1
to Q-192; M-1 to S-191; M-1 to E-190; M-1 to E-189; M-1 to E-188; M-1 to S-187; M-1
to D-186; M-1 to E-185; M-1 to Q-184; M-1 to H-183; M-1 to D-182; M-1 to G-181; M-
30 1 to R-180; M-1 to E-179; M-1 to Q-178; M-1 to R-177; M-1 to Q-176; M-1 to G-175;
M-1 to E-174; M-1 to G-173; M-1 to T-172; M-1 to E-171; M-1 to V-170; M-1 to E-169;

-250-

M-1 to W-168; M-1 to E-167; M-1 to P-166; M-1 to G-165; M-1 to R-164; M-1 to P-163; M-1 to L-162; M-1 to P-161; M-1 to R-160; M-1 to A-159; M-1 to G-158; M-1 to A-157; M-1 to P-156; M-1 to G-155; M-1 to W-154; M-1 to R-153; M-1 to Q-152; M-1 to L-151; M-1 to R-150; M-1 to H-149; M-1 to P-148; M-1 to Q-147; M-1 to A-146; M-1 to L-145; M-1 to S-144; M-1 to G-143; M-1 to G-142; M-1 to A-141; M-1 to G-140; M-1 to Q-139; M-1 to P-138; M-1 to Q-137; M-1 to I-136; M-1 to T-135; M-1 to F-134; M-1 to E-133; M-1 to E-132; M-1 to G-131; M-1 to D-130; M-1 to L-129; M-1 to L-128; M-1 to F-127; M-1 to S-126; M-1 to G-125; M-1 to S-124; M-1 to L-123; M-1 to G-122; M-1 to R-121; M-1 to C-120; M-1 to L-119; M-1 to S-118; M-1 to V-117; M-1 to A-116; M-1 to A-115; M-1 to L-114; M-1 to S-113; M-1 to E-112; M-1 to P-111; M-1 to E-110; M-1 to G-109; M-1 to N-108; M-1 to V-107; M-1 to T-106; M-1 to G-105; M-1 to S-104; M-1 to F-103; M-1 to F-102; M-1 to C-101; M-1 to G-100; M-1 to R-99; M-1 to L-98; M-1 to G-97; M-1 to R-96; M-1 to E-95; M-1 to G-94; M-1 to G-93; M-1 to T-92; M-1 to A-91; M-1 to R-90; M-1 to G-89; M-1 to S-88; M-1 to G-87; M-1 to G-86; M-1 to L-85; M-1 to R-84; M-1 to E-83; M-1 to I-82; M-1 to K-81; M-1 to F-80; M-1 to E-79; M-1 to P-78; M-1 to A-77; M-1 to L-76; M-1 to F-75; M-1 to S-74; M-1 to D-73; M-1 to D-72; M-1 to P-71; M-1 to A-70; M-1 to L-69; M-1 to R-68; M-1 to L-67; M-1 to V-66; M-1 to F-65; M-1 to G-64; M-1 to K-63; M-1 to G-62; M-1 to F-61; M-1 to A-60; M-1 to S-59; M-1 to L-58; M-1 to H-57; M-1 to L-56; M-1 to A-55; M-1 to L-54; M-1 to E-53; M-1 to G-52; M-1 to A-51; M-1 to S-50; M-1 to G-49; M-1 to P-48; M-1 to L-47; M-1 to R-46; M-1 to T-45; M-1 to P-44; M-1 to V-43; M-1 to V-42; M-1 to L-41; M-1 to E-40; M-1 to S-39; M-1 to A-38; M-1 to Q-37; M-1 to G-36; M-1 to G-35; M-1 to A-34; M-1 to A-33; M-1 to P-32; M-1 to R-31; M-1 to A-30; M-1 to P-29; M-1 to A-28; M-1 to G-27; M-1 to R-26; M-1 to A-25; M-1 to L-24; M-1 to P-23; M-1 to L-22; M-1 to L-21; M-1 to L-20; M-1 to L-19; M-1 to L-18; M-1 to L-17; M-1 to L-16; M-1 to L-15; M-1 to L-14; M-1 to F-13; M-1 to P-12; M-1 to L-11; M-1 to W-10; M-1 to R-9; M-1 to P-8; M-1 to A-7; of SEQ ID NO:4. Preferably, any of the above listed N- or C-terminal deletions can be combined to produce a N- and C-terminal deleted METH2 polypeptide.

The invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as

-251-

having residues m_1 - n_1 of SEQ ID NO:2 or m_2 - n_2 SEQ ID NO:4, where n and m are integers as described above.

The invention also provides mutants of the metalloprotease domain of METH1, which are described by the general formula m_3 - n_3 , where m_3 is an integer from 205 to 265, and n_3 is an integer from 285 to 950, where m_3 and n_3 correspond to the position of the amino acid residue identified in SEQ ID NO:2. The invention further provides mutants of the metalloprotease domain of METH1, which are described by the general formula m_4 - n_4 , where m_4 is an integer from 1 to 409, and n_4 is an integer from 429 to 489, where m_4 and n_4 correspond to the position of the amino acid residue identified in SEQ ID NO:2.

The invention also provides mutants of the disintegrin domain of METH1, which are described by the general formula m_5 - n_5 , where m_5 is an integer from 430 to 490, and n_5 is an integer from 510 to 950, where m_5 and n_5 correspond to the position of the amino acid residue identified in SEQ ID NO:2.

The invention further provides mutants of the disintegrin domain of METH1, which are described by the general formula m_6 - n_6 , where m_6 is an integer from 1 to 494, and n_6 is an integer from 514 to 574, where m_6 and n_6 correspond to the position of the amino acid residue identified in SEQ ID NO:2.

The invention further provides mutants of the TSP1 domain of METH1, which are described by the general formula m_7 - n_7 , where m_7 is an integer from 515 to 575, and n_7 is an integer from 595 to 950, where m_7 and n_7 correspond to the position of the amino acid residue identified in SEQ ID NO:2.

The invention also provides mutants of the TSP1 domain of METH1, which are described by the general formula m_8 - n_8 , where m_8 is an integer from 1 to 548, and n_8 is an integer from 568 to 628, where m_8 and n_8 correspond to the position of the amino acid residue identified in SEQ ID NO:2.

The invention further provides mutants of the TSP2 domain of METH1, which are described by the general formula m_9 - n_9 , where m_9 is an integer from 801 to 871, and n_9 is an integer from 891 to 950, where m_9 and n_9 correspond to the position of the amino acid residue identified in SEQ ID NO:2.

-252-

The invention also provides mutants of the TSP2 domain of METH1, which are described by the general formula m_{10} - n_{10} , where m_{10} is an integer from 1 to 834, and n_{10} is an integer from 864 to 924, where m_{10} and n_{10} correspond to the position of the amino acid residue identified in SEQ ID NO:2.

5 The invention further provides mutants of the TSP3 domain of METH1, which are described by the general formula m_{11} - n_{11} , where m_{11} is an integer from 865 to 925, and n_{11} is an integer from 945 to 950, where m_{11} and n_{11} correspond to the position of the amino acid residue identified in SEQ ID NO:2. The invention also provides mutants of the TSP3 domain of METH1, which are described by the general formula m_{12} - n_{12} , where
10 m_{12} is an integer from 1 to 884, and n_{12} is an integer from 904 to 950, where m_{12} and n_{12} correspond to the position of the amino acid residue identified in SEQ ID NO:2.

The invention further provides mutants of the metalloprotease domain of METH2, which are described by the general formula m_{13} - n_{13} , where m_{13} is an integer from 184 to 244, and n_{13} is an integer from 264 to 890, where m_{13} and n_{13} correspond to the position
15 of the amino acid residue identified in SEQ ID NO:4. The invention also provides mutants of the metalloprotease domain of METH2, which are described by the general formula m_{14} - n_{14} , where m_{14} is an integer from 1 to 389, and n_{14} is an integer from 409 to 469, where m_{14} and n_{14} correspond to the position of the amino acid residue identified in SEQ ID NO:4.

20 The invention further provides mutants of the disintegrin domain of METH2, which are described by the general formula m_{15} - n_{15} , where m_{15} is an integer from 400 to 470, and n_{15} is an integer from 490 to 890, where m_{15} and n_{15} correspond to the position of the amino acid residue identified in SEQ ID NO:4. The invention also provides mutants of the disintegrin domain of METH2, which are described by the general formula
25 m_{16} - n_{16} , where m_{16} is an integer from 1 to 479, and n_{16} is an integer from 499 to 559, where m_{16} and n_{16} correspond to the position of the amino acid residue identified in SEQ ID NO:4.

30 The invention further provides mutants of the TSP1 domain of METH2, which are described by the general formula m_{17} - n_{17} , where m_{17} is an integer from 500 to 560, and n_{17} is an integer from 580 to 890, where m_{17} and n_{17} correspond to the position of the amino acid residue identified in SEQ ID NO:4. The invention also provides mutants of

-253-

the TSP1 domain of METH2, which are described by the general formula m_{18} - n_{18} , where m_{18} is an integer from 1 to 533, and n_{18} is an integer from 553 to 613, where m_{18} and n_{18} correspond to the position of the amino acid residue identified in SEQ ID NO:4.

5 The invention further provides mutants of the TSP2 domain of METH2, which are described by the general formula m_{19} - n_{19} , where m_{19} is an integer from 807 to 867, and n_{19} is an integer from 887 to 890, where m_{19} and n_{19} correspond to the position of the amino acid residue identified in SEQ ID NO:4. The invention also provides mutants of the TSP2 domain of METH2, which are described by the general formula m_{20} - n_{20} , where m_{20} is an integer from 1 to 840, and n_{20} is an integer from 860 to 890, where m_{20} and n_{20} correspond to the position of the amino acid residue identified in SEQ ID NO:4.

10 Also preferred are METH1 or METH2 polypeptide and polynucleotide fragments characterized by structural or functional domains. Preferred embodiments of the invention include fragments that comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-sheet and beta-sheet-forming regions ("beta-regions"), turn and turn-forming regions ("turn-regions"), coil and coil-forming regions ("coil-regions"), hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. As set out in the Figures, such preferred regions include Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions, Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle hydrophilic regions and hydrophobic regions, Eisenberg alpha and beta amphipathic regions, Karplus-Schulz flexible regions, Emini surface-forming regions, and Jameson-Wolf high antigenic index regions. Polypeptide fragments of SEQ ID NO:2 falling within conserved domains are specifically contemplated by the present invention. (See Figures 10 & 11 and Tables 1 & 2.) Moreover, polynucleotide fragments encoding these domains are also contemplated.

25 Other preferred fragments are biologically active METH1 or METH2 fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the METH1 or METH2 polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. However, many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences

30

-254-

are related to SEQ ID NO:1 or SEQ ID NO:3 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 936 of SEQ ID NO:1, b is an integer of 15 to 950, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:1, and where the b is greater than or equal to a + 14. Moreover, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 876 of SEQ ID NO:3, b is an integer of 15 to 890, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:3, and where the b is greater than or equal to a + 14.

The above-described fragments may be used to make fusion proteins, for example Fc or Flag fusion proteins, as described below.

Epitopes & Antibodies

In another aspect, the invention provides peptides and polypeptides comprising epitope-bearing portions of the polypeptides of the present invention. These epitopes are immunogenic or antigenic epitopes of the polypeptides of the present invention. An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response *in vivo* when the whole polypeptide of the present invention, or fragment thereof, is the immunogen. On the other hand, a region of a polypeptide to which an antibody can bind is defined as an "antigenic determinant" or "antigenic epitope." The number of *in vivo* immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, e.g., Geysen, *et al.* (1983) *Proc. Natl. Acad. Sci. USA* 81:3998- 4002. However, antibodies can be made to any antigenic epitope, regardless of whether it is an immunogenic epitope, by using methods such as phage display. See e.g., Petersen G. *et al.* (1995) *Mol. Gen. Genet.* 249:425-431. Therefore, included in the present invention are both immunogenic epitopes and antigenic epitopes.

-255-

A list of exemplified amino acid sequences comprising immunogenic epitopes are shown in Tables 1 and 2. It is pointed out that Tables 1 and 2 only list amino acid residues comprising epitopes predicted to have the highest degree of antigenicity using the algorithm of Jameson and Wolf, (1988) *Comp. Appl. Biosci.* 4:181-186 (said references incorporated by reference in their entireties). The Jameson-Wolf antigenic analysis was performed using the computer program PROTEAN, using default parameters (Version 3.11 for the Power MacIntosh, DNASTAR, Inc., 1228 South Park Street Madison, WI). Tables 1 and 2 and portions of polypeptides not listed in Tables 1 and 2 are not considered non-immunogenic. The immunogenic epitopes of Tables 1 and 2 are exemplified lists, not exhaustive lists, because other immunogenic epitopes are merely not recognized as such by the particular algorithm used. Amino acid residues comprising other immunogenic epitopes may be routinely determined using algorithms similar to the Jameson-Wolf analysis or by *in vivo* testing for an antigenic response using methods known in the art. See, e.g., Geysen *et al.*, supra; U.S. Patents 4,708,781; 5,194,392; 4,433,092; and 5,480,971 (said references incorporated by reference in their entireties).

Antigenic epitope-bearing peptides and polypeptides of the invention preferably contain a sequence of at least seven, more preferably at least nine and most preferably between about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention.

Using DNASTar analysis, SEQ ID NO:2 was found antigenic at amino acids: 2-14, 32-44, 47-60, 66-78, 87-103, 109-118, 146-162, 168-180, 183-219, 223-243, 275-284, 296-306, 314-334, 341-354, 357-376, 392-399, 401-410, 418-429, 438-454, 456-471, 474-488, 510-522, 524-538, 550-561, 565-626, 630-643, 659-671, 679-721, 734-749, 784-804, 813-820, 825-832, 845-854, 860-894, 899-917, 919-924 and 928-939.

Using DNASTar analysis, SEQ ID NO:4 was found antigenic at amino acids: 26-38, 45-52, 69-76, 80-99, 105-113, 129-136, 138-217, 254-263, 273-289, 294-313, 321-331, 339-356, 371-383, 417-427, 438-443, 459-471, 479-505, 507-526, 535-546, 550-607, 615-640, 648-653, 660-667, 669-681, 683-704, 717-732, 737-743, 775-787, 797-804, 811-825, 840-867 and 870-884.

-256-

Thus, these regions of METH1 and/or METH2 are non-limiting examples of antigenic polypeptides or peptides that can be used to raise METH1 and/or METH2-specific antibodies include.

It is particularly pointed out that the amino acid sequences of Tables 1 and 2
5 comprise immunogenic epitopes. Tables 1 and 2 list only the critical residues of immunogenic epitopes determined by the Jameson-Wolf analysis. Thus, additional flanking residues on either the N-terminal, C-terminal, or both N- and C-terminal ends may be added to the sequences of Tables 1 and 2 to generate an epitope-bearing polypeptide of the present invention. Therefore, the immunogenic epitopes of Tables 1
10 and 2 may include additional N-terminal or C-terminal amino acid residues. The additional flanking amino acid residues may be contiguous flanking N-terminal and/or C-terminal sequences from the polypeptides of the present invention, heterologous polypeptide sequences, or may include both contiguous flanking sequences from the polypeptides of the present invention and heterologous polypeptide sequences.

15 Polypeptides of the present invention comprising immunogenic or antigenic epitopes are at least 7 amino acids residues in length. "At least" means that a polypeptide of the present invention comprising an immunogenic or antigenic epitope may be 7 amino acid residues in length or any integer between 7 amino acids and the number of amino acid residues of the full length polypeptides of the invention. Preferred polypeptides
20 comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. However, it is pointed out that each and every integer between 7 and the number of amino acid residues of the full length polypeptide are included in the present invention.

The immuno and antigenic epitope-bearing fragments may be specified by either
25 the number of contiguous amino acid residues, as described above, or further specified by N-terminal and C-terminal positions of these fragments on the amino acid sequence of SEQ ID NO:2 or 4. Every combination of a N-terminal and C-terminal position that a fragment of, for example, at least 7 or at least 15 contiguous amino acid residues in length could occupy on the amino acid sequence of SEQ ID NO:2 or 4 is included in the
30 invention. Again, "at least 7 contiguous amino acid residues in length" means 7 amino acid residues in length or any integer between 7 amino acids and the number of amino

acid residues of the full length polypeptide of the present invention. Specifically, each and every integer between 7 and the number of amino acid residues of the full length polypeptide are included in the present invention.

Immunogenic and antigenic epitope-bearing polypeptides of the invention are useful, for example, to make antibodies which specifically bind the polypeptides of the invention, and in immunoassays to detect the polypeptides of the present invention. The antibodies are useful, for example, in affinity purification of the polypeptides of the present invention. The antibodies may also routinely be used in a variety of qualitative or quantitative immunoassays, specifically for the polypeptides of the present invention using methods known in the art. See, e.g., Harlow *et al.*, *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press; 2nd Ed. 1988).

The epitope-bearing polypeptides of the present invention may be produced by any conventional means for making polypeptides including synthetic and recombinant methods known in the art. For instance, epitope-bearing peptides may be synthesized using known methods of chemical synthesis. For instance, Houghten has described a simple method for the synthesis of large numbers of peptides, such as 10-20 mgs of 248 individual and distinct 13 residue peptides representing single amino acid variants of a segment of the HA1 polypeptide, all of which were prepared and characterized (by ELISA-type binding studies) in less than four weeks (Houghten, R. A. *Proc. Natl. Acad. Sci. USA* 82:5131-5135 (1985)). This "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further described in U.S. Patent No. 4,631,211 to Houghten and coworkers (1986). In this procedure the individual resins for the solid-phase synthesis of various peptides are contained in separate solvent-permeable packets, enabling the optimal use of the many identical repetitive steps involved in solid-phase methods. A completely manual procedure allows 500-1000 or more syntheses to be conducted simultaneously (Houghten *et al.* (1985) *Proc. Natl. Acad. Sci.* 82:5131-5135 at 5134).

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID NO:2 and/or 4, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC Deposit No. 209581 or 209582 or PTA 1478 or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:1

and/or 3 or contained in ATCC Deposit No: 209581 or 209582 or PTA 1478 under stringent hybridization conditions or lower stringency hybridization conditions as defined *supra*. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:1 or 3) polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower stringency hybridization conditions defined *supra*.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described *infra*. (See, for example, Geysen *et al.*, *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, *e.g.*, Houghten, *Proc. Natl. Acad. Sci. USA* 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additionally preferred antigenic epitopes of METH1 comprise, or alternatively

-259-

consist of, the amino acid sequence of residues: M-1 to P-15; G-2 to V-16; N-3 to P-17; A-4 to T-18; E-5 to L-19; R-6 to L-20; A-7 to L-21; P-8 to L-22; G-9 to A-23; S-10 to A-24; R-11 to A-25; S-12 to L-26; F-13 to L-27; G-14 to A-28; P-15 to V-29; V-16 to S-30; P-17 to D-31; T-18 to A-32; L-19 to L-33; L-20 to G-34; L-21 to R-35; L-22 to P-36; A-23 to S-37; A-24 to E-38; A-25 to E-39; L-26 to D-40; L-27 to E-41; A-28 to E-42; V-29 to L-43; S-30 to V-44; D-31 to V-45; A-32 to P-46; L-33 to E-47; G-34 to L-48; R-35 to E-49; P-36 to R-50; S-37 to A-51; E-38 to P-52; E-39 to G-53; D-40 to H-54; E-41 to G-55; E-42 to T-56; L-43 to T-57; V-44 to R-58; V-45 to L-59; P-46 to R-60; E-47 to L-61; L-48 to H-62; E-49 to A-63; R-50 to F-64; A-51 to D-65; P-52 to Q-66; G-53 to Q-67; H-54 to L-68; G-55 to D-69; T-56 to L-70; T-57 to E-71; R-58 to L-72; L-59 to R-73; R-60 to P-74; L-61 to D-75; H-62 to S-76; A-63 to S-77; F-64 to F-78; D-65 to L-79; Q-66 to A-80; Q-67 to P-81; L-68 to G-82; D-69 to F-83; L-70 to T-84; E-71 to L-85; L-72 to Q-86; R-73 to N-87; P-74 to V-88; D-75 to G-89; S-76 to R-90; S-77 to K-91; F-78 to S-92; L-79 to G-93; A-80 to S-94; P-81 to E-95; G-82 to T-96; F-83 to P-97; T-84 to L-98; L-85 to P-99; Q-86 to E-100; N-87 to T-101; V-88 to D-102; G-89 to L-103; R-90 to A-104; K-91 to H-105; S-92 to C-106; G-93 to F-107; S-94 to Y-108; E-95 to S-109; T-96 to G-110; P-97 to T-111; L-98 to V-112; P-99 to N-113; E-100 to G-114; T-101 to D-115; D-102 to P-116; L-103 to S-117; A-104 to S-118; H-105 to A-119; C-106 to A-120; F-107 to A-121; Y-108 to L-122; S-109 to S-123; G-110 to L-124; T-111 to C-125; V-112 to E-126; N-113 to G-127; G-114 to V-128; D-115 to R-129; P-116 to G-130; S-117 to A-131; S-118 to F-132; A-119 to Y-133; A-120 to L-134; A-121 to L-135; L-122 to G-136; S-123 to E-137; L-124 to A-138; C-125 to Y-139; E-126 to F-140; G-127 to I-141; V-128 to Q-142; R-129 to P-143; G-130 to L-144; A-131 to P-145; F-132 to A-146; Y-133 to A-147; L-134 to S-148; L-135 to E-149; G-136 to R-150; E-137 to L-151; A-138 to A-152; Y-139 to T-153; F-140 to A-154; I-141 to A-155; Q-142 to P-156; P-143 to G-157; L-144 to E-158; P-145 to K-159; A-146 to P-160; A-147 to P-161; S-148 to A-162; E-149 to P-163; R-150 to L-164; L-151 to Q-165; A-152 to F-166; T-153 to H-167; A-154 to L-168; A-155 to L-169; P-156 to R-170; G-157 to R-171; E-158 to N-172; K-159 to R-173; P-160 to Q-174; P-161 to G-175; A-162 to D-176; P-163 to V-177; L-164 to G-178; Q-165 to G-179; F-166 to T-180; H-167 to C-181; L-168 to G-182; L-169 to

-260-

V-183; R-170 to V-184; R-171 to D-185; N-172 to D-186; R-173 to E-187; Q-174 to P-188; G-175 to R-189; D-176 to P-190; V-177 to T-191; G-178 to G-192; G-179 to K-193; T-180 to A-194; C-181 to E-195; G-182 to T-196; V-183 to E-197; V-184 to D-198; D-185 to E-199; D-186 to D-200; E-187 to E-201; P-188 to G-202; R-189 to T-203; P-190 to E-204; T-191 to G-205; G-192 to E-206; K-193 to D-207; A-194 to E-208; E-195 to G-209; T-196 to P-210; E-197 to Q-211; D-198 to W-212; E-199 to S-213; D-200 to P-214; E-201 to Q-215; G-202 to D-216; T-203 to P-217; E-204 to A-218; G-205 to L-219; E-206 to Q-220; D-207 to G-221; E-208 to V-222; G-209 to G-223; P-210 to Q-224; Q-211 to P-225; W-212 to T-226; S-213 to G-227; P-214 to T-228; Q-215 to G-229; D-216 to S-230; P-217 to I-231; A-218 to R-232; L-219 to K-233; Q-220 to K-234; G-221 to R-235; V-222 to F-236; G-223 to V-237; Q-224 to S-238; P-225 to S-239; T-226 to H-240; G-227 to R-241; T-228 to Y-242; G-229 to V-243; S-230 to E-244; I-231 to T-245; R-232 to M-246; K-233 to L-247; K-234 to V-248; R-235 to A-249; F-236 to D-250; V-237 to Q-251; S-238 to S-252; S-239 to M-253; H-240 to A-254; R-241 to E-255; Y-242 to F-256; V-243 to H-257; E-244 to G-258; T-245 to S-259; M-246 to G-260; L-247 to L-261; V-248 to K-262; A-249 to H-263; D-250 to Y-264; Q-251 to L-265; S-252 to L-266; M-253 to T-267; A-254 to L-268; E-255 to F-269; F-256 to S-270; H-257 to V-271; G-258 to A-272; S-259 to A-273; G-260 to R-274; L-261 to L-275; K-262 to Y-276; H-263 to K-277; Y-264 to H-278; L-265 to P-279; L-266 to S-280; T-267 to I-281; L-268 to R-282; F-269 to N-283; S-270 to S-284; V-271 to V-285; A-272 to S-286; A-273 to L-287; R-274 to V-288; L-275 to V-289; Y-276 to V-290; K-277 to K-291; H-278 to I-292; P-279 to L-293; S-280 to V-294; I-281 to I-295; R-282 to H-296; N-283 to D-297; S-284 to E-298; V-285 to Q-299; S-286 to K-300; L-287 to G-301; V-288 to P-302; V-289 to E-303; V-290 to V-304; K-291 to T-305; I-292 to S-306; L-293 to N-307; V-294 to A-308; I-295 to A-309; H-296 to L-310; D-297 to T-311; E-298 to L-312; Q-299 to R-313; K-300 to N-314; G-301 to F-315; P-302 to C-316; E-303 to N-317; V-304 to W-318; T-305 to Q-319; S-306 to K-320; N-307 to Q-321; A-308 to H-322; A-309 to N-323; L-310 to P-324; T-311 to P-325; L-312 to S-326; R-313 to D-327; N-314 to R-328; F-315 to D-329; C-316 to A-330; N-317 to E-331; W-318 to H-332; Q-319 to Y-333; K-320 to D-334; Q-321 to T-335; H-322 to A-336; N-323 to I-337; P-324 to L-338; P-325 to

-261-

F-339; S-326 to T-340; D-327 to R-341; R-328 to Q-342; D-329 to D-343; A-330 to L-344; E-331 to C-345; H-332 to G-346; Y-333 to S-347; D-334 to Q-348; T-335 to T-349; A-336 to C-350; I-337 to D-351; L-338 to T-352; F-339 to L-353; T-340 to G-354; R-341 to M-355; Q-342 to A-356; D-343 to D-357; L-344 to V-358; C-345 to G-359; G-346 to T-360; S-347 to V-361; Q-348 to C-362; T-349 to D-363; C-350 to P-364; D-351 to S-365; T-352 to R-366; L-353 to S-367; G-354 to C-368; M-355 to S-369; A-356 to V-370; D-357 to I-371; V-358 to E-372; G-359 to D-373; T-360 to D-374; V-361 to G-375; C-362 to L-376; D-363 to Q-377; P-364 to A-378; S-365 to A-379; R-366 to F-380; S-367 to T-381; C-368 to T-382; S-369 to A-383; V-370 to H-384; I-371 to E-385; E-372 to L-386; D-373 to G-387; D-374 to H-388; G-375 to V-389; L-376 to F-390; Q-377 to N-391; A-378 to M-392; A-379 to P-393; F-380 to H-394; T-381 to D-395; T-382 to D-396; A-383 to A-397; H-384 to K-398; E-385 to Q-399; L-386 to C-400; G-387 to A-401; H-388 to S-402; V-389 to L-403; F-390 to N-404; N-391 to G-405; M-392 to V-406; P-393 to N-407; H-394 to Q-408; D-395 to D-409; D-396 to S-410; A-397 to H-411; K-398 to M-412; Q-399 to M-413; C-400 to A-414; A-401 to S-415; S-402 to M-416; L-403 to L-417; N-404 to S-418; G-405 to N-419; V-406 to L-420; N-407 to D-421; Q-408 to H-422; D-409 to S-423; S-410 to Q-424; H-411 to P-425; M-412 to W-426; M-413 to S-427; A-414 to P-428; S-415 to C-429; M-416 to S-430; L-417 to A-431; S-418 to Y-432; N-419 to M-433; L-420 to I-434; D-421 to T-435; H-422 to S-436; S-423 to F-437; Q-424 to L-438; P-425 to D-439; W-426 to N-440; S-427 to G-441; P-428 to H-442; C-429 to G-443; S-430 to E-444; A-431 to C-445; Y-432 to L-446; M-433 to M-447; I-434 to D-448; T-435 to K-449; S-436 to P-450; F-437 to Q-451; L-438 to N-452; D-439 to P-453; N-440 to I-454; G-441 to Q-455; H-442 to L-456; G-443 to P-457; E-444 to G-458; C-445 to D-459; L-446 to L-460; M-447 to P-461; D-448 to G-462; K-449 to T-463; P-450 to S-464; Q-451 to Y-465; N-452 to D-466; P-453 to A-467; I-454 to N-468; Q-455 to R-469; L-456 to Q-470; P-457 to C-471; G-458 to Q-472; D-459 to F-473; L-460 to T-474; P-461 to F-475; G-462 to G-476; T-463 to E-477; S-464 to D-478; Y-465 to S-479; D-466 to K-480; A-467 to H-481; N-468 to C-482; R-469 to P-483; Q-470 to D-484; C-471 to A-485; Q-472 to A-486; F-473 to S-487; T-474 to T-488; F-475 to C-489; G-476 to S-490; E-477 to T-491; D-478 to L-492; S-479 to W-493; K-480 to

-262-

C-494; H-481 to T-495; C-482 to G-496; P-483 to T-497; D-484 to S-498; A-485 to G-499; A-486 to G-500; S-487 to V-501; T-488 to L-502; C-489 to V-503; S-490 to C-504; T-491 to Q-505; L-492 to T-506; W-493 to K-507; C-494 to H-508; T-495 to F-509; G-496 to P-510; T-497 to W-511; S-498 to A-512; G-499 to D-513; G-500 to G-514; V-501 to T-515; L-502 to S-516; V-503 to C-517; C-504 to G-518; Q-505 to E-519; T-506 to G-520; K-507 to K-521; H-508 to W-522; F-509 to C-523; P-510 to I-524; W-511 to N-525; A-512 to G-526; D-513 to K-527; G-514 to C-528; T-515 to V-529; S-516 to N-530; C-517 to K-531; G-518 to T-532; E-519 to D-533; G-520 to R-534; K-521 to K-535; W-522 to H-536; C-523 to F-537; I-524 to D-538; N-525 to T-539; G-526 to P-540; K-527 to F-541; C-528 to H-542; V-529 to G-543; N-530 to S-544; K-531 to W-545; T-532 to G-546; D-533 to M-547; R-534 to W-548; K-535 to G-549; H-536 to P-550; F-537 to W-551; D-538 to G-552; T-539 to D-553; P-540 to C-554; F-541 to S-555; H-542 to R-556; G-543 to T-557; S-544 to C-558; W-545 to G-559; G-546 to G-560; M-547 to G-561; W-548 to V-562; G-549 to Q-563; P-550 to Y-564; W-551 to T-565; G-552 to M-566; D-553 to R-567; C-554 to E-568; S-555 to C-569; R-556 to D-570; T-557 to N-571; C-558 to P-572; G-559 to V-573; G-560 to P-574; G-561 to K-575; V-562 to N-576; Q-563 to G-577; Y-564 to G-578; T-565 to K-579; M-566 to Y-580; R-567 to C-581; E-568 to E-582; C-569 to G-583; D-570 to K-584; N-571 to R-585; P-572 to V-586; V-573 to R-587; P-574 to Y-588; K-575 to R-589; N-576 to S-590; G-577 to C-591; G-578 to N-592; K-579 to L-593; Y-580 to E-594; C-581 to D-595; E-582 to C-596; G-583 to P-597; K-584 to D-598; R-585 to N-599; V-586 to N-600; R-587 to G-601; Y-588 to K-602; R-589 to T-603; S-590 to F-604; C-591 to R-605; N-592 to E-606; L-593 to E-607; E-594 to Q-608; D-595 to C-609; C-596 to E-610; P-597 to A-611; D-598 to H-612; N-599 to N-613; N-600 to E-614; G-601 to F-615; K-602 to S-616; T-603 to K-617; F-604 to A-618; R-605 to S-619; E-606 to F-620; E-607 to G-621; Q-608 to S-622; C-609 to G-623; E-610 to P-624; A-611 to A-625; H-612 to V-626; N-613 to E-627; E-614 to W-628; F-615 to I-629; S-616 to P-630; K-617 to K-631; A-618 to Y-632; S-619 to A-633; F-620 to G-634; G-621 to V-635; S-622 to S-636; G-623 to P-637; P-624 to K-638; A-625 to D-639; V-626 to R-640; E-627 to C-641; W-628 to K-642; I-629 to L-643; P-630 to I-644; K-631 to C-645; Y-632 to Q-646; A-633 to A-647; G-634 to K-648; V-635 to

-263-

G-649; S-636 to I-650; P-637 to G-651; K-638 to Y-652; D-639 to F-653; R-640 to F-654; C-641 to V-655; K-642 to L-656; L-643 to Q-657; I-644 to P-658; C-645 to K-659; Q-646 to V-660; A-647 to V-661; K-648 to D-662; G-649 to G-663; I-650 to T-664; G-651 to P-665; Y-652 to C-666; F-653 to S-667; F-654 to P-668; V-655 to D-669; L-656 to S-670; Q-657 to T-671; P-658 to S-672; K-659 to V-673; V-660 to C-674; V-661 to V-675; D-662 to Q-676; G-663 to G-677; T-664 to Q-678; P-665 to C-679; C-666 to V-680; S-667 to K-681; P-668 to A-682; D-669 to G-683; S-670 to C-684; T-671 to D-685; S-672 to R-686; V-673 to I-687; C-674 to I-688; V-675 to D-689; Q-676 to S-690; G-677 to K-691; Q-678 to K-692; C-679 to K-693; V-680 to F-694; K-681 to D-695; A-682 to K-696; G-683 to C-697; C-684 to G-698; D-685 to V-699; R-686 to C-700; I-687 to G-701; I-688 to G-702; D-689 to N-703; S-690 to G-704; K-691 to S-705; K-692 to T-706; K-693 to C-707; F-694 to K-708; D-695 to K-709; K-696 to I-710; C-697 to S-711; G-698 to G-712; V-699 to S-713; C-700 to V-714; G-701 to T-715; G-702 to S-716; N-703 to A-717; G-704 to K-718; S-705 to P-719; T-706 to G-720; C-707 to Y-721; K-708 to H-722; K-709 to D-723; I-710 to I-724; S-711 to I-725; G-712 to T-726; S-713 to I-727; V-714 to P-728; T-715 to T-729; S-716 to G-730; A-717 to A-731; K-718 to T-732; P-719 to N-733; G-720 to I-734; Y-721 to E-735; H-722 to V-736; D-723 to K-737; I-724 to Q-738; I-725 to R-739; T-726 to N-740; I-727 to Q-741; P-728 to R-742; T-729 to G-743; G-730 to S-744; A-731 to R-745; T-732 to N-746; N-733 to N-747; I-734 to G-748; E-735 to S-749; V-736 to F-750; K-737 to L-751; Q-738 to A-752; R-739 to I-753; N-740 to K-754; Q-741 to A-755; R-742 to A-756; G-743 to D-757; S-744 to G-758; R-745 to T-759; N-746 to Y-760; N-747 to I-761; G-748 to L-762; S-749 to N-763; F-750 to G-764; L-751 to D-765; A-752 to Y-766; I-753 to T-767; K-754 to L-768; A-755 to S-769; A-756 to T-770; D-757 to L-771; G-758 to E-772; T-759 to Q-773; Y-760 to D-774; I-761 to I-775; L-762 to M-776; N-763 to Y-777; G-764 to K-778; D-765 to G-779; Y-766 to V-780; T-767 to V-781; L-768 to L-782; S-769 to R-783; T-770 to Y-784; L-771 to S-785; E-772 to G-786; Q-773 to S-787; D-774 to S-788; I-775 to A-789; M-776 to A-790; Y-777 to L-791; K-778 to E-792; G-779 to R-793; V-780 to I-794; V-781 to R-795; L-782 to S-796; R-783 to F-797; Y-784 to S-798; S-785 to P-799; G-786 to L-800; S-787 to K-801; S-788 to E-802; A-789 to P-803; A-790 to L-804;

-264-

L-791 to T-805; E-792 to I-806; R-793 to Q-807; I-794 to V-808; R-795 to L-809; S-796 to T-810; F-797 to V-811; S-798 to G-812; P-799 to N-813; L-800 to A-814; K-801 to L-815; E-802 to R-816; P-803 to P-817; L-804 to K-818; T-805 to I-819; I-806 to K-820; Q-807 to Y-821; V-808 to T-822; L-809 to Y-823; T-810 to F-824; V-811 to V-825; G-812 to K-826; N-813 to K-827; A-814 to K-828; L-815 to K-829; R-816 to E-830; P-817 to S-831; K-818 to F-832; I-819 to N-833; K-820 to A-834; Y-821 to I-835; T-822 to P-836; Y-823 to T-837; F-824 to F-838; V-825 to S-839; K-826 to A-840; K-827 to W-841; K-828 to V-842; K-829 to I-843; E-830 to E-844; S-831 to E-845; F-832 to W-846; N-833 to G-847; A-834 to E-848; I-835 to C-849; P-836 to S-850; T-837 to K-851; F-838 to S-852; S-839 to C-853; A-840 to E-854; W-841 to L-855; V-842 to G-856; I-843 to W-857; E-844 to Q-858; E-845 to R-859; W-846 to R-860; G-847 to L-861; E-848 to V-862; C-849 to E-863; S-850 to C-864; K-851 to R-865; S-852 to D-866; C-853 to I-867; E-854 to N-868; L-855 to G-869; G-856 to Q-870; W-857 to P-871; Q-858 to A-872; R-859 to S-873; R-860 to E-874; L-861 to C-875; V-862 to A-876; E-863 to K-877; C-864 to E-878; R-865 to V-879; D-866 to K-880; I-867 to P-881; N-868 to A-882; G-869 to S-883; Q-870 to T-884; P-871 to R-885; A-872 to P-886; S-873 to C-887; E-874 to A-888; C-875 to D-889; A-876 to H-890; K-877 to P-891; E-878 to C-892; V-879 to P-893; K-880 to Q-894; P-881 to W-895; A-882 to Q-896; S-883 to L-897; T-884 to G-898; R-885 to E-899; P-886 to W-900; C-887 to S-901; A-888 to S-902; D-889 to C-903; H-890 to S-904; P-891 to K-905; C-892 to T-906; P-893 to C-907; Q-894 to G-908; W-895 to K-909; Q-896 to G-910; L-897 to Y-911; G-898 to K-912; E-899 to K-913; W-900 to R-914; S-901 to S-915; S-902 to L-916; C-903 to K-917; S-904 to C-918; K-905 to L-919; T-906 to S-920; C-907 to H-921; G-908 to D-922; K-909 to G-923; G-910 to G-924; Y-911 to V-925; K-912 to L-926; K-913 to S-927; R-914 to H-928; S-915 to E-929; L-916 to S-930; K-917 to C-931; C-918 to D-932; L-919 to P-933; S-920 to L-934; H-921 to K-935; D-922 to K-936; G-923 to P-937; G-924 to K-938; V-925 to H-939; L-926 to F-940; S-927 to I-941; H-928 to D-942; E-929 to F-943; S-930 to C-944; C-931 to T-945; D-932 to M-946; P-933 to A-947; L-934 to E-948; K-935 to C-949; and/or K-936 to S-950 of SEQ ID NO:2.

-265-

Similarly, preferred antigenic epitopes of METH2 comprise, or alternatively consist of, the amino acid sequence of residues: M-1 to L-15; F-2 to L-16; P-3 to L-17; A-4 to L-18; P-5 to L-19; A-6 to L-20; A-7 to L-21; P-8 to L-22; R-9 to P-23; W-10 to L-24; L-11 to A-25; P-12 to R-26; F-13 to G-27; L-14 to A-28; L-15 to P-29; L-16 to A-30; L-17 to R-31; L-18 to P-32; L-19 to A-33; L-20 to A-34; L-21 to G-35; L-22 to G-36; P-23 to Q-37; L-24 to A-38; A-25 to S-39; R-26 to E-40; G-27 to L-41; A-28 to V-42; P-29 to V-43; A-30 to P-44; R-31 to T-45; P-32 to R-46; A-33 to L-47; A-34 to P-48; G-35 to G-49; G-36 to S-50; Q-37 to A-51; A-38 to G-52; S-39 to E-53; E-40 to L-54; L-41 to A-55; V-42 to L-56; V-43 to H-57; P-44 to L-58; T-45 to S-59; R-46 to A-60; L-47 to F-61; P-48 to G-62; G-49 to K-63; S-50 to G-64; A-51 to F-65; G-52 to V-66; E-53 to L-67; L-54 to R-68; A-55 to L-69; L-56 to A-70; H-57 to P-71; L-58 to D-72; S-59 to D-73; A-60 to S-74; F-61 to F-75; G-62 to L-76; K-63 to A-77; G-64 to P-78; F-65 to E-79; V-66 to F-80; L-67 to K-81; R-68 to I-82; L-69 to E-83; A-70 to R-84; P-71 to L-85; D-72 to G-86; D-73 to G-87; S-74 to S-88; F-75 to G-89; L-76 to R-90; A-77 to A-91; P-78 to T-92; E-79 to G-93; F-80 to G-94; K-81 to E-95; I-82 to R-96; E-83 to G-97; R-84 to L-98; L-85 to R-99; G-86 to G-100; G-87 to C-101; S-88 to F-102; G-89 to F-103; R-90 to S-104; A-91 to G-105; T-92 to T-106; G-93 to V-107; G-94 to N-108; E-95 to G-109; R-96 to E-110; G-97 to P-111; L-98 to E-112; R-99 to S-113; G-100 to L-114; C-101 to A-115; F-102 to A-116; F-103 to V-117; S-104 to S-118; G-105 to L-119; T-106 to C-120; V-107 to R-121; N-108 to G-122; G-109 to L-123; E-110 to S-124; P-111 to G-125; E-112 to S-126; S-113 to F-127; L-114 to L-128; A-115 to L-129; A-116 to D-130; V-117 to G-131; S-118 to E-132; L-119 to E-133; C-120 to F-134; R-121 to T-135; G-122 to I-136; L-123 to Q-137; S-124 to P-138; G-125 to Q-139; S-126 to G-140; F-127 to A-141; L-128 to G-142; L-129 to G-143; D-130 to S-144; G-131 to L-145; E-132 to A-146; E-133 to Q-147; F-134 to P-148; T-135 to H-149; I-136 to R-150; Q-137 to L-151; P-138 to Q-152; Q-139 to R-153; G-140 to W-154; A-141 to G-155; G-142 to P-156; G-143 to A-157; S-144 to G-158; L-145 to A-159; A-146 to R-160; Q-147 to P-161; P-148 to L-162; H-149 to P-163; R-150 to R-164; L-151 to G-165; Q-152 to P-166; R-153 to E-167; W-154 to W-168; G-155 to E-169; P-156 to V-170; A-157 to E-171; G-158 to T-172; A-159 to G-173; R-160 to E-174; P-161 to G-175; L-162 to Q-176; P-163 to R-177; R-164 to Q-178; G-165 to E-179; P-166 to R-180; E-167 to G-181; W-168 to D-182; E-169 to

-266-

H-183; V-170 to Q-184; E-171 to E-185; T-172 to D-186; G-173 to S-187; E-174 to E-188; G-175 to E-189; Q-176 to E-190; R-177 to S-191; Q-178 to Q-192; E-179 to E-193; R-180 to E-194; G-181 to E-195; D-182 to A-196; H-183 to E-197; Q-184 to G-198; E-185 to A-199; D-186 to S-200; S-187 to E-201; E-188 to P-202; E-189 to P-203; E-190 to P-204; S-191 to P-205; Q-192 to L-206; E-193 to G-207; E-194 to A-208; E-195 to T-209; A-196 to S-210; E-197 to R-211; G-198 to T-212; A-199 to K-213; S-200 to R-214; E-201 to F-215; P-202 to V-216; P-203 to S-217; P-204 to E-218; P-205 to A-219; L-206 to R-220; G-207 to F-221; A-208 to V-222; T-209 to E-223; S-210 to T-224; R-211 to L-225; T-212 to L-226; K-213 to V-227; R-214 to A-228; F-215 to D-229; V-216 to A-230; S-217 to S-231; E-218 to M-232; A-219 to A-233; R-220 to A-234; F-221 to F-235; V-222 to Y-236; E-223 to G-237; T-224 to A-238; L-225 to D-239; L-226 to L-240; V-227 to Q-241; A-228 to N-242; D-229 to H-243; A-230 to I-244; S-231 to L-245; M-232 to T-246; A-233 to L-247; A-234 to M-248; F-235 to S-249; Y-236 to V-250; G-237 to A-251; A-238 to A-252; D-239 to R-253; L-240 to I-254; Q-241 to Y-255; N-242 to K-256; H-243 to H-257; I-244 to P-258; L-245 to S-259; T-246 to I-260; L-247 to K-261; M-248 to N-262; S-249 to S-263; V-250 to I-264; A-251 to N-265; A-252 to L-266; R-253 to M-267; I-254 to V-268; Y-255 to V-269; K-256 to K-270; H-257 to V-271; P-258 to L-272; S-259 to I-273; I-260 to V-274; K-261 to E-275; N-262 to D-276; S-263 to E-277; I-264 to K-278; N-265 to W-279; L-266 to G-280; M-267 to P-281; V-268 to E-282; V-269 to V-283; K-270 to S-284; V-271 to D-285; L-272 to N-286; I-273 to G-287; V-274 to G-288; E-275 to L-289; D-276 to T-290; E-277 to L-291; K-278 to R-292; W-279 to N-293; G-280 to F-294; P-281 to C-295; E-282 to N-296; V-283 to W-297; S-284 to Q-298; D-285 to R-299; N-286 to R-300; G-287 to F-301; G-288 to N-302; L-289 to Q-303; T-290 to P-304; L-291 to S-305; R-292 to D-306; N-293 to R-307; F-294 to H-308; C-295 to P-309; N-296 to E-310; W-297 to H-311; Q-298 to Y-312; R-299 to D-313; R-300 to T-314; F-301 to A-315; N-302 to I-316; Q-303 to L-317; P-304 to L-318; S-305 to T-319; D-306 to R-320; R-307 to Q-321; H-308 to N-322; P-309 to F-323; E-310 to C-324; H-311 to G-325; Y-312 to Q-326; D-313 to E-327; T-314 to G-328; A-315 to L-329; I-316 to C-330; L-317 to D-331; L-318 to T-332; T-319 to L-333; R-320 to G-334; Q-321 to V-335; N-322 to A-336; F-323 to D-337; C-324 to I-338; G-325 to G-339; Q-326 to T-340; E-327 to I-341; G-328 to C-342; L-329 to D-343; C-330 to P-344; D-331

-267-

to N-345; T-332 to K-346; L-333 to S-347; G-334 to C-348; V-335 to S-349; A-336 to V-350; D-337 to I-351; I-338 to E-352; G-339 to D-353; T-340 to E-354; I-341 to G-355; C-342 to L-356; D-343 to Q-357; P-344 to A-358; N-345 to A-359; K-346 to H-360; S-347 to T-361; C-348 to L-362; S-349 to A-363; V-350 to H-364; I-351 to E-365; E-352 to L-366; D-353 to G-367; E-354 to H-368; G-355 to V-369; L-356 to L-370; Q-357 to S-371; A-358 to M-372; A-359 to P-373; H-360 to H-374; T-361 to D-375; L-362 to D-376; A-363 to S-377; H-364 to K-378; E-365 to P-379; L-366 to C-380; G-367 to T-381; H-368 to R-382; V-369 to L-383; L-370 to F-384; S-371 to G-385; M-372 to P-386; P-373 to M-387; H-374 to G-388; D-375 to K-389; D-376 to H-390; S-377 to H-391; K-378 to V-392; P-379 to M-393; C-380 to A-394; T-381 to P-395; R-382 to L-396; L-383 to F-397; F-384 to V-398; G-385 to H-399; P-386 to L-400; M-387 to N-401; G-388 to Q-402; K-389 to T-403; H-390 to L-404; H-391 to P-405; V-392 to W-406; M-393 to S-407; A-394 to P-408; P-395 to C-409; L-396 to S-410; F-397 to A-411; V-398 to M-412; H-399 to Y-413; L-400 to L-414; N-401 to T-415; Q-402 to E-416; T-403 to L-417; L-404 to L-418; P-405 to D-419; W-406 to G-420; S-407 to G-421; P-408 to H-422; C-409 to G-423; S-410 to D-424; A-411 to C-425; M-412 to L-426; Y-413 to L-427; L-414 to D-428; T-415 to A-429; E-416 to P-430; L-417 to G-431; L-418 to A-432; D-419 to A-433; G-420 to L-434; G-421 to P-435; H-422 to L-436; G-423 to P-437; D-424 to T-438; C-425 to G-439; L-426 to L-440; L-427 to P-441; D-428 to G-442; A-429 to R-443; P-430 to M-444; G-431 to A-445; A-432 to L-446; A-433 to Y-447; L-434 to Q-448; P-435 to L-449; L-436 to D-450; P-437 to Q-451; T-438 to Q-452; G-439 to C-453; L-440 to R-454; P-441 to Q-455; G-442 to I-456; R-443 to F-457; M-444 to G-458; A-445 to P-459; L-446 to D-460; Y-447 to F-461; Q-448 to R-462; L-449 to H-463; D-450 to C-464; Q-451 to P-465; Q-452 to N-466; C-453 to T-467; R-454 to S-468; Q-455 to A-469; I-456 to Q-470; F-457 to D-471; G-458 to V-472; P-459 to C-473; D-460 to A-474; F-461 to Q-475; R-462 to L-476; H-463 to W-477; C-464 to C-478; P-465 to H-479; N-466 to T-480; T-467 to D-481; S-468 to G-482; A-469 to A-483; Q-470 to E-484; D-471 to P-485; V-472 to L-486; C-473 to C-487; A-474 to H-488; Q-475 to T-489; L-476 to K-490; W-477 to N-491; C-478 to G-492; H-479 to S-493; T-480 to L-494; D-481 to P-495; G-482 to W-496; A-483 to A-497; E-484 to D-498; P-485 to G-499; L-486 to T-500; C-487 to P-501; H-488 to C-502; T-489 to G-503; K-490 to P-504; N-491 to G-505; G-492 to H-506; S-

-268-

493 to L-507; L-494 to C-508; P-495 to S-509; W-496 to E-510; A-497 to G-511; D-498 to S-512; G-499 to C-513; T-500 to L-514; P-501 to P-515; C-502 to E-516; G-503 to E-517; P-504 to E-518; G-505 to V-519; H-506 to E-520; L-507 to R-521; C-508 to P-522; S-509 to K-523; E-510 to P-524; G-511 to V-525; S-512 to V-526; C-513 to D-527;

5 L-514 to G-528; P-515 to G-529; E-516 to W-530; E-517 to A-531; E-518 to P-532; V-519 to W-533; E-520 to G-534; R-521 to P-535; P-522 to W-536; K-523 to G-537; P-524 to E-538; V-525 to C-539; V-526 to S-540; D-527 to R-541; G-528 to T-542; G-529 to C-543; W-530 to G-544; A-531 to G-545; P-532 to G-546; W-533 to V-547; G-534 to Q-548; P-535 to F-549; W-536 to S-550; G-537 to H-551; E-538 to R-552; C-539 to E-553;

10 S-540 to C-554; R-541 to K-555; T-542 to D-556; C-543 to P-557; G-544 to E-558; G-545 to P-559; G-546 to Q-560; V-547 to N-561; Q-548 to G-562; F-549 to G-563; S-550 to R-564; H-551 to Y-565; R-552 to C-566; E-553 to L-567; C-554 to G-568; K-555 to R-569; D-556 to R-570; P-557 to A-571; E-558 to K-572; P-559 to Y-573; Q-560 to Q-574; N-561 to S-575; G-562 to C-576; G-563 to H-577; R-564 to T-578; Y-565 to E-579;

15 C-566 to E-580; L-567 to C-581; G-568 to P-582; R-569 to P-583; R-570 to D-584; A-571 to G-585; K-572 to K-586; Y-573 to S-587; Q-574 to F-588; S-575 to R-589; C-576 to E-590; H-577 to Q-591; T-578 to Q-592; E-579 to C-593; E-580 to E-594; C-581 to K-595; P-582 to Y-596; P-583 to N-597; D-584 to A-598; G-585 to Y-599; K-586 to N-600; S-587 to Y-601; F-588 to T-602; R-589 to D-603; E-590 to M-604; Q-591 to D-605;

20 Q-592 to G-606; C-593 to N-607; E-594 to L-608; K-595 to L-609; Y-596 to Q-610; N-597 to W-611; A-598 to V-612; Y-599 to P-613; N-600 to K-614; Y-601 to Y-615; T-602 to A-616; D-603 to G-617; M-604 to V-618; D-605 to S-619; G-606 to P-620; N-607 to R-621; L-608 to D-622; L-609 to R-623; Q-610 to C-624; W-611 to K-625; V-612 to L-626; P-613 to F-627; K-614 to C-628; Y-615 to R-629; A-616 to A-630; G-617 to R-631; V-618 to G-632; S-619 to R-633; P-620 to S-634; R-621 to E-635; D-622 to F-636;

25 R-623 to K-637; C-624 to V-638; K-625 to F-639; L-626 to E-640; F-627 to A-641; C-628 to K-642; R-629 to V-643; A-630 to I-644; R-631 to D-645; G-632 to G-646; R-633 to T-647; S-634 to L-648; E-635 to C-649; F-636 to G-650; K-637 to P-651; V-638 to E-652; F-639 to T-653; E-640 to L-654; A-641 to A-655; K-642 to I-656; V-643 to C-657; I-644 to V-658; D-645 to R-659; G-646 to G-660; T-647 to Q-661; L-648 to C-662;

30 C-649 to V-663; G-650 to K-664; P-651 to A-665; E-652 to G-666; T-653 to C-667; L-

-269-

654 to D-668; A-655 to H-669; I-656 to V-670; C-657 to V-671; V-658 to D-672; R-659 to S-673; G-660 to P-674; Q-661 to R-675; C-662 to K-676; V-663 to L-677; K-664 to D-678; A-665 to K-679; G-666 to C-680; C-667 to G-681; D-668 to V-682; H-669 to C-683; V-670 to G-684; V-671 to G-685; D-672 to K-686; S-673 to G-687; P-674 to N-688; R-675 to S-689; K-676 to C-690; L-677 to R-691; D-678 to K-692; K-679 to V-693; C-680 to S-694; G-681 to G-695; V-682 to S-696; C-683 to L-697; G-684 to T-698; G-685 to P-699; K-686 to T-700; G-687 to N-701; N-688 to Y-702; S-689 to G-703; C-690 to Y-704; R-691 to N-705; K-692 to D-706; V-693 to I-707; S-694 to V-708; G-695 to T-709; S-696 to I-710; L-697 to P-711; T-698 to A-712; P-699 to G-713; T-700 to A-714; N-701 to T-715; Y-702 to N-716; G-703 to I-717; Y-704 to D-718; N-705 to V-719; D-706 to K-720; I-707 to Q-721; V-708 to R-722; T-709 to S-723; I-710 to H-724; P-711 to P-725; A-712 to G-726; G-713 to V-727; A-714 to Q-728; T-715 to N-729; N-716 to D-730; I-717 to G-731; D-718 to N-732; V-719 to Y-733; K-720 to L-734; Q-721 to A-735; R-722 to L-736; S-723 to K-737; H-724 to T-738; P-725 to A-739; G-726 to D-740; V-727 to G-741; Q-728 to Q-742; N-729 to Y-743; D-730 to L-744; G-731 to L-745; N-732 to N-746; Y-733 to G-747; L-734 to N-748; A-735 to L-749; L-736 to A-750; K-737 to I-751; T-738 to S-752; A-739 to A-753; D-740 to I-754; G-741 to E-755; Q-742 to Q-756; Y-743 to D-757; L-744 to I-758; L-745 to L-759; N-746 to V-760; G-747 to K-761; N-748 to G-762; L-749 to T-763; A-750 to I-764; I-751 to L-765; S-752 to K-766; A-753 to Y-767; I-754 to S-768; E-755 to G-769; Q-756 to S-770; D-757 to I-771; I-758 to A-772; L-759 to T-773; V-760 to L-774; K-761 to E-775; G-762 to R-776; T-763 to L-777; I-764 to Q-778; L-765 to S-779; K-766 to F-780; Y-767 to R-781; S-768 to P-782; G-769 to L-783; S-770 to P-784; I-771 to E-785; A-772 to P-786; T-773 to L-787; L-774 to T-788; E-775 to V-789; R-776 to Q-790; L-777 to L-791; Q-778 to L-792; S-779 to T-793; F-780 to V-794; R-781 to P-795; P-782 to G-796; L-783 to E-797; P-784 to V-798; E-785 to F-799; P-786 to P-800; L-787 to P-801; T-788 to K-802; V-789 to V-803; Q-790 to K-804; L-791 to Y-805; L-792 to T-806; T-793 to F-807; V-794 to F-808; P-795 to V-809; G-796 to P-810; E-797 to N-811; V-798 to D-812; F-799 to V-813; P-800 to D-814; P-801 to F-815; K-802 to S-816; V-803 to M-817; K-804 to Q-818; Y-805 to S-819; T-806 to S-820; F-807 to K-821; F-808 to E-822; V-809 to R-823; P-810 to A-824; N-811 to T-825; D-812 to T-826; V-813 to N-827; D-814 to I-828; F-815 to I-829; S-816 to Q-

-270-

830; M-817 to P-831; Q-818 to L-832; S-819 to L-833; S-820 to H-834; K-821 to A-835; E-822 to Q-836; R-823 to W-837; A-824 to V-838; T-825 to L-839; T-826 to G-840; N-827 to D-841; I-828 to W-842; I-829 to S-843; Q-830 to E-844; P-831 to C-845; L-832 to S-846; L-833 to S-847; H-834 to T-848; A-835 to C-849; Q-836 to G-850; W-837 to A-851; V-838 to G-852; L-839 to W-853; G-840 to Q-854; D-841 to R-855; W-842 to R-856; S-843 to T-857; E-844 to V-858; C-845 to E-859; S-846 to C-860; S-847 to R-861; T-848 to D-862; C-849 to P-863; G-850 to S-864; A-851 to G-865; G-852 to Q-866; W-853 to A-867; Q-854 to S-868; R-855 to A-869; R-856 to T-870; T-857 to C-871; V-858 to N-872; E-859 to K-873; C-860 to A-874; R-861 to L-875; D-862 to K-876; P-863 to P-877; S-864 to E-878; G-865 to D-879; Q-866 to A-880; A-867 to K-881; S-868 to P-882; A-869 to C-883; T-870 to E-884; C-871 to S-885; N-872 to Q-886; K-873 to L-887; A-874 to C-888; L-875 to P-889; and/or K-876 to L-890 of SEQ ID NO:4.

Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson *et al.*, *Cell* 37:767-778 (1984); Sutcliffe *et al.*, *Science* 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe *et al.*, *supra*; Wilson *et al.*, *supra*; Chow *et al.*, *Proc. Natl. Acad. Sci. USA* 82:910-914; and Bittle *et al.*, *J. Gen. Virol.* 66:2347-2354 (1985)). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide

-271-

may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

5 Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, *in vivo* immunization, *in vitro* immunization, and phage display methods. See, e.g., Sutcliffe *et al.*, *supra*; Wilson *et al.*, *supra*, and Bittle *et al.*, *J. Gen. Virol.*, 66:2347-2354 (1985). If *in vivo* immunization is used, animals may be immunized with free peptide;
10 however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as m-maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as
15 glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier-coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a
20 useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

25 As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof)
30 resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life *in vivo*. This has been shown for chimeric proteins consisting of

-272-

the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker *et al.*, *Nature*, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, 5 e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis *et al.*, *J. Biochem.*, 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht *et al.* allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht *et al.*, 1991, *Proc. Natl. Acad. Sci. USA* 88:8972-897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni²⁺ nitriloacetic acid-agarose 10 column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to 25 modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten *et al.*, *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, *et al.*, *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo and Blasco, *Biotechniques* 24(2):308-13 (1998) (each of these 30 patents and publications are hereby incorporated by reference in its entirety). In one

-273-

embodiment, alteration of polynucleotides corresponding to SEQ ID NO:1 or 3 and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion can also be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. *See, e.g., Fountoulakis et al. (1995) J. Biochem. 270:3958-3964.* Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag to aid in detection and purification of the expressed polypeptide.

The present invention further relates to antibodies and T-cell antigen receptors (TCR) which specifically bind the polypeptides of the present invention. The antibodies of the present invention include IgG (including IgG1, IgG2, IgG3, and IgG4), IgA (including IgA1 and IgA2), IgD, IgE, or IgM, and IgY. As used herein, the term "antibody" (Ab) is meant to include whole antibodies, including single-chain whole antibodies, and antigen-binding fragments thereof. Most preferably the antibodies are human antigen binding antibody fragments of the present invention including, but not limited to, Fab, Fab' and F(ab')₂, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a V_L or V_H domain. The antibodies may be from any animal origin including birds and mammals. Preferably, the antibodies are human; murine, rabbit, goat, guinea pig, camel, horse, or chicken.

Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entire or partial of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention

-274-

are any combinations of variable region(s) and hinge region, CH1, CH2, and CH3 domains. The present invention further includes monoclonal, polyclonal, chimeric, humanized, and human monoclonal and polyclonal antibodies which specifically bind the polypeptides of the present invention. The present invention further includes antibodies which are anti-idiotypic to the antibodies of the present invention.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for heterologous compositions, such as a heterologous polypeptide or solid support material. *See, e.g.*, WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, A. *et al.* (1991) *J. Immunol.* 147:60-69; US Patents 5,573,920, 4,474,893, 5,601,819, 4,714,681, 4,925,648; Kostelny, S.A. *et al.* (1992) *J. Immunol.* 148:1547-1553.

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which are recognized or specifically bound by the antibody. The epitope(s) or polypeptide portion(s) may be specified as described herein, *e.g.*, by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of the polypeptides of the present invention are included. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. Further included in the present invention are antibodies which only bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present

-275-

invention may also be described or specified in terms of their binding affinity. Preferred binding affinities include those with a dissociation constant or K_d less than $5 \times 10^{-6}M$, $10^{-6}M$, $5 \times 10^{-7}M$, $10^{-7}M$, $5 \times 10^{-8}M$, $10^{-8}M$, $5 \times 10^{-9}M$, $10^{-9}M$, $5 \times 10^{-10}M$, $10^{-10}M$, $5 \times 10^{-11}M$, $10^{-11}M$, $5 \times 10^{-12}M$, $10^{-12}M$, $5 \times 10^{-13}M$, $10^{-13}M$, $5 \times 10^{-14}M$, $10^{-14}M$, $5 \times 10^{-15}M$, and $10^{-15}M$.

5 Antibodies of the present invention have uses that include, but are not limited to, methods known in the art to purify, detect, and target the polypeptides of the present invention including both *in vitro* and *in vivo* diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See,
10 e.g., Harlow *et al.*, ANTIBODIES: A LABORATORY MANUAL, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference in the entirety).

 The antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated
15 (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, or toxins. See, e.g., WO 92/08495; WO 91/14438; WO 89/12624; US Patent 5,314,995; and EP 0 396 387.

20 The antibodies of the present invention may be prepared by any suitable method known in the art. For example, a polypeptide of the present invention or an antigenic fragment thereof can be administered to an animal in order to induce the production of sera containing polyclonal antibodies. The term "monoclonal antibody" is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody"
25 refers to an antibody that is derived from a single clone, including eukaryotic, prokaryotic, or phage clones, and not by the method which it is produced. Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant and phage display technology.

 Hybridoma techniques include those known in the art and taught in Harlow *et al.*,
30 ANTIBODIES: A LABORATORY MANUAL, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, *et al.*, in: MONOCLONAL ANTIBODIES AND T-CELL

-276-

HYBRIDOMAS 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). Fab and F(ab')₂ fragments may be produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments).

5 Alternatively, antibodies of the present invention can be produced through the application of recombinant DNA and phage display technology or through synthetic chemistry using methods known in the art. For example, the antibodies of the present invention can be prepared using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of a
10 phage particle which carries polynucleotide sequences encoding them. Phage with a desired binding property are selected from a repertoire or combinatorial antibody library (e.g. human or murine) by selecting directly with antigen, typically antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 with Fab, Fv or disulfide stabilized Fv antibody
15 domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman U. *et al.* (1995) *J. Immunol. Methods* 182:41-50; Ames, R.S. *et al.* (1995) *J. Immunol. Methods* 184:177-186; Kettleborough, C.A. *et al.* (1994) *Eur. J. Immunol.* 24:952-958; Persic, L. *et al.* (1997) *Gene* 187:9-18; Burton, D.R. *et al.* (1994) *Advances in Immunology* 57:191-280; PCT/GB91/01134; WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and US Patents 5,698,426, 5,223,409, 5,403,484, 5,580,717, 5,427,908, 5,750,753, 5,821,047, 5,571,698, 5,427,908, 5,516,637, 5,780,225, 5,658,727 and 5,733,743 (said references incorporated by reference in their entireties).

25 As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host including mammalian cells, insect cells, plant cells, yeast, and bacteria. For example, techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also
30 be employed using methods known in the art such as those disclosed in WO 92/22324; Mullinax, R.L. *et al.* (1992) *BioTechniques* 12(6):864-869; and Sawai, H. *et al.* (1995)

-277-

AJRI 34:26-34; and Better, M. *et al.* (1988) *Science* 240:1041-1043 (said references incorporated by reference in their entireties).

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:2 and/or 4, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')₂, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not

-278-

express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati *et al.*

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, *et al.*, *J. Immunol.* 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny *et al.*, *J. Immunol.* 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Preferred epitopes of the invention include: amino acids 2-14, 32-44, 47-60, 66-78, 87-103, 109-118, 146-162, 168-180, 183-219, 223-243, 275-284, 296-306, 314-334, 341-354, 357-376, 392-399, 401-410, 418-429, 438-454, 456-471, 474-488, 510-522, 524-538, 550-561, 565-626, 630-643, 659-671, 679-721, 734-749, 784-804, 813-820, 825-832, 845-854, 860-894, 899-917, 919-924 and 928-939 of SEQ ID NO:2 and amino acids 26-38, 45-52, 69-76, 80-99, 105-113, 129-136, 138-217, 254-263, 273-289, 294-313, 321-331, 339-356, 371-383, 417-427, 438-443, 459-471, 479-505, 507-526, 535-546, 550-607, 615-640, 648-653, 660-667, 669-681, 683-704, 717-732, 737-743, 775-787, 797-804, 811-825, 840-867 and 870-884 of SEQ ID NO:4, as well as polynucleotides that encode these epitopes. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind

-279-

polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, or 10^{-15} M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the

-280-

invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor
5 activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described *supra*). In specific embodiments, antibodies are provided that
10 inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand
15 complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which
20 activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed
25 herein. The above antibody agonists can be made using methods known in the art. *See, e.g.,* PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng *et al.*, *Blood* 92(6):1981-1988 (1998); Chen *et al.*, *Cancer Res.* 58(16):3668-3678 (1998); Harrop *et al.*, *J. Immunol.* 161(4):1786-1794 (1998); Zhu *et al.*, *Cancer Res.* 58(15):3209-3214 (1998); Yoon *et al.*, *J. Immunol.* 160(7):3170-3179 (1998); Prat *et al.*, *J. Cell. Sci.* 111(Pt2):237-247 (1998); Pitard *et al.*, *J. Immunol. Methods* 205(2):177-190 (1997);
30 Liautard *et al.*, *Cytokine* 9(4):233-241 (1997); Carlson *et al.*, *J. Biol. Chem.*

-281-

272(17):11295-11301 (1997); Taryman *et al.*, *Neuron* 14(4):755-762 (1995); Muller *et al.*, *Structure* 6(9):1153-1167 (1998); Bartunek *et al.*, *Cytokine* 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both *in vitro* and *in vivo* diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow *et al.*, *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by

-282-

various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow *et al.*, *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, *et al.*, in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples. In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which

generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')₂ fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). F(ab')₂ fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman *et al.*, *J. Immunol. Methods* 182:41-50 (1995); Ames *et al.*, *J. Immunol. Methods* 184:177-186 (1995); Kettleborough *et al.*, *Eur. J. Immunol.* 24:952-958 (1994); Persic *et al.*, *Gene* 187:9-18 (1997); Burton *et al.*, *Advances in Immunology* 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT

-284-

publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated
5 herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g.,
10 as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax *et al.*, *BioTechniques* 12(6):864-869 (1992); and Sawai *et al.*, *AJRI* 34:26-34 (1995); and Better *et al.*, *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

15 Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston *et al.*, *Methods in Enzymology* 203:46-88 (1991); Shu *et al.*, *PNAS* 90:7995-7999 (1993); and Skerra *et al.*, *Science* 240:1038-1040 (1988). For some uses, including *in vivo* use of antibodies in humans and *in vitro* detection assays, it may be preferable to use
20 chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. *See e.g.*, Morrison, *Science* 229:1202 (1985); Oi *et al.*, *BioTechniques* 4:214 (1986); Gillies *et al.*, (1989) *J. Immunol. Methods* 125:191-202; U.S. Patent Nos.
25 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions
30 will be substituted with the corresponding residue from the CDR donor antibody to alter,

-285-

preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen *et al.*, U.S. Patent No. 5,585,089; Riechmann *et al.*, *Nature* 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, *Molecular Immunology* 28(4/5):489-498 (1991); Studnicka *et al.*, *Protein Engineering* 7(6):805-814 (1994); Roguska. *et al.*, *PNAS* 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then

-286-

5 bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and GenPharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

20 Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers *et al.*, *Bio/technology* 12:899-903 (1988)).

25 Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, *FASEB J.* 7(5):437-444; (1989) and Nissinoff, *J. Immunol.* 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing

30

anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

5 Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston *et al.* (1991) *Methods in Enzymology* 203:46-88; Shu, L. *et al.* (1993) *PNAS* 90:7995-7999; and Skerra, A. *et al.* (1988) *Science* 240:1038-1040. For some uses, including *in vivo* use of antibodies in humans and *in vitro* detection assays, it may be preferable to use
10 chimeric, humanized, or human antibodies. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi *et al.*, *BioTechniques* 4:214 (1986); Gillies, S.D. *et al.* (1989) *J. Immunol. Methods* 125:191-202; and US Patent 5,807,715. Antibodies can be humanized using a variety of techniques including CDR-grafting (EP 0 239 400; WO 91/09967; US Patent 5,530,101; and 5,585,089), veneering or resurfacing (EP 0 592 106; EP 0 519 596; Padlan E.A.,
15 (1991) *Molecular Immunology* 28(4/5):489-498; Studnicka G.M. *et al.* (1994) *Protein Engineering* 7(6):805-814; Roguska M.A. *et al.* (1994) *PNAS* 91:969-973), and chain shuffling (US Patent 5,565,332). Human antibodies can be made by a variety of methods known in the art including phage display methods described above. See also, US Patents
20 4,444,887, 4,716,111, 5,545,806, and 5,814,318; and WO 98/46645 (said references incorporated by reference in their entireties).

 Further included in the present invention are antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide of the present invention. The antibodies may be specific for antigens other
25 than polypeptides of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either *in vitro* or *in vivo*, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in *in vitro* immunoassays and purification
30 methods using methods known in the art. See e.g., Harbor *et al.* *supra* and WO 93/21232; EP 0 439 095; Naramura, M. *et al.* (1994) *Immunol. Lett.* 39:91-99; US Patent 5,474,981;

Gillies, S.O. *et al.* (1992) *PNAS* 89:1428-1432; Fell, H.P. *et al.* (1991) *J. Immunol.* 146:2446-2452 (said references incorporated by reference in their entireties).

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides of the present invention may be fused or conjugated to the above antibody portions to increase the *in vivo* half life of the polypeptides or for use in immunoassays using methods known in the art. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See e.g., US Patents 5,336,603, 5,622,929, 5,359,046, 5,349,053, 5,447,851, 5,112,946; EP 0 307 434, EP 0 367 166; WO 96/04388, WO 91/06570; Ashkenazi, A. *et al.* (1991) *PNAS* 88:10535-10539; Zheng, X.X. *et al.* (1995) *J. Immunol.* 154:5590-5600; and Vil, H. *et al.* (1992) *PNAS* 89:11337-11341 (said references incorporated by reference in their entireties).

The invention further relates to antibodies that act as agonists or antagonists of the polypeptides of the present invention. Antibodies which act as agonists or antagonists of the polypeptides of the present invention include, for example, antibodies which disrupt receptor/ligand interactions with the polypeptides of the invention either partially or fully. For example, the present invention includes antibodies that disrupt the ability of the proteins of the invention to multimerize. In another example, the present invention includes antibodies which allow the proteins of the invention to multimerize, but disrupt the ability of the proteins of the invention to bind one or more METH1 and/or METH2 receptor(s)/ligand(s). In yet another example, the present invention includes antibodies which allow the proteins of the invention to multimerize, and bind METH1 and/or

METH2 receptor(s)/ligand(s), but blocks biological activity associated with the METH1 and/or METH2/receptor/ligand complex.

Antibodies which act as agonists or antagonists of the polypeptides of the present invention also include, both receptor-specific antibodies and ligand-specific antibodies.

5 Included are receptor-specific antibodies that do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. Also included are receptor-specific antibodies which both prevent ligand binding and receptor activation. Likewise, included are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the
10 receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included are antibodies that activate the receptor. These antibodies may act as agonists for either all or less than all of the biological activities affected by ligand-mediated receptor activation. The antibodies may be specified as agonists or antagonists for biological activities
15 comprising specific activities disclosed herein. The above antibody agonists can be made using methods known in the art. See e.g., WO 96/40281; US Patent Number 5,811,097; Deng, B. *et al.*, *Blood* 92(6):1981-1988 (1998); Chen, Z. *et al.*, *Cancer Res.* 58(16):3668-3678 (1998); Harrop, J.A. *et al.*, *J. Immunol.* 161(4):1786-1794 (1998); Zhu, Z. *et al.*, *Cancer Res.* 58(15):3209-3214 (1998); Yoon, D.Y. *et al.*, *J. Immunol.* 160(7):3170-3179
20 (1998); Prat, M. *et al.*, *J. Cell. Sci.* 111(Pt2):237-247 (1998); Pitard, V. *et al.*, *J. Immunol. Methods* 205(2):177-190 (1997); Liautard, J. *et al.*, *Cytokine* 9(4):233-241 (1997); Carlson, N.G. *et al.*, *J. Biol. Chem.* 272(17):11295-11301 (1997); Taryman, R.E. *et al.*, *Neuron* 14(4):755-762 (1995); Muller, Y.A. *et al.*, *Structure* 6(9):1153-1167 (1998); Bartunek, P. *et al.*, *Cytokine* 8(1):14-20 (1996)(said references incorporated by reference
25 in their entireties).

As discussed above, antibodies to the METH1 and/or METH2 proteins of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" METH1 and/or METH2 using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, *FASEB J.* 7(5):437-444; (1989) and Nissinoff, *J. Immunol.* 147(8):2429-2438 (1991)). For example, antibodies which bind to METH1 and/or
30 METH2 and competitively inhibit METH1 and/or METH2 multimerization and/or

-290-

binding to ligand can be used to generate anti-idiotypes that "mimic" the METH1 and/or METH2 mutimerization and/or binding domain and, as a consequence, bind to and neutralize METH1 and/or METH2 and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize METH1 and/or METH2 ligand. For example, such anti-idiotypic antibodies can be used to bind METH1 and/or METH2, or to bind METH1 and/or METH2 ligands/receptors, and thereby block METH1 and/or METH2 biological activity.

Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined *supra*, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:2 and/or 4.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier *et al.*, *BioTechniques* 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A⁺ RNA, isolated from, any tissue or cells

-291-

expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook *et al.*, 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel *et al.*, eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described *supra*. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia *et al.*, *J. Mol. Biol.* 278:457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed *supra*, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions

-292-

of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

5 In addition, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, *Proc. Natl. Acad. Sci.* 81:851-855 (1984); Neuberger *et al.*, *Nature* 312:604-608 (1984); Takeda *et al.*, *Nature* 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described
10 *supra*, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, *Science* 242:423-42 (1988); Huston *et al.*, *Proc. Natl.*
15 *Acad. Sci. USA* 85:5879-5883 (1988); and Ward *et al.*, *Nature* 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in *E. coli* may also be used (Skerra *et al.*, *Science* 242:1038-1041 (1988)).

20 ***Methods of Producing Antibodies***

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

25 Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained,

-293-

the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention *in situ*. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors

containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking *et al.*, *Gene* 45:101 (1986); Cockett *et al.*, *Bio/Technology* 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther *et al.*, *EMBO J.* 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, *Nucleic Acids Res.* 13:3101-3109 (1985); Van Heeke & Schuster, *J. Biol. Chem.* 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

-295-

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, *Proc. Natl. Acad. Sci. USA* 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner *et al.*, *Methods in Enzymol.* 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to

-296-

CHO, VERA, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler *et al.*, *Cell* 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, *Proc. Natl. Acad. Sci. USA* 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy *et al.*, *Cell* 22:817 (1980)) genes can be employed in tk-, hgp^{rt}- or ap^{rt}- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler *et al.*, *Natl. Acad. Sci. USA* 77:357 (1980); O'Hare *et al.*, *Proc. Natl. Acad. Sci. USA* 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, *Proc. Natl. Acad. Sci. USA* 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 (Goldspiel *et al.*, *Clinical Pharmacy* 12:488-505 (1993); Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, 1993, *TIB TECH* 11(5):155-215); and hyg^{ro}, which confers resistance to hygromycin (Santerre *et al.*, *Gene*

-297-

30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); Krieger, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli *et al.* (eds.), *Current Protocols in Human Genetics*, John Wiley & Sons, NY (1994); Colberre-Garapin *et al.*, *J. Mol. Biol.* 150:1 (1981), which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning*, Vol. 3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse *et al.*, *Mol. Cell. Biol.* 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, *Nature* 322:52 (1986); Kohler, *Proc. Natl. Acad. Sci. USA* 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition,

-298-

the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

5 The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, 10 preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either *in vitro* or *in vivo*, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in *in vitro* immunoassays and purification 15 methods using methods known in the art. See e.g., Harbor *et al.*, *supra*, and PCT publication WO 93/21232; EP 439,095; Naramura *et al.*, *Immunol. Lett.* 39:91-99 (1994); U.S. Patent 5,474,981; Gillies *et al.*, *PNAS* 89:1428-1432 (1992); Fell *et al.*, *J. Immunol.* 146:2446-2452(1991), which are incorporated by reference in their entireties.

20 The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, 25 CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present 30 invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos.

5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi *et al.*, *Proc. Natl. Acad. Sci. USA* 88:10535-10539 (1991); Zhenget al., *J. Immunol.* 154:5590-5600 (1995); and Vil *et al.*, *Proc. Natl. Acad. Sci. USA* 89:11337- 11341 (1992) (said references incorporated by reference in their entirety).

As discussed, *supra*, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:2 and/or 4 may be fused or conjugated to the above antibody portions to increase the *in vivo* half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:2 and/or 4 may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker *et al.*, *Nature* 331:84-86 (1988)). The polypeptides of the present invention fused or conjugated to an antibody having disulfide-linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis *et al.*, *J. Biochem.* 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5 receptor, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, Bennett *et al.*, *J. Molecular Recognition* 8:52-58 (1995); Johanson *et al.*, *J. Biol. Chem.* 270:9459-9471 (1995).)

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz *et al.*,

-300-

Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson *et al.*, *Cell* 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{111}In or ^{99}Tc .

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytotoxic agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, ^{213}Bi . A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin,

etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis- dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, α -interferon, β -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- α , TNF- β , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

-302-

Techniques for conjugating such therapeutic moiety to antibodies are well known, *see, e.g.*, Arnon *et al.*, "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld *et al.* (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom *et al.*, "Antibodies For Drug Delivery", in
5 Controlled Drug Delivery (2nd Ed.), Robinson *et al.* (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera *et al.* (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal
10 Antibodies For Cancer Detection And Therapy*, Baldwin *et al.* (eds.), pp. 303-16 (Academic Press 1985), and Thorpe *et al.*, "*The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates*", *Immunol. Rev.* 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is
15 incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

Immunophenotyping

20 The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of
25 epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate),

and flow cytometry. (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

Assays For Antibody Binding

The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel *et al.*, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The

-304-

ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel *et al.*, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., ^{32}P or ^{125}I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel *et al.*, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case,

-305-

a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel *et al.*, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., ^3H or ^{125}I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., ^3H or ^{125}I) in the presence of increasing amounts of an unlabeled second antibody.

Therapeutic Uses Of Antibodies of the Invention

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of

-306-

a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

5 A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided
10 herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

 The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic
15 growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

 The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a
20 species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

 It is preferred to use high affinity and/or potent *in vivo* inhibiting and/or
25 neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred
30 binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M,

-307-

5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, and 10^{-15} M.

Diagnosis and Imaging

5 Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression
10 of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

15 The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the
20 standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative
25 measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

 Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, *et al.*, *J. Cell. Biol.* 101:976-985 (1985); Jalkanen, *et al.*, *J. Cell. Biol.*

-308-

105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (5 ^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium (^{99}Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{m}}\text{Tc}$. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. *In vivo* tumor imaging is described in S.W. Burchiel *et al.*, "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

-309-

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disorder, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for *in vivo* scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston *et al.*, U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

Fusion Proteins

Any METH1 or METH2 polypeptide can be used to generate fusion proteins. For example, the METH1 or METH2 polypeptide, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the METH1 or METH2 polypeptide can be used to indirectly detect the second protein by binding to the METH1 or METH2.

-310-

Moreover, because secreted proteins target cellular locations based on trafficking signals, the METH1 or METH2 polypeptides can be used as a targeting molecule once fused to other proteins.

5 Examples of domains that can be fused to METH1 or METH2 polypeptides include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

10 In certain preferred embodiments, METH1 or METH2 proteins of the invention comprise fusion proteins wherein the METH1 or METH2 polypeptides are those described above as m_1-n_1 or m_2-n_2 , respectively. In preferred embodiments, the application is directed to nucleic acid molecules at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequences encoding polypeptides having the amino acid sequence of the specific – and C-terminal deletions recited herein. Polynucleotides encoding these polypeptides are also
15 encompassed by the invention.

Moreover, fusion proteins may also be engineered to improve characteristics of the METH1 or METH2 polypeptide. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the METH1 or METH2 polypeptide to improve stability and persistence during purification from the
20 host cell or subsequent handling and storage. Also, peptide moieties may be added to the METH1 or METH2 polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the METH1 or METH2 polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

25 Moreover, METH1 or METH2 polypeptides, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-
30 polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker *et al.*, *Nature* 331:84-86

-311-

(1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis *et al.*, *J. Biochem.* 270:3958-3964 (1995).)

5 Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0 232 262.) Alternatively, deleting the Fc
10 part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5 receptor, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett *et al.*, *J. Molecular*
15 *Recognition* 8:52-58 (1995); K. Johanson *et al.*, *J. Biol. Chem.* 270:9459-9471 (1995).)

 Moreover, the METH1 or METH2 polypeptides can be fused to marker sequences, such as a peptide which facilitates purification of METH1 or METH2. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA,
20 91311), among others, many of which are commercially available. As described in Gentz *et al.*, *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson *et al.*, *Cell* 37:767 (1984).)

25 Thus, any of these above fusions can be engineered using the METH1 or METH2 polynucleotides or the polypeptides.

-312-

Biological Activities of METH1 and/or METH2

METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, can be used in assays to test for one or more biological activities. If METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, do exhibit activity in a particular assay, it is likely that METH1 and/or METH2 may be involved in the diseases associated with the biological activity. Therefore, METH1 and/or METH2 could be used to treat the associated disease.

Immune Activity

METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, can be used as a marker or detector of a particular immune system disease or disorder.

METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia,

-313-

dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, can also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting, important in the treatment of heart attacks (infarction), strokes, or scarring.

METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus

Erythematosis, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, may also be used to modulate inflammation. For example, METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, can be used to treat or detect hyperproliferative disorders, including neoplasms. METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Cardiovascular Disorders

METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, encoding METH1 and/or METH2 may be used to treat cardiovascular disorders, including peripheral artery disease, such as limb ischemia.

Cardiovascular disorders include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

Cardiovascular disorders also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular

-317-

tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve diseases include aortic valve insufficiency, aortic valve stenosis, hear
5 murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive
10 cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary
15 aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodyplasia, angiomas, bacillary angiomas, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic
20 diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome,
25 retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, ataxia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart
30 aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular disorders include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, are especially effective for the treatment of critical limb ischemia and coronary disease.

METH1 and/or METH2 polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art.

-319-

METH1 and/or METH2 polypeptides may be administered as part of a pharmaceutical composition, described in more detail below. Methods of delivering METH1 and/or METH2 polynucleotides are described in more detail herein.

Diseases at the Cellular Level

5 Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated or detected by METH1 and/or METH2 polynucleotides or polypeptides, as well as antagonists or agonists of METH1 and/or METH2, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, 10 retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's 15 disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, METH1 and/or METH2 polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit 20 growth, progression, and/or metasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated or detected by METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia 25 (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's

-320-

macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's
5 tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma,
10 choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma.

15 Diseases associated with increased apoptosis that could be treated or detected by METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease);
20 autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver
25 injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Wound Healing and Epithelial Cell Proliferation

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds. METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could be used to promote dermal reestablishment subsequent to dermal loss.

METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are types of grafts that METH1 and/or METH2 polynucleotides or polypeptides, agonists or antagonists of METH1 and/or METH2, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omenpal graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or

-322-

METH2, can be used to promote skin strength and to improve the appearance of aged skin.

It is believed that METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. METH1 and/or METH2 polynucleotides or polypeptides, agonists or antagonists of METH1 and/or METH2, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, may have a cytoprotective effect on the small intestine mucosa. METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could also be used to treat gastric and duodenal ulcers and help

-323-

heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with METH1 and/or METH2 polynucleotides or polypeptides, agonists or antagonists of METH1 and/or METH2, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could be used to treat diseases associated with the under expression of METH1 and/or METH2.

Moreover, METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of alveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated using METH1 and/or METH2 polynucleotides or polypeptides, agonists or antagonists of METH1 and/or METH2. Also, METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could be used to stimulate the proliferation and differentiation of type II pneumocytes, which may help treat or prevent diseases such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could stimulate the proliferation and

differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins known in the art).

5 In addition, METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could be used to treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could be used
10 to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, METH1 and/or METH2 polynucleotides or polypeptides, as well as agonists or antagonists of METH1 and/or METH2, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

Infectious Disease

15 METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by
20 initiating a new immune response. Alternatively, METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

25 Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae

-325-

(such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and
5 Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiollitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps,
10 Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that
15 can be treated or detected by METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Aspergillus, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella,
20 Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Pasteurellaceae Infections (e.g., Actinobacillus, Haemophilus, Pasteurella), Pseudomonas, Rickettsiaceae,
25 Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema,
30 sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria,

-326-

Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, include, but are not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, could either be by administering an effective amount of METH1 and/or METH2 polypeptide to the patient, or by removing cells from the patient, supplying the cells with METH1 and/or METH2 polynucleotide, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the METH1 and/or METH2 polypeptide or polynucleotide can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by

-327-

congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

5 Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

10 Moreover, METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated
15 include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

20 Similarly, nerve and brain tissue could also be regenerated by using METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical
25 therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2.

Chemotaxis

METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as a site of inflammation, infection, or hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. As a chemotactic molecule, METH1 and/or METH2 could also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, METH1 and/or METH2 polynucleotides or polypeptides, or agonists or antagonists of METH1 and/or METH2, could be used as an inhibitor of chemotaxis.

Binding Activity

METH1 and/or METH2 polypeptides may be used to screen for molecules that bind to METH1 and/or METH2 or for molecules to which METH1 and/or METH2 binds. The binding of METH1 and/or METH2 and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the METH1 and/or METH2 or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

-329-

Preferably, the molecule is closely related to the natural ligand of METH1 and/or METH2, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which
5 METH1 and/or METH2 binds, or at least, a fragment of the receptor capable of being bound by METH1 and/or METH2 (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express METH1 and/or METH2, either as a secreted protein or on the cell
10 membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing METH1 and/or METH2 (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either METH1 and/or METH2 or the molecule.

The assay may simply test binding of a candidate compound to METH1 and/or
15 METH2, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to METH1 and/or METH2.

Alternatively, the assay can be carried out using cell-free preparations,
20 polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing METH1 and/or METH2, measuring METH1 and/or METH2/molecule activity or binding, and comparing the METH1 and/or METH2/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure METH1 and/or METH2 level or activity
25 in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure METH1 and/or METH2 level or activity by either binding, directly or indirectly, to METH1 and/or METH2 or by competing with METH1 and/or METH2 for a substrate.

Additionally, the receptor to which METH1 and/or METH2 binds can be
30 identified by numerous methods known to those of skill in the art, for example, ligand

-330-

panning and FACS sorting (Coligan, *et al.*, Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to auto-radiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of METH1 or METH2 thereby effectively generating agonists and antagonists of METH1 or METH2. *See generally*, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458; and Patten, P.A. *et al.*, *Curr. Opinion Biotechnol.* 8:724-733 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L.O. *et al.*, *J. Mol. Biol.* 287:265-276 (1999); and Lorenzo, M.M. and Blasco, R. *Biotechniques* 24(2):308-313 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of METH1 or METH2 polynucleotides and corresponding polypeptides may be achieved by DNA shuffling.

-331-

DNA shuffling involves the assembly of two or more DNA segments into a desired METH1 or METH2 molecule by homologous, or site-specific, recombination.

In another embodiment, METH1 or METH2 polynucleotides and corresponding polypeptides may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion, or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., or METH1 or METH2 may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-6, BMP-7, activins A and B, decapentaplegic (dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active METH1 or METH2 fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the METH1 or METH2 polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, the polypeptide of the present invention, the compound to be screened and 3[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of 3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

-332-

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the METH1 and/or METH2 receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the METH1 and/or METH2/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of METH1 and/or METH2 from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to METH1 and/or METH2 comprising the steps of: (a) incubating a candidate binding compound with METH1 and/or METH2; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with METH1 and/or METH2, (b) assaying a biological activity, and (b) determining if a biological activity of METH1 and/or METH2 has been altered.

Also, one could identify molecules which bind METH1 and/or METH2 experimentally by using the beta-pleated sheet regions disclosed in Figures 10 and 11 and Tables 1 and 2. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions disclosed in Figure 10/Table 1 and Figure 11/Table 2. Additional embodiments of the invention are directed to polynucleotides encoding METH1 and/or METH2 polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions disclosed in Figure 10/Table 1 and Figure 11/Table 2. Additional preferred embodiments of the

-333-

invention are directed to polypeptides which comprise, or alternatively consist of, the METH1 and/or METH2 amino acid sequence of each of the beta pleated sheet regions disclosed in Figure 10/Table 1 and Figure 11/Table 2. Additional embodiments of the invention are directed to METH1 and/or METH2 polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions disclosed in Figure 10/Table 1 and Figure 11/Table 2.

Antisense And Ribozyme (Antagonists)

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:1 or 3, or the complementary strand thereof, and/or to nucleotide sequences contained in the deposited clones. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, J., *Neurochem.* 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, J., *Neurochem.* 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee *et al.*, *Nucleic Acids Research* 6:3073 (1979); Cooney *et al.*, *Science* 241:456 (1988); and Dervan *et al.*, *Science* 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into receptor polypeptide.

-334-

In one embodiment, the METH1 and/or METH2 antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the METH1 and/or METH2 antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding METH1 and/or METH2, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, *Nature* 29:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto *et al.*, *Cell* 22:787-797 (1980)), the herpes thymidine promoter (Wagner *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster, *et al.*, *Nature* 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a METH1 and/or METH2 gene. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded METH1 and/or METH2 antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a METH1 and/or METH2 RNA it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

-335-

Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., 1994, *Nature* 372:333-335. Thus, oligonucleotides complementary to either the 5'- or 3'- non-translated, non-coding regions of METH1 and/or METH2 shown in Figure 1 could be used in an antisense approach to inhibit translation of endogenous METH1 and/or METH2 mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5', 3'- or coding region of METH1 and/or METH2 mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger *et al.*, 1989, *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556; Lemaitre *et al.*, 1987, *Proc. Natl. Acad. Sci.* 84:648-652; PCT Publication No. WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol *et al.*, 1988, *BioTechniques* 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

-336-

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier *et al.*, 1987, *Nucl. Acids Res.* 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue *et al.*, 1987, *Nucl. Acids Res.* 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue *et al.*, 1987, *FEBS Lett.* 215:327-330).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein *et al.* (1988, *Nucl. Acids*

-337-

Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin *et al.*, 1988, *Proc. Natl. Acad. Sci. U.S.A.* 85:7448-7451), etc.

While antisense nucleotides complementary to the METH1 and/or METH2 coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver *et al.*, *Science* 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy METH1 and/or METH2 mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, *Nature* 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within the nucleotide sequence of METH1 and/or METH2 (Figures 1 and 2). Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the METH1 and/or METH2 mRNA; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express METH1 and/or METH2 *in vivo*. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous METH1 and/or METH2 messages and inhibit translation. Since ribozymes, unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

-338-

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

5 The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirous in cases such as restenosis after balloon angioplasty.

10 The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat the diseases described herein.

Other Activities

15 As stated below, METH1 and METH2 share structural and sequence homology with members of the ADAM family. ADAM proteins have been shown to proteolytically process membrane-anchored proteins, including TNF (Black *et al.*, *Nature* 385:729 (1997); Moss *et al.*, *Nature* 385:733 (1997)). Thus, METH1 and/or METH2 may be useful in proteolytic processing of membrane-anchored proteins. Membrane-anchored proteins which may be proteolytically processed by METH1 and/or METH2 include
20 cytokines, growth factors, cytokine receptors and growth factor receptors.

METH1 or METH2 polypeptides or polynucleotides, or agonists or antagonists of METH1 and/or METH2, may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

25 METH1 or METH2 polypeptides or polynucleotides, or agonists or antagonists of METH1 and/or METH2, may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, METH1 or METH2 polypeptides or polynucleotides, or agonists or antagonists of METH1 and/or METH2,

-339-

may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

As angiogenesis is a key factor in supporting adipose tissue, METH1 or METH2 polypeptides or polynucleotides, or agonists or antagonists of METH1 and/or METH2 may be used to control weight, reduce weight, treat obesity, and/or control adipose tissue in an individual.

METH1 or METH2 polypeptides or polynucleotides, or agonists or antagonists of METH1 and/or METH2, may be used to change a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

METH1 or METH2 polypeptides or polynucleotides, or agonists or antagonists of METH1 and/or METH2, may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

Anti-angiogenesis

As shown in Examples 4 and 5, METH1 and METH2 inhibit angiogenesis. Thus, the present invention provides a method of treating an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a METH1 and/or METH2 polynucleotide, polypeptide, and/or agonist.

-340-

For example, METH1 and/or METH2 polynucleotides, polypeptides, and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat a cancer or tumor. Cancers which may be treated with METH1 and/or METH2 polynucleotides, polypeptides and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, METH1 and/or METH2 polynucleotides, polypeptides, and/or agonists may be delivered topically, in order to treat cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma. Within yet other aspects, METH1 and/or METH2 polynucleotides, polypeptides, and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. METH1 and/or METH2 polynucleotides, polypeptides and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

METH1 and/or METH2 polynucleotides, polypeptides and/or agonists may be useful in treating other disorders, besides cancers, which involve angiogenesis. These disorders include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia;

-341-

hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating hypertrophic scars and keloids, comprising the step of administering a METH1 and/or METH2 polynucleotide, polypeptide, and/or agonist to a hypertrophic scar or keloid. Within one embodiment of the present invention METH1 and/or METH2 polynucleotides, polypeptides, and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development.

As noted above, the present invention also provides methods for treating neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a METH1 and/or METH2 compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates.

A wide variety of disorders can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and

-342-

onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, METH1 and/or
5 METH2 may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within
10 preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy.

Topical therapy may also be useful prophylactically in corneal lesions which are
15 known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The
20 preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult
25 in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also
30 be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a METH1 and/or METH2 polypeptide, polynucleotide, and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor.

Within another aspect of the present invention, methods are provided for treating proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a METH1 and/or METH2 polynucleotide, polypeptide, and/or agonist to the eyes, such that the formation of blood vessels is inhibited. Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the METH1 and/or METH2 polynucleotide, polypeptide, and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a METH1 and/or METH2 polynucleotide, polypeptide, and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

METH1 and/or METH2 polynucleotides, polypeptides and/or agonists may be used to treat diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochéle minalia quintosa*), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

METH1 and/or METH2 polynucleotides, polypeptides and/or agonists may be used as a birth control agent by preventing vascularization required for embryo implantation. In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and

-344-

fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method.

METH1 and/or METH2 polynucleotides, polypeptides and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or
5 for peritoneal implantation in the treatment of endometriosis.

METH1 and/or METH2 polynucleotides, polypeptides, and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

METH1 and/or and METH2 polynucleotides, polypeptides, and/or agonists may
10 be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a METH1 and/or METH2 compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention,
15 METH1 and/or METH2 compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti-angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one
20 embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating
25 tumor excision sites, comprising administering a METH1 and/or METH2 polynucleotide, polypeptide, and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or
30 otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into

-345-

known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, METH1 and/or METH2 polynucleotides, polypeptides, and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

The METH1 and/or METH2 polynucleotides, polypeptides, and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes

-346-

include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata *et al.*, *Cancer Res.* 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP-PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, α,α -dipyridyl, 6-aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff *et al.*, *J. Bio. Chem.* 267:17321-17326, 1992); Chymostatin (Tomkinson *et al.*, *Biochem J.* 286:475-480, 1992); 6-Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber *et al.*, *Nature* 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, *J. Clin. Invest.* 79:1440-1446, 1987); 6-1-anticollagenase-serum; α 2-antiplasmin (Holmes *et al.*, *J. Biol. Chem.* 262(4):1659-1664, 1987); Bisantrone (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi *et al.*, *Agents Actions* 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

Diagnostic Methods

The invention also relates to the use of METH1 or METH2 polynucleotides for use as diagnostic reagents. Detection of a mutated form of the METH1 or METH2 gene associated with a dysfunction will provide a diagnostic tool that can add to or define a

diagnosis of a disease or susceptibility to a disease which results from under-expression, overexpression or altered expression of METH1 or METH2. Individuals carrying mutations in the METH1 or METH2 gene may be detected at the DNA level by a variety of techniques.

5 Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified
10 product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled METH1 or METH2 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or
15 without denaturing agents, or by direct DNA sequencing. See, e.g., Myers *et al.*, *Science* 230:1242 (1985). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method. See Cotton *et al.*, *Proc Natl Acad Sci USA* 85:4397-4401 (1985). In another embodiment, an array of oligonucleotides probes comprising METH1 or METH2
20 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability. (See, for example, M. Chee *et al.*, *Science* 274:610-613 (1996).

25 The diagnostic assays offer a process for diagnosing or determining a susceptibility to angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling through detection of mutation in the METH1 or METH2 gene by the methods described.

30 In addition, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic

retinopathy), restenosis, Alzheimer's disease and tissue remodeling can be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of the METH1 or METH2 polypeptide or METH1 or METH2 mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as an METH1 or METH2 polypeptide, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Cancer Diagnosis and Prognosis

It is believed that certain tissues in mammals with cancer express significantly diminished levels of the METH1 or METH2 protein and mRNA encoding the METH1 or METH2 protein when compared to a corresponding "standard" mammal, i.e., a mammal of the same species not having the cancer. Further, it is believed that diminished levels of the METH1 or METH2 protein can be detected in certain body fluids (e.g., sera, plasma, urine, and spinal fluid) from mammals with cancer when compared to sera from mammals of the same species not having the cancer. Thus, the invention provides a diagnostic method useful during tumor diagnosis, which involves assaying the expression level of the gene encoding the METH1 protein in mammalian cells or body fluid and comparing the gene expression level with a standard METH1 gene expression level, whereby a decrease in the gene expression level under the standard is indicative of certain tumors. The invention also provides a diagnostic method useful during tumor diagnosis, which involves assaying the expression level of the gene encoding the METH2 protein in mammalian cells or body fluid and comparing the gene expression level with a standard METH2 gene expression level, whereby a decrease in the gene expression level under the standard is indicative of certain tumors.

Where a tumor diagnosis has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients

exhibiting diminished METH1 or METH2 gene expression will experience a worse clinical outcome relative to patients expressing the gene at a lower level.

By "assaying the expression level of the gene encoding the METH1 or METH2 protein" is intended qualitatively or quantitatively measuring or estimating the level of the METH1 or METH2 protein or the level of the mRNA encoding the METH1 or METH2 protein in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the METH1 or METH2 protein level or mRNA level in a second biological sample).

Preferably, the METH1 or METH2 protein level or mRNA level in the first biological sample is measured or estimated and compared to a standard METH1 or METH2 protein level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the cancer. As will be appreciated in the art, once a standard METH1 or METH2 protein level or mRNA level is known, it can be used repeatedly as a standard for comparison.

By "biological sample" is intended any biological sample obtained from an individual, cell line, tissue culture, or other source which contains METH1 or METH2 protein or mRNA. Biological samples include mammalian body fluids (such as sera, plasma, urine, synovial fluid and spinal fluid) which contain secreted mature METH1 or METH2 protein, and adrenal, thyroid, stomach, brain, heart, placenta, lung, liver, muscle, kidney, pancreas, testis and ovarian tissue (for METH1); and prostate, small intestine, colon, brain and lung tissue (for METH2).

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of the of following types of cancers in mammals: breast, ovarian, prostate, liver, lung, pancreatic, colon, and testicular. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Total cellular RNA can be isolated from a biological sample using the single-step guanidinium-thiocyanate-phenol-chloroform method described in Chomczynski and Sacchi, *Anal. Biochem.* 162:156-159 (1987). Levels of mRNA encoding the METH1 or METH2 protein are then assayed using any appropriate method. These include Northern blot analysis (Harada *et al.*, *Cell* 63:303-312 (1990)), S1 nuclease mapping (Fujita *et al.*,

-350-

Cell 49:357- 367 (1987)), the polymerase chain reaction (PCR), reverse transcription in combination with the polymerase chain reaction (RT-PCR) (Makino *et al.*, *Technique* 2:295-301 (1990)), and reverse transcription in combination with the ligase chain reaction (RT-LCR).

5 Assaying METH1 or METH2 protein levels in a biological sample can occur using antibody-based techniques. For example, METH1 or METH2 protein expression in tissues can be studied with classical immunohistological methods (Jalkanen, M., *et al.*, *J. Cell. Biol.* 101:976-985 (1985); Jalkanen, M., *et al.*, *J. Cell. Biol.* 105:3087-3096 (1987)).

10 Other antibody-based methods useful for detecting METH1 or METH2 protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA).

15 Suitable labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium ($^{99\text{m}}\text{Tc}$), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

Vaccines

20 Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with METH1 or METH2 polypeptide, or a fragment thereof, adequate to produce antibody and/or T cell immune response to protect said animal from angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling, among others. Yet another aspect of the invention relates to a method of
25 inducing immunological response in a mammal which comprises delivering METH1 or METH2 polypeptide via a vector directing expression of METH1 or METH2 polynucleotide *in vivo* in order to induce such an immunological response to produce antibody to protect such animal from diseases.

-351-

Further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a METH1 or METH2 polypeptide wherein the composition comprises a METH1 or METH2 polypeptide or METH1 or METH2 gene. The vaccine formulation may further comprise a suitable carrier. Since METH1 or METH2 polypeptide may be broken down in the stomach, it is preferably administered parenterally (including subcutaneous, intramuscular, intravenous, intradermal etc. injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Modes of administration

It is recognized that an increase in the vascular supply plays a central role in tumor progression and metastasis; therefore, inhibitors of angiogenesis can prove effective as adjuvant therapy for cancer patients. Some of the currently recognized angiogenic suppressors are poor candidates for systemic treatment due to severe collateral effect. The present inventors have found that METH1 and METH2 are potent inhibitors of angiogenesis both *in vitro* and *in vivo*. The advantage of METH1 and METH2 is that these inhibitors are normally associated with suppression of physiological angiogenesis; therefore, they offer lack of toxicity and endothelial specificity over other angiogenic inhibitors. Furthermore, METH1 and METH2 present a restricted pattern of expression providing a possible advantage on organ specificity.

-352-

Accordingly, the polypeptides of the present invention may be employed to treat cancer. The METH1 and METH2 polypeptides of the present invention can also be used to treat individuals with other disorders that are related to angiogenesis, including abnormal wound healing, inflammation, rheumatoid arthritis, psoriasis, endometrial
5 bleeding disorders, diabetic retinopathy, some forms of macular degeneration, hemangiomas, and arterial-venous malformations.

Thus, the invention provides a method of inhibiting angiogenesis in an individual comprising administering to such an individual a pharmaceutical composition comprising an effective amount of an isolated METH1 polypeptide of the invention, effective to
10 increase the METH1 activity level in such an individual. The invention also provides a method of inhibiting angiogenesis in an individual comprising administering to such an individual a pharmaceutical composition comprising an effective amount of an isolated METH2 polypeptide of the invention, effective to increase the METH2 activity level in such an individual.

METH1 polypeptides which may be used to inhibit angiogenesis in this manner include: METH1 polypeptide encoded by the deposited cDNA including the leader; the mature METH1 polypeptide encoded by the deposited the cDNA minus the leader (i.e., the mature protein); a polypeptide comprising amino acids about 1 to about 950 in SEQ ID NO:2; a polypeptide comprising amino acids about 2 to about 950 in SEQ ID NO:2;
20 a polypeptide comprising amino acids about 29 to about 950 in SEQ ID NO:2; a polypeptide comprising amino acids about 30 to about 950 in SEQ ID NO:2; a polypeptide comprising the metalloprotease domain of METH1, amino acids 235 to 459 in SEQ ID NO:2; a polypeptide comprising the disintegrin domain of METH1, amino acids 460 to 544 in SEQ ID NO:2; a polypeptide comprising the first TSP-like domain of METH1, amino acids 545 to 598 in SEQ ID NO:2; a polypeptide comprising the
25 second TSP-like domain of METH1, amino acids 841 to 894 in SEQ ID NO:2; a polypeptide comprising the third TSP-like domain of METH1, amino acids 895 to 934 in SEQ ID NO:2; a polypeptide comprising amino acids 536 to 613 in SEQ ID NO:2; a polypeptide comprising amino acids 549 to 563 in SEQ ID NO:2; a polypeptide comprising amino acids 542 to 894 of SEQ ID NO:2; and a polypeptide comprising amino acids 801 to 950 of SEQ ID NO:2.
30

-353-

METH2 polypeptides which may be used to inhibit angiogenesis in this manner include: the METH2 polypeptide encoded by the deposited cDNA including the leader; the mature METH2 polypeptide encoded by the deposited the cDNA minus the leader (i.e., the mature protein); a polypeptide comprising amino acids about 1 to about 890 in SEQ ID NO:4; a polypeptide comprising amino acids about 2 to about 890 in SEQ ID NO:4; a polypeptide comprising amino acids about 24 to about 890 in SEQ ID NO:4; a polypeptide comprising amino acids about 112 to about 890 in SEQ ID NO:4; a polypeptide comprising the metalloprotease domain of METH2, amino acids 214 to 439 in SEQ ID NO:4; a polypeptide comprising the disintegrin domain of METH2, amino acids 440 to 529 in SEQ ID NO:4; a polypeptide comprising the first TSP-like domain of METH2, amino acids 530 to 583 in SEQ ID NO:4; a polypeptide comprising the second TSP-like domain of METH2, amino acids 837 to 890 in SEQ ID NO:4; a polypeptide comprising amino acids 280 to 606 in SEQ ID NO:4; and a polypeptide comprising amino acids 529 to 548 in SEQ ID NO:4.

Also included are METH1 or METH2 proteins lacking TSP3; a METH1 or METH2 protein lacking TSP2 and TSP3; a METH1 or METH2 protein lacking TSP3, TSP2, and TSP1; a METH1 or METH2 protein lacking the cysteine-rich domain, TSP1, TSP2, and TSP3; a METH1 or METH2 protein lacking the metalloprotease domain, the cysteine-rich domain, TSP1, TSP2 and TSP3; and a METH1 or METH2 protein lacking the prodomain, the metalloprotease domain, the cysteine-rich domain, TSP1, TSP2, and TSP3. Finally, any combination of these domains are also preferred. For example, the cysteine-rich domain of METH1 may be combined with 1, 2, or 3 TSP domains of METH1. The cysteine-rich domain of METH2 may be combined with 1, 2, or 3 TSP domain of METH2. The metalloprotease domain and the cysteine-rich domain of METH1 may be combined with 1,2 or 3 TSP domains of METH1. The metalloprotease domain and the cysteine-rich domain of METH2 may be combined with 1,2 or 3 TSP domains of METH2. The prodomain, the metalloprotease domain, and the cysteine-rich domain of METH1 may be combined with 1,2 or 3 TSP domains of METH1. The prodomain, the metalloprotease domain, and the cysteine-rich domain of METH2 may be combined with 1,2 or 3 TSP domains of METH2. The signal sequence, the prodomain, the metalloprotease domain, and the cysteine-rich domain of METH1 may

-354-

be combined with 1,2, or 3 TSP domains of METH1. The signal sequence, the prodomain, the metalloprotease domain, and the cysteine-rich domain of METH2 may be combined with 1,2, or 3 TSP domains of METH2.

As a general proposition, the total pharmaceutically effective amount of METH1
5 or METH2 polypeptide administered parenterally per dose will be in the range of about 1 µg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the polypeptide. If given continuously, the METH1 or METH2 polypeptide is typically administered at a
10 dose rate of about 1 µg/kg/hour to about 50 µg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed.

Pharmaceutical compositions containing the METH1 or METH2 of the invention may be administered orally, rectally, parenterally, intracisternally, intravaginally,
15 intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), buccally, or as an oral or nasal spray. By "pharmaceutically acceptable carrier" is meant a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal,
20 subcutaneous and intraarticular injection and infusion.

Gene Therapy Methods

Another aspect of the present invention is to gene therapy methods for treating disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to
25 achieve expression of the METH1 and/or METH2 polypeptide of the present invention. This method requires a polynucleotide which codes for a METH1 and/or METH2 polypeptide operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery

-355-

techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a METH1 and/or METH2 polynucleotide ex vivo, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Belldegrun, A., *et al.*, *J. Natl. Cancer Inst.* 85:207-216 (1993); Ferrantini, M. *et al.*, *Cancer Research* 53:1107-1112 (1993); Ferrantini, M. *et al.*, *J. Immunology* 153: 4604-4615 (1994); Kaido, T., *et al.*, *Int. J. Cancer* 60: 221-229 (1995); Ogura, H., *et al.*, *Cancer Research* 50: 5102-5106 (1990); Santodonato, L., *et al.*, *Human Gene Therapy* 7:1-10 (1996); Santodonato, L., *et al.*, *Gene Therapy* 4:1246-1255 (1997); and Zhang, J.-F. *et al.*, *Cancer Gene Therapy* 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the METH1 and/or METH2 polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The METH1 and/or METH2 polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the METH1 and/or METH2 polynucleotide is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the METH1 and/or METH2 polynucleotides can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The METH1 and/or METH2 polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor

-356-

will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of METH1 and/or METH2 DNA. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for METH1 and/or METH2.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The METH1 and/or METH2 polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent,

-357-

non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

5 For the naked acid sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of
10 injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such
15 as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked METH1 and/or METH2 DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous
20 injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc.
25 Such methods of delivery are known in the art.

In certain embodiments, the METH1 and/or METH2 polynucleotide constructs are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic
30 acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid

DNA (Felgner *et al.*, *Proc. Natl. Acad. Sci. USA* (1987) 84:7413-7416, which is herein incorporated by reference); mRNA (Malone *et al.*, *Proc. Natl. Acad. Sci. USA* (1989) 86:6077-6081, which is herein incorporated by reference); and purified transcription factors (Debs *et al.*, *J. Biol. Chem.* (1990) 265:10189-10192, which is herein incorporated by reference), in functional form.

Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy]propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner *et al.*, *Proc. Natl. Acad. Sci. USA* (1987) 84:7413-7416, which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication No. WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., P. Felgner *et al.*, *Proc. Natl. Acad. Sci. USA* 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following

-359-

day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger *et al.*, *Methods of Immunology* (1983), 101:512-527, which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include Ca^{2+} -EDTA chelation (Papahadjopoulos *et al.*, *Biochim. Biophys. Acta* (1975) 394:483; Wilson *et al.*, *Cell* (1979) 17:77); ether injection (Deamer, D. and Bangham, A., *Biochim. Biophys. Acta* (1976) 443:629; Ostro *et al.*, *Biochem. Biophys. Res. Commun.* (1977) 76:836; Fraley *et al.*, *Proc. Natl. Acad. Sci. USA* (1979) 76:3348); detergent dialysis (Enoch, H. and Strittmatter, P., *Proc. Natl. Acad. Sci. USA* (1979) 76:145); and reverse-phase evaporation (REV) (Fraley *et al.*, *J. Biol. Chem.* (1980) 255:10431; Szoka, F. and Papahadjopoulos, D., *Proc. Natl. Acad. Sci. USA* (1978) 75:145; Schaefer-Ridder *et al.*, *Science* (1982) 215:166), which are herein incorporated by reference.

-360-

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ratio will be from about 5:1 to about 1:5. More preferably, the ratio will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent No. 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication no. WO 94/29469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication no. WO 94/29469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding METH1 and/or METH2. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, *Human Gene Therapy 1:5-14* (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO₄ precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding METH1 and/or METH2. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express METH1 and/or METH2.

-361-

In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with METH1 and/or METH2 polynucleotide contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses METH1 and/or METH2, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz, A. R. *et al.* (1974) *Am. Rev. Respir. Dis.* 109:233-238). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld, M. A. *et al.* (1991) *Science* 252:431-434; Rosenfeld *et al.*, (1992) *Cell* 68:143-155). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green, M. *et al.* (1979) *Proc. Natl. Acad. Sci. USA* 76:6606).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, *Curr. Opin. Genet. Devel.* 3:499-503 (1993); Rosenfeld *et al.*, *Cell* 68:143-155 (1992); Engelhardt *et al.*, *Human Genet. Ther.* 4:759-769 (1993); Yang *et al.*, *Nature Genet.* 7:362-369 (1994); Wilson *et al.*, *Nature* 365:691-692 (1993); and U.S. Patent No. 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express E1a and E1b, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

-362-

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, N., *Curr. Topics in Microbiol. Immunol.* 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The METH1 and/or METH2 polynucleotide construct is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the METH1 and/or METH2 polynucleotide construct. These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the METH1 and/or METH2 polynucleotide construct integrated into its genome, and will express METH1 and/or METH2.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding METH1 and/or METH2) via homologous recombination (*see, e.g.*, U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller *et al.*, *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); and Zijlstra *et al.*, *Nature* 342:435-438 (1989). This method involves the activation of a gene which is present in

-363-

the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the METH1 and/or METH2 desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous METH1 and/or METH2 sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous METH1 and/or METH2 sequence.

The polynucleotides encoding METH1 and/or METH2 may be administered along with other polynucleotides encoding other proteins. Such proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2, VEGF-3,

-364-

VEGF-E, PIGF 1 and 2, epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor alpha and beta, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

Preferably, the polynucleotide encoding METH1 and/or METH2 contains a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the rat livers (Kaneda *et al.*, *Science* 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries. Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

-365-

Therapeutic compositions useful in systemic administration include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a particular site.

5 Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling *et al.*, *Proc. Natl. Acad. Sci. USA* 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can
10 be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into
15 the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments
20 depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian.

Therapeutic compositions of the present invention can be administered to any
25 animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly preferred.

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent
30 a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by

-366-

the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel *et al.*, *Clinical Pharmacy* 12:488-505 (1993); Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, *TIBTECH* 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); and Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); Zijlstra *et al.*, *Nature* 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids *in vitro*, then transplanted into the patient. These two approaches are known, respectively, as *in vivo* or *ex vivo* gene therapy.

-367-

In a specific embodiment, the nucleic acid sequences are directly administered *in vivo*, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted *in vivo* for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); Zijlstra *et al.*, *Nature* 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller *et al.*, *Meth. Enzymol.* 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen *et al.*, *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in

gene therapy are: Clowes *et al.*, *J. Clin. Invest.* 93:644-651 (1994); Kiem *et al.*, *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout *et al.*, *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld *et al.*, *Science* 252:431-434 (1991); Rosenfeld *et al.*, *Cell* 68:143-155 (1992); Mastrangeli *et al.*, *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, *et al.*, *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh *et al.*, *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the

art for the introduction of foreign genes into cells (*see, e.g.*, Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen *et al.*, *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered *in vivo* for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained *in vitro* can potentially be used in accordance with this embodiment of the present invention (*see e.g.*, PCT Publication WO 94/08598; Stemple and Anderson, *Cell* 71:973-985 (1992); Rheinwald, *Meth. Cell Bio.* 21A:229 (1980); and Pittelkow and Scott, *Mayo Clinic Proc.* 61:771 (1986)).

-370-

In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

5 The compounds or pharmaceutical compositions of the invention are preferably tested *in vitro*, and then *in vivo* for the desired therapeutic or prophylactic activity, prior to use in humans. For example, *in vitro* assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or
10 composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, *in vitro* assays which can be used to determine whether administration of a specific compound is indicated, include *in vitro* cell culture assays in which a patient tissue sample is grown in culture, and exposed to
15 or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical
20 composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

25 Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

-371-

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (*see, e.g.,* Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (*see* Langer, *Science* 249:1527-1533 (1990); Treat *et al.*, in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; *see generally ibid.*)

-372-

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (*see* Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald *et al.*, *Surgery* 88:507 (1980); Saudek *et al.*, *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (*see* Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J., Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); *see also* Levy *et al.*, *Science* 228:190 (1985); During *et al.*, *Ann. Neurol.* 25:351 (1989); Howard *et al.*, *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (*see, e.g.*, Goodson, in Medical Applications of Controlled Release, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (*see* U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (*see e.g.*, Joliot *et al.*, *Proc. Natl. Acad. Sci. USA* 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized

-373-

pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion,

-374-

it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

5 The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

10 The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

15 For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

20 The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form

-375-

prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Chromosome Assays

5 The nucleic acid molecules of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. The mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

10 In certain preferred embodiments in this regard, the cDNA herein disclosed is used to clone genomic DNA of a METH1 or METH2 protein gene. This can be accomplished using a variety of well known techniques and libraries, which generally are available commercially. The genomic DNA then is used for *in situ* chromosome mapping using well known techniques for this purpose.

15 In addition, in some cases, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis of the 3' untranslated region of the gene is used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual
20 human chromosomes.

 Fluorescence *in situ* hybridization ("FISH") of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with probes from the cDNA as short as 50 or 60 bp. For a review of this technique, see Verma *et al.*, *Human Chromosomes: A Manual Of Basic
25 Techniques*, Pergamon Press, New York (1988).

 Other mapping strategies that can similarly be used to map to its chromosome include radiation hybrid mapping, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries. Radiation hybrid (RH) mapping relies upon fragmentation of human chromosomes with

-376-

X-rays, and retention of these random fragments in Hamster A23 host cells. The DNAs for RH mapping are supplied by Research Genetics (USA). Oligo pairs are designed from EST sequences that will amplify products of between 80bp and 300bp. The PCRs are performed on 93 human/hamster hybrid DNAs and the results compared with a framework map (<http://www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl>; Gyapay *et al.*, *Human Molecular Genetics* 5:39-346 (1996)). RH mapping provides greater precision than FISH and indicates clusters of genes as well as disease locus/gene correlations.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, *Mendelian Inheritance In Man*, available on-line through Johns Hopkins University, Welch Medical Library. The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

Next, it is necessary to determine the differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

The METH1 gene maps between STS markers D21S1435 and D21S1442 which translates as 21q21. This is a similar chromosomal location to amyloid precursor protein (APP). APP and METH1 are approximately 3 million bases apart which is not a massive distance in human genomics. The chromosomal location includes important genes such as enterokinases (enzymes that activate trypsinogen by converting it to trypsin) and genes responsible for Alzheimer's disease.

The METH1 gene can be mapped to 21q21 using the following oligos for radiation hybrid mapping:

5' primer: ACTGTGTGTGATCCGAG (SEQ ID NO:126)

3' primer: GTTGGAAAGCATTGACG (SEQ ID NO:127)

-377-

Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic

-378-

kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Examples

Example 1: Identification and Cloning of METH1 and METH2

To search for novel genes with TSP-like domains, a large human cDNA database consisting of approximately 900,000 expressed sequence tags (ESTs) was screened for sequences homologous to the second type I repeat of TSP1. Several ESTs were predicted to encode proteins with TSP-like domains. Two cDNA clones originated from human heart and lung libraries were further sequenced and chosen for functional analysis.

The amino-terminal end of METH1 was obtained using 5' rapid amplification of cDNA ends (RACE) PCR technique (Marathon cDNA amplification kit, Clontech) according to manufacturer instructions. The amino-terminal end of METH2 was obtained partially through 5'RACE PCR and later confirmed and completed by genomic screening. For the genomic screen, BAC clones (Genome Systems) were initially identified by PCR. Positive BAC clones containing 150-200bp of sequence were subsequently subcloned into pGEM vector as small fragments and sequenced.

Analysis and comparison of the deduced amino acid sequence with the GenBank, EMBL and SwissProt databases suggested that these genes belong to a new family of metalloproteases with homology to the reprolysin family in their NH₂-terminal end and with several TSP-like motifs in the COOH-terminal end. These cDNAs were named METH1 and METH2; ME, for metalloprotease and TH, for thrombospondin. The mouse homologue of METH1 was identified and named ADAMTS1 (Kuno, K., *et al.*, *J. Biol. Chem.* 272:556-562 (1997)). Direct comparison of the human and mouse sequences revealed a high level of conservation (83.4% amino acid identity). Thus far no homologues for METH2 have been identified.

Interestingly, a recently identified protein named pNPI (procollagen I N-proteinase; (Colidge, A., *et al.*, *Proc. Natl. Acad. Sci. USA* 94:2374-2379 (1997)) showed a striking sequence and structural similarity to METH1 and METH2 (Figure 3). As the novel proteins described here, pNPI also contains metalloproteinase (reprolysin subfamily) and TSP domains at the carboxy-terminal end. Although the sequence for

-380-

pNPI is of bovine origin, sequence alignment revealed identical structural features. The amino acid similarity between METH1 and METH2 is 51.7%, and between METH1 or METH2 and pNPI the homology is lesser 33.9% and 36.3%, respectively.

Sequence analysis showed that the ORF of METH1 and METH2 coded for proteins of 950 and 890 amino acids, respectively. In all three proteins, the NH₂ terminal end contains a putative signal peptide followed by another putative transmembrane domain around amino acid 300, deduced from the hydrophilicity plots. It is not clear whether these proteins are bound to the membrane. However, given preliminary data, it is more likely that this second transmembrane domain will consist of a hydrophobic pocket and that METH1, METH2 and pNPI are in fact secreted proteins. The NH₂-terminal end past the signal peptide has homology to the superfamily of zinc metalloproteases and can be subdivided in a prodomain, a metalloprotease domain, and a cysteine-rich region.

The double underlined sequence in METH1 (amino acids 232-235) and METH2 (amino acids 211-214) in Figure 3 localized at the boundary between the prodomain and the metalloprotease domain, are potential cleavage sites for mammalian subtilisins, such as furins (Barr, 1991). Proteolytical processing occurs in SVMPs to yield soluble metalloproteases and disintegrins (Bjarnason, J.B. & Fox, J.W., *Methods Enzymol.* 248:345-368 (1995)) and has also been detected in some ADAMs (reviewed by Wolsberg, T.G. & White, J.M., *Developmental Biology* 180:389-401 (1996)). Proteolytical processing occurs in both METH1 and 2 (see below). Additionally, both METH1 and METH2 present a Zn²⁺ -binding site (dotted line in Figure 3) that is presumed to be catalytically active due to the conservation of certain functionally important amino acids (Rawlings, N.D. & Barrett, A.J., *Methods Enzymol.* 248:183-228 (1995)) suggesting that these proteins may be active proteases.

Following the metalloprotease domain, there is a cysteine-rich region which contains two putative disintegrin loops (Wolsberg, T.G. & White, J.M., *Developmental Biology* 180:389-401 (1996)) (marked by arrows in Figure 3). Disintegrin domains are found within the superfamily of metalloproteases in snake venom metalloproteases (SVMPs) and ADAMs (mammalian proteins containing a disintegrin and a metalloprotease domain) and have a possible function inhibiting binding of integrins to

-381-

their ligands in SVMs. Conversely, the ADAM-disintegrin-like domain, as part of membrane anchored proteins, may promote rather than disrupt, cell-cell interactions (Wolsberg, T.G. & White, J.M., *Developmental Biology* 180:389-401 (1996)). The TSP-like domains are located in the COOH-half of METH1 and METH2 proteins. METH1 contains two conserved TSP domains separated by a spacer region with unknown function, and a subdomain with less homology, and only 5 cysteines, following the second anti-angiogenic region. METH2 contains two TSP domains separated by the spacer region. The alignment of the TSP-like domains of METH1 and METH2 with those of TSP1 and TSP2 are shown in Figure 5. The homology varies between 19.2% to 52% amino acid similarity among all the TSP repeats. The cysteines, numbered 1 to 6, and the tryptophans, labeled by asterisks, are highly conserved.

Southern blot of human genomic DNA revealed the presence of METH1 and METH2 in the genome. METH1 and METH2 probes revealed bands of different size suggesting that they are transcribed from different genes.

The consensus sequence for the type I repeats includes 16 residues with 6 perfectly conserved cysteines. Typically it begins with the sequence motif WSXWS (SEQ ID NO:82) that has also been shown to bind to heparin (Guo, N., *et al.*, *J. Biol. Chem.* 267:19349-19355 (1992)). The affinity of this region to heparin has been proposed to the part of the anti-angiogenic activity of TSP-1 (Guo, N., *et al.*, *J. Peptide Res.* 49(1997)). Among the five members of the TSP family of proteins, only TSP-1 and TSP-2 inhibit angiogenesis and contain the type I repeats (Tolsma, S.S., *et al.*, *J. Cell. Biol.* 122:497-511 (1993); Kyriakides, T.R., *et al.*, *J. Cell Biol.* 140:419-430 (1998)). The type I or properdin repeats were probably added to the precursor of TSP1 and 2 by exon shuffling between 500 and 900 million years ago (Adams, J., *et al.*, *The Thrombospondin Gene Family*, 1 Ed. Molecular Biology Intelligence Unit (Springer, Ed.), R.G. Landes Company, Germany (1995)). It is likely that the acquisition of this domain provided the precursor of TSP1 and TSP2 with functions, such as regulation of new vessel formation. More recently, BAI-1 (brain angiogenic inhibitor-1), a protein isolated from a brain library for its ability to be regulated by p53, has also been shown to contain the type I repeat of TSP-1 and to provide anti-angiogenic potential to this molecule (Nishimori, H., *et al.*, *Oncogene* 15:2145-2150 (1997)). Nevertheless, it

-382-

appears that additional sequences or context are also important, since other proteins containing the type I repeats appear not to have clear or more established anti-angiogenic properties such as: properdin, F-spondin, and other members of the complement family.

Because of the presence of TSP-repeats in METH1 and METH2, along with their anti-angiogenic properties, these proteins were originally considered members of the TSP superfamily. Nevertheless, they have no additional homology to other TSPs, and in fact, the similarity to TSP1 and TSP2 is restricted to the type I repeats. Furthermore, the proteins also have strong sequence and structural homology to members of the ADAM family. These features led Kuno and colleagues to name ADAMTS to the mouse homolog of METH1 (Kuno, K., *et al.*, *J. Biol. Chem.* 272:556-562 (1997)). The recent identification of pNPI and its striking sequence homology to the proteins here described, prompt all these three proteins to be grouped in a subfamily named metallopondins. At this point, it is not clear whether pNIP has anti-angiogenic properties or whether METH1 and/or METH2 participate in the cleavage of the amino terminal pro-peptide of $\alpha 1(I)$ procollagen.

Example 2: Northern and Southern Blot Analysis

Total RNA was purified from cells by guanidinium-isothiocyanate extraction, as previously described (Chomczynski, P. & Sacchi, N., *Anal. Biochem.* 162:156-159 (1987)) Poly(A)+RNA was extracted using a Boehringer Mannheim (BMB, Indianapolis, IN) kit according to the manufacturer conditions. Other poly(A)+RNA blots were purchased from Clontech (Palo Alto, CA). Pre-hybridization was performed in a solution containing: 50% formamide, 6X SSPE, 1X Denhardt's solution, 0.1% SDS and 100 μ g/ml of heat denatured salmon sperm DNA for 12-18h at 42°C. Hybridization with labeled cDNA probes proceeded in the same solution at 42°C for 12-18h. TSP1 and METH1 probes corresponded to the entire human cDNAs. The METH2 probe corresponded to a *KpnI-EcoRI* fragment from the human cDNA. A 1.3Kb *PstI* fragment of the glyceraldehyde-3-phosphate-dehydrogenase (GPDH) was used to normalize for loading and transfer efficiency. Membranes were exposed to Kodak Biomax MS film (Kodak, New Haven, CT).

-383-

For Southern blots, human genomic DNA, purchased from Promega (Madison, WI), was heated at 65°C for 10 min and digested with *EcoRI* and *PstI* overnight at 37°C. 5µg of digested DNA was separated in a 1% agarose gel, transferred to a nytran membrane and cross-linked by ultraviolet light. cDNA probes, as well as, prehybridization and hybridization conditions were identical to those described for Northern blots. Blots were washed with high stringency (0.2X SSC, 0.2% SDS at 50°C).

The expression patterns of METH1 and METH2 were examined in both adult and embryonic tissues. Northern blot analysis was performed under high-stringency conditions with blots that included poly(A)+RNA from human tissues. METH1 and METH2 transcripts revealed a single band of 4.6 and 3.7Kb, respectively. Abundant METH1 mRNA expression was observed in adrenal, heart, placenta, followed by skeletal muscle, thyroid and stomach. From the embryonic tissues analyzed, kidney showed the highest expression of METH1 mRNA. Nevertheless, weaker expression of METH1 mRNA was seen in all tissues analyzed. Distribution of METH2 mRNA was more restricted and weaker than that of METH1. The highest expression was seen in lung, both embryonic and adult. Interestingly, METH1 and METH2 expression do not appear to overlap. In combination, the structural similarities and their pattern of expression suggest functional redundancy yet different transcriptional regulation. The expression levels of TSP1 transcripts in the same blots were also analyzed, for purpose of comparison. TSP1 mRNA highest expression was seen in the adult placenta and in all embryonic tissues analyzed. In contrast to METH1 and METH2 we observed constant levels of TSP1 transcript in all the other tissues examined.

The cell type distribution was also studied by Northern blot analysis of poly(A)+RNA. METH1 mRNA was detectable, at low levels, in dermal fibroblasts, vascular smooth muscle, endometrial stromal cells, and in two cancer cell lines, HeLa and G631, an adenocarcinoma and a melanoma, respectively. METH2 mRNA was detected only on SW480, a colon carcinoma cell line, but no expression was seen in any other of the cell lines or primary strains analyzed.

The possibility that groups of angiogenic and anti-angiogenic factors regulate vascular network formation in specific organs has been a frequently discussed hypothesis likely to be true, yet unproven. The expression patterns of METH1 and METH2, which

are clearly distinct and almost non-overlapping, were puzzling, at least with concern to overall levels. TSP1 and TSP2 also share identical structure, high level of amino acid similarity, yet their pattern of expression differs significantly (Iruela-Arispe, M.L., *Dev. Dyn.* 197:40-56 (1993)). The differences are likely based on dissimilar cis-acting elements in their promoters and different regulatory mechanisms, as previously suggested. Although the promoters for METH1 and 2 have not been characterized, it is likely that they provide unique features for the regulation of each gene. Nevertheless, the possibility that one motif, the anti-angiogenic / type I repeat, with demonstrated anti-angiogenic properties is present in several proteins with different tissue specificities is appealing. Alternatively, the small differences in sequence between closely related members of the same family could possess significance that goes beyond functional redundancy. In the case of TSP1 and TSP2, aside from the striking structural similarities and perhaps having functionally common anti-angiogenic properties, TSP1 and TSP2 also appear to display functions of their own and not likely shared by their similar relative. This became evident with the outcome of the two knock-outs for these genes. TSP1 null animals exhibited primarily lung disorders (Lawler, J., *et al.*, *J. Clin. Invest.* 101:982-992 (1998)) and secondarily vascular abnormalities, but only under specific pathological settings or on a restricted set of organs. In contrast TSP2 knock-out mice exhibited unpredicted collagen assembly anomalies, with carry-on consequences to the skin, tendons, and bone (Kyriakides, T.R., *et al.*, *J. Cell Biol.* 140:419-430 (1998)). In addition, these animals also appear to have overall increase in capillary density in the dermis. It is not understood how the resemblance between the newly described members of the metallospodin family translate functionally. Clearly, pNIP has been shown to display active proteolytic activity by cleaving the N-terminus of type I procollagen (Colidge, A., *et al.*, *Proc. Natl. Acad. Sci. USA* 94:2374-2379 (1997)).

A second region of functional interest corresponds to the disintegrin domain. This domain has been more fully characterized in related members of the snake venom metalloproteases that have been shown to bind to α IIb β 3 and inhibit platelet interaction blocking coagulation (Pfaff, M., *et al.*, *Cell Adhes Commun.* 2:491-501 (1994); Usami, Y., *et al.*, *Biochem. Biophys. Res. Commun.* 201:331-339 (1994)). The disintegrin motif consists of a thirteen to fifteen domain which frequently contain an RGD or a negatively

-385-

charged residue at the position of the aspartic acid. The RGD, or equivalent, binds to integrins and serve as antagonist or signaling ligands (Wolsberg, T.G. & White, J.M., *Developmental Biology* 180:389-401 (1996)). METH2, but not METH1, has an RGD sequence located amino-terminal to the disintegrin domain. In addition, both molecules present relatively high, but not perfect, degree of conservation of cysteines within the disintegrin motif. This appears to display an important role in the tertiary structure of this region and its ability to interact with integrins. In addition, some of these domains have been shown to act as functional adhesion molecules, particularly those with transmembrane regions (Wolsberg, T.G. & White, J.M., *Developmental Biology* 180:389-401 (1996)). It is unlikely that this will be the case for METH1 and METH2, since both these proteins appear to be secreted.

Example 3: Expression and Purification of Recombinant Proteins

Recombinant constructs for expression of His-tagged fusion proteins were generated for expression in bacteria. METH1 nt 605-1839 (from ATG) was amplified by polymerase chain reaction using primers containing *Bam*HI and *Pst*I sites and subcloned into the pRSET vector (Invitrogen, Carlsbad, CA). The construct was sequenced to verify frame and sequence fidelity and were then transformed into BL21;DE3 *E. Coli* strain (Stratagene Cloning Systems, La Jolla, CA). Purification was performed by affinity chromatography on Ni-NTA columns. Recombinant protein was eluted with 500mM imidazole in PBS. Fractions containing recombinant protein were dialyzed against phenol-red free DMEM and used to generate antisera.

Antisera was generated by intramuscular injection of a 1:1 mixture of recombinant protein (500µg/ml) and Freud's adjuvant. Eight animals, including five guinea pigs and three rabbits were injected every 15 days for three cycles. After the third injection, serum was evaluated for presence of anti-METH1 antibodies, only two of the guinea pigs showed significant titers. The antibodies recognized recombinant protein on Western blots, were able to immunoprecipitate METH1 protein from cell extracts and recognize the protein by immunocytochemistry. Pre-immune sera was always included as control. One of the guinea pig antibodies was also able to recognize METH2.

-386-

For mammalian expression, full-length METH1 and METH2 cDNA were cloned into pcDNA3.1 expression vector (Invitrogen). The vector is under the regulatory control of the CMV promoter. Cloning was performed so that constructs contained their own termination codons.

5 Recombinant protein was obtained by transient transfection of the expression vectors in 293T cells using standard calcium phosphate precipitation. Upon transfection, cells were incubated for 6 to 16h in serum-containing media and then switched to serum--free media for 36h for accumulation of recombinant protein. As control, pcDNA3.1 vector alone was transiently transfected in parallel plates. Purification of the protein
10 included 30% ammonium sulfate precipitation followed by dialysis on HS buffer (DB = 10mM HEPES, 150mM NaCl, 1mM CaCl₂ and 1mM MgSO₄). Samples were then subjected to heparin-affinity chromatography. Elution from heparin columns was achieved with HS buffer containing 550mM NaCl. Fractions were then loaded on 5-30% sucrose gradients and spun at 48K. Separation on sucrose gradients was assessed by
15 Western blotting and purity was determined by Commassie blue and silver nitrate staining.

 Generation of recombinant protein was initially done in bacteria. A METH1 expression vector was generated containing an amino terminal His Tag to aid on the purification. The resulting protein coded for all METH1 translated sequence except the
20 prodomain. Affinity chromatography on Ni⁺⁺-beads showed an unique band of 68kD. Isolation and purification was always performed under denatured conditions and attempts to refold the protein met with little success, probably due to a significant number of intramolecular disulfide bonds associated with the large number of cysteines. Nonetheless, the protein was used to generate antibodies. From eight animals injected,
25 only two were able to mount an immune response and generate specific antibodies, possibly due to the high conservation across species. Both antibodies recognized recombinant METH1 protein before and after purification on Ni⁺⁺ columns. The antibody was also used to evaluate expression of the protein on Western blots of cell lysates. A single band of approximately 105-110 kD was detected in stromal fibroblasts and smooth
30 muscle cells.

-387-

To test the hypothesis that METH1 and METH2 could function as regulators of angiogenesis, recombinant full length protein was generated in mammalian cells. Evaluation of correct reading frame and molecular weight was initially tested by *in vitro* translation. Translation of the METH-1 open reading frame revealed a 110kD protein, slightly higher than the size predicted by translation of the cDNA sequence. As previously indicated, there are two putative glycosylation sites, the higher size of the protein is likely due to addition of sugar residues. Similarly, METH2 was also slightly higher than its predicted size, showing a 98kD protein.

Recombinant proteins were isolated from 293T supernatants under native conditions to preserve secondary structure. From analysis of the deduced amino acid sequence and published information on the murine homolog, ADAMTS, it was predicted that both proteins could bind to heparin and used affinity chromatography for purification. Both cell layer and conditioned media of 293T cells transfected with METH1, METH2 and vector control were used for purification. The molecular weight of METH1 and 2 were similar to those from the reticulocyte lysate. As predicted, both proteins are secreted. Interestingly, the media contains both full length (110kD) and two processed forms of 85 and 67kD for METH1, and 79 and 64kD for METH2. The 85 and 79kD molecular weights agree with the predicted size for both proteins after cleavage at the consensus subtilisin site. However, a second processing event must take place to generate the most abundant fragments observed at 67 and 64kD respectively. These forms are stable after purification even in the absence of proteinase inhibitors. For purification, proteins were initially concentrated by ammonium sulfate precipitation, followed by dialysis. The resulting protein suspension was then subjected to heparin-sepharose columns. Recombinant METH1 and METH2 were eluted with washing buffer containing 550mM NaCl. Fractions contained both pro-METH1, as well as the processed forms. Because it was unclear whether processing was relevant for function of the proteins, both forms were separated on sucrose gradients. Both full-length and processed forms were used in angiogenesis assays.

Recombinant constructs for expression of truncated fusion proteins were as follows: (1) pRSET-METH1-Type I: METH1 nt 1605-1839 (from the start codon) was amplified by polymerase chain reaction using the following primers: 5'-GCA TTT TGG

-387-

To test the hypothesis that METH1 and METH2 could function as regulators of angiogenesis, recombinant full length protein was generated in mammalian cells. Evaluation of correct reading frame and molecular weight was initially tested by *in vitro* translation. Translation of the METH-1 open reading frame revealed a 110kD protein, slightly higher than the size predicted by translation of the cDNA sequence. As previously indicated, there are two putative glycosylation sites, the higher size of the protein is likely due to addition of sugar residues. Similarly, METH2 was also slightly higher than its predicted size, showing a 98kD protein.

Recombinant proteins were isolated from 293T supernatants under native conditions to preserve secondary structure. From analysis of the deduced amino acid sequence and published information on the murine homolog, ADAMTS, it was predicted that both proteins could bind to heparin and used affinity chromatography for purification. Both cell layer and conditioned media of 293T cells transfected with METH1, METH2 and vector control were used for purification. The molecular weight of METH1 and 2 were similar to those from the reticulocyte lysate. As predicted, both proteins are secreted. Interestingly, the media contains both full length (110kD) and two processed forms of 85 and 67kD for METH1, and 79 and 64kD for METH2. The 85 and 79kD molecular weights agree with the predicted size for both proteins after cleavage at the consensus subtilisin site. However, a second processing event must take place to generate the most abundant fragments observed at 67 and 64kD respectively. These forms are stable after purification even in the absence of proteinase inhibitors. For purification, proteins were initially concentrated by ammonium sulfate precipitation, followed by dialysis. The resulting protein suspension was then subjected to heparin-sepharose columns. Recombinant METH1 and METH2 were eluted with washing buffer containing 550mM NaCl. Fractions contained both pro-METH1, as well as the processed forms. Because it was unclear whether processing was relevant for function of the proteins, both forms were separated on sucrose gradients. Both full-length and processed forms were used in angiogenesis assays.

Recombinant constructs for expression of truncated fusion proteins were as follows: (1) pRSET-METH1-Type I: METH1 nt 1605-1839 (from the start codon) was amplified by polymerase chain reaction using the following primers: 5'-GCA TTT TGG

-388-

ATC CGC CTT TTC ATG-3' (SEQ ID NO:78) and 5'-GTT GTG TGC TGC AGA TTG TTC C-3' (SEQ ID NO:79). The amplified fragment was then subcloned into the *Bam*HI and *Pst*I sites of the pRSET vector; (2) pGEX-METH1-TSP was generated by ligating the *Bam*HI-*Eco*RI fragment from the pRSET-METH1-TSP into the *Sma*I site of the pGEX-5X vector (Pharmacia Biotech Inc., Piscataway, NJ) by blunt-end ligation; (3) pGEX-1.0-METH2: the fragment nt 838-1818 of METH2 cDNA (from the start codon) was ligated into *Bam*HI-*Eco*RI sites of pGEM-2TK. The METH2 fragment was amplified by PCR using the following primers: 5'-GAAAAATGGGGATCCGAGGTG-3' (SEQ ID NO:80) and 5'-GCAGGAGAATTCCGTCCATG-3' (SEQ ID NO:81) to generate *Bam*HI and *Eco*RI restriction sites; (4) pGEX-METH2-TSP: a 0.5Kb *Xma*I-*Eco*RI fragment isolated from pGEX-1.0-METH2 was subcloned into the *Xma*I and *Eco*RI sites of pGEX-2TK vector. All constructs were sequenced to verify sequence fidelity and correct open reading frame.

The recombinant proteins were named 6H-METH1, the recombinant protein expressed with the plasmid pRSET-METH1-TSP, GST-METH1, the protein expressed with the plasmid pGEX-METH1-TSP and GST-METH2, the protein expressed with the plasmid pGEX-METH2-TSP.

Expression plasmids were transformed into BL21:DE3 *E. coli* strain (Stratagene Cloning Systems, La Jolla, CA) and fusion proteins were induced following manufacturer recommendations. Briefly, induced bacteria pellets were resuspended in PBS and sonicated on ice for 1 min. The suspension was, subsequently, incubated at RT for 20min in the presence of 1% triton X-100 and centrifuged at 4°C. Histidine tagged fusion proteins were then purified on Ni-NTA beads (Qiagen, Chatsworth, CA) by incubating 20ml of supernatant with 1ml of beads (50% slurry) for 2h at 4°C. The suspension was transferred into a column and washed with 10 columns volume of PBS containing 10mM imidazole, followed by 50mM imidazole and finally 100mM imidazole. The protein was eluted with 500mM imidazole in PBS. Fractions containing the recombinant protein were dialyzed against phenol-red free DMEM. Samples were centrifuged for 30min at 4°C, part of the protein was not soluble and was lost during centrifugation. The supernatant was stored at -70°C and used for proliferation, cornea pocket and chorioallantoic membrane (CAM) assays.

-389-

For purification of GST-fusion proteins, the extract was cleared by centrifugation and applied to a GST-affinity column (Pharmacia). The column was washed with PBS-1% triton X-100 in the presence of 0.1mM reduced glutathione and, subsequently, with the same buffer in the presence of 0.5mM reduced glutathione. Fusion proteins were eluted with 10mM reduced glutathione in 50mM Tris-HCl, pH 7.5. Fractions containing the protein were dialyzed against DMEM, stored at -70°C and used for proliferation, cornea pocket and chorioallantoic membrane (CAM) assays.

Integrity and purity of recombinant proteins was analyzed in 12.5% or 15% acrylamide gels stained with Coomassie blue.

A recombinant GST fusion protein containing the first two type I repeats of TSP was also dialyzed against DMEM before used in functional assays. Intact TSP1 was purified from platelets as previously described (Roberts, D.D., *et al.*, *J. Tissue Cult. Methods* 16:217-222 (1994)).

To test the hypothesis that METH1 and METH2 TSP domains could function as regulators of angiogenesis recombinant fusion proteins were generated in bacteria. The constructs included the first TSP domain of METH1 or METH2. This domain is the most conserved, 52% amino acid similarity with the second type I repeat of TSP1, (this domain contains a putative binding site for CD36). All recombinant proteins were isolated under native conditions to preserve their secondary structure as much as possible. 6H-METH1 and GST-METH1 contained the first TSP-like domain of METH1 fused to a histidine tag or a GST, respectively. METH1 recombinant protein was made with two different tags because of purification and structural advantages. The differences in size are due to the size of the tag, 6KDa the histidine and 27KDa the GST. GST-METH2 contained the first TSP domain of METH2 also fused to a GST. A fragment corresponding to the last two type I repeats of TSP1, also fused to a GST, and intact TSP1 purified from platelets were used as positive controls. In addition, GST alone was included in all experiments as negative control.

Example 4: TSP domains in METH1 and METH2 disrupt angiogenesis in vivo***Cornea pocket assay***

Swiss Webster females and males, were purchased from Charles River (Boston, MA) and used between 8-10 weeks-old for implantation of the pellets. Cornea pockets were performed as described by Kenyon and colleagues (Kenyon, B.M., *et al.*, *Invest. Ophthalmol. Vis. Sci.* 37:1625-1632 (1996)) with few modifications. Briefly, a solution of 10µg of recombinant bFGF plus 5 mg of sucralfate were mixed with 10µl of Hydron (200mg/ml in ethanol; New Brunswick, NJ) and the recombinant protein of interest (2µg). The suspension was then smeared onto a sterile nylon mesh square (pore size 500µm; Tetko Inc., Briarcliff Manor, NY) and allowed to dry for 30min. The fibers of the mesh were pulled to produce pellets of 500µm³ that were stored at -20°C. Uniformly sized pellets were selected under a microscope and used for the assays.

Mice were anesthetized with Avertin. An incision was made in the cornea using a Nikon SMZ-U dissecting microscope with the aid of a surgical blade. A single pellet was implanted into the pocket. Five days after pellet implantation, corneal angiogenesis was evaluated and photographed.

CAM assay

Chorioallantoic membrane assays were performed on Leghorn chicken embryos (SPAFAS, MA) at 12-14 days of embryonic development. Matrigel (750µg/ml), VEGF (250ng/mesh) and the protein or peptide to be tested were mixed, placed onto nylon meshes (pore size 250µm; Tetko Inc.) and incubated sequentially at 37°C for 30min and at 4°C for 2h to induce polymerization. A positive (matrigel and VEGF) and a negative (VEGF alone) control were also prepared for each CAM. Polymerized meshes were placed onto the third outer region of the CAM and incubated for 24h. To visualize vessels, 400µl of fluorescein isothiocyanate dextran (10mg/ml, SIGMA) was injected in the chick blood stream. After 5-10min incubation, the chick was topically fixed with 3.7% formaldehyde for 5min. The meshes were then dissected and mounted onto slides.

-391-

Fluorescence intensity was analyzed with a computer-assisted image program (NIH Image 1.59).

Peptides used on these assays were synthesized by Chiron (Raleigh, NC). Sequence corresponded to amino acids: P-TSP1, 430-447; P-METH1, 549-563; P-METH2, 529-548.

The evaluation of angiogenic or anti-angiogenic responses relies heavily on the sensitivity and specificity of the assays used to assess the response. To evaluate the anti-angiogenic activity of these fragments *in vivo*, two popular and well-accepted angiogenesis assays were used: the corneal pocket and the chorioallantoic membrane. The visibility, accessibility, and avascularity of the cornea are highly advantageous and facilitate the visualization of the neovascular response and the topical application of the test substances. A known amount of angiogenesis factor(s) is implanted, as a pellet, in a pocket made in the cornea eye. To test an angiogenesis inhibitor, the molecule is implanted with the stimulator in the same pellet, and the response is compared to the stimulator alone.

In these experiments, bFGF was used as the vascularization stimulator. Pellets containing the recombinant protein were implanted in mouse corneas and their ability to inhibit the bFGF-induced angiogenic response was compared to that of controls. When a bFGF pellet containing GST was implanted new capillary vessels grew from the cornea limbus, across the cornea and into the pellet within 5 days. In contrast, addition of GST-METH1 or GST-METH2 to the bFGF pellets completely abolished blood vessel growth. Table 4 contains a summary of the results obtained from 41 assays performed. Intact TSP1 purified from platelets and GST-TSP1 were used as positive controls. All assays were performed at identical concentrations, suggesting that METH1 and METH2 have similar potency to that of TSP1 in the inhibition of angiogenesis. In addition, when half of the standard concentration was used, a weak, however noticeable response was seen, indicating a dose-dependent effect.

-392-

Table 4.
Activity of METH1 and METH2 recombinant proteins in the
corneal pocket assay

bFGF Pellets	Vascularized corneas/Total corneas
Vehicle	5/5
TSP1	0/5
GST	11/11
GST-TSP1-TI	1/4
GST-METH1-TSP	0/8
GST-METH2-TSP	0/8

In the CAM assay, the angiogenic response is analyzed by measuring the number of vessels that grow within a matrix polymer containing the angiogenic growth factor. To determine whether recombinant METH1 and METH2 proteins inhibited neovascularization in the CAM assay induced by VEGF, a matrigel polymer containing VEGF and the recombinant protein were implanted in the CAM. Quantitative analysis of the experiments, which included three different polymers per treatment are shown in Figure 6A. Matrigels polymers containing VEGF plus 5 μ g of GST-METH1 or GST-METH2 caused greater than 80% inhibition in blood vessel growth. A similar potency was found using the GST recombinant protein derived from the type I repeats of TSP1. Furthermore, the anti-angiogenic effect of the TSP domains in METH1 and METH2 was dose-dependent with a complete inhibition of blood vessel growth when 15 μ g/ml of protein was used (Figure 6C and D). GST alone, at identical concentrations, had no significant effect on VEGF-stimulated angiogenesis. CAM assays performed with the unprocessed form of METH-1 and METH2 provided similar results to the processed forms. It was unclear whether processing is not required for function or if the CAM tissue lead to processing of our proteins. Thus, the intact protein was incubated with CAM tissue for 24h and was evaluated the protein on Western blots. The results demonstrate that the CAM tissue was able to generate a 68kD METH1 processed protein.

Synthetic peptides from the second or the third type I repeats of human TSP1 can mimic the anti-angiogenic effects of the intact TSP1 (Tolsma, S.S., *et al.*, *J. Cell. Biol.*

-393-

122:497-511 (1993)). In fact, a 19-residue polypeptide was shown to be sufficient to block *in vivo* neovascularization in the rat cornea and to inhibit the bFGF-induced migration of cultured endothelial cells (Vogel, T., *et al.*, *J. Cell. Biochem.* 53:74-84 (1993); Tolsma, S.S., *et al.*, *J. Cell. Biol.* 122:497-511 (1993)). To test whether the same was true for the METH1 and METH2 TSP domains, peptides derived from the same region were synthesized and their anti-angiogenic activity was evaluated in the CAM assay. The results are shown in Figure 6B. Peptides derived from both the TSP domain of METH1 and METH2 blocked VEGF-induced angiogenesis similarly to that of TSP1. In contrast, scramble peptides had no significant effects.

Example 5: Proliferation Assays

Human dermal endothelial cells (HDEC) were isolated and grown on Vitrogen™ coated petri-dishes in EBM (Clonetics, San Diego, CA) supplemented with 15% fetal calf serum, 25 µg/ml cAMP, and 1 µg/ml of hydrocortisone-21-acetate and were used from passages 3 to 6. Cells were made quiescent by incubation of confluent monolayers with phenol red-free EBM containing 0.2% BSA for 48h. Human dermal fibroblasts were isolated from neonatal foreskin and by enzymatic dissociation. Both fibroblasts and smooth muscle cells were maintained in DMEM supplemented with 10% fetal calf serum. Human mammary epithelial cells (HMEC) were purchased from Clonetics and maintained in the recommended media (mammary epithelial growth media, MEGM).

Quiescent human dermal endothelial cells, between passage 3 and 6, were plated on Vitrogen™ coated 24-well plates in EBM supplemented with 0.2% BSA, 0.1% fetal calf serum and 1 ng/ml of bFGF in the presence or absence of the recombinant protein and incubated at 5% CO₂ at 37°C for 48h. For vascular smooth muscle (VSM) and fibroblast proliferation assays, cells were incubated under the same conditions but using DMEM instead of EBM. Human mammary epithelial cells were incubated on their growth media. A pulse of [³H]-Thymidine (1 µCi/µl) was added during the last 4h prior harvesting. Cells were washed and fixed in 10% TCA. Incorporation of [³H]-thymidine was determined by scintillation counting, as previously described (Iruela-Arispe, M.L. & Sage, E.H., *J. Cell. Biochem.* 52:414 (1993)).

-394-

Statistical analyses were done using In-Stat software (Graph Pad Software) for Macintosh. Assuming normal distributions, data were analyzed by one-way ANOVA, followed by either T-test Dunnett test for comparisons between groups, or student-Newman-Kleus test for multiple comparisons between groups.

5 To gain insight into the mechanism by which METH1 and METH2 inhibit neovascularization, the direct effect of the purified recombinant fusion proteins on endothelial cell proliferation was tested. Serum-starved endothelial cells were plated into growth medium containing bFGF and FCS. Recombinant proteins (3 μ g/ml) were added at the same time of plating. 40% (GST-METH1), 45% (6H-GST) or 36% (GST-METH2)
10 inhibition was observed, in contrast to a non-significant effect when GST alone was added. The recombinant protein from the type I repeats of TSP1 had similar inhibitory effects. (Figure 7A). Furthermore, suppression of proliferation mediated by METH1 or METH2 was dose-dependent, as shown in Figure 7E. The inhibition was observed as early as one day after treatment and the inhibitory effect was not toxic and reversible
15 since the removal of the recombinant protein and subsequent addition of growth factor alone led to the resumption of endothelial cell proliferation.

The cell specificity of the anti-proliferative effects for METH1 and METH2 on the endothelium was evaluated by additional proliferation assays on a variety of non-endothelial cells. No significant inhibition of proliferation was seen on fibroblasts or
20 smooth muscle cell cultures. In contrast, a non significant, but reproducible stimulation of proliferation for these two cell types could be observed. This result rules out the presence of any potential nonspecific inhibitor of cell growth in the recombinant protein preparations. On mammary epithelial cell, however, METH1 and METH2 inhibited cell proliferation to the same degree as endothelial cells. Interestingly, TSP1 also suppresses
25 mammary epithelial cell proliferation both *in vitro* and in a transgenic model.

The possibility that METH1 and METH2 might act as disintegrins is consistent with their anti-angiogenic properties. Clearly blockade of α v β 3 and β 1 integrins with antibodies has been shown to inhibit neovascularization both during development and in tumors (Brooks, P.C., *et al.*, *Cell* 85:683-693 (1996); Brooks, P.C., *et al.*, *Cell* 92:391-
30 400 (1998); Senger, D.R., *et al.*, *Proc. Natl. Acad. Sci. USA* 94:13612-13617 (1997)). Integrins are essential for the mediation of both proliferative and migratory signals

-395-

(Schwartz, M.A. & Ingber, D.E., *Mol. Biol. Cell* 5:389-393 (1994)), therefore interference with those signals can be highly deleterious to the angiogenic process. The angiogenic functional assays were performed with recombinant protein containing only the type I repeats in METH1 and METH2.

5 The mechanism of action of METH1 and METH2 with regards to their angiogenic activity is not known. To date we have evidence that these proteins are secreted and bind to endothelial cells. Further investigations are guided towards the identification of receptors and signal transduction mechanisms. A likely hypothesis resulting from the lessons learned from TSP1 is that both METH1 and METH2 bind to
10 CD36. Recently, this scavenger receptor has been implicated in the mediation of signals by which TSP-1 exert its anti-angiogenic effects (Dawson, D.W., *et al.*, *J. Cell. Biol.* 138:707-717 (1997)). Both the CSVTCG (SEQ ID NO:83) (Asch, A.S., *et al.*, *Nature* 262:1436-1439 (1993); Catimel, B., *et al.*, *Biochem. J.* 284:231-236 (1992)) and the GCQXR (SEQ ID NO:84) sequences have been proposed as primary binding motifs to
15 CD36 (Dawson, D.W., *et al.*, *J. Cell. Biol.* 138:707-717 (1997)). METH1 and METH2 have almost entire conservation in both these regions. A complementary and also likely occurrence is binding of METH1 and METH2 to bFGF. Binding to heparin and bFGF has been proposed as part of the anti-angiogenic activity of TSP1 (Guo, N., *et al.*, *J. Peptide Res.* 49 (1997)). This property appears to be mediated through the WSXWS
20 (SEQ ID NO:82) motif, also conserved in METH1 and METH2. Future efforts will focus on the signals implicated in the anti-angiogenic properties mediated by these novel proteins and on their potential as proteases of the extracellular milieu.

Example 6: Isolation of the METH1 or METH2 cDNA Clone From the Deposited Sample

25 Two approaches can be used to isolate METH1 or METH2 from the deposited sample. First, the deposited clone is transformed into a suitable host (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a

density of about 150 transformants (colonies) per plate. A single colony is then used to generate DNA using nucleic acid isolation techniques well known to those skilled in the art. (e.g., Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press.)

5 Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:1 or SEQ ID NO:3 (i.e., within the region of SEQ ID NO:1 or SEQ ID NO:3 bounded by the 5' NT and the 3' NT of the clone) are synthesized and used to amplify the METH1 or METH2 cDNA using the deposited cDNA plasmids as templates. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μ l
10 of reaction mixture with 0.5 μ g of the above cDNA template. A convenient reaction mixture is 1.5-5 mM $MgCl_2$, 0.01% (w/v) gelatin, 20 μ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The
15 amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of the METH1 or METH2 gene which may not be present in the deposited
20 clones. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine *et al.*, *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

25 Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the METH1 or METH2 gene of interest is used to PCR amplify the 5' portion of the METH1 or METH2 full-length gene. This amplified product may then
30 be sequenced and used to generate the full length gene.

-397-

This above method starts with total RNA isolated from the desired source, although poly-A⁺ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the METH1 or METH2 gene.

Example 7: Bacterial Expression of METH1 or METH2

A METH1 or METH2 polynucleotide encoding a METH1 or METH2 polypeptide invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 5, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites. The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the *E. coli* strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor

-398-

and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*). Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified METH1 or METH2 protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the METH1 or METH2 protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified METH1 or METH2 protein is stored at 4°C or frozen at -80°C.

-399-

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a METH1 or METH2 polynucleotide, called pHE4a. (ATCC Accession Number 209645, deposited February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically. DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 5, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 8: Purification of METH1 or METH2 Polypeptide from an Inclusion Body

The following alternative method can be used to purify METH1 or METH2 polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

-400-

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the METH1 or METH2 polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under

-401-

constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant METH1 or METH2 polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Coomassie blue stained 16% SDS-PAGE gel when 5 μ g of purified protein is loaded. The purified METH1 or METH2 protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 9: Cloning and Expression of METH1 or METH2 in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert METH1 or METH2 polynucleotide into a baculovirus to express METH1 or METH2. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, XbaI and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that expresses the cloned METH1 or METH2 polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow *et al.*, *Virology* 170:31-39 (1989).

Specifically, the METH1 or METH2 cDNA sequence contained in the deposited clone, including the AUG initiation codon and any naturally associated leader sequence, is amplified using the PCR protocol described in Example 5. If the naturally occurring

-402-

signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold[®] baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417 (1987). One ug of BaculoGold[®] virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 μ l of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μ l Lipofectin plus 90 μ l Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27°C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27°C for four days.

-403-

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a
5 "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μ l of Grace's medium and the suspension
10 containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4°C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the
15 recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of 35 S-methionine and 5 uCi 35 S-cysteine (available from Amersham) are added. The cells are further
20 incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced METH1
25 or METH2 protein.

Example 10: Expression of METH1 or METH2 in Mammalian Cells

METH1 or METH2 polypeptide can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the

termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV I, HIV I and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2DHFR (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, METH1 or METH2 polypeptide can be expressed in stable cell lines containing the METH1 or METH2 polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as DHFR, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected METH1 or METH2 gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., *et al.*, *J. Biol. Chem.* 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., *Biochem. et Biophys. Acta* 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., *Biotechnology* 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy *et al.*, *Biochem J.* 227:277-279 (1991); Bebbington *et al.*, *Bio/Technology* 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-DHFR (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen *et al.*,

-405-

Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart *et al.*, *Cell* 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of METH1 or METH2. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

If a naturally occurring signal sequence is used to produce a secreted protein, the vector does not need a second signal peptide. Alternatively, if a naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence in an effort to secrete the protein from the cell. (See, e.g., WO 96/34891.)

The amplified fragment is then digested with the appropriate restriction enzyme and purified on a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 or pC4 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene are used for transfection. Five μ g of the expression plasmid pC6 or pC4 is cotransfected with 0.5 μ g of the plasmid pSVneo using lipofectin (Felgner *et al.*, *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of METH1 or

METH2 is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 11: Construction of N-Terminal and/or C-Terminal Deletion Mutants

5 The following general approach may be used to clone a N-terminal or C-terminal deletion METH1 or METH2 deletion mutant. Generally, two oligonucleotide primers of about 15-25 nucleotides are derived from the desired 5' and 3' positions of a polynucleotide of SEQ ID NO:1 or SEQ ID NO:3. The 5' and 3' positions of the primers are determined based on the desired METH1 or METH2 polynucleotide fragment. An initiation and stop codon are added to the 5' and 3' primers respectively, if necessary, to
10 express the METH1 or METH2 polypeptide fragment encoded by the polynucleotide fragment. Preferred METH1 or METH2 polynucleotide fragments are those encoding the N-terminal and C-terminal deletion mutants disclosed above in the "Polynucleotide and Polypeptide Fragments" section of the Specification.

15 Additional nucleotides containing restriction sites to facilitate cloning of the METH1 or METH2 polynucleotide fragment in a desired vector may also be added to the 5' and 3' primer sequences. The METH1 or METH2 polynucleotide fragment is amplified from genomic DNA or from the deposited cDNA clone using the appropriate PCR oligonucleotide primers and conditions discussed herein or known in the art. The METH1 or METH2 polypeptide fragments encoded by the METH1 or METH2
20 polynucleotide fragments of the present invention may be expressed and purified in the same general manner as the full length polypeptides, although routine modifications may be necessary due to the differences in chemical and physical properties between a particular fragment and full length polypeptide.

25 As a means of exemplifying but not limiting the present invention, the polynucleotide encoding the METH1 polypeptide fragment R-235 to L-934 or the METH2 polypeptide fragment R-214 to Q-836 is amplified and cloned as follows: A 5' primer is generated comprising a restriction enzyme site followed by an initiation codon in frame with the polynucleotide sequence encoding the N-terminal portion of the polypeptide fragment beginning with R-235 or R-214, respectively. A complementary

-407-

3' primer is generated comprising a restriction enzyme site followed by a stop codon in frame with the polynucleotide sequence encoding C-terminal portion of the METH1 or METH2 polypeptide fragment ending with L-934 or Q-836, respectively.

5 The amplified polynucleotide fragment and the expression vector are digested with restriction enzymes which recognize the sites in the primers. The digested polynucleotides are then ligated together. The METH1 or METH2 polynucleotide fragment is inserted into the restricted expression vector, preferably in a manner which places the METH1 or METH2 polypeptide fragment coding region downstream from the promoter. The ligation mixture is transformed into competent *E. coli* cells using standard
10 procedures and as described in the Examples herein. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA confirmed by restriction analysis, PCR and DNA sequencing.

Example 12: Protein Fusions of METH1 or METH2

METH1 or METH2 polypeptides are preferably fused to other proteins. These
15 fusion proteins can be used for a variety of applications. For example, fusion of METH1 or METH2 polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 7; see also EP A 394,827; Traunecker, *et al.*, *Nature* 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time *in vivo*. Nuclear localization signals fused to METH1
20 or METH2 polypeptides can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described
25 above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 7.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also

-408-

should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and METH1 or METH2 polynucleotide, isolated by the PCR protocol described in Example 5, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGC
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA
ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG
GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:85)

Example 13: Production of an Antibody

a) The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing METH1 or METH2 is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of METH1 or METH2 protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Kohler *et al.*, *Nature* 256:495 (1975); Kohler *et al.*, *Eur. J. Immunol.* 6:511 (1976); Kohler *et al.*, *Eur. J. Immunol.* 6:292 (1976); Hammerling *et al.*, in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N. Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with METH1 or METH2 polypeptide or, more preferably, with a secreted METH1 or METH2 polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al.* (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the METH1 or METH2 polypeptide.

Alternatively, additional antibodies capable of binding to METH1 or METH2 polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies.

-410-

Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the METH1 or METH2 protein-specific antibody can be blocked by METH1 or METH2. Such antibodies comprise anti-idiotypic antibodies to the METH1 or METH2 protein-specific antibody and can be used to immunize an animal to induce formation of further METH1 or METH2 protein-specific antibodies.

It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). Alternatively, secreted METH1 or METH2 protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, *Science* 229:1202 (1985); Oi *et al.*, *BioTechniques* 4:214 (1986); Cabilly *et al.*, U.S. Patent No. 4,816,567; Taniguchi *et al.*, EP 171496; Morrison *et al.*, EP 173494; Neuberger *et al.*, WO 8601533; Robinson *et al.*, WO 8702671; Boulianne *et al.*, *Nature* 312:643 (1984); Neuberger *et al.*, *Nature* 314:268 (1985).)

b) Isolation of antibody fragments directed against METH1 and/or METH2 from a library of scFvs.

Naturally occurring V-genes isolated from human PBLs are constructed into a large library of antibody fragments which contain reactivities against METH1 and/or METH2 to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein in its entirety by reference).

-411-

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in WO92/01047. To rescue phage displaying antibody fragments, approximately 10^9 *E. coli* harbouring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2×10^8 TU of delta gene 3 helper (M13 delta gene III, see WO92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in WO92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harbouring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37°C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8, 4000 revs/min for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook *et al.*, 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10^{13} transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10^{13} TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately

-412-

neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log *E. coli* TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The *E. coli* are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect *E. coli* HB 2151 and soluble scFv is produced (Marks, *et al.*, 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 µg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see e.g., WO92/01047) and then by sequencing.

Example 14: Production Of METH1 or METH2 Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing METH1 or METH2 polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 16-23.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50 µg/ml. Add 200 µl of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-

-413-

604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 µl Lipofectamine (18324-012 Gibco/BRL) and 5 ml Optimem I (31985070 Gibco/BRL)/96-well plate.

5 With a small volume multi-channel pipetter, aliquot approximately 2 µg of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 10-12, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50 µl of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use
10 a multi-channel pipetter to add 150 µl Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells,
15 and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM
20 with 1x penstrep, or HGS CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130 mg/L CuSO₄·5H₂O; 0.050 mg/L of Fe(NO₃)₃·9H₂O; 0.417 mg/L of FeSO₄·7H₂O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄·H₂O; 71.02 mg/L of Na₂HPO₄; .4320 mg/L of ZnSO₄·7H₂O; .002 mg/L of Arachidonic Acid; 1.022 mg/L of Cholesterol; .070 mg/L
25 of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L-Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂O; 6.65
30 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75

-414-

mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; and 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal Acetate. Adjust osmolarity to 327 mOsm with 2mM glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 µl for endotoxin assay in 15 ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300 µl multichannel pipetter, aliquot 600 µl in one 1 ml deep well plate and the remaining supernatant into a 2 ml deep well. The supernatants from each well can then be used in the assays described in Examples 16-23.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the METH1 or METH2 polypeptide directly (e.g., as a secreted protein) or by METH1 or METH2 inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 15: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family: Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, *Ann. Rev. Biochem.* 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:82)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

-416-

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements
5 linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

-417-

	JAKs				STATS	GAS(elements) or ISRE
Ligand	tyk 2	Jak 1	Jak 2	Jak 3		
IFN family						
IFN- α /B	+	+	-	-	1,2,3	ISRE
IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
IL-10	+	?	?	-	1,3	
gp130 family						
IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
IL-11(Pleiotrophic)	?	+	?	?	1,3	
OnM(Pleiotrophic)	?	+	+	?	1,3	
LIF(Pleiotrophic)	?	+	+	?	1,3	
CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
G-CSF(Pleiotrophic	?	+	?	?	1,3	
)	+	-	+	+	1,3	
IL-12(Pleiotrophic)						
g-C family						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4	-	+	-	+	6	GAS (IRF1 = IFP
(lymph/myeloid)	-	+	-	+	5	>>Ly6)(IgH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	?	?	6	GAS
IL-13 (lymphocyte)	?	+	?	+	5	GAS
IL-15						GAS
gp140 family						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
Growth hormone family						
GH	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>L y6)
PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	
Receptor Tyrosine Kinases						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	GAS (not IRF1)
CSF-1	?	+	+	-	1,3	

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 16-17, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of

-418-

the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman *et al.*, *Immunity* 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCTCCCGAAATCTAGATTTCCTCCCGAAATGATTTCCTCCCGAAATGATTTCCTCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:86).

The downstream primer is complementary to the SV40 promoter and is flanked with a HindIII site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:87).

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCTCCCGAAATCTAGATTTCCTCCCGAAATGATTTCCTCCCGAAATGATTTCCTCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:3' (SEQ ID NO:88).

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be used instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, 6-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a

-419-

neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 16-17.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 18 and 19. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 16: High-Throughput Screening Assay for T-cell Activity

The following protocol is used to assess T-cell activity of METH1 or METH2 by determining whether METH1 or METH2 supernatant proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 15. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4⁺ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described

-420-

below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

5 Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 μ l of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1% Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 μ g of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 μ l of
10 DMRJE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1 ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

15 The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing METH1 or METH2 polypeptides or METH1 or METH2 induced polypeptides as produced by the protocol described in Example 14.

On the day of treatment with the supernatant, the cells should be washed and
20 resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

25 Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 μ l of cells into each well (therefore adding 100,000 cells per well).

After all the plates have been seeded, 50 μ l of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is
30 added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

-421-

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 μ l samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20°C until SEAP assays are performed according to Example 20. The plates containing the remaining treated cells are placed at 4°C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

Example 17: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity of METH1 or METH2 by determining whether METH1 or METH2 proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 15. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 15, a DEAE-Dextran method (Kharbanda *et. al.*, 1994, *Cell Growth & Differentiation* 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 μ g GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 μ M $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 1 mM MgCl_2 , and 675 μ M CaCl_2 . Incubate at 37°C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

-422-

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 µg/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 µg/ml G418 for couple of passages.

These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 µl cells per well in the 96-well plate (or 1×10^5 cells/well).

Add 50 µl of the supernatant prepared by the protocol described in Example 14. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 20.

Example 18: High-Throughput Screening Assay Identifying Neuronal Activity

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed by METH1 or METH2.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells by METH1 or METH2 can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K *et al.*, *Oncogene* 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

-423-

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:89)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:90).

Using the GAS:SEAP/Neo vector produced in Example 15, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 14. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

Add 200 μ l of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 μ l supernatant produced by Example 14, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be

used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 20.

Example 19: High-Throughput Screening Assay for T-cell Activity

5 NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB
10 appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses. In non-stimulated conditions, NF-KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2,
15 IL-6, GM-CSF, ICAM-1 and class 1 MHC.

 Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 14. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related
20 to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

 To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTCCCC) (SEQ ID NO:91), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

25 5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTCCGGGGACTTTCCGGGAC
 TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:92).

 The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:93).

-425-

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5 5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC
ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA
CTAATTTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA
10 GCTT:3' (SEQ ID NO:88)

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

15 In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

20 Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 16. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 16. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

25 ***Example 20: Assay for SEAP Activity***

As a reporter molecule for the assays described in Examples 16-19, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following

-426-

general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 μ l of 2.5x dilution buffer into Optiplates containing 35 μ l of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 μ l Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 μ l Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75

-427-

	# of plates	Rxn buffer diluent (ml)	CSPD (ml)
	26	140	7
	27	145	7.25
	28	150	7.5
	29	155	7.75
5	30	160	8
	31	165	8.25
	32	170	8.5
	33	175	8.75
	34	180	9
10	35	185	9.25
	36	190	9.5
	37	195	9.75
	38	200	10
	39	205	10.25
15	40	210	10.5
	41	215	10.75
	42	220	11
	43	225	11.25
	44	230	11.5
20	45	235	11.75
	46	240	12
	47	245	12.25
	48	250	12.5
	49	255	12.75
25	50	260	13

Example 21: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

-428-

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-3, used here.

5 For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 μ l of HBSS (Hank's Balanced Salt Solution) leaving 100 μ l of buffer after the final wash.

10 A stock solution of 1 mg/ml fluo-3 is made in 10% pluronic acid DMSO. To load the cells with fluo-3, 50 μ l of 12 ug/ml fluo-3 is added to each well. The plate is incubated at 37°C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 μ l of buffer.

15 For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2.5×10^6 cells/ml with HBSS in a 50-ml conical tube. 4 μ l of 1 mg/ml fluo-3 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1×10^6 cells/ml, and dispensed into a microplate, 100 μ l/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 μ l, followed by an aspiration step to 100 μ l final volume.

20 For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-3. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and
25 (6) Sample addition is 50 μ l. Increased emission at 530 nm indicates an extracellular signaling event caused by the a molecule, either METH1 or METH2 or a molecule induced by METH1 or METH2, which has resulted in an increase in the intracellular Ca⁺⁺ concentration.

Example 22: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, identifying whether METH1 or METH2 or a molecule induced by METH1 or METH2 is capable of activating tyrosine kinase signal transduction pathways is of interest. Therefore, the following protocol is designed to identify such molecules capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr.

-430-

Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 μ l of the supernatant produced in Example 14, the medium was removed and 100 μ l of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10 μ l of 5 μ M Biotinylated Peptide, then 10 μ l ATP/Mg²⁺ (5mM ATP/50mM MgCl₂), then 10 μ l of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5 μ l of Sodium Vanadate(1mM), and then 5 μ l of water. Mix the

-431-

components gently and preincubate the reaction mix at 30°C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 μ l of 120mm EDTA and place the reactions on ice.

5 Tyrosine kinase activity is determined by transferring 50 μ l aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 μ l of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-
10 POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

15 ***Example 23: High-Throughput Screening Assay Identifying Phosphorylation Activity***

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 22, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine
20 phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

25 Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily

-432-

be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 µl of the supernatants obtained in Example 14 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation by METH1 or METH2 or a molecule induced by METH1 or METH2.

Example 24: Method of Determining Alterations in the METH1 or METH2 Gene

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:1. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D. *et al.*, *Science* 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons of METH1 or METH2 is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring

suspected mutations in METH1 or METH2 is then cloned and sequenced to validate the results of the direct sequencing.

PCR products of METH1 or METH2 are cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., *Nucleic Acids Research* 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations in METH1 or METH2 not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in the METH1 or METH2 gene. Isolated genomic clones are nick-translated with digoxigenin deoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et al., *Methods Cell Biol.* 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the METH1 or METH2 genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., *Genet. Anal. Tech. Appl.* 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region of METH1 or METH2 (hybridized by the probe) are identified as insertions, deletions, and translocations. These METH1 or METH2 alterations are used as a diagnostic marker for an associated disease.

Example 25: Method of Detecting Abnormal Levels of METH1 or METH2 in a Biological Sample

METH1 or METH2 polypeptides can be detected in a biological sample, and if an increased or decreased level of METH1 or METH2 is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is

-434-

understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect METH1 or METH2 in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies to METH1 or METH2, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 13. The wells are blocked so that non-specific binding of METH1 or METH2 to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing METH1 or METH2. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded METH1 or METH2.

Next, 50 μ l of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 μ l of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot METH1 or METH2 polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the METH1 or METH2 in the sample using the standard curve.

Example 26: Formulating a Polypeptide

The METH1 or METH2 composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the METH1 or METH2 polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

-435-

As a general proposition, the total pharmaceutically effective amount of METH1 or METH2 administered parenterally per dose will be in the range of about 1 ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, METH1 or METH2 is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing METH1 or METH2 are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

METH1 or METH2 is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. *et al.*; *Biopolymers* 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer *et al.*, *J. Biomed. Mater. Res.* 15:167-277 (1981), and R. Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (R. Langer *et al.*) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped METH1 or METH2 polypeptides. Liposomes containing the METH1 or METH2 are prepared by methods known per se: DE 3,218,121; Epstein *et al.*, *Proc. Natl. Acad. Sci. USA* 82:3688-3692 (1985); Hwang *et al.*, *Proc. Natl. Acad. Sci. USA* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP

-436-

88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, METH1 or METH2 is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting METH1 or METH2 uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

-437-

METH1 or METH2 is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

5 METH1 or METH2 used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

10 METH1 or METH2 polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous METH1 or METH2 polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized METH1 or METH2 polypeptide using
15 bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed
20 by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, METH1 or METH2 may be employed in conjunction with other therapeutic compounds.

The compositions of the invention may be administered alone or in combination
25 with other therapeutic agents. Therapeutic agents that may be administered in combination with the compositions of the invention include, but are not limited to, other members of the TNF family, chemotherapeutic agents, antibiotic, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combination may be administered either concomitantly, e.g. as an admixture; separately but simultaneously or concurrently; or sequentially. This includes
30 presentations in which the combined agents are administered together as a therapeutic

-438-

mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g. as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

5 In one embodiment, the compositions of the invention are administered in combination with other members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the compositions of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, 10 CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokine-alpha (International Publication No. WO 98/18921), OX40, and nerve growth factor (NGF) and soluble forms of Fas, 15 CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 98/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98 /32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), 20 and TR12, and soluble forms of CD154, CD70 and CD153.

Conventional nonspecific immunosuppressive agents that may be administered in combination with the compositions of the invention include, but are not limited to, 25 steroids, cyclosporine, cyclosporine analogs, ayclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergulain, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In a further embodiment, the compositions of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the compositions of the invention include, but are not limited to, tetracycline, 30 metronidazole, amoxicillin, beta-lactamases, aminoglycosides, macrolides, quinolones, fluoroquinolones, cephalosporins, erythromycin, ciprofloxacin, and streptomycin.

-439-

In an additional embodiment, the compositions of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the compositions of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, eacetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the compositions of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethenyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephallen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

In an additional embodiment, the compositions of the invention are administered in combination with cytokines. Cytokines that may be administered with the compositions of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha.

In an additional embodiment, the compositions of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered

with the compositions of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PlGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PlGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B-186 (VEGF-B 186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the compositions of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the compositions of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the compositions of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

Example 27: Method of Treating Decreased Levels of METH1 or METH2

The present invention relates to a method for treating an individual in need of a decreased level of METH1 or METH2 activity in the body comprising, administering to such an individual a composition comprising a therapeutically effective amount of

-441-

METH1 or METH2 antagonist. Preferred antagonists for use in the present invention are METH1 or METH2-specific antibodies.

Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of METH1 or METH2 in an individual can be treated by administering METH1 or METH2, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of METH1 or METH2 polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of METH1 or METH2 to increase the activity level of METH1 or METH2 in such an individual.

For example, a patient with decreased levels of METH1 or METH2 polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 26.

Example 28: Method of Treating Increased Levels of METH1 or METH2

The present invention also relates to a method for treating an individual in need of an increased level of METH1 or METH2 activity in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of METH1 or METH2 or an agonist thereof.

Antisense technology is used to inhibit production of METH1 or METH2. This technology is one example of a method of decreasing levels of METH1 or METH2 polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of METH1 or METH2 is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 26.

Example 29: Method of Treatment Using Gene Therapy - Ex Vivo

One method of gene therapy transplants fibroblasts, which are capable of expressing METH1 or METH2 polypeptides, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. *et al.*, *DNA* 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding METH1 or METH2 can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 5. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector contains properly inserted METH1 or METH2.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the METH1 or

-443-

METH2 gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the METH1 or METH2 gene (the packaging cells are now referred to as producer cells).

5 Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the
10 titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether METH1 or METH2 protein is produced.

15 The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 30: Method of Treatment Using Gene Therapy - In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the
20 introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) METH1 or METH2 sequences into an animal to increase or decrease the expression of the METH1 or METH2 polypeptide. The METH1 or METH2 polynucleotide may be operatively linked to a promoter or any other genetic elements necessary for the expression of the METH1 or METH2 polypeptide by the target tissue. Such gene therapy
25 and delivery techniques and methods are known in the art, see, for example, WO 90/11092, WO98/11779; U.S. Patent No. 5,693,622, 5,705,151, 5,580,859; Tabata, H. *et al.* (1997) *Cardiovasc. Res.* 35(3):470-479, Chao, J. *et al.* (1997) *Pharmacol. Res.* 35(6):517-522, Wolff, J.A. (1997) *Neuromuscul. Disord.* 7(5):314-318, Schwartz, B. *et*

al. (1996) *Gene Ther.* 3(5):405-411, Tsurumi, Y. *et al.* (1996) *Circulation* 94(12):3281-3290 (incorporated herein by reference).

The METH1 or METH2 polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The METH1 or METH2 polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the METH1 or METH2 polynucleotides may also be delivered in liposome formulations (such as those taught in Felgner, P.L. *et al.* (1995) *Ann. NY Acad. Sci.* 772:126-139 and Abdallah, B. *et al.* (1995) *Biol. Cell* 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The METH1 or METH2 polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The METH1 or METH2 polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the

-445-

lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked METH1 or METH2 polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.0005 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked METH1 or METH2 polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected METH1 or METH2 polynucleotide in muscle *in vivo* is determined as follows. Suitable METH1 or METH2 template DNA for production of mRNA coding for METH1 or METH2 polypeptide is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The METH1 or METH2 template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle

-446-

over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for METH1 or METH2 protein expression. A time course for METH1 or METH2 protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of METH1 or METH2 DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using METH1 or METH2 naked DNA.

Example 31: Gene Therapy Using Endogenous METH1 and/or METH2 Gene

Another method of gene therapy according to the present invention involves operably associating the endogenous METH1 and/or METH2 sequence with a promoter via homologous recombination as described, for example, in U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller *et al.*, *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); and Zijlstra *et al.*, *Nature* 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous METH1 and/or METH2, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of METH1 and/or METH2 so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains

-447-

distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

5 The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an
10 agarose gel then purified by phenol extraction and ethanol precipitation.

 In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

15 Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous METH1 and/or METH2 sequence. This results in the expression of METH1 and/or METH2 in the cell. Expression may be detected by immunological staining, or any other method known in the art. Fibroblasts are obtained from a subject by skin biopsy. The resulting
20 tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl,
25 5 mM KCl, 0.7 mM Na₂ HPO₄, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately 3X10⁶ cells/ml. Electroporation should be performed immediately following resuspension.

30 Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the METH1 and/or METH2 locus, plasmid pUC18

-448-

(MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3' end. Two METH1 and/or METH2 non-coding sequences are amplified via PCR: one METH1 and/or METH2 non-coding sequence (METH1 and/or METH2 fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3' end; the other METH1 and/or METH2 non-coding sequence (METH1 and/or METH2 fragment 2) is amplified with a BamHI site at the 5' end and a HindIII site at the 3' end. The CMV promoter and METH1 and/or METH2 fragments are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; METH1 and/or METH2 fragment 1 - XbaI; METH1 and/or METH2 fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately 1.5×10^6 cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 µF and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37°C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

Example 32: METH1 and/or METH2 Transgenic Animals

The METH1 and/or METH2 polypeptides can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson *et al.*, *Appl. Microbiol. Biotechnol.* 40:691-698 (1994); Carver *et al.*, *Biotechnology (NY)* 11:1263-1270 (1993); Wright *et al.*, *Biotechnology (NY)* 9:830-834 (1991); and Hoppe *et al.*, U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten *et al.*, *Proc. Natl. Acad. Sci. USA* 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson *et al.*, *Cell* 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, *Mol Cell. Biol.* 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e.g., Ulmer *et al.*, *Science* 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano *et al.*, *Cell* 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," *Intl. Rev. Cytol.* 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell *et al.*, *Nature* 380:64-66 (1996); Wilmut *et al.*, *Nature* 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, i.e., mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, e.g., head-to-head tandems or head-to-tail

-450-

tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko *et al.* (Lasko *et al.*, *Proc. Natl. Acad. Sci. USA* 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred.

Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu *et al.* (Gu *et al.*, *Science* 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. The contents of each of the documents recited in this paragraph is herein incorporated by reference in its entirety.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in

-451-

order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of METH1 and/or METH2 polypeptides, studying conditions and/or disorders associated with aberrant METH1 and/or METH2 expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 33: METH1 and/or METH2 Knock-Out Animals

Endogenous METH1 and/or METH2 gene expression can also be reduced by inactivating or "knocking out" the METH1 and/or METH2 gene and/or its promoter using targeted homologous recombination. (E.g., see Smithies *et al.*, *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson *et al.*, *Cell* 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e.g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for

-452-

use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the *et al.* METH1 and/or METH2 polypeptides. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson *et al.* U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange

-453-

of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Knock-out animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of METH1 and/or METH2 polypeptides, studying conditions and/or disorders associated with aberrant METH1 and/or METH2 expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 34: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In vitro Assay- Purified METH1 and/or METH2 protein, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or

-454-

inhibition and/or death in B-cell populations and their precursors. The activity of METH1 and/or METH2 protein on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added 10^5 B-cells suspended in culture medium (RPMI 1640 containing 10% FBS, 5×10^{-5} M 2ME, 100U/ml penicillin, 10 µg/ml streptomycin, and 10^{-5} dilution of SAC) in a total volume of 150 µl. Proliferation or inhibition is quantitated by a 20h pulse (1 µCi/well) with ^3H -thymidine (6.7 Ci/mM) beginning 72 hours post factor addition. The positive and negative controls are IL2 and medium respectively.

In vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of METH1 and/or METH2 protein, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal and METH1 and/or METH2 protein-treated spleens identify the results of the activity of METH1 and/or METH2 protein on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

-455-

Flow cytometric analyses of the spleens from METH1 and/or METH2 protein-treated mice is used to indicate whether METH1 and/or METH2 protein specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

5 Likewise, a predicted consequence of increased mature B-cell representation *in vivo* is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and METH1 and/or METH2 protein-treated mice.

The studies described in this example test activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to
10 test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 35: T Cell Proliferation Assay

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of ³H-thymidine. The assay is performed as follows. Ninety-six well plates
15 are coated with 100 µl/well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4°C (1 mg/ml in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells (5 x 10⁴/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying
20 concentrations of *et al.* METH1 and/or METH2 protein (total volume 200 µl). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37°C, plates are spun for 2 min. at 1000 rpm and 100 µl of supernatant is removed and stored -20°C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 µl of medium containing 0.5 µCi of ³H-thymidine and cultured
25 at 37°C for 18-24 hr. Wells are harvested and incorporation of ³H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative control for the effects of METH1 and/or METH2 proteins.

-456-

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

5 ***Example 36: Effect of METH1 and/or METH2 on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells***

10 Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- α , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC γ RII, upregulation of CD83). These
15 changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

20 FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of METH1 and/or METH2 or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4°C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

25 **Effect on the production of cytokines.** Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells (10^6 /ml) are treated with increasing concentrations of METH1 and/or METH2 for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for

-457-

IL-12 content using commercial ELISA kit (e.g, R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of METH1 and/or METH2 or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4°C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. METH1 and/or METH2, agonists, or antagonists of METH1 and/or METH2 can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

1. Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation.

Propidium iodide (PI) staining is used to measure apoptosis as follows.

-458-

Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of 2×10^6 /ml in PBS containing PI at a final concentration of 5 µg/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

2. Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows: Human monocytes are incubated at a density of 5×10^5 cells/ml with increasing concentrations of METH1 and/or METH2 and under the same conditions, but in the absence of METH1 and/or METH2. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of METH1 and/or METH2. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g., R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

3. Oxidative burst. Purified monocytes are plated in 96-w plate at 2×10^5 cell/well. Increasing concentrations of METH1 and/or METH2 are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20 µl 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of H_2O_2 produced by the macrophages, a standard curve of a H_2O_2 solution of known molarity is performed for each experiment.

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to

test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 37: METH1 and/or METH2 Biological Effects

Astrocyte and Neuronal Assays. Recombinant METH1 and/or METH2, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate METH1 and/or METH2's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke, P. *et al.*, "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of METH1 and/or METH2 to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

Fibroblast and endothelial cell assays. Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium.

-460-

After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE₂ assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or METH1 and/or METH2 with or without IL-1 α for 24 hours. The supernatants are collected and assayed for PGE₂ by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or METH1 and/or METH2 with or without IL-1 α for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or METH1 and/or METH2 for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with METH1 and/or METH2.

Parkinson Models. The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP⁺) and released. Subsequently, MPP⁺ is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP⁺ is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari *et al.*, Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam

-461-

implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, METH1 and/or METH2 can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of METH1 and/or METH2 is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm² on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time. Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if METH1 and/or METH2 acts to prolong the survival of dopaminergic neurons, it would suggest that METH1 and/or METH2 may be involved in Parkinson's Disease.

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 38: The Effect of METH1 and/or METH2 on the Growth of Vascular Endothelial Cells

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at $2-5 \times 10^4$ cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. METH1 and/or METH2 protein of SEQ ID NO. 2, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that METH1 and/or METH2 may proliferate vascular endothelial cells.

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 39: Stimulatory Effect of METH1 and/or METH2 on the Proliferation of Vascular Endothelial Cells

For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) is performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF₁₆₅ or METH1 and/or METH2 in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and

seven wells are performed in parallel for each condition. See, Leak *et al. in vitro Cell. Dev. Biol.* 30A:512-518 (1994).

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 40: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect

HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 °C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida *et al.*, J. Biol. Chem. 6:271(36):21985-21992 (1996).

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 41: Stimulation of Endothelial Migration

This example will be used to explore the possibility that METH1 and/or METH2 may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., *et al.*, *J. Immunological Methods* 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 μ m (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25 μ l of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber, 2.5×10^5 cells suspended in 50 μ l M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO₂ to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 42: Stimulation of Nitric Oxide Production by Endothelial Cells


Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, METH1 and/or METH2 activity can be assayed

-465-

by determining nitric oxide production by endothelial cells in response to METH1 and/or METH2.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and METH1 and/or METH2. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of METH1 and/or METH2 on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of KNO₂ (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and H₂SO₄. The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) to maintain the temperature at 37°C. The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per 1x10⁶ endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 43: Effect of METH1 and/or METH2 on Cord Formation in Angiogenesis

Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

5 CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 µl/well) for 30 min. at 37°C. CADMEC are seeded onto the coated
10 wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 µg Cell Applications' Chord Formation Medium containing control buffer or METH1 and/or METH2 (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are
15 done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-esteradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

The studies described in this example tested activity in METH1 and/or METH2
20 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 44: Rescue of Ischemia in Rabbit Lower Limb Model

To study the *in vivo* effects of METH1 and/or METH2 on ischemia, a rabbit
25 hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita, S. *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent

-467-

upon collateral vessels originating from the internal iliac artery (Takeshita, S. *et al. Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked METH1 and/or METH2 expression plasmid by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen, R. *et al. Hum Gene Ther.* 4:749-758 (1993); Leclerc, G. *et al. J. Clin. Invest.* 90: 936-944 (1992)). When METH1 and/or METH2 is used in the treatment, a single bolus of 500 mg METH1 and/or METH2 protein or control is delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 45: Effect of METH1 and/or METH2 on Vasodilation

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of METH1 and/or METH2 to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the METH1 and/or METH2 are administered to 13-14 week old spontaneously

-468-

hypertensive rats (SHR). Data are expressed as the mean \pm SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as $p < 0.05$ vs. the response to buffer alone.

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 46: Rat Ischemic Skin Flap Model

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. METH1 and/or METH2 expression, during the skin ischemia, is studied using in situ hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- b) Ischemic skin wounds
- c) Normal wounds

The experimental protocol includes:

- a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).
- b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).
- c) Topical treatment with METH1 and/or METH2 of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.
- d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 47: Peripheral Arterial Disease Model

Angiogenic therapy using METH1 and/or METH2 is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

5 a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.

 b) METH1 and/or METH2 protein, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.

10 c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of METH1 and/or METH2 expression and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

 The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 48: Ischemic Myocardial Disease Model

20 METH1 and/or METH2 is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of METH1 and/or METH2 expression is investigated in situ. The experimental protocol includes:

 a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

25 b) METH1 and/or METH2 protein, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.

-470-

c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 49: Rat Corneal Wound Healing Model

This animal model shows the effect of METH1 and/or METH2 on neovascularization. The experimental protocol includes:

- a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.
- c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).
- d) Positioning a pellet, containing 50ng- 5ug of METH1 and/or METH2, within the pocket.
- e) METH1 and/or METH2 treatment can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models

A. Diabetic db+/db+ Mouse Model.

To demonstrate that METH1 and/or METH2 has an effect on the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and

-471-

reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

5 The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria.

10 Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration

15 abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*, *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

20 The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The

25 animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory

30 Animals.

-472-

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

METH1 and/or METH2 is administered using at a range different doses of METH1 and/or METH2, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) METH1 and/or 3) METH2.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

-473-

[Open area on day 8] - [Open area on day 1] / [Open area on day 1]

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with METH1 and/or METH2. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer served as a positive tissue control and human brain tissue is used as a negative tissue control. Each specimen included a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

B. Steroid Impaired Rat Model

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, S.M. Glucocorticoids and Wound healing. *In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects.* 280-302 (1989); Wahl, S.M. *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb, Z. *et al.*, *J. Exp. Med.* 147:1684-1694

(1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert, R.H., *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck, L.S. *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes, B.F. *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes, B.F., *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, S. M., "Glucocorticoids and wound healing", *In: Antiinflammatory Steroid Action: Basic and Clinical Aspects*, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck, L.S. *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes, B.F., *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, S. M., "Glucocorticoids and wound healing", *In: Antiinflammatory Steroid Action: Basic and Clinical Aspects*, Academic Press, New York, pp. 280-302 (1989); Pierce, G.F. *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that METH1 and/or METH2 has an effect on the healing process, the effects of multiple topical applications of METH1 and/or METH2 on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue

-475-

punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

5 Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

10 METH1 and/or METH2 is administered using at a range different doses of METH1 and/or METH2, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

15 Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

 Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) METH1 and 4) METH2 treated groups.

20 Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

25
$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether

-476-

the healing process and the morphologic appearance of the repaired skin is improved by treatment with METH1 and/or METH2. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 51: Lymphadema Animal Model

The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of METH1 and/or METH2 in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the

-477-

lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated or suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

-478-

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca²⁺ comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at -80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics.

The studies described in this example tested activity in METH1 and/or METH2 protein. However, one skilled in the art could easily modify the exemplified studies to test the activity of METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

Example 52. Generation of constructs and expression of METH1

Two constructs having either a Flag peptide sequence or a human IgG1 Fc domain fused to the full-length METH1 gene at its C-terminus were generated, using methods well known in the art. The construct names, pFlag-CMV-5a:METH1 (ID 822) and pC4Fc:METH1 (ID 821) were assigned.

The following primers were used for pFlag-CMV-5a:METH1:
5': AAGAATGCGGCCGCAGCCACCATGGGGAACGCGGAGCGGGCTCC (SEQ ID NO:128)
3': GATCGCGGTACCACTGCATTCTGCCATTGTGCAAAGTCTATG (SEQ ID NO:129)

METH1 was amplified using the indicated primers, and digested with Asp718. The vector pFLAGCMV-5a was also digested with Asp718. The resulting restriction products were ligated together.

The following primers were used for pC4Fc:METH1:

-479-

5': GATCTATGATCAGCCACCATGGGGAACGCGGAGCGGGCTCC (SEQ ID NO:130)

3': GACTGCTCTAGAACTGCATTCTGCCATTGTGCAAAAGTCTATG (SEQ ID NO:131)

5 METH1 was amplified using the indicated primers, and digested with BclI and Xba. The vector pC4Fc was also digested with BclI and Xba. The resulting restriction products were ligated together.

 Constructs pA2gp:METH1(H542-Q894).Fc and pA2gp:METH1(H542-Q894) can also be made.

10 Also, pC4Fc:Meth1.M1-P799 can be made using the following primers:

 5' primer:

GATCTA TGATCA GCCACCATGGGGAACGCGGAGCGGGCTCC (SEQ ID NO:132)

 3' primer:

15 GCGTGC TCTAGA AGGGCTAAAGCTGCGAATTC (SEQ ID NO:133)

 METH1 is amplified using the indicated primers, and digested with BclI and Xba. The vector pC4Fc was also digested with BclI and Xba, and ligated to the digested METH1 fragment.

 pFLAG-CMV-1:Meth1.F236-E614 can be made using the following primers:

20 5' primer: GTACCC AAGCTT TTTGTGTCCAGTCACCGC (SEQ ID NO:134)

3' primer: GCGTGC TCTAGA TTA CTCTGTTGTGTGCTTCAC (SEQ ID NO:135)

 METH1 is amplified using the indicated primers and digested with HindIII and Xba. The vector pFLAG-CMV-1 is also digested with HindIII and Xba and ligated to the digested METH1 fragment.

25 The constructs were made in order to confirm the anti-angiogenesis activity of METH1. The full length METH1 gene was PCR cloned into pC4Fc and pFlagCMV5a vectors. Both pC4Fc:METH1 and pFLAGCMV5a:METH1 were obtained and the sequence confirmed.

30 Transient transfections on 293T cells were done using lipofectamine plus (LTI) reagent and held for production under serum-free conditions. Western analysis was done with either anti-huFc Ab or anti-Flag M2 Ab. METH1-Fc conditioned media showed at

-480-

least five bands with varying degree of intensity. Their estimated MWs are 130-140 kD(weak), 110-120 kD(weak), 52 kD(strong), 45-48 kD(strong) and 32-35 kD(strongest). Two weaker bands at about 60 and 90 kD were also detectable. METH1-Flag conditioned medium revealed three major bands with equal intensity. They are about 100-110 kD, 70-80 kD and 22 kD. Transient transfection of METH1-Fc in 293T cells. A second batch of METH1-Fc protein was produced in medium with 1% serum as described above.

5.5 day conditioned medium from transiently transfected cells was run on a ProteinA column and eluted. The fractions containing protein were examined by SDS-PAGE under reduced and non-reduced conditions and stained with Coomassie Blue. A second gel was also prepared for N-terminal sequence analysis.

197 µg of protein were recovered which demonstrated 4 bands under reducing conditions. Three of the bands were strong, one was weak. N-terminal sequencing of the bands suggested that 2 of the bands contained proteins with a blocked N-termini. Of the 2 bands giving sequence, one was an Fc-derived fragment, the other a cleavage product of the METH1.Fc fusion starting at L800 (containing two of the thrombospondin-like domains). This suggests that METH1 is processed with at least 2 cleavage sites (possibly more) since only the C-terminal fragments still linked to the Fc fragment would be purified on the Protein A column.

The transfected 293T cells were conditioned in medium containing 1% dialyzed, low IgG, fetal calf serum to attempt to decrease the proteolysis of the recombinant secreted protein. The purification and analysis was as described above. The yield of protein was significantly higher than the first batch, possibly reflecting the effect of the serum in the medium. While some processing may have been slowed by the serum, the majority of the protein remained approximately 31 kD on a reducing gel.

N-terminal sequencing of resolved bands under reducing conditions indicated the protein is processed at L800 of the 950 residue METH1 orf, with other possible cleavage occurring N-terminal to this site. The observed cleavage site was considered unusual since it followed a Pro. A total of 197.4 µg of protein was isolated (HG12100 -D293T1). Analysis of flag protein (pFlag-CMV-5a:METH1), consisting of at least three bands on

-481-

the Western blot (120, 97 and 21 Kd) indicated that only one band (21 kd) could be confirmed as METH1 and the other bands were of non-METH1 origin.

Since sequencing of the purified METH1 Fc protein suggested an unusual cleavage site, a second batch of METH1 Fc was prepared with cells grown in 1% FBS, to possibly inhibit undesirable processing. A preliminary assessment of the product suggests that no difference in processing resulted from the change in medium, but protein yields were increased.

Functional assays of the initial Fc and Flag protein supernatants performed included proliferation of Human Microvascular Endothelial Cells (HMVECs) and in vitro cord formation using Bovine aortic endothelial cells (BAECs). The proliferation assay indicated increased rates of HMVEC proliferation in response to both culture supernatants, which may be attributable to high background stimulation from the conditioned medium. Cord formation assays of both the Fc and Flag supernatants indicated inhibition of cord formation relative to a medium/collagen control in two independent experiments.

Example 53. In vitro activity of METH1

Proliferation

HMVECs were used in an alamar blue assay to determine if METH1 supernatants have functional anti-angiogenic activity, detectable by an inhibition of EC proliferation. FGF-2 was used as the primary stimulus for proliferation and culture supernatants were used at a 1:4 final dilution. The proliferation assays indicated significantly increased rates of HMVEC proliferation in response to both culture supernatants, which may be attributable to high background stimulation from the conditioned medium. This problem should be reduced or eliminated by the use of purified proteins.

Cord formation

The addition of soluble type I collagen to endothelial cells and the appropriate growth factors will induce the production of tube-like structures or cords of endothelial cells in culture which involves both the migration of endothelial cells and the selective

-482-

deletion (apoptosis) of cells not involved in these structures. Bovine aortic endothelial cells (BAECs) were used to detect inhibition of stable cord formation when cultured with METH1-Fc and METH1-Flag containing culture supernatants at a 1:4 dilution.. Qualitative assessment of the cord formation indicated inhibition with both of the tested
5 supernatants relative to the collagen-treated control. However, a non-matched conditioned medium control also generated inhibition of cord formation, suggesting that non-specific cellular toxicity might also contribute to the observed inhibition.

The studies described in this example tested activity in METH1 protein. However, one skilled in the art could easily modify the exemplified studies to test the
10 activity of METH2 polypeptides, METH1 and/or METH2 polynucleotides (e.g., gene therapy), agonists, and/or antagonists of METH1 and/or METH2.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples.

Numerous modifications and variations of the present invention are possible in
15 light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of all publications (including patents, patent applications, journal articles, laboratory manuals, books, or other documents) cited herein are hereby incorporated by reference.

The entire disclosures of U.S. Appl. No. 08/845,496, filed April 24, 1997; U.S.
20 Appl. No. 60/072,298, filed January 23, 1998; U.S. Appl. No. 60/098,539, filed August 28, 1998; U.S. Appl. No. 09/235,810, filed January 22, 1999; U.S. Appl. No. 09/318,208, filed May 25, 1999; U.S. Provisional Appl. No. 60/144,882, filed July 20, 1999; U.S. Provisional Appl. No. 60/147,823, filed August 10, 1999; and U.S. Appl. No. 09/373,658, filed August 13, 1999 are herein incorporated by reference.

482.1

Applicant's or agent's file reference number 1488.107PC0A	International application No. To assigned.
--	--

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>2</u> , line <u>16</u> .
--

B. IDENTIFICATION OF DEPOSIT		Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>
Name of depositary institution American Type Culture Collection		
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America		
Previously located at: 12301 Parklawn Drive Rockville, Maryland 20852 United States of America		
Date of deposit	January 15, 1998	Accession Number 209581

C. ADDITIONAL INDICATIONS (leave blank if not applicable)	This information is continued on an additional sheet <input type="checkbox"/>
DNA plasmid, HOUQC17	

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer SIGNEE HOSTAD INTERNATIONAL DIVISION 703 305 3680	Authorized officer

482.2

Applicant's or agent's file reference number 1488.107PC0A	International application No. Tc assigned.
--	--

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>2</u> , line <u>20</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	Previously located at: 12301 Parklawn Drive Rockville, Maryland 20852 United States of America
Date of deposit January 15, 1998	Accession Number 209582
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
DNA plasmid, HCE4D69	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized: ROFRIED HOSIAD INTERNATIONAL DIVISION 703 305 3680	Authorized officer

482.3

Applicant's or agent's file reference number 1488.107PC0A	International application No. T : assigned.
--	---

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>2</u> , line <u>21</u> .	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit March 14, 2000	Accession Number PTA 1478
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
DNA plasmid (Meth2 pCR2.1-TOPO)	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized SIGNEO HOSTAD INTERNATIONAL DIVISION 703-305-3680	Authorized officer

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:

- (a) a polynucleotide encoding amino acids 1 to 950 in SEQ ID NO:2;
- 5 (b) a polynucleotide encoding amino acids 2 to 950 in SEQ ID NO:2;
- (c) a polynucleotide encoding amino acids 29 to 950 in SEQ ID NO:2;
- (d) a polynucleotide encoding amino acids 30 to 950 in SEQ ID NO:2;
- (e) a polynucleotide encoding the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581;
- 10 (f) a polynucleotide encoding the mature amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209581;
- (g) a polynucleotide encoding amino acids 1 to 968 of SEQ ID NO:125;
- (h) a polynucleotide encoding amino acids 235 to 459 in SEQ ID
15 NO:2;
- (i) a polynucleotide encoding amino acids 460 to 544 in SEQ ID NO:2;
- (j) a polynucleotide encoding amino acids 545 to 598 in SEQ ID NO:2;
- 20 (k) a polynucleotide encoding amino acids 841 to 894 in SEQ ID NO:2;
- (l) a polynucleotide encoding amino acids 895 to 934 in SEQ ID NO:2;
- (m) a polynucleotide encoding amino acids 536 to 613 in SEQ ID
25 NO:2; and
- (n) a polynucleotide encoding amino acids 549 to 563 in SEQ ID NO:2.

-484-

2. A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector in operable linkage to a promoter.

3. A recombinant vector produced by the method of claim 2.

4. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 3 into a host cell.

5. A recombinant host cell produced by the method of claim 4.

6. A recombinant method for producing a polypeptide, comprising culturing the recombinant host cell of claim 5 under conditions such that said polypeptide is expressed and recovering said polypeptide.

7. An isolated nucleic acid molecule, comprising 50 contiguous nucleotides of the coding region of SEQ ID NO:1, or the complement thereof, wherein said nucleic acid molecule does not comprise any one of SEQ ID NOs:14-41.

8. An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:

(a) a polynucleotide encoding amino acids 1 to 890 in SEQ ID NO:4;
(b) a polynucleotide encoding amino acids 2 to 890 in SEQ ID NO:4;
(c) a polynucleotide encoding amino acids 24 to 890 in SEQ ID NO:4;
(d) a polynucleotide encoding amino acids 112 to 890 in SEQ ID NO:4;

(e) a polynucleotide encoding the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209582;

(f) a polynucleotide encoding the mature amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209582;

(g) a polynucleotide encoding amino acids 214 to 439 in SEQ ID NO:4;

-485-

(h) a polynucleotide encoding amino acids 440 to 529 in SEQ ID NO:4;

(i) a polynucleotide encoding amino acids 530 to 583 in SEQ ID NO:4;

(j) a polynucleotide encoding amino acids 837 to 890 in SEQ ID NO:4;

(k) a polynucleotide encoding amino acids 280 to 606 in SEQ ID NO:4; and

(l) a polynucleotide encoding amino acids 529 to 548 in SEQ ID NO:4.

9. A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 8 into a vector in operable linkage to a promoter.

10. A recombinant vector produced by the method of claim 9.

11. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 10 into a host cell.

12. A recombinant host cell produced by the method of claim 11.

13. A recombinant method for producing a polypeptide, comprising culturing the recombinant host cell of claim 12 under conditions such that said polypeptide is expressed and recovering said polypeptide.

14. An isolated nucleic acid molecule, comprising 50 contiguous nucleotides of the coding region of SEQ ID NO:3, or the complement thereof, wherein said nucleic acid molecule does not comprise any one of SEQ ID NOs:19-22, 24 or 42-77.

15. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

-486-

- (a) amino acids 1 to 950 in SEQ ID NO:2;
(b) amino acids 2 to 950 in SEQ ID NO:2;
(c) amino acids 29 to 950 in SEQ ID NO:2;
(d) amino acids 30 to 950 in SEQ ID NO:2;
5 (d) the complete amino acid sequence encoded by the cDNA clone
contained in ATCC Deposit No. 209581;
(e) the a mature amino acid sequence encoded by the cDNA clone
contained in ATCC Deposit No. 209581;
(f) amino acids 1 to 968 of SEQ ID NO:125;
10 (g) amino acids 235 to 459 in SEQ ID NO:2;
(h) amino acids 460 to 544 in SEQ ID NO:2;
(i) amino acids 545 to 598 in SEQ ID NO:2;
(j) amino acids 841 to 894 in SEQ ID NO:2;
(k) amino acids 895 to 934 in SEQ ID NO:2;
15 (l) amino acids 536 to 613 in SEQ ID NO:2; and
(m) amino acids 549 to 563 in SEQ ID NO:2.

16. An isolated polypeptide comprising an amino acid sequence selected from
the group consisting of:

- (a) amino acids 1 to 890 in SEQ ID NO:4;
20 (b) amino acids 2 to 890 in SEQ ID NO:4;
(c) amino acids 24 to 890 in SEQ ID NO:4;
(d) amino acids 112 to 890 in SEQ ID NO:4;
(e) the complete amino acid sequence encoded by the cDNA clone
contained in ATCC Deposit No. 209582;
25 (f) the mature amino acid sequence encoded by the cDNA clone
contained in ATCC Deposit No. 209582;
(g) amino acids 214 to 439 in SEQ ID NO:4;
(h) amino acids 440 to 529 in SEQ ID NO:4;
(i) amino acids 530 to 583 in SEQ ID NO:4;
30 (j) amino acids 837 to 890 in SEQ ID NO:4;

-487-

- (k) amino acids 280 to 606 in SEQ ID NO:4; and
- (l) amino acids 529 to 548 in SEQ ID NO:4.

17. A polypeptide comprising the amino acid sequence m-n of SEQ ID NO:2, wherein m is an integer of 1 to 950, and wherein n is an integer of 10 to 950.

5 18. A polypeptide comprising the amino acid sequence m-n of SEQ ID NO:4, wherein m is an integer of 1 to 890, and wherein n is an integer of 10 to 890.

19. A method for inhibiting angiogenesis in an individual, comprising administering an effective amount of METH1 or METH2.

10 20. The method of claim 19, wherein said method is used to treat cancer, benign tumors, an ocular angiogenic disease, rheumatoid arthritis, psoriasis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars, nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrom, plaque neovascularization, telangiectasia, 15 hemophiliac joints, angiofibroma, fibromuscular dysplasia, wound granulation, Crohn's disease or atherosclerosis.

21. The method of claim 19, wherein said method is used in birth control.

22. The method of claim 19, further comprising administering another angiogenic compound.

20 23. The method of claim 19, wherein said METH1 or METH2 is administered by cell or gene therapy means wherein cells have been modified to produce and secrete METH1 or METH2.

1/19

ATGGGAACGCGAGCGGGCTCCGGGTCTCGGAGCTTTGGCCCGTACCCACGCTGCTGCTGCTCGCCGCGGCGCTA
M G N A E R A P G S R S F G P V P T L L L L A A A L
CTGGCCGTGTGCGAGCGCACTCGGGCCCCCTCCGAGGAGGACGAGGAGCTAGTGGTCCGGAGCTGGAGCGCGCCCCG
L A V S D A L G R P S E E D E E L V V P E L E R A P
GGACACGGGACCACGCGCTCCGCTGCACGCTTTGACCAGCAGCTGGATCTGGAGCTCGGGCCCCACAGCAGCTTT
G H G T T R L R L H A F D Q Q L D L E L R P D S S F
TTGGCGCCCGGCTTCACGCTCCAGAACGTGGGGCGCAAATCCGGGTCCGAGACGCGCTTCCGAAACCGACCTGGCG
L A P G F T L Q N V G R K S G S E T P L P E T D L A
CACTGCTTCTACTCCGGCACGCTGAATGGCGATCCCAGCTCGGCTGCCGCCCTCAGCCTCTGCGAGGGCGTCCGCGGC
H C F Y S G T V N G D P S S A A A L S L C E G V R G
GCCTTCTACCTGCTGGGGGAGGCGTATTTATCCAGCCGCTGCCCCCGCCAGCGAGCGCTCGCCACGCGCGCCCCA
A F Y L L G E A Y F I Q P L P A A S E R L A T A A P
GGGAGAAGCCCGCGCACCACTACAGTTCCACCTCCTGCGGCGAATCGGCAGGGCGACGTAGGCGGCACGTGCGGG
G E K P P A P L Q F H L L R R N R Q G D V G G T C G
GTCGTGGACGACGAGCCCCGCGGACTGGGAAAGCGGAGACCGAAGACGAGGACGAAGGGACTGAGGGCGAGGACGAA
V V D D E P R P T G K A E T E D E D E G T E G E D E
GGGCCTCAGTGGTCCGCGCAGGACCCCGCACTGCAAGGCGTAGGACAGCCACAGGAAGTGAAGCATAAGAAAGAAG
G P Q W S P Q D P A L Q G V G Q P T G T G S I R K K
CGATTTGTGTCCAGTCACCGCTATGTGAAACCATGCTTGTGGCAGACCAGTCGATGGCAGAATTCCACGGCAGTGGT
R F V S S H R Y V E T M L V A D Q S M A E F H G S G
CTAAAGCATTACCTTCTACGTTGTTTTCGGTGGCAGCCAGATTGTACAAACACCCAGCATTGTAATTCAGTTAGC
L K H Y L L T L F S V A A R L Y K H P S I R N S V S
CTGGTGGTGGTGAAGATCTTGGTCATCCAGATGAACAGAAGGGCCGGAAGTGACCTCCAATGCTGCCCTCACTCTG
L V V V K I L V I H D E Q K G P E V T S N A A L T L
CGGAACTTTTGCAACTGGCAGAAGCAGCACAACCCACCCAGTGACCGGGATGCAGAGCACTATGACACAGCAATTCTT
R N F C N W Q K Q H N P P S D R D A E H Y D T A I L
TTCACCAGACAGGACTTGTGTGGTCCCAGACATGTGATACTCTTGGGATGGCTGATGTTGGAAGTGTGTGTGATCCG
F T R Q D L C G S Q T C D T L G M A D V G T V C D P
AGCAGAAGCTGCTCCGTCATAGAAGATGATGGTTTACAAGCTGCCTTACCACAGCCCATGAATTAGGCCACGTGTTT
S R S C S V I E D D G L Q A A F T T A H E L G H V F
AACATGCCACATGATGATGCAAAGCAGTGTGCCAGCCTTAATGGTGTGAACCAGGATTCCACATGATGGCGTCAATG
N M P H D D A K Q C A S L N G V N Q D S H M M A S M

FIG. 1A

2/19

CTTTCCAACCTGGACCACAGCCAGCCTTGGTCTCCTTGCACTGCCTACATGATTACATCATTCTCGATAATGGTCAT
L S N L D H S Q P W S P C S A Y M I T S F L D N G H
GGGGAATGTTTGATGGACAAGCCTCAGAATCCCATACAGCTCCCAGCGATCTCCCTGGCACCTCGTACGATGCCAAC
G E C L M D K P Q N P I Q L P G D L P G T S Y D A N
CGGCAGTGCCAGTTTACATTGGGGAGGACTCCAAACACTGCCCTGATGCAGCCAGCACATGTAGCACCTTGTGGTGT
R Q C Q F T F G E D S K H C P D A A S T C S T L W C
ACCGGCACCTCTGGTGGGGTCTGGTGTGTCAAACAAACACTTCCCGTGGGCGGATGGCACCAGCTGTGGAGAAGGG
T G T S G G V L V C Q T K H F P W A D G T S C G E G
AAATGGTGTATCAACGGCAAGTGTGTGAACAAAACGACAGAAAGCATTTTGATACGCCTTTTCATGGAAGCTGGGGA
K W C I N G K C V N K T D R K H F D T P F H G S W G
ATGTGGGGCCTTGGGGAGACTGTTTCGAGAACGTGCGGTGGAGGAGTCCAGTACAGATGAGGGAATGTGACAACCCA
M W G P W G D C S R T C G G G V Q Y T M R E C D N P
GTCCCAAAGAATGGAGGGAAGTACTGTGAAGGCAACGAGTGGCTACAGATCCTGTAACCTTGAGGACTGTCCAGAC
V P K N G G K Y C E G K R V R Y R S C N L E D C P D
AATAATGGAACCACTTTAGAGAGGAACAATGTGAAGCACACAACGAGTTTTCAAAGCTTCCTTTGGGAGTGGGCCT
N N G K T F R E E Q C E A H N E F S K A S F G S G P
GCGGTGGAATGGATTCCCAAGTACGCTGCGGTCTCACCAGGACAGGTGCAAGCTCATCTGCCAAGCCAAAGGCATT
A V E W I P K Y A G V S P K D R C K L I C Q A K G I
GGCTACTTCTTGGTTTTCAGCCCAAGGTTGTAGATGGTACTCCATGTAGCCAGATTCCACCTCTGTCTGTGTGCAA
G Y F F V L Q P K V V D G T P C S P D S T S V C V Q
GGACAGTGTGTAAGGCTGGTTGTGATCGCATCATAGACTCCAAAAAGAAGTTTGATAAATGTGGTGTGTTGGGGGGA
G Q C V K A G C D R I I D S K K K F D K C G V C G G
AATGGATCTACTTGTAAAAAATATCAGGATCAGTTACTAGTGCAAAACCTGGATATCATGATATCATCACAATTCCA
N G S T C K K I S G S V T S A K P G Y H D I I T I P
ACTGGAGCCACCAACATCGAAGTGAAACAGCGGAACAGAGCGGATCCAGGAACAATGGCAGCTTTCTTGCCATCAAA
T G A T N I E V K Q R N Q R G S R N N G S F L A I K
GCTGCTGATGGCACATATATTCTTAATGGTGACTACACTTTGTCCACCTTAGAGCAAGACATTATGTACAAAGGTGTT
A A D G T Y I L N G D Y T L S T L E Q D I M Y K G V
GTCTTGAGGTACAGCGCTCCTCTGCGGCATTGGAAGAATTGCGAGCTTTAGCCCTCTCAAAGAGCCCTTGACCATC
V L R Y S G S S A A L E R I R S F S P L K E P L T I
CAGGTTCTTACTGTGGCAATGCCCTTCGACCTAAAATTAATACACCTACTTCGTAAAGAAGAAGAAGGAATCTTTC
Q V L T V G N A L R P K I K Y T Y F V K K K K E S F

FIG. 1B

3/19

AATGCTATCCCCACTTTTTCAGCATGGGTCATTGAAGAGTGGGGCAATGTTCTAAGTCATGTGAATTGGGTTGGCAG
N A I P T F S A W V I E E W G E C S K S C E L G W Q
AGAAGACTGGTAGAATGCCGAGACATTAATGGACAGCCTGCTTCCGAGTGTGCAAAGGAAGTGAAGCCAGCCAGCACC
R R L V E C R D I N G Q P A S E C A K E V K P A S T
AGACCTTGTGCAGACCATCCCTGCCCCCAGTGGCAGCTGGGGGAGTGGTCATCATGTTCTAAGACCTGTGGGAAGGGT
R P C A D H P C P Q W Q L G E W S S C S K T C G K G
TACAAAAAAGAAGCTTGAAGTGTCTGTCCCATGATGGAGGGGTGTTATCTCATGAGAGCTGTGATCCTTTAAAGAAA
Y K K R S L K C L S H D G G V L S H E S C D P L K K
CCTAAACATTTCATAGACTTTTGCACAATGGCAGAATGCAGTTAAGTGGTTTAAGTGGTGTAGCTTTGAGGCAAGGC
P K H F I D F C T M A E C S
AAAGTGAGGAAGGGCTGGTGCAGGGAAGCAAGAAGGCTGGAGGGATCCAGCGTATCTTGCCAGTAACCACTGAGGTG
TATCAGTAAGGTGGGATTATGGGGTAGATAGAAAAGGAGTTGAATCATCAGAGTAACTGCCAGTTGCAAATTTGAT
AGGATAGTTAGTGAGGATTATTAACCTCTGAGCAGTGATATAGCATAATAAANCCCCGGGCATTATTATTATTATTC
TTTTGTTACATCTATTACAAGTTAGAAAAAACAAGCAATTGTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGG
CGGGCCGCTCTAGAGGATCCCTCGAGGGCCCCAAGCTTACGCGTGCATGNTGTCATNAGTCTN

FIG. 1C

4/19

[illegible]

FIG. 2A

5/19

GCTCAGGACGTCTGCGCCAGCTTTGGTGCCACACTGATGGGGCTGAGCCCCGTGCCACACGAAGAATGGCAGCCTG
A Q D V C A Q L W C H T D G A E P L C H T K N G S L
CCCTGGGCTGACGGCAGCCGTCGGGGCTGGGCACCTCTGCTCAGAAGGCAGCTGTCTACCTGAGGAGGAAGTGGAG
P W A D G T P C G P G H L C S E G S C L P E E E V E
AGCCCCAAGCCCGTGGTAGATGGAGGCTGGGCACCGTGGGGACCCTGGGGAGAATGTTCTCGGACCTGTGGAGGAGGA
R P K P V V D G G W A P W G P W G E C S R T C G G G
GTACAGTTTTACACCGTGAGTGAAGACCCCGAGCCTCAGAATGGAGGAAGATACTGCCCTGGTTCGGAGAGCCAAAG
V Q F S H R E C K D P E P Q N G G R Y C L G R R A K
TACCAGTCATGCCACAGGAGGAATGCCCCCTGACGGGAAAAGCTTCAGGAGCAGCAGTGTGAGAAGTATAATGCC
Y Q S C H T E E C P P D G K S F R E Q Q C E K Y N A
TACAATTACACTGACATGGACGGGAATCTCTGCACTGGGTCCTCAAGTATGCTGGGGTGTCCCCCGGGACCGCTGC
Y N Y T D M D G N L L Q W V P K Y A G V S P R D R C
AAGTTGTTCTGCGGAGCCCGGGGAGGAGCGAGTTCAAAGTGTTCGAGGCCAAGGTGATTGATGGCACCTGTGTGGG
K L F C R A R G R S E F K V F E A K V I D G T L C G
CCAGAAACACTGGCCATCTGTGTCCGTGGCCAGTGTGTCAAGCCGGCTGTGACCATGTGGTGGACTCGCCTCGGAAG
P E T L A I C V R G Q C V K A G C D H V V D S P R K
CTGGACAAATGCGGGGTGTGTGGGGCAAAGGCAACTCCTGCAGGAAGGTCTCCGGGTCCCTCACCCCCACCAATTAT
L D K C G V C G G K G N S C R K V S G S L T P T N Y
GGCTACAATGACATTGTACCATCCCAGCTGGTGCCACTAATATTGACGTGAAGCAGCGGAGCCACCCGGGTGTGCAG
G Y N D I V T I P A G A T N I D V K Q R S H P G V Q
AACGATGGGAACCTACCTGGCGCTGAAGACGGCTGATGGGCAGTACCTGCTCAACGGCAACCTGGCCATCTCTGCCATA
N D G N Y L A L K T A D G Q Y L L N G N L A I S A I
GAGCAGGACATCTTGGTGAAGGGGACCATCCTGAAGTACAGCGGCTCCATCGCCACCCTGGAGCGCTGCAGAGCTTC
E Q D I L V K G T I L K Y S G S I A T L E R L Q S F
CGGCCCTTGCCAGAGCCTCTGACAGTGCAGCTCCTGACAGTCCCTGGCGAGGTCTTCCCCCAAAGTCAAATACACC
R P L P E P L T V Q L L T V P G E V F P P K V K Y T
TTCTTTGTTCTAATGACGTGGACTTTAGCATGCAGAGCAGCAAAGAGAGCAACCACCAACATCATCCAGCCGCTG
F F V P N D V D F S M Q S S K E R A T T N I I Q P L
CTCCACGCACAGTGGGTGCTGGGGGACTGGTCTGAGTGTCTAGCACCTGCGGGGCGGCTGGCAGAGGCGAACTGTA
L H A Q W V L G D W S E C S S T C G A G W Q R R T V
GAGTGCAGGGACCCCTCGGGCAGGCTCTGCCACCTGCAACAAGGCTCTGAAACCGGAGGATGCCAAGCCCTGCGAA
E C R D P S G Q A S A T C N K A L K P E D A K P C E
AGCCAGCTGTGCCCCCTGTGATTACGGGGGCGAGGGCCAGTCTTGTGCTCCTGGACATCGGTAAGTGCAGAC
S Q L C P L
AAGGTCTCCACTGTGGTGAAGTGGTCCCTTGGCCATATCAAGGCAGCAGGCCCCACCCAGGCCTCCCATTGCCGCAAC
CCCTCCAGTACTGCACAAATTCCTAAGGGGAAGAGAAAAGGTATGGGGGGGCAAAACCTATCATCAACTGTCCAWTG
NAATGGAAGTGTCTCGGTTCAATTAAGGCATAAGTTAAAGTAAATTCAATTATGATCAACAGACCTCACNTCATCTG
TTGCANGATACAACANTAAAAA

FIG. 2B

6/19




FIG. 3A

7/19

Cysteine-rich

430 S A Y M I T S F L D N G H G E C L M D K P - Q N P I Q L P G D L P G - - T S Y D A N R Q C Q F T F G E D S K H C P D A A M E T H I
440 S A M Y L T E L L D G G H G D C L L D A P - G A A L P L P T G L P G R M A L Y Q L D Q Q C R Q I F G P D F R H C P N T S M E T H 2
446 S Q Q E L S R Y L H S Y - - D C L R D D P F T H D W P A L P Q L P G - - L H Y S M N E O C R F D F G L G Y M M C T A F R P N P I

487 S - - T C S T L W C T G T S G G V L V C Q T K H - - F P W A D G T S C G E G K W C I N G K C - - V N K T D R K H F D T P M E T H I
469 A Q D V C A Q L W C H T D G A E P L - C H T K N G S L P W A D G T P C G P G H L C S E G S C - - L P E E E V E R P K P V M E T H 2
502 T F D P C K Q L W C - S H P D N P Y F C K T K K G - - P P L D G T M C A P G K H C I W L T P D I L K R - - - P N P I

TSP

541 F H G S W G M W G P W G D C S R T C G G V Q Y T M R E C D N P V P K N G G K Y C E G K R V R Y R S C N L E D C P D N N M E T H I
526 V D G G W A P W G P W G E C S R T C G G V Q F S H R E C K D P E P Q N G G R Y C L G R R A K Y Q S C H T E E C P D - M E T H 2
555 - D G N I W G A W S P F G S C S R T C G T G V K F R T R Q C D N P H P A N G G R T C S G L A Y D F Q L C N S Q D C P D A L P N P I

601 G K T F R E E Q C E A H N E F S K A S F G S G P A V E - W I P K Y A G V S P K D R C K L I C Q A K G I G Y F F V L Q P K M E T H I
585 G K S F R E Q Q C E K Y N A Y N Y T D M D - G N L L Q - W V P K Y A G V S P R D R C K L F C R A R G R S E F K V F E A K M E T H 2
614 A D - F R E E Q C R Q W D L Y - - - F E H G D A Q H H W L P H - E H R D A K E R C H L Y C E S K E T G E V V S M K R M P N P I

660 V V D G T P C S - P D S T S V C V Q G Q C V K A G C D R I L D S K K K F D K C G V C G G N G S T C K K I S G S V T - - S M E T H I
643 V I D G T L C G - P E T L A I C V R G Q C V K A G C D H V V D S P R K L D K C G V C G G K G N S C R K V S G S L I - - P M E T H 2
668 V H D G T R C S Y K D A F S L C V R G D C R K V G C D G V I G S S K Q E D K C G V C G G D N S H C K V V K G T F S R S P P N P I

717 A K P G Y H D I I T I P I G A T N I E V K Q R N Q R G S R N N G S F L A I K A A D - G T Y I L N G D Y T L S T L E Q D I M E T H I
700 T N Y G Y N D I V T I P A G A T N I D V K O R S H P G V Q N D G N Y L A L K T A D - G Q Y L L N G N L A I S A I E O D I M E T H 2
728 K K L G Y I K M F E I P A G A R H L L T Q E - - - A D T I S H H L A V K N L E T G K F I L N E E N D V D P N S K T F P N P I

776 M Y K G V V L R Y S G S S A A L E R I R S F S P L K E P L T I Q V L T V - G N A L R P K I K Y T Y F V - - - - M E T H I
759 L V K G T I L K Y S G S I A T L E R L Q S F R P L P E P L T V Q L L T V P G E V F P P K V K Y I F F V P N D V - - - - M E T H 2
783 I A M G V E W E Y R D E D G R - E T L Q T M G P L H G - - T I T V L V I P E G D A R I T S L T Y K Y M I H E D S L N V D D P N P I

TSP

826 - - - - - K K K K E S F N A I P T F - - - - - M E T H I
814 - - - - - D F S M Q S S K E R A T T N I I Q P L L - - - - - M E T H 2
840 N N V L E D D S V G Y E W A L K K W S P C S K P C G G S Q F T K Y G C R R R L D H K M V H R G F C D S V S K P K A I R P N P I

FIG. 3B

8/19

839 --- --S A W V I E E W G E C S K S C E - L G W Q R R L V E C R D I - - - - - N G Q P A S E C A K E V K P M E T H I
 834 --- --H A Q W V L G D W S E C S S T I C G - A G W Q R R T V E C R D P - - - - - S G O A S A T C N K A L K P M E T H 2
 900 R T C N P Q E C S Q P V W V T I G E W E P C S R S C G R T G M Q V R S V R C V Q P L H N N T T R S V H T K H C N D A - R P P N P I
 TSP
 882 A S T R P C A D H P C P - Q W Q L G E W S S C S K T C G K G Y K K R S L K C L S H D G - - - - - M E T H I
 878 E D A K P C E S Q L C P - L W R A G S W S Q C S V T C G N G T Q E R P V L C R T A D S F G V C R E E R P E T A R I C R P N P I
 959 E G R R A C N R E L C P G R W R A G S W S Q C S V T C G N G T Q E R P V L C R T A D S F G V C R E E R P E T A R I C R P N P I
 924 - G V L S H E S C D P L K K - - - - - P K H F I D - - - - - F C T M A - - - - - M E T H I
 1019 L G P C P R N T S D P S K K S Y V V Q W L S R P D P N S P V Q E T S S K G R C Q G D K S V F C R M E V L S R Y C S I P G P N P I
 948 --- --E C S
 1079 Y N K L C C K S C N P H D N L T D V D D R A E P P S G K H N D I E E L M P T L S V P T L V M E V Q P P P G I P L E V P L P N P I
 1139 N T S S T N A T E D H P E T N A V D V P Y K I P G L E D E V Q P P N L I P R R P S P Y E K T R N Q R I Q E L I D E M R K P N P I
 1199 K E M L G K F
 P N P I

FIG. 3C

9/19




FIG.4

11/19




FIG. 6A




FIG. 6B

12/19




FIG. 6C




FIG. 6D

13/19




FIG. 7A




FIG. 7B

14/19




FIG. 7C




FIG. 7D

15/19




FIG. 7E

16/19




FIG.8

17/19




FIG.9

18/19




FIG.10




FIG. 11

-1-

SEQUENCE LISTING

<110> Human Genome Sciences, Inc.
SmithKline Beecham Corporation
Beth Israel Deaconess Medical Center
Iruela-Arispe, Luisa
Hastings, Gregg A.
Ruben, Steven M.
Jonak, Zdenka L.
Trulli, Stephen H.
Fornwald, James A.
Terrett, Jonathan A.

<120> Meth1 and Meth2 Polynucleotides and Polypeptides

<130> 1488.107PCOA

<140>
<141>

<150> 60/183,792
<151> 2000-02-22

<150> 60/171,503
<151> 1999-12-22

<150> 09/373,658
<151> 1999-08-13

<150> 60/147,823
<151> 1999-08-10

<150> 60/144,882
<151> 1999-07-20

<150> 09/318,208
<151> 1999-05-25

<160> 135

<170> PatentIn Ver. 2.0

<210> 1
<211> 3261
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)..(2853)

<220>
<221> UNSURE
<222> (3095)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (3248)

-2-

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (3255)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (3261)

<223> May be any nucleic acid

<400> 1

atg ggg aac gcg gag cgg gct ccg ggg tct cgg agc ttt ggg ccc gta	48
Met Gly Asn Ala Glu Arg Ala Pro Gly Ser Arg Ser Phe Gly Pro Val	
1 5 10 15	
ccc acg ctg ctg ctg ctc gcc gcg gcg cta ctg gcc gtg tcg gac gca	96
Pro Thr Leu Leu Leu Leu Ala Ala Ala Leu Leu Ala Val Ser Asp Ala	
20 25 30	
ctc ggg cgc ccc tcc gag gag gac gag gag cta gtg gtg ccg gag ctg	144
Leu Gly Arg Pro Ser Glu Glu Asp Glu Glu Leu Val Val Pro Glu Leu	
35 40 45	
gag cgc gcc ccg gga cac ggg acc acg cgc ctc cgc ctg cac gcc ttt	192
Glu Arg Ala Pro Gly His Gly Thr Thr Arg Leu Arg Leu His Ala Phe	
50 55 60	
gac cag cag ctg gat ctg gag ctg ccg ccc gac agc agc ttt ttg gcg	240
Asp Gln Gln Leu Asp Leu Glu Leu Arg Pro Asp Ser Ser Phe Leu Ala	
65 70 75 80	
ccc ggc ttc acg ctc cag aac gtg ggg cgc aaa tcc ggg tcc gag acg	288
Pro Gly Phe Thr Leu Gln Asn Val Gly Arg Lys Ser Gly Ser Glu Thr	
85 90 95	
ccg ctt ccg gaa acc gac ctg gcg cac tgc ttc tac tcc ggc acc gtg	336
Pro Leu Pro Glu Thr Asp Leu Ala His Cys Phe Tyr Ser Gly Thr Val	
100 105 110	
aat ggc gat ccc agc tcg gct gcc gcc ctc agc ctc tgc gag ggc gtg	384
Asn Gly Asp Pro Ser Ser Ala Ala Ala Leu Ser Leu Cys Glu Gly Val	
115 120 125	
cgc ggc gcc ttc tac ctg ctg ggg gag gcg tat ttc atc cag ccg ctg	432
Arg Gly Ala Phe Tyr Leu Leu Gly Glu Ala Tyr Phe Ile Gln Pro Leu	
130 135 140	
ccc gcc gcc agc gag cgc ctc gcc acc gcc gcc cca ggg gag aag ccg	480
Pro Ala Ala Ser Glu Arg Leu Ala Thr Ala Ala Pro Gly Glu Lys Pro	
145 150 155 160	

-3-

cgc gca cca cta cag ttc cac ctc ctg cgg cgg aat cgg cag ggc gac	528
Pro Ala Pro Leu Gln Phe His Leu Leu Arg Arg Asn Arg Gln Gly Asp	
165 170 175	
gta ggc ggc acg tgc ggg gtc gtg gac gac gag ccc cgg ccg act ggg	576
Val Gly Gly Thr Cys Gly Val Val Asp Asp Glu Pro Arg Pro Thr Gly	
180 185 190	
aaa gcg gag acc gaa gac gag gac gaa ggg act gag ggc gag gac gaa	624
Lys Ala Glu Thr Glu Asp Glu Asp Glu Gly Thr Glu Gly Glu Asp Glu	
195 200 205	
ggg cct cag tgg tgc ccg cag gac ccg gca ctg caa ggc gta gga cag	672
Gly Pro Gln Trp Ser Pro Gln Asp Pro Ala Leu Gln Gly Val Gly Gln	
210 215 220	
ccc aca gga act gga agc ata aga aag aag cga ttt gtg tcc agt cac	720
Pro Thr Gly Thr Gly Ser Ile Arg Lys Lys Arg Phe Val Ser Ser His	
225 230 235 240	
cgc tat gtg gaa acc atg ctt gtg gca gac cag tgc atg gca gaa ttc	768
Arg Tyr Val Glu Thr Met Leu Val Ala Asp Gln Ser Met Ala Glu Phe	
245 250 255	
cac ggc agt ggt cta aag cat tac ctt ctc acg ttg ttt tgc gtg gca	816
His Gly Ser Gly Leu Lys His Tyr Leu Leu Thr Leu Phe Ser Val Ala	
260 265 270	
gcc aga ttg tac aaa cac ccc agc att cgt aat tca gtt agc ctg gtg	864
Ala Arg Leu Tyr Lys His Pro Ser Ile Arg Asn Ser Val Ser Leu Val	
275 280 285	
gtg gtg aag atc ttg gtc atc cac gat gaa cag aag ggg ccg gaa gtg	912
Val Val Lys Ile Leu Val Ile His Asp Glu Gln Lys Gly Pro Glu Val	
290 295 300	
acc tcc aat gct gcc ctc act ctg cgg aac ttt tgc aac tgg cag aag	960
Thr Ser Asn Ala Ala Leu Thr Leu Arg Asn Phe Cys Asn Trp Gln Lys	
305 310 315 320	
cag cac aac cca ccc agt gac cgg gat gca gag cac tat gac aca gca	1008
Gln His Asn Pro Pro Ser Asp Arg Asp Ala Glu His Tyr Asp Thr Ala	
325 330 335	
att ctt ttc acc aga cag gac ttg tgt ggg tcc cag aca tgt gat act	1056
Ile Leu Phe Thr Arg Gln Asp Leu Cys Gly Ser Gln Thr Cys Asp Thr	
340 345 350	
ctt ggg atg gct gat gtt gga act gtg tgt gat ccg agc aga agc tgc	1104
Leu Gly Met Ala Asp Val Gly Thr Val Cys Asp Pro Ser Arg Ser Cys	
355 360 365	

-4-

tcc gtc ata gaa gat gat ggt tta caa gct gcc ttc acc aca gcc cat	1152
Ser Val Ile Glu Asp Asp Gly Leu Gln Ala Ala Phe Thr Thr Ala His	
370 375 380	
gaa tta ggc cac gtg ttt aac atg cca cat gat gat gca aag cag tgt	1200
Glu Leu Gly His Val Phe Asn Met Pro His Asp Asp Ala Lys Gln Cys	
385 390 395 400	
gcc agc ctt aat ggt gtg aac cag gat tcc cac atg atg gcg tca atg	1248
Ala Ser Leu Asn Gly Val Asn Gln Asp Ser His Met Met Ala Ser Met	
405 410 415	
ctt tcc aac ctg gac cac agc cag cct tgg tct cct tgc agt gcc tac	1296
Leu Ser Asn Leu Asp His Ser Gln Pro Trp Ser Pro Cys Ser Ala Tyr	
420 425 430	
atg att aca tca ttt ctg gat aat ggt cat ggg gaa tgt ttg atg gac	1344
Met Ile Thr Ser Phe Leu Asp Asn Gly His Gly Glu Cys Leu Met Asp	
435 440 445	
aag cct cag aat ccc ata cag ctc cca ggc gat ctc cct ggc acc tcg	1392
Lys Pro Gln Asn Pro Ile Gln Leu Pro Gly Asp Leu Pro Gly Thr Ser	
450 455 460	
tac gat gcc aac cgg cag tgc cag ttt aca ttt ggg gag gac tcc aaa	1440
Tyr Asp Ala Asn Arg Gln Cys Gln Phe Thr Phe Gly Glu Asp Ser Lys	
465 470 475 480	
cac tgc cct gat gca gcc agc aca tgt agc acc ttg tgg tgt acc ggc	1488
His Cys Pro Asp Ala Ala Ser Thr Cys Ser Thr Leu Trp Cys Thr Gly	
485 490 495	
acc tct ggt ggg gtg ctg gtg tgt caa acc aaa cac ttc ccg tgg gcg	1536
Thr Ser Gly Gly Val Leu Val Cys Gln Thr Lys His Phe Pro Trp Ala	
500 505 510	
gat ggc acc agc tgt gga gaa ggg aaa tgg tgt atc aac ggc aag tgt	1584
Asp Gly Thr Ser Cys Gly Glu Gly Lys Trp Cys Ile Asn Gly Lys Cys	
515 520 525	
gtg aac aaa acc gac aga aag cat ttt gat acg cct ttt cat gga agc	1632
Val Asn Lys Thr Asp Arg Lys His Phe Asp Thr Pro Phe His Gly Ser	
530 535 540	
tgg gga atg tgg ggg cct tgg gga gac tgt tcg aga acg tgc ggt gga	1680
Trp Gly Met Trp Gly Pro Trp Gly Asp Cys Ser Arg Thr Cys Gly Gly	
545 550 555 560	
gga gtc cag tac acg atg agg gaa tgt gac aac cca gtc cca aag aat	1728
Gly Val Gln Tyr Thr Met Arg Glu Cys Asp Asn Pro Val Pro Lys Asn	
565 570 575	

-5-

gga ggg aag tac tgt gaa ggc aaa cga gtg cgc tac aga tcc tgt aac	1776
Gly Gly Lys Tyr Cys Glu Gly Lys Arg Val Arg Tyr Arg Ser Cys Asn	
580 585 590	
ctt gag gac tgt cca gac aat aat gga aaa acc ttt aga gag gaa caa	1824
Leu Glu Asp Cys Pro Asp Asn Asn Gly Lys Thr Phe Arg Glu Glu Gln	
595 600 605	
tgt gaa gca cac aac gag ttt tca aaa gct tcc ttt ggg agt ggg cct	1872
Cys Glu Ala His Asn Glu Phe Ser Lys Ala Ser Phe Gly Ser Gly Pro	
610 615 620	
gcg gtg gaa tgg att ccc aag tac gct ggc gtc tca cca aag gac agg	1920
Ala Val Glu Trp Ile Pro Lys Tyr Ala Gly Val Ser Pro Lys Asp Arg	
625 630 635 640	
tgc aag ctc atc tgc caa gcc aaa ggc att ggc tac ttc ttc gtt ttg	1968
Cys Lys Leu Ile Cys Gln Ala Lys Gly Ile Gly Tyr Phe Phe Val Leu	
645 650 655	
cag ccc aag gtt gta gat ggt act cca tgt agc cca gat tcc acc tct	2016
Gln Pro Lys Val Val Asp Gly Thr Pro Cys Ser Pro Asp Ser Thr Ser	
660 665 670	
gtc tgt gtg caa gga cag tgt gta aaa gct ggt tgt gat cgc atc ata	2064
Val Cys Val Gln Gly Gln Cys Val Lys Ala Gly Cys Asp Arg Ile Ile	
675 680 685	
gac tcc aaa aag aag ttt gat aaa tgt ggt gtt tgc ggg gga aat gga	2112
Asp Ser Lys Lys Lys Phe Asp Lys Cys Gly Val Cys Gly Gly Asn Gly	
690 695 700	
tct act tgt aaa aaa ata tca gga tca gtt act agt gca aaa cct gga	2160
Ser Thr Cys Lys Lys Ile Ser Gly Ser Val Thr Ser Ala Lys Pro Gly	
705 710 715 720	
tat cat gat atc atc aca att cca act gga gcc acc aac atc gaa gtg	2208
Tyr His Asp Ile Ile Thr Ile Pro Thr Gly Ala Thr Asn Ile Glu Val	
725 730 735	
aaa cag cgg aac cag agg gga tcc agg aac aat ggc agc ttt ctt gcc	2256
Lys Gln Arg Asn Gln Arg Gly Ser Arg Asn Asn Gly Ser Phe Leu Ala	
740 745 750	
atc aaa gct gct gat ggc aca tat att ctt aat ggt gac tac act ttg	2304
Ile Lys Ala Ala Asp Gly Thr Tyr Ile Leu Asn Gly Asp Tyr Thr Leu	
755 760 765	
tcc acc tta gag caa gac att atg tac aaa ggt gtt gtc ttg agg tac	2352
Ser Thr Leu Glu Gln Asp Ile Met Tyr Lys Gly Val Val Leu Arg Tyr	
770 775 780	

-6-

agc ggc tcc tct gcg gca ttg gaa aga att cgc agc ttt agc cct ctc 2400
 Ser Gly Ser Ser Ala Ala Leu Glu Arg Ile Arg Ser Phe Ser Pro Leu
 785 790 795 800

aaa gag ccc ttg acc atc cag gtt ctt act gtg ggc aat gcc ctt cga 2448
 Lys Glu Pro Leu Thr Ile Gln Val Leu Thr Val Gly Asn Ala Leu Arg
 805 810 815

cct aaa att aaa tac acc tac ttc gta aag aag aag aag gaa tct ttc 2496
 Pro Lys Ile Lys Tyr Thr Tyr Phe Val Lys Lys Lys Lys Glu Ser Phe
 820 825 830

aat gct atc ccc act ttt tca gca tgg gtc att gaa gag tgg ggc gaa 2544
 Asn Ala Ile Pro Thr Phe Ser Ala Trp Val Ile Glu Glu Trp Gly Glu
 835 840 845

tgt tct aag tca tgt gaa ttg ggt tgg cag aga aga ctg gta gaa tgc 2592
 Cys Ser Lys Ser Cys Glu Leu Gly Trp Gln Arg Arg Leu Val Glu Cys
 850 855 860

cga gac att aat gga cag cct gct tcc gag tgt gca aag gaa gtg aag 2640
 Arg Asp Ile Asn Gly Gln Pro Ala Ser Glu Cys Ala Lys Glu Val Lys
 865 870 875 880

cca gcc agc acc aga cct tgt gca gac cat ccc tgc ccc cag tgg cag 2688
 Pro Ala Ser Thr Arg Pro Cys Ala Asp His Pro Cys Pro Gln Trp Gln
 885 890 895

ctg ggg gag tgg tca tca tgt tct aag acc tgt ggg aag ggt tac aaa 2736
 Leu Gly Glu Trp Ser Ser Cys Ser Lys Thr Cys Gly Lys Gly Tyr Lys
 900 905 910

aaa aga agc ttg aag tgt ctg tcc cat gat gga ggg gtg tta tct cat 2784
 Lys Arg Ser Leu Lys Cys Leu Ser His Asp Gly Gly Val Leu Ser His
 915 920 925

gag agc tgt gat cct tta aag aaa cct aaa cat ttc ata gac ttt tgc 2832
 Glu Ser Cys Asp Pro Leu Lys Lys Pro Lys His Phe Ile Asp Phe Cys
 930 935 940

aca atg gca gaa tgc agt taa gtggtttaag tgggtgtagc tttgaggcaa 2883
 Thr Met Ala Glu Cys Ser
 945 950

ggcaaagtga ggaagggctg gtgcagggaa agcaagaagg ctggagggat ccagcgtatc 2943

ttgccagtaa ccagtgaggt gtatcagtaa ggtgggatta tgggggtaga tagaaaagga 3003

gttgaatcat cagagtaaac tgccagttgc aaatttgata ggatagttag tgaggattat 3063

taacctctga gcagtgatat agcataataa anccccgggc attattatta ttatttcttt 3123

-7-

tgttacatct attacaagtt tagaaaaaac aaagcaattg tcaaaaaaaaa aaaaaaaaaa 3183
 aaaaaaaaaa aaagggcggc cgctctagag gatccctcga ggggcccaag cttacgcgtg 3243
 catgntgtca tnagtctn 3261

<210> 2
 <211> 950
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Gly Asn Ala Glu Arg Ala Pro Gly Ser Arg Ser Phe Gly Pro Val
 1 5 10 15
 Pro Thr Leu Leu Leu Ala Ala Ala Leu Leu Ala Val Ser Asp Ala
 20 25 30
 Leu Gly Arg Pro Ser Glu Glu Asp Glu Glu Leu Val Val Pro Glu Leu
 35 40 45
 Glu Arg Ala Pro Gly His Gly Thr Thr Arg Leu Arg Leu His Ala Phe
 50 55 60
 Asp Gln Gln Leu Asp Leu Glu Leu Arg Pro Asp Ser Ser Phe Leu Ala
 65 70 75 80
 Pro Gly Phe Thr Leu Gln Asn Val Gly Arg Lys Ser Gly Ser Glu Thr
 85 90 95
 Pro Leu Pro Glu Thr Asp Leu Ala His Cys Phe Tyr Ser Gly Thr Val
 100 105 110
 Asn Gly Asp Pro Ser Ser Ala Ala Ala Leu Ser Leu Cys Glu Gly Val
 115 120 125
 Arg Gly Ala Phe Tyr Leu Leu Gly Glu Ala Tyr Phe Ile Gln Pro Leu
 130 135 140
 Pro Ala Ala Ser Glu Arg Leu Ala Thr Ala Ala Pro Gly Glu Lys Pro
 145 150 155 160
 Pro Ala Pro Leu Gln Phe His Leu Leu Arg Arg Asn Arg Gln Gly Asp
 165 170 175
 Val Gly Gly Thr Cys Gly Val Val Asp Asp Glu Pro Arg Pro Thr Gly
 180 185 190
 Lys Ala Glu Thr Glu Asp Glu Asp Glu Gly Thr Glu Gly Glu Asp Glu
 195 200 205

-8-

Gly Pro Gln Trp Ser Pro Gln Asp Pro Ala Leu Gln Gly Val Gly Gln
 210 215 220
 Pro Thr Gly Thr Gly Ser Ile Arg Lys Lys Arg Phe Val Ser Ser His
 225 230 235 240
 Arg Tyr Val Glu Thr Met Leu Val Ala Asp Gln Ser Met Ala Glu Phe
 245 250 255
 His Gly Ser Gly Leu Lys His Tyr Leu Leu Thr Leu Phe Ser Val Ala
 260 265 270
 Ala Arg Leu Tyr Lys His Pro Ser Ile Arg Asn Ser Val Ser Leu Val
 275 280 285
 Val Val Lys Ile Leu Val Ile His Asp Glu Gln Lys Gly Pro Glu Val
 290 295 300
 Thr Ser Asn Ala Ala Leu Thr Leu Arg Asn Phe Cys Asn Trp Gln Lys
 305 310 315 320
 Gln His Asn Pro Pro Ser Asp Arg Asp Ala Glu His Tyr Asp Thr Ala
 325 330 335
 Ile Leu Phe Thr Arg Gln Asp Leu Cys Gly Ser Gln Thr Cys Asp Thr
 340 345 350
 Leu Gly Met Ala Asp Val Gly Thr Val Cys Asp Pro Ser Arg Ser Cys
 355 360 365
 Ser Val Ile Glu Asp Asp Gly Leu Gln Ala Ala Phe Thr Thr Ala His
 370 375 380
 Glu Leu Gly His Val Phe Asn Met Pro His Asp Asp Ala Lys Gln Cys
 385 390 395 400
 Ala Ser Leu Asn Gly Val Asn Gln Asp Ser His Met Met Ala Ser Met
 405 410 415
 Leu Ser Asn Leu Asp His Ser Gln Pro Trp Ser Pro Cys Ser Ala Tyr
 420 425 430
 Met Ile Thr Ser Phe Leu Asp Asn Gly His Gly Glu Cys Leu Met Asp
 435 440 445
 Lys Pro Gln Asn Pro Ile Gln Leu Pro Gly Asp Leu Pro Gly Thr Ser
 450 455 460
 Tyr Asp Ala Asn Arg Gln Cys Gln Phe Thr Phe Gly Glu Asp Ser Lys
 465 470 475 480
 His Cys Pro Asp Ala Ala Ser Thr Cys Ser Thr Leu Trp Cys Thr Gly

-9-

485										490					495				
Thr	Ser	Gly	Gly	Val	Leu	Val	Cys	Gln	Thr	Lys	His	Phe	Pro	Trp	Ala				
			500					505					510						
Asp	Gly	Thr	Ser	Cys	Gly	Glu	Gly	Lys	Trp	Cys	Ile	Asn	Gly	Lys	Cys				
		515					520				525								
Val	Asn	Lys	Thr	Asp	Arg	Lys	His	Phe	Asp	Thr	Pro	Phe	His	Gly	Ser				
	530					535				540									
Trp	Gly	Met	Trp	Gly	Pro	Trp	Gly	Asp	Cys	Ser	Arg	Thr	Cys	Gly	Gly				
545					550				555					560					
Gly	Val	Gln	Tyr	Thr	Met	Arg	Glu	Cys	Asp	Asn	Pro	Val	Pro	Lys	Asn				
				565					570					575					
Gly	Gly	Lys	Tyr	Cys	Glu	Gly	Lys	Arg	Val	Arg	Tyr	Arg	Ser	Cys	Asn				
		580						585					590						
Leu	Glu	Asp	Cys	Pro	Asp	Asn	Asn	Gly	Lys	Thr	Phe	Arg	Glu	Glu	Gln				
		595					600					605							
Cys	Glu	Ala	His	Asn	Glu	Phe	Ser	Lys	Ala	Ser	Phe	Gly	Ser	Gly	Pro				
		610				615					620								
Ala	Val	Glu	Trp	Ile	Pro	Lys	Tyr	Ala	Gly	Val	Ser	Pro	Lys	Asp	Arg				
625					630				635					640					
Cys	Lys	Leu	Ile	Cys	Gln	Ala	Lys	Gly	Ile	Gly	Tyr	Phe	Phe	Val	Leu				
			645					650						655					
Gln	Pro	Lys	Val	Val	Asp	Gly	Thr	Pro	Cys	Ser	Pro	Asp	Ser	Thr	Ser				
			660					665					670						
Val	Cys	Val	Gln	Gly	Gln	Cys	Val	Lys	Ala	Gly	Cys	Asp	Arg	Ile	Ile				
		675					680					685							
Asp	Ser	Lys	Lys	Lys	Phe	Asp	Lys	Cys	Gly	Val	Cys	Gly	Gly	Asn	Gly				
	690					695					700								
Ser	Thr	Cys	Lys	Lys	Ile	Ser	Gly	Ser	Val	Thr	Ser	Ala	Lys	Pro	Gly				
705					710				715					720					
Tyr	His	Asp	Ile	Ile	Thr	Ile	Pro	Thr	Gly	Ala	Thr	Asn	Ile	Glu	Val				
			725						730					735					
Lys	Gln	Arg	Asn	Gln	Arg	Gly	Ser	Arg	Asn	Asn	Gly	Ser	Phe	Leu	Ala				
			740					745					750						
Ile	Lys	Ala	Ala	Asp	Gly	Thr	Tyr	Ile	Leu	Asn	Gly	Asp	Tyr	Thr	Leu				
		755					760					765							

-10-

Ser Thr Leu Glu Gln Asp Ile Met Tyr Lys Gly Val Val Leu Arg Tyr
 770 775 780

Ser Gly Ser Ser Ala Ala Leu Glu Arg Ile Arg Ser Phe Ser Pro Leu
 785 790 795 800

Lys Glu Pro Leu Thr Ile Gln Val Leu Thr Val Gly Asn Ala Leu Arg
 805 810 815

Pro Lys Ile Lys Tyr Thr Tyr Phe Val Lys Lys Lys Lys Glu Ser Phe
 820 825 830

Asn Ala Ile Pro Thr Phe Ser Ala Trp Val Ile Glu Glu Trp Gly Glu
 835 840 845

Cys Ser Lys Ser Cys Glu Leu Gly Trp Gln Arg Arg Leu Val Glu Cys
 850 855 860

Arg Asp Ile Asn Gly Gln Pro Ala Ser Glu Cys Ala Lys Glu Val Lys
 865 870 875 880

Pro Ala Ser Thr Arg Pro Cys Ala Asp His Pro Cys Pro Gln Trp Gln
 885 890 895

Leu Gly Glu Trp Ser Ser Cys Ser Lys Thr Cys Gly Lys Gly Tyr Lys
 900 905 910

Lys Arg Ser Leu Lys Cys Leu Ser His Asp Gly Gly Val Leu Ser His
 915 920 925

Glu Ser Cys Asp Pro Leu Lys Lys Pro Lys His Phe Ile Asp Phe Cys
 930 935 940

Thr Met Ala Glu Cys Ser
 945 950

<210> 3

<211> 3008

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(2670)

<220>

<221> UNSURE

<222> (2887)

<223> May be any nucleic acid

<220>

-11-

<221> UNSURE

<222> (2957)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (2970)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (2981)

<223> May be any nucleic acid

<400> 3

atg ttc ccc gcc ccc gcc gcc ccc cgg tgg ctt ccg ttc ctg ctg ctg	48
Met Phe Pro Ala Pro Ala Ala Pro Arg Trp Leu Pro Phe Leu Leu Leu	
1 5 10 15	
ctg ctg ctg ctg ctg ctg ccg ctg gcc cgc ggc gcc ccg gcc cgg ccc	96
Leu Leu Leu Leu Leu Leu Pro Leu Ala Arg Gly Ala Pro Ala Arg Pro	
20 25 30	
gca gcc ggg ggg cag gcc tcg gag ctg gtg gtg ccc acg cgg ttg ccc	144
Ala Ala Gly Gly Gln Ala Ser Glu Leu Val Val Pro Thr Arg Leu Pro	
35 40 45	
ggc agc gcg ggc gag ctc gcg ctc cac ctg tcc gcc ttc ggc aag ggc	192
Gly Ser Ala Gly Glu Leu Ala Leu His Leu Ser Ala Phe Gly Lys Gly	
50 55 60	
ttc gtg ttg cgc ctg gcg ccc gac gac agc ttc ctg gcg ccc gag ttc	240
Phe Val Leu Arg Leu Ala Pro Asp Asp Ser Phe Leu Ala Pro Glu Phe	
65 70 75 80	
aag atc gag cgc ctc ggg ggc tcc ggc cgg gcg acc ggg ggc gag cgg	288
Lys Ile Glu Arg Leu Gly Gly Ser Gly Arg Ala Thr Gly Gly Glu Arg	
85 90 95	
ggg ctg cgc ggc tgt ttt ttt tcc ggc acc gtg aat ggg gag ccc gag	336
Gly Leu Arg Gly Cys Phe Phe Ser Gly Thr Val Asn Gly Glu Pro Glu	
100 105 110	
tcg ctg gcg gcg gtc agc ctg tgc cgc ggg ctg agc ggc tcc ttc ctg	384
Ser Leu Ala Ala Val Ser Leu Cys Arg Gly Leu Ser Gly Ser Phe Leu	
115 120 125	
ctg gac ggc gag gag ttc acc atc cag ccg cag ggc gcg ggg ggc tcc	432
Leu Asp Gly Glu Glu Phe Thr Ile Gln Pro Gln Gly Ala Gly Gly Ser	
130 135 140	
ctg gct cag ccg cac cgc ctg cag cgc tgg ggt ccc gcc gga gcc cgc	480
Leu Ala Gln Pro His Arg Leu Gln Arg Trp Gly Pro Ala Gly Ala Arg	

-12-

145	150	155	160	
ccc ctc ccg cga gga ccc gag tgg gag gtg gag acg gga gag ggt cag				528
Pro Leu Pro Arg Gly Pro Glu Trp Glu Val Glu Thr Gly Glu Gly Gln				
	165	170	175	
agg cag gag aga gga gac cac cag gag gac agc gag gag gag agc caa				576
Arg Gln Glu Arg Gly Asp His Gln Glu Asp Ser Glu Glu Glu Ser Gln				
	180	185	190	
gaa gag gag gca gaa ggc gct agc gag ccg cca ccg ccc ctg ggg gcc				624
Glu Glu Glu Ala Glu Gly Ala Ser Glu Pro Pro Pro Pro Leu Gly Ala				
	195	200	205	
acg agt agg acc aag cgg ttt gtg tct gag gcg cgc ttc gtg gag acg				672
Thr Ser Arg Thr Lys Arg Phe Val Ser Glu Ala Arg Phe Val Glu Thr				
	210	215	220	
ctg ctg gtg gcc gat gcg tcc atg gct gcc ttc tac ggg gcc gac ctg				720
Leu Leu Val Ala Asp Ala Ser Met Ala Ala Phe Tyr Gly Ala Asp Leu				
	225	230	235	240
cag aac cac atc ctg acg tta atg tct gtg gca gcc cga atc tac aag				768
Gln Asn His Ile Leu Thr Leu Met Ser Val Ala Ala Arg Ile Tyr Lys				
	245	250	255	
cac ccc agc atc aag aat tcc atc aac ctg atg gtg gta aaa gtg ctg				816
His Pro Ser Ile Lys Asn Ser Ile Asn Leu Met Val Val Lys Val Leu				
	260	265	270	
atc gta gaa gat gaa aaa tgg ggc cca gag gtg tcc gac aat ggg ggg				864
Ile Val Glu Asp Glu Lys Trp Gly Pro Glu Val Ser Asp Asn Gly Gly				
	275	280	285	
ctt aca ctg cgt aac ttc tgc aac tgg cag cgg cgt ttc aac cag ccc				912
Leu Thr Leu Arg Asn Phe Cys Asn Trp Gln Arg Arg Phe Asn Gln Pro				
	290	295	300	
agc gac cgc cac cca gag cac tac gac acg gcc atc ctg ctc acc aga				960
Ser Asp Arg His Pro Glu His Tyr Asp Thr Ala Ile Leu Leu Thr Arg				
	305	310	315	320
cag aac ttc tgt ggg cag gag ggg ctg tgt gac acc ctg ggt gtg gca				1008
Gln Asn Phe Cys Gly Gln Glu Gly Leu Cys Asp Thr Leu Gly Val Ala				
	325	330	335	
gac atc ggg acc att tgt gac ccc aac aaa agc tgc tcc gtg atc gag				1056
Asp Ile Gly Thr Ile Cys Asp Pro Asn Lys Ser Cys Ser Val Ile Glu				
	340	345	350	
gat gag ggg ctc cag gcg gcc cac acc ctg gcc cat gaa cta ggg cac				1104
Asp Glu Gly Leu Gln Ala Ala His Thr Leu Ala His Glu Leu Gly His				

-13-

355	360	365	
gtc ctc agc atg ccc cac gac gac tcc aag ccc tgc aca cgg ctc ttc			1152
Val Leu Ser Met Pro His Asp Asp Ser Lys Pro Cys Thr Arg Leu Phe			
370	375	380	
ggg ccc atg ggc aag cac cac gtg atg gca ccg ctg ttc gtc cac ctg			1200
Gly Pro Met Gly Lys His His Val Met Ala Pro Leu Phe Val His Leu			
385	390	395	400
aac cag acg ctg ccc tgg tcc ccc tgc agc gcc atg tat ctc aca gag			1248
Asn Gln Thr Leu Pro Trp Ser Pro Cys Ser Ala Met Tyr Leu Thr Glu			
405	410	415	
ctt ctg gac ggc ggc cac gga gac tgt ctc ctg gat gcc cct ggt gcg			1296
Leu Leu Asp Gly Gly His Gly Asp Cys Leu Leu Asp Ala Pro Gly Ala			
420	425	430	
gcc ctg ccc ctc ccc aca ggc ctc ccg ggc cgc atg gcc ctg tac cag			1344
Ala Leu Pro Leu Pro Thr Gly Leu Pro Gly Arg Met Ala Leu Tyr Gln			
435	440	445	
ctg gac cag cag tgc agg cag atc ttt ggg ccg gat ttc cgc cac tgc			1392
Leu Asp Gln Gln Cys Arg Gln Ile Phe Gly Pro Asp Phe Arg His Cys			
450	455	460	
ccc aac acc tct gct cag gac gtc tgc gcc cag ctt tgg tgc cac act			1440
Pro Asn Thr Ser Ala Gln Asp Val Cys Ala Gln Leu Trp Cys His Thr			
465	470	475	480
gat ggg gct gag ccc ctg tgc cac acg aag aat ggc agc ctg ccc tgg			1488
Asp Gly Ala Glu Pro Leu Cys His Thr Lys Asn Gly Ser Leu Pro Trp			
485	490	495	
gct gac ggc acg ccg tgc ggg cct ggg cac ctc tgc tca gaa ggc agc			1536
Ala Asp Gly Thr Pro Cys Gly Pro Gly His Leu Cys Ser Glu Gly Ser			
500	505	510	
tgt cta cct gag gag gaa gtg gag agg ccc aag ccc gtg gta gat gga			1584
Cys Leu Pro Glu Glu Glu Val Glu Arg Pro Lys Pro Val Val Asp Gly			
515	520	525	
ggc tgg gca ccg tgg gga ccc tgg gga gaa tgt tct cgg acc tgt gga			1632
Gly Trp Ala Pro Trp Gly Pro Trp Gly Glu Cys Ser Arg Thr Cys Gly			
530	535	540	
gga gga gta cag ttt tca cac cgt gag tgc aag gac ccc gag cct cag			1680
Gly Gly Val Gln Phe Ser His Arg Glu Cys Lys Asp Pro Glu Pro Gln			
545	550	555	560
aat gga gga aga tac tgc ctg ggt cgg aga gcc aag tac cag tca tgc			1728
Asn Gly Gly Arg Tyr Cys Leu Gly Arg Arg Ala Lys Tyr Gln Ser Cys			

-14-

565	570	575	
cac acg gag gaa tgc ccc cct gac ggg aaa agc ttc agg gag cag cag			1776
His Thr Glu Glu Cys Pro Pro Asp Gly Lys Ser Phe Arg Glu Gln Gln			
580	585	590	
tgt gag aag tat aat gcc tac aat tac act gac atg gac ggg aat ctc			1824
Cys Glu Lys Tyr Asn Ala Tyr Asn Tyr Thr Asp Met Asp Gly Asn Leu			
595	600	605	
ctg cag tgg gtc ccc aag tat gct ggg gtg tcc ccc cgg gac cgc tgc			1872
Leu Gln Trp Val Pro Lys Tyr Ala Gly Val Ser Pro Arg Asp Arg Cys			
610	615	620	
aag ttg ttc tgc cga gcc cgg ggg agg agc gag ttc aaa gtg ttc gag			1920
Lys Leu Phe Cys Arg Ala Arg Gly Arg Ser Glu Phe Lys Val Phe Glu			
625	630	635	640
gcc aag gtg att gat ggc acc ctg tgt ggg cca gaa aca ctg gcc atc			1968
Ala Lys Val Ile Asp Gly Thr Leu Cys Gly Pro Glu Thr Leu Ala Ile			
645	650	655	
tgt gtc cgt ggc cag tgt gtc aag gcc ggc tgt gac cat gtg gtg gac			2016
Cys Val Arg Gly Gln Cys Val Lys Ala Gly Cys Asp His Val Val Asp			
660	665	670	
tcg cct cgg aag ctg gac aaa tgc ggg gtg tgt ggg ggc aaa ggc aac			2064
Ser Pro Arg Lys Leu Asp Lys Cys Gly Val Cys Gly Gly Lys Gly Asn			
675	680	685	
tcc tgc agg aag gtc tcc ggg tcc ctc acc ccc acc aat tat ggc tac			2112
Ser Cys Arg Lys Val Ser Gly Ser Leu Thr Pro Thr Asn Tyr Gly Tyr			
690	695	700	
aat gac att gtc acc atc cca gct ggt gcc act aat att gac gtg aag			2160
Asn Asp Ile Val Thr Ile Pro Ala Gly Ala Thr Asn Ile Asp Val Lys			
705	710	715	720
cag cgg agc cac ccg ggt gtg cag aac gat ggg aac tac ctg gcg ctg			2208
Gln Arg Ser His Pro Gly Val Gln Asn Asp Gly Asn Tyr Leu Ala Leu			
725	730	735	
aag acg gct gat ggg cag tac ctg ctc aac ggc aac ctg gcc atc tct			2256
Lys Thr Ala Asp Gly Gln Tyr Leu Leu Asn Gly Asn Leu Ala Ile Ser			
740	745	750	
gcc ata gag cag gac atc ttg gtg aag ggg acc atc ctg aag tac agc			2304
Ala Ile Glu Gln Asp Ile Leu Val Lys Gly Thr Ile Leu Lys Tyr Ser			
755	760	765	
ggc tcc atc gcc acc ctg gag cgc ctg cag agc ttc cgg ccc ttg cca			2352
Gly Ser Ile Ala Thr Leu Glu Arg Leu Gln Ser Phe Arg Pro Leu Pro			

-15-

770	775	780	
gag cct ctg aca gtg cag ctc ctg aca gtc cct ggc gag gtc ttc ccc			2400
Glu Pro Leu Thr Val Gln Leu Leu Thr Val Pro Gly Glu Val Phe Pro			
785	790	795	800
cca aaa gtc aaa tac acc ttc ttt gtt cct aat gac gtg gac ttt agc			2448
Pro Lys Val Lys Tyr Thr Phe Phe Val Pro Asn Asp Val Asp Phe Ser			
	805	810	815
atg cag agc agc aaa gag aga gca acc acc aac atc atc cag ccg ctg			2496
Met Gln Ser Ser Lys Glu Arg Ala Thr Thr Asn Ile Ile Gln Pro Leu			
	820	825	830
ctc cac gca cag tgg gtg ctg ggg gac tgg tct gag tgc tct agc acc			2544
Leu His Ala Gln Trp Val Leu Gly Asp Trp Ser Glu Cys Ser Ser Thr			
	835	840	845
tgc ggg gcc ggc tgg cag agg cga act gta gag tgc agg gac ccc tcc			2592
Cys Gly Ala Gly Trp Gln Arg Ala Thr Val Glu Cys Arg Asp Pro Ser			
	850	855	860
ggc cag gcc tct gcc acc tgc aac aag gct ctg aaa ccc gag gat gcc			2640
Gly Gln Ala Ser Ala Thr Cys Asn Lys Ala Leu Lys Pro Glu Asp Ala			
865	870	875	880
aag ccc tgc gaa agc cag ctg tgc ccc ctg tgattcaggg gggcaggggc			2690
Lys Pro Cys Glu Ser Gln Leu Cys Pro Leu			
	885	890	
cagtcttgtg ctcttgga cagcgtactg aggtgcagac aaggtctcca ctgtggtgac			2750
tggtgctcctt ggccatatca aggcagcacg gccacccag gcctccatt gccgcaacc			2810
ctccagtact gcacaaattc ctaaggggga agagaaaagg tatggggcgg caaacctat			2870
catcaactgt ccawtgnaat ggaacttgct cgggttcaat taaaggcata agttaagta			2930
aattcattat gatcaacaga cctcacntca tctgttgcan gatacaacta ntaaaaaaaa			2990
aaaaaaaaaa aaaaaaaaaa			3008

<210> 4

<211> 890

<212> PRT

<213> Homo sapiens

<400> 4

Met Phe Pro Ala Pro Ala Ala Pro Arg Trp Leu Pro Phe Leu Leu Leu

1

5

10

15

-16-

Leu Leu Leu Leu Leu Leu Pro Leu Ala Arg Gly Ala Pro Ala Arg Pro
 20 25 30

Ala Ala Gly Gly Gln Ala Ser Glu Leu Val Val Pro Thr Arg Leu Pro
 35 40 45

Gly Ser Ala Gly Glu Leu Ala Leu His Leu Ser Ala Phe Gly Lys Gly
 50 55 60

Phe Val Leu Arg Leu Ala Pro Asp Asp Ser Phe Leu Ala Pro Glu Phe
 65 70 75 80

Lys Ile Glu Arg Leu Gly Gly Ser Gly Arg Ala Thr Gly Gly Glu Arg
 85 90 95

Gly Leu Arg Gly Cys Phe Phe Ser Gly Thr Val Asn Gly Glu Pro Glu
 100 105 110

Ser Leu Ala Ala Val Ser Leu Cys Arg Gly Leu Ser Gly Ser Phe Leu
 115 120 125

Leu Asp Gly Glu Glu Phe Thr Ile Gln Pro Gln Gly Ala Gly Gly Ser
 130 135 140

Leu Ala Gln Pro His Arg Leu Gln Arg Trp Gly Pro Ala Gly Ala Arg
 145 150 155 160

Pro Leu Pro Arg Gly Pro Glu Trp Glu Val Glu Thr Gly Glu Gly Gln
 165 170 175

Arg Gln Glu Arg Gly Asp His Gln Glu Asp Ser Glu Glu Glu Ser Gln
 180 185 190

Glu Glu Glu Ala Glu Gly Ala Ser Glu Pro Pro Pro Pro Leu Gly Ala
 195 200 205

Thr Ser Arg Thr Lys Arg Phe Val Ser Glu Ala Arg Phe Val Glu Thr
 210 215 220

Leu Leu Val Ala Asp Ala Ser Met Ala Ala Phe Tyr Gly Ala Asp Leu
 225 230 235 240

Gln Asn His Ile Leu Thr Leu Met Ser Val Ala Ala Arg Ile Tyr Lys
 245 250 255

His Pro Ser Ile Lys Asn Ser Ile Asn Leu Met Val Val Lys Val Leu
 260 265 270

Ile Val Glu Asp Glu Lys Trp Gly Pro Glu Val Ser Asp Asn Gly Gly
 275 280 285

Leu Thr Leu Arg Asn Phe Cys Asn Trp Gln Arg Arg Phe Asn Gln Pro

-17-

290	295	300
Ser Asp Arg His Pro Glu His Tyr Asp Thr Ala Ile Leu Leu Thr Arg		
305	310	315 320
Gln Asn Phe Cys Gly Gln Glu Gly Leu Cys Asp Thr Leu Gly Val Ala		
	325	330 335
Asp Ile Gly Thr Ile Cys Asp Pro Asn Lys Ser Cys Ser Val Ile Glu		
	340	345 350
Asp Glu Gly Leu Gln Ala Ala His Thr Leu Ala His Glu Leu Gly His		
	355	360 365
Val Leu Ser Met Pro His Asp Asp Ser Lys Pro Cys Thr Arg Leu Phe		
	370	375 380
Gly Pro Met Gly Lys His His Val Met Ala Pro Leu Phe Val His Leu		
	385	390 395 400
Asn Gln Thr Leu Pro Trp Ser Pro Cys Ser Ala Met Tyr Leu Thr Glu		
	405	410 415
Leu Leu Asp Gly Gly His Gly Asp Cys Leu Leu Asp Ala Pro Gly Ala		
	420	425 430
Ala Leu Pro Leu Pro Thr Gly Leu Pro Gly Arg Met Ala Leu Tyr Gln		
	435	440 445
Leu Asp Gln Gln Cys Arg Gln Ile Phe Gly Pro Asp Phe Arg His Cys		
	450	455 460
Pro Asn Thr Ser Ala Gln Asp Val Cys Ala Gln Leu Trp Cys His Thr		
	465	470 475 480
Asp Gly Ala Glu Pro Leu Cys His Thr Lys Asn Gly Ser Leu Pro Trp		
	485	490 495
Ala Asp Gly Thr Pro Cys Gly Pro Gly His Leu Cys Ser Glu Gly Ser		
	500	505 510
Cys Leu Pro Glu Glu Glu Val Glu Arg Pro Lys Pro Val Val Asp Gly		
	515	520 525
Gly Trp Ala Pro Trp Gly Pro Trp Gly Glu Cys Ser Arg Thr Cys Gly		
	530	535 540
Gly Gly Val Gln Phe Ser His Arg Glu Cys Lys Asp Pro Glu Pro Gln		
	545	550 555 560
Asn Gly Gly Arg Tyr Cys Leu Gly Arg Arg Ala Lys Tyr Gln Ser Cys		
	565	570 575

-18-

His Thr Glu Glu Cys Pro Pro Asp Gly Lys Ser Phe Arg Glu Gln Gln
 580 585 590

Cys Glu Lys Tyr Asn Ala Tyr Asn Tyr Thr Asp Met Asp Gly Asn Leu
 595 600 605

Leu Gln Trp Val Pro Lys Tyr Ala Gly Val Ser Pro Arg Asp Arg Cys
 610 615 620

Lys Leu Phe Cys Arg Ala Arg Gly Arg Ser Glu Phe Lys Val Phe Glu
 625 630 635 640

Ala Lys Val Ile Asp Gly Thr Leu Cys Gly Pro Glu Thr Leu Ala Ile
 645 650 655

Cys Val Arg Gly Gln Cys Val Lys Ala Gly Cys Asp His Val Val Asp
 660 665 670

Ser Pro Arg Lys Leu Asp Lys Cys Gly Val Cys Gly Gly Lys Gly Asn
 675 680 685

Ser Cys Arg Lys Val Ser Gly Ser Leu Thr Pro Thr Asn Tyr Gly Tyr
 690 695 700

Asn Asp Ile Val Thr Ile Pro Ala Gly Ala Thr Asn Ile Asp Val Lys
 705 710 715 720

Gln Arg Ser His Pro Gly Val Gln Asn Asp Gly Asn Tyr Leu Ala Leu
 725 730 735

Lys Thr Ala Asp Gly Gln Tyr Leu Leu Asn Gly Asn Leu Ala Ile Ser
 740 745 750

Ala Ile Glu Gln Asp Ile Leu Val Lys Gly Thr Ile Leu Lys Tyr Ser
 755 760 765

Gly Ser Ile Ala Thr Leu Glu Arg Leu Gln Ser Phe Arg Pro Leu Pro
 770 775 780

Glu Pro Leu Thr Val Gln Leu Leu Thr Val Pro Gly Glu Val Phe Pro
 785 790 795 800

Pro Lys Val Lys Tyr Thr Phe Phe Val Pro Asn Asp Val Asp Phe Ser
 805 810 815

Met Gln Ser Ser Lys Glu Arg Ala Thr Thr Asn Ile Ile Gln Pro Leu
 820 825 830

Leu His Ala Gln Trp Val Leu Gly Asp Trp Ser Glu Cys Ser Ser Thr
 835 840 845

-19-

Cys Gly Ala Gly Trp Gln Arg Arg Thr Val Glu Cys Arg Asp Pro Ser
850 855 860

Gly Gln Ala Ser Ala Thr Cys Asn Lys Ala Leu Lys Pro Glu Asp Ala
865 870 875 880

Lys Pro Cys Glu Ser Gln Leu Cys Pro Leu
885 890

<210> 5

<211> 1203

<212> PRT

<213> Bovine

<400> 5

Met Asp Pro Pro Ala Gly Ala Ala Gly Arg Leu Leu Cys Pro Ala Leu
1 5 10 15

Leu Leu Leu Leu Leu Leu Pro Leu Pro Ala Asp Ala Arg Leu Ala Ala
20 25 30

Ala Ala Ala Asp Pro Pro Gly Gly Pro Gln Gly His Gly Ala Glu Arg
35 40 45

Ile Leu Ala Val Pro Val Arg Thr Asp Ala Gln Gly Arg Leu Val Ser
50 55 60

His Val Val Ser Ala Ala Thr Ala Pro Ala Gly Val Arg Thr Arg Arg
65 70 75 80

Ala Ala Pro Ala Gln Ile Pro Gly Leu Ser Gly Gly Ser Glu Glu Asp
85 90 95

Pro Gly Gly Arg Leu Phe Tyr Asn Val Thr Val Phe Gly Arg Asp Leu
100 105 110

His Leu Arg Leu Arg Pro Asn Ala Arg Leu Val Ala Pro Gly Ala Thr
115 120 125

Val Glu Trp Gln Gly Glu Ser Gly Ala Thr Arg Val Glu Pro Leu Leu
130 135 140

Gly Thr Cys Leu Tyr Val Gly Asp Val Ala Gly Leu Ala Glu Ser Ser
145 150 155 160

Ser Val Ala Leu Ser Asn Cys Asp Gly Leu Ala Gly Leu Ile Arg Met
165 170 175

Glu Glu Glu Glu Phe Phe Ile Glu Pro Leu Glu Lys Gly Leu Ala Ala
180 185 190

-20-

Lys Glu Ala Glu Gln Gly Arg Val His Val Val Tyr His Arg Pro Thr
 195 200 205
 Thr Ser Arg Pro Pro Pro Leu Gly Gln Ala Leu Asp Thr Gly Ile Ser
 210 215 220
 Ala Asp Ser Leu Asp Ser Leu Ser Arg Ala Leu Gly Val Leu Glu Glu
 225 230 235 240
 Arg Val Asn Ser Ser Arg Arg Arg Met Arg Arg His Ala Ala Asp Asp
 245 250 255
 Asp Tyr Asn Ile Glu Val Leu Leu Gly Val Asp Asp Ser Val Val Gln
 260 265 270
 Phe His Gly Thr Glu His Val Gln Lys Tyr Leu Leu Thr Leu Met Asn
 275 280 285
 Ile Val Asn Glu Ile Tyr His Asp Glu Ser Leu Gly Ala His Ile Asn
 290 295 300
 Val Val Leu Val Arg Ile Ile Leu Leu Ser Tyr Gly Lys Ser Met Ser
 305 310 315 320
 Leu Ile Glu Ile Gly Asn Pro Ser Gln Ser Leu Glu Asn Val Cys Arg
 325 330 335
 Trp Ala Tyr Leu Gln Gln Lys Pro Asp Thr Asp His Asp Glu Tyr His
 340 345 350
 Asp His Ala Ile Phe Leu Thr Arg Gln Asp Phe Gly Pro Ser Gly Met
 355 360 365
 Gln Gly Tyr Ala Pro Val Thr Gly Met Cys His Pro Val Arg Ser Cys
 370 375 380
 Thr Leu Asn His Glu Asp Gly Phe Ser Ser Ala Phe Val Val Ala His
 385 390 395 400
 Glu Thr Gly His Val Leu Gly Met Glu His Asp Gly Gln Gly Asn Arg
 405 410 415
 Cys Gly Asp Glu Val Arg Leu Gly Ser Ile Met Ala Pro Leu Val Gln
 420 425 430
 Ala Ala Phe His Arg Phe His Trp Ser Arg Cys Ser Gln Gln Glu Leu
 435 440 445
 Ser Arg Tyr Leu His Ser Tyr Asp Cys Leu Arg Asp Asp Pro Phe Thr
 450 455 460
 His Asp Trp Pro Ala Leu Pro Gln Leu Pro Gly Leu His Tyr Ser Met

-21-

465	470	475	480
Asn Glu Gln Cys Arg Phe Asp Phe Gly Leu Gly Tyr Met Met Cys Thr	485	490	495
Ala Phe Arg Thr Phe Asp Pro Cys Lys Gln Leu Trp Cys Ser His Pro	500	505	510
Asp Asn Pro Tyr Phe Cys Lys Thr Lys Lys Gly Pro Pro Leu Asp Gly	515	520	525
Thr Met Cys Ala Pro Gly Lys His Cys Phe Lys Gly His Cys Ile Trp	530	535	540
Leu Thr Pro Asp Ile Leu Lys Arg Asp Gly Asn Trp Gly Ala Trp Ser	545	550	555
Pro Phe Gly Ser Cys Ser Arg Thr Cys Gly Thr Gly Val Lys Phe Arg	565	570	575
Thr Arg Gln Cys Asp Asn Pro His Pro Ala Asn Gly Gly Arg Thr Cys	580	585	590
Ser Gly Leu Ala Tyr Asp Phe Gln Leu Cys Asn Ser Gln Asp Cys Pro	595	600	605
Asp Ala Leu Ala Asp Phe Arg Glu Glu Gln Cys Arg Gln Trp Asp Leu	610	615	620
Tyr Phe Glu His Gly Asp Ala Gln His His Trp Leu Pro His Glu His	625	630	635
Arg Asp Ala Lys Glu Arg Cys His Leu Tyr Cys Glu Ser Lys Glu Thr	645	650	655
Gly Glu Val Val Ser Met Lys Arg Met Val His Asp Gly Thr Arg Cys	660	665	670
Ser Tyr Lys Asp Ala Phe Ser Leu Cys Val Arg Gly Asp Cys Arg Lys	675	680	685
Val Gly Cys Asp Gly Val Ile Gly Ser Ser Lys Gln Glu Asp Lys Cys	690	695	700
Gly Val Cys Gly Gly Asp Asn Ser His Cys Lys Val Val Lys Gly Thr	705	710	715
Phe Ser Arg Ser Pro Lys Lys Leu Gly Tyr Ile Lys Met Phe Glu Ile	725	730	735
Pro Ala Gly Ala Arg His Leu Leu Ile Gln Glu Ala Asp Thr Thr Ser	740	745	750

-22-

His His Leu Ala Val Lys Asn Leu Glu Thr Gly Lys Phe Ile Leu Asn
 755 760 765
 Glu Glu Asn Asp Val Asp Pro Asn Ser Lys Thr Phe Ile Ala Met Gly
 770 775 780
 Val Glu Trp Glu Tyr Arg Asp Glu Asp Gly Arg Glu Thr Leu Gln Thr
 785 790 795 800
 Met Gly Pro Leu His Gly Thr Ile Thr Val Leu Val Ile Pro Glu Gly
 805 810 815
 Asp Ala Arg Ile Ser Leu Thr Tyr Lys Tyr Met Ile His Glu Asp Ser
 820 825 830
 Leu Asn Val Asp Asp Asn Asn Val Leu Glu Asp Asp Ser Val Gly Tyr
 835 840 845
 Glu Trp Ala Leu Lys Lys Trp Ser Pro Cys Ser Lys Pro Cys Gly Gly
 850 855 860
 Gly Ser Gln Phe Thr Lys Tyr Gly Cys Arg Arg Arg Leu Asp His Lys
 865 870 875 880
 Met Val His Arg Gly Phe Cys Asp Ser Val Ser Lys Pro Lys Ala Ile
 885 890 895
 Arg Arg Thr Cys Asn Pro Gln Glu Cys Ser Gln Pro Val Trp Val Thr
 900 905 910
 Gly Glu Trp Glu Pro Cys Ser Arg Ser Cys Gly Arg Thr Gly Met Gln
 915 920 925
 Val Arg Ser Val Arg Cys Val Gln Pro Leu His Asn Asn Thr Thr Arg
 930 935 940
 Ser Val His Thr Lys His Cys Asn Asp Ala Arg Pro Glu Gly Arg Arg
 945 950 955 960
 Ala Cys Asn Arg Glu Leu Cys Pro Gly Arg Trp Arg Ala Gly Ser Trp
 965 970 975
 Ser Gln Cys Ser Val Thr Cys Gly Asn Gly Thr Gln Glu Arg Pro Val
 980 985 990
 Leu Cys Arg Thr Ala Asp Asp Ser Phe Gly Val Cys Arg Glu Glu Arg
 995 1000 1005
 Pro Glu Thr Ala Arg Ile Cys Arg Leu Gly Pro Cys Pro Arg Asn Thr
 1010 1015 1020

-23-

Ser Asp Pro Ser Lys Lys Ser Tyr Val Val Gln Trp Leu Ser Arg Pro
 1025 1030 1035 1040

Asp Pro Asn Ser Pro Val Gln Glu Thr Ser Ser Lys Gly Arg Cys Gln
 1045 1050 1055

Gly Asp Lys Ser Val Phe Cys Arg Met Glu Val Leu Ser Arg Tyr Cys
 1060 1065 1070

Ser Ile Pro Gly Tyr Asn Lys Leu Cys Cys Lys Ser Cys Asn Pro His
 1075 1080 1085

Asp Asn Leu Thr Asp Val Asp Asp Arg Ala Glu Pro Pro Ser Gly Lys
 1090 1095 1100

His Asn Asp Ile Glu Glu Leu Met Pro Thr Leu Ser Val Pro Thr Leu
 1105 1110 1115 1120

Val Met Glu Val Gln Pro Pro Pro Gly Ile Pro Leu Glu Val Pro Leu
 1125 1130 1135

Asn Thr Ser Ser Thr Asn Ala Thr Glu Asp His Pro Glu Thr Asn Ala
 1140 1145 1150

Val Asp Val Pro Tyr Lys Ile Pro Gly Leu Glu Asp Glu Val Gln Pro
 1155 1160 1165

Pro Asn Leu Ile Pro Arg Arg Pro Ser Pro Tyr Glu Lys Thr Arg Asn
 1170 1175 1180

Gln Arg Ile Gln Glu Leu Ile Asp Glu Met Arg Lys Lys Glu Met Leu
 1185 1190 1195 1200

Gly Lys Phe

<210> 6

<211> 50

<212> PRT

<213> Homo sapiens

<400> 6

Asp Asp Gly Trp Ser Pro Trp Ser Glu Trp Thr Ser Cys Ser Thr Ser
 1 5 10 15

Cys Gly Asn Gly Ile Gln Gln Arg Gly Arg Ser Cys Asp Ser Leu Asn
 20 25 30

Asn Arg Cys Glu Gly Ser Ser Val Gln Thr Arg Thr Cys His Ile Gln
 35 40 45

-24-

Glu Cys
50

<210> 7
<211> 57
<212> PRT
<213> Homo sapiens

<400> 7
Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys Ser Val Thr
1 5 10 15
Cys Gly Asp Gly Val Ile Thr Arg Ile Arg Leu Cys Asn Ser Pro Ser
20 25 30
Pro Gln Met Asn Gly Lys Pro Cys Glu Gly Glu Ala Arg Glu Thr Lys
35 40 45
Ala Cys Lys Lys Asp Ala Cys Pro Ile
50 55

<210> 8
<211> 57
<212> PRT
<213> Homo sapiens

<400> 8
Asn Gly Gly Trp Gly Pro Trp Ser Pro Trp Asp Ile Cys Ser Val Thr
1 5 10 15
Cys Gly Gly Gly Val Gln Lys Arg Ser Arg Leu Cys Asn Asn Pro Thr
20 25 30
Pro Gln Phe Gly Gly Lys Asp Cys Val Gly Asp Val Thr Glu Asn Gln
35 40 45
Ile Cys Asn Lys Gln Asp Cys Pro Ile
50 55

<210> 9
<211> 50
<212> PRT
<213> Homo sapiens

<400> 9
Glu Glu Gly Trp Ser Pro Trp Ala Glu Trp Thr Gln Cys Ser Val Thr
1 5 10 15
Cys Gly Ser Gly Thr Gln Gln Arg Gly Arg Ser Cys Asp Val Thr Ser

-25-

20 25 30

Asn Thr Cys Leu Gly Pro Ser Ile Gln Thr Arg Ala Cys Ser Leu Ser
 35 40 45

Lys Cys
 50

<210> 10
 <211> 57
 <212> PRT
 <213> Homo sapiens

<400> 10

Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys Ser Val Thr
 1 5 10 15

Cys Gly Val Gly Asn Ile Thr Arg Ile Arg Leu Cys Asn Ser Pro Val
 20 25 30

Pro Gln Met Gly Gly Lys Asn Cys Lys Gly Ser Gly Arg Glu Thr Lys
 35 40 45

Ala Cys Gln Gly Ala Pro Cys Pro Ile
 50 55

<210> 11
 <211> 56
 <212> PRT
 <213> Homo sapiens

<400> 11

Asp Gly Arg Trp Ser Pro Trp Ser Pro Trp Ser Ala Cys Thr Val Thr
 1 5 10 15

Cys Ala Gly Gly Ile Arg Glu Arg Thr Arg Val Cys Asn Ser Pro Glu
 20 25 30

Pro Gln Tyr Gly Gly Lys Ala Cys Val Gly Asp Val Gln Glu Arg Gln
 35 40 45

Met Cys Asn Lys Arg Ser Cys Pro
 50 55

<210> 12
 <211> 3974
 <212> DNA
 <213> Homo sapiens

-26-

<400> 12
ggtagcctaag tgagtagggc gtccgatcga cggacgcctt ttttttgaat tcgtaatcat 60
ggtagcatagct gtttcctgtg tgaaattgtt atccgctcac aattccacac aacatacgag 120
ccggaagcat aaagtgtaaa gcctgggggtg cctaatagag gagctaactc acattaattg 180
cggtgcgctc actgcccgtt ttccagtcgg gaaacctgtc gtgccagctg cattaatgaa 240
tcggccaacg cgcggggaga ggcggtttgc gtattgggag ctcttcgctt tctcgtctca 300
ctgactcgct gcgctcggtc gttcggctgc ggcgagcggg atcagctcac tcaaaggcgg 360
taatacgggt atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc 420
agcaaaaggc caggaaccgt aaaaaggccg cggtgctggc gtttttccat aggtccgccc 480
cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac ccgacaggac 540
tataagata ccaggcggtt cccctggaa gctccctcgt gcgctctcct gttccgaccc 600
tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg ctttctcata 660
gctcacgctg taggtatctc agttcgggtg aggtcgttcg ctccaagctg ggctgtgtgc 720
acgaaccccc cggtcagccc gaccgctgcg ccttatccgg taactatcgt cttgagtcca 780
accgggtaag acacgactta tcgccactgg cagcagccac tggtaacagg attagcagag 840
cgaggtatgt aggcgggtgct acagagttct tgaagtgggt gcctaactac ggctacacta 900
gaagaacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga aaaagagttg 960
gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tgggtttttt gtttgcaagc 1020
agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt totacggggg 1080
ctgacgctca gtggaacgaa aactcacgtt aagggtttt ggtcatgaga ttatcgtcga 1140
caattcgcgc gcgaaggcga agcggcatgc atttacgttg acaccatcga atggtgcaaa 1200
acctttcgcg gtatggcatg atagcggccg gaagagagtc aattcagggt ggtgaatgtg 1260
aaaccagtaa cggtatacga tgtcgagag tatgccggtg tctcttatca gaccgtttcc 1320
cgcggtgtga accaggccag ccacgtttct gcgaaaacgc gggaaaaagt ggaagcggcg 1380
atggcgagc tgaattacat tcccaaccgc gtggcacaac aactggcggg caaacagtcg 1440
ttgctgattg gcgttgccac ctccagtcgt gccctgcacg cgcgctcgca aattgtcgcg 1500
gcgattaaat ctgcgcccga tcaactgggt gccagcgtgg tgggtgcgat ggtagaacga 1560

-27-

agcggcgctcg aagcctgtaa agcggcggtg cacaatcttc tcgcgcaacg cgtcagtggg 1620
ctgatcatta actatccgct ggatgaccag gatgccattg ctgtggaagc tgcctgcact 1680
aatgttccgg cggtatttct tgatgtctct gaccagacac ccatcaacag tattattttc 1740
tcccatgaag acggtacgcg actgggctg gagcatctgg tcgcattggg tcaccagcaa 1800
atcgcgctgt tagcggggccc attaagttct gtctcggcgc gtctgctct ggctggctgg 1860
cataaatatc tcaactcgaa tcaaattcag ccgatagcgg aacgggaagg cgactggagt 1920
gccatgtccg gttttcaaca aaccatgcaa atgctgaatg agggcatcgt tcccactgcg 1980
atgctgggtg ccaacgatca gatggcgctg ggcgcaatgc gcgccattac cgagtccggg 2040
ctgcgcgttg gtgcggatat ctcggtagtg ggatacgacg ataccgaaga cagctcatgt 2100
tatatcccg cgttaaccac catcaaacag gattttcgcc tgctggggca aaccagcgtg 2160
gaccgcttgc tgcaactctc tcagggccag gcggtgaagg gcaatcagct gttgcccgtc 2220
tcaactggtga aaagaaaaac caccctggcg cccaatacgc aaaccgcctc tccccgcgcg 2280
ttggccgatt cattaatgca gctggcacga caggtttccc gactggaaag cgggcagtga 2340
gcgcaacgca attaatgtaa gttagcgcg attgtcgacc aaagcggcca tcgtgcctcc 2400
ccactcctgc agttcggggg catggatgcg cggatagccg ctgctggttt cctggatgcc 2460
gacggatttg cactgccggt agaactccgc gaggtcgtcc agcctcaggc agcagctgaa 2520
ccaactcgcg aggggatcga gcccggggtg ggcgaagaac tccagcatga gatccccgcg 2580
ctggaggatc atccagccgg cgtcccggaa aacgattccg aagcccaacc tttcatagaa 2640
ggcggcggtg gaatcgaaat ctctgatgg caggttgggc gtcgcttggg cggtcatttc 2700
gaaccccaga gtcccgtca gaagaactcg tcaagaaggc gatagaaggc gatgcgctgc 2760
gaatcgggag cggcgatacc gtaaagcacg aggaagcggc cagccattc gccgccaagc 2820
tcttcagcaa tatcacgggt agccaacgct atgtcctgat agcggtcgcg cacaccagc 2880
cggccacagt cgatgaatcc agaaaagcgg ccattttcca ccatgatatt cggcaagcag 2940
gcatcgccat gggtcacgac gagatcctcg ccgtcgggca tgcgcgcctt gagcctggcg 3000
aacagttcgg ctggcgcgag ccctgatgc tcttcgtcca gatcatcctg atcgacaaga 3060
ccggcttcca tccgagtaag tgctcgctcg atgcgatgtt tcgcttgggtg gtcgaatggg 3120

-28-

caggtagccg gatcaagcgt atgcagccgc cgcattgcat cagccatgat ggatactttc 3180
 tcggcaggag caaggtgaga tgacaggaga tcctgccccg gcacttcgcc caatagcagc 3240
 cagtcccttc ccgcttcagt gacaacgtcg agcacagctg cgcaaggaac gcccgtcgtg 3300
 gccagccacg atagccgcgc tgccctgtcc tgcagttcat tcagggcacc ggacaggctg 3360
 gtcttgacaa aaagaaccgg gcgcccctgc gctgacagcc ggaacacggc ggcatcagag 3420
 cagccgattg tctgttggtg ccagtcatag ccgaatagcc tctccacca agcgggccgga 3480
 gaacctgctg gcaatccatc ttgttcaatc atgcgaaacg atcctcatcc tgtctcttga 3540
 tcagatcttg atcccctgcg ccatcagatc cttggcgga agaaagccat ccagtttact 3600
 ttgcagggct tcccaacctt accagagggc gcccagctg gcaattccgg ttcgcttgct 3660
 gtccataaaa ccgcccagtc tagctatcgc catgtaagcc cactgcaagc tacctgcttt 3720
 ctctttgcgc ttgcgttttc ccttgccag atagcccagt agctgacatt catccggggg 3780
 cagcaccgtt tctgcggact ggctttctac gtgttcgct tccttttagca gcccttgccg 3840
 cctgagtgtg tgcggcagcg tgaagcttaa aaaactgcaa aaaatagttt gacttgtgag 3900
 cggataacaa ttaagatgta cccaattgtg agcggataac aatttcacac attaaagagg 3960
 agaaattaca tatg 3974

<210> 13
 <211> 112
 <212> DNA
 <213> Homo sapiens

<400> 13
 aagcttaaaa aactgcaaaa aatagtttga cttgtgagcg gataacaatt aagatgtacc 60
 caattgtgag cggataacaa tttcacacat taaagaggag aaattacata tg 112

<210> 14
 <211> 542
 <212> DNA
 <213> Mus musculus

<220>
 <221> UNSURE
 <222> (3)
 <223> May be any nucleic acid

-29-

<220>
<221> UNSURE
<222> (21)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (22)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (361)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (369)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (407)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (427)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (479)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (482)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (535)
<223> May be any nucleic acid

<400> 14
gtncgaattt cggcacgaga nnttagacgc cttttcatgg aagctgggga atgtgggggc 60

cttggggaga ctgttcgaga acgtgcggtg gaggagtcca gtacacgatg agggaatgtg 120

acaacccagt cccaaagaat ggagggaagt actgtgaagg caaacgagtg cgctacagat 180

cctgtaacct tgaggactgt ccagacaata atggaaaaac ctttagagag gaacaatgtg 240

aagcacacaa cgagttttca aaagcttctt ttgggagtgg gcctgcggtg gaatggattc 300

-30-

ccaagtacgc tggcgtctca ccaaaggaca ggtgcaagtt catgttgcca agccaaaggc 360
 nttggctant tctttcgttt tgcagcccaa ggttgtagg tgggtantcc atgttaggcc 420
 cagattncac ctttgtctgt gtgcaaggac agtgtgttaa aagttggtg tgatccgcnt 480
 cntagattcc aaaaggagtt ttgttaatgt ggtgttttcn gggggaatgg tctantttta 540
 aa 542

<210> 15
 <211> 320
 <212> DNA
 <213> Unknown

<220>
 <223> Description of Unknown Organism:Unknown

<400> 15
 cagagaacat tcgccccact cttcaatgac ccatgctgaa aaagtgggga tagcattgaa 60
 agattccttc ttcttcttta cgaagtaggt gtatttaatt ttaggtcgaa gggcattgcc 120
 cacagtaaga acctggatgg tcaagggtc tttgagagg ctaaagctgc gaattctttc 180
 caatgccgca gaggagccgc tgtacctcaa gacaacacct ttgtacataa tgtcttgctc 240
 taagggtggac aaagtgtagt caccattaag aatatatgtg ccatcagcag ctttgatggc 300
 aagaaagctg ccttgttcc 320

<210> 16
 <211> 316
 <212> DNA
 <213> Eimeria tenella

<400> 16
 aatgccgaga cattaatgga cagcctgctt ccgagtgtgc aaaggaagtg aagccagcca 60
 gcaccagacc ttgtgcagac catccctgcc ccagtgga gctgggggag tggatcat 120
 gttctaagac ctgtgggaag gggtacaaa aaagaagctt gaagtgtctg tccatgatg 180
 gagggtgtt atctcatgag agctgtgatc ctttaaagaa acctaaacat tcatagact 240
 tttgcacaat ggcagaatgc agttaagtgg tttaagtgg gttagctttg agggcaaggc 300
 aaagtgagga agggct 316

-31-

<210> 17
<211> 383
<212> DNA
<213> *Caenorhabditis elegans*

<220>
<221> UNSURE
<222> (160)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (326)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (358)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (366)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (377)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (379)
<223> May be any nucleic acid

<400> .17
gtcgaccac gcgctccggat ggtactccat gtagcccaga ttccacctct gtctgtgtgc 60
aaggacagtg tgtaaaagct gggtgtgatc gcatcataga ctcaaaaag aagtttgata 120
aatgtggtgt ttgcggggga aatggatcta cttgtaaaaan aatatcagga tcagttacta 180
gtgcaaaacc tgggatatca tgatatcatc acaattccaa ctgggagcca ccaacatcga 240
agtgaacag cggaaccaga ggggatccag ggaacaatgg gcagctttct tgccatcaaa 300
gtgtgtggat ggcacatata ttcttnaatg gtgactacac tttgtccacc ttagaganag 360
acattntgtg acaaagngnt tgt 383

<210> 18
<211> 404
<212> DNA

-32-

<213> Crotalus atrox

<220>

<221> UNSURE

<222> (21)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (301)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (335)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (373)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (378)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (382)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (383)

<223> May be any nucleic acid

<400> 18

```

cccacgcgtc cgcccacggt nccgggactt gtgtgggtcc cagacatgtg atactcttgg 60
gatggctgat gttggaactg tgtgtgatcc gagcagaagc tgctccgtca tagaagatga 120
tggtttacaa gctgccttca ccacagccca tgaattaggc cacgtgttta acatgccaca 180
tgatggatgc aaagcagtgt gccagcctta aatgggtgtga accagggatt cccacatgat 240
ggcgtcaatg ctttccaacc tgggaccaca gccagccttg ggtcctcctt gcagtggcct 300
nacatggatt gacatcattt ctgggatgaa tggtncatgg gggaatgttt tgattggaca 360
agccttcaga atnccctnac annttcccag gggttctccc tggg                               404

```

<210> 19

<211> 152

-33-

<212> DNA
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (105)
 <223> May be any nucleic acid

<220>
 <221> UNSURE
 <222> (122)
 <223> May be any nucleic acid

<220>
 <221> UNSURE
 <222> (135)
 <223> May be any nucleic acid

<400> 19
 atcgtagaag atgaaaaatg gggcccagag gtgtccgaca atggggggct tacactgcgt 60
 aactttctgca actggcagcg gcgtttcaac cagcccagcg accgncaccc agagcactac 120
 gncacggcca tctnctcac cagacagaac tt 152

<210> 20
 <211> 4180
 <212> DNA
 <213> Unknown

<220>
 <223> Description of Unknown Organism:Unknown

<400> 20
 gcagctccga gctaggtgct atcgcaaggc cagagcgcac agcccggcgg agagagcaga 60
 tccttgctca gatcgagtca aatcgggcca aggcggagga cgaagagtcc aggctcctat 120
 tctggacttg ttcccagct cggggggcgc ttctaggtcc tgcagcagcc agcagtgcgg 180
 agccaccaac tcggtgctgg aatgaaaaaa ttcccgcgcg ccagtgcaga atctttctaa 240
 gtgacccgga gcttcgggtg ctagctctgc acgaactttc ccatcaaagt gatcgtgaat 300
 tttaagcatc aggagcaggc cagcgaagct ctacgcgtct aaacgtctat ccagaccaag 360
 agttctctgc ggtgcagggt gcggtgccat gcagccaaaa gtcccttttg gggtcacgca 420
 agcagaagcc ctgctccgac atgggggacg tcacgcgggc agcgagatct cggggctctc 480
 tgtccgcaca catgctgttg ctgctcctcg cttccataac aatgctgcta tgtgcgcggg 540
 gcgcaçacgg gcgccccacg gaggaagatg aggagctggg cctgccctcg ctggagcgcg 600

-34-

ccccgggcca cgattccacc accacacgcc ttcgtctgga cgcctttggc cagcagctac 660
atctgaagtt gcagccggac agcggtttct tggcgccctgg cttcaccctg cagactgtgg 720
ggcgcagtc ccgggtccgag gcacaacatc tggacccac cggggacctg gctcactgct 780
tctactctgg cacggtgaac ggtgatcccg gctctgccgc agccctcagc ctctgtgaag 840
gtgtgctgg tgccttctac ctacaaggag aggagttctt cattcagcca gcgcctggag 900
tggccaccga gcgcctggcc cctgccgtgc ccgaggagga gtcacccga cggccgcagt 960
tccacatcct gaggcgaagg cggcggggca gtggcgccgc caagtgcggc gtcattggacg 1020
acgagaccct gcccaaccagc gactcgcgac ccgagagcca gaacaccgg aaccagtggc 1080
ctgtgcggga cccacgcct caggacgcgg gaaagccatc aggaccagga agcataagga 1140
agaagcgatt tgtgtccagc ccccgttatg tggaaacat gctcgtagct gaccagtcca 1200
tggccgactt ccacggcagc ggtctaaagc attacctct aaccctgttc tcggtggcag 1260
ccaggtttta caagcatccc agcattagga attcaattag cctgggtgtg gtgaagatct 1320
tggcatata cgaggagcag aagggaccag aagttacctc caatgcagct ctcacccttc 1380
ggaatttctg cagctggcag aaacaacaca acagccccag tgaccgggat ccagagcact 1440
atgacactgc aattctgttc accagacagg atttatgtgg ctcccacag tgtgacactc 1500
tcggaatggc agatgttga accgtatgtg accccagcag gagctgctca gtcatagaag 1560
atgatggttt gcaagccgcc ttcaccacag cccatgaatt gggccatgtg tttaacatgc 1620
cgcacgatga tgctaagcac tgtgccagct tgaatggtgt gagtggcgat tctcatctga 1680
tggcctcgat gctctccagc ttagaccata gccagccctg gtcaccttgc agtgcctaca 1740
tggtcacgtc cttcctagat aatggacacg gggaatgttt gatggacaag cccagaatc 1800
caatcaagct cccttctgat cttcccggtc ccttgtacga tgccaaccgc cagtgtcagt 1860
ttacattcgg agaggaatcc aagcactgcc ctgatgcagc cagcacatgt actaccctgt 1920
ggtgcactgg cacctccggt ggcttactgg tgtgccaaac aaaacacttc ccttgggcag 1980
atggcaccag ctgtggagaa ggggaagtgg gtgtcagtg caagtgcgtg aacaagacag 2040
acatgaagca ttttgctact cctgttcatg gaagctgggg accatgggga ccgtggggag 2100

-35-

actgctcaag aacctgtggt ggtggagttc aatacacaat gagagaatgt gacaacccag 2160
tocc aaagaa cggagggaag tactgtgaag gcaaacgagt ccgctacagg tcctgtaaca 2220
tcgaggactg tccagacaat aacggaaaaa cgttcagaga ggagcagtgc gaggcgcaca 2280
atgagttttc caaagcttcc tttgggaatg agccactgt agagtggaca cccaagtacg 2340
ccggcgtctc gccaaaggac aggtgcaagc tcacctgtga agccaaaggc attggctact 2400
ttttcgtctt acagcccaag gttgtagatg gcactccctg tagtccagac tctacctctg 2460
tctgtgtgca agggcagtgt gtgaaagctg gctgtgatcg catcatagac tccaaaaaga 2520
agtttgataa gtgtggcggt tgtggaggaa acggttccac atgcaagaag atgtcaggaa 2580
tagtcactag tacaagacct gggatatcatg acattgtcac aattcctgct ggagccacca 2640
acattgaagt gaaacatcgg aatcaaaggg ggtccagaaa caatggcagc tttctggcta 2700
ttagagccgc tgatggtacc tatattctga atggaaactt cactctgtcc aactagagc 2760
aagacctcac ctacaaaggt actgtcttaa ggtacagtgg ttcctcggct gcgctggaaa 2820
gaatccgcag ctttagtcca ctcaaagaac ccttaacct ccaggttctt atggtaggcc 2880
atgctctccg acccaaaatt aaattcacct actttatgaa gaagaagaca gagtcattca 2940
acgccattcc cacatcttct gagtgggtga ttgaagagtg gggggagtgc tccaagacat 3000
gcggctcagg ttggcagaga agagttagtc agtgcagaga cattaacgga caccctgctt 3060
ccgaatgtgc aaaggaagtg aagccagcca gtaccagacc ttgtgcagac cttccttgcc 3120
cacactggca ggtgggggat tggtcacat gttccaaaac ttgcgggaag ggttacaaga 3180
agagaacctt gaaatgtgtg tcccacgatg ggggcgtgtt atcaaatgag agctgtgatc 3240
ctttgaagaa gccaaagcat tacattgact ttgacact gacacagtgc agttaagagg 3300
cgtagagga caaggtagcg tggggagggg ctgatacact gagtgcaaga gtactggagg 3360
gatccagtga gtcaaaccag taagcagtga ggtgtggcaa ggaggtgtgt gtaggggata 3420
catagcaaaag gaggtagatc aggacactac cctgccagtt acattctgat aaggtagtta 3480
atgaggcaca gtagcatctg aaagaccata cagagcacta aggagcccca aagcactatt 3540
agtatctctt ttcttatatc tatcgcccaa ataattttca gagtctggca gaagccctgt 3600
tgcactgtac taactagata cttcttatca caaagattgg gaaaggcaaa gcagaaagat 3660

-36-

ggtaagactg ggtttcaaac aaggcttggg ttcaatcact ggaggcaagg aggaggggac 3720
 aaacaagatc attattcgaa gtcgctgggt gctgtgggtt tacggaagg t gatgcatca 3780
 ttctatcaa cagtgaagaa ttcagcttgt tcaacgtgac agaaaggctc atctccgtga 3840
 aagagctcct gatttcttct tacaccatct cagttcttaa ctatagttca t gttgaggta 3900
 gaaacaattc atctatttat aaaatgtaca ttggaaaaaa aaagtgaagt ttatgaggta 3960
 cacataaaaa ctgaaggaaa caatgagcaa catgcctcct gctttgcttc ctctgaggt 4020
 aaacctgcct ggggattgag gttgtttaag attatccatg gctcacaaga ggcagtaaaa 4080
 taatacatgt tgtgccagag ttagaatggg gtatagagat cagggtccca tgagatgggg 4140
 aacatggtga tcactcatct cacatgggag gctgctgcag 4180

<210> 21

<211> 9248

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 21

gcagctccga gctaggtgct atcgcaaggc cagagcgcac agcccggcgg agagagcaga 60
 tccttgctca gatcgagtca aatcggggcc aaggcggagg acgaagagtc caggctccta 120
 ttctggactt gttccccagc tccgggggag cttctaggtc ctgcagcagc caggagtgcg 180
 gagccacca ctcgggtgctg gaatgaaaaa attcccgcgc gccagtgcag aatctttcta 240
 agtgaccggg agcttcgggt gctagctctg cacgaacttt cccatcaaag tgatcgtgaa 300
 ttttaagcat caggagcagg ccagcgaagc tctacgcgtc taaacgtcta tccagaccaa 360
 gagttctctg cgggtgcaggg tgcgggtgcca tgcagccaaa agtccctttg gggtcacgca 420
 agcagaagcc ctgctccgac atgggggacg tccagcgggc agcgagatct cggggctctc 480
 tgtccgcaca catgctgttg ctgctcctcg cttccataac aatgctgcta tgtgcgcggg 540
 ggcacacggg ggcgccacg gaggaagatg aggagctggg cctgccctcg ctggagcgcg 600
 cccggggcca cgattccacc accacacgcc ttcgtctgga cgcctttggc cagcagctac 660
 atctgaagtt gcagccggac agcggtttct tggcgcctgg cttcaccctg cagactgtgg 720

-37-

ggcgagctcc cgggtccgag gcacaacatc tggaccccccac cggggacctg gctcactgct 780
tctactctgg cacggtgaac ggtgatcccg gctctgccgc agccctcagc ctctgtgaag 840
gtgtgctggg tgccttctac ctacaaggag aggagtctt cattcagcca gcgcctggag 900
tggccaccga gcgcctggcc cctgccgtgc ccgaggagga gtcacccgca cggccgcagt 960
tccacatcct gaggcgaagg cggcggggca gtggcggcgc caagtgcggc gtcattggacg 1020
acgagaccct gcccaaccagc gactcgcgac ccgagagcca gaacaccgga aaccagtggc 1080
ctgtgcggga cccacgcct caggacgcgg gaaagccatc aggtataaga gtgaccccca 1140
tctctcagtc ttacgaggc gtgacttggg gtcacactcc agatgcctc taaatgcga 1200
tgactcagac ttgcagtga ttgaagtctt gggctgtgac cttcccgctc ccccccccc 1260
aaaaaagtg tgaccatact ctgctagaac acttatttgc ccgaatagtt aataatttga 1320
gaaagagaga aagaatcggg ggtcctgtag ataagggcta agcgtttcct ccgcgaagcc 1380
aataaccgga ctccttacac tggagaatct ctctccatcc ctttaatgcc tttagtgaat 1440
gtatgagttc actttaacta ggttgtagtt tcgcgtgag ttttgtaacg tcagtccgtg 1500
tgagcacgta gcgctcaaag gagggcggag tagaggagcc atggtgacct ggatgtgcgt 1560
tcaggagcct gggcaacggc agtgggtgatc tcatttctgt ggccctccgt ctgtcccctt 1620
ccccatttg aaaagctgac ccgatggct ggtggctccg ttgggcccct ctgcagaacc 1680
tgcttgggag gtctttgctt ggttcgcccc gcctccacgc gcctcctacc tcggcctcgt 1740
tgctcgcact ccctctcccg gcagagggtg gactccccag cgctgtggaa tgttagcctg 1800
gactgatcct ccctgctaca cattcgcctg actctgccgt gttcagtctc taccagccag 1860
ttagttcttt ttaatcattc aaatttcttt ttgccctttt ctgatttctt ccctcttttc 1920
cgacttgtcc ctaggagctg gtattcatat cctactttac gatttctctg accgctgagt 1980
ctcagcagcc cgaaaaaggc ctttttccaa attggcaacc ctgggttgag aaaggaactt 2040
attccccccg gggcactggg agtgagagga ggcaggaaaa cactgctggg cagagtgggt 2100
ggtcctagtg cccggaactg gatcaagcag agaaccacct gggaccctt gaatgagaga 2160
gctgagcctt acagactgag actcctcaag cccacacctt tggctgagct cccgcacctg 2220
cccatgcct tcacgtgga gctggatgat ctcatcggg atttcagccc tggcttcaat 2280

-38-

agtgaagggtg tgactcagggtg cgtccgcctg cttctcttgc caagttttta ctacagctgg 2340
gtagaaatga tagccatact gcctcactca ggctgtggag tcttcaaaga ccacaaaaga 2400
aatctgcgga cacatatata gacagtttga tcactctgtt gcttgctttg ttttgttttg 2460
ttttgtctta tttaaagcaa aagaaaaaag acttaaaaaat aactcacagt ttttagaaga 2520
tgcaaatatt tgttttatct ttgttccagg tgtatttcag ttttatttac tttgactagg 2580
ttgactttcc taatatatccc cgagaagggtc actattagga gaaggactgc ccatgagcaa 2640
acttcctttt cttttttacag gaccaggaag cataaggaag aagcgatttg tgtccagccc 2700
ccgttatgtg gaaaccatgc tcgtgggtga ccagtccatg gccgacttcc acggcagcgg 2760
tctaaagcat taccttctaa ccctgttctc ggtggcagcc aggtttttaca agcatcccag 2820
cattaggaat tcaattagcc tgggtgggtg gaagatcttg gtcatatatg aggagcagaa 2880
gggaccagaa gttacctcca atgcagctct cacccttcgg aatttctgca actggcagaa 2940
acaacacaac agccccagtg accgggatcc agagcactat gacactgcaa ttctgttcac 3000
cagacaggta agacaggagc ttatcaacca tttcatcaac tcaactcggg ggtcagcctt 3060
gtgttggtg ggtgagagg gtgggggtgt ggcggagagg aaaccagaa ggggatgaca 3120
tttgaaatgt aaacaaaata accaattaaa aaaaaaaggc atctcatctg tattgcctca 3180
tttcctttcg gttataggct agctcaatct gtcttgctta tttctatctt aaacttcac 3240
atctcaagtt ctacagttct attttaaaag cattacaggg aatcttgctt agagtcatgc 3300
cttcaagccc agcaataatg aatggacagg cttcaaagt catgtgaaga cagcccaac 3360
tgaagagcta agtatcactc tctcctactt aaaagggtt tcccttgctt cttttagga 3420
tttatgtggc tcccacacgt gtgacactct cgggatggca gatgttgga ctgtatgtga 3480
ccccagcagg agctgctcag tcatagaaga tgatggtttg caagccgctt tcaccacagc 3540
ccacgaattg ggtaagtccg cttcagagta caagttaagc ccaaatgcat ggatacaacc 3600
caataagtca atctgatgtg acgagagaga aaacatctca gactatgttg ctacctcagc 3660
caccagcaat tttagaagggt gtaggtata tttccacga tttcaagtat ggtcttacta 3720
ggacaggaga aagtgttaca aacatttgaa cgttgacatt tttatacttg ccctgatcaa 3780
agtgaqtatg agccccaata cagggtgtct aataagagag ccattgagcc tcaactcaata 3840

-39-

atacagctga atgtccttct tgtctgcttc ccaggccatg tgtttaacat gccgcacgat 3900
gatgctaagc actgtgccag cttgaatggg gtgactggcg attctcatct gatggcctcg 3960
atgctctcca gcttagacca tagccagccc tggtcacctt gcagtgccta catggtcacg 4020
tccttcctag ataatggaca cggtaagatg acagctcttc tttccagatg gtgttcaacc 4080
ttccttgtgt agggctctct ctggctaagt gagctccatg gctcttgctc atttccctc 4140
cttcagagtt ttctctggca ggatcataag tagtagatct ttacctccat tgcactctgc 4200
tcccaaagtc cattcattca taaacaataa cttctcgcca ttgtaaaatc agaagtcccc 4260
tattgaggat aacgtctcga taaaaatcta aagttcccta gcattgattt tccccaaaat 4320
gcatgatttc accaaacatg tattaataat tgcctctttt ttcttttctt tttttttttt 4380
tattatttta ggggaatggt tgatggacaa gcccagaat ccaatcaagc tcccttctga 4440
tcttcccggt acctgtacg atgccaaccg ccagtgtcag ttacattcg gagaggaatc 4500
caagcactgc cctgatgcag ccagcacatg tactaccctg tggtgactg gcacctccgg 4560
tggcttactg gtgtgccaaa caaaacactt cccttgggca gatggcacca gctgtggaga 4620
agggaaagtgg tgtgtcagtg gcaagtgcgt gaacaagaca gacatgaagc attttgctgt 4680
gagttttccc aatgaaacat atccgtttgc aactcagggg tgagaagggc aaagtgatgg 4740
tttagttcct ttcttagaca aactcctcta cctgtgtcct gtagtgggac tatgagatgg 4800
tagcgtattt tgagaattga ttgtctgttt tacatttttc tctgattccc taaaatgtct 4860
ttatagttct aacactgata tctgtatctc catttagact cctgttcatg gaagctgggg 4920
accatgggga ccgtggggag actgctcaag aacctgtggg ggtggagttc aatacacaat 4980
gagagaatgt gacaacccag tcccaaagaa cggaggggaag tactgtgaag gcaaacgagt 5040
ccgctacagg tcctgtaaca tcgaggactg tccagacaat aacggtgagt catactggac 5100
ttcagctctc agaaaccggg caaaggcggc gtgccacaac atgtggttgg aagttggaaa 5160
ctgggaacat catcgccgtc gttctctttt caggaaaaac gttcagagag gagcagtgcg 5220
aggcgacaaa tgagttttcc aaagcttcct ttgggaatga gccactgta gagtggacac 5280
ccaagtacgc cggcgtctcg ccaaaggaca ggtgcaagct cacctgtgaa gccaaaggca 5340
ttggctactt tttcgtctta cagcccaagg taggtgcttt tacacttgaa tctttgcaaa 5400

-40-

ggagcctcag ctgggcttgc tgccatgcc aacaaatgtt tgggctgtct ttacctattg 5460
atctgtgttc cgttttgaat ttggaatact tctaaatgca ggaacaactc cttgctttgg 5520
gatttgttgt tgccttctgt tgggaaggaa gcttaaactc agctagcact taaaagagtc 5580
ttgcatgtgt ttaatatgtc ttctctatcc ccaaagaatg gccctttgaa aactcaagag 5640
ccctctctgt ataactaggt ttcacataca aaaattcatg gttagataaa ttatatatta 5700
acatggcacc caggagtttt agaaagtagt ccaaagtact tgttactggg tacctagcag 5760
ccgcacatac gagcacacta actaaggtaa gagtttgaga attaaaaatt catcgttgga 5820
acatgtactt tgaccaaaga gactcgccat ttcttttggg gttttgcaga aaggataaat 5880
cctgctttga agaagaaaat tgaatgaaat ttgcttaagc ttgtcatgta ttcttagcat 5940
tataagatag caaactatat ccaagttgtg gatgaagtat ttagcaagtg atttataaag 6000
taccttcaac tacagcatat tattctaggt actgaccatg gaacaataat cagtgtgaca 6060
gtgaaccctg cttccattga cctaggccag caaatatata aaatcaagac atttataagc 6120
cttacagata gctatatgaa ctgttgaaaa agccaaaatg aaagtgaaca tgtggcacgt 6180
gacaaggaga ctacttgtag cctgggagga gagcattccc agttgccatc acatcagatg 6240
tttaaccacc atggtgcatg ttgtctccac aggttgtaga tggcactccc tgtagtccag 6300
actctacctc tgtctgtgtg caagggcagt gtgtgaaagc tggctgtgat cgcacatag 6360
actccaaaaa gaagtttgat aagtgtggcg tttgtggagg aaacggttcc acatgcaaga 6420
agatgtcagg aatagtcact agtacaaggt gagtttcaga acgctcactt ctgcagtaga 6480
cacgctgtgt tgctcagttg gtccctagca tctacaagac cttgggttca atccgcatgc 6540
atgtacctgt agtcccagtg tatgggagac agagacaagt gtgacaagac ggtcagatgt 6600
tcaggtcac tttgctacat agtgactttc agttcacctt ggggaacatg aaaaacctga 6660
ctggaaacac aaacacacac aaaacaatta acccaggtac ttcattgtaat cccagtgttc 6720
agtaggctga cttgggagga tggttgctat aaggcctagg ttagcttggt ctacataatg 6780
agttccagta taacctggcc cacaagtga ccctaaagt aattaatcga cacatgaaac 6840
aaaacacatg ctttggagac cctgtaattt tgatatacga tttttagga ctaaggaaaa 6900
gtcacattta aaagaattgc ctatttttta agcaatgtga ttgattaact cattgaaaga 6960

-41-

catatacctg ttttctttgt ccacagacct gggatatcatg acattgtcac aattcctgct 7020
ggagccacca acattgaagt gaaacatcgg aatcaaaggg ggtccagaaa caatggcagc 7080
tttctggcta ttagagccgc tgatggtacc tatattctga atggaaactt cactctgtcc 7140
aactagagc aagacctcac ctacaaaggt actgtcttaa ggtacagtgg ttcctcggct 7200
gcgctggaga gaatccgag ctttagtcca ctcaaagaac ccttaaccat ccaggttctt 7260
atggtaggcc atgctctccg acccaaaatt aaattcacct actttatgaa gaagaagaca 7320
gagtcattca acgccattcc cacatcttct gagtgggtga ttgaagagtg gggggagtgc 7380
tcaaagacat gcggctcagg ttggcagaga agagtagtgc agtgcagaga cattaatgga 7440
caccctgctt ccgaatgtgc aaaggaagtg aagccagcca gtaccagacc ttgtgcagac 7500
cttccttgcc cacactggca ggtgggggat tggtcacat gttccaaaac ttgcgggaag 7560
ggttacaaga agagaacctt gaaatgtgtg tcccacgatg ggggcgtgtt atcaaatgag 7620
agctgtgatc ctttgaagaa gccaaagcat tacattgact tttgcacact gacacagtgc 7680
agttaagagg cgtagagga caaggtagcg tggggagggg ctgatacact gagtgtgga 7740
gggatccagt gagtcaaacc agtaagcagt gaggtgtggc aaggaggtgt gtgtagggga 7800
tacatagcaa aggaggtaga tcaggacact accctgccag ttacattctg ataaggtagt 7860
taatgaggca cagtagcatc tgaaagacca tacagagcac taaggagccc caaagcacta 7920
ttagtatctc ttttcttata tctatcgccc aaataatctt cagagtctgg cagaagccct 7980
gttgactgt actgactaga tacttcttat cacaaagatt gggaaaggca aagcagaaaag 8040
atggtaaagac tgggtttcaa acaaggcttg gtttctatca ctggaggcaa ggaggagggg 8100
acaaacaaga tcattattcg aagtcgctgg ttgctgtggt ttacggaag gttgatgcat 8160
cattcctatc aacagtgaag agttcagctt gttcaactg acagaaaggc tcctctccgt 8220
gaaagagctc ctgatttctt cttacacat ctgattctt aactataatt catgttgagg 8280
tagaaacaat tcctctatct ataaaatgta cattggaaaa aaaaaagtga agtttatgag 8340
gtacacataa aaactgaagg aaacaatgag caacatgcct cctgctttgc ttcctctga 8400
ggtaaacctg cctggggatt gaggttgttt aagattatcc atggctcaca agaggcagta 8460
aaataataca tgttgtgcca gagttagaat ggggtataga gatcagggtc ccatgagatg 8520

-42-

gggaacatgg tgatcactca tctcacatgg gaggctgctg cagggtagca ggtccactcc 8580
tggcagctgg tccaacagtc gtatcctggt gaatgtctgt tcagctcttc tactgagaga 8640
gaatatgact gtttccatat gtatatgtat atagtaaaat atgttactat gaattgcatg 8700
tactttataa gtattggtgt gtctgttcct tctaagaagg actatagttt ataataaatg 8760
cctataataa catatttatt ttatacatt tatttctaata gataaaacct ttaagttata 8820
tcgcttttgt aaaagtgcac ataaaaatag agtatttata caatatatgt taactagaaa 8880
taataaaaga acacttttga atgtgtatgc ctattttctg gagggtgatt aacttctggg 8940
caagaaatct gatgagacac aaacattgga cttcaagaca gttttaaaat ttgggtaaat 9000
gaactgtatt tcctgtttat agacgtacta ataaaaaga agttgatgat gtcttttagtg 9060
gtaagattgt tactaatgtg gttggcaaata tgctgtaaag agccagatag taagcattta 9120
tggcattgta ggctatcttt cctgccacaa ccatgtgaca gtgagtgtt tgtaggactg 9180
agagcagcca taaatgacat gttaatgata aactgtggct gtgctttaat aaaactttat 9240
ttacaaaa 9248

<210> 22

<211> 5722

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 22

ggacgcacag gcattccccg cgcctccca gccctcgccg cctcgccac cgctccccgc 60
cgccgcgctc cggtacacac aggatccctg ctgggcacca acagctccac catggggctg 120
gcctggggac taggcgtcct gttcctgatg catgtgtgtg gcaccaaccg cattccagag 180
tctggcgag acaacagcgt gtttgacatc ttgaaactca ccggggccgc ccgcaagggg 240
tctgggcgcc gactggtgaa gggccccgac ccttcagcc cagctttccg catcgaggat 300
gccaacctga tccccctgt gcctgatgac aagttccaag acctggtgga tgctgtgcgg 360
gcagaaaagg gtttctcct tctggcatcc ctgaggcaga tgaagaagac ccggggcacg 420
ctgctggccc tggagcgaa agaccactct ggccaggtct tcagcgtggt gtccaatggc 480

-43-

aaggcgggca ccttggacct cagcctgacc gtccaaggaa agcagcacgt ggtgtctgtg 540
gaagaagctc tcctggcaac cggccagtgg aagagcatca cctgtttgt gcaggaagac 600
agggcccagc tgtacatcga ctgtgaaaag atggagaatg ctgagttgga cgtccccatc 660
caaagcgtct tcaccagaga cctggccagc atcgccagac tccgcatcgc aaaggggggc 720
gtcaatgaca atttccaggg ggtgctgcag aatgtgaggt ttgtctttgg aaccacacca 780
gaagacatcc tcaggaacaa aggctgctcc agctctacca gtgtcctcct cacccttgac 840
aacaocgtgg tgaatgggtc cagccctgcc atccgacta actacattgg ccacaagaca 900
aaggacttgc aagccatctg cggcatctcc tgtgatgagc tgtccagcat ggtcctggaa 960
ctcaggggcc tgcgcaccat tgtgaccacg ctgcaggaca gcatccgcaa agtgactgaa 1020
gagaacaaag agttggccaa tgagctgagg cggcctcccc tatgctatca caacggagtt 1080
cagtacagaa ataacgagga atggactgtt gatagctgca ctgagtgta ctgtcagaac 1140
tcagttacca tctgcaaaaa ggtgtcctgc cccatcatgc cctgtccaa tgccacagtt 1200
cctgatggag aatgctgtcc tcgctgttgg ccagcgact ctgcggacga tggctggtct 1260
ccatggtccg agtggacctc ctgttctacg agctgtggca atggaattca gcagcgcggc 1320
cgctcctgcg atagcctcaa caaccgatgt gagggtcctt cggctccagac acggacctgc 1380
cacattcagg agtgtgacaa aagatttaaa caggatggtg gctggagcca ctgggtccccg 1440
tggtcatctt gttctgtgac atgtggtgat ggtgtgatca caaggatccg gctctgcaac 1500
tctcccagcc ccagatgaa tgggaaaccc tgtgaaggcg aagcgcgga gaccaaagcc 1560
tgcaagaaag acgcctgccc catcaatgga ggctggggtc cttggtcacc atgggacatc 1620
tggtctgtca cctgtggagg aggggtacag aaacgtagtc gtctctgcaa caaccccgca 1680
ccccagtttg gaggcaagga ctgcgttggg gatgtaacag aaaaccagat ctgcaacaag 1740
caggactgtc caattgatgg atgcctgtcc aatccctgct ttgccggcgt gaagtgtact 1800
agctaccctg atggcagctg gaaatgtggt gcttgtcccc ctggttacag tggaaatggc 1860
atccagtgca cagatgttga tgagtgcaa gaagtgcctg atgcctgctt caaccacaat 1920
ggagagcacc ggtgtgagaa cacggacccc ggctacaact gcctgccctg ccccccacgc 1980
ttcaccgggt cacagccctt cggccagggg gtcgaacatg ccacggccaa caaacagggtg 2040

-44-

tgaagcccc gtaaccctg cacggatggg acccacgact gcaacaagaa cgccaagtgc 2100
aactacctgg gccactatag cgaccccatg taccgctgcg agtgcaagcc tggctacgct 2160
ggcaatggca tcatctgcgg ggaggacaca gacctggatg gctggcccaa tgagaacctg 2220
gtgtgcgtgg ccaatgcgac ttaccactgc aaaaaggata attgccccaa ccttcccaac 2280
tcagggcagg aagactatga caaggatgga attggtgatg cctgtgatga tgacgatgac 2340
aatgataaaa ttccagatga cagggacaac tgtccattcc attacaacc agctcagtat 2400
gactatgaca gagatgatgt gggagaccgc tgtgacaact gtccctacaa ccacaacca 2460
gatcaggcag acacagacaa caatggggaa ggagacgcct gtgctgcaga cattgatgga 2520
gacggtatcc tcaatgaacg ggacaactgc cagtacgtct acaatgtgga ccagagagac 2580
actgatatgg atggggttgg agatcagtgt gacaattgcc ccttggaaca caatccggat 2640
cagctggact ctgactcaga ccgcattgga gatacctgtg acaacaatca ggatattgat 2700
gaagatggcc accagaacaa tctggacaac tgtccctatg tgcccaatgc caaccaggct 2760
gaccatgaca aagatggcaa gggagatgcc tgtgaccacg atgatgacaa cgatggcatt 2820
cctgatgaca aggacaactg cagactcgtg cccaatcccg accagaagga ctctgacggc 2880
gatggtcgag gtgatgcctg caaagatgat tttgaccatg acagtgtgcc agacatcgat 2940
gacatctgtc ctgagaatgt tgacatcagt gagaccgatt tccgccgatt ccagatgatt 3000
cctctggacc ccaaaggac atcccaaat gaccctaact gggttgtacg ccatcagggt 3060
aaagaactcg tccagactgt caactgtgat cctggactcg ctgtaggtta tgatgagttt 3120
aatgctgtgg acttcagtgg caccttcttc atcaacaccg aaaggacga tgactatgct 3180
ggatttgtct ttggctacca gtccagcagc cgcttttatg ttgtgatgtg gaagcaagtc 3240
accagtcct actgggacac caacccacg agggctcagg gatactcggg cctttctgtg 3300
aaagttgtaa actccaccac agggcctggc gagcacctgc ggaacgccct gtggcacaca 3360
ggaaacaccc ctggccagggt gcgcaccctg tggcatgacc ctcgtcacat aggctggaaa 3420
gatttcaccg cctacagatg gcgtctcagc cacaggccaa agacgggttt cattagagtg 3480
gtgatgtatg aagggaagaa aatcatggct gactcaggac ccattctatga taaaacctat 3540
gctggtggtg gactaggggt gtttgtcttc tctcaagaaa tgggtgttctt ctctgacctg 3600

-45-

aaatacgaat gtagagatcc ctaatcatca aattgttgat tgaaagactg atcataaacc 3660
aatgctggta ttgcaccttc tggaactatg ggcttgagaa aacccccagg atcacttctc 3720
cttggcttcc ttcttttctg tgcttgcac agtgtggact cctagaacgt gcgacctgcc 3780
tcaagaaaat gcagttttca aaaacagact catcagcatt cagcctccaa tgaataagac 3840
atcttccaag catataaaca attgctttgg ttctcttttg aaaaagcatc tacttgcttc 3900
agttgggaag gtgcccattc cactctgcct ttgtcacaga gcagggtgct attgtgaggc 3960
catctctgag cagtggactc aaaagcattt tcaggcatgt cagagaaggg aggactcact 4020
agaattagca aacaaaacca ccctgacatc ctccttcagg aacacgggga gcagaggcca 4080
aagcactaag gggaggggcg atacccgaga cgattgtatg aagaaaatat ggaggaactg 4140
ttacatgttc ggtactaagt ctttttcagg ggattgaaag actattgctg gatttcatga 4200
tgctgactgg cgttagctga ttaacccatg taaataggca cttaaataga agcaggaaaag 4260
ggagacaaaag actggcttct ggacttcctc cctgatcccc acccttactc atcaccttgc 4320
agtggccaga attaggggaat cagaatcaaa ccagtgtgaa gcagtgtgctg ctgccattgc 4380
ctggtcacat tgaaatttgt ggcttcattc tagatgtagc ttgtgcagat gtagcaggaa 4440
aataggaaaa cctaccatct cagtgcacac cagctgcctc ccaaaggagg ggcagccgtg 4500
cttatatttt tatggttaca atggcacaaa attattatca acctaactaa aacattcctt 4560
ttctcttttt tccgtaatta ctaggtagt ttctaattct ctcttttga agtatgattt 4620
ttttaaagtc ttacgatgt aaaatattta ttttttactt attctggaag atctggctga 4680
aggattattc atggaacagg aagaagcgtg aagactatcc atgtcatctt tgttgagagt 4740
cttcgtgact gtaagattgt aaatacagat tttttattaa ctctgttctg cctggaaatt 4800
taggcttcat acggaaagtg ttgagagca agtagttgac atttatcagc aaatctcttg 4860
caagaacagc acaaggaaaa tcagtctaata agctgctct gcccttctg ctgagagtgg 4920
atgttatggg attccttttt tctctgtttt atcttttcaa gtggaattag ttggttatcc 4980
atttgcaaat gttttaaatt gcaaagaaag ccatgaggtc ttcaatactg ttttacccca 5040
tcccttgtgc atatttccag ggagaaggaa agcatataca cttttttctt tcatttttcc 5100
aaaagagaaa aaaatgacaa aaggtgaaac ttacatacaa atattacctc atttgttgtg 5160

-46-

tgactgagta aagaattttt ggatcaagcg gaaagagttt aagtgtctaa caaacttaaa 5220
gctactgtag tacctaaaaa gtcagtgttg tacatagcat aaaaactctg cagagaagta 5280
ttccaataa ggaaatagca ttgaaatgtt aaatacaatt totgaaagtt atgttttttt 5340
tctatcatct ggtataccat tgetttattt ttataaatta ttttctcatt gccattggaa 5400
tagaatattc agattgtgta gatatgctat ttataaatt tatcaggaaa tactgcctgt 5460
agagttagta tttctatttt tatataatgt ttgcacactg aattgaagaa ttgttggttt 5520
tttctttttt ttgttttttt tttttttttt tttttttttg cttttgacct cccattttta 5580
ctatttgcca ataccttttt ctaggaatgt gctttttttt gtacacattt ttatccattt 5640
tacattctaa agcagtgtaa gttgtatatt actgtttctt atgtacaagg aacaacaata 5700
aatcatatgg aaatttatat tt 5722

<210> 23

<211> 42521

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 23

gatcgttttc cagacatttt tgttctctgt tcatttcctt atcgatttca aaaagttatc 60
acaaatgacc ttctctatct gtctgcgtct cttttaactc tcaccgtttg ggacctttca 120
aatagttttt cgctatcaaa tctaaacatt agttgcgttg actcgacatt tgaccctca 180
ctatcatctc cagttctctt ttttgttaca ctttagcagt ggcagcagag agcaagtagg 240
tggagccaaa gtgtgcgcca ttcatcgga aaaatttgtt tcttcatcaa attttgggca 300
atttactcgg gatttgcgtt aatttgaaa caaaaattca aattcctgcc aattgttttg 360
tttgcttttt ttcttttttt ttgctctc ccatctctca tcaaattgct cttttttcga 420
ttctaacata tcagccatct tcagagtgtg tcaactaacc ccatTTTTat tcaaggttag 480
tgatatagta tctaactac agacgtcaca ccatgaggtt gctgctcttc tcggcagccc 540
ttcttctgtg ctccgtccca acgtgggcct tctctctgtc atcattcttc ggaagcgatg 600
ttgcacaagt aagcaagctc tcctatacct agaattctgt aaattgaaaa ctctaatttc 660

-47-

cagaagccat accttcatcc aaactcccca ccggagcgtg acccggcgag ttccagaatg 720
aagagacagg catatcaagt gtacgttgat ggagatgttt ccgttactgt tgacaagtct 780
ggacaaaagg aaaccggcaa ctggggacca tgggtgcccg agaacgagtg ctcacgttcg 840
tgtggtggag gagttcaact cgagaagaga cagtgcaggt tcgtggactt ttcatttttt 900
aggaatttc ctagacgttc taaaagctta ttttcaaaaa ttttggtttc ctgatcttca 960
tgcctttatg aacgtggtga aagatcaacc taggctagcc tgtgacatac attttttgaa 1020
gcagatccaa ctttatcaag agccatcgaa ttctcgtttt aaagtgtttt ttttttctga 1080
taactttttt ctaatagctt taccattttt tatgtcaaga ctgaaagcaa tgaatcacia 1140
gaggctatct acgtttgttt ttgaagctct gtaggaatca tcttaaaaaa ttaagtaaag 1200
taatggagat gaaattctaa ttttttaaaa tcataatcat tactttctgt attatcttca 1260
agttcaaaact tttcaaacgg ttattctcaa gaaactcaca tagaatttta acaatttcct 1320
ctatctatct cttgcaagca acccaccgaa ctcaaactct atccaaacta aacttttagt 1380
ggtgactgca ctggagcttc agtccgtac atctcgtgta acttgaacgc atgcgagtct 1440
ggtactgatt tccgtgctga gcaatgctcc aaattcaacg atgaggctct tgatggaaac 1500
taccacaagt ggactccata caagggaaag aacaagtaag ttaactttct tcaagatgtt 1560
tttctaattt tcgagttttc aggtgcgagc tcgtctgtaa gccagaatct ggaaacttct 1620
actacaagtg ggctgataag gttgttgatg gaaccaagtg cgactccaag agcaacgata 1680
tctgtgttga tggggaatgt cttccagttg gatgtgacgg aaagcttgga tcttgtaagt 1740
ttaaaattta attcaaaatc ttcatttcat gccgaatatt tcagctctca aattcgacia 1800
gtgcggaaag tgcgatggag atggttctac ctgcaagact attgaaggac gtttcgatga 1860
gcgcaatctc tctccaggat accatgatat tatcaaactt ccagaaggag ccaccaacat 1920
taagattcag gaagccagaa agagcaccaa caacttggct ctgaagaacg gttccgatca 1980
cttttatctg aatggaaatg gattgatcca agttgagaag gaggttgaag tcggaggaac 2040
tatcttcgtt tacgatgacg ctgaaccaga aactctcagt gctcaaggac cactctccga 2100
ggagctcacc gttgctcttc tcttcagaaa gggaagccgt gatactgcta tcaagtacga 2160
gttctctatt ccacttgagg aggaagtga ctacatgtac aagtttgaca actggactcc 2220

-48-

gtgctctgta tcatgcgga aggggtgttca aaccgtaat ctctactgta ttgatggaaa 2280
gaacaaggga cgcgttgagg atgatctctg cgaggagaac aatgccacaa agccagagtt 2340
cgaaaagagc tgtgaaactg ttgactgtga agccgaatgg ttcactggag actgggaatc 2400
ttgctcatcc acctgcgag atcaaggaca gcaataccgt gtcgtctact gccatcaagt 2460
attogctaac ggacgtcgtg ttaccgttga ggatggaaac tgcaccgttg agagaccacc 2520
agtaaagcag acttgcaatc ggtaagttga ttttataaat gcataaacia ctctgtgaat 2580
ctatttgttt atgcgatgct atccatata attaccagat ggtgttggtg cccaaaactt 2640
ataaacaatt attttctctt tgcagttttg cctgccaga gtggcaagct ggtccgtggt 2700
cggttgctc agagaagtgt ggagacgcct tccaatacag atcggtgacc tgccgcagtg 2760
agaaggaagg agaagaggga aaactcttgg ccgctgatgc ttgccagct gatgagcaag 2820
agaagttcga cacagagaga acttgcaatt tgggaccatg cgagggactt acatttgtca 2880
ctggagaatg gaacttggtt agattttgca aaatatggg acctggggaa aagcacta 2940
aataagatca actttatgaa acaataatt tttagtgcac ccgctgcaac gatactgagg 3000
agactcgtga agtcacctgc aaggactccc aaggaagagc ctatccactc gagaagtgtt 3060
tggttgataa ctccaccgag attccaactg atactaggtg agtcattcca gatatgacat 3120
tgaacttga ttaatttttt tcttcagat catgcgccac ccaaccacca tgtgagtacg 3180
agtggaccgt cagtgagtgg agcaagtgt ccaccgaatg cggacacgga cacaagactc 3240
gtcgtgttat ctgtgccatc caccaaacg gaggactcga ggttgttgat gaaggacact 3300
gtcaagctga gaagccagaa ggaaagacta actgcaccaa tgaggagaag tgtactggaa 3360
catggtacac atcttcatgg tccgagtgt cgcgtgaatg tgggtgtgga tccaagatc 3420
gtgtcgtgt ttgcttgaac tacgataaga agccagttcc agaattgtgc gacgaagccg 3480
tcaagccatc tgagaaacia gattgtaacg ttgatgactg cccaacttgc gttgactctg 3540
agttcggatg ctgccagat aactctactt ttgtaccgg agaattcaac ttcgatgct 3600
ctaactgctc ggaaacagaa ttcgatgct gtgtgacaa tgttaccgtt gccactggac 3660
ctaactcaa gggatgcgaa gaattcgtt agtctccact taacctgaa gctgatgtt 3720
ccaatgctga cgcgtgaagct tcaggagatg ctccagaact ctgcagcgtc acaaacgaga 3780

-49-

acggagaagc tgttgatgtt gagtgtgcc aatttgctcc aatcactgct cttcttggag 3840
atggggaact tatcggaat gatactgatg cttccaatga gaccatacac tgctcgaaga 3900
ccgaattcgg atgctgtcca gattggtaca ccgccgcctc tggaaagggc aacgaaggat 3960
gcccatcggt cactcttggg ggatgtaacg agactcaatt cggatgttgt cacgatgatg 4020
tcactcttgc tcgtggagcc aaccttgaag gatgaggaga gccatcttgc gctgcttccc 4080
tctatggatg ctgtaaagat cgtaagacaa ttgccttcgg accacactat tctggatgtg 4140
agcgatcatc cttcccatgt gagcttagcg acttcggatg ctgccagat ggtgagactg 4200
ctgctcttgg aaagaatgga accggatgag gagagaactg cttgaccacc aagttcggat 4260
gctgccctga tggaaagacc accgccaagg ggtcccacaa cgagggatgc ggatgcgagt 4320
tcgcccaata cggatgctgc ccagacggaa aatcagttgc caaggagcc ggattttacg 4380
gatgcccaga aagctgcgcc cagagccagt tcggatgctg cccagacgga aagactcgtg 4440
ctcgaggaga gaacaaggaa ggatgtccat gccagtacac ccgttacgga tgctgccag 4500
atggggagac tactgctctt ggaccacgca atgatggatg tgataactgc cgctacgcca 4560
agcacggatg ttgccagat ggagagacca aggtcttgg accagatgga gccggatgcc 4620
caccaactac cagccacca ttctcatgg gaggaactgt tgcccacat aaaatcgccg 4680
cctgtaatca gacacaagaa agtgaaccg tctgaggagc cgatacaag cttgtaagta 4740
attaacctca tgaaaaagaa ttggagcaac acatttcagt tataaatatt tcaatttcag 4800
gcatggcatt atgataccac tgagggacgt tgcaaccagt tctggtacgg aggatgcggt 4860
ggaaatgaca acaactttgc tagccaggat atgtgcgaga ctatctgctg cgaaccacca 4920
ggcaaggga gatgttacct gccacgtgtt gatggaccac tccggtgtga ccaacttcag 4980
ccaagatact attatgatca ttccaagaag cactgtgtgg cttctgttg gagaggatgt 5040
ctcgaaatg ccaacaactt caactcttgc gaagaatgct ccatgttctg taaggacgtt 5100
ggaccgtacg atgctccaac caccgtgct ccaccaccac caccacagca aaatgctcag 5160
caataccttc caactccaga agttcaacag attgagattc aatctgctga gcaacctcaa 5220
ccacaacagc cacaacaaca gcaacagcaa caacagcaac aaccacagca accacgtcaa 5280
tcaatggaag acatctgcag atcccgccaa gacgccggac catgcgagac ttactccgat 5340

-50-

caatggttct acaacgcttt cagccaagaa tgcgaaacct tcacttatgg aggatgtgga 5400
ggaaatctca atcgtttccg cagcaaggat gaatgcgagc agcgttggtt cttcggtcac 5460
ggagctcagc catcogctgc ccggcaggaa caagctcagc cagcagctca accagctcaa 5520
ccagctcagc caagtaacat cgtctctcca ccacaacagt cagctagtcc agttgtggtt 5580
ccatgtaagt tctttagaat gcatttattt cttactataa gtttctataa gttcgcatgt 5640
gaagcatccc catttcagcg aacagcaaac aacgcgatgc ttgccacctc aacgttgacc 5700
aaggacgttg taagggggct tttgactcct ggtactacga agttgccacc ggatcctgcg 5760
tcacattcaa gtacaccgga tgcggaggaa acgccaacag atttgctagc aaggatcagt 5820
gcgagtcact ctgtgtgaag ccagcttctg aagctgcttc agccggaatt ggtatgcttt 5880
gagttataga gaatgttcac tatttttggt aaatgtttga gtaaatagaga aactggctca 5940
gtttgaaaat gtttgcacca tgtttcaaaa tagtttttga gttgaatagt tgaggccatg 6000
aaaaatctta ttacactcca gaagtacatt ttaaaacatt tttgagaatt aggtcttcaa 6060
aaaaagggtt aatattgagg tttcaaatta gaaatattaa tatacgggga tttgggttta 6120
aaactgattt ttaaaatctt atttttgaag tttcgctttg atattcgtgc aaaaaaaaaa 6180
ccaacttttt cagacgggtgc agctggaatc aactcagttt gtgacgaagc caaggacacc 6240
ggaccgtgca ccaactttgt cacgaaatgg tactacaaca aagccgacgg aacctgcaac 6300
cgattocatt acggtggatg ccaaggaacc aacaatcgat tcgacaacga gcaacagtgc 6360
aaggctgctt gtcaaaatca taaggatgct tgtcaacttc caaaggttca aggaccatgc 6420
tctggaaagc attcctatta ttactacaac actgccagtc atcaatgcga gacgttcact 6480
tatggtggct gcctcgaaa tactaacaga ttcgctacca ttgaggagtg tcaagcgaga 6540
tgcccgagta agttctaagt taatagtgat atatgctttg tttcccctt attctttgac 6600
aattttcaa tactttttgc ataattacct tatttctatt cccttctgtt tccattttc 6660
ctccaccgcg tacaaattgt ttccgtact ctctcctttc tcactttccc gtccgaaggg 6720
acacggcaat gctgcctaaa tgaactgcct aataatattt atgaattttc caattttcta 6780
aaaaaaaaa attctctcaa aaaattccct gccgttcgc cactgctttc ttcaccatt 6840
gttgcgctat tttttttaa taaatgaata aagctgaaat agttaacagt ttctgaaatt 6900

-51-

gcatgtaagt ttgtagtgta tcagtgtgtt tgcgtgaaa gttttttttt acctgcatga 6960
tttctgaac tgcatgaaac tgttcttatt acgtttttaga tttgctgaag tgtgctagaa 7020
gtgtgatttt gtttcagaag acgaccagac tacaacaaca tcacaaccag aagagctccc 7080
aagtttgcca cttgttcaag aagatcctca gccacgaccg gcattttcat tgaagtaagc 7140
acgtgtagtc caagtgccta cttctcgtat gaccaaaaaa tttaatataa ggtttccaag 7200
tattaaggaa tcagtagcat gtaaattgtg tggattgttc tcctgggttg atgggttttt 7260
ttctcactca caatcagata tggagtagct tatatgggaa tttatttgag aaatagaata 7320
tgtcataaca tccaaattta attattaataa agttgtgaag tttctcatta tgtatataaa 7380
attcgccttt caaataagaa caaaaattaa ctgtatgaaa gagctgaatt caatttgaaa 7440
ttgagaaaat aactggttca aaaagaagaa aaacgttgga aaatctagac gtaaattctat 7500
ggattttctt ttcaggtcgg ggaaatttcg acgattttta tattttcaaa aatcattcac 7560
aaatatacac caaaaattat ttttaccata ataaaatacg gaatttcact ggattactgt 7620
agtattcatg taaggttact gtattgttac tctagggata ctacaagaat atttttgcaa 7680
agttgtaaga agtatagaga ttactgtaga ttgaaaatct agacaaaaat cattttccgt 7740
aataatctgt ggggatagaa tgttgaaggc acaaggctta taaagcacca tgggaaaaaa 7800
ttttaacagt gattttttta agcatatcct ctttcccagg aaatccactt ttcaaatata 7860
ttcccactaa actctttaag acaatccttc gcccatagtc gtcgccgtga tgctccattt 7920
gcacgttccg tatccgcccg tcaccatact cctgattccg aagaggaacg agttgactgt 7980
tatgctgttc cagatccagg atcttgcggt taataaatct cacctatcca ttacaaccat 8040
taccgtctta atgattcaga gactaccgtc ttgtttggca ctactctgcc acgagtaact 8100
catgccgtca attctactat ggtggatgtg ctgggaatac gaatcgcttc gagaccggg 8160
ataaatgtga aacatcgtgt gttgctaaga ttgaagaacg cgtggaaagt gtgtcagaag 8220
cttcaaaatc tctggaagag gttagactaa cggatccaag gatggattct cactttggat 8280
atcatgatcc agaagttgat caaatcgaag aagaagctga atatgtcatt gttgataccg 8340
gagctctacc tgaattatgc atgcttcag aacaaagagg gtcttggtat gataacattt 8400
tgagatggag gtaagtcaaa tcaagaatag aaaattcgaa aatccgaaaa actttataat 8460

-52-

tataactaaaa gcaaaatctt aaaatctttc agattcgact ctgaaaagtc tcaatgtgta 8520
acottcatgt attctggatg taatccaaat gcaaatcact tcactagtca ggtagtttc 8580
attattttgt gtcctttcgt ggaactggcc ccttggtttc taacttgatc ttctccttcc 8640
gaatacccaa tttgagcacc gctggctcac tttttcgacg gtgacgttcc tcaattctag 8700
cggcctctgt attttctgag cactcttgag caacagtttc ctactggaa atgtttgttt 8760
ttcaagaggg agtgagagag agaaataaac gtacaatttt tgaagccgca catgatttgt 8820
tagaagtcga tgccgttctg cagtatcctt catgtttcgt agttgtttct gtagtaattt 8880
ttatggatta ggaactaaga aatcatcact cactgcggtg gttgcatttt tgtgcatgca 8940
tcttcccata aaagcaacaa atgcaacaac tgatagagcc gccacacaaa ttgcaataat 9000
tcgaagtcga tttctaattc ctttctttac tttttgtcta tgctcagctg ctttttcgat 9060
gtgcttcttc ttgctggggt cgagctcgca atgaggaaat gggtcgatga gtggaccgtg 9120
ttttttgcat tgttcacaac ggcgtccagt gtatttgtct gggcagtcac acgaaagagt 9180
gcggtttttg aaatctgaaa attttaaatt taagaacagg atctatagca gttttgccca 9240
tcacagtcct atgtctatat taaaaaaaaat tatcggacat taaaaaaaaat gttttctcat 9300
tttttcagta tttctataaa aactgcattc gcatttaatc ataactttta atcgtaaaaa 9360
acttagtctt taagtacctg gggatccgta aacacagaca atttcatcac aataatcgcc 9420
ttcaaatccc acatcacaga tgcatcttcc atttctcaaa aaccctcga cacatttact 9480
tgtatattgg cattcacttc caaaatatga gccacacat tcacatcggg ccccttcca 9540
ttctccttg tttccgcact gaaataattc aatagatttt ggaagtttag ggcctcaaaa 9600
atataccttt tccgctggcc gatagtcaca catttcacct ttccatccga cttcgcaaat 9660
gcacgggtca ctgaatagaa ggctttccgg gtcgaagcgg aatccgaccg agagtccgtg 9720
aactgtaaat tgaaaatttg taattccaaa aaaaaaacag cttttgcaaa aatcgtccaa 9780
aagaatttta gagttagaca ttatttttct caaaaagttc aaagttgtat cagttttaaa 9840
ataaaatatt taataggatt gtagagcttg ttagaaaaaa taaaagctac ttgaaaaaag 9900
aaaggatatcc aaaaaggat tgagatagtt tcaagcaact ctatttgtaa actgtcgagt 9960
ttttaagttc tacaatctc ttataacatc gctacatcta ctatcaaact ttgaaaaaaa 10020

-53-

accataccac attcaaaatg ttcacattta tctccagtct gtcccttgat acaatgacaa 10080
atccctccag catagattcc tccattacga cattcggctc tcggatcatc cagagcaaca 10140
ttgtctagaa tactttctctt ttgaagaata cgatgcacgt cgctcaatat attttcatct 10200
agatctagtg agtcatctcg tgattgtgct tttgttggtg ataaaaatag gaagagtaaa 10260
gtggaaaatt gtaaacagta catagcgta gatactgaca agtctactat caattgattt 10320
atttattgcy tcttgaaagg ggtatcaatg agagaaatag ggagatgggt aaaatgcatt 10380
tataagagaa tacaaaagat gacgtaattg attaatacga gatcagttga aaatactttt 10440
aagtatcaat tattatctgt gaagacagtc acgtgactct gactcgaact caatttgcat 10500
gttgatagtt ccaatgttaa agaaagtctt tgggttttct ccagatgaaa caaatgattt 10560
tggaatatta aacgtgactc ttctctgaca aggtttgagt ccgtcatcac aatcgtgata 10620
gatattaagt tttggatcaa tagtcatcac ttcggaagtg tgtccggtaa gaaggaattg 10680
accaagagag tctgtagttc cttcggcaag aagatcgtca agatccggtc ctgaaaaaaaa 10740
cttttatttt gaaaaatttc aatgagttgc ttcattgtag aatttggaat ttttaaagat 10800
gttagcaatt ggtattttaa tgttcaagct aacgtaatta gagttattca aacaagcttt 10860
atataaaaac tttgtgtaag attcggctta attagaacat caatttttaa cgcagctgat 10920
aaaaaacttt aatttcaagc ttcacataat tctacttacc ggtatcatca tcgtagagct 10980
tcaccttcgt gttagccagt ggtttgtctc cacacatcag aacaccctta actccagctg 11040
attgggtgaa tacagcttcg gagccaattg caciaagtat gaaaagtgat gaaatgcacg 11100
cgagtcgtga cattattttt gtctgaaaat acaaactg actgatctga cttcatcgg 11160
agaaactctc ttatagcaca gttgggtaga aaaagatacg gagaggagaa gtgggaaatc 11220
gaattgacca aacaaaagaa ctggttttca cttgaaatag aagacgatga aagatatata 11280
acagagaaga tcggaagtga ttcattctgga gaagaaaatt gagaggagca acttcttgta 11340
ttttccactt atttatatac ccaatagaat tcacctgatt ctttccgatt tgtgtacatt 11400
tcgctgacta acgtgtgctt cttcggtttt gtcatttctt attgttcatt gaaaataaac 11460
agaacaaagc aatcataagg tcgaaaatcc catttagaga tcaagaggtg tacctttaat 11520
tgtgcggcat ggcatagttt tatcttgctg aactctcacc aattgatgag tatgtcagta 11580

-54-

gaatggattc catccgatcg ttgctccacg gtgatctctt ccgccgcctt ttcattccacc 11640
ataccggttg tgtatggctg gcaactgtga acagcgccctc agtggaatgt ttagtttgat 11700
atacagttta aaataatttt cttaaactaaa gaaatcagtt tttgaaacca gtcttgtagg 11760
catgtcgggc gcaggcacgc taacgtgaaa aatagaattt cgagtgggta actattttat 11820
tttcaattaa aatacaatca actacacaat gaatgacccg gataaatgaa atacaaatac 11880
aagaatttaa aaaaaacatg gaaatttaaa cttttccatc atctcccttt gctggaatat 11940
tatatttcat tcgataagct tccaattcgg cttttctctg atcggatcgt aactgtgtc 12000
tctcatccat ctcttggtga gctgtcattc tcttctcatt ccatttctga gcttttgctt 12060
ttttgtggat tctgttgat tctttgcaat tgcagcagca ataacagaag caggcaatga 12120
gaattacagc aatgattcca gcgcagatgg caataacgat tgcggcggct gatgtgctca 12180
cccagcagac attgtatttg acatgcttga tattacagtc tggatagtag cagtcgaatg 12240
gcatacatct tttcgttttt ccaccacacc agaagcaatt ctgaaaaaat gtgtttttga 12300
aattttcaat atgtttgctt ataaaattga atttaatttt tcaaacagtg tttcagaaac 12360
tcaacttctg aaattaggaa agtattctca attgagagct gtttttgat taaaagtctc 12420
agttttagaac tacagggtgtg aaaaaatctg agcaagtga caccaacgta ttgcatcaca 12480
gtttacgcgt caatttatcc gagtggtcat tgtagagaaa gttaggtcac cttccagaaa 12540
attaagaaac ttgtttcaga ctttttgct ctttttagagg aatttttttt tagaggaaac 12600
acgcaagttt ctttgaaaac aaaaacaaa tatatttttt atccacttac cgagcccttg 12660
ccaacacatg tttcacaagt gttcaaatcg ttcgatccaa ttctacagta ttcttgtttc 12720
tctgaccatg tcatgttatc cgcacatact gatactagaa caattgagaa aaagagtagt 12780
aatcggtgaa tcatcgttct gaaaaatcaa taaatagtaa caactgagc aagtctcgta 12840
actgagcgac aaaaccaaag tagtaatgaa atagaaagat agaaaggtaa actcaaaggg 12900
ctcgcgtgtg tttgtctatc gagtgccaat gagttttagg agtagcgaca gaaataagtt 12960
ggcagaagaa gaacatacga actatgtcgg gctacaagat tcttggtgtt actttttgaa 13020
aaagaaaatg catttgagaa aatgcaaatg ttcggcagaa atcgaatgga gtttagagca 13080
gaatggtaaa aataaagggtg gatcagcaaa aatagttgaa caaatatttt gtagatttca 13140

-55-

tgaaagataa caaaaaaaaa taaatacaga aaacaatata tgacgtatTT ttcaatcatt 13200
gtttttgtat agtgcaaatt cagtagttgt acctgttata agtacagcga agttatacat 13260
tttagagtgg gtcttgtcac gatccatatt ttttgaacgc aatatttgaa atccaaaaaa 13320
aaataaagaa actaggcgcc aagaagctat agtagctata cgcataaatt gtgaatacct 13380
tgaattacat taaattccaa caaaatagga aatcatata aaaacgaagt tagttgtcaa 13440
ttcaaaaacg tttttaaaat tgttcataag cgccgagctg tccccctcag ttttcgttta 13500
ttcagctttt ctctctctct ctattctcta tcgtcaccta tatttcatag tccccctatc 13560
caaaagtgga agtgaatgag gatggaaata tgataccgca tgcttcaaaa aaatttgctt 13620
atgagaaacc aacatttgaa aatttccagg aaacttgatga acgagcctgt ggtaaattgga 13680
gaaatgtggc agtgtgcgag ttgccggccg aacacggaga ttgccaaactt gcgattccca 13740
ggatatgtact gttgacacat tttaaaaatg ggatgggaag tggtcggtga tcagggtgga 13800
atgttgatgg caaggtttta aatagatgta gtaactgaaa acaaaatgac agatgtacat 13860
acataaatta ggattaaaac aaaaatacta tgcggagtca ggtgactaat ttttctggaa 13920
attccagaat ttgaaaatgt ttttctctgt ttgaaagtag aacgggacct tttaaaaaat 13980
aggctgaggt aggtaggctg tagaaagtgc ctttggtgtc tttgtaattt ttgttttcaa 14040
aaaatcactt gtaagcacat gaaaatcaca tgaataatga tgtaaaattt agaaaattag 14100
tataaagaag atttacattt taataataat aattccagat ggtaccatga cccaaaaaca 14160
tcccaatgtc aatgatgat gtggactgga tgcggaggaa atggaaacgc gttctcttca 14220
aaagcagact gtgaatctct ttgccgagtt gagacattat ggtccaaca cactgacttc 14280
tgtacattgg aacgatcggc cgggtccatgt acagattcta tttcaatgtg gtatttcgat 14340
tcaactcatc tcgattgtaa gccattcaat tatggagggt gccgtggaaa tcagaatcga 14400
ttcgttagca aagagcaatg tcagcagagc tgccgtcctg gagacacaaa atctgaggat 14460
atctgcacac tccgcccaga gccgggaccg tgtcggctgg gactcgagaa atacttttac 14520
gaccoggtga tccaatcctg tcatatgttc cattatggag gttgtgaggg aaatgcaaac 14580
cggttcgatt cagagttgga ctgcttccga cgatgctcga gtgtcaaggt tgaagcaagt 14640
gaaagcgaga gagtgggaca gctgacgtct gcatccacgc cagttattta tattgttaac 14700

-56-

aaaacagcga tttttgttgg aaatactgta agttattaat ttttaattcga agattttctta 14760
atattttaaac tgggtcccatg agagtttgggt tcattttccg acaatagact gcaaaattga 14820
taacttttca tgaacacttt agccgatttt agctagtttt gtttattaaa atttggtaat 14880
tcaaaataaa aaccttacgc cactccactt ttgaatactt gtcaaataca ttttttcagt 14940
tccgaatccg atgcaacagt tacggagtgc ttccaataac atggtacaag aacggagggtc 15000
tcctccagtt cggtcgcga atcactgaag agaattgatga cactttggaa attgtggatg 15060
ctttaactgc tgacgccggt gtctacactt gcattgccgg ccaggatagt acaatgagcg 15120
agggagtcga ggttgtgatc aagagacttc ctggtcacag aactacatct cgtccaatgc 15180
tgacaccatc caagaacttc tccttgggaa cccaccgac accatctcca tctacagttt 15240
ctacaacacc cttccgaatc tatagcctg gatctgctcc atctgatgct cgtgtaagcc 15300
gcccgacaag caattcctgt atggatgtgg gtaacgcgag cacgtgcgat ttgatcgtga 15360
agaacggttt gtgcggaag aagcgatatg gaacattctg ctgtcacact tgcacccggg 15420
ttcataattt taaattttaa gtttggattt tttgatttca aattttcatt aatcttttaa 15480
tgttttctcc ttcataatat ctccattgag agatctcttt ttcccttctc ttcctatact 15540
ttcccctcag acaattggct aattactcgt tcggtccagt aaataaatat gaatttattt 15600
cttcttctca tactttggta tacataatca tggcatgaaa tacaagacaa aaaaaacaag 15660
aaaaaacaat ccacttgaaa tccattcagg tgtgaactaa catcttactc tattaacttc 15720
gtgccattac ttccacttat tttgcctatt cactaatgaa gtctctgaga attattttct 15780
gtctaactct gctgattgca agcttcccag ctcagcggag ccgccgaaaa cagaaatttg 15840
tacgccttcc tagtgggttc acgtttcctg cggatgcggc gagtaatttt caaagagatg 15900
cgtatattcc agcgacggta aattttcgct ttttggtaaa tgaatttcag gtttcaaatt 15960
attttctagg acaaaaattt aaagtaggct tgcgcatact catttccctg ccttacctgc 16020
caacaggcta gcttttggag agaaatcaaa agtttgggtg ctgtaaatct aagctttccg 16080
aagcgtccga aagtttttgg gaatccgcta tacactttaa gattgataaa tatttgaatc 16140
aggtttattt tgcactatta aggcgtgtag gcactaggcc ggcaaagctc gcctacgggg 16200
agccttacia tcaagtatta ttcattgaag tcttgatttg gttacagaat tccatctaaa 16260

-57-

attacttata caaaaacatg aaaaatttca gtttgccccg ccatctgaga agattcttca 16320
agctccacca cgctatttaa ctggagaaca caatccagct tatggtaggc ccaatttttt 16380
atctgatttt ctaaatttaa cttcaagctc acaataccga tgtgcaagga atgaactacg 16440
ctgagtacaa gcaagcgatg gcccacaac cacatccagt cgatgcttat tctccaccac 16500
ctcctgcacc aatgggtcca cgggttactg tagttgaacc acctgcaatg ccgtatgaaa 16560
tgactacgat tgcattctgtt ggaccactta ctactcccgc atcagtcggc ttgaagaagg 16620
gaaagtttgt gatttttagtt aattgatctt tcaagtaatt ggatacaatt tccagcatcg 16680
gaggaattgc taaaacttg aacgacaggt acaccagctt aacaccagaa gctcaacgtg 16740
ctcagaaagg tcatacctat acggctcttg gcggtggaca attctatcaa agtttacttg 16800
gaggggtaag atgcaagggt agaacttaca aactcaattc attttacaga aaggaggccc 16860
cggaggattc tccccactct cgttctttct aaacggcggc ctaggaggtta ctggtggtgg 16920
tggtacaat ggattcttcg ttccggtgcc tgtagtcatt ccgcctccac cgccaccgcc 16980
accaggacca aactgtttca cgaaccctgc gggattcctt tgctgtaacg tgacacttga 17040
gaaaactatg gaagacgct acctggccgc aaaagcagat ggtgcatcac tgtgcaatgt 17100
acagaaaatg gcaactgcag tgcaagcggg ggggtttatg gatttcattt tataatgtaa 17160
tgtgctcttc cctagaattg aataagctta caacttgaat tacgacttga attacaactt 17220
gaataagctt aaaatatcca ccaaatttca gcaagccgaa aaaaattcg gaacaacttt 17280
cgaatcagtc gctgctcatt cggacttcgt cgcaaaaatt aattttgccg gtgacctgaa 17340
ctgtaaaata gaaatcgatg ggaaattcat actagctac gcaactcaa tcgccgagca 17400
agagggaac attgtcgatg ctagctcatt cttctcggga gctgctgata aggatttga 17460
tggtgtcaat ggtaccaagc ccacctacat tgtctacggt ccattaaat aatggagggt 17520
ctagctttta agatttctgt atattaaagc tgaaatgtga attaattgtt tatttgccaa 17580
tcacaataaa gttggaaata tcatttgaat agttcgaaag ttttcaatcg gaatgggaga 17640
aaattcgaaa atttaggtgg aggtgaaaag ttgatgaagt aacacaatta actgtgctcg 17700
aatcctgaat agaaggagaa aagagcctat aaacagattt tcaatttaca catattacac 17760
aacaattcag gaagaagaca gtagttgcaa aagaaaatac gtagaaaaaa gagtgaagga 17820

-58-

ctggcgggat gtcagtttgg atgtacaaat agaactcctg aagcataaga aacagaagaa 17880
tcgaccgatg atcgaacctg aaatggattt attgttgatt gaaaaatatt aagcaattct 17940
gaatctctac cttgtttgat tgtgtgtaat gcaagaatct aaactcgtga gtgtgattgt 18000
tactgatccg gaaatgttcg gctgcttgca gcattatcaa tatcggatta cgcccacaaa 18060
tcgtgttctg ggtctttttg aggtagtcac taaaagctgc cggattaagc gtctcaattg 18120
cgctcattcc ctgcttatcc atattgggta tctgctcata aatcggaata gaactatgac 18180
gatcgtacgg agaaaagctg aagcgttctc cccaatggca aaagtccgaa gagatcacia 18240
acaagtttct tggatcctcc atgtaatgag caaaaatatt tccatacgtt tgctgcctag 18300
atcctggtaa agatccaaca agtaccgaa caatggtgta acgttttgaa ccataacct 18360
ttgcaataaa tgggagttgc atttcaatac tatgctctga ttcttcatct cggcgatcca 18420
tcaaatcgaa atgacgagtg gcacgaagct cctcgtaac tgcaaagggc aatgttgtaa 18480
aagatgtact aagagtgcaa tagattactt ttgtgatcaa cgatcaagtc gccgagtggg 18540
gttctgtact tgctgcatgt gggtatagca catccattta gagcaacaac gtgagatggg 18600
ccaagaatga agactcttct actgaaagtt attgagtaag ccctgttgcc aagtacaaat 18660
ttcaacaact cacactgctg atgaaacaac ttgtttgaaa gcatatgcag ctgtttctcc 18720
acaatacgaa tatcccgcat gtctgaaagt tatcagaaaa taaatattaa atgcatttag 18780
agtattacgg tgaaatcaac gctcgagccg ttccaatccg tggaccggcg ttgtcaagcc 18840
attttgtgag ttgccgatca agatctcgct gggtggcggt gtaccatgat ccggcatgtg 18900
aggcagatct cgtgtgctcg ccgaatccgt ttagtgacat tttaaattca gatggtctga 18960
atattaaagt ttgataaat tgttgataac gacttgatta atatgttttag tagggttttc 19020
aactactgtg tgtttcccaa atagtcaaca ttgaaaaatg gaaaagtttg aatttaaata 19080
ttcaaataat ttttaattaat taatattaaa attcacaata cagtgtaca tcacacttaa 19140
ttcaagatgt tctaaaaata tgagccatcg ggctagctct acttcacgaa ttcgaatcaa 19200
gtccggggaa ctggctcgaa agaaaataaa tttttaattt gggttatgtc cgaaatagaa 19260
atgggaatct gggttttcat tctgaataat ttccgagaaa cacttacaaa ataaaattca 19320
gatatcttgc aaaaggaagg ccaaatgtcc tgagaaatag agcacgagag ttttgaaata 19380

-59-

cctgcaacaa caggatttgc ttctatcttg ttttttgaac tgaattttta actattatct 19440
attctgaaaa cattttttgt ccaaaaaaaaa tcaagaacaa tttagagcaa aatgtggcaa 19500
tccgaaaatg ttgatgcaac aaaaaagtgt ttttttttc attgaatttc agttttgaaa 19560
actgatttct ttccaaaaaa aaaacgaagg aaaattttga gaaaaaagtg aaaatccaaa 19620
aatgctgatt ttgggtttttt tttcaaaaaa aaagcatttt gcaaagtgtg tgcttttttt 19680
cgaaagtttc agaaccttga gacaaaaaac caaaattgtg tccccgagtg aagcccgcga 19740
cgtggacatg gtcagacgaa tcttggtcgt gttcgcagcc aattttcatt tttgctgaac 19800
gcataattgt tcaaagaaga ttcggtctaa aaagacgaaa ttgaaataga ttgtggaatc 19860
ctttgaaatt ttcttttgac aaaaggtcac cgttattcaa aaattgagat ggtctcgtga 19920
ctaaaattaa acaatcaaga taatcatgat tgtgggcctg ttttaaaata cacttttcaa 19980
aaacgaaatg taggctccaa tccaaactgc gcatcaagac caagaatata aaatttttaa 20040
actcgggaga cgtagagaaa ctttgaatat taaacatcgc cgtcaagttt cgtcagagc 20100
gcgcctgaaa ttttttagag gcttctttca aaaagctacc catacaaata atcataagaa 20160
aaacgtttta aaactttgca ttccacccaa aaatgtctga aattaccgtg aaaaagaatg 20220
tgtgaaggga gtgatttgag ggttctgtca aacagtttga ctgtttcgcg ttcgacgtgt 20280
ctcgacgtgg atggtattga agaggaccgc gctgatcttg tgctggctgt cgtcgtcttg 20340
tcggaccgcc gcgagtagtc ttcagtctac caattacctg aaaatttgac actttttgtg 20400
atgtgaaact ggctgcctga agcaatgcca tataataatc ataataataa taatgaagag 20460
ggatgaggat gcatgcaaaa agaagaaag gaaagacgct cttctacaac accagccgat 20520
agtatttaga agaaaaagaa gactaaaaag agagtattgg gtgatgggag aaagaacaca 20580
ataggggagg cagtgaaata gaacgagaac aatggaatcg gcagacattt gacactagag 20640
gggccactgt ttcagtcttt ttcgcacttg aatattggaa gagggccaag aaggggagtt 20700
ccaagaatgg aaaaagtggg aggtttgtag aaaatctgcc tttttttttt taaaatttcg 20760
tgttcactac tttatttcgt gttcactcgt ttatgtcttc cattataggc aggcaaagtt 20820
tcatgcctac atacctgcct catgcctatt tgactttcaa tataaaactt gatttttggc 20880
attcttcatt ttataacaat tgtaactaat aataagcttt gcaaagtttt ctgaaagaaa 20940

-60-

ttgtctaaat tttctggtta cactgaacat ttttcggtat aaaatctatg cgtatcaagc 21000
ctatctctaa gagccgtaag tattttcagc tgaaaatgta aaccacggag tcaatattta 21060
cttcgtatca tccatcttcc attccgtctt gtttacacct acggcaggta tttagacacg 21120
aatgattgtt tttctcgttg cctaatactt tttccccga aatattccca tattccagtt 21180
ctgaacaatg cacttttcag cgggtcatcg gtccatccag ccctcattca gccctttcat 21240
ttatcttcgt ttctactttt agacgaaaat gcaaaaaaaaa gagaaaaaga cactctcttt 21300
tgacgctcac attcgtcac attgctgtgg tagaaaaaca ctactcgggt ggctgctggg 21360
aagggaac gagaaaatgt ttggtcacgc aatacgcta tatctttgat ttgactttga 21420
atctttatac atttttcacg gggttcaaaa acaattatga agaaaattgt ttgattaaat 21480
tagaatgtag attctttata ttttcaatca aaaattaatt ttggaaaaat aactatccaa 21540
aaaacgaaaa aagtaataaa tgagtacttg aaagtgaat ggggcaatta aacaagataa 21600
aaaagactaa aacgtgagac atctcacaac gggtcacggg caagaagtac acgagaaatc 21660
gaacgtgagt ggggaggcag agacactcag ctgactgcct ggctgacgc tcgctcacia 21720
aacgctctca ctctcttct cgttttgccc gctctccgcc ccgggtcgtc agttcggctc 21780
atccatgttt gttcattttt ataggtgaaa atttatgtaa gggaacggaa aatgtaaagt 21840
gatcgtggga aaatagaaaa acaattacat tgtaactttt ctggaccaag ttgtaccag 21900
atgcaatatg tatatttttc tcagaaaata ctgtgttggg tttcgacagg atcgatttat 21960
caaaagcaaa cgagtgtgcg tctcaacgag cactaaagt ccactaga gcatccttgt 22020
tgtggtagaa ctacatagaa atttttaatt ttgatttcaa tagcttttct cttgttttct 22080
caaaatttat tgaaaaactt atttactata aaacgaccaa cgacggatct ggaaactaca 22140
gtactcetta atgcaaaagg caacgaaaa tcagccagtg acttatttt tgttctggat 22200
aaaaatcggg aatatttgca ttttgaattc gcactgtatc gataaacia acaccgaaga 22260
tcacgcaaaa atgactattg taactaacag gtacgagaaa gggacgcttg ttctacaaaa 22320
ataattcaac aaattttccc caaaaaatg tgaagtccgc aattctcgta gttttacgta 22380
aatcaaaccg agcatgacac tctgacacca cgtgcgcctg aagatgtgcc tgctaccat 22440
ggatgcttta catttgctag ttccatgaca ccccatcctt tcagcttcca agatgaagga 22500

-61-

gttcggagaa aattcgaaaa aatattgaga aaaataaccc aaaacattct gaaacattgc 22560
ggaaaaaagt tagaaattat gtcgaatata tctgaaccaa tcaacaattt caaataaaat 22620
acaaaaaaaa attggaagac cttaaatagt ctccgcccat attttggtt caaatgaccg 22680
tacttcggaa tatggccgat ggccgtggca agacctcaa tcgtagtttt gagcggtcag 22740
taagtgaaga ttaaaatagg aacagtaccg taagatcagc ccaggtgcgg atgtgggata 22800
gaggaactga aaataatcga agaagcatga taactaagcc acgtggccac gttcgttttt 22860
gcatgtttaa tagatcgcca ctctgtccat tctgttttg tttgtactaa gtctccttag 22920
caattctctc gaaggcgggc cattgctatt agtaaaataa gctaccaatt ttacctttca 22980
atacattcat tcaactgatg ttttcctatc aggtgatcat tttttgttc ttctcaatta 23040
cactatctaa aaatgatgaa gtttttgctt cgcggctatt tggttgaagt gatgatatat 23100
ccattgattg tctctccac ttgtgctctt tttacgtctt acaacttctt ttttaagtgtt 23160
ttcgtattc actgtttcat ttattttttg cagaaaatga gcctgttcag caaatttttc 23220
ggaggcatga tgcaagaagc tccgattact ccacaagaat ctattcaaaa acttcgggaa 23280
acagaagata ttcttgagaa gaaacaagaa ttcttgagaa aaaaaattga cgacgtaagt 23340
tggaagatca gttttggtcg aattaatcac attaaaaagt gctgaaatcg aaatttttaa 23400
actctcgagt ctcaagtgc tgtgacgtaa ttaaaacatt gctcagcatt tacattgttt 23460
actgacgtct tttcgaagtt tagtcgagca aatccaaaaa agagcaataa aaatttctgc 23520
tacgatacgt ttgggaaatt ggaatcatag ttttttaaac tccatttttc aaaaaatata 23580
ttattagaaa atcagtaagt ttcggaatt atttgagaaa cgtttcagga aagcaaaatg 23640
ccgtgaagta tggaacaaaa aacaagcgga tggctctcca gtgtttgagt aggaagaaag 23700
ctttcgagaa gcagttgatc catattgacg gagttttggc tactctcgaa catcaggttg 23760
gtatataaaa atattagaga aataaattga ataacacggt ttttcttcca gagagaaacc 23820
ctcgaaaatg cttcaacgaa tgctgaagtt ctacaggta tgaaacttgc tagcgatgcg 23880
ttgaaagcgg ttcataataa catggatagc gaccaagttc gtgatatgat ggataacata 23940
gatgaacaac gagaagtggc gaaggaaatc gcggatgcta tttcaaacc tggctttaac 24000
aacgcaattg acgaggccga tttgctgcgc gagttggtg atcttgaaca ggctcgtcta 24060

-62-

taccaccaac atcgtgtaat tattagaaaa tataccagga agcacttgac aaagatttgc 24120
ttgatgagag agctccccc gtcacgcttc cggatactcc caatattgca cttccagcct 24180
ccagaccgag agctaaagaa gctgacaagg atctagaaga cctcgaaagt tgggcaaact 24240
aacttctcta agtcactttc atatttaatt ttcggctatt tttgtttcat ttgcatcccc 24300
ttcatcaatc ctaccattct ccggagattc toctaaatca acttttctaact tacgacaaat 24360
tcaaatagtt gaatgatttc tgttttagcca tttcattcga aacaaatttc cccaaggcta 24420
cgatcaacac tcatcaaaat tgtaacatat tatcgagctt tttggaaatt tgtcatttta 24480
tacatcttgg tccctttctc caaaatcttc caagcatgca ttaaagttcc aacttttatt 24540
aaaaattcat tctggcaaac atgttatttg taccggttga aaacgaaaac caagcgagaa 24600
atagttacat ctcagatctc cctaacgatg gctcaacccc tttgacgctc atttactaat 24660
gtttatactt ttgctcattt actaatgaat ggctcattta ctaacttgct gagatttttt 24720
aatttactac tgctaattgt aagatatata tcatttatca tttactatat ataaagcgct 24780
tattccgttt gtccatagtt tgtagtctat gtagtctttg tagtctgtga cgttttggct 24840
tctggaagga tagtgagttg ggcttagtgt agggatatag ggggtactgt agtggtaaa 24900
tagtggtagc gtaggagtag tgtatgatta cggtagtttc agaaaaatta gttttcagct 24960
ccagaagtcg ggggccgcgc cggaggtgcg gtccacggct ggttttacat aaggtagttc 25020
caaaaaatgt cctacttcca attactcata actcagttag cgcgctatag ctatagcgtt 25080
tgagtttaaa aaaattgtgg ccaactgaaa tgctgtttgt cagagatgcg agctctaaaa 25140
gatgatcgaa atattctatt tctgcggatc tagaatattt cgatcatctt ttggagctga 25200
catctccgca atcgctaaag ataactaaaa ggtaccaatt aacaaaatgt gttttacaat 25260
attgccaaca acatttttagg tttctttcgc tgattgtttc cttttgggtt tggatgaggt 25320
cccgagtggt tttttttcgc tgggttctact attttttgga tcggcaggct ctgaacaatt 25380
ggttgtaaa tcttcttcaa cttcatcaaa ttatccagag ttatgtgtgc gcttctgctg 25440
tccaacatat tcatgcattt gacggaactc ttcaactttc tgcattgtca ctggattctt 25500
ctttttcgat tttattttat gaaaacttta ctatcataaa caatagtatt tatcatgtta 25560
caaatcagtt tggaatgatc tocttcattc aaaattctta atgatcagtc gattcactct 25620

-63-

tagagccacg aaaaatgtgg gacaattgtt tgagaagtga aaaatagtta ttaatgttgc 25680
aattagttgt acatataagt aatacatgaa aatacatctt aaaaatacag ttactactag 25740
gtattattgc ttaaaattgt gttccaatct gccagtacta tgagcgtaat tcgttgatcc 25800
aatcttcgaa tagccgtgag cacaggcttc gccggcactg cacacaaact tcacgattgc 25860
acgatttgca gaggtagagg acgaacgact ttcctgtaat tggcgaaata ttgttttaag 25920
ataaagttag taggaacgat cgtactgttt ttagaacgag actgtctagc tgggtggccgc 25980
atcgagcatt gatggcatcc aagacctga acttcttcgc tgaatgatat acgatgcttg 26040
aatatggatc cactgaaaat tgaggttata gtagattatt gggagctatt atgatttcac 26100
ccatgaagaa ctgcgctcagt aactcgtttc agattctcgc tctcttttc accgcttttt 26160
cgttgtaatt ctatgagaaa acggtagaat ttggtgacat ttgtcgagtt aaacaattcc 26220
acgaggcaga caaacatctg aaatttgctt tttttccaca aatgcataaa ctttcaataa 26280
aacaaccgc ttctagggca acatcagcta aactgtgatc atgctcgtat tcggcgttta 26340
gcgagaagca taaatggtag aataaatgaa agatatcggg aggttcgcgg gaatccggat 26400
tgtagtcttt gagataatca acgcaatttt gtttcagatt cgtcatcagg tatttgctgc 26460
atagcctgag aactgtgcac acgttttggt ctgaaaataa atttggcatt cattgaaact 26520
acatcgatca tgaactacca tcaataacat ccgatataa accaagagaa ttgggagaaa 26580
tgacagtgat caacttgaga atatcttccg gtgactcatc aaggatattc agctgcttta 26640
tggcgccttc aaggaaaaaac ttgttctcca tcaagatgcg gaaataatcc gaatttcttg 26700
caaagattgc tggatccaca aagtactttt gattaccaac aataataggc cagtttcgaa 26760
gcttgcttgt cgactcaaaa tcgacctgaa agaaaaatcg aaaaattcca atttaaaaaa 26820
cgtttgttta cgtaatcgga tccttctagg aaggtttcat gacttgttgt cggctgcatt 26880
agaatgacgt ttacggggaa atcattatct attccgaaac gtgcttgggc ttgttctgtt 26940
tgctgaaatt ttgaaagggt ctccgaatat taagcgaaaa aaacttacat taataatata 27000
aggtctcata gcgccgagta gctaaacaat taatatttga ttacaagttt ggaaagatct 27060
ttctgagctc gatcaggaag aaaaacttct tgaaacttta gaagatgaaa tgtgtgctac 27120
cgataaaact ttaaagggtc atgaataaat ttctcctttt ggtcctgcga cgattaaact 27180

-64-

ttttaatcaa ttctctgggc tagtttttat tcaataacta gaaatgttgt ttatttttgt 27240
tccctactta aatcatatgt tattttcttt ttcctttgtg tcttacaggc ttttttagct 27300
gaagaaatag caattttccg ataaaatttg ttgctctatg ttaaaggcgc atgcatttat 27360
ttgagagacg ggtctcgcaa cgtgctcact cctcggcccg atttgttctt cgtttgcgcg 27420
gttttcaggc ctttaaaaga tagttccgtc gtttttttct caatttctgc tgaaataagg 27480
tttaattaaa ttatttttca aaatcttggg aaacatttaa actcatatat tcagaatttt 27540
cattctcttt tcaccagaa aaccgaattt caatattaag attaagaaca catctagaac 27600
atgcaaaaaa cacaattgct atctctctac ttctatttta aggctgattt tttgaagaaa 27660
aatcatgaaa tacgtccatt attgttgat cccttgtttg catccaaagt tgactcgatt 27720
gatctcttaa atgtggtatt ccgttcgaaa ttcgattgat ttttagaagt taacacattc 27780
ggaatgatga taattcgtat caaaccaaaa ttgtcttctt ttcgcctttt ttgtgcagtg 27840
tcagcattaa acaaacgag aatattgaaa gttacgtggc gtttgcattc ctcaccacga 27900
tgacatcacg aaatgcagac gacaaagacc ggtgaaaaat agtgcgctga atggtgaaaa 27960
cttgcgaaaga taacgtgtta cgggttgaga gagaaaacat tccgcgagac aatgcttttg 28020
gtgagaggcg cagatggttc agagaacact agagaaaacc gcgcctctgt ccgctcacag 28080
ccagcccat caagcctctt cgggcatcga cgcatagaca cacatcattt tgccccaatt 28140
tcctttcatt ccgtcaagta tttcgcaact aatcgttatt gctcattaca atacacattt 28200
tacagaagtt cctcttcttc tacttggtcc gaccgcatca gataactggg agatccagtt 28260
gtgcatgttc ttgtgcccac aaaaactcgc gccatttac aattttatga tcgacaaccc 28320
tcaagaaggc aagcatttaa acgtgttggc cgtgcgtctc aaaaaattgt taaaaaacct 28380
ggcgacacgc gtttttccac aatttcattc cctagggcat tttgtatttg aagtaattct 28440
attacgcgta cgcaatcgga cgaatcctgc aggtttgttg gtagtcaatt ttatcaagtc 28500
gactgcctct tatgctttct gaaaaagag aatgacagtt ttcgctaagt agtactaaag 28560
cgatctttta tctttggcaa aacctgata taagcattat cacagcatat catgcagatt 28620
gatttagagt taagcatgaa atgtgcaagg ctaaaataaa ttacaaaata agtccatagt 28680
ccattttagt aacagtatac atcagctgat agaatcacat gcgtaatgac aggtctaaaa 28740

-65-

cattatcaaa caaaagacat taacaaaaaca agaaaaatac aatataatag aacgactatt 28800
tgaaatgagc gtagttaaat tcggaacttc aatagattat catacgcgct tttaaaaaaa 28860
tgtgtgttcc cttttctccg cgtttgcccg ctacaaaccg gtgagtcgga aggcataatc 28920
gggttgaaaa aaaagtatca aacactgatg gtgtcttttt tagggagggt gtccagaaaag 28980
agaaagaaac tgaagatttg cgaatcgata gcgtcgatcat ctctcgacgc cagtgaagtc 29040
aagatcgggtt acaatagtgt atgcgattcc caaaatccac atatcaaccg gactcgtgat 29100
atttatcatt tgtaagtact aacaagagat gtgaacgtat ttacactcaa cattagcaaa 29160
ttccagaaga agatctaacc aaaaactatc gaaatggctc tcaacgtgaa ccgcgctgtc 29220
gctgatccat tctaccgcta caagatgccc aagctgtcag caaaagtcga aggcaaagga 29280
aacggaatca aaacggatcat ttccaacatg tctgagatcg cgaaagctct cgagcgtccg 29340
ccgatgtgta tgtttatcgc cagttggctc gccattggac aaaaaataa ccattgtttt 29400
tcagacccca cgaagtactt tggctgtgag ctgggggctc aaacgaactt cgatgccaag 29460
aacgagcgtt acattgtcaa cggcgagcat gatgccaaca agctccagga tatttttagat 29520
ggtttcatta aaaagtttgt gctttgcaaa tcatgtgaaa acccggaac tcagttggta 29580
cgagatcatt gaattaataa tctgtctaatt ttattattt cagtttgtcc gtaaaaaataa 29640
catcaagagc aagtgaagg catgtggatg ttcgttcgac attgatctca aacataagct 29700
gtctacattc atcatgaaga atctccaaa gattgatgtc gatttttgta agtatcgttt 29760
actaacattt ttcgattgaa cttatgcaaa attctgcaa aaattctatt tgcattttta 29820
atcctttcaa ttcgattttc cgtgtgcttc cagtgcatac aaacatgcta atttttggtt 29880
tccagccaaa gccgaacaaa agaattgaaa gaagacatcg ggtgctgacg ccgcgcgcgc 29940
cgtggctgcc gacataatcc acaacagcga caaaggcagt tcgaatgatg acgacgacga 30000
cgattgggaa cctgaaccag tcgagccgaa tggcatgctg tcggcgggaa tgggcaagct 30060
cgtgctggac aaggatcttg agaagagcga agaacagcgt ctcgacatgc ttcacacatt 30120
cttcttgaaa gccaaaggaag aaggtaagaa ttctgagcat tgataaaaag tattctcgtt 30180
atttcagata gaatttctga tgccaaggga caaactgctc tacgtgacga agctgagaga 30240
cttgagctga agcaaaaagc atctctcctt ctgcggaacg tttttcttga tgagaaagta 30300

-66-

atcactgaca aacaaatcag caaacaccgc aatcttctgc ttcgcttcac gttgaatgac 30360
aagaaagctc aaagatacct gttgggagga gttgagcaag taattcacia acatgaagcg 30420
gaacttctgt ctaaatacag tcacatcatt aagtcattgt atgatgaaga tgtctgagaa 30480
gaggattcgc ttatttcatg gggagagaag gttagtagca aatggagctt tgtttcgaat 30540
taaagtttat atttacagcc gtcgagtaag tatgtctcca aatcttttgc caagaagatt 30600
attgagaact ctcaaccagt gctcaactgg ctgaaagaag cggaagaaga aaccgaagaa 30660
gagtcagcag atgagattgc ggtaagaaat atcagatttg tttttttttt ttcaatgggt 30720
ggttttcagt tcggaggaga cgtcaaggag agtgaattcc ttcgtcaaca gaaggagaag 30780
gctgctagag aagctcagca aaaatcagcc aaggctacaa acggcaatgc tgctgctgca 30840
tccggagcaa atgatgaaga ggacttggat attgatgaca ttaattgta cagatgcttt 30900
tttaaaattt acctgggcta cttatgtttt ttgtgtattt cttcccatat tcgaaccaat 30960
tcaactaatt tcgaagaagc ctcaagtttt ttttgctttc tcccccttc aatagtaagc 31020
atcatttcat ttctgtcttc tgtcttttct gttcctacgc tgttttccct tcaccaaate 31080
caattcattt attcgtaaag tcattactat ttgttgtaa tcgtaaacad ttgggaatat 31140
tcttgttcaa ttcagtccta tattacaaaa acacaatgtt caaaaaaaaa gaatcacttc 31200
agatgggaac ccgtcgaatt cggcggtccg atggagaata cacattgttt tttcggaaag 31260
ttagccatt ttcaaatcat caccagctg atttcatttg cgacgaagcg ataaattgta 31320
aagagccgaa aaccttttgc tgctcggaac agtactatat gtacaataag gcttcactat 31380
tgatggattc aaaactgatg gcagcgattc tagaagcaac ttgtccgaaa acaatgaaga 31440
caatgtgttc taaatggctg ttgaaaggat ggaaggattc ggtgtaagtt ttaaatcagt 31500
ttgataataa aatatgtttt tcttttacag atgggatgag aacaaagaag aagtgatgag 31560
aataggatgc ttggcaaaat tccgtgcttc tcgccatctt cgttatgctc tttttctcac 31620
aactggtagc aaactagctg aatgtagtcc gttcgataaa atatggggaa tcggtagtt 31680
tccaacggat cgtcttattc ttccatcgcc catcacaatg caatcagaat ctcaaactg 31740
gaaatgtttt gaaatcattg aaatcatctt tgagctgata tggtagcgga agaaaaggac 31800
gtctgaaaat ggctgaatta ttataggaaa agatatgcaa gccgcacaat gggctccatt 31860

-67-

gagctctggc aagaatctgc tgggaaagat tttggatgga atccgagagg aattgtggga 31920
tgattcaaat tacaagttag ctctggaatc agaaaattat tattatataa aattactatt 31980
tcagagatga acgagaagaa gtggagaaac gaatggaaac tgaaagagat tatctattca 32040
ctgctataga gcacatggac ttgatgtaca aagaagagc aacaaaaaga gtattgtaag 32100
aatcagaaaa tctgcgtaat tgtcgacaga aataacgtat tccagattgt tcgaggaaga 32160
attgttaact gatgatagat cctacatcac accagatatt cagaggctcc ttcccgactg 32220
ggcttggccg ccgatcctcg tgaaaaacga gcctattcaa ccatcgctgc ctgtaataat 32280
cgatttcctt aggtacttgc ctgatcttt aatttatcag aattaacttt caaattccag 32340
atcatctcca cttagagcag ctgaaatata acgtaggaag agcacatctc attcgacaag 32400
cttgagtaaa aggcggtacc tcaggagcag atcgagaagt ctgtccaaaa gcccggtctg 32460
aagacgtctc agacatcttt cccgaagtgg atcccgtaac ccagctcaac ggcattccag 32520
aagatccgaa agtacatctc gaagacgttc cggacggcac tctagaagtc gatctagaag 32580
cccaccacga aaacgtccgg tacgccgata aagaagcaga tccaggagca ggacaccaa 32640
ccgaaattgg acaagagcac ggagcagaac aagaagtcag gctaaaagta gcagcacttt 32700
aacctggcca ctgagcccat cgagaagcag aagtaacagt aatgaaagga atttgaaaga 32760
gaagaaagac cggaaaaaga aaaaatctga gaagaaacgg aagcatcatt ctaaattccag 32820
aaaacaccgt tctaaaagat ccgaatccag agaagaacgt cacagaagac ggaaggagaa 32880
gaaaagagag aaaaagaaga aacgacgtcg gagaagttcc actacttcag attaaacttt 32940
atttttgaaa actagtcata actttaaaag tcataacttt tttaaaagtc ataactctgg 33000
tttaatatca aatgtctttt caaatattct ctattttatt attcttcgta attaaactga 33060
gattaagtac tgggtatatc attaataaaa ttacgatact ttgccgaata aatcagttat 33120
aattacaatc tgtctgctgg tgaaaattgt acatgctatt ttcttggtcc tcattctttt 33180
ttcattctct gtaaggtttt gttcgttttt tggaaaattc tgagagtagc cggaaaaaaa 33240
aaaaaaaaa actaaatacc tacagtaatg ccagaggcat atgctcaata attatcaaaa 33300
attagttttc cgcggcgaga cccatcccca caaaagtatg actcccttga aagtcgtaaa 33360
tgacaatttc ttgaaacaag aacatttgta tattaacgaa acacaaaatt ccgagaatgc 33420

-68-

gtattgagca gcatatttgc cgagccaaat atctcgtagc gaaaactaca ttaattctta 33480
aaaacactac tgtagcgctt gtgtcgattt acgggctctt tgaattatca ttgatttatc 33540
gatagaatat ttaaaaaata aattcatttc gaaattagag ccataaatac gacacaaaca 33600
ctacagtagc catttaaaga attactgtag ttttcgctat gagatatttt gcgcatcaaa 33660
tatgttgcgc aatacgcatt ctcagaattg tgtcttcctt aataatagac agtggcttcg 33720
ctaaaaacta agaacaaagt aaattaaagt ttttttctgt tcacttcaaa ttttacacga 33780
tcttgaagca aagttcaaaa gagcatgaat caattggaaa gtgttcaatg caccctacag 33840
atatgatttc ggggcagtgt aaactacagg gcacagacat aaaaatttaa attgttgaag 33900
actaaaatat aaacatatga attcaagggt cataataaat gtattttttt aaataatatt 33960
tattaaatgt atgcatacaa ttaaatacaa cataattatc aaatacaaat attataattg 34020
caacctgtcg gacaacaact ttgctgaggt gtcgtgtgac agtcagaatc cttgtcacac 34080
cagctgaccg gctcagagac gatacatcgg aagttgagat gagtgactgg tggacattgc 34140
cgacgcgttg gagcacaaca ctcacgatat cgagtcatgt cgatgcagcg ctgaaactca 34200
ggaaactatg tggaatttag gtggatcacc caaccagctg cccttcaccg cactgataat 34260
ttggagtgcg gtacatgtaa tgggcagagc attgctgcat ttgcatcaca atcaatgaat 34320
ttgcaaaggg cctggagatt ggcttggtcg aaagagttga tattatttct attgatataa 34380
taccctaaat ttacgaaaat tatgctaaat taggatttta gttataatcc tcgtcacatc 34440
tgatctctga aaacttaaaa atatcctttt tggtagtgtg gcaccaaatt cgtgctgtaa 34500
cagagaccaa aaacactact ttttcgacat ttcctctcct tgcagcgaaa aataaaattt 34560
tttgaaaatc tgtgttttct catacccgga aaaaaccaac aaaaacggcc ttgttcaaaa 34620
ggcggtagt atttctattt tatgaaagtg gccgagattt ctctttttct acgccaagta 34680
gttaattctt cgcggcaaga cccatcaatt ttctaacctc taatctcttt ttcaacatga 34740
atatccacgt catcatagaa tttgcactcg ggcttataga tttggagcct ttgaaagtat 34800
atgcaccagt ctatatgggt gttgggaaac gaataggcag tagttttttg gaccaattgt 34860
agaatagaca gtagtaatag ggaagaatat aagaatttca taattcagat ttcaataaaa 34920
aataaattta attgagaaaa aaaacgggtg atattctttt gttaagcag acaagtatgc 34980

-69-

ggaagtgaat cttgagcacc tcgtaaatca cgggaggcgt acttgtagag aagagagata 35040
agggattaag aggcgcaagc tttgccactt tgaagttaaa aaataaagaa agagacatgc 35100
aaattggtgg acaaatagcg gaaggttagc gggagggtggg aggggggaca ggtgcatgta 35160
acacaatgga ttttacaata ggaatattga aaatacgcac atgggaaatc ggaacagata 35220
tgaaggtgtc aatattttgag gtcaactgtc tggtttttcc ccgatttttg aattttttga 35280
aaaaaagtgc ataattcaca gattgaaatt ggaaattggt cgagaaaaga ataaggagtg 35340
ttatgaattg atggtggcaa caaacacaa attctacatt tgtacaaaa tgcccactaa 35400
aatgggcata ttgcacaca ttccacacaa attgcataca tattccacaa tggggaatat 35460
tttgaatatt tagattaata aagatgaaat aattgagttt tatttgtaat taaaatattt 35520
ttctgtttat cattaattga aaatgttgaa ttacttttta atagacgaat catcaaagaa 35580
cttgatccct gcattatcag gcaatcctac ataaccttc aacgttgctg ttttaccaat 35640
tgcaacattt ctgctactg gaacacgcac actggaatac gatgacgatt ccaattggaa 35700
gaatatattg gtgcccggtt ggaagttaac aattgaattg ttgttaagcg ataaaggata 35760
cacattgata acatccaaaa gttcagttat gtatatccat ccgtataaat cttgcgatct 35820
tccattcacc aaaagctggt cgccatcttg tataggaatg aatggagtta aggatcccgt 35880
aacagtacga gttgtgagcg tagttccact gaaaattact aaatatttag ttcaaagggt 35940
ttctgttact actttttggt tgcaacaact ctgagaaatt ttagttttca ccaaattttt 36000
tcgattttgt acagaattgc acaatatatt ttggaatagc aagaaattgt tcagtgaatg 36060
tcaaacttga caaaaaaaaa ttttttttaa aggtgcctat caatttttaa aaatgttcta 36120
atattttgtt ggaaagtttc aataatttca ctacatttac tatttctttt ttaggcctat 36180
tttggtatt caaaatatta accacacgac cttcaataga ggaaaactgt caaatttttt 36240
ttaaattatg aacaattaac tcactttaca ttttgtcctc cattccttgt agttaatata 36300
agacttccca acgcttcttg agaactattc gaaataatat aaatcttcga atttcttcct 36360
actatatatc ctagtgtgtt gctcgttgca acgtctagag tatccaatat aaaccacta 36420
gaagctgata taaagaaaaa taatagaaat atatttttca ttttttccaa atgactaaat 36480
gaccaacttc aagacatttt atatgcttaa aatcacgtca cagaactata atcatgttga 36540

-70-

tttttgatag aaaatgataa gaaatgcgac caaaatgtgt attttctccg tttgtcctct 36600
gaatgagtca aattcacgta aaacttggca tttgtcacag tgtgtcagac acaaggcaca 36660
tatgtattta cgggactttt caagacttta ttattattga gatcaaacca gattacagaa 36720
gacgggagaa aggtaccaac aaatatcaga atattgcaaa aaaaaattaa aaatttcaaa 36780
acgcaaactt caaactagga gagctaattc aaactttgaa atcatgttcc ataaccggta 36840
gcatttggtc ggtgacttgt ttgacagccc attgaaggaa gagaagtact cccgacaggc 36900
tgaaacatat gaaatagtcc aggccttcca ttagagaatg tgatgtttga aggaagaaca 36960
atgggacgta gagtactccg aatagagcag taagtccatt gatgagctga aacagtaaata 37020
aatcgaaaag ttagtaaata tgttcaagga atggaagtaa accggaatta tccgagtatg 37080
ggcgttttat agttttttct ctttttttga cttcgttttt catcctatta aaatatcatc 37140
ggttttttcg agttccagaa aaaatattta aaaaatcatc cgaaatccga acacaaaatc 37200
cgaaggctac tccaaggtaa gttaacccta ctcggaat ctctcgtcct ggagcgcgga 37260
cggggcgcgga ctagatcacg ggttcgctct ccagtcaccc tttttttcgc gcttcttacg 37320
cgccacgtcc gcgcttcagg aggagcgatt tgcggagtag cttttatgca ttcagactgg 37380
tacttaaaaa ttaatcgatt tttttaaaaa gtgtcataaa ctttttctac gtctttttct 37440
gacacaatgt tgaaccgtac tagattgttg taaacacggc cttcaaattt gattttcgcg 37500
aaaaaatttg aataattttt ttctaacttt tttcttttta aaatcttacc aacttagca 37560
aataaccatg aagcacaact tcataagtgg atcctatttt tcgtttgaag aggcaaaata 37620
ctgaaaacaa aagagctgat atggagcaag acacgtggat ccagaagagt atacgcacaa 37680
tcacactatc cccttcgatt ttgacgcggt acagaattct ggaatttttt tttgaacttt 37740
aatggattgc gattcaaaaag aaaacgtagc ttaatctcca gttaaagctg attttcattg 37800
caaatgtat ttagaaaaaa ctcacgctaa taaggcggag agtattgtct gtagaaccgc 37860
catgattact gtagatgcat agagtgagaa tgagcacata taagcgctcg gctgtttttg 37920
aacgacaatc gaattggccg ccatcatctc attcttcgac ctccgtttt atttctgaaa 37980
atatatgaca ctttttaaat gaattgacag aaatctgatg ctaactacat ttaacttgt 38040
aggagtgggt caaatgattc ataaaggga tacaatttct gaatgatcaa agaagaaaga 38100

-71-

aaaaaatat tggatgaatgt ataatttttt aggggttaaag taaataaata aacacaaggc 38160
cgaagattag caagagtttg gggataaccc ccgtgaagaa aaatatgaaa aaaaatgggt 38220
tgaaagaatt aaaaaaatcc tttcaaattt gagattcaaa ttttgttcat ctgttctgtt 38280
cgaacattga gcagaagaag cttttaccaa taaatccaaa atttggttaag agaatatagt 38340
ttaaggatat caccagttc aaaatagtag ttcaaaaact cgagtcttaa ttttttcagt 38400
attcgaattt ttacagtaca ttgatcgttt cgttatttga tcgctttttg ataaaacaaa 38460
aaatagataa tgaagctgcc aagtttaaaa aaatcggggc taaggctaag ggagcataca 38520
cggatatatca ctacctggat attagtttta gacttcatca gatatttagt cagaaaagta 38580
cgtcaagaag tcggatacga aatgtataaa tttcttaaaa cttaaaactt cgagatatcc 38640
agactgtggc totcaagctt cagtgccttg agaaatagtt taatagtcag aatatgtttt 38700
aaatttctta atttttctga agaagtcgta aaagtataaa tgttgctaga tcaaactc 38760
tagaaaacct tcaccacttg agaatactcc agtctcaaat tttccctcga cgcggaagtg 38820
tagaaggcg cgagattcag aagtaggtga aaattagacg gaaaactctc tcaaaattga 38880
aatcaatgaa taggacaact gagacaatgt gcagggtgtat gtgtatgcac atggcaccca 38940
cgtacacgca tacatcttat gttagagaag tacgtgtgct ccgctcatca tgtcttctcc 39000
ttctctaca tctacatttt ttgctccgtg agccacgccg ggaaaaacga cgacgacgac 39060
ggcgacgggg gacgactact cgactctaatt tggccctaaa cgcaagtaaa tttttaggca 39120
atgtatgttt gcgagagttg agagccccac cgccacgagg agaagtgggg gaagattccg 39180
aagagattcc ccctcctcct tctgacacc tcgtctttcc tttttgttc catttccgtg 39240
aaaaagctgt ggaaggagg agaagaactt accggctaaa tggaaaaaaa ggaactctaa 39300
cttattctga ctctacggaa ataggaagcc tacttgtaa ttagaccgcc ctgcacaga 39360
tttctttttt tttgtagata caaatataaa aactaactgc gtgtgatgca gcagatatct 39420
tgaattggaa agtgtcagt ctcagaggga atagccaatc attgacagaa atttgactac 39480
ttcagaagga atcaactaga acatttgacg cctgaaacct aacaagaaaa atctataatt 39540
tggagatccc tagattgat ccaactttat taaaaactaa gtatacttat atatatacga 39600
tttttttaaa aataaacctg attgtctgaa tttctacaag attgcgacca aattttccgt 39660

-72-

atttccaaaa totaatatta ggggttttcta ctaaaattca acgagaactc ttaacattat 39720
ggttattttta acacatgggt caccgccggc tcaaacttca ttcttagtcc tctgattttt 39780
ggtaaatacga cgcctacgtc tcaacaatta gtttgtgcag aaaataagta aaaagagttg 39840
tgctccatct tgcacacata cacatcgctt gtaatgaaga ggttcggagt cagatgacta 39900
ggcgtagaaa tgtgcgaaat tcacggataa cagagatttt tgatgtttca tcagacttac 39960
acgttttggg agtatgaatt ggggtctagac aacggagtgg cagatgttcg gaaaattttg 40020
cagaaaagag aacctagag cgttgatggg ttggtgacta acgaacttaa aagaaaattg 40080
gtcattgaaa attttaaaat tttaaatttt gcttgcagtt catctttctc tattaacaaa 40140
aattattttg tagcttttct caatttcagg caattaaaac atttcaattt attcttctat 40200
tatggaagtt tatctctaata tgaaactctc caattttgat caaagaacaa acgttctcgt 40260
tgtttgaaaa aaaaaacagt tcttttttga aactcgcgcg caaattatta accaatcatc 40320
ctcgtttgcg cgcaaaattg tagaaaaaat catttaaatt tatcaaaaat agtttaccat 40380
tctgatgagt ttttcatata caaaaatgcc ctggcaattg ttgttttctc tgaaatagca 40440
cataataatt gaactctacc cacataaagt tegtcttgaa aaacacctta caattattgt 40500
gattgagagc caccccaaga gggattagaa aaacggatgt aatctgtata ccttcgagat 40560
tcgtttattt ccttgtataa ccaatagcag gaaaattaca gctttttcta agtaagcggg 40620
gaaactagag agattctata gaatatgggc gtaataaatt gtatgttaaa gttttagaat 40680
aacacaagtc cagagtaagg gcaagaaaag taatgagcaa cggaaccag catgcaagac 40740
accogaattc cggttctctt ctgaaactaa aagttgcgtg tactaaacct taaaccagca 40800
gctggctagt ctcaagaaat aatagaaaaa aggaaggaat gaagatatgg gaataatata 40860
aattgaaaat gttgtgtgag ctccgaataa ttttcaatat caaaaattta tgaattgtgt 40920
ggacggctgt gtgtgcgtgt gcgtatgcgt cggcaagaaa aagaagcgac cgaataagaa 40980
aatggttgat tcagtgaaca aaaaaagaga gaaagatatc caacaaaaat tattcaaaac 41040
tattatcaat cggtaggtat tgctctagag cacaccttctc tggacactca gcagacatgc 41100
gtagagaggg attatgtggg acatatagtg gatggaggaa cagatattta taaatactta 41160
tggaagagag gatgaagata ggatgaggtg gatgaattga gaagatttta aatgataat 41220

-73-

ggatattgaa tttgaataag gagattctaa attatccgaa gaacacaaac tatatcaaga 41280
ctacaaaata atctagacga gtcccagttt tgcaaggtaa ggattaatct taaaaggatc 41340
ttttaaatat ttatttcaat gtcctataa attttaaaaa gtaggtgcat tctaatatgt 41400
acagtgatta ggagatatgt gacgttacgt gaggtctcga taaagtacgg tattcgagct 41460
aaatttcaaa cattgtcaag gtagattcgg tacacagcca ccataaatgt tccactaaaa 41520
atgtgttgct cttctccttt ggaacacaaa tctagctgct gaactttttc acttcactac 41580
atgtcaatgg gattgatatg catctaggac atttttttgg ttatcaatag tccgcatagc 41640
ttgcgtaacc aatacaaccg attgtccaaa aaaatttgaa cactacaaaa cgtattttatt 41700
attcggatac ccgttgcat tcaatacaca agttgatact tgctgcccct cggggctctc 41760
agacactcat tgactgaaaa cagacgattg ctgcgtcgtc tagtctgaag gctcggagag 41820
ctgaggaaga tatgaggaca taatgaattg atgtgtgaga atgagaaaat gaaaaaggaa 41880
aatgagaaa aaaaagatga tgaagaatgt acaaatgaat aatcaagtag caatgacgag 41940
aaaagaacca ggtccttttg gcaggcaatt ttcgaaattt tcagatcaaa tttgtcgcca 42000
ttgcttctgg attaataatg gatgacgctt tgacaatggg gctcaatata agtgcaaaca 42060
gattggtttg ggatggcgta tagaaataga gccggtgaga cgatgtgatg aagttctgag 42120
agacgagatg tgatcgaggc gtttgtagtc gaggcaaacc gaggccgcat atggggttcc 42180
gataggcaat cggagaccag tgtccatctg aaagagataa aagttattcg agttgtgaat 42240
gttgcaagga aaattaaagg tacagtagag acaatcgaga cttttttcgg gaggacgcca 42300
tctaaaaact gtggaagcac gtggcttttg tagctfgatg tcacagaagt tgattccata 42360
agaattacat tagaaagctt gcgacgctaa atggataaat ctggtaacgg cttcctaata 42420
gcaagttaag ttttttcaca ataaattttt cagaattgaa tagatgcatt ttataactta 42480
cacatcgagt gggcacgttg gtggacaaga caagccccga t 42521

<210> 24

<211> 4434

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

-74-

<400> 24

gcccctcg ccaccgtcc cggccgccgc gctccgttac acacaggatc cctgctgggc 60
accaacagct ccaccatggg gctggcctgg ggactaggcg tcctgttcct gatgcatgtg 120
tgtggcacca accgcattcc agagtctggc ggagacaaca gcgtgtttga catctttgaa 180
ctcaccgggg ccgccgcaa ggggtctggg cgccgactgg tgaagggcc cgacccttcc 240
agcccagctt tccgcatcga ggatgccaac ctgatcccc ctgtgcctga tgacaagttc 300
caagacctgg tggatgctgt gggacagaa aagggtttcc tccttctggc atccctgagg 360
cagatgaaga agaccgggg cacgtgctg gccctggagc ggaaagacca ctctggccag 420
gtcttcagcg tgggtgtcaa tggcaaggcg ggcacctgg acctcagcct gaccgtcaa 480
ggaaagcagc acgtggtgtc tgtggaagaa gctctcctgg caaccggcca gtggaagagc 540
atcacctgt ttgtgcagga agacagggcc cagctgtaca tcgactgtga aaagatggag 600
aatgctgagt tggacgtccc catcaaagc gtcttcacca gagacctggc cagcatcgcc 660
agactccgca tcgcaaagg gggcgtcaat gacaatttcc agggggtgct gcagaatgtg 720
aggtttgtct ttggaaccac accagaagac atcctcagga acaaaggctg ctccagctct 780
accagtgtcc tcctcaccct tgacaacaac gtggtgaatg gttccagccc tgccatccgc 840
actaactaca ttggccacaa gacaaaggac ttgcaagcca tctgcggcat ctctgtgat 900
gagctgtcca gcatggtcct ggaactcagg ggctgcgca ccattgtgac cacgtgcag 960
gacagcatcc gcaaagtgc tgaagagaac aaagagttgg ccaatgagct gaggcggcct 1020
cccctatgct atcacaacgg agttcagtac agaaataacg aggaatggac tgttgatagc 1080
tgactgagt gtcactgtca gaactcagtt accatctgca aaaagggtgc ctgccccatc 1140
atgccctgct ccaatgccac agttcctgat ggagaatgct gtcctcgctg ttggcccagc 1200
gaactctcgg acgatggctg gtctccatgg tccgagtga cctcctgttc tacgagctgt 1260
ggcaatggaa ttcagcagcg cggccgtcc tgcgatagcc tcaacaaccg atgtgagggc 1320
tcctcgttcc agacacggac ctgccacatt caggagtgtg acaagagatt taaacaggat 1380
ggtggctgga gccactggtc cccgtggtca tcttgttctg tgacatgtgg tgatggtgtg 1440
atcacaagga tccggtctg caactctccc agccccaga tgaacgggaa accctgtgaa 1500

-75-

ggcgaagcgc gggagaccaa agcctgcaag aaagacgcct gcccacatcaa tggaggctgg 1560
ggtccttggt caccatggga catctgttct gtcacctgtg gaggaggggt acagaaacgt 1620
agtcgtctct gcaacaaccc cacaccccag tttggaggca aggactgcgt tggatgatga 1680
acagaaaacc agatctgcaa caagcaggac tgtccaattg atggatgcct gtccaatccc 1740
tgctttgccg gcgtgaagtg tactagctac cctgatggca gctggaaatg tggatgctgt 1800
ccccctggtt acagtggaaa tggcatccag tgcacagatg ttgatgagtg caaagaagtg 1860
cctgatgcct gcttcaacca caatggagag caccggtgtg agaacacgga ccccggttac 1920
aactgcctgc cctgcccccc acgcttcacc ggctcacagc ccttcggcca ggggtgtcga 1980
catgccacgg ccaacaaaca ggtgtgcaag ccccgtaacc cctgcacgga tgggaccac 2040
gactgcaaca agaacgccaa gtgcaactac ctgggccact atagcgaccc catgtaccgc 2100
tgcgagtga agcctggcta cgctggcaat ggcatcatct gcggggagga cacagacctg 2160
gatggctggc ccaatgagaa cctggtgtgc gtggccaatg cgacttacca ctgcaaaaag 2220
gataattgcc ccaaccttcc caactcaggg caggaagact atgacaagga tggatttgg 2280
gatgcctgtg atgatgacga tgacaatgat aaaattccag atgacaggga caactgtcca 2340
ttccattaca acccagctca gtatgactat gacagagatg atgtgggaga ccgctgtgac 2400
aactgtccct acaaccacaa ccagatcag gcagacacag acaacaatgg ggaaggagac 2460
gcctgtgctg cagacattga tggagacggt atcctcaatg aacgggacaa ctgccagtac 2520
gtctacaatg tggaccagag agacactgat atggatgggg ttggagatca gtgtgacaat 2580
tgccccttgg aacacaatcc ggatcagctg gactctgact cagaccgcat tggagatacc 2640
tgtgacaaca atcaggatat tgatgaagat ggccaccaga acaatctgga caactgtccc 2700
tatgtgcca atgccaacca ggctgaccat gacaaagatg gcaagggaga tgctgtgac 2760
cacgatgatg acaacgatgg cattcctgat gacaaggaca actgcagact cgtgcccaat 2820
cccgaccaga aggactctga cggcgatggc cgaggatgat cctgcaaaga tgattttgac 2880
catgacagtg tgccagacat cgatgacatc tgtcctgaga atgttgacat cagtgaagacc 2940
gatttcggcc gattccagat gattcctctg gaccccaaag ggacatccca aaatgaccct 3000
aactgggttg tacgccatca gggtaaagaa ctctccaga ctgtcaactg tgatcctgga 3060

-76-

ctgcgtgtag gttatgatga gtttaatgct gtggacttca gtggcacctt cttcatcaac 3120
 accgaaaggg acgatgacta tgctggattt gtctttggct accagtccag cagccgcttt 3180
 tatgttgtga tgtggaagca agtcaccag tcctactggg acaccaaccc cacgagggt 3240
 cagggatact cgggcctttc tgtgaaagt gtaaactcca ccacagggcc tggcgagcac 3300
 ctgcggaacg ccctgtggca cacaggaaac acccctggcc aggtgcgcac cctgtggcat 3360
 gaccctcgtc acataggctg gaaagatttc accgcctaca gatggcgtct cagccacagg 3420
 ccaaagacgg gtttcattag agtgggtgatg tatgaaggga agaaaatcat ggtgactca 3480
 ggacctctct atgataaaac ctatgctggt ggtagactag ggttgtttgt cttctctcaa 3540
 gaaatggtgt tcttctctga cctgaaatac gaatgtagag atccctaata atcaaattgt 3600
 tgattgaaag actgatcata aaccaatgct ggtattgcac cttctggaac tatgggcttg 3660
 agaaaacccc caggatcact tctccttggc ttccttcttt tctgtgcttg catcagtgtg 3720
 gactcctaga acgtgcgacc tgctcaaga aaatgcagtt ttcaaaaaca gactcagcat 3780
 tcagcctcca atgaataaga catcttccaa gcatataaac aattgctttg gtttcctttt 3840
 gaaaaagcat ctacttgctt cagttgggaa ggtgccatt ccactctgcc tttgtcacag 3900
 agcagggtgc tattgtgagg ccatctctga gcagtggact caaaagcatt ttcaggcatg 3960
 tcagagaagg gaggactcac tagaattagc aaacaaaacc accctgacat cctccttcag 4020
 gaacacgggg agcagaggcc aaagcactaa ggggagggcg catacccgag acgattgtat 4080
 gaagaaaata tggaggaact gttacatgtt cgggtactaag tcattttcag gggattgaaa 4140
 gactattgct ggatttcatt atgctgactg gcgttagctg attaaccat gttaaaggc 4200
 acttaaatag aagcaggaaa gggagacaaa gactggcttc tggacttcct ccctgatccc 4260
 cacccttact catcacctgc agtggccaga attaggaat cagaatcgaa accagtgtaa 4320
 ggcagtgtg gctgccattg cctggtcaca ttgaaattgg tggcttcatt ctagatgtag 4380
 cttgtgcaga tgtagcagga aaataggaaa acctaccatc tcagtgcagc ccag 4434

<210> 25

<211> 2837

<212> DNA

<213> Unknown

-77-

<220>

<223> Description of Unknown Organism:Unknown

<400> 25

agagagccag tccgatgtct gcagcctccc tggccaggcc tctcctctcc tgccgcagct 60
agtccccttc aggacagaca gactactggc gtcggtcacc attcacttgc aaacacacca 120
ggtcacgtga agaaacttcc tggtgacact caggctgtag ctgtgcactc ttcaaccacg 180
aggttggttt tctcctaagt gtcacagggtg gagacaagat gctctgggca ctggccctgc 240
tggtctctggg catagggcca agagcttctg ctggtgacca cgtcaaggac acttcatttg 300
accttttcag catcagcaac attaaccgga agaccatcgg tgccaagcag ttccgagggc 360
ctgaccccgg ggtgcccggc taccgttttg tacggtttga ctacatcccc ccagtgaaca 420
cagatgatct caacaggatt gtcaagcttg caaggagaaa ggagggttc ttcctcacag 480
cccaactgaa gcaggaccgc aagtctcggg gaacgctcct ggtgttgga ggccccggca 540
cctcccagag gcagtttgag attgtgtcca atggcccagg ggacactttg gacctcaact 600
actgggtaga aggcaatcag cataccaact tcctggagga tgtgggcctg gctgactccc 660
agtgaagaa tgtgactgtg cagggtggcca gtgacaccta tagcctgtat gtgggctgcg 720
atcttatcga cagtgtcacc ctggaagaac cattctatga gcagctagaa gtagacagga 780
gcaggatgta cgtggccaaa ggtgcatctc gagagagtca cttcaggggc ttgctgcaga 840
atgtccatct cgtgtttgca gattctgtgg aagatatctt aagcaagaaa agctgtcaac 900
acagccaggg agctgaagtc aacaccatca gtgaacatac agagactctc catctgagcc 960
ctcacatcac cacagatctc gtggtccagg gtgtggagaa ggcacaggag gtgtgtacgc 1020
actcctgcga ggagttgagc aacatgatga atgagctctc tggactgcac gtcattggtga 1080
accagctgag caagaacctg gagagagtgt ctagtataa ccagttcctt ttggagctca 1140
ttggggggccc tctgaagaca agaaacatgt cagcctgtgt gcaggagggc cgaatctttg 1200
cagaaaatga aacctgggtt gtggatagtt gtaccacatg cacctgcaag aaatttaaaa 1260
cagtctgcca tcagatcacc tgctcacctg caacttgtgc caaccatct tttgtggaag 1320
gagagtgtg tccatcctgt tcacactctg cagacagtga tgagggtgg tctccgtggg 1380
cagagtggac cgagtgttct gtcacctgtg gctctgggac ccagcagaga ggccggtctt 1440

-78-

gtgatgtcac cagcaacacc tgcctgggcc cctccattca gacaaggaca tgcagcctgg 1500
 gcaaattgtga tacgagaatc cgtcagaatg gaggctggag tcaactggta ccctggctctt 1560
 catgctccgt gacttgtgga gttggcaatg tcacccgcat acgtctctgc aactcaccag 1620
 tgccccagat ggggtggcaag aactgcaagg gcagcggccg ggaaaccaa ccctgtcagc 1680
 gtgatccgtg cccaattgat ggccgctgga gcccctggtc cccttggta gcctgcacag 1740
 ttacctgtgc tggagggatc cgtgagcgct cacgtgtttg caacagccct gagccccagt 1800
 atggagggaa ggactgtgtc ggggatgtga cagaacacca aatgtgcaac aagagaagct 1860
 gccctattga tgggtgctta tccaacccgt gttttcctgg agccaagtgc aacagcttcc 1920
 ctgatgggtc ctggctcctgt ggctcctgcc cagtgggctt tctgggcaat ggtaccact 1980
 gtgaggacct ggatgagtgt gctgtggtca cagatatttg cttctcaact acaaagctc 2040
 ccgctgtgt caacaccaac ccgggcttcc actgctgcc ttgtccacca cgctacaagg 2100
 ggaaccaacc cttcgggtgtt ggccctggagg atgctaggac agaaaaaaa gtgtgtgagc 2160
 cagagaatcc atgtaaggac aagactcaca gctgccacaa gaatgcagag tgcactacc 2220
 tgggccactt tagtgacccc atgtacaagt gtgagtgcc gattggctac gcaggatg 2280
 ggctcatctg cggggaggac tcagacctgg atggctggcc caacaacaac ctgggtgtgtg 2340
 ctactaatgc cacctaccac tgcataagg acaactgcc caaactgcca aattccgggc 2400
 aggaggattt tgataaggat ggaatcggag atgcttgtga cgaggacgat gacaatgacg 2460
 gtgtgagcga tgagaaggac aattgccagc ttctcttcaa tccccgtcaa ttagactatg 2520
 acaaggatga ggttgagac cgctgtgaca actgccccta tgtgcacaac ccagcacaga 2580
 togacacaga caacaatggc gagggggatg cctgctctgt ggacattgac ggagacgatg 2640
 ttttcaatga gcgagacaat tgtccatag tctacaacac tgaccagaga gatacggatg 2700
 gtgatggcgt gggtgaccac tgtgacaatt gtcctctgat gcacaacca gatcagatcg 2760
 atcaggacaa tgatctcgtt ggagaccagt gtgacaacaa tgaggacata gatgatgacg 2820
 gccaccagaa caaccaa 2837

<210> 26

<211> 4108

<212> DNA

-79-

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 26

agagagccag tccgatgtct gcagcctccc tggccaggcc tctcctctcc tgccgcagct 60
agtccccctc aggacagaca gactactggc gtcggtcacc attcacttgc aaacacacca 120
ggtcacgtga agaaacttcc tgggtgacact caggctgtag ctgtgcactc ttcaaccacg 180
aggttggttt tctcctaagt gtcacagggtg gagacaagat gctctgggca ctggccctgc 240
tggctctggg catagggccca agagcttctg ctggtgacca cgtcaaggac acttcatttg 300
accttttcag catcagcaac attaaccgga agaccatcgg tgccaagcag ttccgagggc 360
ctgaccccggt ggtgcccggc taccgttttg tacggtttga ctacatcccc ccagtgaaca 420
cagatgatct caacaggatt gtcaagcttg caaggagaaa ggagggttc ttcctcacag 480
cccaactgaa gcaggaccgc aagtctcggg gaacgctcct ggtgttgga ggccccggca 540
cctccagag gcagtttgag attgtgtcca atggcccagg ggacactttg gacctcaact 600
actgggtaga aggcaatcag catacctaact tcttgagga tgtgggcctg gctgactccc 660
agtgaagaa tgtgactgtg cagggtggcca gtgacaccta tagcctgtat gtgggctgcg 720
atcttatcga cagtgtcacc ctggaagaac cattctatga gcagctagaa gtagacagga 780
gcaggatgta cgtggccaaa ggtgcatctc gagagagtca cttcaggggc ttgctgcaga 840
atgtccatct cgtgtttgca gattctgtgg aagatajctt aagcaagaaa agctgtcaac 900
acagccaggg agctgaagtc aacaccatca gtgaacatac agagactctc catctgagcc 960
ctcacatcac cacagatctc gtggtccagg gtgtggagaa ggcacaggag gtgtgtacgc 1020
actcctgcga ggagttgagc aacatgatga atgagctctc tggactgcac gtcattgtga 1080
accagctgag caagaacctg gagagagtgt ctagtataa ccagttcctt ttggagctca 1140
ttgggggccc tctgaagaca agaaacatgt cagcctgtgt gcaggagggc cgaatctttg 1200
cagaaaatga aacctgggtt gtggatagtt gtaccacatg cacctgcaag aaatttaaaa 1260
cagtctgcca tcagatcacc tgctcacctg caacttgtgc caaccatct tttgtggaag 1320
gcgagtgtctg tccatcctgt tcacactctg cagacagtga tgagggtctg tctccgtggg 1380

-80-

cagagtggac cgagtgttct gtcacctgtg gctctgggac ccagcagaga ggccggtctt 1440
gtgatgtcac cagcaacacc tgccctgggcc cctccattca gacaaggaca tgcagcctgg 1500
gcaaattgtga tacgagaatc cgtcagaatg gaggctggag tcaactggta ccctggtctt 1560
catgctccgt gacttgtgga gttggcaatg tcaccgcgcat acgtctctgc aactcaccag 1620
tgccccagat ggggtggcaag aactgcaagg gcagcggccg ggaaaccaa ccctgtcagc 1680
gtgatccgtg cccaattgat ggccgctgga gccctgggtc cccttggta gcctgcacag 1740
ttacctgtgc tggagggatc cgtgagcgt cacgtgtttg caacagccct gagccccagt 1800
atggagggaa ggactgtgtc ggggatgtga cagaacacca aatgtgcaac aagagaagct 1860
gccctattga tgggtgctta tccaacccgt gttttcctgg agccaagtgc aacagcttcc 1920
ctgatgggtc ctggtcctgt ggctcctgcc cagtgggctt tctgggcaat ggtaccact 1980
gtgaggacct ggatgagtgt gctgtggtca cagatatttg cttctcaact aacaaagctc 2040
cccgctgtgt caacaccaac ccgggcttcc actgcctgcc ttgtccacca cgtacaagg 2100
ggaaccaacc cttcggtgtt ggccctggagg atgctaggac agaaaaacaa gtgtgtgagc 2160
cagagaatcc atgtaaggac aagactcaca gctgccacaa gaatgcagag tgcattacc 2220
tgggccactt tagtgacccc atgtacaagt gtgagtcca gattggctac gcagggtgat 2280
ggctcatctg cggggaggac tcagacctgg atggctggcc caacaacaac ctggtgtgtg 2340
ctactaatgc cacctaccac tgcattcaagg acaactgcc caaactgcca aattccgggc 2400
aggaggattt tgataaggat ggaatcggag atgcttgtga cgaggacgat gacaatgacg 2460
gtgtgagcga tgagaaggac aattgccagc ttctcttcaa tccccgtcaa ttagactatg 2520
acaaggatga ggttgagac cgctgtgaca actgccccta tgtgcacaac ccagcacaga 2580
tcgacacaga caacaatggc gagggggatg cctgctctgt ggacattgac ggagacgatg 2640
ttttcaatga gcgagacaat tgtccatag tctacaacac tgaccagaga gatacggatg 2700
gtgatggcgt gggtgaccac tgtgacaatt gtcctctgat gcacaacca gatcagatcg 2760
atcaggacaa tgatctcgtt ggagaccagt gtgacaacaa tgaggacata gatgatgacg 2820
gcaccagaa caaccaagac aactgcccac acatctccaa ctccaaccag gctgaccatg 2880
acaacgacgg caagggcgat gcctgcgact ctgatgatga caatgatggt gttccagatg 2940

-81-

acagggacaa ctgtcggctt gtgttcaacc cagaccagga agactcggac ggtgacggcc 3000
gaggtgacat ttgtaaagat gactttgaca atgataatgt cccagatatt gatgatgtgt 3060
gccctgagaa caatgccatc actgagacag acttcagaaa cttccagatg gtccctcttg 3120
atcccaaggg gaccacacaa attgatccca actgggtaat tcgtcaccaa ggcaaagagc 3180
tgggtgcagac agcaaaactca gaccctggca tcgctgtagg ttctgacgag tttgggtctg 3240
tggacttcag tggcactttc tatgtcaaca ctgaccggga tgatgactac gctggctttg 3300
tctttggcta tcagtcaagc agccgcttct atgtggtgat gtggaagcag gtgaccaga 3360
cctactggga agacaagccc agtcgggctt acggctactc tgggtgtgtca ctcaaagtgg 3420
taaaactccac gactggtact ggcgagcacc tgaggaatgc cctgtggcac acgggaaaca 3480
cagaaggcca ggtccggact ctatggcatg acccaaaaa cattggctgg aaagactaca 3540
ctgcctacag gtggcacctg attcacaggc ctaagacagg ctacatgaga gtcttagtgc 3600
atgaaggaaa gcaagtcatg gctgactcag gaccaattta tgaccaaacc tacgctggtg 3660
gacggctggg cctgtttgtc ttctccaag agatggtcta tttctcggac ctcaagtatg 3720
agtgcagaga tgcctagaga gcagggctcc agctccagca atgtgctgca aacaccctt 3780
cttagacaca tcagtccatc ttggcacttg tggcttttct gtcatttggc atttctgtt 3840
tcttgacctt aactgagtgg atctacacct ccttcacag caccaagtcc aagtgtcttc 3900
aaaggagaaa catcaattgc actccaagag cttccagcct gctgctggaa aacatttgg 3960
tgagatatga ggctcaccgt ggagcgaaga ccgagcattc cgctgtgttg ccttttcttg 4020
tttgtttaa aagaatgacg ttacatgta aatgtaatta cttgcagtat ttatgtgtat 4080
atggagtcga agggagcttt agagcaca 4108

<210> 27

<211> 820

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 27

tcgaccagag gaggggaggc cagttcctct cccaagggtg ccacacaccc ctcctgttc 60

-82-

atcaccagac aggcoccttcc ttcttagcca tatgctaacc ttctcctccc tgggaaattt 120
cctctgcagg agccaaagca gatgggagct ggagttgctg gagctcctgg tctgtatgca 180
gagcaggcat ccaggaaagg agaagagagt gtgacaatcc agcacctcag aatggagggg 240
cctcgtgttc agggcggaag gtacagacgc aggccttctg agggcctctg gacacaggct 300
ggaccagatg ctgtggatgt cgacccctgc actgactatt ggataaagac ttctttcaac 360
taagagaaga tgcaaatcag cacacttttt tctttgttct gccagcttcc aggcctaaga 420
ctaggttttg ctgtctacag ccaactattc tattagttac aaaactcaat cattttattc 480
agcaactgga tgttgactgt taactagaag ctctgtccta cttacagcac tttggatcat 540
caaaaaata aagtaaaata gaaaactgag aaaactcaat ccatgaccag ggagaactta 600
caggatgtta gagacaaaac aagcagacac ctgaaacaat caacgcccaa taaaacaaag 660
taggatgaaa attctcttag ttctttgata acaatttggt cactcataga aacattatta 720
attggtaggg taagcagaca ctctgaaaca atgagaaaaa tactaaaaat tgacttgagt 780
tatttcaaat tgcctcattg acctgttata tcataactct 820

<210> 28

<211> 2397

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 28

tttttttttt catcctactt tgttttattg ggcgttgatt gttacaggtc ccagcctgta 60
gacatctttt actccaattt cctgaataga tagctttatt ccttcaaggc aatatagtgc 120
ggtggtcttct ggctgagatg tttgctgttg ttttcttcat cttgtctttg atgacttgtc 180
agcctggggg aactgcacag gagaagggtg accagagagt aagacgggca gctacacccg 240
cagcagttac ctgccagctg agcaactggc cagagtggac agattgcttt ccgtgccagg 300
acaaaaagta ccgacaccgg agcctcttgc agccaaacaa gtttggggga accatctgca 360
gtggtgacat ctgggatcaa gccagctgct ccagttctac aacttggtgta aggcaagcac 420
agtgtggaca ggatttccag tgtaaggaga caggctgctg cctgaaacgc caccttggtg 480

-83-

gtaatggaga ccaggactgc cttgatggct ctgatgagga cgactgtgaa gatgtcaggg 540
ccattgacga agactgcagc cagtatgaac caattccagg atcacagaag gcagccttgg 600
ggtacaatat cctgaccagc gaagatgctc agagtgtgta cgatgccagt tattatgggg 660
gccagtgtga gacgggtatac aatggggaat ggaggagct tcgatatgac tccacctgtg 720
aacgtctcta ctatggagat gatgagaaat actttcggaa accctacaac tttctgaagt 780
accactttga agcctggca gatactggaa tctcctcaga gttttatgat aatgcaaagt 840
accttctttc caaagttaaa aaagacaagt ctgactcatt tggagtgacc atcggcatag 900
gccagcccg cagcccttta ttggtgggtg taggtgtatc ccactcaca gacacttcat 960
tcttgaacga attaaacaag tataatgaga agaaattcat tttcacaaga atcttcacaa 1020
aggtgcagac tgcacathtt aagatgagga aggatgacat tatgctggat gaaggaatgc 1080
tgcagtcatt aatggagctt ccagatcagt acaattatgg catgtatgcc aagttcatca 1140
atgactatgg caccattac atcacatctg gatccatggg tggcatttat gaatatatcc 1200
tggtgattga caaagcaaaa atggaatccc ttggtattac cagcagagat atcacgacat 1260
gttttgagg ctccttgggc attcaatatg aagacaaaat aaatgttggg ggaggtttat 1320
caggagacca ttgtaaaaaa tttggagggtg gcaaaactga aagggccagg aaggccatgg 1380
ctgtggaaga cattathtt cgggtgcgag gtggcagttc tggctggagc ggtggcttgg 1440
cacagaacag gagcaccatt acataccgtt cctgggggag gtcattaaag tataatcctg 1500
ttgttatcga ttttgagatg cagcctatcc acgaggtgct gcggcacaca agcctggggc 1560
ctctggaggc caagcgccag aacctgcgcc gcgccttggg ccagtatctg atggaattca 1620
atgcctgccg atgtgggcct tgcttcaaca atggggtgcc catcctcgag ggcaccagct 1680
gcagggtcca gtgcgcctg ggtagcttgg gtgctgcctg tgagcaaaca cagacagaag 1740
gagccaaagc agatgggagc tggagttgct ggagctcctg gtctgtatgc agagcaggca 1800
tccaggaaag gagaagagag tgtgacaatc cagcacctca gaatggagg gcctcgtgtc 1860
caggcggaag agtacagacg caggcttgct gagggcctct ggacacaggc tggaccagat 1920
gctgtggatg tcgaccctg cactgactat tggataaaga cttctttcaa ctaagagaag 1980
atgcaaatca gcacactttt ttctttgttc tgccagcttc caggcctaag actaggtttt 2040

-84-

gctgtctaca gccaaactatt ctattagtta caaaactcaa tcatttttatt cagcaactgg 2100
atgttgactg ttaactagaa gctctgtcct acttacagca ctttgatca tcaaaaaaat 2160
aaagtaaaat agaaaactga gaaaactcaa tccatgacca gggagaactt acaggatgtt 2220
agagacaaaa caagcagaca cctgaaacaa tcaacgcca ataaaacaaa gtaggatgaa 2280
aattctctta gttctttgat aacaatttgt tcaactcatag aaacattatt aattggtagg 2340
gtaagcagac actctgaaac aatgagaaaa atactaaaaa ttgacttgag ttatttc 2397

<210> 29

<211> 4100

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 29

ggatcccccc gctccgctac catcttcac gacctcacc aggacgacga ctgagctccc 60
tcttcctcgc cgcggactgg ggcgaccctg ttgctgctgc ggccgcccgc gctcctgccc 120
ccacttcggc tcccgtcct gctcctgctc ccggccccac tctgttcct gttcctgttc 180
ctgttcctgt tcccggcct gctccggtc ccggccccgc acccacctcc gctcctgctg 240
cgggtctcca ggcccagaca aaataaaaaa agatataattt tttagtccg tctctccgc 300
ccggtgtctt ctatggctga gggagtctgg ctctcggggc tctcgggtcg gctggcgggc 360
tcggctggtt ggctggctgg cgagatggac cgctccggcg cgcagcgtcc gcggctgctg 420
tgatgggtgg gcggagcgcg gaccgggat tatatacacg atgtgcatcc ataattgatg 480
ttgtttgaga aaaacaaagt cataaagtgg cactcagaca gcactttggc ctggcgccc 540
gccaccatct gagtgcccaa ccgggcccgc cggttacatc accccacat ggaccatcac 600
ggcccattag caccaattgg ccagagtgtc gggagccacc gctaattgca gtaacgcgcg 660
gctgccagac tgcaatttac cgcgcgatac tgcagtttac tgcagccgcg gtaaaactgca 720
gtacgcggcg gccgcaggaa atctactgta gtatttggcg gcggcgcgcg gtactgcaac 780
tgtagtaaac tgtagctgca gtagagttac tgcagcgcca tcgggcccgt gtggccgcca 840
gggtaactgc acccgagta aatttactgc agccggactt tgtgcgctgt ggagaccgcg 900

-85-

ccgaactggg acccccccca ctcccccccg actccccccc gactcccccc cgactcccc 960
ccgactcccc cccgactccc ccccgactcc cccccgactc ccccgggacg cgtccgcgcc 1020
tcgatgcgcc ccacgcgcc cggttccgct tcgccacgct ccagttgccc cgccccggc 1080
acgtggcacg tatttcccc cggtaaata agagggatta tgcggatgtc tagtttatgt 1140
ctcaatttcc tctttccgga gataaaagcc gggacccccg cgccgaaaaa ggatacacca 1200
gccgcgatgt cgccgctcgt gggggtgctg gtgttttttt cggcgggcgt gggggttcct 1260
ggccccggcg tcgcgggaaa cccccgtggg ctcgatgcca tcttcgaggc cccggtcacg 1320
cccgcgcccc ccactcgcca tctcgggcgc gaggagctgg agtgggacga tgaggatcac 1380
ccgctgctgg acctcgagcc gcccggtgga tcacgctgcc atccctacat cgcgtactcg 1440
ctgccgccgg acatgaacgc cgtcacgagc gtggtcgtga agccctactg ctgccgccg 1500
gaggtcatcc tgtgggcgtc tggcaccgcc tacctggtca acccctttgt cgccatccag 1560
gccctggccg tcggagagcc cttaaagag gggccctca aggagctcgg agaggtggcc 1620
gtgcacaagg actccctgcc gccgctgcgc tataatggag ggccccccgc cgagtaagag 1680
accctgcggc ctgccgccg ggggtgcgct cgtcgtgcct gccgccgccg ccgcttctgc 1740
ctctaagcc gccaccgccg ctgcagcagc agccccgcc ggggccgggg ccggggcctc 1800
gaagccggcc cgaccccccg ccgccgccg gccgcgaag ggcacgccg cggcgtcggc 1860
ggcaacaaca gccacggggg ccgacgcctc cgccccggc cccgaccccc gggcgccac 1920
gtgggacgcc ttgccgccg agttcgacgt gggccctcg tggcgcggc tgcaggagcc 1980
cgagatgcc aagccgtacg cgcgcctgct gctggccgag taccgcggcc gctgcctgac 2040
cgaggagggtg ctgcccggc gcgaggacgt gttcgctgg acgcgcctca cggcgcccga 2100
ggacgtcaag gtggtcatca tcggccagga cccgtaccac gggccgggcc agggccacgg 2160
gctggccttc agcgtccggc ggggggtgcc gatecccccg agcctggcca acatcttcgc 2220
ggcggtcggg gcgacgtacc cgacgtgcc cgcgccgcc cacggctgcc tggaggcctg 2280
ggcgcgccgc ggggtgctgc tgcgaacac gacgtgacc gtgcggcgcg gggccccg 2340
ctccacgcc ccgctoggct gggcgcggt cgtgcgcgcc gtcgtccagc ggctctgcga 2400
gacccgcccc aagctggtgt tcatgctctg gggcgccac gctcaaaagg cctgcgcgcc 2460

-86-

ggacccgcgc cgccacaagg tgctcacctt cagccatccg tcgccgctgg cccgcacgcc 2520
cttcaggacc tgcccgcact ttggagaggc gaacgcgtac ctctccaga cgggccgggc 2580
ccccgtcgac tggagcgtgg actgagtcgg gcgtgcgcgc acaccgccgg cggaggacga 2640
ggagggggga ggggggtggg atggacggag gagagcggat gatggagccc gcgctcgccg 2700
gcgccccggc cagcgcgtg ccggtcctgg cgggtctgcg cgagtgggga tgggccgtgg 2760
aggaggtcga gccctccggg ccgtgcccg aggacgcgga cgcgccccgg gagagcgcac 2820
cccctccccg ggaggggggtg cgcgggagcg aagacggaga ggggggcgtg gaagacggcg 2880
aggaggggaa ggcgacggag aaggaggaga cggaagacga ggaagacggg ggggacgaag 2940
ggacgacgac ggcggcgcg gcgccgcgc gggcgagca cgtggagttt gacacgtgt 3000
ttatggtcgc gtccgtggac gagctcgggc gccggcggt gacggacacg atccgccggg 3060
acctggccgc ggcctggcc ggcctccccg tcgcctgcac caagacgtcc gcgtttgcgc 3120
ggggcgcgcg cggcccgcg ggcgcccccg ggcgcggcca taaaagcctg cagatgttta 3180
tcctgtgccg cagagccac gcggcgcgcg tacgcgatca gctccggtcc gcggtgcgcg 3240
cccgacgccc acgcgagccc cgcgcgcgc cgacgagcgg acgggcgcgg ccggccgcgc 3300
cgggtgtcat ccacgagttc atcacccccg agccggtgcg gctgcaccgg gacaacgtgt 3360
ttgcggcgcc atgagcacct tcggacgcgc gtccgtggcc acggtcgatg actaccaccg 3420
gttctgcag gccaacgaga cggccgcccc ggcctggcc gcggcctccc gccgcgtctc 3480
caccggcggg ggcgagacgc gggcccccg gtctcgcgc gggccccacg acgatgaggc 3540
gcccctgcgc gccggcggcc tgggcaccgc ccgcgggcgc tcgcgccagc gcggcgcgac 3600
cgagccggac cccgtctacg ccaccgtcgt ccagcctacc caccaccacc accagcagca 3660
ccaccaccgc tctcagcatc cgcagcagca gcaacaacag cagcgggccc cagccgccc 3720
cggcagcgtg cacgcctcgg cgacggccgc ggacggaccc gagtcgtgcg cggccgcacc 3780
cccgcgccgc cgcggcagcg tgcacgcctc ggcgacggcc gccccggcg tccagctgcc 3840
ccggccccgg caacggagca tcaacgcctc gacgacggcc gccccgacgc cccagctgcc 3900
gagaccccg cagcgcagcg tcaacgcctc ggcccgcgcc gccgtcccct cgacggccac 3960
cctcccgcg ccccgaccc cgtccgggg ccggcgcgcg cccccgcct catgtgtta 4020

-87-

tcgcgatcaa taaagggcga ggcgccacgg accagacaaa agacacaacc gggtcgggtct 4080
ctctgtccgc gcacgcgcgg 4100

<210> 30

<211> 38734

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 30

gatactcgtg accgggtaca ccgacgcctc ctggacgccg ctgttcgccca tcgcggggcg 60
ggtcgtcacc gacatcgggt cgatgctctc gcacagttcc atcgtggccc gcgagttcca 120
cgtcccgtcg gtggtgaaca ccaaggacgc caccagcgc atcaacaccg gcgacctgat 180
cgtggtggac ggcgacgcgg gcacggtcga ggtcgtcgag agcgcggaca ccgaccgcga 240
gggcccggcc ggggcccggc ggaccccggc cggagccacc accgactgaa gccggccacc 300
gccgcaacac cggaccacga ccgccccgc gaggggcgga ccacaccca gacgggagac 360
gacctgatga tccccaacca gtggtatccc atcgtcgagg cgcaggaggt gggcaacgac 420
aaaccgctcg gtgtgcgccg catgggccag gacctgtgc tctggcgca catcgacggc 480
aacctcgtct gccagggcgc ccgctgcccg cacaagggcg ccaacctcgg cgacggccgc 540
atgaagggca acaccatcga atgcccgtac cagggcttcc gctacggagc cgacggtgcc 600
tgccgggtga tccggcgat gggctccgag gcccgcatcc ccggctcgct gcgggtaccc 660
acctaccgg tccgggagca gttcggcctg gtgtggatgt ggtggggcga cgagcgccc 720
acggccgacc tgccgccggt ggcggccccg gccgaggtga cggacaaccg gaagctgtac 780
gccaccaagc gctggacccg cccggtgcac tacacccgtt acatcgagag cctgctcgag 840
ttctaccacg tgacctacgt gcaccgggac cactggttca actacatcga ctacctgctc 900
ctgtacggca ccccgagcaa gttcggcctc gacggccgcg agcgggtacct ggccgccacc 960
cggatcacca accaccgggt ggagacggag gcggaggggc agaccatccg ctactccttc 1020
gaccactgcc aggaggacga cccaccaaac accaccact acgtcatcac gttcaccttc 1080
ccgtgcatgg tgcacgtgca gaccgagcag ttcgagacca cctcctggct ggtgcccatc 1140

-88-

gacgaccaga acaccgagca catcctgcgc tggtagcagt acgaacaggt caagcccgtc 1200
ctgaggttcg aaccgctgcg ccgtctgctg ccctgggcgt ccctctacat ggagaagtgg 1260
gtgcaggacc cccaggacgt ccgcatcatg gaacaccagg aaccaagat cagcgccggc 1320
ggcgtgaaca agttcatccc cgtcgacgag atgaacgcca agtacatctc gatgcgcgcc 1380
aagctgatcg cggacgcctc ggccgcgccc tcgtcaccgg cgccggcgcc ggagcccag 1440
ccggaagcgg cggggcgggg cggatcagcg gcccgcgcca cgggcaacgg caggggagcg 1500
gccggcggac gacgcggcac caagcccaag gaggacgccg ccgcgcgccc gtagaccga 1560
agacggggga cggacaagag agagcgagag tgagagatgt acggcggata cgacgcgtcg 1620
accggcccca aggccctggg gacggccttc aacaccgtcg ccgtggccgg cgccgtgtgg 1680
ttcctgttcg gcggcgcgga caccgtggcc gactggttcg gcaccgactt cgacgagcg 1740
gtgaccctgc gccgggtcct gctggcgacc ctgtcggtgc tctacctgct gcgttcatc 1800
gccacgaact tcgtgatgct ccagcgcaag atggagtggg cggagtcggc caccatcggg 1860
atctgggtcc tggatgacca cggcacgatg gcgtacttcg gcggcaccaa cgacgccggc 1920
gtgagcgcgt tcacctggct gggcgctcgtg ctgtacctcc tcgggtccta cctgaacacg 1980
gggtcggagt accagcgcaa actctggaag aagcgcccgg agaacaaggg caagctctac 2040
accgaaggcc tgttcaagca ctgatgcac atcaactact tcggtgacgc cgtgtcttc 2100
tcgggttcg cgctggtcac gggcaccctg tgggccttcg ccatccctc gatcatggtc 2160
tgcatgttcg tcttctgaa catcccatg ctcgacaagt acctcgccga gcgatacggc 2220
gaggccttcg acgagtacgc gtcccgacg gcgaagttcg tccctacgt gtactgacc 2280
cgcccgtcac gcgcgtacgg cggcctcccc gggcgagggg ggccgccgta ccgggtggca 2340
accacagatc ccacagatcc ccacagatcc ccacagagcc cctccacaga cccctccag 2400
agatccacag atccctcca cagatccgag acgaggcacg tatgaccgga gacattccct 2460
tcggagaggc cgaggcgtcc ctgaccgcg aggtgctgcg cgaggtcctg gccggcgggc 2520
ccgaggcgtt cgcccggtg acctccgacg agggcgccgt cgacgacttc ggcttcgacc 2580
cggagctgac cgacgactac ctgctccccg ccctgcgcct gctgtacgag aagtacttcc 2640
gggtcgacct ggagggactg gagaacgtgc cggccgaggg gggcgactc ctggtcgcca 2700

-89-

accactccgg caccctgccg ctcgacgccc tgatgctcca ggtggcgctg cacgaccatc 2760
acagcacgca ccgcaggctc cggctgctcg ccgccgacct tgccttcgac ctccccgtcg 2820
tccgtgacct cggccgcaag gccggccacg tacgcgcctg ccccgagaac gcgctgcggg 2880
tgctcggctc cggcgaactg gtcggcggtga tgccggaggg ctacaagggg ctcggaagc 2940
ccttcgagga gcgctaccgg ctgcagcgct tcggccgggg aggttcgcg gcggtggcac 3000
tgcggtcgcg gcgccccatg gtgccgtgct cgatcgctcg ccgcgaggag atctaccga 3060
tgatcggtc ggccccacc ctggcccga tgctgaagct gccgtacttc ccgatcacc 3120
cgaccttccc gctgctgggc gcgctgggccc tgatcccgat gccgaccaag tggaccatcc 3180
gcttcggtgc ccgatccac acggacggct tccccgagga cgcgcggag gaccgctgg 3240
tggtcgagaa gctcgccggc gaggtgaagg acaccatcca gcacacgctc aacgagatgc 3300
tgaggggccg cggctccccg ttcgtctgag ggccgcggt cccggttcgc ccgagggcgg 3360
cggctccccg ttcgcccag gaccgtccct ctctccggg gccccgcctc agccccccgc 3420
cgacgatccc cggcggcaga tgctgcgaac gctggcgaag gccagaacgg cgaggccgac 3480
gagcgtgacg ccgccgccga ccagctccgc ggacagatgc atgggatctc cctcaggggg 3540
acgacggacg gtgatggcca tatagccatg cgaacccccgc cgtccgcccg atccgcagcc 3600
gcaccgcccc gcgaattcac ccgtagagca gaccggtgcg gccgaggagg ggtggcgatt 3660
gggtggtcgc gcgttcgaac gcttacgatc ctctgttgtg tccaaactga ccgacgtgcc 3720
caagcggatc ctcatcgggc gcgcactgcg cagcgaccgg ctgggtgaaa cgctcctgcc 3780
gaagcgcata gcgcttcccc tgctcgcgtc cgaccgctg tctccgtgg cgtacgcgcc 3840
cggcgagggtg ctgctcgtcc tgtccatcgc gggcgtgtcg gctaccact tcagcccgtg 3900
gatcgcggtc gcggtcgtgg tctgatgtt caccgtggtc gctcctacc ggcagaacgt 3960
gcacgcctac ccgagcggcg gggcgacta cgaggtggcc accaccaacc tcgggcccga 4020
ggccggtctg accgtcgcca gcgccctgct ggtcgactac gtcctgaccg tcgcggtctc 4080
catctcctcc ggcatcgaga acctgggctc cgcgatcccc ttcgtcgtcg agcacaaggt 4140
cctgtgcgcg gtcgccgtga tctgctgct cactgtgatg aacctgcgcg gggtcaggga 4200
gtcgggcacc ctgttcgca ttccgacgta cgtcttcgtc gggggcgtct tcatcatgat 4260

-90-

cgtgtggggg gogttccgcg gactggtcct ggacgacacc atgctgccc cgaccgcgga 4320
ctacgagatc aagccggagc acggcggcct ggccggcttc gcgctgatct tcctcctcct 4380
gogcgccttc tcctccggct gtgccgcgct caccggtgtc gaggcgatct ccaacggcgt 4440
cccggccttc cgcaagccca agtccaagaa cgcggggaac accctcgcga tgatgggtct 4500
gctggccgtc accatgttct gcggcatcat cgcgctggcc gccgcgaccg acgtgcggat 4560
gtcggagaac ccggccaccg acctcttcca caacggcgtc gcggtcggcg cggactacgt 4620
ccagcaccgc gtgatctcgc aggtcgcga ggcggtcttc ggcgaggga gcttcctgtt 4680
catcgtgtg gccgcagcca ccgcgtggt cctcttcctc gccgccaaca ccgcgtacaa 4740
cggcttcccgc ctgctcggct cgatcctcgc ccaggaccgc tacctgccgc gccagctgca 4800
caccgcggc gaccgcctgg ccttctccaa cggcatcgtg ctctcgcgc gagcgcgcat 4860
gtcctggtc gtcgtctacg gcgcgactc gaccggctg atccagctct acatcgtcgg 4920
cgtcttcgtg tccttcacgc tcagccagat cggcatggc cgccactgga accgcaacct 4980
ggccggcgag cgggaccagt ccaagcgacg ccacatgatg cgctcccgc cgatcaacgc 5040
cttcggcgcc ttcttcaccg gcctcgtcct ggtggtggtc ctggcgacca agttcacgca 5100
cggcgctgg gtcgcgtgc tcggcatgtg catcttcttc gcgaccatga cggcgatccg 5160
caagcactac gaccgggtcg ccgaggagat cgcggccccc gaggaccccg aggaggcaca 5220
gagcgacgac atggtgcgcc cctcacgctg tctactcggg gtcctgatct ccaagatcca 5280
ccgccccacg ctccgcgccc tcgcctacgc caagctgatg cgctccgaca gcctggaggc 5340
gctcagcgtc aacgtcgacc cggccgagac gaaggcgtg cgcgaggagt gggagcgccg 5400
cggcatcgcc gtaccgctga aggtcctgga ctgcgcgtac cgcgagatca cccggccggt 5460
catcgagtac gtcaagagcc tgcgcaagga gtccccgcgc gacgcggtct cggatgatcat 5520
ccccgagtac gtggtcggcc actggtacga gcacctgctg cacaaccaga gcgcctgctg 5580
cctcaagggc cggctgctgt tcacgccggg cgtcatggc acgtcgggtc cgtaccagct 5640
ggagtctcc gaggccgcca ggccggggc gcgcaagcgc caggactgga gcgcgccggg 5700
tgcggtgcgg cgcggaccgg cccaccacca ccaggaccgt gaccgtacga aggactcctc 5760
ctcgtccacg tagactggac ggctgtgtc cctgtcatcc ccccgttctc tggagtacc 5820

-91-

ccgccatgca ggcagaaccg aagaagtcgc aggcggaaca gcgagcggtc gcggagccgg 5880
tctcggagcc ggtctcgtg gtggcgagg agtacgaggt cgaggtcggc cccgtcgccc 5940
acggcgccca ctgcatcgcc cgcacgtccg agggccaggt gctgttcgtc cggcacacgc 6000
tgcccgccga gcgggtcgtg gcccgggtga cggagggcga ggaggggtgcc cgcttcctgc 6060
gggcggacgc ggtcgagatc ctggaccct ccaaggaccg catcgaagcc ccctgcccct 6120
tcgcccggccc cgcccgctgc ggcggctgcg actggcagca cgccaagccg ggcgcccagc 6180
gacgcctgaa gggcgagggtg gtcgccgagc agttgcagcg cctggcggggt ctacccccgg 6240
aggagggccgg ctgggacggc acggtgatgc cgcccgaggg cgacaagctg ccggccggcc 6300
agggtccgtc gtggcgacg cgcgtgcagt tcgcggtgga cgccgacggt cgcgccggtc 6360
tgcccgccca ccgctccac gagatcgagc cgatcgacca ctgcatgac gcggcgagg 6420
gcgtcagcga actgggcac gagcgccgtg actggcccgg catggcgacg gtcgaggcga 6480
tcgcgggcgc gggctcccag gaccgccagg tcatcctgac ccgcgcccc ggcgcccggc 6540
tccccatcgt cgaactggac cgcccgtct cggtcatgcg cgtcggggag aaggacggcg 6600
gcgtccaccg cgtccacggc cgccccttcg tccgcgagcg cgccgacgac cgcacctacc 6660
gcgtcggctc cggggcttc tggcaggtcc acccgaaggc cgccgacacc ctggtcaccg 6720
cggtcatgca gggcctgctg ccccgcaagg gcgacatggc cctggacctc tactgcggcg 6780
tcggcctctt cgccggcgcc ctggccgacc gcgtcgggga ccaggagcg gtcctcggca 6840
tcgagtcggg caagcgcgcc gtcgaggacg ccgccacaa cctcgccgcc ttcgaccggc 6900
tccgcatcga gcagggaag gtcgagtcg tcctgccccg caccggcatc gacgaggtcg 6960
acctcatcgt cctcgaccg ccccgcgccg gcgcccggcg caagacggtc cagcacctct 7020
cgaccctggg cgcccgagg atcgctacg tggcctgcga ccggcccgcg ctggcccggg 7080
acctggggta cttccaggac ggggggtacc ggggtcgagc gctcggggtg ttgatctgt 7140
tccgatgac tgcgcacgtt gagtgcgtgg cgattttgga gcccgcgca aaggggtct 7200
gacctgcatt tttcttggt ggatcaggag cggcctgttg cgctcgacct gttctccaaa 7260
gcgcacgacg tagagcttgc ggaccgctcg tgaaagccgc ctgacctggc gttgcacgag 7320
cggtgccgcg atgtcggcgt ggtcggccct tctcctggcg cgaaggga cgaaggtct 7380

-92-

tgacgctcgg gtgacgctat ttctgaaggg tcgtcaccga ctggggaggc agggccctgc 7440
ctctcgcgcc cgatgaagca ggttctctct gctccaggta atcgtcgagg gtgccctgac 7500
ggatcaggta gacggtcagg gaccgcaggg tgcagggcgt cgacgcccag gtcgaggatc 7560
atcagggcgc tgtcattggt gatggcgaag gcgccgatca caccgtcgac ggaacaggtt 7620
gcgttcagga gtctgtgcgg gcgccgcacc ggcacggtct ggaagctcgg ctccgaccgc 7680
agctcgccac cagtccgaga ggagccgata ctgtccggtg ccgggtgacc ctctgtgcaa 7740
gcgttgctgc ccccgctcgg cagaccgggg cagcaacgct tgcacgatcg gccggtactc 7800
aacgggatcg tgtggagttt cggaccggaa cggttgga ggacgtgcc gagcggtagc 7860
gtcctgggc cacattgcac acccgcttcc gtcgatgggt gaaaggcggc acctttcagt 7920
gaaaggggggt tccgcccccc cccgggacct tgcgccacc gtcgccgacc ggctgatgaa 7980
ccggctccgc gctcccgcca ccaacctgac ccgacgtgag accgaagtcc tctaccggt 8040
cgccgacgga ctgtccgacc aggccatcgg cgcacgcctc cacttgaccg aaggcaccgt 8100
cgatatcacc tggcctgcat ctatgccaac ctcggaaccg actcgcgcac cgccgctgtg 8160
gccactgtca cggccatcga cgacctcggg ctcattccgc gctgaacagt atgtggtggg 8220
cggtgtttcc gttctccacg acttcagcgg cgtccggagt tgtggtgctg gctgggcttg 8280
gtgccgctc ctctgaacct atgtgaacgc ccacggccag ttcgagccgg acacgcccc 8340
cggacctggc ctccgccgg gccagaaatgc ccggccctg cacctggtct gcctacctgt 8400
acaggcgagg gcggtccctc ggagccactg cctgtaactc cgaggggccc cccttggccg 8460
actcggcggc caccgcggac gcggtgcggc caggaggcac cgtctgcgtc atcaggcgcg 8520
gtcggccga gcgagttatt ccggcaccgg tgggaccaga aatgtcagcc ctgcgtgacc 8580
gtttcgaaga ccgtgacgcg gttgtcgtc gagagcgagt ggggtgggtc ggcgtgcgcg 8640
gcgcggaatg cctccgacga ggtgtaggcg gtgaatgcgg cgtcgtcctc gaagttgagg 8700
acggccagggt agccgtgtgc gcccttgccg ggacgcagca gccgtgcgtt gcgcagcccc 8760
ggcacgttg aaagggggc gcgcatgctg gcggtgcagt tgttctcgaa cgcgccctgg 8820
gcgggcgcgg cgacggtgaa ctccggtgac gcggtgctca tttctgtctt ctctcggttg 8880
ttggtgtgat gtcggtggt gtcccgccc gccggggccc gcacggcgat ggcgatgatg 8940

-93-

tgcaccgcgt gtccgatcga gttccgttgc ggggtgcggt tacagggctg gagttgggct 9000
cgggtccgcg gtccggtgag ggagcctgcc tgtgcggcgg gccagattt cgaacgcgat 9060
agtcatgaac gggggtacgg cggccagcag ggccaagatc gttgtccggc ccagccgcca 9120
cttcagccgg atcgcgacca ggacggtcag ggacacgtag acgatgaagg cggcgccgtg 9180
gagggtgccg aagatccgta cgccgagttc ggtggtttcg gggatgtact tgaggtacat 9240
cccggccagc agacctgccc acgtgcacgc ttcgatgatc gcgatccagg tgaacgcgcg 9300
cagcagacgg ctggtgccgg ttccggcagc ccgtgcggcc ggcgcgctcg cggaaggcgg 9360
ttcggaggtg ggcgtggagg gtgtctgcgg ggtgcctggg cgtgcggggc acagggcgcg 9420
gttgccgagc aggcggacga tggcggggac caggagcggg cggatgagga aggtgtccag 9480
caggatgccg caggccatgg cgaagccgaa ctggaacagt tcgcggatcg gctgggtcat 9540
caggacggcg aaggtcgccg cgaggatgag gcccgcgag gagatgacgc cgccggtgcg 9600
tgtcagtgcg gcggtgatcg ccttcgctgg gggctgggtg cgcagttcct gcttgaaccg 9660
gctcatgatg aagatgttgt agtcgacgcc gagcgcgacg aggaagacga agatgtacgc 9720
ggtgacgcgg ttgccgatgc cgtcgtcacc gaggacggtc acggtgaaga aggtggtggc 9780
gccaggggtg gccaggaacg acaggagcag ggtcgcgacc aggtagagcg gggcaaggag 9840
cgagcggagc agcaggacga ggaccacggt gacgatggct aggaccagca gcacgatgag 9900
ggtcgtgtcg cggtcgaggg cgagcgggat gtcggcgctt tgccggtct cgccgccgat 9960
gagcaccgtg gcgtcctgga cgccggcggc ctgggctgcg gatttgtgtg cctgcttgag 10020
gggaccgatc gcgtcgagtg ccttgagct gtaggggtcg aggtcgagga tgacgtcgta 10080
gaagacggtc ttgccgtcct tgcccatgcg ggggtctgcg acacggctga cgtgatcggc 10140
gtcggtgagc gcggtggcga tgtcggcggg tcgggggtg gagcgcaggt tgcctggga 10200
atggacgacg acggtactgg gggcgatctc gccgggcccg aattcctccc gaatgaggtg 10260
ctgtccgtgc tccgactcgg tggcggcgcg gaagccgtg aggggtgtga agctctcctg 10320
gtagccgagc agtcccgcgc tcagtaccac caggagtgcg atcacggccg aggccacctt 10380
gacggggggc cgtgcgacca gggcggcgat gcggtgccag atgcctgcgc cgcgactgcg 10440
ttcggcggcc ttgtccacgc ccccgggcca gaagacgctc ctgccagca ggaggaccag 10500

-94-

ggcggggatg aaggtgaacg ccaccagcgc catgacggcc acgcccagag cgagggtacgg 10560
tccgaagccg tgaagtgccg gggagacggc cacgagcagg gcaaacatgg cgagcacgat 10620
ggtcgaggcg ctggcgagga cggactcggc ggtgcggcgc acggcggcct gcatcgcgcg 10680
ggcgcggtct ggctcgtcga gcagggtctc gcggtagcgg gcggtgatga tcagcgcgta 10740
gtccgtgccc accccgaaca gcagcacggt catgatcgag gcggtctggg agctgaccgt 10800
gatgactccg gcgtccgcga gaatcgcgcc gagagtctcc gccacgcgca tagccacgcc 10860
cacggcaaga agcggcacga gcgccatcag gggcgagcgg tagatcgcca gcaggatgat 10920
caggacgagc acgacggtgg ccagcagcag gactttgtca ccgccgctga agaccttcac 10980
ggtgtcggtg gcgatcccgg cggggccggg caccgcgacg tcggcggggc cggcccggtc 11040
ggacgcgagg gcacgcacct cgtcgaccgc attctggaag gactcgtccg aggggctgcc 11100
ctccatgggc acgatgacca gctgagcacc gcggtcctgc gagaccaact cggccgcagc 11160
gtcgggagcg gtcaccgtgg agaccacgct caccacatgg tcgggtcggc tggttccgga 11220
aagggccgag gtgatggcgg cgaccgattg cgtggcgctc ttcgcggcgt cggtgccctt 11280
gccgcggacc acgatgatcg ccggcgctgc gtcctggccc ggaagctggg cgcgagcag 11340
atcacgggcc ttcattggagt ccgaggcggc gggcggcagg ttggcgagg cgttgtcctc 11400
gacggattcc agggccgggg cgaccccggc gaggaggccc gcgatcagga ccagaaggc 11460
caccaccaag gcggcgcgct tcttcgatcc caggagacat cgcagcagag cgggggagtt 11520
catcggttgc atcgggcagc cttcggcagg aagtacggac agaacttagc gacagggtgt 11580
ctctaagttg cgtcaagcta acacgcccc tcggcctctc gggcgtggg gtaggttggc 11640
gggagacggc acagcgtccg aggtgaagcg gagaaaatgc ccaagattga agccggcagc 11700
gtccgggagc accgggcgca gcggctcgcg cagctgattg acgcggccga ggagctcctg 11760
gaagagggcg gtgccgaagc cctcacagcc ggagcggttg ccgcgcgagc cgggatcgcc 11820
cgcaacagca tctaccgcta cttcaactcc atcgacgacc tgctcgaact cgtcgtcacc 11880
cgcgaattcc ccgcctggat cgacgcagtg gagcaggcca tcgcggccga gaccacacc 11940
gccgcccagg ctgccgccta cgtcaggggc aacctgaac aggcagctcg cggcacccac 12000
ggctggcggg ccgcgctcac gcgcgactcg ctctccccgt cggcgcggga gcgggtgagg 12060

-95-

aatctgcaca tctcgctaca cgaggcgctc gcccggtcg tgcgcgaact ggggcagcca 12120
cagccccgagc tgaccgtggc ggtggtccaa gcagtcgtcg atgctgcat ccgcagaatc 12180
gaccaaggcg acgatctgac aaccgtgtcc gacttcgcgg ccggagcgac gcgtcgactg 12240
ctcgcggtatg acgacttgcc acatcacccg tgacgcaccc cgtccaggcg gctcgcaggc 12300
ccgtcgacag cgaagccccg gcagaacgag ccgatcttg agccgcaccg gagcgtgacg 12360
cagaccgtg gtggtcatg cctcgtctca tccgatcttg ccaccggcg gccgaccggt 12420
cagtgccga cgccatcga ttacgacgtc cacgaccga accagcgct tcagtgcgtt 12480
gacgttcgtg gtgcgtcat tggtcacccg gcctctggg gtcaccagcg ctttagggc 12540
acgagactcg acggtggcg gtgataccag gcaggcatca tgacctatg gcgatgacac 12600
tccggttcc cgacgacctg gacacgaagc ttacggagcg ggctcgtggg gagggttgca 12660
gcaagcagga acttgccatc ggggccattc gtgatgccg ggaccgggc gagctgaag 12720
tcgatgacgt tctggccggt ctgatggaca gcgatgcga gattctggac tacctgaagt 12780
gagcggcgtg cgctacctcc agatcgacga gatcctggcc atcgtgcga cggtaacgg 12840
tgccgagcac agcgtgcgtg acatggcct ccttgtgtcg gcgatcgaac ggccccggac 12900
gaacgtcttc ggagccgagc tgtatccac cctgcacgag aagccgcggc actactgcac 12960
tccgtcgccc gcaatcacgc gctgatcgac ggcaacaagc gcaccgcctg gttcgccatg 13020
cgcgtcttcc tgcggttcaa cggcgccagc gccagtaccg tccgccccca cgggcgcccg 13080
cccgacggac ccgaggcccg tcacgcgctg ctcaccagca gccctctcct cagcagcgca 13140
ctgggaccgg cgctgctgat cgccctgtcc gccctgggg ttctcgccct ggacacggcg 13200
ttgtgggtct cgggtgtcag tgaggtggcg gcgccggccc ggtggggctt cgtgggcggg 13260
ctgcgtgtcg gcgccggcg tctgggagcc ctgatcgcc gcgtactcaa cgccgtgatc 13320
ggtcttggcg tggtcgctgt caaactcatc gccgggcact gagaggcct gtggtggtgt 13380
tcgcggagcg catacgttg cagaccggtc ggaatcctcg gcgcccggc cggagcggtc 13440
ccggcaccoc ggcaacagc cgacgtccc cgtccggtcg ggtcaggctc gagccgtcag 13500
atccaggtca gtcgccacag gcgcagaagc ccggtgccgt ccaccgcgta ctggccgccg 13560
cccacgtcct ccccgacac cacgaagtc ttggcctgcc acagcgggac gacgggcacg 13620

-96-

tcgcgggcga cgatccgctg aagggtctcg aggtcggctt cggcgtcgt ccggtcggcg 13680
aagcgtgac tgctcgtgat cagccggtcg gggccttgc tgccgtaccc cgtcgccatg 13740
gtgccgtccg tgccgacgag aggaccgccg aaggtgtcgg gatcggggta gtcggcgacc 13800
cagccgacgg cgtaggcgtc gagctctccc tcggcccagc tcttctggaa ttcgtcccat 13860
tcatatcctc tgagggtcac cttgaacagc ccgtcggcct ctagtgtctt tttcacctcc 13920
gcagcctcct cgtgggctga tccggtccc gccgcgtaac cgtagggtgaa agacagcggg 13980
atttctcac cggcctcgac gaggaggcgg cgtgcctttt cggcgtcctt gtgagggtag 14040
ttgtcgaaga aggaggtggt gtggcccgtg atgctcgtcg ggatgaggga gtagagcggg 14100
tccacgggtc cgtcgtagac gtcgtaggaa atccggtccc tgtctatcag ccaggccgcc 14160
gcctgccgtg cgcgtctgtc gtgaaacggc ttgccgcggc ggttggtgag gtacagggtt 14220
cgagtctccg cgctctgcgc ctccgtcacg cgaagccccg gatcgtcgg gttcagatcg 14280
gcgagcattt cggggggaag ctgtctgagg gcgacatcga tcgggtggga tatccaggcc 14340
cgggcgagtg agtcgggggt gtcgtagaag tggagttcga tcggccggcc ggtgttctcg 14400
ggggcgccct tgtaccgagg gttgggcgag agggagatct tctcgccctt cgcgtaggag 14460
acgacgccgt acggtccggt cccgtcgatc cggcgtccg agcgcaggga gtccgccggg 14520
tacgtggtcg agtcgacgat cgagcccgcc ccggtcgtca gcttgaaggg gaacgtggcg 14580
tccggtgcgg tcagtggaa agtgacggtc cggtcgcggg cgtccatcga ctcgatggtg 14640
tccaggaggg acgacggccc cacgtcgga tctatcttct tgaccgttc gaacgagaac 14700
cggacgtcct tggctgtcat tctgcgtccg ctggagaagg tgatgtcatc ccgcagccgg 14760
catcgatagg tgcgtaggcc ggaatcgtg aaggagcagc tttcggctgc gtcgggaacg 14820
ggctccgcca ctccgggtc cagggtcagc agtgtctgga agacattgct gtacagagtg 14880
gtcgagccgg agtcgtagcc gccggccggg tcgagtgcg tcggcggttc cgtcgtcccg 14940
accttgatgg tgggtccctc ctggtcgtcc gtcgggtaaa gcagcagacc ggctgccagt 15000
gccgtggcga tcaccgtggg tgtgatgacg gacgcacgga tgtgcgcacg aataggtctc 15060
atgaggctcg tctcgcaag atcgagacga acaggaattt tcgtaccctt ggggtggagag 15120
tgcgtcggcc aagtatgcg aggcgtcgt tcttcggag cccgacggca cttccggaac 15180

-97-

gaagtcttat gactgacacg gtggaactgc tatgccccgt tcggcgagag ggccgccagg 15240
ggtcggcacc ccctctcagc agccgttccg cctcgtctcc ggtggtcctg cggacccgct 15300
tgcgcgggtc ccgccacagc tctcactcct cgatgccatt ccctgtgcaa tgtcacctgt 15360
gccatgttcc gtgttgacag gcgtggccat gccaagtcgg gaggtcgttc gtcttcctgc 15420
aggtggcagt gcggtactcc gtttcccacg tcctctcccc cttcagtcgg ccgtgctccg 15480
cacggccgga tccctcatgg gaggcgctgt gagaaagtca ctggtacggc gaggtctggg 15540
ggcgggcgtg ccgctggccc tgaccgtcgc catgagcgtg ggctgctgt cgcagccggc 15600
cggcgacagc gggaacaccg ggtccgtcgt gcacgtcgc gcggacgacc cggagcacgc 15660
gggacccccg ccgctcgcgc agtccccac cgcgagacg gagcacgtc cgcagggacg 15720
cacgagggcg tccgagcttc cgcctgtggc cgcgagtaag gacgcgtca aggaggtgta 15780
cggcaagacc gcgaaggcgc cggctcgtcc ctcgaagtcg acggacaagg cggctgcggg 15840
caagaccggc aactcccggt cgcgtgccgc cgcgtgcaac gtctccgact tcaccagccg 15900
gagcgccggc gcgctggtcc agcagatcaa ggctccacg accgactgcg tcaacaccct 15960
gttcaacctg accgggaacg acgcctacta cgccttccgt gagtcgcaga tgacctcgtt 16020
cgctacgcc ctgcgcgacg gctcgacgtc ctaccgggc aacgcctcca ccggtatgcc 16080
gcagctcgtg ctctacctgc gcgcggcta ctacgtgcac tactacaacg ccggcacggt 16140
gggcacctac ggcagcagcc tgcagaccgc gatacgcgcc gggatcgacg ccttcttcgc 16200
cagcccgac tcccgcgacg tcaacgacgc caacggcgag acgctcggc aggccgtcac 16260
gctcatcgac agcgccgagg agaacgccc ctacatccac gtcgtcaagc gactgctggc 16320
ggactacgac tccacctgga actcgtcgtg gtggatgctc aacgcggtca acaacgtgta 16380
cacggtgacc ttccgcggtc accaggtgcc cgcgttcgtg agtgccgtgc agtctgacct 16440
cggcctgatc gacgcgtct acaacttcgc gagcgccac ctcgcgtgc tgggaacgga 16500
ccagtctac ctcacgtcga acgcgggacg tgaactcggc cggttcctgc agcattccgc 16560
actgcgtcc aaggtcagcc ctctggccgg cggcctgctc aactccagct ccatcaaggg 16620
ccggacggcc ccgctgtggg tcggtgtcgc cgagatgacc gactactacg acaaggccaa 16680
ctgctcctac tacggcacct gcgacctcca ggcacaactg gcccgctccg tcctgacggt 16740

-98-

gacctacca tgcagctcca gcatcaccat caaggcgag cagatgacct cgggagagct 16800
gtcctccagc tgcagcagcc tgcgcaacca ggacgcctac ttccacaacg tggcccgta 16860
caacggcccc gtgcgaacg acaacaacag caccatcgag gtcgtggtct tcgactccag 16920
caccgactac cagacctacg ccggcgcgat gtacgggatc gacaccaaca acggcggcag 16980
gtacctggag gggaatccgt ccggggcccg caaccagccg cgcttcacg cctacgaggc 17040
cgagtggctg cgccggact tccagatctg gaacctcaac cagagtaca cccactacct 17100
cgacggccgc ttcgacatgt acggcgactt caacgccaac atcaccacc cgacctctg 17160
gtgggtcgaa ggcttcgccc agtacgtctc ctactcctac cggggcgctc cctacaccga 17220
ggccacgacc gagggggggc gtgcacgta cgcgctgagc accctgttcg acaccacgta 17280
cagccacgac accacgcgca tctaccgctg gggctacctc gccgtgcggt acatgctcga 17340
aaaccaccgc gccgacatgg acaccgtcct cagccactac cgcgcgggaa actggaacgc 17400
cgcccgagc tacctgaccg gcacctcgg caccgctac gacaacgact ggtacacctg 17460
gctggcgccc tgcgcggccg gcaactgcgg tggcgggggc accaaccgc ccgggaacca 17520
ggcgcccacc gccgcgttca ccaccgccc ccagggcctg aacgtcacct tcaccgacca 17580
gtccaccgac gccgacggca ccatgcctc ccgctcctgg agcttcggcg acggcaccac 17640
ctccacggcc accaaccg tcaagacgta cgggtcggcc gggctcctaca cggtaagct 17700
gaccgtcacc gacgacaagg gagccaccgc caccgccagc aggcgggtca ccgtcggcag 17760
cggcgaggc ggcggcaccg aatgcaacgg gaccgacacc cgggaactgg gccagaactg 17820
ccaacgcggc aaccagtccg ccaccaccgg caactacgcc tacctgtacc tctacgtccc 17880
ggccggcacc accagctga agatcaccac ctccggcggg acggcgagc cggacctgta 17940
ctacagcacc agcggtggc ccggcaccac gagctacagc cagcgggcca cgggagccgg 18000
caacaaccac accctgacca tcaccaacc gccggccggc gccaaactaca tcagcctgca 18060
cgccgtcagc agcttcagcg gcgtcaccgt gagttccgcc tactgacca cggctccgca 18120
ccaaggcacg accctcacga cggccgggg cggctctccc cggccggggc gggtccggg 18180
ggggcgagc gggggagacc tccgtcgccc cggaccgaga acacatgcc cggccgcaca 18240
cgggcatccc tacctcccag gaggcagagc gtgaagtcac taccgcagc caggcgagc 18300

-99-

cgcgccatgt ggtccctcat catgtccgtc ggtctcacct gcgcactcgc cacacccgcc 18360
gtcggcagcg gtgaccaggg cacgtcacgg ctgagcgctt cgcaacaggc cgcggccggc 18420
caactcgagc cggaccagca catctccacc caggaggcac agcggcgcggt actgcggcag 18480
gagcggctca cggcgctcgc aacagcgctg cgtgagcgcc tgggttcccg cttcgagga 18540
gcctggatcg accagaagca cggcggcagg ctgaccgtcg ccgtcacccg gtcgacggcc 18600
acggccctcg tcgaggcccg gtccgctcag gctcaggcac ccgacacgac caccgtcgtc 18660
gtcgaccgca gcctgcggca actcgaccgc atgtccgag gactggccca ccgtatcgcc 18720
gcagcgaaca agggcgccgc ccacggcctg cagtcccgcg tgggtgtgca ggacaacaag 18780
gttcgtctgg acctgccag gggcaagacc ctaccccccg ccagcacgc agtcgtggag 18840
tgggcgaagc ggaccctcgg cgatggcctc gaggtcagca cctacgcgca tgcctccgaa 18900
cccttctact gggcgggcca gtactcgtgc gacccccgc tgcgctcggg cctggccatc 18960
tacggcacga acgtccgctg ctccagcgcc ttcattggcg acagcggcag cagctactac 19020
atgatgaccg ccggccactg tgcggaggac agctcgtact gggagggtccc cacctacagc 19080
tacggctacc agggggtcgg tcacgtcgcc gactacacct tcggctacta cggcgactcc 19140
gcgatcgtca gggtcgacga ccccggttc tggcagccgc gcggctgggt ctaccctcgc 19200
acccgcatca ccaactggga ctacgactac gtcggccagt acgtgtgcaa gcagggtcc 19260
acgaccggct acacctcggg gcagatcacc gagaccaacg caacggtgtc ctaccagggc 19320
cgcacctga cggcatgac ctggtccacc gcatgcgacg ctcccgtga cagcggcagc 19380
ggcgtctacg acggctcaac ggcccacggc atcctcagcg gggggccgaa cagcggatgc 19440
ggcatgatcc acgaaccgat cagccgagca ctggcggacc gcggggtcac gctgctggcc 19500
ggctaagcag cccgggcgga ccgtgagtag gccgccccgg tcacatcacg aggacgtcga 19560
ccgccgacg cgcggtcggc gtctttcccc gtgctccgct ccgtccgcca ccagcggac 19620
tgggggcccc ggctggcac gtcgtgcacg ccgacgcggt gtggaacccg tcggccgatt 19680
agaccgtacc ggggagcgcc tttccggctc cgttcgtggg acgggcgggt gcgtatgcgc 19740
gcgtcaccca tttctggaag tgcggagcct gcgacagcag ttgccagtgg gcgctacgg 19800
catgatggtg caccacctcg acggccgacg cctcgaccga atccccccgc cagacgagca 19860

-100-

gatgccgctg ccacagcgga tccccgcga ggggtttaac cagtactccg cccaccgggc 19920
gcatggtggg ctggacggcg gccaccccca gacccttggc gatcatcgac tgcagttggt 19980
cgagcatgtg gaactcgtgg gtgacggcgg gcctgaatcc cgcgcccca caagcgtcgt 20040
agaaggcgcc gggccagccc acccgcgtcgt ccgcgagac gaaccacgcg tcctccgaca 20100
ggtcggccaa ggacacctcc agccggtgcg ccagtgggtg atcggcaggg gtggccacga 20160
acaccgggac ggttctgata gctcgggtgg ccagcttcgg agagtgtcga agaggcagcc 20220
ctgggtagtc gcaaccaggg gcgacgtcga gctcgccggc ctctaggaga tcgatgagtt 20280
ctccggtcgc gtacacactg ctgaccgaga cggtcagatc ggggcaggct tcacggagga 20340
cgtcgagcaa ggtgggtacc accggtgtgt tgatggcccc gaggcgaagc cgacgtgtcg 20400
ccccggacga gcggggaggc cgcagccgtg cgagattgtc ggagagcgcc aggatctccc 20460
gggcccggcc gacgacctgg gcgcgtagg cgggtgagtc cagccccgcg ctgctgcgca 20520
ggaagacccc ctgcgcgagc agtccctcga tgcggcgag ttgggtactc atcgccggct 20580
gggtgtatcc gagcgccgca gcagccggc cgacgcccc cgctcggct atcgcacaca 20640
gcacgcgcaa gtggcgagc tcaagttcca cgggggcacc tcgctccggg cgaacagagt 20700
tccattatgc gccaggagga aggcggtggg gaatccggga cggcctgacg ccttcggtcg 20760
accagtagcc cgagggttat ggatgagccg gagcctctgg tatggcctgg ccggttggtc 20820
ccgggtgacc gccgtgaaa tctcggacct gcgtgttggc ccgagaggc gactgcgga 20880
gcctgaagcg caccgccatc gaggagcgac atcatgcctc acacctgcat cagcttcacc 20940
gtcgaagcga ccggggccgc ggttcaccgc gccgccacc gcgtctccac cgcgctgagc 21000
tggtggggag ggccggtcga ggaagagtc cgcttcagcg cggaactcgt gacctccgag 21060
ctcctacca acgggctgcg gcacgcgggc gggcccatga ccgtcgagtt gacgctggtg 21120
cacgacatgg tcgtcgtcgc ggtcctcgat gacagccggg agctgccgcg gcctcggcag 21180
acggaggcgg acgacgagtg cgggcgggga ctgcctga tcgaggacct cagtctgata 21240
cggggagtcg agaccacttc ccgcgggaag cgctgctggg cggttctgcc gctgcggacg 21300
ccacaggagc gggctatcga gtcggctccg gctgaggagg cgaccacgg cttcgaggca 21360
gaccgggaac gctggtcact ggctcccaa ggaagcgac tactggcgag tctgtttccg 21420

-101-

gcgatgtgag ttcgtcctcc tcgggcggcc cagtagccga cccagggcag gcgggcgtgc 21480
ctgagggcgt gatgacgctc gtctgacgct ctggccgctt tcaagctgca cagcgagccg 21540
agaaacagcc tttgacctgg ccttttctgc ggctgcctca ggccgacatc tttccgatga 21600
cgcaccacgt ggagtacgtg gcgattctgg agcctgctgg caaggggttc tgacctgcgc 21660
ttttgttctc ctgcgccggg cgcggaagc tcgtgcgggg cagttgggtt tccgaaggc 21720
cgggtgctcgt gtgtccggcc ggcggtggg ctgccttcgt ttcagtgggt gcgagagggc 21780
actcggacgc ctgagccgag atgcggttcg ttcggcacca tgggtccgc aggatgacc 21840
ggtcagcgac cgctggcacc tgtggaagaa cctttgcgac aaggccctgg ccgaggttcg 21900
ctccacagc gcctgctgga ccacagcgaa cacacccgc ccggtcggcg tccatgagca 21960
gaccacccgc gaacgttggc atcagctcca cgacctctc ggcaaggtg tcggcttgct 22020
cgaatgcgcc cgccgcctga acctgtccct caacaccgtc aagcgctacc cgcgacccg 22080
cgatcctgaa gccctgcgcc ccgtgaagca gctgtttcgc gaggtccagg agcagggctg 22140
caccggcagc ttcacctgc tctaccgag caccagggc cgggcagaag gcgaccggc 22200
cgtcggaggg tcgcggttg acgtcaccg tatccatcac tggaacggcg acgtctgatc 22260
ccgtctgccc ggggcttggg tcccggtgc ggccgtagg ccggtcac ccagcacc 22320
atactgttc gagagtgatt acctctcgc cggacacatg gaaatctgca tcggctggag 22380
tagacattgg gcagcagtg gtattgttt ctctgtaac ccagaaggac cgcagggccc 22440
ggcagagacg aactgccggg cagcagtacc cgcagttgca ggacggtgcg gtggtggagt 22500
gtcgaagcca ggatggtgca ggacggcgac gggactgacg accggaccgg gcggcccga 22560
gtggtcaggg gccgccaccg cagtgcagta ccagcagcg aagtcagtga gcggtacctc 22620
ggtgaaggcg tcggctgcgg acgcgcgcgc cgggaggttc ggcaagtgtg gttccaagcc 22680
agagcagacg caggacgggc aacggggccg actgtcggac agtggcgctg tcacaggtca 22740
ctgagaggtt cgtgtcacca gcagtagagc agtaccagag gaaagaacgg aggaaccaag 22800
cgccatcagg atcgccggg cgcagttttg ggccgggta ccgcaggaca tcgatagtga 22860
ggtggtctcc ggtcaagaaa ccgcgatccc cgcgccccg gcagcaggca ggtcgggtcc 22920
gcggacacag aaggccggtg cagtatcagg gccggcagat ggtgtaggag ttccttcggg 22980

-102-

gccctggtgc cgcattggcac cagggcccct ccatgcgttc cgcagagagg tgcagatgac 23040
agcagacgat tcgtacggcc gtctogacga cgacgattac cccgcctaca ccatggggcg 23100
ggcggccgag atgctcggta cgacccccgc ttctctgcgg gccgtcggag aagccccgct 23160
gatcacgccg ctccgctcgg agggcgggcca ccgcgctac tcccgtacc agttgcgcat 23220
cgcgggccgc gcccggaac tcgtcgacca gggcactccc gtcgaggcgg cctgccgcat 23280
cgtcatcttg gaagaccagc tccaagaagc gcggcgatc aacgaggaac tgcagaggcg 23340
cccggccggc ctggtggaca agggcgaggc ctgaggccgc atctgccggc cggctctgtg 23400
agggctcgcc tgccaagacg ggaagccctt gccgcaacga gaagaggcaa ctgtccgcac 23460
cgatgtgctg ggcccggtcc tggctaggac tcccgcttc ttgccggagc gatgcggctg 23520
tggacgcgga accggacggc agtgtcgtcg ggcgcggagc gcggggcgca cgtcgatggc 23580
gacaggaccg gcgaagggtg attcgtgttc ggcggtgtga cggcgcacct ggccggcgag 23640
ggcgggcgcg caggtgtcac agggacatcg gttccgactt ccaccaccg tccgggttcc 23700
accagcgtgt catccacctg atccaggctg ccgcggtagg tgctcgacgt cgggggtgta 23760
cgggggcagt tgtaccgttc cgccgcgagg agtgaccga ttgaccaccg gcctgtggcg 23820
ctcaggaacg ggctggactg tcgcagtcgg ggccaactca agcccgacca tgaggccgac 23880
cacggcgccg cgcgaccccg accacagcta cacgcgtggc atgaccaagg cggcacatgc 23940
ttcgaacgag ccatctcatg tgtgccggtg tgaacgtgat cgacgtcccc ggcaactctg 24000
tgcggaacga agcgtcttg ggcgccacc acgactggct cgccgccccg ccccgcggc 24060
gccaccgtcc gtcccgccct gcgtcgtcgc ccgtgtggcg tcatgacggc gacagacttc 24120
ctcgcgtatg ggccgaccat acggccaacg ccagaggtaa agcgtgtcc atggtgagtt 24180
ccctgaacag aagggtggc gggacctcct ttccaagacc gtgctgcagg agtcgctcag 24240
agcgcaggta atccgtgct gtccgcgacc cagggtgtc ctccgtctgg ccgagggtcc 24300
tcgtcttctg ggcgacatcc ctttagcgtg ggcggtagcc gccgaaggga ggcgccatgt 24360
cggacgaatt gacggggccg ttgggaacg caatgcggga ggtcacgttt ccggaccggt 24420
ctcgcgggat catcttggtg cgggctggaa caccgcaggc cgaggccgag gcaatggccg 24480
cccgtatgtg ggccgagatg ccggaaggct gacgtgcccg aacgcagaca acccgtaaccg 24540

-103-

tcctcacacg cattcccctg agccgtcggc catggaacgg aaccagccgt acgaaccccg 24600
gaggcgccgt tgcggtctct gcggcgaggg cggggccacg cagggcgaag aggcgcgcc 24660
gcgttctgcc gcctggcgcg gctgccggct gttcacgaga acaccgaggg aggagtgcgc 24720
cgctcttgc cggcgcggtt gccgggtgga gagcagggtg tgaaggactg gctcgctgaa 24780
ggcgcccgag gcgacctcgt cggccggcct gaacggcttt cactgtcca gcggcggcag 24840
gccgccgaca caggcatgct ttgccatctc cctcgctgtc tactgacccc agcagcagga 24900
tccagtacgg cgtcgcgggc ctgcccctc actcgcgcat cgatcgggga atgcggcatg 24960
tggtgagggc cggccggcg tgccggtcgg gccctcacac tgttttggtg tcggcgcggt 25020
tgtcgtgtcg gtcagacgga cagggtgggg gcgccgagca tggcggaagc ccgctgcaac 25080
ggactgtcgc tgcgcgcggg ggccggcctc ggaaggggtg ggcagggtgaa gccagctgg 25140
gccatggccc ttaggatttc gccggtgctg aagtcgcggc ggtcctggcg ggtgatgacc 25200
tgcccgacct gcttggcggg gtagtggcgt cgtccgatga tcacggactc gcgggtgacc 25260
ggttcgggtt tgacgccctt catogattcc agcacgccgc tcttggtcag gtcgaacggg 25320
aagcgggcaa tgacacagcg catgatgcct cacaggcagg agagttacgg ggccggccgc 25380
cgtctggcgg ttcagcggga gagagcgagg acgccaggg cgtgccgtg ttcgtcgacc 25440
acgggcacca gcccgagccg tccgaagggc accgcgtcct cggttcctc cctcgtggcc 25500
gacggtgaga cgaagggtc gctgtcgtcg gtgatgtcac cgaggcggag ccggtcgggt 25560
tatcgggagc tgtcccgac gccggtgagc cgggcctggg tgaccaggcc gacgcaccgg 25620
gcatcctcgt cgcagacgac cagatgctcg gcacgggcgg cggccatcac ggacagcgcc 25680
acctcgacgg tcatgtcgta ccagacctgt ggcccggcgg cgtccatgac gtcggccacc 25740
gtgcgcgca atgggagagc gcctacggag cgatcctgca actgtcctgg cgtcaagggg 25800
tgctcctgc gcagacgggc ggggttcctg atcaggacgg tcctaggcgg ccgcgccagc 25860
cgtggacttg agtgcggggg tacgccgct cgccgaggcg gggcggcgtc ggccgcgtga 25920
ggtggcgccg cgcttcttgg ggcgttcagt cgcggggcg gtgatgacga ccgggatgcc 25980
ggtcggggcc tgggtccgg tgatccggct gagggcctcg tcgccgggc tgacctgggt 26040
ggtctcgggc cggatcccg cttccgacat gagacggacc atgccgcggc gctgggtcgg 26100

-104-

ggtgacgagc gtgacgacgc tgccggactc gccggcgcg ggcgtgcggc cgccccggtg 26160
gaggtagtcc ttgtggtcgg tcggcggtc gacgttgacg acgaggtcga ggttggtcgac 26220
gtggattccg cgtgccgcga cgttggtcgc caccagcacg gtgacgtgcc cggctcttgaa 26280
ctgcgccaga gtgcggtgct gctgcggctg ggacttgccg ccgtgcaggg cggcgggccc 26340
taccgccgtg ttgagcaggt cccgggtcag tctgtcgacg gcgtgcttgg tgtcgaggaa 26400
catgatcacg cggccgtcgc gtgcggcgat ctcggtggtg gccgcgtgct tgtcgggccc 26460
gtggacatgg agtacgtggt gctccatcgt ggtgacggcg ccggccgagg ggtcgacgga 26520
gtgcacgacg gggtcgctga ggtagcgcg tacgagcagg tcgacgttgc ggtcgaggg 26580
ggcggagaac agcatgcgct ggccctcggg acgcacctg tcgagcagt cggtgacctg 26640
cggcatgaag cccatatcgg ccatctggtc ggccctcgtc aggacggtga cggagacctg 26700
gttcaaccgg cagtcgccgc ggtcgatgag gtccttgaga cgtcccggag tggcgacgac 26760
gacctcggcg ccaccacgca gcgccgacgc ctgcctgccg atcgacatcc cgcccaccac 26820
cgtggccagc cgcagcttca cagagcgggc gtacggggtg agcgcgtcgg tgacctgctg 26880
cgccagctca cgtgtcggta cgaggaccag cccagcggc tgccgaggct cggcccggcc 26940
gccggccgta cgggcccagca gagccaggcc gaaggcgagg gtctttccgg aaccggtgcg 27000
cccgcggccc atgatgtcgc ggccggcgag ggagttcggc agggtcgcgg cctggatcgg 27060
gaacggcacg gtcacccctt gttggccgag cgcggccagc agttccccgg gcatgtcgag 27120
atcggcgaag ccctccgag cgggaagcgc gggggtgatc gtccggggga gggcgaactc 27180
cccctgaacg gcgccgggccc ggccggcgta accgcggag cggtgggtc cggccggccc 27240
gcgcggcgcc ggcgaaaccga agcggctgcc gccctttccg gagtggcac cgccatgacg 27300
ggtgcgagcg aagcggctct tcgtgcgtgt gcggttcata cggaaccttc ctgatgcgg 27360
cacatatcaa ggaatttccg aagcaatgag cagcacggag aatcgcaaga atggaccggt 27420
gggccttgcc agcggatctg gccgacagaa aatctgtgcg gcacgtgcgc tggaatgatt 27480
gggggtgctg tgggctcgat attcgaagcg tccactgcac thtagctatg aaggatgcgg 27540
ctgcaccttc gaaggacgat ccgtgtgcgg taaacacacg ctgtccggag cgtcgtccgc 27600
aggtgaaatc actgcgggaa acgcatgtag ctggggccc caccocgaag gatgcggggc 27660

-105-

ccagctacaa gtacgtgaca gtcggcgtca ggcgggaacg atgttctcgg ccgtcgggcc 27720
cttctggccc tgcgcgatgt cgaagttcac cttctggcct tcgagcagct cgcggaagcc 27780
ctggggcggc atgttcagat agtgggcgaa cacatcagcg ccgccaccgt cctgctcgat 27840
gaagccgaag cccttttccg cgttgaacca cttcacggta ccagcagcca tgtcatttct 27900
ccttcggggc agtcgtacgg gatccgcacc gcgcggacct cgtgtcgccg caatgatcac 27960
cccggccgga aaaagaccgg agatgtaaaa gtgcttccag gggactgag ccgaccgga 28020
gcacttgaat tttcgggaac cacaactgca actgacatcg acagtagcac gccacagcag 28080
ccactgtgcg gtgaagaacg ccaccttgct tattgcggca gagaatctat ccgcatgctc 28140
cgatgaaaac tcaaaccgcg cgcacagata ttgaccttcg cgcgacgcca tatatcgcat 28200
gccgcgctcg cgtgatccgg tccccacca cgtctctcgc tactgcacgg gtcgcaccgc 28260
cgcgggggca gacaggtccg gccatgacgc cggccatgct cggggcgtag cggacgcctg 28320
ccggtcgggt gtacgtctcg cgcgcggcga gcactgcggg ggaggggccc gttgccagac 28380
gtcttgcccg gcaaccggct gtcggctcgg gctgggttgg cagccgtggc aggtgatgtg 28440
gttctgcgcg cccgcttccg tgaacgcgcc gcagccccgg ctgccttcta ccaggccgac 28500
cctcaggagg cgtgaccgcg ggaagccgag gatcagcggg agtcgtcagg ggaggcttcc 28560
ttgcgcgctg aggtgacgtc ctogaagtat gcccaggcat ccggccggct gccgtccacg 28620
tccgtcaccg cgtatgccct ggccagttcc ccgtggagg tggacttgcc gttccaccgc 28680
ttcgcgcggt ctgggtcggc ggccagcgcc gcgaccgtac gggccaggta gtgcggggac 28740
tccgcgatcg cgaacgtcgg ctcttgggcg atcgcgtcac gccagttctc ctcaactaca 28800
ccgaagtggg agagcatctg ctccgaacgc aggaagcccg gggacaccgc gaccgccgtg 28860
ccctcgtact ccgccagctc ctgagccagc ccgaacgcga ggccggatcg ggcgttcttc 28920
gccaggtcgt agtagatgtt ctgcgggtag cggcggttgg agtcgcgggt accgtcgggtg 28980
acttccacat gcagcggcgc gtcggagcgg atcagcagcg gaagcagcag cgcgcgctg 29040
atcacgtgcg agcgcgcgcc cagctccagg atccgcaggc cgtcggcgag cgggtgtctc 29100
cagctcttct tcccgaacac cgaggtggcc agaaggtgct cgcgcgcccc caggctgttg 29160
acgagaatgt cgagccgctc gtactcccgg tcgatccgct cgacgagggc gcggacctgg 29220

-106-

gcttcgtcga gatggtcggt gggaactgcg attccggtgc cgcccgtgc ggtgacgagt 29280
tcggcggtct cctcgatggt ctcggtcgtc cgcccgacct cgctggcccc ggcccgggtg 29340
gttcggcccg tcacatacac ggtagcgccg gcccgcacca gttccacagc ctgagctcgt 29400
cccgcgccgc gggtagcgcc cgccacgagg gcgatccgtc ctgccagcgg acccttcgga 29460
ccggcctgct cgggtgttctc agtgggtctgc ctggtgatgt cctcgttgct catgtcatcc 29520
atcgttcacg ctaaaaccga cagaacacgt caccttttat gtggggggta ccgcgcatca 29580
tcccggccat agcgccaact acgtcctcgc actgagcgtt ttcagcgtgg gccaccgatc 29640
gggtgacgcc ggtcagggtcg gggtaggggc cgcaacgcac aaggctcgcg tgcacgacat 29700
ggccaccgcg cgcatgatct ccagcgggga gccagccgt ccccggcagc cccagccgct 29760
gagaccagct caccgggac acccggtccg acaccgcaca cgatcaagta gtcgacctcc 29820
agacgcgttc agcagccac atcccaggag cgtctaccg tcccaggaa cctgctccg 29880
ggaccatcgg gctcggcacc gggagtgcac agttgatcag taactggcaa cgagctcgtg 29940
cacggtaaac ggtgaggtgt cgaggtccag atgggcggcg gcggtggtgc cccagcggt 30000
cgcccgaccg gcatgccgag cgggcagccc accggtgtgc cgagcggcgg accggcggc 30060
ggcacgggca tggcgggcac cccacccc cagcacctga agtcggtcag gaccggccgc 30120
gtgacgggct tcgggtcaga cctgtgcggg gaacagcagg cagtcgtccg ggcggtgat 30180
caggttgatc tcgccgtccg tgtgccggac ggggtctctg gcatggacgc gcacgtcgcc 30240
gatgctgagc tcgtactcga atcgcgctcc ggtgtacgag cactgctcga tcctcgcccc 30300
gagcacgttg acggcaccgt cgtgcggggc gtcggcgcgg tcggtgagcg tgatgcgttc 30360
cgagcgcagg ccacgggtg cgacgaccc cgcgagcag gcgccggcca ccctcaagcg 30420
ctgaccggtc tcaccagtt cgacctgtac ggctccgcc tcggtggcgc cgacgcgcc 30480
ctccaggagg ttgcagcggc cgatgaagcc ggcgacctc ggagtggcg gagtctcgta 30540
gatctcggtc ggtgtgcca cctgctggag gtgtccgtgc atgaacacg cgatgcggtc 30600
ggacagggac atggcctcga cctggctcgtg ggtgacgtac acggtggtga tgccgacctc 30660
ccgctggagg tccttgagcc agacggggc ctggtcgcgc atcttcgct ccaggttga 30720
gagcggttcg tccaggagca gcacgccggg ggagtagacg atgcctcggg cgagggcgac 30780

-107-

gcgctgctgc tgtccgccgg agagctgggtg ggggtagcgg tcgcgcaggt gagccatgtc 30840
gaccttggtg aggacgtcgt cgatgaggcg ccgttgctcg cccttggtga ccttgcgagg 30900
cttcagcggc agtgcgaggt tgtcggcgac ggtcatgtgt ggccagagcg cgtacgactg 30960
gaagaccagg ccgagattgc ggccttcggg gggcaccgtg ctgcgccggg tgccgtcgaa 31020
gaagacctgg tcgccgacac ggatggtgcc cgagtcgggg gtctccagac ccgcgacgca 31080
cgacaaggtg gtggacttgc cgcagcccga cgggccgagc agagtgaaga actccccgtc 31140
cgcgacggtg aagttgacgt cctccaggac cgcggtcccg tggaaggact tcttgatgtt 31200
ctcgacgacc agctcaggca tgcttcttcc ccttcaggag gagaccggcg aggccggcga 31260
cgacggcggg gacggcgatc tggaggggtg cgagggcggc cacggagccg gtctcaccct 31320
gggtccacag atcgatggcg gtggtgccga tgacctgtga ctcggtccg gcgaggaaca 31380
tggcgggggc gtactcgcg atcatctggg tccagatgag caggaacgag gcgagcatcg 31440
cgggcacgag gagacggagc atgatccggg acaccgtgcg ccaccagtcg gcgccggcga 31500
cgcgtcgggc gttgtcgagt tcggctccga gctgcatggt cgccggggag atcgcgccgt 31560
acgccgacgg gagtgcccgg atgccgaagg cgatgatcag cgcaagagc gtgccgcgca 31620
ccggtcgcc gccgggtatc caggtgaagg ccagaaacag gccgatgccg acgatcaggc 31680
ccgggaccgc gtgcggtgac tgcgctgtcg tctccaggag acgggcgaag cggaagtcgg 31740
agcggcgtgc cacgaggacg accaccgtgc cgaacagggt cacggccacc gccccacga 31800
aggccacggt gatgctgttg acgatcgact cgggtgtaggg ggcgtagtcg aagatcagac 31860
ggaagttgtc cagggtgagc aggtcgaacg ggttcaccag cggagtgage agcgaggtga 31920
acgcgcgag gatgagcgcg agcatcgga gcagtgcgcc gaagacgacg tacagaccga 31980
cgaaggcgaa gccagccac ttccaggcac cgatgtcgag caggtcggag cgggtcgcct 32040
tgccgcgcac cgacacgaac cgctgggctg gcccagcag ccgctcttg aacacgacca 32100
gggcgatggt ggtgagcagc atgaagggtg acgccgcgcc cagcaggccg tagtccggat 32160
tgatcgagtc gatgccctgc tcgtagagga agttggagaa gagggatgag ccggcgggct 32220
cgcccaggat gagcgggatg gacagggtct cgatcgccgt gccgaagatc agcagaccgg 32280
cgtagagcat cggcggggcg agcatcgga ccacgaccga gcgcaggacg cgagaggcc 32340

-108-

ccgcgccgac gctgcggggc gcgttctcca gagaggtgtc ggaggcggcc agcgcgttgg 32400
cgcagaacag gtaggcgatg gggacctggg cgacggcctc gacgaacgcc ataccgggca 32460
gtgagtacag gttccagggc acccagccga agccctcgcg caccgcgccg gtcaggaagc 32520
cgcccgggcc gtagacgacg atccacccga aggccaggac gagcggggag atgtagatgg 32580
gccagcgagc cacctgcccg aacaggcggg cggcggggaa gcgggtgcgc tccagcagaa 32640
tcgccatcgg caccgcgatg gcgagcgca acacggtcgt caggacggcg aagaggaggg 32700
tgtcaggac gatcgaaccg aagcccgcg acgtgaacag gtgggtgtag ttcgagaggg 32760
tgaaggcgcc gccggccgcg tacaggggct ggttgcggac cgactggtag aggatcggtg 32820
cgacgggggc gaggacgagc acggcgggtga cgaggaacgt cagccagtgg atggtgacct 32880
cacgtccggc gccgaacagg cgcgggtact ggggcgtgcc cagctcgccc gcgcgcggga 32940
tgccggacgg cgccgggtggc gccgggggtg tctggatggc catgacgact ccgtacgaac 33000
ggggtgggga caggggcgtt gggcggggcg gggcgggtca gccggccgcc ttctcccagc 33060
gcgcgacgta cgctcccgc acgcgtccg gcacccgcac gggccggtac agatggacgc 33120
ggtccgcgcc gagcctgcgc cgcatgtcct gcagactgtc catggcgtcc tggcgcacgt 33180
ccggccggtg cggcaccagg ccgcctcgcg cgaccgccgc ctgcccttcg gcggagagca 33240
ggaagtccag gaagagacgg gccgcgttcg ggtgcggggc ggtcttcacg acggacagcg 33300
cgcgcgcat gacgacggtg ccctccgcgt agtagctcca cccagcagt ccccgctgt 33360
gctcggcggc gggatatcgc acgccatcac gtacggcagg atcccgcgt gccgcaggta 33420
ggccagttcc tggcgcgagt ggaggcgag cctgagacgg accgtggcg gcgggtgcgtc 33480
gggcccgcg agggacagg cgacgggggt cgtgccgacg cacaggtcgg cgaggccgtc 33540
gaaggatgaat tcctcctctc cggatgaagg gtgggccgat gcgggtgtcg cctcctcgaa 33600
ctccaggggc agtacacca tgccgatcag gttgttgccg tggatgcgct cgaaggactc 33660
ggctatcacc gccgcactc ccagcagcg ctgtgccttg gggcccagt cgcggtgga 33720
gccggcgccg tagttgcggc ccgcgaccac gacgagatcg tggcccgcg cgcggtaggt 33780
cgccgcggct tcgtggacgg gcccacccg cagttgcgtg cccgatggc cgccctgcgc 33840
atggacgatg cgcccggtc cttcgaggg cctggccgcc gggtcgttcc tgaccgagg 33900

-109-

cgccgatcag gacgacgccg tgcaacggac gcgaggacag cgtcagcttc gtccgcggca 33960
acagcgacga ccccggtgac ttccgatgac gcgcacgccc ccgccgcccg aaccgagct 34020
gaccgtcgac cgcgccgcct gctctgggtc accctcccgc tccgcctgcg agatcagatc 34080
gccgacgcgc cgcggggcac cgtcgtccac gtctgcgcca ccgacccccg cggcaccgct 34140
cgacctgccc acctggtgcc acatgacagg tcacacctgt ctccggcacgc ccccggcgaa 34200
cgcccggtgt acgccccgaa gtcaccgcc gacgcgcgcg ccaccgccc ggacgcaccc 34260
tggcacccgc tccggcggcg gcaggagcag ccccggaacc ggtgacgcat ctctgcggcc 34320
ggccgtttcg agtgaccgc ggacgcggaa cgtcacggcg tccggaaacc ccggaagggtg 34380
accggcctgc gtgtcttgaa gccgagccgt tcgtacaagg cgatcgcgcc ggtgttcgcc 34440
tcggccacgt gcaggaaggg acgatcaccg cgcgccgaga tgcgtcgggt gagagcgcg 34500
acgaggcggg cggcataacc ctgccgcgc gcctcgggag cggcgcgac ggcgctgac 34560
tcggtccagc ccggaggacg caggcgttcc ccggccatcg ccaccagggt gccgtcgacc 34620
cggacaccca ggtaggtgcc gagttcatgg gtacggggcc agaacggccc cggctcggtc 34680
cgcgcggcga gatccagcat ctcaggcacg ctgtccgcgc ccagctcgac cacgtcgggtg 34740
tcggacgcgg agcgagttcg gccggggcgg ccgtcgccgg gccaggtcat ctgacggccc 34800
tcaagactga aaaccggctc ccaaccggc ggcggaacgg ccggggagct gaacatgtcg 34860
gcgaaggcgc cgggaccgag taggcggcc aggtcggccc agtcctccgc gtccgggtcg 34920
acggacacgg aggagaaggc cgcacgtcg gtgagatagg tggctgctcg accgaaccgt 34980
cgggcgagat gagcgtgccg accactgagc gactgacctc cggggtcgtc gagtgcgggg 35040
tcgtcgtcgt tcatcatcgt gccgtttcct tcctggtgag cgcggtggtc gaagggtggc 35100
cgcggtaggc gaaaagtcgg cggcggggcc cgtggcccga tagtcgtagc cttgtcacc 35160
gtgcagtttg ccgggtcgcc tgaggacttc cggctggagg ccaatgcaa agcgtctc 35220
tgccggcgga ggcacgcctt ctgacgtgcc tcaccggca ccactcagtt caggcagatt 35280
gagcttgagc gatgcagcgc cgcgggaagt cgagcgctc aatgcatcga gggcgactt 35340
cctcgttctg ggtgagagca gtctgcctt gtcgagtgat gggcggttcg gaccgtcacc 35400
ccggcgaagg ccaggacctg tccacggag tggctcatcc acctccccct cctcgggcca 35460

-110-

cagcttcagg cccgacgtag ggggaggggc gactcggaac ccggcgcccc gctcgcgaag 35520
gtcggtcaga cctgttcgaa gtggaacgcc ttgatgaagc agtcccgggg ttgggcgacg 35580
gcgaagagga tgcactccac gagggactgc gcggtgaggg cgtcctcggc ttcgcgtgaa 35640
gtggtcgcgc actcctcgga gagcggtcg gcgttgtcga agtcgggcgg gtagagcgag 35700
atcacccgga ctcttgggc gcgcaggcgc ttggagagga tttcggtgaa ccctgcctgg 35760
gcgtcttg cgcgtagaa ggcgtcgtgt gcgtccgagc ggtggtggcc cgggtgtccg 35820
caggcgaga ccatcgcac gacgtcgggt gtgtccgagt tgagcaggag ggggaggaaa 35880
ctcctcgtgg tcaggaccgt gccggtggct ccggaggcga tgggtgccac gacgtcggcg 35940
tcggttgccg acagcaggtc cggcccgtg aggtagcggg agccgttgtt gacgagtacg 36000
tcgacgcggt cgggtgtgtc cgcgacccg gaggcgaagt cgcggatcga ggcaggatcc 36060
gtcaggtcgc aggcgaaggc gtgcaccgc tgggtgccgc ggtcgcggat ctctcgcgg 36120
accggttgg cggcggcgag ccggcggtcc gagaggaaga cctccgcgcc gaggtccgcg 36180
aggcggtgg ccagggttcg tccgaagtcc cggccggcgg ccgtgatgac gacgcggtgg 36240
ttgtcccatc tcatggtgtc gttccccagt cgcgtttcg tggatcgggt ggtgccgtgc 36300
accgcgtctc tacgtatcgc gtcattggtc ctcacgaacg gtcgttcacg gtcaatgatg 36360
atgttgaggt gcccaacccc ggtgcggacg aggtctggac cgtcggcgcg gtcattctca 36420
atcggaagg tcgtgccttt gccagaagc ggagccggga ccgtcgctg tccccgggg 36480
cctgggacat cgtgggcggt catgtcgagg agggcgagac gcttctggag gccctcgcgc 36540
gtgaagtcga ggaggagacc ggctggcgcc tgaccgtgt gcggcggttc ctccgcacca 36600
cgacctggac gggggacgac ggcggcggcc tgcgtcacga ggccgactac ctggtcgagg 36660
tggacggcga cctggaccac ccgaggtgg aatggtccaa gcactccgcc tacgactggt 36720
tcggccccgg cgatctcacc cgcctcaagg agaaccgcgg accaggggag tacctgatcc 36780
acgacctcat agccggtgcc gttgccgact cgcctttcga cttgctccgg gcggacgccc 36840
tcaccagccc ggaccggtg cgcgagctct acccgagcc gaaccggaac tcgtgcgca 36900
aggagaccga ccgctgacc gaggagaccc gggcgctgat cggctgttcg tactggtgt 36960
tcatcggcag cgcggaccgc gagggccggg cggacgtgac gccacgtggc ggcccgccg 37020

-111-

ggttcgtctc ggtgctggac gagcagaccc tggatgatccc cgacgcgacc ggcaacaaac 37080
ggctcgacac cctgcacaac gtgctggaga ccggacgcct ggggctgctc ttcctcgtcc 37140
ccggccgccc gaccacgctg cgcatcaacg gacgcgcctg tgtttcggcc cgcccgagc 37200
tgctcgcccg cctcactccc gtcggaagc cgccggtcac cgcgctggtg gtgcaggtcg 37260
agcaggtgta tccgactgc ccgaagtcac tgatgcgcgc cgacgcctgg cgacccgagc 37320
agtggatgcc cgccgacgcc cagccgagca gcgccgaggt gacccttgcg cagctgaacc 37380
tgcccgccct gaccctggac cggatcgagg atgccgaacg ggagtcgctg cgctgcggt 37440
acgaatgacg acgagtcgat gagcgccgat gagccgatga gaccgacgg gatccgacgg 37500
gtcggcgctc gggcgagca gaccggtcgc gaaggtcacc gccgcacgg cggcgaccct 37560
cgcgacggtc agtactgtcc ggtcaggtgc ggggtccagcg ttggttgctg ccgttgagc 37620
aggtgtacag ctggatcagg gtgcggttg ccgtgccgtt cccgacggcg tcgaggcaga 37680
ggccggactg gacgccgacg acggaccctg cgaggttgag gcgccacttc tggttgtcgc 37740
cgccccagca gctgtagatc tggaccttg agcgttgcc ggtgcctgcg gcgtccaggc 37800
acttgctgcc gtagaccctg agtcgcccc cgtcagtggc ggccactgc tggttggtgc 37860
cgctgtggca gtccacagc tggagctggg tgccgtcgga ggtgctggcg tcgggcacgt 37920
cgaggcagcg gccgaaccg acgcccttga tctgtcccc gtccgcggg ggctccgagg 37980
agtcgccgcc gttgagtgcg tcgaggacgg cgggtgtacgc ggccttcttg ctgccgtcgt 38040
tgttgaacag caacggcgtc tgctccgacc gccaggagtc gctgtcgcgc acacccaga 38100
cggatgatcc gaggcagcgc gagacggcca ggcagtcgtt ggtcacgttg gcgtaggtcg 38160
aggccggggc gccctggatg tccagctcgg tgatggccac gtcgacgccg agggcggcga 38220
agttctgcag tgtggtgcgg aagttgctgt ttaggggct gccgctgttg aagtgcgact 38280
ggaagccgac gcagtcgatc ggcacgccgc gctgcttgaa gtccgcacc atgttgata 38340
tggcctgggt cttggcccag gtccagttct cgacgttgta gtcgttgtag cagagcttg 38400
cggacgggtc ggcggcgcg gcggtgcgga aggcgacctc gatccagtcg ttgccgctgc 38460
gttgcaagtt ggagtccgc cgcgctccc aactgccgc ggcaaggcc tcgttcacga 38520
gtccactg gacgatcttg cccttgtagt gggccatcac gccgttgatg tggatgatca 38580

-112-

tgcctggcg cagcgcgctg ccgctgaggc tctgcatcca gccgggctgc tgggagtgcc 38640
agggcagggt gtggccgcgc acctgcttgc cgttctgcac cgcccagttg tagacgcggt 38700
cggcggagct gaagttgaac tggccccgct gcgg 38734

<210> 31

<211> 3331

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 31

tcggtatctcc ccacacaaca tagatagagg atatccgcct gggttcacia tgaagttact 60
gggtggttctc accaccctcg tgggcttttag ctcagcacta agtttcggtt gtaattacag 120
accagtatta ggcttcaatt cacagtatat gctgggagga ctaagacttt tctgtatgcc 180
tgccatgggt tatgatccat ggcatgtgg ttgcgtttcg gcatggagca gtgcaggctct 240
ttacgggtgc ggagggggcg gagggcgctg gggagctggc ggtgctggag gagccgacgg 300
cggacgcggc ggcgggcggtg gagattggga atatgactat gatgacgaca gcgatgacga 360
tgatgaatgg gactgggatg atgacgggtg aatgggagct ggcgccggag gtggtgctgg 420
tggtggtgcc ggaggtggtg ctggtgctgg tgctggagca ggcgcaggag caggagcagg 480
tgctggactc ggacttgat tgggcggagg tctcggaggt ggacttggcg gacttgagg 540
tcttgccgga cttggcggtg gagacgattt atttgattta gatttcgatg atcttggtgc 600
agctcttgcc ctgggtggag ctggtggagc tggaggtgct gctgctgctg ctgcagctgc 660
cgctgctgcc gccgggggtg gagttggtg agctgctgcc gcagccgag ccgctgctgc 720
cgctgcagga ggaggcgag gtagacttgg aggagctgct gctgcagccg cagccgctgc 780
tgccgctgca ggaggcgag gtggacttgg aggactcgtt ggcggacttg gaggactcgg 840
tggcggactt ggaggcctcg gaggtcttgg tggcctcgga ggatatggag gatctgctgc 900
tgccgctgct gctgctgcc cgctgctgc cggaggtgga ggactcgggt gtgttggttt 960
ctacggtgga cgaggaggta gacgcggtcg aggaagagga ggccgcagac gtgctgctgc 1020
tgccgctgct gcagctgcc cgcagccgc tgggtggtggc ggaggaggtg gaggtggtgg 1080

-113-

aggaggaggc ggaggcgctg gtgctgccgc tgccgctgca gccgctgctg catctgcttc 1140
agcttctaga caaatgagtg gtataaggga cgcattagga gacattaaag accttctcag 1200
gagtaatgga gcctctgcaa aagcctctgc taaagcatca gcagtagcaa gcacaaaatc 1260
tcaaattgac gatttgaagg atgtcttaaa ggatcttgca ggtctattga aaagctcagc 1320
atctgcttca gcatctgcat ctgcatcagc ttcagctgga ggtggaggcg gtggtggtta 1380
cggaggtggt aacggaggag gaggcggcgg tggagctgga gctctagctg ctgctctcgc 1440
tgctgcagga gccggagggt gacttgagg tggaggcgga ggaggagctt tagccgctgc 1500
actagctgct gctggtgcag gtggaggagg ttttggtgga cttggaggac taggcggtct 1560
tggtggggga tctgccgcag ctgctgcagc cgctgccgct gctgcatcag gtggtggagg 1620
aagagcactt agaagggtt tgagaagaca aatgcgtgga ggtggatccg ctgctgccgc 1680
tgctgctgct gctgcagctg ctgctggagg tggatgggga ggtggaatgg gtggaggatt 1740
cggagtaggt ctgggtggag gattcggagg aggatttggg ggtggatcat cagcagcagc 1800
tgctgccgct gctgcagccg ccgctggatt tgggtggagg ggacgaagag gtagaggtag 1860
aggacgtgga ggcatggcg acggtaacgg agctagtgtc gtagctgcag ccgccgccgc 1920
tgctgctgct gctggaggat ctgctgctga tgttgccgct gccgctgctg cagccgcagc 1980
tatgtacggt gacggtgctg atggacctga tttcgataat ggattcggtg gtggaaacgg 2040
aaatggagggt ggcgatctg gtggtggcgg atccggcgga ggtggatccg gtggcggtac 2100
tggagggtggc ggtggatctg gtggatcagg cgggtggcggc ggatctggtg gttcaggcgg 2160
tggcggtatca ggcggcggtg gaaacaatgg atggggaaat aacggcaaca ataaatatga 2220
cgatgatgac tgtgatgaat atggtaaccc tattagaagg gggtaaatta tttgacatta 2280
tccgccattt gactcatttt tcttagttct ctatgtttta tacttcacct tagattgttt 2340
tagtttgatt gaataaatta tgttttcgat ataaattttt tttaaattaa attaaacttt 2400
attagttgac ctgtaaacct tttcatggag ttataatcta aggaacaaaa aacatacata 2460
atatgttcag tattgtggtg aagcacctgt accgcaaaca caatcacctc tatacatgta 2520
tacaaaatca gtaatgctga caaaatcttc tacactctca cctacacact cgcacacagt 2580
cctcttacat acacagcact ataatatcct gaacatgaag tttgtgttga taaaagttc 2640

-114-

agaaaaatct cccctacatc acctgatctt tcaactgaaaa ttacgacaa gtattgaaaa 2700
tagcagaaaag aaaacgggaa attgagaagt tttctataaa aaacaatcgg aacaatgact 2760
ggaatgacaa ggatgaaaat aatgataact tacattaatt aaggcccaa taatctctct 2820
atattcaaac ttttttttca aatgttctct ctaactcact tgcattctatg tggaaattca 2880
catactatac taaattacca caagtatcaa ggtttcacaa cctctcatgc cttcatggca 2940
gaccatgctg ggtatttgtc taacaatgcc tcataaatac ataaaactaa ctaacaaaat 3000
aggtcagtct gtaacaaatt attaatgcac cattattgca ttttctaaaa caaagcatac 3060
actggatatt ggcagacaaa atgttggtat tggatacctt tccattctat ctagacactt 3120
gctttccaca agtcatcata aataaatccc ccctatccca aatgtcaatg gaatgcccc 3180
acccttcccc cataatttta aaacctagaa taaattaaaa catctatagt tcgtcatgat 3240
catctttctt atcatctctt tcttcttctt cctctctctt cttcttcttc ctctctctca 3300
ggttcttggc tgctgctcc ttccttgcca a 3331

<210> 32

<211> 5224

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 32

ggatcccctg ctcgacgccg ggggccggt acacctccat cgtgcggacg ttgttcccgc 60
gcccgcgagg gtggacggag gtgccggcgt gacgctccac cagcatgtgc cgcaccccga 120
gccggcccag gaacacggac gtcgacaggc ccacgagcga tccgccgacg acgaggaccg 180
gaacctgtg gaccgtgtcc cgggccgat cggtcttgc gttcatcttt ctctccagc 240
gcgtgatgtc cgcacctcg gccggttctg gccggggtca tgcattcccc gcgaggctgg 300
agcgcggtgc gccggggacc acacttcacc cgcttaacct gctgcgttcg cgcaggggca 360
cggcacgccc gacgatcgtg ctcacgggcc gacgcaccgt catgtgacgc gtcggccgcc 420
ttaccgttcc tccaggaaga ggtgcgcctc aatgacggtc tctgccgctg tgtccacggc 480
cccggaccgt gtccccctca ccgtgttcga cggttcccgg gtgcgggctg tgcgtgatgct 540

-115-

ggacatccgc gacgggacgc aagcggaggt cctggacgcc tacgagcgga tgtccgaccg 600
ggtcgccgcc gtgccggggc acatcagcga ccagctgtgc cagtcgctgg agaaccacac 660
ccagtggctc atcaccagcg agtgggagag cgcaccggag ttctctgcct gggccaacag 720
cgaggaacac ctggagatgg tccgtcccct ggagccctac gtccgcgga cccactcgat 780
gcgctactcg gtgtgcgcg agacggccga ggagcgggcc ggggcgggtg cggcgggccg 840
gggcgcgctg cagccccggc cgcgcacg cgacaacgtg gtccggcacg ccgtcaccta 900
caccgtcaag cccgacagcg tcaccgaggt cgtgaagatc ctctccgcct acacctcgcc 960
cgaggtgcgc gtggacgaca ccacgcggct cgtgcgcacc tccctcttcc tgtacggcaa 1020
ccgggtcgtc cgggcgatcg aggtgcgggg cgacctgcag gcgcacctgc gccacgtggc 1080
ccggcagccg gaggtgcgcg ccgtcgagga agccctcacc ccgcacatcg aacaggaccg 1140
ggacctcacc gaccgcgggt ccgcccggct gttcttcacc cgggcgcgc tgccggccgt 1200
ccaccacgtg -gtgtccggc gcgggacggg cgggcacacg cagcggtgcg cgctgtacta 1260
cccgccacac cccggcgccg gaccggcgct cggccggctg ctggcgcggc agggcgaggc 1320
caccgtgggc gaccgggca gtccggtcgt cgcctgcacc gtcttcacc gcgacgacct 1380
cgtcgtacgg ctgctgaca cggcgggcgc accggagcgc gcgcccggg ccgtcctggc 1440
cctgcacgag ccggacgccc tcgcccaggc cgggcgggtg ctggacgccg ccgcgctcgg 1500
cgccgacggc cccccggacg accgggcgct gccgacgttc ctgcgcacg cccggatgcg 1560
gcctctgaca gaccgtcagt cgcgggctc ctgaccccc gctcgcccga cctcaggag 1620
tgaccgacat gacagaacag caggcacgca tcgtcgcctt cgacgacgtc ccgccaacc 1680
ggcggcgcg cgggcacgtc cgggcctgc tcacggccac gaccgcggg gcgaccagcg 1740
gcttcatggg cgtggccgtc gtacggccc gagaacgcat ctccgagcac taccaccgt 1800
actccgagga gttcgtgtac gtcaccgcc gcgccttcga ggtggacctg gacgacgtgc 1860
cgcatcccct gcgcaccgg cagggcctgc tcatcccaa ggacgtgcgc caccgttcc 1920
gcaacaccgg cgacgtcgag gcgcgcctc tcttcacac gggtcgctg gcccccg 1980
cggacctcgg gcacgtcgac accgaggaga ccgacgagac cgcgcggcc ggggtggtgt 2040
catgagccgc cgggtcgtcg tcaccggcat aggcgtcgtc gccccggcg gcatcggcg 2100

-116-

ggcccgggttc tgggacctgc tggccggcgg gcgtacggcg acgcgccgga tctccctggt 2160
cgacccggcg cgctgcgct cgagatcgc cgccgagtgc gacttcgacc cgtccgcgca 2220
cggcctggac gacgagacgg tccggcgggtg cgaccggtac gtgcagttcg cgctggtcgc 2280
caccgccgag gcggtccgcg acgcgggcct ggacaccacg cgcgaggacc cctggcgcat 2340
ggggggcgtc ctccggcacgg cggtcggcgg caccacccgc ctggagcacg actacgtcct 2400
ggtcagcgag ggcggctcgc gctgggacgt ggaccaccgg cgggccgagc cgcacctgca 2460
ccgcgccttc gccccagca cgctcgctc caccgtcgcc gagaccttcg gcgcgcaggg 2520
cccgtgcag accgtctcca ccggctgcac gtccgggctg gacgcggtgg ggtacgccta 2580
ccacgccatc gccgagggcc gtccgacgt gtgcctggcg ggcgcctcgg actcgccgat 2640
atcgccgatc accatggcgt gttcgcgcg catcaaggcg acctcgcca gcaacgacga 2700
cccggagcac gcctcccgcc cttcgcgcg ccgccgaac gggttcgtga tgggcgaggg 2760
cggcgcggtg ctcggtcgtg aggagctgga gcacgcccg gcccgggcg cgacgtcta 2820
ctgcgagctc gccggctacg ccaccttcg caacgccac cacatgaccg ggctcaccgg 2880
ggagggcctg gagatggcgc gggccatcga caccgcgctg gacatggccc gcctggacgg 2940
cacggacatc gactacgtca acgcgcacgg ctccggcacc cagcagaacg accggcacga 3000
gaccgcggcg gtcaagcggc cgctgggcga gcacgcgtac cggaccccga tgagctcgat 3060
caagtcgatg gtgggccact cgctcggcgc gatcggctcg atcgaggtcg tcgcctgcgt 3120
cctcgccctg gcgcaccagg tggcgccgc cacggccaac tacgagacac cggaccccga 3180
gtgcgacctg gactacgtgc cgcgcgaggc acgcgagcgg gagctgcgca gcgtgctgtc 3240
ggtgggcagc ggcttcggcg gcttccagtc cgcggtcgtg ctgaccggac cgagaggag 3300
gctgagatga gcgcaccccg gcgagccgtc gtcaccggac tcggagtggg ggcaccccac 3360
ggcatcgggt ccgagacgtt ctggaagacg gccgtggacg gcaccagcag cctggcccgg 3420
atcgaccggg agggctgcgg ccacctgcc ctgaagatcg ccggccaggt ccccgacttc 3480
gaccggccg ccctgatcga ggacaacctc ctcgccaga ccgaccgctt caccacttc 3540
gcgatggcgg ccacccagct cgccctcgac gacgcccggc tctccgcgc cgacatcgac 3600
tcgcgctact cgggtggcgt ggtgacggcc gcgggctccg gcggcggcga gttcggccag 3660

-117-

cgcgagctgc agaaactgtg gggccagggc tgaagtacg tcggccccta ccagtcgatc 3720
gcctggttct acgcggcgag caccggccag atctccatcc gcggcggtt caagggcccc 3780
tgcggcgtgg tggccgccga cgaggccggc ggcctggacg ccctcgcgca cgccgcgctg 3840
gcggtacggc gcggcaccgc caccgtcgtc gccggcgcgga ccgaggcccc gctggccccg 3900
tactcgatgg tctgccagct gggttaccgg gagctcagcc gcagcgccga cccgggcccgg 3960
gcctaccgtc ccttcacctc cgccgcctgc gggttcgtgc ccgccgaggg cggggcgatg 4020
ttcgtcctgg aggaggaggg cgcggcacgc gagcgcgcg ccgacgcgcg ggcgacggtg 4080
gccggccacg cggccacgtt caccggcgcc tcccgtggg aggagtccag ggccggcctg 4140
gcgcacgcga tcggcacggc gctggcgcgg gccggctgcc gtccgcagga cgtggacgtc 4200
gtgttcgccg acgccctcgg cgtgccggag gccgaccggg ccgaggccct ggccctggcc 4260
gacgcgctcg gccgcacgc gcggcgggtc ccgtcaccg cccgaaggc gggcatcggc 4320
cgggcgttct gcgcggccgc ggtgctcgac gtggcgaccg cgctgctcg catggagcac 4380
gagctgatcc cgccaccccc ccatgtgtc gagctctgcc acgacctgga cctggtggtc 4440
ggccgggcgc gtcccgcccg gccgcgcacc gcgctggtgc tcagccgcgg actcatgggc 4500
aacaactcgg cgctcgtcct gcgcaggggc gccgcgccgt tccccgagta agtacccca 4560
acaggtgtct cacgtcccct tcgggcgcgg gcacccgagt caaggagctc aaccacatga 4620
ccgacatgac cgaacgcgtg ggcacccagg tgacctcga ggaactgtcc gccctgatga 4680
agcgcaccgc gggcgtgcac gtggaaccgc ctgacctgcg ggcgcgggcc gaggagggct 4740
tcgacggctt cggcctggac tccctgggcc tgctgggcat cgtggccgag ctggagaaga 4800
agcacggcgt gggactgccc gagcaggtgg agcgtgcaa gacgcccgcg gagttcctcg 4860
cgcaggtgaa cgccaccctc aggacggcgg tgtgacatgg ccgggcacac cgagaacgag 4920
atcgtcatcg ccgcgccgct ggacctggtc tgggacatga ccaacgacgt cgagaactgg 4980
ccgcggctgt tcagcgagta cgctccgcc gagatcctgg agcgcgaggg cgaccgcgtc 5040
cgcttccggc tcaccatgca cccggacgac gagggccggg tgtggagctg ggtctccgaa 5100
cgcgtcgccg accgcgcctc cctgacggtc cgcgccacc gcgtggagac cggccccttc 5160
cagttcatgg acatccagtg ggtgtacgag cagacgcccg agggcgtgct gatgcgctgg 5220

-118-

atcc

5224

<210> 33

<211> 30601

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 33

gatcttagac cttattcact tgatacgtgt aatagttatt acgatagtat gtttttggcc 60
gattcctccg cgtcttcttt cgacgacgtg gaggtggagg caaaagcgaa gtagttgttg 120
aagaataaga attatgatta tcatgattat tattcaaatt aactctattg ttacgtaccg 180
cgctccatgc agacgtttgc caggagacga cgggtggaag gataggaagc gaagaagcgg 240
aagcggaaga cgctcgtatth gaattcgaag atgataatga tgtcattgat gctgatgatg 300
ttttgttgtg ataatgagat cggcattggag gcatttcaca atctctttgt tcgcgaggct 360
taatctctga gcactcgata tcgtcttgtt tacgaccgga aagcacgtct tcacaccaga 420
ttttgcggcg ttgaactccc ccgccacacg atacagaaca ctggaattat tattagaagc 480
ttcaatgatg ttctaagaac ttacgtgagt ccatggagat atctgccaag aattatttgt 540
gagtgggtgga catagttctt cattgcattt atcaaacatc tttggttttc tggtttcac 600
gcaagaagac gaagtgaag atacactgcg acgacgccat cccccaccac aagaagcaga 660
gcactgaaca atcgtaacatt agtaaattct aaatctgaaa attatatatc ccacttttga 720
ccaatctcca ataatecagg atccaatatg ttcttctccc ttggacagg gttcaagtcg 780
gcaatttctt gcacttggtg gtctcttttg cacatcaca tcaacatctt tcaaaatcgt 840
ccgaccaccg tcttccgcac tgacgcatgt aacatttcta ctttggtgaa catgagttcc 900
acaagtagct ggacactctt cccattccgc cattttccag tatgaacaat cacgaaggcg 960
acaatttctt gttgatactt ccttatccaa atgattgcaa tactcatcag gaagatcacg 1020
aacatgatct cggcacttga gaagacgacg ttgagtacca ttaccacaag ttgctgaaca 1080
ggctgtccat ggtccggttg cccatcggat tgggtgtacg tcggcttgaa gtttttgaag 1140
tactctgggc ccatcacaag tatctttttc acaagtcttt tttaggcgtg gacgagtatt 1200

-119-

ctgaaatgat attttcgttc aagattaaaa gcaaactgaa acgtactcga tcacaaaaat 1260
attcatcaac aatagttcct tcagatccac gagtacacga aacacttcta gtctgaattc 1320
ctgatccaca agtgactgag caaggggacc aatgacttgg tttccaagat gtacatggca 1380
gaagatggca agtttgacta gtttctggca ttttggtatc tccacaaaaa gaagcatcaa 1440
cagattgttc gcggtatatg cattcggttg tacgttcccg atgaccgatt ccacaagata 1500
cagaacactg aaacgtatth atggtattga caacagcaat tctggagtat ttgaataaac 1560
ttacagcact ccaatcagta tttctccaaa atgggcaagt gcctaaatta catgtctgat 1620
gagaagcagg ccgatcagat gcagtaccac aaagtacat atcgacttca gttccatttc 1680
cagaaacaca tgaaactctt cttgacgacc atccatcctc acaagaaaca ctacactgag 1740
accattctcc aagtttatat tttggacatg attctctatg acatggtttt gtaattatct 1800
tttccatttt aaggcaacga tgttccggtg gtactgatct atgacgatcg gtacaattag 1860
cgtctcgata ctgtacacca tctccacact tagctgagca gtcagaccag actccgaact 1920
gccaccaagt acaagcatgt tcattacaat gttcttgtgt ctgtgctgga ccacatctgg 1980
atgtatgtgt ttcccgatcg gctgcatcca aacattgagc atgacgcatt ttgactccac 2040
catcacaact tcgagagcac tctgaccaat gcccataaac ccatcttgga catggaattc 2100
tgttacattc ccgttctgtc gcctctttct gttctctgcc gcacaatgac tcatcaactc 2160
gacgattcga atcatcaacg caatatgact tccgatgcat ttttccattc gatccgcaag 2220
tttcagaaca tgaagtccat tctccatagt tccattttct tccagagcag tcaatgtaac 2280
aactggcaat atcggatggg tttgaattac gatcacatag atgttcggat gctggagttt 2340
gacgatcacc ctccattttt acgcaagaaa ctcgttgacg tttctgtcca gatccacatt 2400
tggcactaca actagacaca tcttcagtga tccatctgta aatataaaaa tttattatag 2460
aaatctaatag aaaatatgta gtttaccttg tagaacaatc tatattgcac attcgtgttg 2520
cttgttttgg tttgagaaca ttttgacaat ttctatcatg actttgacga tgagtcgaca 2580
tgtccagaca cattaattht tgcgattgct gtccacgaca ggctctatca cattctgtcc 2640
aagtatccgt aactctccac aaatacaatg cactggatat tggccgaatt acagcatttg 2700
gaacagccgc agtcatgtac tcatatgaga tgtcgggtgg atgactacca acagaaagaa 2760

-120-

catgaacata aatgtcactt ctaatcggac cagttccatt tatccgttca ataattgcat 2820
cagaaccaga atattcgaga acagtgtcctt ggaatgcaat ttgttggcga gccagtgata 2880
cttgaaatg accgttaagt aggaattcac cattggcggc acggagagct gaagggtaaa 2940
ataaagattt tcatgggtat tgataacaca agggtgagtg atgaaaaaag taaatgttcc 3000
aaaaaactt tgtatagaaa ctcacaaaga taattgtcat cttctttcat attattatat 3060
cctttctgcc ggatatcaat atttgcagaa ccagctggaa tottcattac ttcgttataa 3120
ccaaagggtc cttgctcatt aaatgttcct ttgacaacct tacaggaaga atcatcccca 3180
ccgcaaacac cacatttgtc tcttcggaga gttgaatgaa gttgatgatc acagcctgaa 3240
aatccactta ttttcaattt tcttttgaaa tcagatcaat gttacctgct ggcatacaag 3300
ctccagctac acaaatatcg tctccatttc tatcacatgg tgttccatca acaactttat 3360
ctcgaagcag atagaacgct gcagatccac tgagccgaca atacagcttg caacgttcat 3420
ttggtgcaac attcgcataat tttggaaccc agtgagtatt cgttgaagcg acaccttgga 3480
ttccaatatc tttattgttg aattcagaac attgaacttc acggtatggt tgagtatccc 3540
atgggcattc ttgtgtatta catgaccgat aacgttctcg ttgaccaaca cagtactttc 3600
caccatttcg aggtctaaag taatatggga aaatgtcatt ttaatattga taggaaagct 3660
tagccagtgt ggcctaaaag ctggaagttt ttttaaagat gcgttttcta tcaatttaag 3720
ataaccggct acttcaggtg attctataaa ttttataaag cttggaagct aggtaaatct 3780
gaaaagcctt aaactatctc gaagcggccc gaaagcccag aaaagcagag acggacaaac 3840
atttaagagt gatcagaagc actccatacc ttgatgttac atttgatttt agtgtttcca 3900
cctcgttttc acttctgaac tcgccgattg aaaatatttt gattgaatat attatttgct 3960
ttcagactat ttgatatcat ttcgtttggc agtttaactc actttgggct gtcacaatct 4020
cttaatcctt tttgaacacc accaccacaa gtacgactgc attctcccca tgatcgccag 4080
tcacccatt gtccgtcaat tttggtaagg gattcggggg ctagacgaac acaggctcca 4140
tgatgacaga actaaatatc caagttttta tgagtttctt ttgtgattaa tttctgagat 4200
actcaccatg cttcttgatt cgtcacaagg agttccgtcg gccatggca tatgctgagt 4260
tcgacagccc atctggcttc cgtagaatgt tgcacaccaa agacggcggc atgtcggctg 4320

-121-

taaaatatca atgtttcatc ttaaagaata tatttaggca aactaaccat ataagggcac 4380
aactcagaag ctggtccaaa tacaaacttg cactgttgat gagcatcgta tttctttcct 4440
ggttcatcac gtacaaagac atcctcgtag taacgacgtt cgaccggctg atcgaataga 4500
cattgagttt gacctcgatt atttctgaca aattgacaat taaatagaat caaaatttta 4560
atagctatct tactcgagga atcgttcgag cattccagct gaacatggcg accaactcca 4620
tggatgagtg ttatattcca acgttggtgc cattatgtgg aagttgttct gaaactgcgt 4680
tttatcaaat ttagtgcttt ggaacttgca aaccttatta accggcatgt aggtagagca 4740
ttttcgttcg tcatcatgag gaatcgaaaa cacatgacc aattcatgag caattgtgaa 4800
tgcagcactc aatccattgt cttctatgat tgcacaactt ttttgcata cacaattgt 4860
tccaagttca gcaagtccaa gtgtatcgca ttttcttgt gatcgacaaa tatctttacg 4920
cgtcaaaagg attgcaacgt catgatgttg gacactcgaa tcatctggat cattgtaata 4980
ctgtgccat ctacagaaat cttgaagtgt ttgttgagcg ttctgagtga ttcgtggtcc 5040
agcgttttcc gttttcaaaa cgatcaactt gacaacaacg acattgatag atgcacgaag 5100
ggattggtga cgatagatgg aggcaactgt ggagaagaga gtgagaacgt agtcttcaag 5160
agatcttccg tgatattcgt acatttttgt atccgccacc acaaggactt caacatagtg 5220
atcccaagag ttggcagctc ttogggatct tgctttgcgt tctataatta aatccttttg 5280
tttcataaaa ttatttaaac atttttttac tgtatccttc ctattaatct tgcacccag 5340
agctccactt tgacctatct ttgttgtcat tgactctatc aaaaactgtt caactatgaa 5400
aatggggatg caagactaat aaaaggtatt ggtaactggt tccagtagag ctttttttac 5460
tatctgtttc attgattcaa ttttcagatg tttatataac catcttaacc gttcaaactt 5520
cataacatag aacagcctgg cagcccgta aaaggtgctg aaatcccagt aatttcaatg 5580
gcattcgacc acacacaagt gatccattat cctttgctct tttacttcgt taactacat 5640
tagctatagg ggaccacga gcaaaattct atagtttctg tgtgtgttag ggtgttttaa 5700
tgggctatta cacaacaccc gatgggatca gcagaatctg agatcttttg ggaaccggaa 5760
aaaaatattg tgataacttc tcttttttct acatttttta cagaactagc aggtaaactt 5820
tcagattgaa atctcgaaaa atgcatccgc ctactcaaaa agtcgtttttt aaaatgattg 5880

-122-

tttctttgtg tttgtcctct ttttcccgga cgtacgcaac acaaaaccgc ttgcgcgagg 5940
atgtacacaa aacgtacgtt ctgcgcaatc ttttccctgc agctctctct ctctcacttt 6000
ttctactcca taaatcagtt ctctgtctgt ctcccaccac ctaaatacatc atcagcatca 6060
tcacagtccc occaccaagt tcttgtgtct tctctgacct ttacacgtcg actagggaaa 6120
agctctcaag cagacactcg agcgccagtt gaaaaaata gtgtgtccaa atgagcagtt 6180
tcgaatttga accgtttgtt cttgttctga cataaaccca aaaaaacgaa ctaggcggca 6240
aaagagatct ggataatcta aagaatctag acaaatttca gaagttctta ccaataacat 6300
cttcccactg atcttgccac gtggcaaccg tcgtctccgt ctcgttgaca ctggtcgagt 6360
taagatggtc aaacgatttg aagtgcattg gatcgaaactt tcggacgaga tgttgccat 6420
ggcgacttgc tccgtcgtgc tctagatgtt taaagtgtca gagaaagtga ttacaaagt 6480
tctacctgtt cgtttccac taataattgg ctcaaccgta tggattccgc tgggtagtgc 6540
aagcattccg tactgaaaaa ggcttttatt caccaaaatt cgaacttata caaaccaatc 6600
cgtcttccga gtgcgataaa ttgacgatgc tgtgctgatg tacaccttta acgtgtgcac 6660
ggtagataca atcgggatct gttcgagaca ttccacctct aacctcctcc tccgagtcca 6720
aatataagac catcggcgcg aaatttgaat tggaaaagtg gggaacactt ctggaattga 6780
aaattaatac gactgttata ataaaattga aatctcatac ttgttatgtg agtccggtat 6840
ttgattccat ctgtgcaaat gaacgatgta gacggcatca tctgatcgta atcgtaagt 6900
acaagcatgt ccacagtctc tggcaactcc ttggagtcga cgtcgccgat ctgttgacgt 6960
gacatcacgt tttccacgac gtccataaga atctcttcgg acgatgtgat ggctgtcgat 7020
gacgtgtata ccggcgtctt gacgccatcg actgtgatgc actggcacac ctgaaactta 7080
gaacattatt tcaacttcaa actttttgga ttgttacctg agtacttggc cctggagaac 7140
agcacatctg atgagaattc tgagatcgtg ccactccctg ctgaaaggaa catttggtta 7200
aaaacaaaag ctgataaatt aaaataatta gataaaaacg aacattgcaa cgcataaacg 7260
aggcagacga cgaggagtat gagagcggcg acgacgggct gcagcagatg gaatgagccg 7320
ccgatggagc gcataccaac agctccgtga tgatgattat gattgtgtgg agagcagcaa 7380
agaaaaaaga gatggaaaga agcagaagct ccgataaagt tcgtccgtct cttctgaaac 7440

-123-

cttccaaaaa ctacctgctc gaggtgaagg gaagtcgtct gattgaactg ctactgcttc 7500
tgatcttttg ataactctccc gagtttgtgt tttcgtttag tcgaattaaa attgtagatt 7560
gtggaatgag cacttgcaat agggaacaga gcatcacaga ctgaaaaatt aaaaattatc 7620
tagaatgcaa gcaattttta aatttgtttt aaaatcactt attctgacgc catcttcttt 7680
tccgatttgc gcagaataaa taaaaacttg actgtaatat tgggaaaatt tcgaaaaaaa 7740
acaccgttaa gtctgagccc accttcgcc ttttttgtt gacgaaaaaa accaacaag 7800
ctttaaattc ataaaattcc caattttaaa aacatctaaa gtcaattcct cccaataatg 7860
catttgata tgaacaaaag tctgttgacc ataagtcgtt atattactac aagcaattgg 7920
tcatcaacaa acctcataaa aatcagtttt gaacgggagc aatttatata aactctgtgt 7980
gctcttttgc totttttctt atttcttagt tgtcttctag ttccgccacc actttcgctg 8040
ctcttgacga aatctgtaaa ttgttcgtca tttttgattt ataagatttg tttggctctc 8100
ggtaggagct ctcaagctgc taatagtcct atagtaaagt actaaaaaca caaagaagca 8160
gatgaaggty tcataaaaca ctgataagaa tcatcatgat taggttggtg cagagaaaag 8220
aagaagaaga aaaaggagat ttagagaaga gaaacaagaa taaaaatgca aaaataaaaa 8280
aaatagtaat aacaatgaac gcagagtctt ccatgttgga gaaggaacag gacccatgtt 8340
gatgtgtatc tgaggggatc caatgtgtag tgatggtagt aaacacttga gagggaaactt 8400
ccacccccga ctagatgatt ggaagcaatt gatgatagat gtagagcaa agaattggga 8460
cctactaatg atctagtcaa gattcttctg ataagagaaa aagacaagga agaacatgaa 8520
aatgactggt gattgaaaaa taaaacggtt tatgaagtcg ggggtgtacta aagatgcaag 8580
gtctcttggt acgtatTTTT tcttcaggc acgttcgctg tattcacgat tttatgcaaa 8640
caaggtaagg agtgTTTTga attttgaata taaaaattta aaagaaatta aagttagaca 8700
tttgaaaaat tagacaccct catgggaaaa atttataggc gaggagaggc ggtgagaggc 8760
gccctaattt ctgctcggtc gggtagaatg tctaacttaa atcctacctc atgtttggct 8820
ccttcttaaa tcaaaagctt aaggatcatc ctgaaacgtg cagttgacaa gttcaatggt 8880
aagaacaggg agcaagcatt tacaacaaaa aagtaaacaa aaattgcatt tgtcgcagtt 8940
caaatggaa caactcactc ccactcgaga acgttttgaa ggggagagga agaagaggaa 9000

-124-

aatcatcaca caggcacatg gaacttcttg gacacaaaac aatacaaact ggggtgccgtg 9060
aatctcagta cacacacaca aaaatcaaaa aagacggaaa ttaggagcag atgtggtaaa 9120
gggtggttca atgctgatgg gagagagagg gagaaacttc aaaaaaagaa gtttagattt 9180
atgttggcta tttcaatcct aaatttatct aaacaattct aaaaatgctg gttttggaag 9240
gttatctggt aatggtgaag ttttataaac aaaacaagac aaacaattct tgagatctta 9300
aaaatcttag cgactacaac aatatttagg ttttttttaa tggaaaaaag tattgattgt 9360
tgacttgga aattgaacag caattttttg tactttttaa tcagttatat ttttaactttt 9420
tagagcacat ttcgtagaca aaagggaaaa cgattggtcc aacatgtgaa gatgatgatg 9480
tcaacaagtt ttggatcgga gccaaaaaag aaacaaaaca ttcataccat gatgggaaac 9540
aagaggtgca gcaacaactt ttatcaatat tttgtttatg ttttgattat ttttctggca 9600
cccagccagt aattcttttc cgtagagttg acctagaaaa tgttgagggc ggagtcttag 9660
gatcaagaga cgcagactat caaagtaaaa tgagtaaaag gaagtgatat aaacttagga 9720
aacggaggaa aaaaggacga tgataagaga ttgaagactt ggaagagtgt gctctttgcg 9780
ggagagcata ttcttttgag aaaaatggga cctaggggca actgacgcaa ttgaaacatg 9840
gtcgagcggc cggcgggaag acaaaaagtg aagaaggatg ggcaagaaga agcaagagaa 9900
atggcaccca ccgtggaaca tgatcatgat gattgagagt gaaaattgga aatctcgaac 9960
ttttttgcaa cggcgcgttt tggaaaacta acaaagtga ccaaaaaatt attttacatg 10020
tataccggga tgtctaagaa ttgtaaaatt gagtgatcct ttctgtgaca taatttaaag 10080
caatttattt tggttatttc taagcgcctt ttatactag catgttatat tgttaatttt 10140
attatctaaa ctgccgttct tcctatatatt attattgcac cccctttgtt cattctgaca 10200
gactatacct cgattaatca taaaaatgtc aaaaagaat aaaaacaact aaaattaaga 10260
aaatacaaga aatttatcaa ttgccaaaaa ttcggccaat cggaataatg cttggttgcc 10320
aatttgtcaa aaatttagtc aattggaatt tgtcgatttt ccgaaatgat atgaaagttt 10380
gaatgatgca gctaattttg cagttaaagt ttacattttc aagtttactg taatttttcc 10440
aaaatatgaa gaagagtttt acgaaattaa aagataataa aaaagcaatg caaacatagc 10500
tatgaaatct gatcccgact aagtttgatg gacataggat taataatatt agtctaactt 10560

-125-

tctatagaac actaaataaa tacattcact ctcgaaactc tcccttttct gccatcaact 10620
accgtactca cttttgactc aatgaccgc aactgtcaag atgagttagt ttcaagattc 10680
tctgaaacag caataatcta acaagagaaa ctgaaaaaat agagtaaac taataataat 10740
accacataaa ttgacatgca tgatagatga ttttccggtt ttcaacaaga aaaacaacaa 10800
tttccgagaa atcctcatag tttttggtaa gaaaaataa attgatagt atacggtatg 10860
actattactt ctaaagactt acctgattag aaactgttag taattgaaga agaaaagttg 10920
aatttgagaa gttgaatcga gtttacgatg tctgaaaaaa acatagatat tatggtaaga 10980
tcaagcatag aaaaaatgga aaaatacaag aaaatagaga ctagagattg cataggtttt 11040
gcggtggcga aaccgcacac atttttgtct gtgttatctc taattttacg ctctcgggtg 11100
tctctattta ctgtccagaa gaatgaagaa tatgggggaa aagtgcgcgg gaaaattgag 11160
agaccgagt atgagagccg cagttttgca aaactttttc gggcaataat ccgccggcga 11220
gtactacgag aagcacacac acatacgaaa actggttagt taaaacctaa aaaattgttt 11280
cgacatattt aattttcgaa ctaaagttaa gaggggtctgt gcgtgcattt ttgaattttc 11340
caaacaactt tcagttttgc ggaagaaaat tacagcgatt ttttcgaata tttctgaaaa 11400
caacactatt gcgtatcaaa aatttttcga tttgccaaaa ttcagactaa gttttggtgg 11460
ttttggtttg caaacattta aaagaactca aaaaacattt ttagatgttc gaaaccgtac 11520
aattgtagga tacaaatagc tacagaacaa ttagaatata aaatagagtt gtcaaactg 11580
tttaactaat acaaaaacac agaaactttg aaactcgaaa tttttatatc aaaattgaaa 11640
aagcttgtaa aatttaaata tggatacagt acaacaata taatcataga tcaaatagtt 11700
catttattta tatactttgg caaatcaaat cgtatccctt acccactcat attcgatgag 11760
tctacaatta aatcagttgt tttttcatcc tcccggacta ttagtttaac ttccacttga 11820
acaagggcaa agagtacatt aggaagagtt tatgatgaca ggaaaaaagc tatgtaaaat 11880
gacctctttg gattgaaaaa gcgaacgaat tgaggtttag gacccccgga aaatgaagaa 11940
ttcgtggcct cgagaatagc aaattggcgg aattaattat ccgtaagagt gtgaattgga 12000
aacaaccggg acgaatggat tactgaatca aaaatgaaag aaagaagaga tgaaaatacg 12060
tgtgaatcgg atgaaatgtg atgatttttag aataacctaa atgcaacaaa acgacgtaaa 12120

-126-

gacgcggaag aacaggaatg atcaaggggt acatcttata ggggaaaaat gcactttttg 12180
tgctccaaat gtgagagata atcaggtagg aagagacgta gaataggaac aggaaacggt 12240
aacgatagtg cgcaggtgct tgatttctgt gcttttgcgcat gtgttccgat ggaatttttg 12300
gaacttttca aggggtttcg gaaaggggtc gagatttcgc atgtgagctt tggaagaatt 12360
ttggaagaac tttcaggata acatcgctca agcttgtttg ttagatttca gacttcaaag 12420
tatataccga ttattgaaac attttaatcg tttcttacta ttagtaaagt ttaatcacag 12480
tttgaaaaaa aaatcacaat tttttcaatt atttagacca aactaattat ggtacagaaa 12540
ataacttgca acccgggtat ttcattctaa tttttttcat ttggaaccac tagtttttga 12600
aatagaaact cgtaggatt cttcacatat tatcataact atcagtattt tgttgacat 12660
cagatctaag ttcagtctaa ttagaatcgc aaatttgacc atcacacttt aaaacaaatt 12720
tacttaggca cagggcatcc ttctaacttt tttgtcccg acaaatgat gacaaaaatg 12780
acgtgaggaa tcaaggagaa aaaggaaaag aacaggaagc gaaaagtagg agaagctctt 12840
gatttctgtg ctcatcctt gttcggatga gctcactgtt tgcaacattg gcgttggtgc 12900
gcgggaatcg ccattgccga actttttcaa gagacagaga gagagagaaa gagaaggaaa 12960
acgttccgat ttttaaaatg gaaaaaatg aaagaggaag atgatgaaaa aatgaactct 13020
gcgtgacatt tgtaatatg gaaaaagcat gattacttca aaattgtaca ctaatcccca 13080
cagcacacat tttgaagact tttttacaaa acaatgggt taagcaagct ttaaaaaatt 13140
gatagtatcc ttaatgctta atcatatcca agtttagttt taagttttga tttcaaaaat 13200
ttctacatca aaaaatcata cttagtgtt atatgcaaaa caatttttaa attcaaggac 13260
atatttttga tttttggaag gatgataact tttttgtgat tccgaaaaag attaaagtag 13320
gtttaaaacc totgacctc tacagaaaaa acattacctc tatgaatttt tttcatctc 13380
gttcagaact tgtctcgggt caagccatga agacatgaga tagggtgtaa aacgttccga 13440
agagagggtt atgactatta ttgtagtga agagaaaaat gatattctca tggatttcat 13500
acagatggtc ggatttcatt cataaaatat cataagaaaa ggtacgttta tgactgtcta 13560
ggccaactgg ttttaggtt cttggaattg tttcaaact ttttaggaaa tattttcttg 13620
caaatatcta ctaaattgaa gtttggtatt gtttttgaca tattgtagat ttagagaag 13680

-127-

aatcactcag agcaaaaatg ttgggaaaac gtgagaaaaa tccaagagac aaaagaatgg 13740
tcttactatt agtagatcaa aaaaccagac caattattca tattcctact attcaatata 13800
tattcaaaaa tgagcaaacc aagaaattgc acctaattta tcatcccaca tatattccga 13860
cgaaacattc gctctacctt ctttttttct gtctaggaat tataaagggc cataattata 13920
atttcagtca aggttttggg aaattgttcg actaaccatt atgaaagtta aaaaccaatc 13980
agtcaaaaaca cacaatagga atataaaatt cgtagaagaa aagctttttt tttggtcgaa 14040
agcaaaatca aattctggaa ctgcgacttt tttagtgcga ttatccattc aacgcaagtt 14100
gtctttcaaa atttaaattc cagaagagtt ataacaaaac agacagggtg acaagtaaaa 14160
gaaaaataca agttttatcg taaaaactga tacgaatcta gatacacctg ttaaaaaagg 14220
ctttctcgaa acccagatgc cgtacgaagt aagcagcagc caactaaaca ttttgagtaa 14280
acatatggca agtggttttg cgcaaattgt aaagattttc cgtgtgggta actagaattt 14340
gaaactgtaa gtatgacgac ttaaccacac aaaatcaaatt tcaaaaagat cttaaaatgt 14400
tcgaactttc aaaactttta agctctctcg catctaccgt agtcttctaa taacaacagt 14460
cgtaagagaa agctcaaaat ttttcaaact ttttctgaat gacagaatca gttgtatata 14520
aaaaaaaccc ccaaaatgag agcccatga acctgacaac cagacaagtc gaaattgtaa 14580
aatcgtatag atcttggttc acgacatgaa gagcaccgag ggggcacacg agagcaacta 14640
ctgcaagcgc tcctgaagag aagaaacatc ttttttccag gaccactggc cagtagtgct 14700
ccccagatc actttctttt ttcttgcttc atctgatttg tgtctgcgtc gtctgatctc 14760
tttagaacct atccttcttc ttcttctttt tgatacttcg acatcagaac aacatcgaca 14820
tgtatcatct tttctctttt ttttttgta tctattcatt cattcacttt tcatttagtt 14880
tgattaatag gtgacatgaa ctcttgtcac ttttcaattt caacttctta aatcttaaac 14940
tcacagtgat tccagatatg agcaactcca atgaggtggt gagtagaaac ctaaataata 15000
cattttggat gttttgataa tgttggaaca aataaattga aacaaacaag acttgaaata 15060
gagacaacgt gcagaataat gtctaccagc tgggttcagt ggcattattg accacgaacg 15120
tccgacagaa cgaataacat aaagatcaag aaaaactggt tgggagcaga caaacaatca 15180
gaacacagtt ttgttgaggg gaccaaacta taattaatga ctaaatttta acgaagaaag 15240

-128-

tgctcgaaaa gaacagaatt tagaagttga tgaacaatat ttttactttt agattaacaa 15300
ttatgcttta caaatgacat ccaatctaaa gcatctggta atctgaaatt tgtcaaaaaca 15360
gctttcaaga ctagtttcaa atttgtcgat tcaatggatc aagtgtgtaa ttgatccaat 15420
aaaaaagagt ataaagtgag aaggaagaaa gtgtgaaaaa agaagaacgt gaaacgtgca 15480
gaagatacga aatgagtttg aagactgcac ttttcgagcc tcgatgggtca gtcacttggt 15540
cagttgcgaa aaagctgtga aaatgataca ttgtgtcggc tctcgtagag aagaaagcca 15600
catggtcagg atgactccaa ctgggatatt cagttgtaaa gaacacaatt gatatttttg 15660
catctttttt aactagtttt tacaatatga gaaattgttc tgtgcgaaaa atatgacttc 15720
ttccttggtg ccgaagtgtg tttccctgga aattccagta aatacctaata gtaaaaaatc 15780
tcagcagaat gtgttcttac attttgttgt aataataatg tattaataat gcattaatta 15840
aaaatttctt caaatgttc ctacgtcttc tatgcacatt atttaggtca cagtttcatg 15900
gagcacaaaa cacctgccga cgcctctaaa atagttataa ctgcgcatga aatcaggtag 15960
aaaaaactac aaaataacca atacaaattg agtagggcga tggagaggtg ggcggttgga 16020
gaggcgggca acaagcgtcc tcatgacgcc ttgttcattt agaatgtgtt tgctttgaat 16080
tacatacaag tttctaaaat ttaacttaca aaatttaaaa aaagtcacaa caataataaa 16140
agttgtggca atgaaatgtt ttaaaaatct aaatattgag ttttaataaa atgatttttg 16200
aaaattcaca aagaaatgtt acaatctgtg aatgaagacg aacaatgaaa aagtgaggaa 16260
cggacgcgga tattacacat tcagtcacac aataaacgtt cggacactac cacacatttc 16320
tctcatcatt tttttccaaa gtttattcta aagttcaata ttttagtttg attatttttg 16380
acactattct taaaattaat gtataatagt ttagaaaata ttttgaaaca tgaaactttt 16440
ttgttgataa aatagtgcc aacatcctta tgttacgcag ttatccaacc acatttttct 16500
catttttcca ccaaaaaaca ctgaaatggt ccataaaacc tattcaaatg gatatgagaa 16560
tattactttt ttgacatgaa attttcaatg atgtaatgta aaacaaagaa aaatattgag 16620
ggaaaaattg aacggcgtat tgcaaaaatc ggtgtgcgga ggaggagaag gaaaaggaag 16680
agcaggagaa gcggaccgaa gaattcagaa gcttttaaaa taagaacggc gactttcaga 16740
caaacaatgg actgttgtat aaaaataaag cggaggcggt agagagtcaa agctttcaga 16800

-129-

aatgtattag aataggtttc actacctgtt gttgaactca aaaaggtgtg aaaaagtga 16860
agtttgtctg aagtttatga cgggaagtgt ccatcaaata actttcaaaa tttgacttat 16920
cagtgaagaa aacacgtcat tttggaacgt taaaatgggt ggcaccgcaa aatgttcaca 16980
atgtgaagtg aattacgtaa taaaatcagt tttattaagc ttattaaact aacccttccg 17040
gactatttgt ggaatgaaac aattgggggg gttttttttt ccaattttcg attttttttt 17100
gaatttataa ttaccggaac aaaaatatct ttaaattatt aagatttgag tgatgtttga 17160
aattttgaac ctgcaaaaca taagcacaaa ataatggagt ttttgtttta aaatatcaat 17220
agggtgtttt tcacagaact ttaaacaaca aatactcata atttgaatga aaacagtaga 17280
tcccacaata ttttgaaaac ttatctatat atatatatat atatataaa ttacgaaaaa 17340
aaaacaaaaa gaaaaaaaca aataatttgt cagttgataa tttttagata tgagttgcc 17400
aaattgggca atatggtgaa gaaatacggg agttcgtcgc actgtcagac taattttcaa 17460
gtgttcctag tggaatgaaa ctaacagaag ctatacggta tataatatta ggaacacaat 17520
taaaacgaac agcgggaagaa aagatctagt ggtcacttcc gatttctcag ctgacttttg 17580
aatgggcacc tatcatcatc tcacttgttt atttgaacag tctcgacttt ttccaattgt 17640
tggcttctag ttcaagaac gaaaaaaga gcaataacgg aacagaaaat tcagaaagt 17700
gaagagaaat atgagaaaat gatgatgata ataataataa gttagaagag ggttatcgat 17760
gaggaacgga aacgttatct ctgatcgcca tctcattatt attatgagac acaaagatgt 17820
aagttatggt atctttgaaa gaaaagaaaa caggaaatta tacagaacac acacaatttc 17880
ggagatttca ttcgaagaac ctaaccaat ttgaactcac tcccacttcc tcttgtctat 17940
aaaacagtca atcacaggaa caggtgtctg tcttttcaaa atgtatacgt tttccgaata 18000
atgacacaca atatcacaga caaatgatc aatgaggttg cagaaaagaa tgcaaaaaa 18060
tatagaaaga gaggggtgaa aggagataga gaatcaaat ttgcatagat aaatatgcaa 18120
tagaaaataa caatttttga acaacaaaga aataatttag tggcatataa tatagcgatg 18180
gaacttgcaa atttttagaa ttatcatata aaaataacaa tgtttctata ttttatgccc 18240
tataagtctt gcagtatttc ttaaatttaa cagttcattt cttggtaatc tttattttta 18300
tcaagaagtg ttcaggaaat tttaggacat caaattttta tttattttct aaatctactt 18360

-130-

ttatcaaaat tttagaggtc tagtacacat ctacccaaaa agaagacttt ggagctctca 18420
aaaaccacct agtgtatggt aaagtacatg agaagtgacg tgtctttggg cagctggcca 18480
tctttgtcga tatgcgggtg atgggtgttc tgtgagcagt aacaggaaat tctggacacc 18540
tgctaggggtg tcaaaccaaa tttatttcaa cccattcttg cttcaaaaaa cccccaacta 18600
aattattcaa attctcgtaa tttaatgaat cactcagtaa ctgtaacgtt ttttttttca 18660
gagacaatga tcgaaagtta acaaaaaaaaa ctgaggatta aacgttattt ggtatctaca 18720
gctgacattg gaacatatca aaaagtggta agtgaaagtg aaacgaaaag tgcaacattt 18780
gaaattgaga gtagaaaaga tcattgaagc agaaatatgg aagtgaattg aaagccgtgg 18840
cgccaaaacg acggtcaggc gccattgaga aaattaatga gagttcggaa ggttgaaaca 18900
acacaaagac aacgtgaaaa attagtttgg agaagataaa aaatgtctgg agatggacga 18960
tttcttagtt agctgagaat agtttacatt gattttcggg aaaacgcaga atgttagaaa 19020
aatggaaaca tgtctagact tcagataaat ttgtagaatt tatatttgta gcaaaagcac 19080
actaaciaag gttacaaagc tattaggaaa aatacggaaat gtatttttga aaatttttga 19140
tttctctaaa ataataacac cattaatttg ctatatttgc tatatatgct atatagtatg 19200
ttcgcattac tgagcacaaa acttgaaaaa agtttaaaaa aaaaggaaac ttgttttctg 19260
gagaaatcat taaaaacagt acaatttcag acagaaataa atctttcagt gaaagctttt 19320
ttttgagtaa gactaagtat gcactcacia cttttctgag tgttccaaaa atgtttaaag 19380
aaaatactag taaaaatgag catttcgaaa agcaatatat catacaacta caciaacatt 19440
tcaattaaag gaatcaattt tataatagtt ctaggcaatc ccacttttag attcaatttt 19500
ctagcacagg gagcattgga agatataaaa acataaagat aaagggtgata aaagatccat 19560
taaacacatc atatctatca aaccatcact tccatcaaat ccacagattt atcaciaatc 19620
agtgtgtgac aaatataccg taatattaag ttcaaattgg ggaaaagacg cagacaaagc 19680
ttttgcataa atactaaata attgaaagaa acgcagagaa tgtaagagaa aaatatacaa 19740
tatgtgtatt atcaaccatc aacagttttt gattaaaacc atggagaagc gatatacagg 19800
agcaaattag gagacgcaga ttgagaaaaa atgagaaaat aatgaaagta cggaagggtt 19860
attgtacaat aagacaggta gcatctctca aagaacctat tgtcaagcag tttaaacatt 19920

-131-

caacaacggt catttatttt ttagccttca ttatgatata tcattgggtc tataattgga 19980
ttttttaaat tcagatttct cattcatgta caagtaaagt tgtaattgg ttattatgcc 20040
caaagttaa ttatttgagc gcagaaaatt tgaatggaaa tttcagaaaa ctgattcatg 20100
ctaacttcaa aaaatcctga ataaatacca attcttttcc aagtatgatt ctgagcctg 20160
tttacgtgcc tgcctacggt ctattttcta atttttttaa tgataaaatt ttagagtaga 20220
tcttcaaaaa tcttccttaa aaaatctcca aaaaaatcaa gttcaggaaa actaaagtac 20280
tccaataaaa tactcttatg caaaaacccc ccattcattt tgcagaaaaa gacaaacaag 20340
aattaaagat aaaaagttat gatagacagg aagctgattt attagatcaa tgaatcgact 20400
tttagttttt ctggaactct aatttgaaat agtattcgaa tgagaaaatt gaaaatatac 20460
aaagatcaaa agttataatt gaaaatcaac aaattgatag tgtttgtata ggattaaatt 20520
aaaatgtgcg gtacatgaga cagtagtagt agtagccata gtacgtattg gtggctccac 20580
tcggctactg ataatttcct tttttactga taatttgatg tcatttcgta attttatttg 20640
tgtttccaaa aattgtgggc gtggtttatg aattggtaa gacatgaatt aaaggaattg 20700
taaagtaaag aagaaaatga cagaggagaa attattttcg tttgctttgg aaattgcaaa 20760
ataaattaga ttattaaaga taatagttac ggtttaaaat aaatagggtg taaaaaata 20820
tccaaaagtt caagtcctaa gaatcttgct attttgcaaa aaaaagcat gagcttttg 20880
cctaaaaatg gcggacagct gtcgggacac tatccaagaa ttcgtgataa acgggtgaag 20940
cacgctctct tatcatcatg ccatttttcg aattttaaac tcagactttg ataaagaaaa 21000
ttaaaaagag agagtgtgag aaataagagt acacatggaa aatgcaagat ttgaatttgt 21060
ttccaatttt taaaatgtat ttaaaagagt taccgttcca tttttgatta gctttataag 21120
tgaaaaaatc gtttttgat tattttttga ggaatatttt tgaatgcgct ttcaattttc 21180
ctataaaaaa ctttgtgttc acttttttat cccgttttta tttttatttt tacaactttc 21240
aaatttttat gaatgtttta ttgtaaaatc ataaaaaggt gcgaaacatc taaattgcct 21300
ggattgcatt taaaagtga ttagcagaaa tgtattccta tggaatgttt tttgtgcaac 21360
gagatccaga agctcgaaaa acatccaaat ttcttccaag aaagttgatg ttccaaaaat 21420
aaaaagatt ttagcccaat caactaaaaa aaaactctcg ttttttcat atttcacatt 21480

-132-

ttctggtcac tttgaaggaa acactaatcc caaactgaga accgaacatg gattaaacca 21540
tcccatttac tatttcttgt tgtcttcaaa aagtcttaga attgtgcaaa aaatagaatg 21600
tttcgaaata ttgcgggtttt cgttaaaacc ttttttgagt agattgaggg tccattagaa 21660
ttoccaagag aacttgatga ccttcatcat caaaattagt ggtcattgaa tgtttgatca 21720
gacaaaaatg gaaatgactg aatcggaag agcaagaaaa tcgaaaaaaa aagtatttgg 21780
aaattctgga aaacttttta aaatttaaga agggcaacga taagaaacag gaaattaggg 21840
atTTTTtagt gatggagaag tacgtgataa ggtaagggtg gaacactagt gcacacgttt 21900
tgaatacact acgtgttttt atttatggta gaatatagca cttaaagaac gtttttaata 21960
caaactgaaa taaaaatacg gaaatgtaat tttttttttt gaaagaatcc gcctgaaact 22020
gaattttcac atcaaacggt agtgattctc tttatgcgtt gggatgatatg tatttacgct 22080
gtcttaaagt tttcgactat aatttaagta atatgtttgt caaaaatcat catgggtgctg 22140
tgtcctatgt agccttttct acacttgaaa aatgataatt tttatttgaa aatgggtattt 22200
aaattcaagt agaaagttat ttagtcttgt gtgccaagca ataaacacat agtctattag 22260
gcaataaaaa gtcagctact gtttgattta aaaacttaga ctactgggtg gcctgtgcaa 22320
gttactcccg tagtacggat acagagtga aactagtgat tgtactttag atcgggtgat 22380
agtgaattta cagagaaata attataaaac ttaaaatttt tagcagctca gtcttcaggc 22440
tgcacagcca tattgttaca cttggagtta caaattctgc aaaccatcta ggattgaatg 22500
caaaaactct gaaagtcaca tcaagaaatt ccaacaaaaa acacattaga tgccaactca 22560
ttgaattgca ttgattccca agagaaatag tagtaaaagt gaccctatc cattcctccg 22620
ttacatacaa atatacacac aaaaagagt gtagacctt tccttctaac ccaaccaaca 22680
cacaacaata tcgttccctt ttatctctaa ttctctgcgt ctccataagc tttgagagct 22740
cttcggagca tcttgtgctt gtccttgta cggcgggtaca gtttctccc tctgctccct 22800
tatgtgtgtt taggtgttgt ttgaacaaat aagtttttgg ccatccacct ccttctcaaa 22860
accttttct tatgcttctt cttgttttgt gcacattttg gctcttgctt gtctgctcga 22920
gccatagaca aggcggcgac atttttgaaa aaattatatt agtactgtta tatagtactt 22980
aatacaacga tcacaacaac aacacaacga aatgaaaaca tgagatcaaa agacaaattg 23040

-133-

ttaggaggag ttggagtttc tacaatcatg aaatgtttat ctagttatta taaaactgaa 23100
attgctcata aaattgtgat accatgaaga ccgaaaaact ctatgcaact gcatactgca 23160
catacttaca acctttattc tgacttgaat ttcagttttt ggtgtttgca gttattctat 23220
tttgtttaaa agaaaattca attaggaaat aagcaataaa ttttggtcatg tatttcgata 23280
gaaggcacgt gtaaattgcca cccggaaatt agaaaaata agattttctca aactgaaaat 23340
gattgtgaat tgaaaattta agagaatcat tgcaaaagta cacaaatgaa tcatttttca 23400
gattgaacag gaaagtgcag aaatatcaga ttaccgtccc aacagaaacc ggaaataaca 23460
cttttcaggt aaagaattat acagaaatcg taataaattt aaaacaaaag agagttatga 23520
cacattgcag aacggtctct gtggaaaata ggaggagggtg ctgcaaaaac tccttagaca 23580
tggtcactact tacaaaaaaa acagagttta actaaaaatt aaattaagtg agaaaatgaa 23640
gaaaatggag gtctttcgcg gattcatttt acttcttctt ttttccactt ttcgttgcaa 23700
gctttggttt aaaagtttcg caaacaata aacaatgaac attgtgttga gaagacaagc 23760
caagtgaag gaaaccattg agagcaaaaa caacaatcaa ttgaaataaa gagtaaagtt 23820
tattgaatat actgatatgt gaatactgga aaaataatta gtctctataa ttggtaccgc 23880
ctggaagatt catttctgat tcccttgtgt ctttgaccaa aactttattt ttttcagttc 23940
aaaattacaa aaaataaata ctcatcttca tcgattcagt ggtgttttaa actcctacgt 24000
ttttctttta caataaaggt aatgtaaacg ttccgagcgt gtagttttct ctgaaaattt 24060
tttaaaaata acaactttat ggtatttttc ttaaagtctt aaactgaaac cgaaacattt 24120
ttgataggaa aactatttta acattttggg aactcggcaa aagctctgca ggcttgccga 24180
acaactctca tttgaaagta ataaatatga aaataaatta tcgaagtttt tttttttgat 24240
attttatgaa tacggctctt ggtagttttt gacgagaaaa ttacatgttg cataaatttc 24300
aagagttata actcatggag accctaattt ctggtttcac tagaaaatca aaaaatcaag 24360
cgtttgagca gaagactgta ggaagagcac acgtcataaa aattagggga tcaacgatcc 24420
gaaacgggga attgaaatac gatatgcgat gagttttggt tcgaaccggc tttgtcccaa 24480
aaaacaacag aacgatggtc tcaggctcac ttgactcatc tcggtgggaa caatttttat 24540
ttgtttttat tccgtacgca cagaaacttt ttttgaggta tttttgatcg tgggtgggtg 24600

-134-

gaatggtagc acccaatttc aaatagtgtt tgatttgaag agacaatgaa agaaacaagt 24660
gggagataat ggaaatgacg tgatgaaatg gaacggagga aaactggtat aaatatcggt 24720
gactatcaaa actacaataa tactaatgga gaaaagttca ggattcttga agattttaca 24780
ttatgatagt tgggattttac tggtttcaag ttcaaatgtc aaacatctgg aagaaaaacg 24840
tataagatta catcaaaata aaactaaaat ttgaaggata aagtaaaaca gcataatata 24900
gtgttttaca tctcatgtag gaaacgaaca aaatctttga acacctagat aacttcaaac 24960
ggaagtggg tgaagaaaag aataggggcc agaatagaag gtcattttga caaagtgaac 25020
agacaaagac attcctaact cggaggtatt ccaaaaactg ttccaatatt gaagaatgac 25080
actatttgat tttatatcat aacattatta atcacatggc tttttctta ggaaatttat 25140
atcgcaaaat aaaaagtggc cttgatgagt cattcattca aaacatgcct aaaaaccttc 25200
ataattaatt ataaaaatgc tgatacttga ggaccggtt ttttatattt ataaacagtt 25260
gttttcttta ttccgttctc actttgagtt tttttctgaa aatactaaaa aaattaacaa 25320
agttcggcgt tttttgtcga taattccatc tgattatttt cggttttttt acctaattat 25380
caaatatttt agccagagtg aaatttatta tcttattaat atgtttttca atttgttttg 25440
gtattattct gttgaaggaa catgttgcat tttaaatctg ttgttaatac agcggccaca 25500
tgtttagaac ttataacct cgtttaaaca taaattgtat gccatattta ttgcaagtac 25560
tacatgagtt tgaaacagta tcagatacta tattttaaac aaaaatacac attttccccg 25620
ctatgagaga ttctgataca ttggtttcca atttttttaa aaacttgaaa ttcctcaagt 25680
ctcccactga attacagatt tctgttctag atacctcaa agacacctag attcgacttc 25740
ggcatcttcc tcatttttat cttcagtttc atcttttgtc taattttccg tacatttctt 25800
tgcactctta ccatctctcc ctctctcact cactcttctt gttcactaaa tctcaattca 25860
aaatgttttc tgccacgtca tcatcatcat caatgccacc ttctcagagc ccattcgaaa 25920
aattaccacg gcatcaaaat attogatatc acgaaaaatg cttctcaatt ccacttcata 25980
cacttaacta ttttctatgc gttattattt tttatttctt tgttttcact atattttatc 26040
acgaacgtta tgggtgaaaa cctgaaaatg ttcaagttac atcagcaatt tatgattcaa 26100
attcaaacga actgtcatta atctttctat ttgattcttc aattcgtcga cgggaaatat 26160

-135-

tccttggatt tgggtccaaat gactcaaaaa catcaagaaa tgaaactcaa attgagctta 26220
aaccaccacc cggatttggt gataactcac aaatttcagt aagtttagga ttttttttca 26280
aaaaaacttg atatgaagtg ttgaaaaatt gataattggg ccgggcttac atcagagtat 26340
ctagttatct tgtatttcaa atattaatat tcaaacattg tagagattcg aaatgcgaca 26400
gtacttcagt aattaccacc cacattttga ctgtcaaaaa agttcccaaa aattgtcgaa 26460
aacttttatt aggatgtttt ctcatTTTgg cacgattgga gtgttttttt aacaaatccc 26520
ttttatgcat caaattaata tctaattttt aaatcaataa tttggattaa ttcaacttgt 26580
tttataagat tttctcgcta tttaaattagc aaaaaaaaaac tatcttcaaa caattagcgt 26640
gctttaaaac tactaggcct ttgttgcaa cgtcttttca ctttttgga caaaactata 26700
aactatgctc agaatttggg aatgtttgaa aatgttttgg gcaagcatat agttattcca 26760
attctaaagt aagattagtc atctattttc cattccattt ttccattttt cacctatttt 26820
ttccattatt taacaaccaa gactgagcaa acattttcct gttttaattt tcatatatga 26880
aaagacataa gcaaaagctg gatcaaagct tgggcaaatc ctattcaaag tattttccaa 26940
cgtttccatt ccctcgtttg taaagtacaa ttggtaatct taaggcttaa ttaattattg 27000
tgggagattc ataatgtgaa aactaaatgt taagatttgg tcatcaattg aaaaggaaaa 27060
acccagtcct ttaactgtga atgcagaaca tccaaagtca ttgcttttac gagatcacac 27120
aggacatcca tatttagaag taagttcaaa tcagaaatcc ccaatccatt ttttcttgta 27180
gttaccactt caagaaccat actccgattt tcgcgacatt gttagtgtt tcagtccaat 27240
ttatggagat ttgagatgg ttttaacagg ttttaacaaat taatttggtt tcttttttaa 27300
aacatttaat ttttatagct ttaacatcat ccatatcaat gggatcattt gttagtatac 27360
catatgaaga gcttactgga gagctttaca agtttctacg tgtatttgaa aaaacgggac 27420
atgtcagggt aactgcattt ccaatgatac gtcacagcc tcgcttcgat tcggaaaatg 27480
aaaattatca ttgaaaatg atcaaaacta aaacagattt aacgcatttg cattgttggc 27540
taatgcataa aaaccgggcc aaattcatga tcttccaaaa ctctgctgaa attgttttac 27600
cgatttcctc gagctggaa aatcccaatt acgcctctga atttacacga atatttgaaa 27660
caccacgagt tgaaggatat gatattttag aatataatgt caaaatttca acggataaac 27720

-136-

gcttaggcga cttttcggat ttctccatca ggcagacaat tgaagcagca aaagcagaag 27780
aattaaccgg aaattctaaa acattaatca tgagaatggt atcacttttt ttcaaaataa 27840
tttactgttt ctattttggc atttatttca gcattctcca actccacaga atctcttaaa 27900
acgcggtaaa atgtatccat ttttcaaaaa tttcccatct ccaccacaag ttattccaaa 27960
gaaaacattg gacaaattgg atacaataac agaataatt gaagaatctg atgcattctg 28020
gacacttatc aaagaatggt cagaaaattc gaaatcttgg aaatgctcgt caagaaaatg 28080
tgtaagacca tcagtttagac atcgatctct tcatggatgg tattcatatg atattcattt 28140
ttctaaattt ttgaatgttg aaagtttttt ttgttcagat tttcaataaa cttttaagaa 28200
aagaataatt ttaaattcta taattcctga atttccaact atgtttatca tttcccaaag 28260
tacattcgaa aaagctcaat aagcaaacg accacgaaat aacagtatta aaaaaaaga 28320
tgttgtcatt tgaagttctg gagtgcgatg aaaagtctct cacctcggac tttctgtaat 28380
ttatttagca tacaacatga atttgaccaa ctcgaaataa ggtaagact gaaaattttt 28440
cacaaaaatt ggaacacttg cgaagcgaat tcaagacttt tcgaagtatt taaacaagct 28500
ttcaaattct cagtaaaact gaacgttttt tttatgctct ccaaattcatt ttaatatggc 28560
tgctcgcgtc gctgaagtat tttctagagt atgtttaata aaactaatat gtaaatgaaa 28620
aaccaaaaac tcagataaag agcataactt ttataacgca ttttcagaac ttttcaagct 28680
ttttcagatc acttctatca gcagtattct tcttttttcc aaagacacca agaactgaaa 28740
aggttgaagg agcatcaccg gaaatagagg atgactgctt attgttcttc tttttctgaa 28800
taaaatcaaa ttaaaccaccg aaaatatgaa acatattcac taacctgaac agctttcagg 28860
tttgatttat totgattttc cgccgtgat ctgctctgac ttttgaaacc gggacttgga 28920
gagttaccat tgcgtatgcg agttcgaact ggacgccgat tcttctttct gaataaacga 28980
attatacaaa ttgtattttg aaaacggaca acatacactc cttcttccgc cgaattgctc 29040
atcgattttc tcatttcttg tgttttttcc tggcggtcag gttcaaaagg tggagcaact 29100
ggtttggaac tatacgggaag aatgttcgag acttgaatct tttttggttg ctcaatattc 29160
tocattggaa tatgatcggg aagttcaaag tagctgttgg atcctggagc ttgatcaaat 29220
ccttcgagag ttaaaagttc acgaactgct tcaactcattg tgaccctttc ctcttcggca 29280

-137-

ccagcacaga ttctatactg aaattgcttg ttgtgttggt ttactcaaaa gaatagtga 29340
caaaattttc tcaccgtaat gaatctgaca atggctggtg ggacgttagc ttcaaattggc 29400
attcgggtatc cggttctgaac acgtggtaaa acctcagcaa ctttcattcc cgataaggt 29460
tcgattccat catggtacac ttccaacac atgactccat aagcgaaaac atcagtcttt 29520
ggagtataga acccagttct tggaaacttct ggagccaacc atctaataagg aactctgaaa 29580
aatttgaaaa gggttgaatt ttgacgttc tctaactttt tgtgaggatt catccgatag 29640
ctatagcctt ctctgacag tccaaagtcg gatattctta cttgtccatt cccgtagaga 29700
caatttcttg acgcaatatc gcgatgaatt atttgaagt aatgaagata ttcaagacca 29760
agaccagctt gaagaaccat cgtatgtttc ttggaaattg gcaatgaacc aatgttcttc 29820
tttagatatg aatccaaagc tccattgtca gcctaaaata atttacataa gacatttttt 29880
cttagtaaaa taaaattaat cagttaatta attaacatac caactccatt atgaccatca 29940
aaggttcctg tcctgcagcc acaccataaa aagtgcgac attcggatgt ttgaactttc 30000
tcatcaatct ggcttcgtgc atgatttctt tgatctgctc ttttgtcaaa gattccaact 30060
ttgccagctt gattgcagct tttttgacgg tatttcctat gcgaatttct cccaattgaa 30120
cctctccaaa tgctccttct cctaatttct tgattaatgt cacgtcagaa tgttgctttt 30180
cccacggttc acgaccaatt ggacggatga ttacagtttc tgggccctaa aagcaaaca 30240
atgaaaataa gtttactcac ttaatttgta agatcaccac agcaacaggt tctttagaac 30300
gatgatagta attgagaaga tctgcgatac tagaaaacca ttttttatca actgcaaact 30360
tgttattgtg ctctcgaatt acataatgac gaatctgaaa taatattctt aaaaattatg 30420
agcaatcgtt ttacgtacgt cctcaattac tccaacatag acagagagaa caaatttcct 30480
tggctctccc acttttggtat cagtaaactg aactagaaaa tcgcctcgtt gagtgagcaa 30540
ctgtttcata tcctcacgtg gcaataagcc atggtaccag gggtcttttg caagtacttg 30600

c

30601

<210> 34

<211> 8009

<212> DNA

<213> Unknown

-138-

<220>

<223> Description of Unknown Organism:Unknown

<400> 34

ggatccttgg ccacgccatg ggcgatgaaa ttgaccgcgt cgtaacgggt catgtcctgc 60
tcctgcagga agaaggccgc gttcgattcc cgttccgcaa agatcgcgac aaggacattc 120
gccccgtca cctcgggtccg gcccagactt tgcacatgga tcgcggcgcg ctggatcacc 180
cgctggaagg cggcgggtcgg cacggcttcc gagccttcga cttcgggtgat cagcgtcgag 240
agatcatcgt cgatgaactc ggtcaggggtg gtgcgcaact cgccaagatc gacgccgcag 300
gcgcgcacat cgcggtcggc gtcggggtcg tcgatcagcg cgacgagaag atgttcgagc 360
gtcgccagtt catgtttgcg cgtgttgccc agcgccagtg cggcgtgaat tgcttgctcg 420
agcgtggtcg aaaacgaagg catgcggcgc tcctttcctc ggggtctccc atactggcct 480
catgtgatta agtttcggtg gatttcgccg cgcttcaagg cccggacgcg tgttttttcc 540
acctctcgcc gctctgttgc aaaactgacc agcgcggcgg gctttcgcgc gatccgcag 600
cagcgcgcgga aagtgttttc agaaccggtc cttgcgcgcc cgcgccgcgg tgaagacggc 660
gagcggcgcg gcatccccgg gcaggccgag cgcggcgcgc aacgcagcgt catcggcgcg 720
caaaaaggga ttcgttgccc gttcctcgcc caaagtcacc ggcaaactgg gttccccggc 780
cagccgcaag gccgtcaccg ggtccatccg gtcgtgcagc cgaccgttcc ccggttcag 840
gctgagcgcg aaccggccgt tcgcggcggt gtattcatgc cccgaacaga cccgggtttc 900
gggcggcagc gcggccagac gggtcagcgt gtcgaacatc tcgcgggggg tcccctcgaa 960
gagacgcccg cagccccagc tcatcaggct gtcgccgaa aagagcagcc ccgccccggg 1020
cagataccag gcgatatggc cgagcgatg gccgtcgcc gcgatcacct gcgcggcctc 1080
catccccaga tgcagcacgt cgcggggggc caccggatga tcgagcgcg gcagccggtg 1140
ggcatcgcc gcggcccccg ccacctggc cccggtcgcc tcgccagcg cctcgacccc 1200
cgcatgtga tcggcgtggt gatgggtgat caggatgtgg tgcagctgcc agcgccggtc 1260
ggtcagcacc ttcagcaccg gggccgcctc ggggacatcg accaccacca cggtatcggt 1320
ggcgggtgctg tgccagagcc aggcgtaatt gtcggtcagg caggggatcg gggtcagttc 1380
gagggtcatg gccttttgcg catctttcgc tctcctgacc cagcttcgcc caaggaaggc 1440

-139-

caacctgcaa tgcattctga cgtgctcgac ctgctgatt tctactaccg cacccaattg 1500
gggcgcacgg cgcaaaaggc gatccgcgac aagggtggtcg aactctggcc ggacacccag 1560
tccggcatgg ccgggctgac ggtggcgggc tacggcttcg cggtgccgct gttgcgcccc 1620
tatctgggcc gggcgcggcg ggtgatcggg ctgatgcccg cgcagcaggg cgtgatgccc 1680
tggcccgcgg gagagcccaa tgtctcgggtg ctctgtgccg aaaccagctg gccgctggag 1740
accgggatga tcgaccggct ggtggtgctg cacgggcttg aagtctccga cgaccccgat 1800
gcgctgatgg aggaatgctg gcgcacgctg ggccccggcg ggccggcgct gttcatcgtg 1860
ccgaaccggg tcgggctttg ggccgcgcgc gaaaccacgc ccttcggctt tggccgcccc 1920
tatacgatgg gccagctcga ggccgaggca cgacgggtgg ggtttgcccc cgaacgtcag 1980
gcggcggcgc tgtacattcc gccctcgag cgcggttct ggctgcgctc ctccgagatg 2040
tgggaacggc tgggcacaag ggccgggggc tatctggcgg cgggggtggt gatgcttgag 2100
gtgatcaagc aggtgcattc ggtgcgcgc tcggggcttg gcggggcggt gcgcaagccg 2160
ctctcgatcc ttgaaggggc gcccaagccg gtggtcgggc ggatgtgagc cgcccgcggc 2220
cgcaagaatc gccgggccgg aaaagcccgt ttccgcggca cttcgccctg cgccggggaa 2280
acgcagcggg gcgggcttcg accctttgcg ctaacactcc gtgccggtgc agaaaatgtg 2340
ccagcctgat gcggattcct gccgccaaga tggttgcgag ggtcttgatg ctctgctaga 2400
cgcaaccccg aatgcggcgt gcgagatcat tttgggcgcc gaggggggccc tctgaatcgg 2460
tgacggaacg attggttccg gtgtccgct gcggaggcaa aagcatcgga agggtggaacg 2520
tgtccgaacc agcttcgatt tccgcagcca ttgccggcg ttatgccacg gccatcttcg 2580
acctcgcgca ggaggccaag ggcatcgac cgctctcggc cgacgtggac gcgctgacgg 2640
ccgccttggc cggttcggcc gagctgcgtg acctgatttc ctgcgggtc tacacccgcg 2700
aggagcaggg ggacgcgatc gccgcgggtg ctgcgaagat gggcctgtcg gcgcggcttg 2760
ccaacggtct gaaactgatg gcgacgaagc gccgtctgtt cgcgctgccg cagctgctca 2820
agggcctggc cgccgcgatc gccgaagcca agggcgagat gaccgcggat gtcacctcg 2880
ccaccgcgct gagcggggcg caggccgaga agctggcggc gacgctggcg aaacagacgg 2940
gcaagaccgt caaactgaac gtcgocgtcg atgaaagcct catcggtggc atgatcgtca 3000

-140-

agctgggttc gcgcgatgac gacaccacgg tcaaagccaa actcgcttcc cttcagaacg 3060
ccatgaaaga ggtcggataa atgggcatcc aagcagctga gatttctgcg atcctcaagg 3120
agcagatcaa gaacttcggg caggatgcc aggtcgccga agtgggcccgc gtgctctcgg 3180
tcggtgacgg gatcgcgcg gcgtcacgggc tcgacaacgt ccaggcgggc gagatggtcg 3240
aattccccgg cggcatccgc gggatggcgc tgaaccttga agtcgacaac gtcgggatcg 3300
tgatcttcgg gtcggaccgc gacatcaagg aaggcgacac cgtcaagcgc accaacgcca 3360
tcgtggacgt tccggcgggc gaaggcctgc tgggcccgcgt cgtggacggc cttggcaacc 3420
cgatcgacgg caagggcccgc atcgtggcga aagagcgtcg catcgccgac gtcaaagccc 3480
cgggcatcat tccgcggaaa tcggtgcatg agccgatggc gaccggcctc aagtcggtcg 3540
acgcgatgat cccgatcggc cgcggccagc gcgagctgat catcggcgac cgtcagaccg 3600
gcaagaccgc gatcgcgctc gacaccattc tgaaccagaa gtcgtacaac gacgccaacc 3660
cgggcaacaa gctgcactgc ttctatgtcg ccatcgggca gaagcgctcg accgtggcgc 3720
agctggtgaa gaagctcgaa gaagccggcg cgatggaata caccaccgtc gtcgccgcga 3780
ccgcttcgga cccggcgccg atgcagttcc ttgcccccta ttcggcgacc gcgatggcgg 3840
aatacttccg cgacaacggc atgcacgcgc tgatcatcta tgatgacctc tcgaagcaag 3900
ccgtggccta tcgtcagatg tcgctgctgc tgcgccgtcc gccggggcgt gaagcctatc 3960
cgggcgacgt gttctatctg cactcgcgcc tgetggaacg ttcggcgaaa ctgaacgagg 4020
atttcgggtc gggctcgctg accgcgctgc cggtcatcga aaccagggc ggcgacgtgt 4080
cggccttcac cccgaccaac gtgatctcga tcaccgacgg tcagatcttc ctggaaaccg 4140
aactgttcta ccagggcatc cggcggccgc tgaacaccgg tctctcggtg tcgcgcgtcg 4200
gttcgtcggc ccagaccaac tcgatgaagt cgggtgccgg tccggtgaaa ctggagcttg 4260
cgcagtatcg cgaaatggcc gcctttgcgc agttcgggtc cgacctgac gccgcgacgc 4320
aaaagctgct gaaccgcggt gccgctctga ccgagctgat gaaacagccg caatattcgc 4380
cgctgacca cgcgaaatc gtggcggtga tctttgcggg caccaacggc ttcctcgatg 4440
ccgttcgggt gaaggaagtc ggccgggtcg agaaaggcct gctggcctat ctgcgctcga 4500
cccgcaagga cgtgcttgag tggctcacca aggaagaccc caagatcaag ggcgacgccg 4560

-141-

agaagaagct caaagacgcg atcgccgagt tcgccaagac cttcgcttga cggcctgaaa 4620
ggacagggag atgcccagcc ttaaggacct caagaaccgg atcgtgagtg tcaagaacac 4680
tcgcaagatc acgaaagcga tgcagatggt cgcggcggcg aacattcgcc gcgcccagga 4740
aagcgccgaa gctgcccggc cctatgccga gcggatgaac gccgtgatgt cgagccttgc 4800
cgggtgcggtg ggctcgaccg acggtgcgcc gcgcctactt gcgggcacgg gctccgacaa 4860
ggtccatctc ctcgtcatca tgacgggcga gcgcgggctt tgcggcggct tcaacgcaa 4920
tatcgcgaaa ctcgcgaagg cgaaggcgat ggaactgctg gcccagggca agacggtgaa 4980
gatcctcacc gtcggcaaga aaggtcgcga cgcgctgcgt cgtgatctgg gccagtatta 5040
catcgatcac atcgacctga gcgacgtgaa gaaactgagc taccgggtgg cgcagaagat 5100
ttcgcaaaac atcatcgacc gtttcgaggc gggcgaatac gatgtggcga cgatcttctt 5160
ctcggctctc cagagcgtga tcagccaggt gccgaccgcc aagcaggtga tcccggcgca 5220
gttcgaaaacc gatgcggcct cggcctcggc ggtttacgac tacgaaccgg gcgatcagga 5280
aatcctgacc gcgctgctgc cgcgtgcggt ggccacggcg atctttgccg cgctgctgga 5340
aaacaacgcg tccttcaacg gggcgcagat gtcggccatg gacaacgcca cccgcaacgc 5400
gggtgacatg atcgatcgt tgaccatcga gtataaccgc tcgctcagg ccgcatcac 5460
caaagagctc atcgaaatca tctcgggcgc cgaggcgctc tgacggaacc ggagatagaa 5520
gagaatggca agcaaaggca aagtgaccga ggtcatcggc gccgtcgtcg acgtgcagtt 5580
cgaagacggc ctcggcgga ttctgaacgc ccttgaaacc accaacaacg gcaagcgcct 5640
cgttctcgaa gtggcgagc acctgggcga gaacaccgtc cgcaccatcg cgatggacgc 5700
gaccgagggg ctcgtgcgcg gcggggccgt gtccgacacc ggcgggccga tcaccgttcc 5760
ggtgggcaac gccaccctgg gccgcaccc gaacgtcatc ggcgagccgg tggacgaacg 5820
cgggtgacgtg tcgaaagccg aagcccggc gatccaccag cccgcgccc atttcgcggc 5880
gcagtcgacg gaaagccaga tcctcgtcac cggcatcaag gtgatcgacc tgctcgcccc 5940
ctattccaag ggcggcaaga tcggtctctt cggcggcgcc ggtgtgggca agaccgttct 6000
gatcatggaa ctgatcaaca acatcgcgaa agtgactcgg ggcttctcgg tgttcgcggg 6060
cgttggcgaa cggaccctg agggcaacga cctttaccac gagatgatcg aatcgggcgt 6120

-142-

tatcaacctc gagaagctcg aagaatcgaa agtggcgctg gtctacggcc agatgaacga 6180
acccccgggg gcccggtgcc gcgtggcgct gaccggcctg accctggcgg aacagttccg 6240
cgaccagtcg ggcaccgacg tgctgttctt cgctgacaac atcttccgct tcacccaggc 6300
cggttcggaa gtgtcggcgc tccttgcccg tatccctcg gccgtgggct accagccgac 6360
gctggccacc gacatgggcg cgctgcaaga acgcatcacc tcgaccaaag ccggttcgat 6420
cacctcggtt caggccatct acgttccgjc cgacgacctt accgaccgg ccccggccac 6480
gtcctttgcc cacctcgacg ccacgaccgt tctgtcgcgt gcgatctcgg aactcgggat 6540
ctaccgggcc gtcgaccgc tcgactccac ctgcgggatc cttgaccgc aagtcgtcgg 6600
cgaagagcac tatcaggtcg ccggtgacgt ccaagggatg ctgcaacgct acaagtcgct 6660
gcaggacatc atcgccatcc tcggcatgga cgaactgtcg gaagaagaca agctgacggt 6720
ggcccgcgcc cggaagatcc agcgcttcct gtcgcagccc ttcgacgtgg cgaaagtctt 6780
cacgggctcg gacggcgtgc aggttccgct cgaagacacc atcaagtcgt tcaaggcgg 6840
ggttgcgggc gaatacgacc acctgccgga agcggccttc tacatggtcg ggggcatcga 6900
tgacgtgatc gcgaaagccc agcgctcgc cgctgcggcg taagggggaa ccatggccga 6960
taccatgcag ttcgatctcg tgtcgcgga acggcggtt gcctccgtg ccgcgagcga 7020
ggtccgtctt cccggcggtg aaggcgatct gacggcgatg ccgggccatg cgcccgcat 7080
cctctcgctg cgtcccgga tcctgaccgt ggtcagcgcc gcgggcacgg ccgaatacgc 7140
cgtgaccggc ggcttcgccg aggtttcggg cgagaagggt accgttctgg ccgagcgcg 7200
tctgaccgg gcggaactga ccgccgggt tcatgccgag atgctggccg aggccaaaga 7260
agtcgaggac gccgcgcatc cgtcgggtgg cgatgccgcc gcgaagatgc tggccgacat 7320
ggaagcgctt ggctcgaca tcaatctctg acgggacatc ccgccggata tctcgggcc 7380
cggtcacgc gccggggccc ttgctttttg cttttgtctt gccgcggcg atattagcgt 7440
gaaggtgcag gcagccggag tgagcgacag gaacggatga agaagttttc ctcgaccgg 7500
atcggcggtg ccaggggatc gctgggtgtg ttttcggatt atctggacgg cggcggtgat 7560
tggaacggcg agggcccgcg cgaattgcgc aggttggtg tgttcgacga agccttccgc 7620
gagatcccg cggtgcagg gtgcgtgtcg atgtgggaca tcgaccagaa gcacaatccg 7680

-143-

cgcatggaca tttccgccga catggtgacg gccgagggct tcgtgatcgt ctttcgcacc 7740
tggggcgaca cccgcgtcgc ccgcgtccgc gcggactggc tggcgatcgg cggctgcgcc 7800
aatgacgacg actgggacgt ggcctgatcc cgcccggtt gactttccgc cccccgcgc 7860
cgatggtgcg cgcgactttc ccatccaacg aggcccgccc gtgcaacaag atgcccccg 7920
ctggcagctc gtggtgatcc tgtgggggac gaaatatccg gtcgccgaac tcaacgccct 7980
gatcgagacc gtgtggcccg ggcctcgag 8009

<210> 35

<211> 9810

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 35

gatatcgggc ttgtcatttt cgattgcgac ggggttcttg ttgattcgga agttctggcc 60
gtggcgcgtc tcatcgaga actggaccgg gcgggcgtgc gggtcgacga ggccttcgtg 120
catcggcatt ttctgggccc gagcttcccg gctgttcagg aggtcgtgca gcgccagttc 180
ggcgtgaccc tgcccagac cttccaggtc gaggaacgtg cccggctgct gtcagccttc 240
gagaccggcc tgccggccat gctcggggcc gcggagaccg tccgcgcgct gtcggtgccc 300
tactgcctcg ccacgtcgag cacgccggcc cggtcacgc gctcgtgga gatcacgggc 360
cttgccggcc tcttcgagg acgtgcttc accgcgagcc aggtggcgcg cggcaagccc 420
gcgcccgatc tgttctgct cgcccgggcc gagatggcg tcgcgccga acgtgcctc 480
gtgatcgagg ataccgagcc cggcgtgcgc gcaggcctcg cggccgggat gcaggctctg 540
cgcttcaccg gcggtagcca tttcggaac cgatccccg aggatgcgc cgatgcctg 600
ccgcaccggc ggctcgacag cttcgaccgt ttctacgaga ccctgcccg cctgcgcgg 660
gccaaagtgc agaccctgac atgatcgacc gggccgagag cgagccgacg cccctcgacg 720
atgcgcgcgc cgcgggctg ctctattatg tcgcaggcct gactcaggat cagatcgcg 780
gggagctcgc cacctcgcgt cagcggggcg agcggctgg gagccgggccc atctccgaac 840
ggctgatcca cgtccggctc gagcaccggg tctcgggctg cctgcatctg gaagccgcgc 900

-144-

tctctccggcg cttcgggttg aagctggccc gcgtggcgcc gagtctcggg tccgaggtgg 960
atcccctgcc ctccatcgcc cccaccgccg ccgccgaggt ggagcgggtg ctgcgctcgg 1020
agcggccgat ggtggtggcc ttcggcaccg gccggtcgct gcgcgccacc gtcgaggaga 1080
tgacctgat ggtctgcgaa cagcacaaga tcgtgtcgct caacggaaat atttctcggg 1140
atggctcggc ctccactac gatgtgatct tccgcatcgc cgaccgtgtg cgtgcgccgc 1200
actatccgat gccgatgccg gtcacgcgc aggatgcggc ggagcgggag ctgtttcatg 1260
cgctaaagcc cgtgcagtcg gtgctgcggc ttgcgcgcaa tgccgatgtg accttcgtcg 1320
ggctgggaca gatgggcgag gacgcgccgc tcctgaagga cgggttcac acgcccagg 1380
agctgaccga gatgcaggat ctgggcgccg tcggagaggt ggccgggatg gtcttcgact 1440
cggagggtcg ctacctgaa accagcatca atcagcgggt tcggggcgtc cgtgtcgaac 1500
tttccgagga tcggacggtg gtcgccatcg ccggtggcag gcgcaagctc gcggcgctgc 1560
acgcaggctt aaggggccgt cttttcaacg gcctgatcac cgacgagttc acggcgagg 1620
cacttctgtc ctgaagccgc cgaaaggcgc ggcaaaaagt atttgacagg ctggcacccc 1680
tcggtgagta attattcgcc gcacgaaata atgctcaccg tgcaggccag ggaggatact 1740
gatgaccgca agatttcgag ccctgatggg cgctgcgcc gtggctgcgc tctcgtccgc 1800
cgccggcgcc gaaaccatca ccgtggcgac tgtcaacaac ggcgacatga tccgcatgca 1860
ggggctcatg tccgagttca acgcgcagca cccgacatc accgtcgagt gggtgacgct 1920
cgaggaaaac gtgctgcgcc agaaggtcac gaccgacatc gccaccaagg gcgggcagtt 1980
cgacgtgctg accatcggca cctacgaggt tccgatctgg ggcaagcagg gctggctcgt 2040
gagcctgaac gacctgccgc cggagtatga tgccgacgac atcctgcccg cgatccgcaa 2100
cggcctgacc gtcgacggcg agctctatgc cgcgcccttc tacggcgaga gctcgatgat 2160
catgtatcgc aaggacctga tggagaaggc ggggctgacc atgcccgacg ccccccactg 2220
ggacttcgtg aaggaagcgg cgagaagat gaccgacaag gatgccgagg tctacggcat 2280
ctgcctgcgc ggcaaggccg gctggggcga gaacatggcc ttctcagcg ccatggccaa 2340
cagctacggc gcgcgctggt tcgacgagaa ctggcagccg cagttcgacg gcgaggcctg 2400
gaagggcacg ctgaccgact atctcgacat gatgacgaac tacggcccgc ccggcgccctc 2460

-145-

gaaaaacggc ttcaacgaga acctcgcgct gttccagcag ggcaagtgcg gcatgtggat 2520
cgacgcgacg gtggccgcct ccttcgtgac caaccccgag gaatccacgg tggccgacaa 2580
ggtagggcttc gcgctcgcgc ccgataccgg caagggcaag cgggccaact ggctcggggc 2640
ctggaacctc gcgatcccg cggtctcgca gaaggtcgat gccgccaagc agttcatcgc 2700
ctgggcgacc tcgaaggact atgccgagct ggtggcctcg aaggaaggct gggccaacgt 2760
gcctccgggg acgcggaact cgctctacga gaacccggaa tatcagaagg tgccgttcgc 2820
gaagatgacg ctcgacagca tcaacgcggc tgacccgacc caccggcgcg tcgatccggt 2880
gccttacgtc ggtgtgcagt tcgtggcaat ccccgagttc cagggcacgc gcaccgccgt 2940
gggccagcag ttctcggcag ccctcgcggg ctcgatgtcg gccgagcagg cgcttcaggc 3000
ggcccagcag ttcacgacgc gcgaaatgac ccgcgcgggc tacatcaagt gagcccttcc 3060
gcgggccggc cctgagcggc cggccgcac cgcttgccgc ttccggccgt atccgccgga 3120
ggcctttccg ccccatcagc cccgaggcct ccattggcgc ccagcattca aagactgcgg 3180
cgctctgat gatttccccg gccgtgatcc tcctgttct gtggatgatc gtccgctgt 3240
cgatgacgct ctacttcagc ttctgcgct acaacctcct catgccgggg atggagagct 3300
tcaccggctg ggacaattac tattacttcc tgaccgatcc ggccttctcc gcggccctga 3360
ccaacacgat cctcctcgtg gtcggcgctc ttctcatcac cgtggtgggc ggggtcctgc 3420
tcgcgctcct gctcgaccag cccttctggg ggcagggcat cgtgcgcgtg ctggtgatcg 3480
ctcccttctt cgtcatgcc accgtctcgg cgctggtctg gaagaacatg ttcatgaacc 3540
ccgtgaacgg gatgttcgcc catatcgccc gcgggctcgg ccttcgccg ttcgacttcc 3600
tgtcgcaggc gccgctggcc tcgatcatcg gcatcgggc ctggcagtgg ctgcccttcg 3660
ccacgctgat ccttctgacg gcgctccagt cgctcgaccg cgagcagatg gaggcggccg 3720
agatggacgg cgcctcggcg ctcgaccggt tcatccacat caccgtgccg cacctgacgc 3780
gtgccatcac cgtggtggtg ctgatccaga ccatcttct tctgggcgtc ttcgccgaga 3840
tcctcgtcac gacgaacggt ggacccggca ccgcctcgac caacatcacc tacctcgtct 3900
atgcgcagtc gctcctgaat tacgacgtgg ggggcgggtc ggccggcggc atcgtcgccg 3960
tggtgctcgc caatatcgtg gcgatcttcc tgatgcgcat gatcggcaag aatctggacg 4020

-146-

cctgacatgt cacgccgcac ctcaaccgc cgcaagctga tcgtcacgct cgccgcctgg 4080
acgatagcct tcctcatctt cttcccgatc ctctggacgg tgctgatgag cttcaaactc 4140
gaaggagacg ccatcaaggc gcccttcgcc atgctcttct cggactggac cctgcaatcc 4200
tacgccgatg tgcaggaacg gtcgaactac gcccgccact tcatgaattc ggtggtgatc 4260
tcgctgggct cgaccctcgt ggcgctcgcc atcgcgatcc ccgccgcctg ggccatggcc 4320
ttcgtgccgg gccggcggac gaaggacgtg ctgatgtgga tgctgtcgac caagatgatg 4380
ccggcggtgg gcgtgctcat ccgctctat ctgatcttcc gcgacacggg ccttctcgac 4440
acgcggatcg gcctcgtgat cgtgctcacg ctcatcaacc tgccgatcgt ggtctggatg 4500
ctctacacct acttcaagga gatcccgggc gagatcctcg aggcggcgcg gatggacggg 4560
gcgacgctcg gctccgagat cctctatata ctcaagccga tggccgtgcc gggcatcgcc 4620
tcgacgctgc ttctgaacgt gatcctcgcc tggaacgagg ccttctggac gctgcagctg 4680
accacctcgc gggcgggccc gctcacgcag ttcacgcga gctattccag ccccgagggc 4740
ctcttctacg ccaaactgtc ggcggcctcg accatggcca tcgcgccgat cctgatcctt 4800
ggtggttca gccagaaaca actcgtccgc ggctgacct tcggcgcggt gaagtgagga 4860
ccacatgggc aagataacct tgcgcaacgt ccagaagcgg ttccgtgagg cggtcgtcat 4920
cccctcgctc gacctcgaca tcgaggatgg cgagtctcgc gtcttcgctc gccctcggg 4980
ctgcggcaaa tccacgctcc tgccctgat cgcgggcctc gaggatgtgt cggacggcca 5040
gatcatgatc gacgggcgcg acgccaccga gatgccgcc gcgaagcgcg gcctcgccat 5100
ggtgtttcag agctacgcgc tctatccgca catgacggtg aagaagaaca tcgccttccc 5160
gctgcggatg gcgaagatgg agccacagga gatcgagcgg cgcgtgtcga acgcggccaa 5220
gatcctgaac ctcaaccaact atctcgaccg ccgccccggc cagctctcgg gcgggcaacg 5280
gcagcgggtg gccatcgggc gcgccatcgt gcgcgagccg gcggccttcc tgttcgacga 5340
gccgctctcg aacctcgatg cggcgctgcg ggtcaacatg cggctcgaga tcaccgagct 5400
gcaccagtcg ctcgagacca cgatgatcta tgtacccac gatcaggctc aggccatgac 5460
catggccgac aagatcgtgg tgctgaacgc gggccggatc gagcagggtg gctcgcccct 5520
caccctctac cgcaatccgg cgaacctctt cgtggcgggc ttcacggca gccgaagat 5580

-147-

gaacctgatac gagggggcccg agggcgccaa gcacggcgcc accaccatcg ggatccgccc 5640
cgaacatatc gacctgtcgc gcgaggcggg ggcggtgggag ggcgaggtcg gcgtctcggg 5700
acatctcggc tcggacacgt tcctgcatgt gcatgtcgcg gggatgccc aacctaccgt 5760
gcggacgggc ggagagttcg gcgtccatca cggcgaccgg gtctgggtca cgcgcaggc 5820
cgacaagatc caccgcttcg gcgccgacgg aaaggcgctc tgacatgcgg ctgcacggca 5880
agaccgccct catcaccggc tcggcgcgcg gcataggccg cgccttcgcc gaggcctatg 5940
tgcgtagaag cgcgcgcggt gccatcgccg acatcaacct cgaggcagcc cgcgccaccg 6000
cggccgagat cggcccccg gcctgcgcca tcgccctcga cgtgaccgat caggccagca 6060
tcgaccgctg cgtggccgag cttctcgacc gctggggcag catcgacatc ctcgtagaaca 6120
atgcggccct cttcgatctg gcgcccacgc tcgagatcac ccgcgagagc tacgaccggc 6180
tgttcgcat caacgtctcg ggcacgtctc tcatgatgca ggcggtggca cgggcgatga 6240
tcgcgggcgg ccggggcggc aagatcatca acatggcaag ccaggccggc cgcgcggcg 6300
aggcgctggt gggcgctctat tgcgcgacca aggcgcgct catctcgctc acccagagcg 6360
cggggctgaa cctcatccgc caccggatca acgtcaatgc catcgccccg ggcggtggtg 6420
acggcgagca ctgggacggg gtggatgcga agttcgccga ctacgagaac ctgcccccg 6480
gcgagaagaa gcgtcaggtc ggcgcggcgg tgcccttcgg ccgcattggc cgcgcaggg 6540
acctgaccgg catggcgatc ttctcgcca cggcgaggc cgactacatc gtggccaga 6600
cctacaacgt ggacggcggc aactggatga gctgaggccc aaggccggc cctcccccg 6660
tcgaacgcgc cccctatccg aggtaatccc atgaccgct ccgtcaccg tccctcctat 6720
gaccgcaagg cgctcactcc cggcatcgtc catatcgcg tcggcaactt ccaccggcg 6780
catcaggcgg tctatctcga cgatctcttc gcgtggcg agggccacga ctgggccatc 6840
ctcggcgcgg gcgtccgcc gaccgatgcg cggatgcgc aggtcttggc cgcgcaggac 6900
aatctctcga cggatgatga gctcgatccg gcgggccacc gggcccgga ggtggggcg 6960
atggtgggct tcctgccggt cgaggccgac aatgcggccc tgatcgaggc catgtcggat 7020
ccgcgcatcc gcatcgtctc gctgaccgtg accgaggcg gctattatgt cgatgcctcg 7080
ggcgccctcg atccgacga tccgatatc gtggccgat cggcccatcc tgcgcgccc 7140

-148-

gcgaccgcct tcggcgcgat cctcgccgcc ctccgcgccc gccgcgacgc ggggggttaca 7200
cccttcaccg tgatgtcctg cgacaacctc cccggcaacg gccatgtcac ccgcaacgcc 7260
gtggtgggccc tggccgagct ctacgacgcc gagcttgccg gctgggtgaa ggcgaggtg 7320
gccttcccga acggcatggt cgaccgcac acccccgcca ccggcccgca cgagcgcgaa 7380
ctggcgaggg gcttcggcct cgccgatccg gtgcccgtca cctgcgagcc gttccggcag 7440
tgggtgatcg aggatcatth ccccgccgga cggccgcgc tcgagaagggt gggcgtagacc 7500
ttcaccgccg atgtccatgc ctacgaggcg atgaagatcc gcatcctgaa cggggggccat 7560
gcggtgatcg cctatccgtc ggcgctcatg gacatccagc tctgtcacgc ggccatggcc 7620
catccgctga tcgcggcctt cctgcacaag gtcgaggtcg aggagatcct gccccatgtc 7680
ccgcccgtgc ccgacaccag catccccgac tatcttacc tgatcgagag ccgcttctcg 7740
aaccgccaga tcgccgacac gacgcgaggg ctctgcctcg acggttcgaa ccggcgagccg 7800
aagttcatcg tgccgtcgct gcgcgacaat ctggcgggcg gcacgggtgcc gaaggggctg 7860
gtgctgctct cgcgctctg gtgcccgtac tgcttcggca cgacggactc gggcgttgtg 7920
gtcgagccga acgatccgaa ctggacggcg ctgcaggacc gggcgggcg ggcaaggag 7980
acgccggccg agtggctggc gatgaccgaa gtctacggcg atctggcgca gaacgatctt 8040
ctggcgcccg agttcgggc agccctcgag gcggtctggc gcgacggggc cgaggcggtg 8100
ctgcggcgct tctcgcggc ctgatccgca gggcccagcc gctcgagca ccgaagcgga 8160
gcccctgccc cttgcggcg accgtgaggc gaaacgaccg ggccaccccg gggccaccgc 8220
ctcgtaaca ccatggtatc gcgcaagaat gccggcgccct ctgccgaacg ggcccggctg 8280
ccggcgaggg cggcggaactt gtcaaggcg cgccctcg gtagagagg cgggcggtggc 8340
cccgttagca cagtggtagt gcagcgctct tgtaaagcga aggtcggtcg ttcaaactcg 8400
acacggggca cgcgatcctc cctccgcac ggcgctcgcc ccggtctgg actgcctctt 8460
cggaaggcac ctgcccgtt gtgcgcgcg ccctttctc gttcccaag cgtctgtcac 8520
ggcttgcgga aagccgtgcg cctcggttct ggacagccgc cccttgcggt gtaatctgcc 8580
ctcagcgcg agccggcgga cagaagccgg cccgccacgt ccacaaggga ggaatgccat 8640
ggatcgctcg tcattcatca ccaaggccgc cgtgggaggg gccgcgcga gcgccctcgc 8700

-149-

cgcgccggcg cttgccagtg ccgcgcccaa ggacacgtgg aggtcgcct cctccttccc 8760
 gaaatcgctc gacacgatct tcggcgggcg cgaagtgttg tcgaagatgc tctccgaggc 8820
 caccgacggc aacttcaga tccaggtctt ctggcgggcg gagctgggtg cgggcctgca 8880
 ggccgcccgc gccgtgaccg agggcaccgt cgaatgtgac cacacgggtg gctactatta 8940
 ctggggcaag gatcccatat tcgcgtggcg cgcgccgttg cccttctcgc tgcggcgcg 9000
 cgcatcaac gcctggcact accatggcg cgggatcgac ctctacaacg atttctcgc 9060
 gcagcacaac atcgtggcct tcccggcgcg caacaccggc gtgcagatgg ggggctggtt 9120
 ccggcgcgag atcaacaccg tggccgacat gcagggcctg aagatgcggg tcggcggtt 9180
 tgcggggaag gtgatggagc gtctggcggt cgtgcccgag cagatcgcg gggcgacat 9240
 ctatccggcg ctggagaagg ggacgatcga cgcgaccgaa tgggtcgcc cctatgacga 9300
 cgagaagctc ggcttcttca aggtggcgcc ctactactac tatccgggtt ggtgggaagg 9360
 cggcccgacc gtccatttca tgttcaacaa gagcgcttac gaggggctga ccccgcccta 9420
 tcagtcgctg ctgcgcaccg cctgccacgc ggccgatgag aacatgtctc agctctacga 9480
 ctggaagaac ccgacggcga tcaagtctgt ggtggcgag ggaaccagc tcaggccctt 9540
 cagccccgag atcctgcagg cctgtttcga ggccgcgaac gaggtctatg ccgagatgga 9600
 agcctcgaac cccgccttca agaagatctg ggactcgatc aaggccttcc gctccgagca 9660
 ctacacctgg gcgcagatcg ccgaatacaa ctacgacacc ttcagatgag tgcagcagaa 9720
 cgccggcaag ctctgagccc gagcgccgag cgaaagagga ccccgagcc gcgttccggg 9780
 gtcttttcat gggcgacagg ggccggcgcg 9810

<210> 36

<211> 1886

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 36

tgagtgtcta ttttttttcg ggttttttta agtgtgaatc acatggttag gagcagttgt 60

cttcaatgtg accaaccatc ccaaggctct aattcaacgt ttgggtgtgg gggcccgctg 120

-150-

gcagctgtgt gtgccactgg gctgttggtg ttggtgcttt actccccctc atcgcaaacg 180
gctaattggt cggcacaggg tatttccaca aaggcgctgt atccggcagt gcctgtgcct 240
tccactctgc tgcttgaag cgcgcctgcc aaacaccagc tgcattgttg gagggcacat 300
gcgatgtcgg aggccacaac aaacaattca ttcaaacagt cattatttgg gtacaatgcc 360
atctcctcca tttggettca actggctggt gtggccgcca ctttctttgc atttgagct 420
ttgatggcag ctgtaacgca acgcaaggag atcgccgtct tctccgcctc gggtcaggct 480
gctgagccgg agggggcgga gcccctgaag cggccttttc cgtctcctgc tgccaaacct 540
aagccgtctt tctccacccc ggcaaattcc ttcagcaaca tcttccaggc gcctccatcg 600
ctgcgcacgg actccaccta tggccgaggc cgcgcctcga ccagcttcac cgacatcagc 660
aactggccct ccaacaacgc actccgcaac cccagtcgg tgattgacat cgggggagga 720
gtcgacttcc tgggggacag aagccctgga aaccggttca cgcggctgcg ggggtccccg 780
agctccaccc tcagcaacct cggcatgggc ctaggcctgg ggctgggcaa gggcaagggc 840
ttcggcaagg gcttcggcaa aggccggggg ttccccgtgg aggaggaggt ggaggaggag 900
caggaggtgc tgtcgtgggc cgaccgccgg cgggcgctgg cggaccccga cgccccgccg 960
atgaacgagg acatcaagta cccgcagctg cggctggtgc gggccgtgcc gggcggccgg 1020
gacgagaagc tcggtgtgat gtcgaggcag gaggcgctgg agctggcgga ggcggaagac 1080
atcgacctcg tctcgtcag catcgacacc gaccccccg tggccaagct agtcaattac 1140
tcgaagttga agtacgagtc cgagaagaag aagaaggaca gccacaagaa ggggaagggtg 1200
aaggaggtga aggagctgaa ggtgtcccat aagatcggcc agcacgacta cgacgtccgc 1260
gtgaagcagg cccgaaagtt cctggagggc ggccaccgca tcaagggtgc gatggagttc 1320
aaggggcgcg agaaccagtt cgtggagatc ggccgcgcgg tgatgaagcg cttccagaac 1380
gacctggcgg acatgggcaa ggcgacgcc gtgcccaaga agctcggcac ccggctgac 1440
ctgaacctgg ccccgcccg ggaggcgctg aaggtgattg cggagcggag ggcagagcgc 1500
gacaggaaag ccgcggtgga ggaggagggg gagggcgacg acctcgactt cgtggacgag 1560
aacgaggacg aggatgtgga gggggagggc gaggaggaag aggccgagga gctggaggag 1620
gagacagcgg aggggacgga ggtgcccaacc cgcagctgat cgccgatccg cgggggacag 1680

-151-

ccacctcccc cccggcctcc ctgccggggg ccggcaccat ccgtcgttgc ggtgcggcgc 1740
tgccatcaac ggccgtcctt gagcttaatg ctcccgccct ccgttgcccc gggcggtcg 1800
ccaggttgct ggctggctg ccgcagctc ctccctccc cgactgacac agtgtggatg 1860
accgtgatgt gcgccttttc gccttc 1886

<210> 37

<211> 3015

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 37

ccgctcatct ccaggcctcc ctgagtgcgt acccgagagc ggcaagtaga gaaaggaaca 60
cagatacagc accatggcct ctaggctcgt ccgtgtgctg gcggccgcca tgctggttgc 120
agcggccgtg tcggtcgacg cgcgcttcgt ggtgcgcatg gtgcaggtgg tacaccgcca 180
cggtgcgcg cgcgcactca tcgacgacaa cacgacggag atttgtggca ccctgtacct 240
gtgcggtgag ctgaccggcg aggggtgtcga gatggctcgt gctatcggcg agtttgcccg 300
cagccgctac aacaacctct cattggtgga gagccctctc ttcccgctga cgcggtacaa 360
ctcctctgtc gtgcacacac gctccacca caccagcgc accatccaga gcgcgaccgc 420
ctttctgcgc ggctcttcc aggacgacta cttctaccg gtggtgtact cgaccaacag 480
aacgaccgaa acgctgtca gcactgacgc ggtgccgtcc gtggtgggcc gtagctggct 540
cgacaacccg gcgctgcacg ccgccctcaa cccggtgac gatgagcacc tcagctggga 600
cgccatccag agcgtgcca aggacgcatg ggtcgagggc ctgtgcgcgg actacaacgc 660
ccgcaqcaae tgcgtcctcg acatgtacga cgtggccgccc gccttcgagg ccgccgggcg 720
tcttgacaat gccaccaatc tcaaggcggg gtatcccggc cttcaggagg tgaacgccgc 780
ctggttcaag tatgtcttca gctggaacca cacgagcaag ctcgatctca cgcagggctc 840
cgcctcgag aaccttgcgc agacggtgct ggccaacatc aacgcccacc gcctctctcc 900
gtcgtacaac atgttccagt acagcgtca cgacacaacg gtgactccct tggctgtcac 960
gttcggtgac cagggcgaga cgacgatgcg tccgcccttc gcggttacca tcttcgtgga 1020

-152-

gctgctccag gacaccgag atgccagtgg ctggtacgtg cgcctcatcc gcggcaaccc 1080
tgtgaaggca gccgacggca cctatgtctt ccaggagtct ggtatcaagg catactgcat 1140
cgatgaagcc gggaacaagt acctcgaca caccggcatc tgcccgtga atagcttccg 1200
ccgcatggtc gactactcgc gcccgcctt ggctgacggc cactgcgcca tgacacagac 1260
tcagtacagc aacatggatt gcccgcgcac tatcgcggac aacaagccgg tgccgtcgcg 1320
ctgctggctc taccgccacg ttgcccctag caaggcatgc ccggacagct acattctctc 1380
cgcggtcgcac caccagtgtc accccgggccc cgacgttacg aaccaccca gcagcagcag 1440
cagcagaggt accaccacca gcagcagcga ggggtaccgcc accagcagca gcgacgttac 1500
caccaccagc agcagcgagg gtaccgccac cagcagcagc gacgtacca ccagcagcag 1560
cgagggtacc gccaccagca gcagcgacgc taccaccagc agcagcagcg acgctaccac 1620
caccagcagc agcgagggtta ccaccagcag cagcagcgac gctaccacca gcagcagcga 1680
cgctaccacc accagtagca gcgagggtac cgccaccagc agcagcgacg ctaccaccac 1740
cagcagcgag ggtaccgcca ccagcagcag cgacgttacc accaccagca gcgagggtac 1800
cgccaccagc agcagcgacg ctaccaccac cagcagcagc gagggtacca ccagcagcag 1860
cagcgacgct accaccagca gcagcgaggg taccgccacc accagcagcg acgctaccac 1920
cagcagcagc agcgagggtta ccaccagcag cagcagcgac gctaccacca gcagcagcga 1980
cggtaccacc accagcagca gcagcgaggg taccgccacc agcagcagcg acgctaccac 2040
cagcagcagc gagggtaccg ccaccaccag cagcgacgct accaccagca gcagcagcga 2100
gggtaccacc agcagcagca gcgacgttac caccagcagc agcgagggtta ccgccaccac 2160
cagcagcgac gctaccacca gcagcagcag cgagggtacc accagcagca gaagtgcgc 2220
taccaccagc agcagcgagg gtaccgccac caccagcagc gacgtacca ccagcagcag 2280
cagcgaggggt accaccagca gcagcagcga cgctaccacc agcagcagcg aggggtaccgc 2340
caccaccagc agcgacgcta ccaccagcag cagcagcgag ggtaccacca gcagcagcag 2400
cgacgtacc accaccagca gcgacgttac caccaccagc agcagcagcg aggggtaccgc 2460
caccagcagc agcgacgcta ccaccaccag cagcgacgtt accaccacca gcagcagcag 2520
cgagggtacc accaccagca gcagcagcag cagcagcaaa agcacaagtt catcggtatgt 2580

-153-

cccttccttc aaaaagcccg cgaactggag ccgcgcggtt ctctcgccg aaaggggccg 2640
ccacattgcc ggggacatca tccgcgcgt gacgaacggt gttacgatcg gtgcgggtgt 2700
ccgaaagcac gatgagtaca gccggcaccg ccaacagtag cacaacggca tgtaactctt 2760
ttgtgcatgt ttgaatggag aggaggcttc tgtacagcgt acattgtttc gagaaggat 2820
cacaaccgct cgtttcacc cgcgcctctt ttcattttga tctccgctgt ctcatactgc 2880
ctttgtgggc tctctctggg tgtgggcgct tgtgcgtgtg tcgctgtaa gtcgttgacg 2940
ccatcgctct tacctgtggg ctattttttt aattatggtt tattattact tccctctctg 3000
cgcgccctc tgcag 3015

<210> 38

<211> 38186

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 38

gaccttcct gcctctccg gcgtctggg ctccaggcgc ccttggttg cagattgatc 60
tccctgatct ctgcctccat ctgctcacag ccttctcccc tgttgtctc tgtctcttct 120
tgtaaattca tccgtcgttg gatcagggcc caccgggtc ctcgtggcct cgccttaact 180
gggccatgtc tgcagagacc ctatttccac ataaggtcct attcacagga accgggggtc 240
aggatgtcag cctgtctttc tgggagatgt agttcaacc acaacacaca tcaaacagtt 300
attgagcgcc gactgcgtgc cctgccgtgt gcttgaaggt cccaccctca ggaagcgggg 360
cctagggatg gcggccgtga tcacgcaggc agcagagagc agctctggga agcggggagg 420
gacgaggacg gggaggcgac atcagcaagg ccgtgtgtga gccaggcagg gtgtccccgg 480
tgtagcacct ggctcgggca gaggccccga ggaggggctg gaggagctgg gcgaggaggc 540
gggcaggacg ggctgacac tagggacctc gggccccggg aatgcctctg ggggggcgtg 600
tacaccggtt gctcccagga ggcacacact gcggttcgct tcgccaagaa tgtttaattg 660
catttgatga ctacggtttc cattcattca tttgtagaga tataaactc agaccacaaa 720
atgcataaaa tgcggtggct tttagtatta acagagtgt gcaccgata ccacagcctc 780

-154-

actccagaac attctcatgg gcccaaaagg agacctgggg tgtagtcac cagctcactc 840
cccgccccca gcccttgga acccacgcta cttagtcatt atttaggtgt ttaggagttg 900
caaagtcaaa tctttaaac cacaatggc caggcgtggg ggctcacgcc tgtaatccca 960
gcactttcag aggccgagac gggcagatca cctgaggtca ggagttcgag accagcctgg 1020
ccaacatggg gaagccccgt ctccactaaa aatacaaaat tagccgggcg tgggtggggg 1080
cgctgtaat ccagctact ctggaggctg agacaggaga atcgcttgaa ccaggaggc 1140
ggcggttgca gtgagccgag attgtgccac tgcactccag cctggacaac agagcgagac 1200
tccgtctcaa aaaaaaaaa agtaccataa agtgccccag gtcataaggg cacagctcga 1260
tagctggtcc ctaaaggga cgtggtgtaa ccaccacaca gaacgaagct ggaacgttcc 1320
tgccgtcctt agaagctgcc ttgctaagg ggaattgcc tgacttccca caccattgat 1380
tcctctccag acccttggtt ttcattgga tttttcaaaa atcacctgat agtctgaccg 1440
aatgtagctt tccactggtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg tgagagagag 1500
atggagtctc gctctgtcac ccgggctcca gtgcagttgt gtgatcttgg ttcactgtaa 1560
cctctcctc ccgggttcaa gagactcgtg cctcagcctc ccgagtagct gggattacag 1620
gcacccgcca ccacaccag ctaatttttt gtatttttag tagagatggg gtttcacat 1680
gttggccagg ctggtctcga actcctgaca tcaggcgatc caccacctt ggctcccag 1740
agtgtggga ttacaggtgt gagccaccac gccggcctt atttttcccc cattttcttt 1800
tttttttttt ttgagtcagg gtcttgttct gcgctcaggc tggagggcag tgggtgtggg 1860
atcacggctc actgcagcct cgacttcctg caccaccacg cctggctgtt tttttttttt 1920
ccggtagaga cgggggtctt accgtgttgc ccaggctggg ctagaactcc tgggctcaag 1980
cgatcctccc gcctcggcct ccgcaaatgc tgagatcaca cgcgtgagcc ccgcacccg 2040
gcctcctttc caccgtctt gtctacagcc gccctcctg gtccgattgt attggcagat 2100
gtcgccaata cgggtgtcaaa cggcgaaggg gcactgagcg tttttcttt ctccgtcct 2160
tggcggcagc agctcggtt cggctacggg gctgagccc tctctcagac gaggaactg 2220
gggtccgaga ggtgagccg tcccagaggc agggcgaggg ggaagcgga gtgggggtccg 2280
cagcggaccc agcctgcct cccccctgca ggagatcgtc aacttcaact gccggaagct 2340

-155-

ggtggcctcc atgccgctgt tcgccaacgc cgaccccaac ttcgtcacgg ccatgctgac 2400
caagctcaag ttcgaggtct tccagccggg tgactacatc atccgcgaag gcaccatcgg 2460
gaagaagatg tacttcatcc agcacggcgt ggtcagcgtg ctactaagg gcaacaagga 2520
gatgaagctg tccgatggct cctacttcgg ggggtgagctt gaggggggcg cgcttgagg 2580
gggagggggc acgcgacccc cgcggtgtgc agagccaggg ggccggggcc ggggcccggg 2640
ccgggggatgg ggatggggat ggggatgggg ccgggggatgg ggatggggat ggggatgggg 2700
ccgggggatgg ggatggggat ggggcccggg atgggggatgg ggccggggat ggggcccggg 2760
atggggcccg ggatggggcc ggggcccggc ccaggagag cctgggtggg aagcgccac 2820
gctggccaag gtgcagaggc cgggccgtgt gcctgggcgg ggagggccgc ggcgcccgc 2880
tcgtccagca accccccct gcgcgccacg tgagagatc tgctgtca cccggggccg 2940
ccgcacggcg agcgtgcggg ctgacaccta ctgccctc tattcgtga gcgtggacaa 3000
cttcaacgag gtgctggagg agtaccat gatgcggcg gccttcgaga cgggtggccat 3060
cgaccgcctg gaccgcatcg gtgagcggc cggggcgctg gccggggcg gtgccctggc 3120
gggggagggg cgtggccaag gcatcaggag agtggttg acagtggcag ggggaagggc 3180
gtggctgtgg catcaggggc acggttgggg cagagacgtg gccaaggcat caggagtgtg 3240
gccatggcag cagggcgctg gctggggcag gggcagcggc tggccgctc taggaccct 3300
ttgggtctag aggctgattt tctgacctat tgcctactt cagccagagg cagcctgtt 3360
ccaagggag ggaatgcaca ggggtgttgc ggttgtgccg aatgctcgtg gagcacctgc 3420
tgtgtgctgg ggggtcaggg gacagaccg ggggcccact cagactcca gggaggctta 3480
tgactggtg atgaaatcac acacgactgg gctgtgtgcc agcagggcag gtggggcccg 3540
tggtctccc tgagttggga atgcagagtg gagaccagg taagggatgc catgtgaaa 3600
cggggaggaa gatgtgttcg tggagtggac acagcacatc ccaaggccct gaggtgaaa 3660
agaggcctag agtccagaga gccaggagg cctggaggag gttggggaag aagggaggc 3720
cagacacaca gggcccagtg ggcggcagg agagtttaga ctaaatacagg agcatcagg 3780
agccatggag ggttctaggt gggcgaggga cctggtcaga ttgtatccgc caaggcggg 3840
cgtgtccagg agggagacgg tgacctggcc tctcagggg gcagtctctg gggcaggag 3900

-156-

cggcagagcc ctgatgactg gatgtaggcg ccagagagat ggcggctcat gctgctgttc 3960
gtgggaatgg gaatgaagac catggctgaa acgcaggaca ggtgcgacgg agtggtgtca 4020
gggagctccc tgggtgtacag taggaagctc tccacaactt gctctataca gtgagtatgc 4080
aaccggttcc tgagtatcag gtgcttaggt tataacttct gtatacagca ggtgctcagc 4140
acaggctgtg tacaggcagg tgttttcggg atgcctgtgg cactctggag gcagtcatta 4200
cataatcagc gtatacagggt ggtacacatg catacttggg gcacagtgat acctgctcca 4260
tgtacacagc aggcattaaa tacctgttta ctgccaggcg cgggtggctca cgcctgtagt 4320
cccagcactt tcggaggcca aggtgggtgg atcacgagggt caggagattg agaccatcct 4380
ggctaacatg gtgaaacccc gtctctacta aaaaaaaaaat aaaaaaatt agccgggtgt 4440
ggtggcgggc gcctgtagtc ccagctactc gggaggatga ggcaggagaa tgggtgtgaac 4500
ccgggagggtg gaccttgagc tgggccgaga tcgcgccact gcactccagc ccgggcgaca 4560
gagcaagact ccgtctcaga aacaaagcaa aacaaaagcc ctgctttctg tatgcagggtg 4620
cttcatgcat gctggctgtg catagcagggt gctcagcctg tatatggcag gtactcaata 4680
tccatactat aggccagaga tgctacatat gtgcttattg tatacagtag gtggtaaattg 4740
catgcttgct ctacacggca agcactgtgt gcgcacccgc ggtgcagagt aggtgctcgg 4800
tgcccgtgt acgcagcagg cgctccctgt gcacacgcta acgccccctc tcccgcaggc 4860
aagaagaatt ccctctcct gcacaagggtg cagcatgacc tcaactcggg cgtattcaac 4920
aaccaggaga acgcatcat ccaggagatc gtcaagtacg accgcgagat ggtgcagcag 4980
gccgagctgg gtcagcgcgt gggcctcttc ccgcgcgcgc cgccgcgcgc gcaggtcacc 5040
tcggccatcg ccacgtgca gcaggcggcg gccatgagct tctgcccgca ggtggcgcg 5100
ccgtcgtgg ggcgctggc gctcggctcg ccgcgcctcg tgcgcgcgc gcccccggg 5160
ccgcacctg ccgcgcctc acccgggccc ccgcccccg ccagcccccc gggcgcgccc 5220
gccagcccc gggcaccgag gacctcgccc tacggcgggc tgcccgccgc ccccttgct 5280
gggcccgcgc tgcccgcgcg ccgcctgagc cgcgcgtcgc gccactgtc cgcctcgag 5340
ccctcgctgc ctacggcg ccccgggccc gggcctcca cagcccggc cagcagctcc 5400
acaccgcgct tggggcccac gccgctgcc cgggcgcgc cgccagccc ggaccgcagg 5460

-157-

gactcggcct caccocggcgc cgcggcggcg ctggaccccc aggactccgc gcgctcgcgc 5520
ctctcgtcca acttgtgacc ctcccgacc gccccgcggg ccagggcggg ccgggggcgg 5580
ggcgcgtcatc cagaccaaag ccatgccatt gcgctgcccc ggccgccagt ccgccagaa 5640
gccatagacg agacgtaggt agccgtagtt ggacggacgg gcagggccgg cggggcagcc 5700
ccctccgcgc ccccgggcgt ccccccctcat cgcggcggc ccacccccat cgcctcgtcc 5760
cccgggcgcg gcctcgcgtg cgagggggct cccttcacct cgggtgcctca gttccccag 5820
ctgtaagaca gggacggggc ggcccagtgg ctgagaggag ccggctgtgg agccccgcc 5880
gccccccacc ctctaggtgg ccccggtccg aggaggatcg ttttctaagt gcaatacttg 5940
gcccgcgggc ttcccgctgc ccccatcgcg ctacgcgaat aaccggcccg gccccgtcc 6000
gcgcgcgtcc cccggtgacc tcggggagca gcacccgcc tccctccagc actggcaccg 6060
agaggcaggc ctggctgcgc agggcgcggg ggggaggctg ggggtccgcc gccgtgatga 6120
atgtactgac gagccgaggc agcagtgcgc ccacgtggc cccccacgcc ccattaaccc 6180
ccacaccccc attccgcgca ataaacgaca gcattggcg caagcctggc cgcgtgtgat 6240
tgcccgagac ccgcagggcg tgcacccttc ctgaagacag tggctcctgg ggggtggaaa 6300
agagctttat ttacacactg acaaggctca cggggtgtca gctgaagaag taggtggaac 6360
gcttcacctg ctccaggtcg aaggccctg cggaggaagc agagcggacg gcgtgggtgg 6420
cgggaaagcc ccgcctggc ccgcagttcg agccaccctt gcgaggctgc ccaccgcct 6480
acctggcttg ggcaccgcct gcagtgtctc ctccagctgg ctggcctcca agatcttctg 6540
gggcctgggg ttggaagcag ggtggggtga ggctgaggcc aggttttggg gtgggggggg 6600
aatccaggta gttggggtca gggagcgct tactcagagc agaaccgctt gaccaggaat 6660
ctggacaggt cctgcaggat gggctcgtg tgcaagcgga caaactgctc ccggcacacc 6720
tgggcaggag tcagaggatc ccaggggtg atcaggcagg ctctgggcac caccctacc 6780
caacgcccc a gtgtgggggc cccacccatg ggtggactga ggctcagact acgggggcac 6840
ctggttcatg acggagacat cagctgcgtg agtccagtaa cagtcgtgca cagagacgaa 6900
ggtcaggccc ttctgtggc agagcggagg actcctgaag ggaggggagc tcacagggcc 6960
accagtgac cagcatcctg gccctgcgt cagccccctc cacttgaggt ccagggaagc 7020

-158-

ccaccctcct gcaggcctcg cccacccct cgcccgcgc ctccccaac atcctgggtt 7080
aggtatcagt acagggggag gaaatgttcc cagaagcctc ctgccccac ccctgccgcc 7140
ccccacgtg ctgtgggagc ctgagctccg agggcggtta cgaggtcccc tcctgccagg 7200
gccaccaccc cgcctcctga gcattcccag ctcccggtgc cggtagattc tgctggaacg 7260
acctccacgt gctccagatc taaccacaca tcgcggtgcc aagaaatgcc cagcaggaag 7320
gggcagcgcc catgctcggc tctccctgtc gggccacagg aggggagctg ccaggaccac 7380
ctacattcgg ggcacacagc ctgaggcct ctacacaggc ccacagaca cagcagatcc 7440
actctgcca gtccctgccc ccagctagac ccagccttgc cagctgtgcc ctgctagcca 7500
gaagacgccc ctgggaggcg agcggcacc acgcgtccg gagacgcca cctgtagcag 7560
tgcaggcgcg tgagcatcat gtgggaggag tcagcgagt ggatgaagt gggcggaag 7620
ccgtttctt gcttacgtgt gttgggcttt ctgaggacgg aacagggtcc ggtggggcg 7680
gccagggac acccctaact ggccgtgtc tccaccgtgg ctgctctcca gaccccgcc 7740
caggccccag ccggggcccc cactcaccg gctgatgtct ccgttggtgg tgtaggtgat 7800
gctctgaatt ccacctcta ttgtctaaaa aggggaagg gccggtgagt cccaccgag 7860
gccagcacg gtggtgttac attgaggtgg tggtagctg gggtagtgg acgctaggat 7920
ggtggcacac tggcgcgga tgggtggca cactggggcg gtggtacact ggggtgtg 7980
tacgtgggg cactgtgaca ctgggacgt gttacactg gatggtggca cactggggag 8040
ggatgggtg gtacactgac cttgacctg ggtccaggc gatagggtg gatgacggg 8100
acgcccagg gtgtgacca ctccaccaca gagccatgt gggagatgag gcgggcactc 8160
tcggtcagcc agtgctgtg gacacaggc gtctcaggc agggggctca ggccgggat 8220
ccgtccact tgcttaggga gtctggcg agcggggaca ggacaggac tacctggatg 8280
gcccgggtcc ccgagaacat ctctgtaga ctctgaaga cctggcgtag gagatagtga 8340
gaggcctccc acacgaactc ctgcagagg cgggcagcag gtgcaggctc tcaggggtg 8400
gcccgttac gccctactcc cccctatttc agagccact agggccaagg cctagggcct 8460
agcaggggg caggggaatg gggcctggcg cccacgcagt cagcaagaaa cgccaagcc 8520
ctaacaggca gccagtgtc tgggggagca gccagggtc ctgctgggag gctgggtcgg 8580

-159-

gggcacacccc gtctgagttt taaatggcag tgaaaccaac gtgttcgcag cgcgacatgc 8640
ctggcgccacc tggggaaagt cgctcagctc cgggagggcg ttctcaatct gcaggcgccc 8700
gccatagcgc gtgaccccgt acaccaccgt catcaccgtc tgcttcacca ccttgcggt 8760
gatgaaacct tccagcacct gtgccaccgc catgccccgc tgggcgtcct gcctacggaa 8820
cacctccacc tgcacggcgg gtgggcccgg ggcgcgggtc agccccgcta gcagcccagg 8880
ggccaccaag caccatgaa gccccgccc cagccccacc acatcctcag gacaggccaa 8940
ggtgagggca cctggggccg agactcaggg ctcacattgc cccacgccc agatgcccc 9000
gggcagcagg gcacacccta cctgcgcggc cagcgcgtg tacacgtcct gcggcacatc 9060
cgagggctcc aggttgacgg aggcggcgcc cagctgtcg cggcccagag cagcataatg 9120
ctgcaggccg ttgcaagagc cgtcctgagg aagggcgggc aaacgggaga tggaagctag 9180
agaggcagag acgtgtggga ccccaaacca cccccagggt cgagccgttc ctagggccgt 9240
gcacccccca gccaaagtga cggagcccc cgcacgtcct cgggagagac caggagccat 9300
ggctcccgca cactctagga ccacctccag agaataccac gagcgaagg gaaatctcac 9360
accctcaagt cgagccccag gccagtgca cactgcacgg cctcgggggc cagaccagc 9420
tggtcacct gatggacggg gaggtgggag acataggcgg cagggtcgga ggcgcgaca 9480
gcgttcgcca cctccataca gcaggccagc gtctgccagg gttcctccgc gccatccac 9540
cactttcggc cctgcgggga cagcggatgg ggggcagtga ggccggggc cgatccctga 9600
gccgctggg aggtgtgtt gcggggaggt gggaaatggg gaggagacgc acaccgtga 9660
tagtgaacac gggacgcatg tgggcgagag acggggcggt ggctggatga gttctccata 9720
gccacggatg gaggatggga gctgcgggtg gaccgggtg aaacaagcgt gtccggagct 9780
gccgggggag gaggtggac agaggacctg ggggcgccg gggaggaagc agctcggcg 9840
atgcagggga ggggggaacg tggggaacgc gggggccctg gggcagggga gaaggagaa 9900
gcaggacggg cagggggcgc gggggaggag agcgggcggg ggacgtgggg gcgccagggg 9960
agggggaggg gaggaggaag acgggcaggg ggcgccaggg gagggggagg ggaggaggaa 10020
gacgggcagg gggcgcgggg gcgcggggg agggcgcggg ggcgccgggg gagggcgcg 10080
gggtgccggg agggcgggga atgcggggg cccgcccta ccgtcaagg ttggtccgcg 10140

-160-

gagtccagga tgtcatccat cacctcctcc gcaaaggcca ggcgcttccg cagcggctcc 10200
cgctttcttca accccgtgag attgaccagg tggatcttga gccaatccag gccgtgcggg 10260
ccgagcgggc ggccctgggc gaactccagc agggcccgcg ccacgtcgct gccaggtgg 10320
ttgaagtgcg gcgggcaggg gtaggtgcgg ccgcggaagt ccatgtttgt cggcagccag 10380
aagacgcggt cccgcaggtg ctgcgccagc gagaggcggg acagcgcctc cggccgcagg 10440
ctgtgcatct cccgggccac cttctggcag tgcgccagct cacggcgag ctgggccttg 10500
cgggcggggc cggcgctgtg cggcaggtgg gcctcggggc gctggggcgc ctcggagggg 10560
ggggccggca cgcctagctg ggggcagccc ttggcctgga agagctgcag caccaggtcc 10620
agcacgcgcc cgttgacgcg ccaggcgagc ttgccagtt gggtaggggc gtccagtgcg 10680
ccatgcagcg cggtagggcg gcaggtttcc agcagctcct ggtgctgcgt ggcgccttcc 10740
accgtgcgca tcagcttggg ggggctgagc aggaaagcac cagagtgcgg cgatgtccag 10800
ggcagcgggg ggcaaagcat gggtagatcc accgcctcga aggtcagcgt gggctccgcg 10860
gccttctcca gcagctgcac gtaggccggg tgcggcttca ggatgccgat ctgggggtgcg 10920
acaggcagac gggtagggc cccggtgctg gggctttcct gttcccaccc cttaaacttg 10980
ggtagagagg gccggctccc cggccaacaa gaaaccagtg tggcctcca cgaacagaag 11040
ccacctccag aaacggcccg acacctgcat ggacacccat ggtgtgtccc ggtcctggg 11100
aggtagtgac ggctgcgctg agatcaaggc tccgccaaa ggcgccaacc ccatggggtc 11160
cctggctctc ccagcgggat gccccccagc tcaggagggc actgcctggc acctgctgga 11220
cgttgcggaa ggaatacacg tggtagagca cggggacaag ccgagaggaa cgatgcggct 11280
tgtccaggct gcatggcatc tgcgtagcct gcaccagcat ctccgccagc agcttgccca 11340
gtccatctg cactggcagg ggccagggt gctcccgcag ggctcgggc gccccagct 11400
cctcccagta ctgccgcggc aggcagggt cgggcacctg taggacaggc cggtagggc 11460
gctgggcacc gggggccctg agctagatgc cccaccgcc gtgcctgacg cccggtgggg 11520
catctgtcag cccaagcata cagatgaaca gactgaagct tgggtgcaa cccggtgct 11580
ccaggagggg agagcgcca cccaccactg gcccagcca ggaggagagg gggtagcagc 11640
ctcacctcgg cgtcggaggc cagcaagcag aggtacttcc tgtagtggtt ctgcagcgcc 11700

-161-

tgcacctggc cactgacccg ctgcctctgc accacgtgcc ggctgaaagt gcgcgcactc 11760
agctccccggg ccagggtggt gaaggactca ccttggggcg gcagcgctg caggacctgc 11820
ggaaggcagc cgtgagtgcc tgcccgcccc gcccggggac ccggccgcgc ggaggaagac 11880
gcacctgcag gagcatccgc accacctcgc gctcgtccag caggcacagg aaggggtaaa 11940
gtgagaaccg gccctcgtac acctcgcgct ctaggcggtt cttggtctcc cgcagcgccc 12000
ggcacagtgc tttctcccat tgggtccgca gggctcttcag ggtcttccgc tgcgggggat 12060
gaacggggccc ggtgagcccc gtggcagctg gtgggaccca ggctcacagg acgggggtca 12120
ccgcagctcc ctgcagagac ctcatggccc tcaagggtccc tgctgtgtgt tccgggtagc 12180
tcctcacccc ggcctgccct ctgccggctt cagcgtgcct gacgcagcca agagcaaaag 12240
cccagctgca gtgtgcgcag aagcacaggc caagacccaa cctcgggacc ccacaagttt 12300
tccttgagcg gcagccaggc tgagttccta ggcctgcat gaccagacca gggcatgagc 12360
aattcaaccg catacacgga gctcagcccc tgcggcggac acgcgacccc ggctcagccc 12420
ctgcggcgga cacgggaccc cggtcagcc cgtgcggtg acacgcgacc ccggctcagc 12480
ccctgcggcg gacacgggac ccgggtcag cccctaccgc gtgcttgacc tccttgcttg 12540
gcaacgtggg cttctccacg gacaccacgc acacctgct ggccagctcc atgtggagct 12600
gtttctcaaa gaggcactgc agggcttca agggcaggtg cagcttcggg taggacacac 12660
gcccattctg cagggatggg ggtagtgagg ttgggggctt gccagagggc gacctgccct 12720
cccaggaccc cgagacagca tgggtgcacg cgtttctgcg tctcctgcaa gttgctggtg 12780
gctatcgctg acgcggggaa aggcgggctg cgggtaaagt cagtgccagc agtgcaaacc 12840
aaaggccttg accctcctgg cctcgacccc tctagaaggg aactgggca ccgtgcaggg 12900
ggtggcaggg gcggtgatgc tgggagctgg cagagcctgg ggagaccgtt cactgcaccc 12960
ccagatgttg gctgttttct cctcaaactc agaactgtat gaatgtgacc catccagaaa 13020
tagatgaatt aaaaataaca actaaagcct agcgctttga gaatcaaaga cgcacgtcca 13080
cataaaagct tgtacacaaa cgttcacagc tgcatgactc gcagtcgata agtagaaaca 13140
gcccacgctc ccataaacgg acgaacagac gggcacggcg cggccatcca cgcaccggag 13200
catgactcag ccctgaccca ggtcgccctc cggaaggcacc atgaggacgt cacgctcagt 13260

-162-

gggagatgcc aaacacaaaa ggtctcgag tgtgtggtcc catttctatg gaatgtccag 13320
agcagactca tccacagatg gggaggggat ggggagtgc ggggatggg acgaggcttc 13380
cttttagggg gatggaacat tctagaatta gacaaccgtg actacactaa aatcgctgaa 13440
ttacaccttt aagagggttt tatggcaggt gaattacacc tcagtaacag acgagcccac 13500
tgcgtagcacc tggcagcccc actcaaacgc actgctctcc tgtcaccca ccctctctct 13560
gcggccccc accacctcgt cccctgagc ccacaccctc agggccaaga ccctcccagc 13620
tctgggtcct cccatcttct cagaggagga agggaggaat tcagggccca gccaggtga 13680
gccctgggca ccggggaggc ccattggtct gagctgaggc tccaggaacc cccaaagggc 13740
agctataagg actgaagtct gccggggccc acgtgggctc accttgcat acacgtccct 13800
gagcagcttg gaggtgttga ccgggggagg cagctgcggc gggaggctga aggtgggctt 13860
caccttgtgc acggccttca gaacagtggc ccgatcctcc tcagacagca gaacggcgg 13920
gaagagtgcc tgcagcttca gcccctcctg gctcatctgt tccagacacc tgtggtgcag 13980
gcggcctgct cgagggacgg gccagcccca cgctgggctt ccacagacc cagggaacc 14040
tcgtgaccac ctctgctag cctgcaggtc tcggtgtggc tgtcaggccc tctgggggtc 14100
cccagcccc agccaggca ccgtcccaga tcttaaaacc ctgggaggga catggtggg 14160
ggtgggggcc ctccgacac cacctacctt tcgatgttcc cggcgctctg gtcctgcctc 14220
cccatgcact ggagggcagc cgcataggac agcaggtccg gagtcaagcc ggcatccttc 14280
accatgaata acacatatac cagctccttg aaggcaccct gggagaccaa gccagggtga 14340
gggtctggg ggatggcca acctccacat cctccctgct ccctggagac cccttctctg 14400
tagccaccag ctgagcagg gacagggtca ccaggcagga gtggccagct gggcagaccg 14460
atgcatcccc ctgaggttct gacacacaag ctccacctgc agaggcagcc gcatggccc 14520
ccagggtgga ctgtgggagg ttcacgttcc tctgggaggc agcttgtaa acctccagat 14580
ttgtcaattg tgtgatctt ttcaaaggac tgacttggtc tgactgttct ctgctgtttc 14640
tgccctccat ttcacgatt tgttttaatc tttgtaactt cctctcatct acttgcttta 14700
ggtttagtga cagcttcttc ttctagtctt ctaagggtgaa aggtgacgta tttggtctga 14760
gatgtttcac tttttttccc cccaagatgg agtcttgctc tgttgcccag gctggagtgc 14820

-163-

agtggcacia tctcagctgg gccgggttct ctgcctcca ggttccagca cttctcctgc 14880
ctcagcctcc tgagtagctg ggattacagg cacacgccac cacaccagct aatTTTTTgt 14940
attcttagca gatacggggt ttcacatgc tggccaggct ggtctgaac tcctgacatc 15000
gtgatccgcc agcctcagcc tcccaaagt ctgggatgac aggtgtgcac caccgcgcc 15060
ggccatcacc tttccgaata taggcatttt gtgactataa attaccctgc gagcactgtg 15120
tcagctgcat ccagagactt ctgacagggtg gtgttttcat tttcattatc tccaagtgtt 15180
ttcgaacttc atagtttact tcttctttgg aaattttatt taattatttt tttagataga 15240
gtctcgtctc gtcgcccagg ctggagtga gtggcgcaat ctcagctcac tgtcaacctc 15300
cgctcccgg gttcaaccga ttctcctgcc tcagcctcct gagtagctgg gactacaggc 15360
acatgccacc acaccagct aattattttg tatttttagt agagatgggg tttcgccctg 15420
ttggccaggc tgggtctcaa ctctgacct caggggatcc accgcctcg gcctcccaa 15480
gtgctgggat tacagggtgtg agccaccacg ccagccatg tatagcttaa atatccctg 15540
caattttttt ttttttcatt taatttttgg ccaggcacag tggctcatgc ctgtaacccc 15600
agcactttgg gaggccaaga caggaggatc acaaggtcag gagtttaaga ccagcctggc 15660
caacatagtg aaaccccatc tccactaaaa atacaaaaaa aaaaaaaaaa aattagctgg 15720
gcgtggtggc tcatgcctgt gtcctcca ctaaaatac aaaaaaaaaa aaaaattagc 15780
tgggcgtggt ggcacatgcc tgtaatctca gctactggga gcctggggca ggagaatcac 15840
ttgaacgcag aaagcgaaa ttgoggtaag ccgggatctc accactgcac tccagcctgg 15900
gagacagaaa ctttgctgtc gacagacttg gagactctgt cttaaaatat acacacacac 15960
acatatatat atatataaa aataacatat atatataatt ttttcttgt attcattttt 16020
cctgacatcc ctgttctgag caatttctcc ttgaccagc tggctgctta agagtggcct 16080
gtaactgtaa cagactattc caaaggaaa aaaattccct tacatcctcc caccatag 16140
tcctgcagct gaagacatgc tgtgacatga ggtggccaca caccagagac cagagacatg 16200
agttttgggg cattttttt tttttttttt ttgagacgg agtctcgtc tgtcgccag 16260
gctggagtgc agtggctcga tctoggctca ctgcaagctc tgccctccag gttcactcca 16320
tcctcctgcc tcagcctccc aagtagctgg gactgcaggc gcccgccacc acaccggct 16380

-164-

aattttttgt atatttttag tagagacggg gtttctactgt gttagccagg atggtctcat 16440
ctcctgacct cgtgatccgc ccgcctcagc ctcccaaagt gctgggatta caggcgtgag 16500
ccactgtgcc cgcccggttt tggggcagtt tctaaacaac ctctgtatgg tagacctcac 16560
tggccacaca tagtccttaa attgaaatat tcagttcttc cctttcacca gtttcaagt 16620
ttcagtagca cacacagctg ttggcagatg cggaaaattc ccaacatcat agaaagttct 16680
actggatggg gctgggttaga atacgtggcc gggcgcggtc gctcacgcct gtaatcccag 16740
cacttaggga ggctgaggcg ggcggattac ctgaggtcag gagtttgaga ccagcccggc 16800
caacatggca aaagcccgtc tctactaaaa atacaaaaat tggccgggcg tgggtggtgag 16860
tccctgtaat ccagccact caggaggctg cggcaggag aattattgaa ccaggaggc 16920
ggaggctgta gtgagccgag atcatggcac tgcaccctag cctgggcaac agacagagag 16980
tctatctcaa aaaaaaaaaa aaaaaaaga tagaagcaat gccttagcct ggctaacatg 17040
ctgaaacccc acctctacta aaaataaaaa ttaaaacaat tatccggggg tgggtggcaca 17100
cgctgtaat ccagctgct cgggaggctg agctcgagc ccagcgacat ccaggactgc 17160
tggccacccc ggaacgctgg gagaggcagg aggggccct gctagagcct ctggagagac 17220
ttcgggtctg cagacatctt gattccagac ttctgggctc gtgctaagag tgcgtttctg 17280
ctgtgcaagc cgccaggttt gggacacttt cgtaggggcc gatcccaaaa gcgcctgtt 17340
acagtgtggg ctctctgccc agggaatcca gggggcttgt gaccttgag gggaaaatac 17400
acgacctca tccctagctc tcccggagtc tggcgcccc tgcagcaagg aggaaccagg 17460
cagcacgccg cctccacctc gcggtaaagag cactgcggac ttcaccgca gactggcccc 17520
acctgatcct gaatttcgct gtttgatgcg ttaataaaga agcacatcaa gttctctacc 17580
acgaattggg cttaatatg cgatatctgt attttaatat aatagtatcc catgtttacc 17640
caaatattaa gagaagcttt tactgttggt tctcaaatta gggctgaagg atcatggggg 17700
gggagaaagc tgggaacgtt tgctgctttg aaagggtgtg taaacaacac cctccaaaac 17760
aaccaagagt tccgaggaga aactttggcc ggatacgtg gctcacgcct gtaatctcag 17820
ctcctcggga ggctcagggg ggcagatcac gaggtcagga gtttgagacc agcttgcca 17880
acacggtgaa acccccgtct ctactcaaaa tacaaaaatt aatcgggggt ggtggcgggc 17940

-165-

acctgtaact ccagctactt aggaggctga ggcaggataa tcacttgaac ctgggaggtg 18000
gaggtggcca tgagccgaga tcgcaccacc gcactccaac ctagtaacag ggagagtatg 18060
tcccagaaaa caaataaata aacaaacaaa aagaaaacgg caagggaat tggaataac 18120
tccagatgaa ccacaacgaa gatgggtggg atacatctaa agctgtgctc agagggaatg 18180
cgggcccaagt gaacaccac atttcacaca gaaggatctc agcacagcag cccgaccttc 18240
cacctcagga aaccagaaaa aggagcaaag tcaaccccaa caccaaagcc tcctcctgac 18300
gagggctctg caggctgccc cccgacgagg ccaaaagcac cctgcccag acagattcac 18360
gagccccgag aaagaacgga aggaaatgct caaggcatta gcagaatttc tccctacttt 18420
tttggtcatt ttcaaatatt gagagtcaca cgtgatttgt atttgaaaag cctaaaagaa 18480
ttattaaaat aaaaaacaaa ggacttgaac ctgggggcta agagagaaaa gtccagtcta 18540
aatgagggca agttcctgtc tccaacgacc agggcaggtg gcccggtcc cggctgcact 18600
cacctgccgc gccagccaa gcatcacggc gttgtacatg tccagcgtga gcagcttccg 18660
cttctgccgc tggccgtggt ggacgaccag caggtggtgg gcgaggggca gctggtcagt 18720
gagcaggcag cacttgaaga aggccaggag cctctgctgc tgacctgaga gctgggcctg 18780
cgagtgtgc cccgacgggg cctgctccac atcgaggctc agcttcccag gggcctcctg 18840
cagcagccgg gccagctgct cctcccagg gctctcgggg gcctggcgcg tgcagtcctc 18900
caggcaccgg gccatctgct tgctcaggag cgggggtcc acctgcaggc gcctggtcag 18960
cgcttgaac tccccgtct ggaatggcat ctgcagcttc gccttcaacc gctgcatacg 19020
catctgctgg gtccgcttat cttctccag tatctttgcc cagcgccac agggcaccgg 19080
ggtggcatcc ttggcccca tctggacctt cctgggtggc tggaggctac catctccact 19140
gccacattct gggagccgcg ccacatccac cctgttcacc accacctccg acacgtctc 19200
agcctgcagc tgccgcacc gcgctggag cactgtgagg ggcagaaggc gaggacatga 19260
gagggacccc ctccccattc gagcaccgt ctctctggac cctgagccag gccaggaggt 19320
gcaggtggct gagctcgtg ggaccaagg cgtgaattcc tcatacttgc caacaacgtt 19380
gtaaggtctg cccgtgctt tccagacaca cgcacccac cacctccgca cctccccacc 19440
cgagcctcac agaactcagc agccctaaca agctgccacc gaaacctgca gcaccacgtc 19500

-166-

tccccggtca ctggccgctc agaccctcca ggtgcacagg cccagaaccc ggggtctgtg 19560
acaactccct cgtccacct ctcagtacct cctctgggct tgcctccaga atctatccag 19620
gtggcccccg cctcccctgc cctctcact gtctagctca gggcctctgc acagactccc 19680
aggaccctga accgcccact ccttggtcct accatggcct gcaagttcgc accccgcctc 19740
agcaagaccc cccagctgg tggagctgcc acacacacac tcctaggctc ccagtgtcta 19800
caccggtgga cgctgagcca ctagctcgca gggaaaacgc ggctcctgct cgtgccgcct 19860
caggttgcat ttttgccaac caatcaatgc ctaagtgttc tgtatctctt taaagaagcc 19920
ttgttgaaa totattgctg gccgggcatg gcggctcacg tcggatcatcc cagcactttg 19980
ggaggccgag gcaggaagat cacctaaggt caggagttcg agaccagcct ggccaacatg 20040
gtgaaacccc gtctctatta gaaatccaaa aaattagctg ggcgtggtgg catgtgtcta 20100
tagtaccagc tacttgggag gctgaggcag gagaattgct tgagcctggg aggcagaggt 20160
tgcagtgact caagatagcg ccattgaact ccagcctggg caacagaaca ataatccatc 20220
taaaaaaaaa agactgttga aataagccgg gtacagggcc gcgcacctgt ggtcccagct 20280
actccggtgg ctgaggtgaa agaatacact aagcctagga gttcctggct gctgtgagcc 20340
gtgatcaggc caccgtgctg cagcctgaga gacagagcag gaccctgtct caaaaaaaaa 20400
aagggggggg gggaccagc tgtccagatg tgggtggtca cgcctgtaat cccagcactt 20460
taggaggccg aggcaggcgg atcacgaggt caggagatca agaccatcct ggctaacacg 20520
gtgaaacccc gtccctacta aaaatacgaa aaattaaccg ggcgtggtgg tgcgcgcctg 20580
tagttccagc tactcgggag gttgaggcag gagaattgct tgaactcggg aggcggaggc 20640
tgcagtgagc caagatcgca ccattgcact ccagcctagc aacagattga gaatccgtct 20700
caagaaaaaa aaaattgctg aaataaaaag acaagcgtga tgtccgcctt cagagtgtc 20760
caaaactcag gagatacttt taggattaac agttgagagc tttgttttgt tttgttttgt 20820
ttttgagatg gaatttccct cgttgcccag gctagagtgc aatggcatga tctcggtc 20880
ccgcaacctc caccttcggg gttcaagcga ttctcctgtc tcagtctccc cgggttcaag 20940
cgattttcct gcctcagcct cctgagtagc tggcactgca ggcgttcacc accatgccca 21000
gctaattttt gtatttttag tagagacagt gtttcacat gttggccagg ctggtcttga 21060

-167-

actcatgacc tcttgatccg cccgcctcgg cctcccaaag tgctgggatt acaggcgtga 21120
gccaccgcac caggcctcgg acccttgacc tcttgatccg cccaccttgg ccacccaaaa 21180
tgctggggag tacaggcgtg agccaccgca ccaggcctcg aacccccgac ctcttgatcc 21240
gcccacctcg gccacccaaa agtgctggga ttacaggcgt gagccaccgc acctggccag 21300
gttttttccc ttataaaagg ttctcccgcc tctoccttcc cggtgccta atggacgcag 21360
acaggatgtg ggacagaagc accggcgggga agcaagcaca gggaagctcc cacctccctc 21420
ccacaccacc agccaggcca ggacgagggc ctgccaccgc tggagcctgg gctgtccctc 21480
ccaagtttcg cagtcacca gtctccatta ggcgctacc cccagagcc aagccaggac 21540
agctgagtca gttcaggggt cacatcctgg ctctgcacat gtggccttgg cggcggggcc 21600
gggggggggg tctctccaga cataatcttg ggctcacct atgtccctgg aaagtgggag 21660
cacctggttg ggttctgggg agggggaatt acgagagctc caggaaggag cctgctcagc 21720
aaggacaggg cccatgagcg gtgcaagaga tgtttcagca acgctgtctg ggctgtcct 21780
gggacccgag aggtggagac cgccctcagc ctgtctcaga atctgagcct ttgccttttc 21840
tccggcgagc agggagcgga ctctctctc ccgggcccgc gtgggggtcg cgctcacct 21900
ccagcagctc cacgtggccc cagtccttcc tgcggtcttg gtcttgctcc tgggggctgg 21960
cggacgagct cctcctgggg ccgcagacgc caccggcgt cctgcggga aagacgagag 22020
cggctgagcg gggccggggc tgtggggcgg ggctccata aaggcagaag ccgaagggtc 22080
gaagggcaaa ggagccctaa acgcagcgga aactctcgga gcacgggctt aagttgaaa 22140
gaaactaaga cagcgaaggt ggaaggggcc cgccgcgcg aacacgggcg cggaaccgcc 22200
gagagagggt tcctcgact cgaggtgcag caggtcaaag gttaagagcc ctaaaccacca 22260
cacctggggt caggaggctg cataagaaac cacgagtcaa aggtcagact gcacggagga 22320
gcctcagtcg aaaagcgggc aagggcgagt ggaaagcggg gccgggtcgg tgggctgcgc 22380
acgccaggt gcaaagaggc aaaggtcaaa gcgcaaaagg ccccgccgc gcggggagga 22440
gcccacgcg tggcccccg gctgcctggc cgtctcctt tgtgttacct tctttgccg 22500
ggagtcccgg gcggccgcaa ggccgtaggg ctggtttgag ccccgccgt ccgcggcccc 22560
agcaaagtgc cgacattacg cagccgctc caggccaccc caccggccc cgctgcgca 22620

-168-

tgcgcccgcg ccgcctgccg ggagttgtgg tttcatggtc gacggaggct gcgaagggaa 22680
acccagccg gaagtagact ccaggatgc agcggaggcg cgaaggcatg cgccggtgga 22740
cgctctgatt ggttcctcct gctgttttta aaggaggagg gcgggacaga gctgttgccg 22800
tggcaactgg gaggcactct caggctgttt tcccaggac ctcaaaccg gacttttttt 22860
ctgtttttct ttcttttttg gttttgtttt ggacgcgttg tggcccaggc tggagtgcag 22920
tggcgtgatc atagctcagt gcagcttcga actgctgggg taaagagatc ctgcccctc 22980
ggcttcccaa agcgtggga ttgcagacgc cgccaccgtg cccggctttt tttttttttt 23040
tttcaaggca tactcatcta ataacgagga cagcatctgc aatttagaga ttctgtccg 23100
caaccttcat tgctccaacg acaacttttg ggtaagagtc attaggatgc cgtctatcat 23160
ggaggaagct gaggtcaga gaggccacc aagttgctgg aagacacagc acgtgcgacc 23220
tcaggaggc tgcaaggaga gaaagcccca gtccgcgaga ctccagcct ccagcttcag 23280
tttaccctcc aatccccaag ccctcagggg caggagccga atggagcggc aggcttgat 23340
tcacctgcta agtgggtga ggtcaaggga atgaaataaa cctcgagacc tagagcctgc 23400
cctggctctcc gcgtgatcct gcctaggagg agcagggcgg gagctttaga atggaacctg 23460
gaagggtgac ccacctgtgt cgttcagccg gggcagcagg ccagaggcgg gagcgcctgc 23520
tgtggggcag taggcttggg aagggtgaga ataggaatat ctgggggtaa ctgtgttcca 23580
ggctaataatc ccagttgcaa aggggagctg gtttggtggc tcaggcctgt catcccagca 23640
ctttgggagg ctgaggcggg cggatcacct aaggtcagag ttcgagacca gcttggcaaa 23700
tacgcaagca tgcttgcaa catggcaaaa cccgctctct agtaaaaata caaaaattat 23760
ccgggggtgg tggcgggcac ctgtaatccc agctactcgg gaggtgagg caggagaatc 23820
gcttgaaccc gggaggcgga ggttgacgtg agccaagatc tcgccactgc actccagcct 23880
gggtgacaga gcgagaacct gtctcaaaaa aaaaaaagtg caaaggagg tcagttcagt 23940
gcctcaggcc tgtaatccca gcactttggg aggctgcggc gggaggatcg cttgagccca 24000
ggagttccag acaagccttg ggcaaccgag atactgagac ccagtctcca ccaaaggaaa 24060
aaaagaaatt agccaggcat ggtggtgcac acctgtggtc ccagatactc gggaggctga 24120
ggcaggagga ctgcttgagc ccaggaggtt tagactgcag tgagctgaga tggcgccact 24180

-169-

gtactccagc ctgggttgac agaacaggac cctgtctcaa aacaaaacaa gtgcaaaggc 24240
cctgaggcag gaacaagcgt ggacagagga gcaatttgag cagagtgggg ctggggagag 24300
ggagcaaaga tgtagctggg gctcagttag ggggcctgac cacacggggg ctggggggcc 24360
tcagctcaag ctatcctcca tccccaaacc ctggcacttc agtttcccca tcagcccaga 24420
acgaggactc gacctcactc tggaagggcc tggcagcctc cttacagcac attccagacg 24480
ctgctgccga cgctgcgtg agcgactga tgccaccggc tgggaatgtt ttcgacagac 24540
ggcagcacc cccctcacct gcctcagtc acctcagggt gcccagcgg gctgtgacct 24600
cagacctcac ccactactgg ggtcacctgc ctggccctga atcagccagg cctggtgtgc 24660
caagacctac agacaccccc tgcaccctg caggctggca gagccagaaa cttgggtgga 24720
aaccgacttc tgaactatct caccattcct tatgcgttag tcttttcttt tatttgatga 24780
gatcccagca ctttgaggag ccgaggcggg cggtacacgt gaggtcagga gtttgagacc 24840
agcctggcca acatggtgaa acccgtctc tactaaaaat acgaaaatta gccgggcatg 24900
gtggcctgtg cctgtaatcc cagctactca ggaggccaag ggaggaaaat cacttgaacc 24960
tgagaggtgg aggttacagt gagccaagat cgcaccactg cactccagcc ttgggcaatg 25020
tagccaaacc ccatcactac aaataataca aaaaaatctt gttggctgtg atggtgcctg 25080
cctgtggccc catctacttg ggaggctgag gtgggaagat gtagaattgc ttgagccagg 25140
aggcagaggc tgcagtgagc tgtgattgag ccactgcact ccagcctggg cgacagagcg 25200
agaccctgtc tcaaaaaaaaa aagaacataa tctgggtttt ggaataagac agcagtttct 25260
gaaacagctc attgccc aaa ttccagcctc gcaactctgt agccgccacc acccccagc 25320
cccaccattt attttaacta catctgtctc caccactcct gtattaagta aatgcaatat 25380
tggctggtca tgggtggtca tgctgtaat tccagcactt tgggaggctg aggcaggcag 25440
atcccctgag gtcaggagtt cgagactggc ctggccaacg tggtgaaacc ctgtctccac 25500
taaaaattca aaaattagcc ggacgtggta gtgggtggtg cctgtaatcc cagctacttg 25560
ggaggctgag gtaagagaaa tgcttgaatc caagagactg aggttgagc gagctgagat 25620
ctgcgcgtg cactccagcc tgaacgacag agcgagactc cgtctcaaaa ataaattaat 25680
aaatacaaca ttaattatct ttcttgctta agttttacga agagacttaa tatcaccatc 25740

-170-

aaaagtggga aaccatatat ctggccgggc gtggtggctc ccgcctgtca tcccagcact 25800
acgggaggcc gaggcgggcg gatccccctga ggccgggagc tggagaccag cctggctaac 25860
atggtgaaac cctcatctcc aataaaaata acaaaaatta gccgggcatg gtgggtgcct 25920
gtaatcccag ctattcagga ggctgaggca gaagaatcac ttgaaccggg gaggcggagg 25980
ttgcaggagg ccgagatcac accactgccc tccggcctgg gcgacagagc gagactctgt 26040
ctaaaaacaa aacaaaacaa aaccaacca agcaaacccc acagagtcga gaatcgctag 26100
atggaagggg atggcccagg tccctggagc ccctgtgaca aattaccaca aactcgggtg 26160
cttaaagcaa cgttcatttt cttacatttc tggaaatgaa aagtccaaaa tcaggactgc 26220
ggggctgaag tcaagggtgtg tggaggcctc gctccctcca gaggccttg ggctccttcc 26280
tgctctccc agcttttgaa ggctccaggt gtgcttgccc tgcggccaca tcaactcccg 26340
ctcggctctc gtggtcgcac tgcagcctcc tegtctgcct gtgtgaaatc tctcctgtc 26400
tccgtattgt gaccgcgttt aggatgcccc aggacaatct tctccatctc gttcagatct 26460
tcatggtgtc aatatattga gactcttttt ccaaataagg caaatgtcac attctagga 26520
tcagggtggg gacttacctt tgggccaacc acagaggcta caaagaggaa gacaccactc 26580
aatacaaagc gtgcgccagc ccagccctga tcggtgtttg ttgttggtgt ttttgttga 26640
gacagagtct cgctctgtcg ccaggctgg agggcagtgg catgatctca gtcattgca 26700
acctccgcct cctgggttgt atagattctc ctgcctcagc ctctgagta gctgggatta 26760
caggcgtgaa aaggagcaag gctctgcccc agccacagcg cggatgcacc ttgaggatgt 26820
catgctcagt gaaagacgcc agacacagaa ggacacacag tgtgtgatcc ctttatatg 26880
aaatgtccac aacaggccca tccacagagg caggaagggg atgtgtgggt gccgggggct 26940
ggcagagggg atgagtgaca gctgatgggg cttcttcttg cggatgatga atcttctgga 27000
actagacagt cgtggtggtt gcacaactct acgaggtact aaaatcactg aactggctgg 27060
gtgcagtggc tcatgcctgt aatcccagca ctttgggagg cagaagcagg tagatcacga 27120
ggtcaggagt ttgagaccag cctggccaac atggtaaac tctgtctcta ctaaaaatac 27180
aaaaattagc tgggtgtggt ggcaggtgcc tgtaatcca gctactcagg aggctgaggc 27240
aggagaatcg cttgaaccag ggaggcagag tttgcagtga gccgagatcg caccactgca 27300

-171-

ctccagtctg ggtgacagag ccagactccg tctcaaagaa ataataataa aataaaatca 27360
ctgaactgta cagtgttaagt ggggtgaattg tgtggtatat gagtgatgtt tccgaggtgt 27420
cattaaagaa actcagacgc ctgggggtggg gccagtctca ccgctgtggg tcccatcccc 27480
atcattttctc acaaggccct cagatcaccc ttccgcggtg gggggcggac actctaagaa 27540
gggaagacct gggctcctgc tggcgagaag gcggtggaca tttcttcagt gtctgggtgcc 27600
gcgccctctg cccagcgtgc tccgtggagg gtctcattgt cttcctccag acgtctcttt 27660
actggcccat ttacagagg cggaaccgaa gcttgggggtg ttggccacag ggctctagtg 27720
tgggaagcca ggccaggctg gacctcagcc atggggaccc ctgtccctga gactgtggca 27780
cctgccacac cctctgtgtg acccgccctaa gccaggaaga gagggtcagg agatgcctga 27840
gccaccaaga aggcattcca gcgtccagcc agaccggtta tccctccaga gggctccccg 27900
gcaggacagg ctggtcgcca tgtcttcagc ctggtgctat tttaaagggtg gtgccacctg 27960
gggctgtggc cgcagggcca ggactgggct gctgggagct gtgtcccccac agcggaggtc 28020
gccgcccctc tcaggcctcg gtttccccag ttgtcaatgc ctccacttg gtgtgagtct 28080
gtgagggtea ctgtgctcac cttttggggc ccagcgcag gggcaggcag aggaagggtg 28140
ggggccagcc gccttgtgtg gtggttcccc gtggggcctg gggtatggct ctaaggagg 28200
agcaagtgtg ggtgcgaatg gggccgcccc attcctgccg cctccgacgt gccccgccag 28260
ccggccaccg acaggtctac gtggctatcc tccctcctgc ccacctacct gccaaaacac 28320
acgtccccag tcgtcacctg cccaccacc cgcgcattcc cacacccttg tgggcctggc 28380
tttcgggaaa ctacaatttg cggggagaga agtcccacga gggcatgccc cggagcctgg 28440
ctggtccac ggctgacgca cgcggcagga cctcccgtgt ccatctctgt cccaagcat 28500
ctccgcctct gcccctctct gtctctgtgt ctctctcgtc tctcccgtc atcttccttg 28560
tgtctcttga ctgccgccgt ctttctgtct ctgtctccct ccgggtctct gtctccctcc 28620
aggtctctgc ggcccgctc tcacactccc gccccgcaa cccgaggtcc tagcccgccc 28680
ggggactcgg ctgactcacg gacacgcccc gcgagacaaa caacaaacgc gcggaggccg 28740
agcgcggagt ccgcacggc cgcgcccctg tgcacctggc ccccgcccc gagacgtccc 28800
attggccggc gccctagcct ggtcccggc aagtggaccc cgccccgcc ccgaggcacc 28860

-172-

ccattggccg gcgtccccgc cccagcgaac ccggccccgc ccccgaggcg cccattggc 28920
cccgccgcgc gaaggcagag ccgcggacgc ccgggagcga cgagcgcgca gcgaaccggg 28980
tgccgggtca tgcgccgccg cctgtggctg ggcctggcct ggctgctgct ggcgcgggcg 29040
ccggacgccg cgggaacccc gagcgcgtcg cggggaccgc gcagctaccc gcacctggag 29100
ggcgacgtgc gctggcgggc cctcttctcc tccactcact tcttcctgcg cgtggatccc 29160
ggcgcccgcg tgcaggcac ccgctggcgc cacggccagg acagtgagtg cggggcgcg 29220
ggggcctggg gtggggaggc ggcggtgac ggcaacgcgg ccgccgtctt cacggtgacc 29280
tgcgcccgcg ggggagtcct ggaggctcct ctgtgcagcc tcggcctcag tttccgtggt 29340
ctgtgagatg ggtgcagcct gcctggtggg agggttgcac tgttaaagcg aaggctgcag 29400
cggcgacccc ggctcagggg cagagaagcg tccgtgtggt acaaccctgt ggggtggggcc 29460
acctatctgc aggtgggaaa ctgaggctcc agaggggctg gggcaggccc agctgcatgg 29520
cgggaagcggc ggggggctga cctccggact cctgacatca cagaatccag tcagggctgc 29580
ctgagtcggg gccccctctg cttcttccca gacacccat ctggcaggtg aggacaagga 29640
ggcacacaga agggatggga cctgcccagg gtcacactga caggggtggc ggagctgggt 29700
ccccacaggg ccaggacgt cacggagcgg gcgtctctgt cccagggtc tgccgagcac 29760
actgaggtag gccctcagtg tttgtggaat gtcaggagca agaggagagg ctgggcacag 29820
caggggatgt gggtagctgg aggccagggg agtcggtgtc cccgccgggc ggggggcact 29880
gggaaggggg cccgggcccg ctggctgccg cctgaatcac caccatcagg gcaggtaatc 29940
acccctgtc cttcccaccg ctttcatctg ggcgccaagg ccctcattag gccgcacgtg 30000
acgagggcgg acaggggact ggctgggccc gtccatccat ggcgggcatg gccaggcggg 30060
gtggcctcgg gccggggcag aggcctggct ccgctgcctg acctggaaca gtctctgcct 30120
ctctccaagc ctcggtttcc ccagctggac ggtgatggg gtgagggcta gctgagggct 30180
ctcctgccct tcgtgcatte gctggtcact aatcgggcac cttgtgggtg ctgtgctccg 30240
catgggggac ccagtgggta cagagacgcc caccctcctg gggctcccag agcagaggcg 30300
cgcagcagtt agacacgtga acaagggcgc aggtgggtgc acagaacagt gaacggttgg 30360
ccgggtgcag tggctcacgt cggtaatccc agcactttgg gaggccgagg cgggcagatc 30420

-173-

acgaggtcag gagatcgaga ccatcccggc taacacggtg aaaccccgctc tctaccaaaa 30480
atacaaaaat tagccgggtg tgggtggcggg cgcctgtagt cccagctact cgggagggtg 30540
aggcaggaga atgacgtgaa gccgggaggt ggagcttgca gtgagctgag atcgcgccac 30600
tgccctccac cctgggcgac agagcgagac tccgtctcaa aaaaaaaaaa aaaaaaagaa 30660
cagtgaatga cgtgaacaag ggtgcaggtg ggtgcgcaga acagtgaacg gcggtgttgg 30720
gaggcacctt gccaggggag gggaggtgca gggcgaggaa ggggccaggg gagatcgtga 30780
cacagacgcc ccagaacaac cacctcaaag acgttcctgt gtgtcctgga aggtcgggct 30840
gggaggctgc cccgaggagc ttctactttg acaggagct ggccgggcac gcagggaact 30900
gtacaccag ctgacaaagc ggcagacacc caggccgggg tgagcgagtg tgggtgagga 30960
gtggcggctg gcccagggt ccttgctgga caagacactt cagctcaggg tggggcaggg 31020
ctcaccaggg gctaccaca gacgatggcg tccaaatctg gctctgccac tcccaggcct 31080
caactgcccc ctctgcaacg tgggctgctg agcgggcttg gtaggacagc tggcatacag 31140
tcggcgctca agcatgtctg tgggtgtcca taaaccaccg gtgtccact ctaggccact 31200
gccagcccgg cctccagtcc agagtcccag tccggagtcc cagtactgt gcgtgggccg 31260
ggcagctgag ctgtgagggc cgggctgggg gctccatatg ggggtggtgtg agctgtgagg 31320
gccgggctgg gggctccata tggggtggtg tgagctgtga gggccgggct gggggctcca 31380
tatggggtgg tgtgagctgt gagggccggg ctgggggctc catatggggt ggtgtgagct 31440
gtgagggccg ggctgggggg tccctggggt ggtgtgagct gtgagggccg ggctgggggg 31500
tctctggggt ggtgtgagct gtgagggccg ggctgggggc tccatatggg gtggtgtgag 31560
ctgtgagggc cgggctgggg gctccatatg ggggtggtgtg agctgtgagg gccgggctgg 31620
ggggtccctg ggggtggtgtg agctgtgagg gccgggctgg gggctccctg ggggtggtgtg 31680
agctctgagg gccgggctgg ggggtctctg ggggtggtgtg agctgtgagg gccgggctgg 31740
gggctccata tggggtggtg tgagctctga gggccgggct gggggctccc tggggtgctg 31800
ctggtcgctg gctcattgac agttatcagt ggtctgggtg ggccctgccc cttctgactc 31860
ccacatccca ggaacccttt cccaaccttc ctggtggtgt tgctgcccc ctgacgtccg 31920
tccctctggg tgtgtgggag ccccccgcc atacacacac acagatgctg ctcttgggct 31980

-174-

gagctgcagg gacagcgctg acctggccct cccacggggt cctcatcgat ctctgcactc 32040
ccccagctcg tggggggccgt cctgcttccc gtccctctg cctgtccctt gtcctccct 32100
cacatgctgg ggggggctcc tgggtgcagt cacggctctg ggggacctg agtgccgctc 32160
gtggtcggga ggggactcgt ggtcccgggg gtctcctggg atctgtcgtg gtcctgaggg 32220
ccctgcacga agcacagcgg acagcagcgg tgctgggggt gagccagcaa ggccctcccc 32280
gacccccgcc tccccaggc atcctggaga tccgctctgt acacgtgggc gtctgtgtca 32340
tcaaagcagt gtctcaggc ttctacgtgg ccatgaaccg cgggggccc ctctacgggt 32400
cggtagtgct cgggcagggc tgggcggcgc gggcagggtg gggagggtgg gccggcctca 32460
ccccgcccc cagcgactct acaccgtgga ctgcagggtc cgggagcgca tcgaagagaa 32520
cgccacaac acctacgcct cacagcgctg gcgcggcgc gccagccca tgttcttggc 32580
gctggacagg aggggggggc ccggccagg cggccggacg cggcgggtacc acctgtccgc 32640
ccacttctg ccgctcctgg tctcctgagg ccctgagagg ccggcggtc cccaagggtc 32700
ctgggctggg ggcgaggggc ccggccacgc ttgttcttcc ccctgcgggc tctgtaagcg 32760
ctgagtggcc accgtgtgcg ggcgctgtgg acacagccca ggagccctcc aggggggtcc 32820
cagcctgagg ggggtgtggc caccaagcag gttcaatcct gagttgggga cctcgaggac 32880
ccaacagggc gcctctcggg ctgaaggacg cagacgtcga aaggctcagg gggacgtccc 32940
aggcagggcc cggcagaggc aggggctcgg ggtggggagc acgttgggag tgggggcagg 33000
agcggagggg aggggagggg gccggggaga cggtagaca gccgcagaa caccagcctc 33060
gaagccggtc ccgtcccggg aatctgcaaa tacaacgcct tgcgaggaca aaggcacctg 33120
caggtgggac ggagatggag gagcatccag ggtggggggt ccaggggccc agtgctctca 33180
cagggtcctc acgacaggag gcgggacagt gagagccaga gagagatggg gatgggccc 33240
gctgtggccg tgaaggggag gaagggccct aagctgaggg acgtgggtgc ctccagatgc 33300
tggggaaggc gggaacggtt ccgcactgga gccccggga gggaccggcc tgctcctgcc 33360
ttgatatgag ccagtgga cccagtttgg actctggcct ccagaaccgc cagaaaataa 33420
acgtagtaag ccatcaactt tgtggtcttt tgttacagca gacgtcggaa atatgcacac 33480
ggtgtctgaa actgttctca tgacaaaata agcctcagat cccccggga agggcgagg 33540

-175-

ccaacgcctc ggtgttcctc cgatcccccg ggaagggcgg aggccgacgc ctcggtgttc 33600
ctcggatccc ccgggaaggg cagaggccga cgctcggtg ctctcagat ccccgggaa 33660
gggcagaggc tgagggcagg agccgtgctg ggtgcagggc aggcctgggg gcttcattgcc 33720
gctgtcctgc gggacgcaga gagggtggc cgtcggtgtg ggggcgcccc cacctgtgcc 33780
cagcgccctc ctgacatcct gactccgtg ggacttctgc ctacagccct gggagtcaaa 33840
ctccagcctc tcagagaaaa ggtcagagcc aagagcccca cagcctggag ccaggcagtg 33900
acaccctggg cctgtctccc cttctgtgtg tggggcgaca gcagcatcg cctggtgaag 33960
tccccgggga cggccagggc tccatcccca gccgcgcct tccacataaa tacaggaaga 34020
ctgggccgag gcacttgctg ggaggtgctg agcagcctga cacgaaaac cttctggga 34080
agggagggtc gtgccggcc cgagagcttc tgctcaccct gcagacagaa gcgagcccca 34140
cccagggga caccaggcgg cctctgggga catctttggc tggcatggag tgggtggagg 34200
acagggtgctg acccaggatg tccccagggt ggagtgatga ggggagatcg gccacgttg 34260
gccagtcgga gggcgctgcc acttgagttg tcaactgggag ctgcacaggt caccacagct 34320
gaaataaaac ttgtggcac ccacgcagg aacgtaacat gtgcctcgaa gaaacgggtc 34380
agcaggccgg gcgcgggggc tcacgcctgt catccagca ctttgggagg ccgaggcggg 34440
tggatcacga ggtcaggaga tcaaggccat cttggtcaac atggtgaaac cccgtgtcta 34500
ctaaaaatac aaaaaattag ccgggcgtgg tggcgggcgc ctgtaattcc agctacttga 34560
gaggctgagg cggggaatcg cttgaatccg ggaggcggag gttgcagtga gctgagatcg 34620
cgccactgca ctccagcctg ggcgacagag cgagactccg tctcaaaaaa aaaaaaaaaa 34680
aagaaacagg tcagcagttg tttctttgtt tctaaaacag agcgtggaat gggcgtagag 34740
ctccgcacat ccagggcag tgaaatcccg gttcacacag agccctcagc agcttattcg 34800
caagccaaa cctggggacc ccggtgtcc tcaggcagtg aggtgggggc ccccaacag 34860
agaggagcgg cctgggggca cagaaccagc ggctccccag gaaatcgcca gcagtgaaaa 34920
taagacaacc ccaaactgtt gcaaactgtg cttccgctta cgaagcactc ctgagcggca 34980
gggcggatgg ggagagggcg gctgcaggcg cgagggggcc ggggacgcag ggggtcgggc 35040
cttaccaggg ccctgtcctg tcgtgcagca ggctcctggg gcagggaaga caccaggggc 35100

-176-

ggccacttct tactgtgtc tgacctcgag caatgcggcc tcacagcccc caccaggggtg 35160
ccggtgtcct ctgggccag cgccccgag gctcatgcct ggggtggggcg aaccaatcgg 35220
tcctgtcct ctggccactc cacgcgaggg aagtcccagc ctcacaggca ggcgcacacc 35280
ccggcagcat ctctgacaaa ggccctccag ttccgagtct ccagggtcccg ccgctgcaag 35340
cctcacctgc ccagccctcc tctccagctc caactccaac tccaagaac caccacggac 35400
acacagaacc cgagccttgt ctccctcaac gcctcctgac tcaaaactcc atcttccaac 35460
aggaaaacgg ctggccggg ggactgtgac ccggagcagg cggcccagcc tgtcgcgag 35520
actcggggcc taaaacactt gttctctcag tccggagatc aaggacgatc cgaggtaacc 35580
tccctacctc ggtgtcctcc atgcaacctc gtcttagggc accgggtacg ttacctcgtg 35640
aggagccgag tccgcgggtc ctgggggtga gatgtggacg ccctcagggc tggcactctg 35700
ccctggcggc cacagtcagt gaagtcccaa cgcttctctc ggctccgcaa cccagaggg 35760
cggccacgag gagggccgc cacgcacgac ccagagggc ggccaccagg agggcccgcc 35820
acgcgcgacc ccagagggcg gccaccagga gggcccgcca cggcgttgcg gcagcagccc 35880
agaaggtgcc ctgcgcagcg tccggacagg tgggatccga gttacctggc caagggggct 35940
gacgcagaca cgtcgcggga cacagtgaag agtgtggtgc agagcggagg gcgggagtct 36000
ttggagaaca ggtagggggcg tggggcacgc gcctcccacg cgcaggagcc gtctaccgtg 36060
gagggaacag ggtggctcctg ctggaggctc ctctccgtta gctgtctcca tegtctgatt 36120
cttgatccc aggatggtgg gatcatcagc aactgagatg aaccactgc cccggcccc 36180
tgagcccgca ggtccccacg ccttgccagc tgtgcccag ctggctgcac cccgggccag 36240
gcatccagca accttgagca gtgggtccg gcttttcaga aggggcccagg aaccgcgtg 36300
gctgaggtgt gaccgaagcg tggggcagag gcgctgggccc ctggcgcttt aacgctggtg 36360
tttctggttt taaatttcac gaccagtga cactgccacc ctgtacctc gccagcagcc 36420
ctcctgggct taacttcggg agagcagttt tgctagccgg ccctgggtgc caagccctgc 36480
aggaggcgca gaccctgga gacaggaccg gactctgcag agccgacca gcctccagc 36540
ttggcctttt cctgacgcac gggcgagaa ggaaagccac agcaccggct tctctttgta 36600
agtagtgtat tttaaatagc tttcaagata cacatatttt ttcctttaa aaagtctgtt 36660

-177-

ggagcagttt tgttcttgaa ttttgctggt catcctcatg gtcccagacc cccctactcc 36720
gggtcgtgga ggcggccgag ggggaggctg ggggccacg tggccgtcc tggcggcacc 36780
tgcagcactg ggggagccgc tgaaccccgt gcttcagcgc tgggggagcc gctgggcccc 36840
gtcttccgcc acaaaccatg catggccgcc acgtgagctc aaacgtccgt ttatttcaaa 36900
gcagtaataa tttaaaatta taaaaatctt tocaccgctg aacgtttaga gggtagaggtt 36960
agacagagga cggggaggct ggggacgccc cagaggggac catgtggccc acgccttccc 37020
aagccagggg gccggtgggc cggggccggg tcctgccctg gaacaggcgg gacctgcagc 37080
gctgaccagc caagcgtggc gccgccgggg caccagttct gtgggtgccg tgtggcgctg 37140
gctgaggggtg ggtgggaaag gccccgtgct ttcccgacgg ccgacgtggg ctcacgagtt 37200
gcttggtggcg ttctcgttgc tgggcgagct ggaggaggac gatgacgacg aggaggagaa 37260
gctcacccca gtgaggccag ggggggtcgt ggccgtgttc tgtcccgta ggctttttcg 37320
gcagacgggg cagctgtcgt gctttgtggg gacagaggca gggacgggag aaggggcagg 37380
ttagaggcgg gagggccgcg gtcgggggtg gggggcgggt gggcggggca ctcacctgct 37440
ccagccaggg cacgatgcag ccgtcgtgga acaggtggtt gcagggcagc tgccgcacac 37500
gctcaccag cgcgtagtcg tccttgaca cagggcactc gagcccggag cctgcgggag 37560
tgtgcagctg cggtcacagc gggcgtgggg ggccgtccga gccttcaagg gcaggctact 37620
ccacagcctc agccggaggc cggccctgag ccagcgagg ggagaaaagc cgtgtgtgtg 37680
tccccgggc tgccagaggg gacctggaca gaacctctc ctccagccc accttcaggg 37740
aaatgctcga ggccgggtgc ggtggctcac gcctgtcatc ccagcacttt gggaggccga 37800
ggcaggagga tcacctgagg tcaggagtgc gagacctgcc tgaccaacat ggtgaaaccc 37860
tgtctctact gaaaatacaa gtatgagcca ggcgtggcgg cgggtgcctg taattccac 37920
tactcgggag gctgagctct catacctacg tgctcctcag tgacggggac ggtggggagg 37980
gcctggattt tctctttatc tgccggtggg gggcctgtgt tttcaaactg attgaggagc 38040
tgaaagacaa gaggcgagag tgccgggagc tcctcggggg ccgggcccgg ggctctgaaa 38100
cgcgaggctg caggacctgc aaaagcaccg aggccgcgtt tgtcctgggc cctgggcccc 38160
ttggagcccg ccgggggtcg gagatc 38186

-178-

<210> 39
<211> 720
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<400> 39
cgccggcgct tgacctgact ttcatgaatc gaaaaggaaa tcctctatga acgcactgca 60
tcgcatcggc gccggaacgc tactggccgt gttgctcgct tttggcctga cgggctgcgg 120
ggagaaggag gaggttcagc agtcgctcga gccggtggct tttcacgact ctgacgagtg 180
tcacgtgtgc ggcatgatca tcaactgactt ccccggtccc aagggccagg cggtcgaaaa 240
gcggggagtg aagaaatttt gttccaccgc cgaaatgctt ggttggtggc tgcagccgga 300
aaaccgtctg ctgatgccca agctctacgt ccacgacatg gggcgagcg tttgggaaaa 360
gccggatgac ggtcatctga tcgacgcaac cagcgccctac tatgtggtcg gtacgtcact 420
caaaggcgcc atggggcgct cgcttgcaag ctttgccgag gagcaggacg ccaaggcgct 480
tgccggcatg cacggcggtc gtgtgctgcg cttcgaggaa atcgatcagg cgctgctgca 540
ggaggctgca agcatgcagc acggcggtcat gcacgaccat gcgcaaacg gtgcacataa 600
cgcacacgca ggccactgag cagcagtggc ctgaacagca cacacaagaa atcgaggtaa 660
gcacaatgat gggatcagc gtctggcaac tcctgatcat tcttctgatc gtcgtcatgc 720

<210> 40
<211> 127
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<220>
<221> UNSURE
<222> (9)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (101)
<223> May be any nucleic acid
<220>

-179-

<221> UNSURE

<222> (119)

<223> May be any nucleic acid

<400> 40

g'cggccgcnc ggcgctggct gctgtgcgga ggccacggcg ggccgcgagc cgcctcgctcc 60

tcgcctcct g'ccctgggtg cggccccccg ggtcccggcg nccactcgc cccggcgtn 120

ccgcgct

127

<210> 41

<211> 6858

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> .41

actcgccaag tgatcgaccg gccctgagg gccgcgacgc agagggcgcc ccgtgcactg 60

gcacaggcgg ccttgtgctg tagactctga tttcgtgcg ccctctcgtt ggcaggacca 120

tccatcctgt gtgccggggg ccgcgcacac cgateccgga tccgcctcgg ccctgccctg 180

cgcgccctc cgttctcgac ctccccgacg ctgtctgaac acgcgtcgcc gggggacgac 240

ggcgggcggc ccgcctcggg ggaggggtaa gcgtcccggg atgcccgttc aaccgttccg 300

caaggctcgc ccatcgtagg ggagaaccgg cgcgacgcta ggagagacaa gtgatccagc 360

aggagtcgcg gctcaaggtc gccgacaaca ccggtgcgaa ggaaatcctg accatccgtg 420

tgctcggcgg ttccggacgc cgctacgcag gcatcggcga caccatcgtc gccaccgtga 480

aggacgccat ccccgggcgg aacgtcaaga aggcgcacgt cgtcaaggcc gtggtggtcc 540

gcaccgcgaa gcagtcggcg cgtcccgacg gctcgtacat caagtccgac gagaacgcgg 600

cggtcctcct gaagaccgac ggcgagcccc gtggcacgcg catcttcggc cccgtgggtc 660

gcgagctgcg tgacaagaag ttcataaga tegtgtcgt cgcggcgag gtgatctgac 720

ctcatggcca agatcaagaa ggacgacctc gtgcaggtca tcagtggcaa ggacaagggc 780

aagcagggca aggtcctgcg cgtgttcccg acggatgagc gcgtgctcgt cgagggcgtg 840

aaccgcgtga ccaagcacct gcgcgccggc caggacaaca acggttcac cgagggcggc 900

ctgcaggtcg tcgaggcccc gatccacatc tcgaacgtgg ccgtggtgga cccggagacc 960

-180-

aagaagccga cccgtgtggg ctaccgcttc gagaccgtcg agaaggacgg cgtgacgaag 1020
accgtgaagg tccgcttcgc caaggcctcg gggaaggagc tgtgatgacc gaggtgcagc 1080
agaccgagaa ggtcaccccg cgtctgaaga ccaagtaccg cgaggagatc cgcggaacgcc 1140
tgcaggagca gttccagtac gggaacgtca tgcagggtgcc gggcctcgtg aagggtcgtcg 1200
tcaacatggg cgtcggcgag gccgccaagg actccaagat catcgacgac gccgtcaccg 1260
acctcaccgc catcaccggc cagaagccga tgatcaccaa ggcccgaag tccatcgcg 1320
agttcaagct gcgtgagggc atgccatcg gcacgcacgc caccctccgt ggcatcgca 1380
tgtgggagtt cctggaccgc ctggtcacgc tgcggtgcc gcgcatccgt gacttcgcg 1440
gcctgtccga ccgccagttc gacggcaacg gcaactacac cttcggcctg tccgagcaga 1500
ccgtgttcca cgagatcgat caggacaaga tcgaccgctg gcgcgcatg gacatcaccg 1560
tggtgacgac cgccaagaac gacgacgag gccgcgcgt gctcaaggcg ctgggcttcc 1620
cgttcaagac cgaccagtaa gacctccacg ccacaggctc tccaccggtg aaccggtggc 1680
ggaaaccacg gcgagaaagg gcgtgaagca catgaccatg accgatcccg tcgagacat 1740
gctgaccgt ctgcgcaacg caaactcggc ctaccacgac accgtgtcca tgccgtcctc 1800
gaagctgaag actcgcgtcg ccgagatcct caaggccgag ggctacatcc aggactggcg 1860
cgaggaggag gccgaggtcg gcaagaagct gaccatcgac ctgaagtctg gccgcgagcg 1920
tgagcgtcg atcgccggc tcgcccgcac ctccaagccg ggcctgcgcg tgtacgcgaa 1980
gtccacgaac ctgccccacg tgctgggagg cctcggcatc gccatcctgt ccacctcctc 2040
tggtctcctc acgaaccagc aggcgcgcaa gaaggctggc gtgggcggag aagtcctcgc 2100
ctacgtctgg tgacgggcaa gacggaagaa aggctgaact gacatgtctc gaatcgagc 2160
tctcccgatc accatccccg ccggcgctga tgtgaccatc gacggcgacc gcgtctccgt 2220
gaaggggccc aaggggccca agggtcagct cgagcactcg ctgcccacgc ccatcacggc 2280
caccctcgag gaggggcagg tcaccgtggc ccgccccgac gacgagcgtg agtcccgtc 2340
cctgcacggt ctgaccgta cctcatcag caacatggtc gagggcgtga ccaacggctt 2400
ctccaagcag ctcgaggtcg tcggcaccgg ctaccgctg caggccaagg gccaggacct 2460
cgagttcgac ctgggctact cccaccccgt ccggtgaag gtgtcccagg gcatcacctt 2520

-181-

cacggtggag ggtaacaggg tcaccgtcgc cggtatcgac aagcagcagc aggtcggcga 2580
gaccgccgcc aacatccgca agctgcgccg ccccgaccgc tacaaggga agggcgctta 2640
cgcgggcgag cagatccgcc gcaaggccgg aaagaagtga tgtctactct gaaggagaag 2700
ggcaaggga agttcaacgc ccgcacccgc cgccacctcc gggcgcgaa gcggatctcc 2760
ggcaccacgt ccgtcccccgc cctcgtcgtc aaccgctctg cacggcacat gttcgtgcag 2820
gtcgtggacg acacgcagag ccgcacgacg cgtacgcct ccaccatgga ggccgacgtg 2880
cgtgcgctcg agggcgacaa gacggccaag gccaaagcgc tggcgagct cgtcgccgag 2940
cgtgccaaag cgcccgcat cgaggccgcg gtcttcgacc gggcgggcaa caagtaccac 3000
ggcgcgctcg cgcccggtgc cgacggtgcg cgagagggcg ggctgcagct gtgaccgaga 3060
acatcaacca gaaggacact caggcgaccg agagcaccga gaccaccgtc tccgagaccg 3120
ggcggggtc gcgagccaga ccaccgagcg cgccaccggt ggccgcgccg gtcgagacgg 3180
cgcccgcggt ggccgacgg cgatcgtcgt ggccggcggt ggacgaccga accgtcgtgg 3240
cgccaggac gacgaggaag gaccagttcc tcgagcgct cgtgggcatc aaccgctct 3300
ccaaggtcgc cgccgcttc tccttcaccg ccctcgtggt ggtgggtgac ggcgacggca 3360
ccgtcggcgt cggtacggc aaggcgaag aggtccccgc tgcgatccag aaggccgtgg 3420
aggaggccaa gaagtccttc ttccggtcc ccgcgctcg ctcaccatc ccgcacctgg 3480
tgcagggtga ggacgccgcc ggcgctcgtc tgcctcgccc ggctccccg ggtaccgagg 3540
tgatcgccg cggtccggtg cgcgcgtgc tcgagtgcg cgcatccac gacgtgctct 3600
ccaagtccat gggctccgtg aacgcgatca acatcgtgc cgccacggtg gagggcctca 3660
agaagctgaa gagccccag gccgtcgccg ccgcgcgcg caaggccctg gacgagatcg 3720
cccccatgc gatgctgcg accatggaga acgatcgcg ccagaagagc gcaaggcag 3780
gtcgtgacg cgtgtttgag tccactcgca agaaccatca gccctcggac gccaccctgg 3840
tcacaccca gaccgcggc gtcacgggct ccaagcagaa ccatcgggac accctgcgct 3900
cgctgggcct gaagcggatc ggccaccagg tcaccgcga ggccgacgc gtgacggctc 3960
gcatggtcaa caccgtgccg cactggtgt ccgtggagga ggtcaacaat ggctgacaac 4020
gacgccatca aggtccacga cctcgtccg gccccgggt ccaagaccgc caagaccgc 4080

-182-

gtgggtcgcg gtgaggcgtc gaagggcaag accgccggtc gcggcaccaa gggcaccaag 4140
gcccgttacc aggtccgtgc gggcttcgag ggcggtcagc tgcccctgca gatgcgtctg 4200
ccgaagctcc gcggcttcaa gaacccgttc cgcacggagt accaggtcgt gaacctggac 4260
aagctctccg cgcacttccc cgagggcggt gaggtcaccg tggacgcgct cgtctccaag 4320
ggcctcgctc gtcgtggcca gcccgtgaag gtgctgggca cgggggagat caccgcggcc 4380
gtgcaggatga aggcgaacgc cttctctgcg tccgccgtgg agaagatcca ggccgccggc 4440
gggtccaccg agaccctctg acacgccgac ccatcgaccg agggccctgg ccggagcagc 4500
cgctcggggc agggccctggt cgtccgtgt agactcgac agccgccccg gtgtggccgc 4560
cgtctcgctc ccccgccccg cggaacggcg cacgccccac aggaccagcc gcaggaggac 4620
tcgtgtcaa ggccatcgcc cggatcgctc ggacgcctga cctgttgagg aagatcgctc 4680
tcacgctcgg gctcatcgcc gtctatcgga tgggcgactt cgtgccggcc accggcgtgg 4740
actaccggc ggtgcagcag tgcttggcag cgggcaacgc ccagggcggc ctgtactcct 4800
tcgtgaacat gttctcgggc ggggcgctcc tgcagggtgc tgtcttcgcg ctgggcatca 4860
tgccgtacat cacggcgtcg atcatcgctc agctgctgcg cgtggtgatc ccgcgcttcg 4920
agcagctcca ccaggagcgc cgcaggggcc aggcgacgct gacgcagtac acccgctacc 4980
tgaccctcgc cctcgccctg ctgcaggcga ccacgatggc ctcgctggcc cgcaccgggg 5040
ccctgctcgg atgcagcctg ccgctgctgc gcgacggctc catcctcacg gtgctgctcg 5100
tggatcatgc cctgaccacc ggctgtctca tcgtcatgtg gttcggggag cggatcaccg 5160
agaacggcgt gggcaacggc atgtccctgc tcattctcac ctccatcgcg gcaggcttcc 5220
cggccggctc cggccagggtg gtccagacgc agggctggcg cgtgttcgcg atcgtcatgg 5280
ggatcggcct gctcaccatg ctggccatcg tcttcgtgga ggagtcgcag cgcgggatcc 5340
cgggtccagta cgccaagcgg cagatcggct cacggaccgt gggcgggtcg agcacctaca 5400
tcccggtaa ggtgaacatg gccaacgtca tcccggcat cttcgctcc tccgtgctga 5460
tgctcccggg catcctcatc cagttcaaca cgccgcagga cggcagtgcg ccggccccgt 5520
ggatcacgtg gctgagccgg tacttcggct ccggtgacca cccggtgtac atggccctgt 5580
acttctgct catcatcggc ttacgtact tctacgtgtc catcacgttc aaccgggtgg 5640

-183-

agatctcggga caacatgaag cgctacggcg gcttcatccc ggcgtccgcg ccggccggcc 5700
ccaccgagcg ttacctgcag tacgtcatca gccgcatcac gttcgtggtg ggggccctct 5760
acctcggtat cgtggccatg atcccgtga tcgccttcgc ggtgatcggc accagccaga 5820
acttcccgtc cgggggcacg tccatcctca tcatggtggg cgtcggcctc cagaccgtga 5880
agcaggtcag cgcacagatg gagcagcgcc actacgaggg cctgctgcgc tgagccccga 5940
ccgatccccg caacgccgtc cgtatcgaca gtgaggaaca cacgatgacc cgcgtgctgc 6000
tcatgggccc tcccgttcc ggcaaggga cccaggccac ccgatcgcc gacaagctgg 6060
ggatcgtccc gatctccacc ggtgacatct tccgccacaa cgtgaagtcg atgacgccgc 6120
tcggcgctga ggccaagagg tacatcgaca acggcgactt cgtccccgat gaggtcacga 6180
accgcatggt cgccgaccgc atcgcccagg ccgacgcgga gcacggcttc ctgctggacg 6240
gctaccgcg cacaagggc caggctcgagg cgctggacgc catgctcgcc gaggccggcc 6300
agtcgctgtc cgccgctgtc gagctggagg tgcccagcga ggagctcgtg gagcgctgc 6360
tcaagcgtgc cgagatcgag ggccgcgcgg acgacacca ggaggtcatc gagcaccgcc 6420
tggaacctga ccaccgcgag accgagtcgg tcatccagga gtacgtggag cgcggcatcg 6480
tcgcccgcgt ggacggcacc ggccagatcg acgacgtcac cgagcgctg ctgcaggccg 6540
tgtactccgt gcgctccgcc acgggctccc tgcccgtgat ccagccgggc gcggagtcct 6600
gaccccgta tcggccgccg ctgctcgag ctcaagaccg cccccagct gctggccatg 6660
cagcgcgcg gggtggtcct gtccgaggca ctggacgccg cgctggccgg cgcgccgggc 6720
ttcaccaccg cggagctgga cgccgtgttc gcggtggtgc tggccgaacg cgggtgcgacc 6780
tccaacttcc tgggctacta cgacttcccg gcctcgatct gcacctcgtt caacgaggag 6840
gtcgtgcacg gcatcccc 6858

<210> 42

<211> 578

<212> DNA

<213> Homo sapiens

<220>

<221> UNSURE

<222> (5)

-184-

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (23)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (31)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (48)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (211)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (292)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (308)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (350)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (384)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (477)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (507)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (529)

<223> May be any nucleic acid

<220>

-185-

<221> UNSURE
 <222> (549)
 <223> May be any nucleic acid

<220>
 <221> UNSURE
 <222> (551)
 <223> May be any nucleic acid

<220>
 <221> UNSURE
 <222> (558)
 <223> May be any nucleic acid

<400> 42
 ttctngtcta tggcagagat ggncaggttg ncgttgagca ggtactgncc atcagccgtc 60
 ttcagcgcca ggtagttccc atcgttctgc acaccgggt ggctccgtg cttcacgtca 120
 atattagtgg caccagctgg gatggtgaca atgtcattgt agccataatt ggtgggggtg 180
 agggacccgg agaccttcct gcaggagttg nctttgcccc cacacacccc gcatttgtcc 240
 agcttccgag gcgagtccac cacatggtca cagccggcct tgacacactg gncacggaca 300
 cagatggnca gtgtttctgg cccacacagg gtgccatcaa tcaccttgn ctcgaacact 360
 ttggaactcg ctctccccc gggntcggga ggaacaactt gcaggggtcc cgggggggac 420
 aaccagcat tcttggggga cccactgcag gaggattccc cgtccatgtc aagtgtgnatt 480
 ggtgggcatt attcttctca caattgntgc tccctgaagg ttttcccgnc aaggggggat 540
 tccccccng ntggaatnat tggacttgg gtctccga 578

<210> 43
 <211> 305
 <212> DNA
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (128)
 <223> May be any nucleic acid

<220>
 <221> UNSURE
 <222> (146)
 <223> May be any nucleic acid

<400> 43
 catttaagtt tgctagtcct ttgcaaacag actgacgctg agtgtcctgt ctgagtcaat 60

-186-

aagtgcactt ttacctttta acctatgccc tctacttgaa ccgagcaag gtccagtcca 120
ctggacangt tgatgatagg gtctgncgcc ccataccctc tcctcttccc ccttaggaat 180
ttgtgcagta ctggaggggt tgcggcaatg ggaggcctgg gtgggccgtg ctgccttgat 240
atggccaagg gaccagtcac ccacagtgga gacccttgtc tgcacctcag taccgcatgt 300
ccagg 305

<210> 44
<211> 333
<212> DNA
<213> Homo sapiens

<220>
<221> UNSURE
<222> (82)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (255)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (275)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (299)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (313)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (324)
<223> May be any nucleic acid

<400> 44
ggcacaggtg acttttagcat gcagagcagc aaagagagag caaccaccaa catcatccag 60
ccgctgctcc acgcacagtg gntgctgggg gactggtctg agtgctctag cactgcgggg 120
ccggctggca gaggcgaact gtagagtgca gggaccctc cggtgcaggc ctctgccacc 180
tgcaacaagg ctctggaaac ccgaggatgc caagccctgg cagaaccagc tgtgccccct 240

-187-

gtgatttcag ggggncaggg gccattttgt gctcngggac atgcggtaat ggaggttgnc 300

agacaaggtc ttncattgtg gtgnatgggt tcc 333

<210> 45
<211> 102
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<400> 45
<220>
<221> UNSURE
<222> (64)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (69)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (71)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (72)
<223> May be any nucleic acid

gcagcagcag cgcagcgagc agagagcagc agcagcagca gcagcagcag cagagcagat 60

cntnctggna nnaaaaaatc gcggcagcag ctgctctagc ag 102

<210> 46
<211> 123
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<220>
<221> UNSURE
<222> (9)
<223> May be any nucleic acid

-188-

<220>
<221> UNSURE
<222> (51)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (52)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (57)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (67)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (123)
<223> May be any nucleic acid

<400> 46
caggcaagnc ggcacgtagg agcagcagca gcagcagcag cagcagtaac nnagtcnacg 60
agggggngcc cgggacccaa ggcgcccga cagagaggcg gagcacaatc cactggtcgg 120
cgn 123

<210> 47
<211> 109
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<220>
<221> UNSURE
<222> (87)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (95)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (102)
<223> May be any nucleic acid

-189-

<220>
<221> UNSURE
<222> (106)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (107)
<223> May be any nucleic acid

<400> 47
ggcagcgagg agcagcagca gcagcagcag cagcagcagc agagagagag cagcagagag 60
agagagcagc agagcagagc agagcanagt agagnagagc anagcnnac 109

<210> 48
<211> 293
<212> DNA
<213> Homo sapiens

<220>
<221> UNSURE
<222> (86)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (166)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (185)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (209)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (214)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (219)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (234)
<223> May be any nucleic acid

-190-

<220>

<221> UNSURE

<222> (290)

<223> May be any nucleic acid

<400> 48

ggcacgaggg ggaaactgct ccgcgcgcgc cggggaggag gaaccgcccg gtcctttagg 60

gtccggggccc ggccgggcat ggattnaatg cctgagcccg ggtcccgtg tcttctgctt 120

cttccttgct tgctgctgct gctgctgctg ctgccggccc cggagntggg cccgagccag 180

gccgnagctg aggagaacga cttgggttng cctnccana aaatgggaag ggantgggg 240

ttaatcgaag tcattgggac cattttaaaa ggggcttcct ggattatagn ctt 293

<210> 49

<211> 506

<212> DNA

<213> Homo sapiens

<220>

<221> UNSURE

<222> (283)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (342)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (356)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (362)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (364)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (368)

<223> May be any nucleic acid

<220>

<221> UNSURE

-191-

<222> (429)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (454)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (461)
<223> May be any nucleic acid

<400> 49
aattcggcac gagcaccgga ccaactgcagt cttctgccct gctggacagc agcagcagca 60
gcagcagcag cagcagcagc agcagcaaca gtaacagcag cagttcgtcc ggacccaacc 120
cttctacctc ctttgagccc atcaaggcag accccacagg tgttttggaa ctcccaaaag 180
agctgtcaga aatctttgat cccacacgag agtgcattgag ctgggagctg ctggaggagt 240
tgatgtcttc agaagtgttt gccctctgc tttcgtcttt ctncaccccc gggagaccac 300
gattatatct acaacctgga cgagagtga ggtgtttgtg anctcttttg atgtgncgtg 360
tntnaacntt tgactgacag ggacatgcct tttttggttg ggaccagat tttttgactt 420
gggggtttnc ttgggacttt tcaaccgacc ctanagagtt nagagcaaan aggttggttt 480
ttcggcttcc ttaacgaaag ttttgg 506

<210> 50
<211> 419
<212> DNA
<213> Homo sapiens
<220>
<221> UNSURE
<222> (137)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (221)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (259)
<223> May be any nucleic acid
<220>

-192-

<221> UNSURE
<222> (327)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (385)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (389)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (416)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (418)
<223> May be any nucleic acid

<400> 50
tttaagcacc aaaacttggtg ttttaatgat gttggatgga aatctttcct aaatgtgtca 60
tgcatgctct tgtctccctt aatggagaga gtgtgacact gcttagcact tggatggctt 120
ggggtggtgg ttatgancag cagtctgtca cagctcagcg aggtgaagcc tgtgggcgtt 180
ttgctctgtg ctgaatggct cagtggccct acaaagcgga ntcagctctt ggtggctttc 240
tggtgtggtg ggtgctgnt gctgctgctg ctgctgctgc tgctgccctt gcctctaaaa 300
gaactcactt cctcttcctc ctgctgncac ctgtcttttg gcttgtggga ttggagtcac 360
ggggcccaga tggagccttg ctccntgant tatgataggc cctcgggtct cttttntnc 419

<210> 51
<211> 495
<212> DNA
<213> *Saccharomyces cerevisiae*

<220>
<221> UNSURE
<222> (177)
<223> May be any nucleic acid

<220>
<221> UNSURE

-193-

<222> (322)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (328)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (342)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (368)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (371)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (375)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (380)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (386)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (396)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (404)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (423)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (426)
<223> May be any nucleic acid

-194-

<220>
<221> UNSURE
<222> (436)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (443)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (456)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (460)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (467)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (468)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (471)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (474)
<223> May be any nucleic acid

<400> 51
aattcggcac gagcaaagtt ctgcgtcca ttgtgggcat caaacgacac gtcaaagccc 60
tccatctggg ggacacagtg gactctgatc agttcaagcg ggaggaggat ttctactaca 120
cagaggtgca gctgaaggag gaatctgctg ctgctgctgc tgctgctgcc gcagacnccc 180
agtccctggg actccacact ccgagccagc tcccaccccc agcatgactg gctgcctct 240
gtctgctctt ccaccacctc ttgcacaaag ccagtcctc cggcccagaa catcctgggc 300
ccggagttcc ttccttgcc ttaggggntt ttcagcaagt tnagttcctt gggtcctttt 360
tgggaaantt naggnaagtn aaggantacc aggttnttgc catnctttcc agatccaagt 420
ttnacnaaaa attttnaaca gtntaaattg gggttnttgn ccctttnnng nggntgtttt 480

-195-

ttttttcggg tccgg

495

<210> 52

<211> 81

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<220>

<221> UNSURE

<222> (65)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (67)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (71)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (75)

<223> May be any nucleic acid

<400> 52

ggcacgcagg agcagagcag cagcagcaga gagagcagca gcagcagcag cagcagcaga 60

gagananata natanatata t

81

<210> 53

<211> 305

<212> DNA

<213> Homo sapiens

<220>

<221> UNSURE

<222> (11)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (62)

<223> May be any nucleic acid

<220>

-196-

<221> UNSURE
<222> (81)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (256)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (289)
<223> May be any nucleic acid

<400> 53
aggcacttga nttgaaaatg gaaaacccta ctgctggtgg tgctgcggtg atgaggccta 60
tnatgcagcc ccagggtttt nttaatgctc aaatggtcgc ccaacgcagc agagagctgc 120
taagtcatca cttccgacaa cagaggggtg ctataatgat gcagcagcag cagcagcagc 180
aacagcagca gcagcagcag cagcagcagc aacagcaaca gcaacagcaa cagcagcaac 240
agcagcaaac ccaggncctc agcccacctc ctaatgtgac tgcttcccnc agcatggatg 300
ggctt 305

<210> 54
<211> 307
<212> DNA
<213> Hepatitis C virus

<220>
<221> UNSURE
<222> (212)
<223> May be any nucleic acid

<400> 54
tggggtgtga agctccggtg ctggtgcggc gggggactgc ggggccagcc tcagtttaaa 60
ccccctcagc agtctttctg tcgttgccct ccacactgcg agactctgga gggcgatctg 120
gaggtctgga agataaccga ttcctgggag atttgggggt agtctccaat ctgtccctgg 180
ctcatcttgt gaccogaagc cggcggcctt gncaggagta ttctagaatg agtgcacata 240
aaaatacctt caaacggtag cagcagcagc agcagcagca gcagcaagca gcagcagcag 300
cagcagc 307

-197-

<210> 55
<211> 88
<212> DNA
<213> Unknown

<220>
<221> UNSURE
<222> (6)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (7)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (78)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (83)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (87)
<223> May be any nucleic acid

<220>
<223> Description of Unknown Organism:Unknown

<400> 55
ggacannnac tactctctct ctctctctct ctctctctgc tgetgctgct gtgctgctgc 60
tgctgctgct gctgccgntg tngcana 88

<210> 56
<211> 346
<212> DNA
<213> Unknown

<220>
<221> UNSURE
<222> (278)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (288)
<223> May be any nucleic acid

<220>
<221> UNSURE

-198-

<222> (299)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (313)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (342)
<223> May be any nucleic acid

<220>
<223> Description of Unknown Organism:Unknown

<400> 56
ggcacagccc aactggtgat gctgctgctg ctgctgctgc tgccgcccgc gcctctattg 60
ctgatactct agtggggctg gaaggggtgt tcctattcgc accatcgcca accagagaca 120
gagggaaaaa aaaaaccggc agccactgct gaatgttggg ttcgaggagct gcatccgact 180
cggtcacaag gaaaatggat tcagtttgca tctctccctc ctttaaacag cttctccggg 240
tctcagcatg ggcttccagg gcagcgattg aggagacntt accaaggngc accacacant 300
agatgctgag acntcgtgac tccaggataa gaaacattaa cngggg 346

<210> 57
<211> 496
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<220>
<221> UNSURE
<222> (11)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (78)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (195)
<223> May be any nucleic acid

<220>
<221> UNSURE

-199-

<222> (197)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (286)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (291)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (293)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (315)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (328)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (329)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (344)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (346)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (352)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (354)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (358)
<223> May be any nucleic acid
<220>
<221> UNSURE

-200-

<222> (366)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (399)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (406)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (410)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (418)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (420)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (435)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (443)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (453)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (454)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (459)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (471)
<223> May be any nucleic acid

-201-

<220>
<221> UNSURE
<222> (473)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (474)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (481)
<223> May be any nucleic acid

<400> 57
gaattcggca naggtgcaca gatgtggtgg atggggaggg ccgcacggga cagaagttct 60
ccctgtgtat tctgacgnct gagaaaggag catttcatcc gggcggagac caaggagatc 120
gtcaatgggt ggctggagat gctcatggtc tatccccgga ccaacaagca gaatcagaag 180
aagaaacgga aagtgnagc cccccacacc acaggagcct gggactgcc a gttgggctg 240
ttaccagcag cagcagcagc agcagcagca gcagcagcat ccccantgct ntnggaaagt 300
tcccaccacc aagtncaca atttgggna aaaccaaggt t gtnagnagac gngntttngg 360
gatttnggca ttgtgggttg cttgcatgga aggacattng gttgtnggtn ccttggangn 420
tacaattacc atttncggtt gtnaaggta aanntccgnc attcagaagg nttnaagggtg 480
ntttgaagtc catttg 496

<210> 58
<211> 268
<212> DNA
<213> Drosophila sp.

<220>
<221> UNSURE
<222> (16)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (51)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (60)
<223> May be any nucleic acid

-202-

<220>

<221> UNSURE

<222> (202)

<223> May be any nucleic acid

<400> 58

aacacttatc cttganagct ctgtttggga agcaggacaa agctacatgt naggaaactn 60
tggagcctcc gcagactctc caccagcagc agcagcagca gcagcagcag caagagaagc 120
ttccaattag gcaggggggt gtacgctccc tgtcctatga ggaaccaga agacactcac 180
ccccattga gaagcagctc tntccagcca ttcagaaact catggtcagg agcgcagacc 240
tccacccatt gtcagagctg cctgaaaa 268

<210> 59

<211> 471

<212> DNA

<213> Homo sapiens

<220>

<221> UNSURE

<222> (249)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (386)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (449)

<223> May be any nucleic acid

<400> 59

tgcaccacg cgtccgctga ggaacagacg ttccctggcg gccctggcgc cttcaaacc 60
agacatgctg ctgctgctgc tgctgctgcc cctgctctgg gggacaaagg ggatggaggg 120
agacagacaa tatggggatg gttacttgct gcaagtgcag gagctggatga cggatgcagga 180
gggcctgtgt gtccatgtgc cctgctcctt ctcctacccc caggatggct ggactgactc 240
tgaccagnt catggctact ggttccgggc aggagacaga ccataccaag acgctccagt 300
ggccacaaac aaccagaca gagaagtgcg ggcagagacc cagggccgat tccaactcct 360
tggggacatt tggagcaacg actgcncctt gagcatcaga gacgccagga agagggataa 420
ggggcatat ttctttcggc tagagagang aagcatgaaa tggagttaca a 471

-203-

<210> 60
<211> 379
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<220>
<221> UNSURE
<222> (2)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (14)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (31)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (135)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (315)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (332)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (349)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (357)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (374)
<223> May be any nucleic acid

-204-

<400> 60
anttcggcan aggnaaggga gaggggtgacc ngcatcccaa ctagatttca gtggagtga 60
gttcaggagg catggagctg acaaccatga ggctcggca gccaccgcca ccaccgccgc 120
ggccaccacc gtagncagca gcagcagcag cagcagcagc aagagttaac tctgacttag 180
ggaatagaga cagccagaga gaaatgtgat caatgaagga gacatctgga gtgtgctgctgc 240
ttcttcagag gggacgggtg atgggcagat ttggaaaaag caccgcagat tgggaacctt 300
atcttttctt tttcntaaaa ttgttggttat gnaaatttgg gtttttccng taacttntta 360
aaaacttaaa agtnggttt 379

<210> 61
<211> 255
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<220>
<221> UNSURE
<222> (121)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (183)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (254)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (255)
<223> May be any nucleic acid

<400> 61
aattccgaca atggaaagca ctcttagcct tgcagtggctc tacattttta aggaaccaat 60
atttcagcat tctttattac ccggcacgct gtgtcctttg tcagagttca agtttatggt 120
nactgccagg gtcagacagt ccatttgctg ctgctgctgc tgctgctgct ttctcgaact 180
ggnatggcat tagggaagct gctgtctgag tgtagggaa tgtcttggtc aagtaaagcc 240

-205-

aatgttcttt cctnn

255

<210> 62

<211> 5289

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 62

cgagctctcc cagccgcagc ctccgaatcc acggcctcca ccccgcgct ctccagcgct 60
ctatcccgtc gctgcgcct tgtcgccggc cccggccgct gcatccgct ccgcacaggc 120
tccttgctgg gcacaaatag ctccaccatg gggctggcct ggggactcgg tgcctgctc 180
ctgttgcatg cctgcggctc caaccgcatt ccagagtctg ggggagacaa cagtgtgttt 240
gacatctttg aactcaccgg agctgccgc aagcggctctg ggcgccgact ggtgaagggc 300
cctgaccctt ctagccagc tttccgcatc gaggatgcca acctgatccc cctgtgcct 360
gacaagaagt tccaagacct agtggatgct gtgcgggcgg agaaagggtt cctcctcctg 420
gcctccctga ggcaaatgaa gaagaccgg ggtaccctgc tggctgtgga gcggaaagac 480
cactctggcc aggtcttcag cgtgatctcc aatggcaagg cgggcaccct ggacctgagc 540
ctgaccgtgc aggggaagca gcatgtggtg tcggtggaag aagcactcct ggcgactggc 600
cagtgaaga gcatcaccct gtttgtgcag gaggacagg cccagctgta catcgactgt 660
gagaagatgg agaatgcgga gctggatgtc cccatccaga gcatcttcac cagggacctg 720
gccagcatcg ccaggctccg cattgccaaa ggaggtgtca acgacaattt ccagggggtg 780
ctgcagaatg taaggtttgt ctttgaacc acaccagaag acatcctcag gaacaaaggc 840
tgctccagct ctaccagtgt ctttgtcacc cttgacaaca acgtggtgaa tgggtccagc 900
cctgccatcc gcaccgacta cattggccac aagacaaagg acctgcaagc catctgtggc 960
atctcatgtg acgagctgtc cagcatggtc ctggagctca ggggtctacg caccatcgtg 1020
accacgctgc aggacagtat ccgcaaagt accgaagaga acaaagagct ggccaacgag 1080
ctgaggaggc cccactctg ctaccacaac ggagtgcagt acaggactgg cgacgagtgg 1140
acggtggaca gctgcactga gtgtcgctgc cagaactcag ttaccatctg caaaaaagtg 1200

-206-

tctgtccca tcatgccctg ctccaatgcc acagttccgg atggagaatg ctgcccacgg 1260
tgctggccca gcgactctgc agacgatggc tggccccgt ggtctgagtg gacctcttgc 1320
tctgtgacct gtggcaatgg aatccagcag cgtggccgct cctgcgacag cctcaacaac 1380
agatgcgagg gtcctctgt gcagacgagg acctgccaca tccaggagtg tgacaagaga 1440
tttaaacagg atggcggctg gagccactgg tccccatggt catcttgctc cgtaacatgt 1500
ggagacggtg tgatcacaag gatccggctc tgcaactccc ccagcccca gatgaatggg 1560
aagccatgtg agggcaaagc ccgggagacc aaagcctgcc agaaagactc ctgccccatc 1620
aatggaggct ggggacctg gtcaccatgg gacatctgtt ctgtcacctg tggaggaggg 1680
gtacagaaac gtagccggct ctgcaacaac cccaaacccc agtttgagg caaggactgc 1740
gttggatgag tgacagaaaa ccagatctgc aacaagcagg actgtcccat tgacggatgc 1800
ctgtccaatc cctgctttgc tgggtgtccag tgtaccagct accctgatgg cagctggaag 1860
tgtggtgcct gtcccccagg ctatagtga gatggagtcg agtgcaaaga cgttgatgag 1920
tgcaaagaag tccctgatgc ctgcttcaac cacaatggag agcacagggtg tgagaacaca 1980
gaccccggt acaactgcct gccctgccca ccgcgttca ctggctcgca gccctttggc 2040
cggggcggtg aacatgccac cgccaacaag caggtatgca agccccgaaa cccctgcaca 2100
gacgggacac acgactgcaa caagaacgcc aagtgcaact acctgggcca ctacagcgac 2160
cccatgtacc gctgcgagtg caagcctggc tacgccggca acggcatcat ctgccccgag 2220
gacacagacc tggacggctg gcccaatgag gacctgctgt gcgtggcaca cgcaacttac 2280
cactgcagaa aggataattg ccccaacctt cccaactcag ggaggaaga ctatgacaag 2340
gatggaatcg gcgatgcctg cgatgatgac gatgacaatg ataagattcc agatgacagg 2400
gacaactgtc cattccatta caaccagcc cagtacgact atgacagaga tgacgtggga 2460
gaccgctgtg acaactgccc ctacaaccac aaccagacc aggctgacac agataacaat 2520
ggggaaggag acgcctgtgc agctgacatt gatggggaca gtatcctcaa tgaacgggac 2580
aactgccagt atgtctacaa tgtggaccag aaagacactg acatggacgg ggttggatg 2640
cagtgtgaca actgccccct ggaacacaat ccagaccagc tcgactctga ctcggaccgc 2700
attggagaca cctgtgacaa caatcaggat attgatgaag acggccacca gaacaatctg 2760

-207-

gacaactgtc cctacgtgcc caacgccaac caggctgacc atgacaagga tggcaaaggc 2820
gatgcctgtg accatgatga cgacaatgat ggcattcctg atgaccggga caactgcagg 2880
ctggtgcccc atcctgacca gaaggactct gatggtgatg gtcgaggtga tgcttgcaaa 2940
gatgattttg accaggacaa ggtgccagac attgatgaca tctgtcccg aaatgttgat 3000
atcagtgaga ctgatttccg ccgattccag atgattcctc tagatcccaa agggacatcc 3060
cagaatgacc ctaactgggt tgtacgccat cagggtaaag aactcgtcca gactgtcaac 3120
tgtgaccctg gacttgctgt aggttatgac gaatttaacg ccgtggactt cagtggcacc 3180
ttcttcatca acaccgagag ggatgacgac tatgccggct ttgtgtttgg ctaccagtcc 3240
agcagccgct tctatgttgt gatgtggaag caagtactc agtcctactg ggacaccaac 3300
cccacgaggg ctcaggggta ctctggactt tccgtgaagg ttgtaaactc caccacgggg 3360
cctggcgagc acctgcggaa tgccctgtgg cacacaggaa acacctctgg ccagggtgcg 3420
aactgtggc atgaccctcg tcacattggc tggaagatt tcaactgccta cagatggcat 3480
ctgagccaca ggccaaagac aggtttcatc agagtggtaa tgtatgaagg gaagaaaatc 3540
atggctgact caggacccat ctatgacaaa acctatgctg gtgggaggct aggcttggtc 3600
gtcttctctc aagaaatggg gttcttctcc gacctgaaat atgaatgcag agactcctaa 3660
tcatcaaact gttgatcaaa agactgatca taaaccaatg ctggtattgc accttctgga 3720
accatgggct tagaaaaccc ccaggatcgc gcctcgctgc ctgcctttgc tctctgcttg 3780
catgagtgtg gactcctaga acatgtgact tgcccaaga aaatgcaatt ttccaaatca 3840
gaccctgcat tcagcctctg actgagaaga atcttccaag gagacaaaca atgacttttg 3900
ttggcttttg caaaagcaaa agcatccaca tgctttggtt ggaagggtgcc tgtcccactc 3960
tgcttttgtc agagcagaat gcgactgtga ggccagctct gagcagtga ctccaaaatg 4020
tttccaggca tgtgagagaa gggaggactc actagaattg acaaacaaaa ccagccctga 4080
cctactccct ctggaatggg ggcgggtggg ggggccaaag cccaaagggg aggatgcata 4140
cccaagagat gattgtatga agaaaatatg gaggaactgt tacatttttg gtactaaatc 4200
attttcaggg gattgaaaga ctattgctgg atttcatgat gctgaccggg gttagctgat 4260
taaccacat aaataggcac ttaaatagga gcagggaagg aaggaaaaga ctggcttctg 4320

-208-

gacttcctcc cagatttcca ccccttaaca catcacctgt agtgaccaga acagggagtc 4380
 ggagttaaac cgacacaagg cagggccagc tgctgcagct tggttctatt gaaattgtca 4440
 gttgtattcc agatgtagct tctgcagatg tagcagcaaa ataagaatac ccaccatctc 4500
 agcgagcacc aggctgtctc ccaagggacg gcagccatgc ttgtattttt atgggtagaa 4560
 aggcacaaaa ttatcaacta agacattcct tctttctctt tttttcctga acatcatgga 4620
 gttttccagt tgtctctttt ggactgtagt ttttagtggt ttaaacaac actttacaat 4680
 gtaaactatt tattttttac ttattctggg ggatctgtct gaaagactat tcatggaaca 4740
 ggaagaagcg taaggactat ccatatcatc tttgctacaa gtcattatga ctgtaagatt 4800
 gtaaatacag attattttatt aactctgttc tacctggaat ctagtttcat atggaaagtg 4860
 tttgagagca ggtagttgag atcgatcagc aaatctttca caggaatggc acaaggaaac 4920
 cagcatagca agctgtctctt caccttgtgc ttagactgga tgatttgga ttcttttttc 4980
 cttttttttc ccaagtggaa ttacttggtt gtccatttgc aagtgttttt agtttgcaaa 5040
 gaaagccaag aggccattaa tactgtctta tcccatccct tgtgcctatt tccagggaga 5100
 tgaaaagcat ctacatttat tatttttgcc tttttccaaa agaaaaaaat gacaaagggtg 5160
 aaacttgtat acaaataatta cctcatttgt tgtgtgactg agtaaagaat tttgggatca 5220
 aacagaaaga gtttaagtgt ctaacaaact taaagctact gtagtaccta aaaaaaaaaa 5280
 aaaaaaaaaa 5289

<210> 63

<211> 2053

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 63

gaattccggc ggccgctgag agcccaccct ggcgagctct ccagccgca gcctccgaat 60
 ccacggcctc caccgcgc ctctccagcg ctctatcccg tcgctgcgcc cttgtcgccg 120
 gccccggcgc tgcatccgcg tccgcacagg ctcttgact gggcacaat agtccacca 180
 tggggctggc ctggggactc ggtgtcctgc tcctgttgca tgctgcggc tccaaccgca 240

-209-

ttccagagtc tgggggagac aacagtgtgt ttgacatctt tgaactcacc ggagctgccc 300
gcaacgggtac tgggcgccga ctggtgaagg gccctgaccc ttctagccca gctttccgca 360
tcgaggatgc caacctgac cccctgtgc ctgacaagaa gttccaagac ctagtggatg 420
ctgtgcgggc ggagaaaggt ttcctcctcc tggcctccct gaggcaaag aagaagacc 480
ggggtaccct gctggctgtg gagcggaag accactctgg ccaggtcttc agcgtgatct 540
ccaatggcaa ggccggcacc ctggacctga gcctgaccgt gcaggggaag cagcatgtgg 600
tgtcggtgga agaagcactc ctggcgactg gccagtggaa gagcatcacc ctgtttgtgc 660
aggaggacag ggcccagctg tacatcgact gtgagaagat ggagaatgcg gagctggatg 720
tccccatcca gagcatcttc accagggacc tggccagcat cgccaggctc cgcattgcca 780
aaggaggtgt caacgacaat ttccaggggg tctgcagaa tgtaaggttt gtctttggaa 840
ccacaccaga agacatctc aggaacaaag gctgctccag ctctaccagt gtctttgtca 900
cccttgacaa caacgtggtg aatgggtcca gccctgccat ccgcaccgac tacattggcc 960
acaagacaaa ggacctgcaa gccatctgtg gcatctcatg tgacgagctg tccagcatgg 1020
tcttgagct caggggtcta cgcaccatcg tgaccacgct gcaggacagt atccgcaaag 1080
tgaccgaaga gaacaaagag ctggccaacg agctgaggag gccccactc tgctaccaca 1140
acggagtga gtacaggact ggcgacgagt ggacggtgga cagctgcact gagtgtcgct 1200
gccagaactc agttaccatc tgcaaaaaag tgtcctgtcc catcatgccc tgctccaatg 1260
ccacagttcc gcatggagaa tgctgccac ggtgctggcc cagcgactct gcagacgacg 1320
gctggtcccc gtggtctgag tggacctctt gctctgtgac ctgtggcaat ggaatccagc 1380
agctggccgc tctgcgaca gcctcaacaa cagatgcgag ggctcctctg tgacagcgcg 1440
gacctgccac atccaggagt gtgacaagag atttaaacag gatggcggct ggagccactg 1500
gtccccatgg tcatcttgct ccgtaacatg tggagacggt gtgatcaciaa ggatccggct 1560
ctgcaactcc ccagcccc agatgaatgg gaagccatgt gagggcaaag cccgggagac 1620
caaagcctgc cagaaagact cctgccccat caatggaggc tggggacctt ggtcaccatg 1680
ggacatctgt tctgtcacct gtggaggagg ggtacagaaa cgtagccggc tctgcaaciaa 1740
ccccacaccc cagtttgag gcaaggactg cattggtgat gtgacagaaa accagatctg 1800

-210-

caacaagcag gactgtccca ttgacggatg cctgtccaat ccctgctttg ctggtgtcca 1860
gtgtaccagc taccctgatg gcagctggaa gtgtggtgcc tgtccccag gctatagtgg 1920
agatggagtc gagtgcaaag acgttgatga gtgcaaagaa gtcctgatg cctgcttcaa 1980
ccacaatgga gagcacaggt gtgagaacac agaccccgcc tacaactgcc tgccctgccc 2040
accgcccgga att 2053

<210> 64

<211> 4339

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 64

agccactgcc tggagtcagc cagcctcatc ggacttctgc aggcaatcgc gaagctgcta 60
tccagttctg ccacggtctc tcccggcgca ccggcagttc cagcgtcttc accggactca 120
gcgctccttg ccttcacttc acctttgcca cctctccggg ttactgagcc ccggtgcaca 180
caggctccgt gttgggcaca aaggctccac catggagctc ctgcggggac taggtgtcct 240
gttcctgttg catatgtgtg gaagcaaccg cattccagag tctgggggag ataacggtgt 300
gtttgacatc tttgaactca ttggaggtgc acgaaggggc cccggtcgcc gactggtgaa 360
gggccaagat ctatccagcc ccgccttccg cattgagaat gccaacctga tccccgctgt 420
gccggatgac aagttccaag acctactgga cgctgtgtgg gccgacaaag gcttcattct 480
cttggttcc ttgaggcaga tgaagaagac ccggggcaca ctctggctg tggaacggaa 540
agacaacact ggccagatct tcagtgtggt ctccaacggc aaagctggca ccctggacct 600
gagcctgagc ctgccaggga agcaacaagt ggtgtcagtg gaggaagctc tcctggccac 660
tggccagtgg aagagcatca cgctgtttgt tcaagaggac cgggctcaac tctacataga 720
ctgtgataag atggagagcg cggagctgga tgtaccatc cagagcatct tcaccaggga 780
tctggccagc gttgccaggc tccgagttgc aaagggagat gtcaatgaca attttcaggg 840
ggtgctgcag aatgtgaggt ttgtctttgg aaccaccca gaagacattc tcaggaacaa 900
aggctgctcc agctctacca acgtccttct tacccttgac aacaacgtgg tgaacggttc 960

-211-

cagccctgct atccgcacca actacatcgg ccacaaaaca aaggacctcc aagctatctg 1020
tggcctctcc tgtgatgaac tatccagcat ggtcctggaa ctgaagggcc tgcgcaccat 1080
cgtgaccact ctgcaggaca gcatccgaaa agtgacggaa gagaacagag agctggtcag 1140
tgagctgaag cggcctcccc tctgctttca caatggagtc cagtacaaga acaacgagga 1200
gtggactgta gacagttgca cagagtgtca ctgccagaac tcggttacca tctgcaaaaa 1260
ggtgtcctgt cccatcatgc cctgctccaa cgccacagtt cctgatggtg aatgctgccc 1320
acggtgctgg ccagcgact ctgctgacga tggtgtgtct ccctggtctg agtggacctc 1380
ctgctctgcc acatgtggca atggaattca gcaacgtggt cgttcctgtg acagcctcaa 1440
caacagatgc gagggtctt cggtagacac gaggacctgc cacattcagg agtgtgacaa 1500
aagatttaaa caggatggtg gctggagtca ctggtctcca tggctgtcct gttctgtgac 1560
ctgtggtgac ggtgtgatca caaggatccg tctctgcaac tccccagcc ccagatgaa 1620
cgggaagccc tgtgaagggtg aagcccggga gaccaaagcc tgcaagaaag acgcctgccc 1680
aattaatgga ggctggggtc cctggtcacc atgggacatc tgctctgtca cctgtggagg 1740
aggagtgcag agacgcagcc gactctgtaa caaccacaca cccagtttg gaggcaaaga 1800
ctgtgttggc gatgtgacag aaaatcaagt ttgcaacaag caggactgcc caattgatgg 1860
atgcctgtcc aatccctgct ttgctggtgc caagtgtact agctaccctg atggtagctg 1920
gaaatgtggt gcgtgtcctc ctggctacag tggaaatggc atccagtgc aagacgtcga 1980
tgagtgcaaa gaagtgcctg atgcttgctt caatcacaaac ggagaacatc ggtgcaagaa 2040
cacagatcct ggctacaact gcctgccctg cccaccacga ttcactggct cacagccctt 2100
cggccgaggt gtcgaacatg ccatggccaa caaacagggtg tgcaaaccgc gaaaccctg 2160
cacggacggg acgcatgact gcaacaagaa cgctaagtgc aactacctgg gtcactacag 2220
cgaccccatg taccgtgtg agtgcaagcc cggtatgca ggcaatggca tcactctgcg 2280
agaggacaca gacctggacg gctggcctaa tgaaaacctg gtgtgtgtgg ccaacgcaac 2340
ctaccactgc aaaaaggaca actgcccac ccttcccaac tcggggcagg aagactatga 2400
caaggacggg attggcgatg cctgcgatga tgacgatgac aacgacaaga tccctgatga 2460
cagggacaac tgtccattcc attacaaccc agcccagtat gactatgaca gagatgatgt 2520

-212-

gggagaccgc tgtgacaact gccctacaa ccacaaccct gaccaagcag acacagacaa 2580
aaacggggag ggcgatgcct gtgctgtgga catcgatgga gatggaatcc tcaatgaacg 2640
agacaactgc cagtacgttt acaacgtgga ccagaggac acggacatgg atgggggttg 2700
agatcagtgt gacaactgcc ccctggaaca caatccagac cagctggact ctgactcaga 2760
cctcataggg gacacttgtg acaacaatca ggacatcgat gaggatggcc atcagaacaa 2820
cctggacaac tgtccctatg tgcctaacgc caaccaggcc gaccatgata aagatggcaa 2880
aggagatgcc tgtgaccatg acgatgacaa tgacggcatc cctgatgaca gagacaactg 2940
caggctggtg cccaatcctg accagaagga ctctgatggt gatggccgag gtgacgcctg 3000
caaagacgac tttgaccatg acaatgtgcc agatattgat gacatctgtc ctgagaattt 3060
tgacatcagt gaaaccgatt tccgacgatt ccagatgatt cctctagatc ccaaaggaac 3120
ctcccaaat gaccctaact gggttgtccg ccatcagggc aaagaactcg tccagactgt 3180
aaactgtgac cctggacttg ctgtaggtta tgatgagttt aatgctgtgg acttcagcgg 3240
taccttcttc atcaacaccg agagagatga tgactacgct ggcttggtat tcggctacca 3300
gtccagcagc cgcttctacg ttgtgatgtg gaaacaagtc acccagtcct actgggacac 3360
caaccacaca agggctcagg gatactcagg cctgtctgta aaggttgtga actccaccac 3420
cgcccttggc gagcacctgc ggaatgcact gtggcacaca ggaaacaccc ctggccagg 3480
gcgcaccctg tggcatgacc ctgccacat cggttgaaa gatttcactg cgtacagatg 3540
gcgtctcagc cacaggccaa agaccggtta tatcagagtgt gtgatgtatg aaggaaagaa 3600
aatcatggct gactcgggac ccatctatga caaacctac gccggcggtg gactaggcct 3660
gttcgtcttc tctcaggaaa tgggtgttctt ctgacatg aaatacgagt gtcgagattc 3720
ctaactcatca gctgccaatc ataaccagcg ctggcaatgc accttctaaa aacaagggct 3780
agagaaaccc cccaccctg ccgggatcgc ctttcctcgc cttccttgcc tctcttcttg 3840
catagtgtgg acttgtaaag cctgagacct gcctcaagaa aatgcagttt tcgaaccag 3900
agtcagcact cggcctttaa cgaatgagaa tgcatcttcc aagaccatga agagttcctt 3960
gggtttgctt ttgggaaagc caaagcgctt atttacttcc cactaggaag gtgccgctc 4020
cactctgcct tactcacaga gccagaactt cttcgaggcc acctctgagc agcacacaca 4080

-213-

gaagcatttt caggcatgtc aaagaaagga aaaatgactc actagaactc accgccaaac 4140
aacctctgac ataggtcctg agatgtgggg aggcaggagc caaagctcta gggagggcat 4200
gtaccaaga gatgactgta tgaagaaaat gtggaggagc tgttcggtac taaatcattt 4260
tcaggggaca gacagacttg ctgcatttcc gcatgctgct ggtgagagct gattgaccca 4320
atcttcaca caggcactt 4339

<210> 65
<211> 186
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<400> 65
gcacagttaa tggaggctgg ggtccctggg caccatggga catctgctct gtcacctgtg 60
gaggaggagt gcagagacgc agccgactct gtaacaaccc cacaccccag tttggaggca 120
aagactgtgt tggcgatgtg acagaaaatc aagtttgcaa caagcaggac tgcccaattg 180
gtaagc 186

<210> 66
<211> 5774
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<400> 66
gtcactttgg ttgatagcag ccgctctggg agaggttagg acttcagctg atggacaagc 60
tggtaatgaa gaaatgggtc aaatagattt accaataaag agatatagag agtatgagct 120
ggtgactcca gtcagcacia atctagaagg acgctatctc tcccatactc tttctgagc 180
tcacaaaaag aggtcagcga gggacgtgtc ttccaaccct gagcagttgt tctttaacat 240
cacggcattt ggaaaagatt ttcattctgcg actaaagccc aacactcaac tagtagctcc 300
tggggctgtt gtggagtggc atgagacatc tctgggtgcct gggaatataa ccgatcccat 360
taacaacat caaccaggaa gtgctacgta tagaatccgg aaaacagagc ctttgcagac 420

-214-

taactgtgct tatgttggtg acatcgtgga cattccagga acctctgttg ccatcagcaa 480
ctgtgatggt ctggctggaa tgataaaaag tgataatgaa gagtatttca ttgaaccctt 540
ggaaagaggt aaacagatgg aggaagaaaa aggaaggatt catgttgtct acaagagatc 600
agctgtagaa caggctccca tagacatgtc caaagacttc cactacagag agtcggacct 660
ggaaggcctt gatgatctag gtactgttta tggcaacatc caccagcagc tgaatgaaac 720
aatgagacgc cgcagacacg cgggagaaaa cgattacaat atcgaggtag tgctgggagt 780
ggatgactct gtggtcctgt tccatggcaa agagcacgtc caaaactacc tcctgaccct 840
aatgaacatt gtgaatgaaa ttaccatga tgagtccctc ggagtgcata taaatgtggt 900
cctggtgctc atgataatgc tgggatatgc aaagtcctc agcctcatag aaaggggaaa 960
cccatccaga agcttgaga atgtgtgtcg ctgggctcc caacagcaaa gatctgatct 1020
caaccactct gaacaccatg accatgcaat ttttttaacc aggcaagact ttggacctgc 1080
tggaatgcaa ggatagtctc cagtcaccgg catgtgtcat ccagtgagaa gttgtaccct 1140
gaatcatgag gatgggtttt catctgcttt tgtagtagcc catgaaacgg gccatgtgtt 1200
gggaatggag catgatggac aaggcaacag gtgtggtgat gagactgcta tgggaagtgt 1260
catggctccc ttggtacaag cagcattcca tcgttaccac tgggtccgat gcagtgggtca 1320
agaactgaaa agatatatcc attcctatga ctgtctcctt gatgaccctt ttgatcatga 1380
ttggcctaaa ctcccagaac ttcctggaat caattattct atggatgagc aatgtcgttt 1440
tgattttggg gttggctata aaatgtgcac cgcgttccga accttgacc catgtaaaca 1500
gctgtggtgt agccatcctg ataatcccta cttttgtaag actaaaaagg gacctccact 1560
tgatgggact gaatgtgctg ctggaaaatg gtgctataag ggtcattgca tgtggaagaa 1620
tgctaatacag caaaaacaag atggcaattg ggggtcatgg actaaatttg gctcctgttc 1680
tcggacatgt ggaactggtg ttcgtttcag aacacgccag tgcaataatc ccatgcccac 1740
caatggtggt caggattgtc ctggtgttaa ttttgagtac cagctttgta acacagaaga 1800
atgccaaaaa cactttgagg acttcagagc acagcagtgt cagcagcgaa actcccactt 1860
tgaataccag aataccaaac accactggtt gccatatgaa catcctgacc ccaagaaaag 1920
atgccacctt tactgtcagt ccaaggagac tggagatgtt gcttacatga aacaactggt 1980

-215-

gcatgatgga acgcactgtt cttacaaaga tccatatagc atatgtgtgc gaggagagtg 2040
tgtgaaagtg ggctgtgata aagaaattgg ttctaataag gttgaggata agtgtggtgt 2100
ctgtggagga gataattccc actgccgaac cgtgaagggg acatttacca gaactcccag 2160
gaagcttggg taccttaaga tgtttgatat accccctggg gctagacatg tgttaatcca 2220
agaagacgag gcttctctc atattcttgc tattaagaac caggctacag gccattatat 2280
tttaaatggc aaaggggagg aagccaagtc gcggaccttc atagatcttg gtgtggagtg 2340
ggattataac attgaagatg acattgaaag tcttcacacc gatggacctt tacatgatcc 2400
tgttattgtt ttgattatac ctcaagaaaa tgatacccg cctagcctga catataagta 2460
catcatccat gaagactctg tacctacaat caacagcaac aatgtcatcc aggaagaatt 2520
agatactttt gagtgggctt tgaagagctg gtctcaggtt tccaaccct gtggtggagg 2580
tttcagtag actaaatatg gatgccgtag gaaaagtgat aataaaatgg tccatcgag 2640
cttctgtgag gccaacaaaa agccgaaacc tattagacga atgtgcaata ttcaagagtg 2700
tacacatcca ctctgggtag cagaagaatg ggaacactgc accaaaacct gtggaagttc 2760
tggctatcag cttcgactg tacgtgcct tcagccactc cttgatggca ccaaccgctc 2820
tgtgcacagc aaatactgca tgggtgaccg tcccagagc cgccggccct gtaacagagt 2880
gccctgccct gcacagtga aaacaggacc ctggagtga tgttcagtga cctgcggtga 2940
aggaacggag gtgaggcagg tcctctgcag ggctggggac cactgtgatg gtgaaaagcc 3000
tgagtcggtc agagcctgtc aactgcctcc ttgtaatgat gaaccatgtt tgggagacaa 3060
gtccatattc tgtcaaatgg aagtgttggc acgatactgc tccataccag gttataacaa 3120
gttatgttgt gagtcttgc gcaagcgag tagcaccctg ccaccaccat accttctaga 3180
agctgtgaa actcatgat atgtcatctc taaccctagt gacctccta gatctctagt 3240
gatgcctaca tctttggtc cttatcttc agagaccct gcaaagaaga tgtctttgag 3300
tagcatctct tcagtgggag gtccaaatgc atatgtgtc ttcaggccaa acagtaaacc 3360
tgatggtgct aatttacgcc agaggagtgc tcagcaagca ggaagtaaga ctgtgagact 3420
ggtcaccgta ccactctccc caccaccaa gagggccac ctcagttcag cttcacaat 3480
ggctgtgct tccttctttg cagccagtga ttcaataggt gcttcttctc aggcaagaac 3540

-216-

ctcaaagaaa gatggaaaga tcattgacaa cagacgtccg acaagatcat ccaccttaga 3600
aagatgagaa agtgaaccaa aaaggctaga aaccagagga aaacctggac aacctctctc 3660
ttcccatggt gcatatgctt gtttaaagtg gaaatctcta tagatcgtca gctcatttta 3720
tctgtaattg gaagaacaga aagtgcctggc tcactttcta gttgctttca tctcctttt 3780
gttctgcatt gactcattta ccagaattca ttggaagaaa tcaccaaaga ttattacaaa 3840
agaaaaatat gttgctaaga ttgtgttggc cgctctctga agcagaaaag ggactggaac 3900
caattgtgca tatcagctga ctttttgctt gttttagaaa agttacagta aaaattaaaa 3960
agagatacca atgggtttaca ctttaacaag aaattttgga tatggaacaa agaattctta 4020
gacttgattt cctatttatc tatattagaa atattgtatg agcaaatttg cagctgttgt 4080
gtaaatactg tatattgcaa aaatcagtat tattttaaga gatgtgttct caaatgattg 4140
tttactatat tacatttctg gatgttctag gtgcctgtcg ttgagtattg ccttgtttga 4200
cattctatag gttaattttc aaagcagagt attacaaaag agaagttaga attacagcta 4260
ctgacaatat aaagggtttt gttgaatcaa caatgtgata cgtaaattat agaaaaagaa 4320
aagaaacaca aaagctatag atatacagat atcagcttac ctattgcctt ctatacttat 4380
aatttaaaag attggtgtct tagtacactt gtggtcacag ggatcaacga atagtaaata 4440
atgaactcgt gcaagacaaa actgaaaccc tctttccagg acctcagtag gcaccgttga 4500
ggtgtccttt gtttttgctg gtgtgtgttc ttttttaatt ttgcgattgt tgacagatac 4560
aaacagttat actcaatgta ctgtaataat cgcaaaggaa aaagttttgg gataacttat 4620
ttgtatgttg gtagctgaga aaaatatcat cagtctagaa ttgatatttg agtatagtag 4680
agctttgggg ctttgaaggc aggttcaaga aagcatatgt cgatggttga gatatttatt 4740
ttccatatgg ttcattgtca aatgttcaca accacaatgc atctgactgc aataatgtgc 4800
taataattta tgtcagtagt caccttgctc acagcaaagc cagaaatgct ctctccaggg 4860
agtagatgta aagtacttgt acatagaatt cagaactgaa gatatttatt aaaagttgat 4920
ttttttttct tgatagtatt tttatgtact aaatatttac actaatatca attacatatt 4980
ttggtaaact agagagacat aattagagat gcatgctttg ttctgtgcat agagaccttt 5040
aagcaaacta ctacagccaa ctcaaaagct aaaactgaac aaatttgatg ttatgcaaac 5100

-217-

atcttgcatt tttagtagtt gatattaagt tgatgacttg tttcccttca aggaaacatt 5160
 aaattgtatg gactcagcta gctgttcaat gaaattgtga attagaaaca tttttaaaag 5220
 tttttgaaag agataagtgc atcatgaatt acatgtacat gagaggagat agtgatatca 5280
 gcataatgat tttgaggtca gtacctgagc tgtctaaaaa tatattatac aaactaaaat 5340
 gtagatgaat taacctctca aagcacagaa tgtgcaagaa cttttgcatt ttaatcgttg 5400
 taaactaaca gcttaaacta ttgactctat acctctaaag aattgctgct actttgtgca 5460
 agaactttga aggtcaaatt aggcaaattc cagatagtaa aacaatccct aagccttaag 5520
 tttttttttt ttctaaaaa ttcccataga ataaaattct ctctagttaa cttgtgtgtg 5580
 catacatctc atccacaggg gaagataaag atggtcacac aaacagtttc cataaagatg 5640
 tacatattca ttataacttct gacctttggg ctttcttttc tactaagcta aaaattcctt 5700
 tttatcaaag tgtacactac tgatgctggt tgttgactg agagcacgta ccaataaaaa 5760
 tgtaacaaa atat 5774

<210> 67

<211> 5535

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 67

ggactttaga agccgttgct gccctctctg tcacctgaag cggggccctc tcccatccca 60
 cccttgcccc gctccctgc cccacccggg ccggccctgc ccgcccggc accctggcat 120
 gtcaagacct ggtccgcgcc tgccctgccc gcccgcgga ccccgccggc ccgcccagct 180
 aggatgaggg gccaggccgc cggcccggc cccgtctgga tctcgcccc gctgctactg 240
 ctgctgctgc tgctgggacg ccgcccggc gggcccggc gagcagacgc gggggccggg 300
 cccgagccgt gcgccacgt ggtgcaggga aagtcttcg gctacttctc cggggccgcc 360
 gtgttcccgg ccaacgcctc gcgtgctcc tggacgtac gcaaccgga ccccgccgc 420
 tacactctct acatgaaggg ggccaaggcg cccgtgccct gcagcggccc cggcccgtg 480
 cgcacctacc agttcgactc cttcctcgag tccacgcga cctacctggg cgtggagagc 540

-218-

ttcgacgagg tgctgcggct ctgcgacccc tccgcacccc tggccttcct gcaggccagc 600
aagcagttcc tgcagatgcg gcgccagcag ccgccccagc acgacgggct ccggccccgg 660
gccggggccgc cgggccccac cgacgacttc tccgtggagt acctggtggt ggggaaccgc 720
aaccacagcc gtgcgcctg ccagatgctg tgccgctggc tggacgcgtg tctggccggt 780
agtcgcagct cgcaccctg cgggatcatg cagaccccct gcgcctgcct gggcggcgag 840
gcgggcgggc ctgccgcggg acccctggcc cccgcggggg atgtctgctt gagagatgcg 900
gtggctggtg gccctgaaaa ctgcctcacc agcctgaccc aggaccgggg cgggcacggc 960
gccacaggcg gctggaagct gtggtccctg tggggcgaat gcacgcggga ctgcggggga 1020
ggcctccaga cgcggaacgc cacctgcctg cccgcgcggg gcgtggaggg cggcggctgc 1080
gagggggtgc tggaggaggg tcgccagtgc aaccgcgagg cctgcggccc cgctgggcgc 1140
accagctccc ggagccagtc cctgcggtcc acagatgccc ggcggcgcga ggagctgggg 1200
gacgagctgc agcagtttg gttcccagcc cccagaccg gtgaccagc agccgaggag 1260
tgggtccccgt ggagcgtgtg ctocagcacc tgcggcgagg gctggcagac ccgcacgcgc 1320
ttctgcgtgt cctcctccta cagcacgcag tgcagcggac ccctgcgcga gcagcggctg 1380
tgcaacaact ctgccgtgtg cccagtgcac ggtgcctggg atgagtggtc gccctggagc 1440
ctctgctcca gcacctgtgg ccgtggcttt cgggatcgca cgcgcacctg caggcccccc 1500
cagtttgggg gcaaccctg tgagggccct gagaagcaaa ccaagttctg caacattgcc 1560
ctgtgcctg gccgggcagt ggatggaaac tggaatgagt ggtcgagctg gagcgcctgc 1620
tccgccagct gctcccaggg ccgacagcag cgcacgcgtg aatgcaacgg gccttcctac 1680
gggggtgcgg agtgccaggg ccaactgggtg gagaccgag actgcttcct gcagcagtgc 1740
ccagtggatg gcaagtggca ggccctgggcg tcatggggca gttgcagcgt cacgtgtggg 1800
gctggcagcc agcgacggga gcgtgtctgc tctgggccct tcttcggggg agcagcctgc 1860
cagggcccccc aggatgagta ccggcagtgc ggcaccagc ggtgtcccga gcccattgag 1920
atctgtgatg aggacaactt tgggtgctgtg atctggaagg agacccagc gggagagggtg 1980
gctgctgtcc ggtgtccccg caacgccaca ggactcatcc tgcgacgggtg tgagctggac 2040
gaggaaggca tcgcctactg ggagcccccc acctacatcc gctgtgtttc cattgactac 2100

-219-

agaacatcc agatgatgac ccgggagcac ctggccaagg ctcagcgagg gctgcctggg 2160
gaggggggtct cggagggtcat ccagacactg gtggagatct ctcaggacgg gaccagctac 2220
agtgggggacc tgctgtccac catcgatgtc ctgaggaaca tgacagagat tttccggaga 2280
gcgtactaca gccccacccc tggggacgta cagaactttg tccagatcct tagcaacctg 2340
ttggcagagg agaatcggga caagtgggag gagggccagc tggcggggccc caacgccaag 2400
gagctgttcc ggctggtgga ggactttgtg gacgtcatcg gcttccgcat gaaggacctg 2460
agggatgcat accagggtgac agacaacctg gttctcagca tccataagct cccagccagc 2520
ggagccactg acatcagctt ccccatgaag ggctggcggg ccacgggtga ctggggccaag 2580
gtgccagagg acagggtcac tgtgtccaag agtgtcttct ccacggggct gacagaggcc 2640
gatgaagcat ccgtgtttgt ggtgggcacc gtgctctaca ggaacctggg cagcttcctg 2700
gccctgcaga ggaacacgac cgtcctgaat tctaaggtga tctccgtgac tgtgaaacct 2760
ccgcctcgct ccctgcgcac acccttgagg atcgagtttg cccacatgta taatggcacc 2820
accaaccaga cctgtatcct gtgggatgag acggatgtac cctcctcctc cgcccccccg 2880
cagctcgggc cctggtcgtg gcgcggtgc cgcacggtgc cctcgacgc cctcgggacg 2940
cgctgcctct gtgaccggct ctccaccttc gccatcttag cccagctcag cgccgacgcg 3000
aacatggaga aggcgactct gccgtcgggtg acgctcatcg tgggctgtgg cgtgtcctct 3060
ctcaccctgc tcatgtcgtt catcatctac gtgtccgtgt ggaggtacat tcgctcagag 3120
cgttctgtca tcctcatcaa cttctgcctg tccatcatct cctccaatgc cctcatcctc 3180
atcgggcaga cccagacccg caacaagggtg atgtgcacgc tgggtggccgc cttcctgcac 3240
ttcttcttcc tgtcctcctt ctgctgggtg ctcaccgagg cctggcagtc ctacatggcc 3300
gtgacggggc acctccggaa ccgcctcatc cgcaagcgct tcctctgcct gggctggggg 3360
ctccctgcac tggttgtggc catttctgtg ggattcacca aggccaaagg gtacagcacc 3420
atgaactact gctggctctc cctggagggg ggactgctct atgccttcgt gggacctgcc 3480
gctgccgttg tgctggtgaa catggtcatt gggatcctgg tgttcaaaa gctcgtgtcc 3540
aaagacggca tcacggacaa gaagctgaag gagcgggcag gggcctccct gtggagctcc 3600
tgcgtggtgc tgccgtgct gccgctgacc tggatgtcgg ctgtgctcgc cgtcaccgac 3660

-220-

cgccgctccg ccctcttcca gatcctcttc gctgtcttcg actcgttga gggcttcgtc 3720
atcgtcatgg tgcactgtat cctccgtaga gaggtccagg acgctgtgaa atgccgtgtg 3780
gttgaccggc aggaggaggg caacggggac tcagggggct ccttccagaa cggccacgcc 3840
cagctcatga ccgacttcga gaaggacgtg gatctggcct gtagatcagt gctgaacaag 3900
gacatcgcgg cctgccgcac tgccaccatc acgggcacac tgaagcggcc gtctctgccc 3960
gaggaggaga agctgaagct ggcccatgcc aaggggcccgc ccaccaattt caacagcctg 4020
ccggccaacg tgtccaagct gcacctgcac ggctcacccc gctatcccgg cggggcccctg 4080
cccgacttcc ccaaccactc actgacctc aagagggaca aggcgcccac gtcctccttc 4140
gtcggtgacg gggacatctt caagaagctg gactcggagc tgagccgggc ccaggagaag 4200
gctctggaca cgagctacgt gatcctgcc acggccacgg ccacgctgcg gcccagccc 4260
aaggaggagc ccaagtacag catccacatt gaccagatgc cgcagaccgc cctcatccac 4320
ctcagcacgg cccccgaggc cagcctcccc gccgcagcc cgcctcccg ccagccccc 4380
agcggcgggc cccccgaggc acccctgcc cagcccccac cgcctccgc cccaccgcca 4440
ccacctcccc agcagcccct gccccaccg cccaatctgg agccggcacc cccagcctg 4500
ggggatcccg gggagcctgc cgccatccg ggaccagca cggggcccag caccaagaac 4560
gagaatgtcg ccacctgtc tgtgagctc ctggagcggc ggaagtcgc gtatgcagaa 4620
ctggactttg agaagatcat gcacaccgcg aagcggcacc aagacatgtt ccaggacctg 4680
aaccggaagc tgcagcacgc agcggagaag gacaaggagg tgctggggcc ggacagcaag 4740
ccggaaaagc agcagacgcc caacaagagg ccctgggaga gcctccgga agcccacggg 4800
acgcccacgt gggatgaaga ggagctggag ccgctgcagc cgtgccgct ggagcttcgc 4860
agcgtggagt gggagaggtc gggcgccacg atcccgctgg tgggcccagga catcatcgac 4920
ctccagaccg aggtctgagc ggggtgggcg cgccacgca ctgggcccag gaggaggat 4980
gctgctccgc ccgctcctgc cgcagacggg cacagacag ctcgcgggca gcgggcccag 5040
cccgcacccc ggctcaggg cgctcagacg gcggccaggc acagggcccg cagtgtctgg 5100
accagagcca gatgcaggac aggagggcgg ccggccagcg ggcacagggc accagaggcc 5160
gaaggtgcct cagactccgc cctcctcggg ccgaggccca gcgggcagat gggcggacgg 5220

-221-

ctgtggaccg tggacaggcc cagcgcggcc agcgtcccag ggtaccgcc tgagctcctg 5280
ctgcggagga gctgcctgct tggcccggcc ggcctggcac cgttttttaa acaccccat 5340
ccctcgggaa gcagccagct cccacacct tccagggcc taggcccctc ctagaccag 5400
gtggagggca cagccctccg accctcatgg cccccagggg caggactgag tcccctccag 5460
gaagaagcag gggggaatct attttttctc tcottttctt ttcttcaata aaaagaatta 5520
aaaacccaaa aaaaa 5535

<210> 68
<211> 398
<212> DNA
<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 68
cggggcaacc cgctggagtg gacgggccag gtgacggtgc gcaagaagcg caagccctac 60
tccaagttcc agacgctcga gctcgagaag gagttcctct tcaacgcgta cgtcagcaag 120
cagaagcgtt gggagctggc gcgcaacctc aacctcaccg agcgccaggt caagatctgg 180
ttccagaacc ggcgcatgaa gaacaagaag aacagccagc gccaggcggc cagcagcagc 240
agcagcaaca gcagcagcag cagcagcagc aacagcagca agcggccgcc ggcggggcgt 300
cggccgccgc caacggccac cagggccacc aagcgcacca ccacgcgcc cccaacggcg 360
ccgtcgagc cctcaagcac caccagtgc ccgtagcg 398

<210> 69
<211> 8670
<212> DNA
<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 69
cccgggtgcg gtgtcgtgtg tggggctggg cgccatgttc ctggacatgc tgagggccaa 60
gcgcgacacg gcgcccagc gccgccagct ggacgaccg atgatggggg cggaccggg 120
ggacatagcg gccaaagtga gggcaggggt ttgcgtgcgt gcttgattgt gcgtgtgcgt 180

-222-

gcgtgcgtgc gtgcgtgcgg tgttgcgtgt gtatttgaac tgtgttttgt gtatgtactt 240
aggggtaaga gtgcatacac atgcatgcga ccggtggcct taaaaatcaa caacacgtac 300
gcctgcatgt atccaggtgg cagcgtggcg acgagcacgt ggcttcgagg gccagggcac 360
ggcgggcccc agcggcagcg ccgccagtgg cagcggcgcc agcggctcgg caccgcaggc 420
gcgctcgcgc cgacctcagc caccgcggcc gcgctcacct tcacgcgggt gaaccccggc 480
gaggagccgc ccgtgtacgc gtgcgagcaa acaggtgcgt aagcgacgtg tgggcagcgc 540
gaagaggcgt gggggcgaga gagcaaagg actagggaaa cgcacagcca aatacggtat 600
gcgggcaacg aggcgatggc cctggaaatc gcagggccct tttgaaatcg tgtaaggcgc 660
aattgctggg cgactaccgt agtctactga tgcattgcac tacttgtatt actgtatcct 720
actgcagtag tgccgttgcc agccgcgctg ctgccctttg gctcccttcc caatccaaat 780
ggcccatgcc tcgcgcactc cgagcaccca gagcacccag aagccgttgc gtgcgctccg 840
ccgcgcacct ctccccgcc ttcaacttctt aattaatcgt gaatgtaatc ccccccccc 900
ccgcttcctc aggctgggtg cacgtgtgcg cgacgcctgc acggagggtg tggtggtatg 960
ccgcagcgaa ctgctggtgt gcccggtgag tcgacgagga ggagggtgcaa gggggatacc 1020
agcgcgtgtt tctcagggcc tgtgtgggac accgaaacgt ggtaaaagag acccgcccg 1080
gaactgtgta tgtggagtag cgtggcgtgt gcggccggac cgacaaggca gcttgtggac 1140
tgccccacgt tgcagagtca gctgacaacg acacgtgcgc cttcctgtca ttgccgtgc 1200
gcacgcacgt cctccgcact cccaacaaat tgacagcgac acgtgcgcct tcctataagc 1260
ctatgcccgc acacgctccc gcgccctcag gtgtcggggc agaccacaga ccggttggtc 1320
cacgagtgcg aggaggatga ggcgggcggc tgcggcggcg ccggcggggc gccgcggcga 1380
ggaggacggc ctgggactgg gcatcacagg tgggtggcag gctggcaggg actcacgcat 1440
gggccttgta cgtgactgcg gttctgcatg gctagtggct cagcgctgc gcacgttcac 1500
gtacggcttg tgggcatgca gtgccttgac gtgaggctgc gctgccttgc tgctgccgcc 1560
ttgccccgt cctgcacac actgcagccg gcttcggggc ctacttcacc gcgggctacg 1620
agtgcgagaa cgcgcagcag ctcaacaggc tgctggggta caaggcgtg tgagagcgcg 1680
ccgcaggggg agtgtgttca tattgtggtt gtttggggcg tgggcgcggg ctgcatgtgc 1740

-223-

gtattgcacg cgtacagcat tggtagctgg tcaggtgtaa gcggccggca gtgcgcgcg 1800
aggcgctgca gcgagttgtg gggcatgcgt catgcgcaga cggcccctgg acgacaaggc 1860
gttgagttgg cgtttggagg tgtgggacga cgtggggttt gtgccgtcaa agcacagaac 1920
agaaggcgtg accgtttttac gagctcgtat gatgtagcat ggattgaata atgacatgtg 1980
atTTTTgtta caagcgacga atgcgtgggg ttttgatgg caggggtttc agtcgccccg 2040
ttgcgcacgc acacgtgacc aaatttatgc tcaacgacgt gaccattgct ttatacatac 2100
ttgtgtatcg gttggcactt ataacaattg gctcgtcaaa ttgacgcgag gctgcacttc 2160
gatcctgaaa gcccagttc aacaagtcgg atagccaaat ggcccgcgtc gctctccagc 2220
atcaaggggc ctctaagtgc ctgcggcaa cccagcgcaa gtgtgctcgc gttgcggtga 2280
gctggactcg tgcacttgtc gacgccgtcg gcaccgcaat cgaaagacgc gtgcgtcgag 2340
caattgtgga agccgctgac gaattgtccg catgtgacat tgcaggctcg cgtccccgct 2400
cgtctcagcg tcatggccca ggtgcggacg ttgggactgc acttgacga atgtgatggg 2460
gccgcaccga gtctgcgcgg acgtctcgtc gacgtttcgc gttgaatgca tctcgcaata 2520
ggcagctgct gcgcctgctg acaacactaa gaagctgtgg ggcggtcgtc tcacgggcaa 2580
gacggacccg ctcatggaga agttcaacga gtcgctgccc tttgacaagc gcctgtgggc 2640
tgaggacatc aaggtgcggc acagggaggg gggcgagtgg tggggtgggg ctggggggga 2700
cgcggtttt gtggccaggg cagggaggga agacgtgcgg ggctaggcaa gaggctgcga 2760
gggccaggg taacaccaga ccgtgccgtg tcgctgccc ggcttgctgc ccaccttgcc 2820
cgcccatccc caccgccctc cccaccagca atgacacgta cacattcaca cactcccca 2880
caccacata cccacacacc caccgattcc ccaacagggc agccaggcgt acgccaaggc 2940
tcttgccaag gccggcattc tggcacatga cgaggccgtg accattgtgg aggggctggc 3000
caaggtgcgc acaccggca gcagggcggg tgggtgggtg ggtggggtgg gggggcagag 3060
agaggcgcg gctgagaggg ggctgagagg ggggtcagcg aggcgcaggc tcagggggag 3120
gcgtctgagg ggggctgaga tgggtgggtg ggagctgcgg gtgctggggc tgctgcggtg 3180
gcgggcgggc gggggggcgg gcgacgtgta cgtgagtagc cgctgaccgg gcgctgggcc 3240
tttgcgcacg ccacagccca catgacaccg ccgcaaggcc cgccgcgcc caccacgtt 3300

-224-

cacacactcc ccacaccac gcgtgcgcgc gcctccttcc cctcaataca cgcgcctcct 3360
tcccctggcc cccgcctgct ccccccaccc ggccgccccg cctgcaggtg gctgaggagt 3420
ggaaggcggg tgcctttgtg atcaaggcgg gtgacgagga catccacacg gccaacgagc 3480
ggcgcctcac ggagctggtg ggggcgggtg ggggcaagct gcacaccggc cgctcgcgca 3540
acgaccaggt gagggtgggt ggggtgggggt ggggtgggtg ggtgggtggg tgggtgggtg 3600
ggtgggtggg tgggtgggtg ggtgggtggg ggtttgagat accggtacca ggccaaacta 3660
aaccgaaccc aaggggggtg cgtaggggcg tgggaggggg ggagtgcgga agccgggagg 3720
caggagtaag ggcgggagga gggggccgga ggagaagcag ggacgaagtc gatgacaggc 3780
gcagtcggtg ggcggcgggtg cgggtgtgcc gttgtgcagt ggctgtggag gccatgtgca 3840
gggcggcggc ggggcccggc cgggggtggg agacttgtcc agaccccggt gccctcttcc 3900
agcccccgtcc gccactgccg ccaccaccac cgcgcgccgc gtagccacca cccctcacgt 3960
cgaggcactt cacagatgcg aagcaaccac accgttctcc acatgaacag ctaccctccc 4020
aaaccaact ttccttccc gccttaccta accatgaccc gctaccccc cccctttat 4080
ttcttaacta accatgaatg ccccccccg gctgtacctg gctacgactt cacttcgtaa 4140
acttaatgtg tgtaaccccc cttacacaca cacacacacc cctccccgcc cctccaaagg 4200
ttgccaccga ctaccggctg tggctggtg gtcaggtgga ggtgatgcgg tccgaggtgg 4260
gcgagctgat gcgcgtggcg gcggaccgct ccgaggcaga ggtggaggtg ctcatgccgg 4320
gtgagggggc agggaggggg ggagggggag ggggaggtgc tcatgccggg gagggtaggg 4380
aggggagggg cagaggaggg agggggagga gggggcggct gagtgcggga gaggcaggga 4440
tgagggcgat agaaagttgc gtattgtcgg taaactcaaa ggactagacg aagagaacaa 4500
acctaaacaa gggagctgga gcgaggccaa atctgaacgt gacatcgccc gcctcctccc 4560
gctgcctgct ccccccctc ctccccatc tcgccccccc cccacacac acacaggctt 4620
cacgcacctt cagaatgcca tgactgtgcg ctggagccac tggctgatga gccacgccgc 4680
ggcctggcag cgcgacgaca tgcggctgcg ggacctgctg ccgcgggtgg ccacactgcc 4740
gctgggctcg ggtgggtgag ggaggggagg ggaggggagg gggggagggg gagggagagg 4800
aggggagaag ggggggggag acgaggaggg tggaagggtg ggggcggggc ggtggaggct 4860

-225-

agaggggtggg gctgggtggg tggacggagt gcactggtag aggagggata gggtagattg 4920
agacgggagg agggatgcag gggcgaaggt ggggaggagg ggaggggagg aggcgtggag 4980
ctggagtggg ccgacgagtg tgcggacggg gcaggcgga acggggatta aacggcgggg 5040
ggccggggcg tgtgcacgac aggggcttgc gcgctctgca ttgtgggggc acacagggac 5100
aggagcacga cgtgggacac gcatagatac gccgcattga caacacacac acacacacac 5160
acacacacac acacacacac acacacacaa acacaaacac acacaaacac aaacacacac 5220
acgccccccc ccctacacac acgccccctc cccaggcgcc ctggccggca acccctttct 5280
gggtggaccgc cagttcatcg ccaaggagtt gggtttcggc ggcggcgtgt gcccactc 5340
catggacgcg gtgaggggag gaggaggggg aggagggcgg gggggggcag gaggggggag 5400
gaggaggggg ggaggggggt aactttgaag cgtaaggaaa cagtcgggag gaggggggga 5460
aggagggggc ctggaggagg gggggaggag gaggggtggc ggagggggct gggggaggag 5520
gagggggagg attgggaggg ggctggggga ggggtgccgc agctggggga ggtggggagg 5580
gaggggggtg ctgctggtgt aaagggcctg taggcactga gagcactgtg gggagccggg 5640
gtactgcctg gggccccgcg ctgcagaggt gtcgcgcagt gtggcggcgc atccccgca 5700
tccccacacg cgggccgctg ccgctgcccc ccacaccctt gccactttgt gtgctttcct 5760
aggatataca cacacacaca cacacacaca cacacacaca cacacacaaa cacaacaca 5820
cacgggcgcg ggctttcgtt tcgtttttta acacaaacac aactcccc tgtgctcctc 5880
aacacactcc atctttctca cacaacaca cacgcacaca cacatgcgca ggtgtctgac 5940
cgcgactttg tgatcgagac ggtgtttgcg gccagcctgc tgtgcgtgca cctgtcgcgc 6000
tgggcggagg acctcatcat ctacagctcc gggcccttcg gctacgtgca gtgcagcgac 6060
gcctacgcca cgggtcctc gctcatgccg cagaagaaga acccgacgc cctggagctc 6120
atcaggtgcg ggaggatgg ggtgggggtg ggggggttac attcatggtt agttaagaag 6180
tgaaggcgta ggggggtgat ggggtgggtt acattcatga acatttaaga agtgaaggcg 6240
tagccaggaa cagtagtaga gcagacgcgt tgtagtgtgt gggtttgggt gggagggatg 6300
gttgggtaaa gcggtacagg atgtactgag gactgcagac cgaaggagcg ggggaggggg 6360
agcaggcagg cggggcgagg ggcgtggggg cgggggttac tggcaccgtg ccgggtaagc 6420

-226-

aacacgtgac acggagatgc accacacaaa gagggacgtg gggagtggca ggcggggggcc 6480
agggctgaga ggcgcgtgtg gaggggtgcg ggggtggcg gggggctgtt tcatgatacc 6540
gctgcctcca cctcctccac cgcctcctgc cacctccacc tccccactg cccctccccg 6600
cctcctcctg ctgcaggggc aagggcggtc gtgtgcaggg caacctgatg ggcgtcatgg 6660
cgggtgctcaa gggcacgccc accacatata acaaggactt ccaggcgaga gagcgagagc 6720
gagggagggga gggagagcga gggagagggga gggagagggga gggagagggga gacagagggga 6780
cagggacagg gacagggaca gggacagggga cagggacagg ggcaggggca ggggcagggg 6840
caggggcagg ggcaggggag gcccccggg ggcggcgggc cggggcatg aggtcagaca 6900
taggggcgct gcactgaggc cgcgaggcgg gcgggaggca gggggcgggg ggcggggggc 6960
gggagcggac atgcgccga aacacagacg ggttgagaaa gcacaacgac tggaacgcag 7020
tgggcttact gacaattcat cattgtgcgc atatgtgtgt atgtgtatgt gtgtgtttgt 7080
ttgtgcagga gtgttgggag ctgctgtttg acacggtgga cacggtgcac gacgtggtgc 7140
gcatcgccac cggcgtgctg tccaccctgc ggatcaagcc cgaccgcatg aaggccggtg 7200
agcgtagccg agcagggctg gagcagcagc cgggcagcag tagcagcagg gcaggggagc 7260
agcgggagcg ggagcagcag gaggggtggt tgggaagcgg tgggggtagg gtgggagcgg 7320
aggaagggaa ggaggagcag gagcaggagg aagaggagga ggaaggcgcg tggggggtgg 7380
ggggtcgtgt ccttggccgc atgggcggag gcggggaggc ggggaggagg cggggaagca 7440
gagcctgcac ccacgtccg cgggtcccta ccgtcttgcg cctaaccocg tgcgcctagc 7500
ctcttgcgcc caccocctta gtgcatcctg taccctctt tccaaacatc cttgcaactc 7560
cctgacctcc tcgcaaacc tccccgcc ccaggcctgt ccgccgacat gctcgccacg 7620
gacttgccg agtacctgt gcgcaaggc gtgccgttcc gggagacaca ccaccacagg 7680
tgcggccggg cgggagggcg tgagggcgtg ggtggggcat gcccggggtt gtgagagcta 7740
tcgaacgttg tgccgcgcct gtttcacaat gtccggccac agggtatgca gtttcctctc 7800
catatgtata acaaactgac caccaatcat gcacgtcac acgtctccc acacacagc 7860
gcaccacgcc accacagcgg cgcgcctgt aagatggccg aggaccgcgg ctgcacgtg 7920
ttcgacctca ccgtggacga cctcaagacc atccaccgc tcttcaccga cgacgtggcg 7980

-227-

gcggtgagcg gcggcgcgga gcagcagcag cagcagcagc agcagcagca gcagcagcag 8040
tagcctgggg gggagcgtgt gggaggaacg gcgggggagg ggaggcgggg ggtgtcgttt 8100
gcagccgagc gcacgtggtg ctttgcccca ttccatgcca gcagggtgac acacctgacc 8160
atgctggtgt gctgctaggt gggtcacacc tacgtgtgaa tttgtgctgg cgtgcgcaca 8220
ccttactgtg gccatgtgaa cggcatcctc atgtcctcgt gattgcgccc ggcacattgc 8280
ccacaacccc gcaccaccca gctcctcaat ccagtgaag gaaaggaaat gcacgcccgc 8340
cgcaccaaca acacgacgca tgtgtttgcc acgtgcgcgc acacacgcgc aggtgtggga 8400
cttcaaccgc agcgccgaga tgcgcgacac ggaggcgggc accagcaagc gtcggtgct 8460
ggagcaggtg cagaagatgc gcacctacct ggcgcgagg ggacagcact gagcggtcg 8520
ggggaggggg ggcggtgtg tatgtgtgtg tgtgtgctg tgtaagtctc ggtggagggg 8580
tggtcctcta tatggcgcg ggccacagg gggacgggtg tgacagagtt acggccggag 8640
ccagcgaggt cccgggatgg attaaggatc 8670

<210> 70

<211> 745

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 70

atgagatggc gacgcgcccc gcgcgcctcc gggcgctccc gccccgggc ccagcgcccc 60
ggctccgccc cccgctcgtc gccgcgctg ccgctgctgc cactactgct gctgctggg 120
accgcggccc tggcgccggg ggcgcgggcc ggcaacgagg cggctcccgc gggggcctcg 180
gtgtgctact cgtccccgcc cagcgtggga tcggtgcagg agctagctca gcgcgccgcg 240
gtggtgatcg agggaaaggt gcaccgcag cggcggcagc agggggcact cgacaggaag 300
gcggcggcgg cgcgggcgga ggcagggcg tggggcggcg atcgcgagcc gccagccgcg 360
ggcccacggg cgctggggcc gcccgccgag gagccgctgc tcgccgcaa cgggaccgtg 420
ccctcttggc ccaccgcccc ggtgcccagc gccggcgagc ccggggagga ggcgccctat 480
ctggtgaagg tgcaccaggt gtggcggtg aaagccgggg gcttgaagaa ggactcgctg 540

-228-

ctcaccgtgc gcctggggac ctggggccac cccgccttcc cctcctgcgg gaggtcaag 600
gaggacagca ggtacatctt cttcatggag cccgacgcca acagcaccag ccgcgcgccg 660
gccgccttcc gagcctcttt cccccctctg gagacgggcc ggaacctcaa gaaggaggtc 720
agccgggtgc tgtgcaagcg gtgcg 745

<210> 71

<211> 1986

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 71

gaattccttt tttttttttt ttttttcttt ttttttttgc ccttatacct cttgccttt 60
ctgtggttcc atccacttct tccccctcct cctcccataa acaactctcc taccctgca 120
cccccaataa ataaataaaa ggaggagggc aaggggggag gaggaggagt ggtgctgcga 180
ggggaaggaa aaggagggca gcgcgagaag agccgggcag agtccgaacc gacagccaga 240
agccgcacg cacctcgac catgagatgg cgacgcgcc cgcccgctc cggcgctccc 300
ggcccccggg ccagcgccc cggtccgcc gccgctcgt cgcccgctt gccgctgctg 360
ccactactgc tgctgctggg gaccgcggcc ctggcgccgg gggcgggcgc cggcaacgag 420
ggcgctcccc cgggggcctc ggtgtgctac tcgtccccgc ccagcgctggg atcggtgcag 480
gagctagctc agcgcgccgc ggtggtgatc gagggaaagg tgcacccgca gggcgggcag 540
cagggggcac tcgacaggaa ggcgggcgcg gcggcgggcg aggcaggggc gtggggcggc 600
gatcgcgagc cgccagccgc gggcccacgg gcgctggggc cgcccgccga ggagccgctg 660
ctcgccgcca acgggaccgt gccctcttgg cccaccgcc cggtgccag cgccggcgag 720
cccggggagg aggcgccta tctggtgaag gtgcaccagg tgtgggcggt gaaagccggg 780
ggcttgaaga aggactcgct gctcaccgtg cgctgggga cctggggcca cccgccttc 840
ccctcctgcy ggaggctcaa ggaggacagc aggtacatct tcttcatgga gcccgacgcc 900
aacagacca gccgcgcgcc ggccgccttc cgagcctctt tccccctct ggagacgggc 960
cggaacctca agaaggaggt cagccgggtg ctgtgcaagc ggtgcgcctt gcctcccaa 1020

-229-

```

ttgaaagaga tgaaaagcca ggaatcggct gcaggttcca aactagtcct tcggtgtgaa 1080
accagttctg aatactctc tctcagattc aagtgggtca agaatgggaa tgaattgaat 1140
cgaaaaaaca aaccacaaaa tatcaagata caaaaaaagc cagggaagtc agaacttcgc 1200
attaacaaag catcactggc tgattctgga gagtatatgt gcaaagtgat cagcaaatta 1260
ggaaatgaca gtgcctctgc caatatcacc atcgtggaat caaacgctac atctacatcc 1320
accactggga caagccatct tgtaaatgt gcggagaagg agaaaacttt ctgtgtgaat 1380
ggaggggagt gcttcatggt gaaagacctt tcaaaccctt cgagatactt gtgcaagtgc 1440
ccaaatgagt ttactggtga tcgctgcaa aactacgtaa tggccagctt ctacagtacg 1500
tccactccct ttctgtctct gcctgaatag gagcatgctc agttgggtgct gctttcttgt 1560
tgctgcatct cccctcagat tccacctaga gctagatgtg tcttaccaga tctaatttg 1620
actgcctctg cctgtcgcat gagaacatta acaaaagcaa ttgtattact tcctctgttc 1680
gcgactagtt ggctctgaga tactaatagg tgtgtgaggc tccggatgtt tctggaattg 1740
atattgaatg atgtgataca aattgatagt caatatcaag cagtgaata tgataataaa 1800
ggcatttcaa agtctcactt ttattgataa aataaaaatc attctactga acagtccatc 1860
ttctttatac aatgaccaca tcctgaaaag ggtgttgcta agctgtaacc gatatgcact 1920
tgaaatgatg gtaagttaat ttgattcag aatgtgttat ttgtcacaaa taaacataat 1980
aaaagg

```

1986

<210> 72
 <211> 2003
 <212> DNA
 <213> Unknown

<220>
 <223> Description of Unknown Organism:Unknown

<220>
 <221> UNSURE
 <222> (31)
 <223> May be any nucleic acid

<220>
 <221> UNSURE
 <222> (32)
 <223> May be any nucleic acid

-230-

<400> 72
ggaattcctt tttttttttt tttttttctt nntttttttt tgcccttata cctcttcgcc 60
tttctgtggt tccatccact tcttccccct cctctccca taaacaactc toctaccct 120
gcacccccaa taaataaata aaaggaggag ggcaaggggg gaggaggagg agtgggtgctg 180
cgaggggaag gaaaaggag gcagcgcgag aagagccggg cagagtccga accgacagcc 240
agaagcccg cgcacctcg caccatgaga tggcgacgcg ccccgcgccg ctccggggcgt 300
cccgccccc gggcccagcg cccgggtcc gcgcgcgct cgtcgccgcc gctgccgctg 360
ctgccactac tgctgctgct ggggaccgcg gccctggcg cgggggcggc ggccggcaac 420
gaggcggtc ccgcgggggc ctgggtgtgc tactcgtccc cgccagcgt gggatcggtg 480
caggagctag ctgagcgcg cgcggtggtg atcgaggaa aggtgcacc gcagcgcgcg 540
cagcaggggg cactcgacag gaaggcgcg gcggcgcg gcgaggcagg ggcgtggggc 600
ggcgatcgcg agccgccagc cgcgggccca cgggcgctgg ggccgccgc cgaggagccg 660
ctgctcgccg ccaacgggac cgtgccctct tgggccaccg ccccggtgcc cagcgccggc 720
gagcccgggg agggaggcgc ctatctggtg aaggtgcacc aggtgtgggc ggtgaaagcc 780
gggggcttga agaaggactc gctgctcacc gtgcgcctgg ggacctgggg ccaaccgcc 840
ttccctcct gcgggaggct caaggaggac agcaggtaca tcttcttcat ggagccgac 900
gccaacagca ccagccgcg gcgggccgcc ttccgagcct ctttcccccc tctggagacg 960
ggccggaacc tcaagaagga ggtcagccg gtgctgtgca agcggtgcgc cttgcctccc 1020
caattgaaag agatgaaaag ccaggaatcg gctgcaggtt ccaaactagt ccttcggtgt 1080
gaaaccagt ctgaatactc ctctctcaga ttcaagtgt tcaagaatgg gaatgaattg 1140
aatcgaaaaa acaaaccaca aaatatcaag atacaaaaa agccaggga gtcagaactt 1200
cgcatthaaca aagcatcact ggctgattct ggagagtata tgtgcaaagt gatcagcaaa 1260
ttaggaaatg acagtgcctc tgccaatata accatcgtgg aatcaaacgc tacatctaca 1320
tccaccactg ggacaagcca tcttgtaaaa tgtgcggaga aggagaaaac tttctgtgtg 1380
aatggagggg agtgcttcat ggtgaaagac ctttcaaacc cctcgagata cttgtgcaag 1440
tgcccaaag agtttactgg tgatcgctgc caaaactacg taatggccag cttctacagt 1500

-231-

acgtccactc cctttctgtc tctgcctgaa taggagcatg ctcagttggt gctgctttct 1560
tgttgctgca tctccctca gattccacct agagctagat gtgtcttacc agatctaata 1620
ttgactgcct ctgcctgtcg catgagaaca ttaacaaaag caattgtatt acttcctctg 1680
ttcgcgacta gttggctctg agatactaata aggtgtgtga ggctccggat gtttctggaa 1740
ttgatattga atgatgtgat acaaattgat agtcaatatc aagcagtga atatgataat 1800
aaaggcattt caaagtctca cttttattga taaaataaaa atcattctac tgaacagtcc 1860
atcttcttta tacaatgacc acatcctgaa aagggtgttg ctaagctga accgatatgc 1920
acttgaaatg atggttaagt aattttgatt cagaatgtgt tatttgtcac aaataaacat 1980
aataaaagga aaaaaaaaaaaa aaa 2003

<210> 73
<211> 957
<212> DNA
<213> Unknown

<220>
<223> Description of Unknown Organism:Unknown

<220>
<221> UNSURE
<222> (809)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (810)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (811)
<223> May be any nucleic acid

<400> 73
tctcgcccca actttttccc ccgcgctccg cagcagcagc agcagcagca gcagcagcag 60
caaatggca gacctcttca gcggactcgt gggcggcgtc gtcggcgctg ttgctgcagc 120
agatttgctt gcggagggcg agagggcccc ccgccccgcc ccgggactg cctggacttg 180
ctgctgcagc aaactgcaag aaggggcccc cgagctggag ggttttgtgc agcagctgag 240
ttttgttgca gggaagctgg cctgctgcct gcgggtgggg gcggagcagc tggcgcgctg 300

-232-

cgctgcggag gggcggtgc ccagcagcag cagcagcagc agctgctgcg cgctgctgca 360
gctcgagaag caggacctcg agcagagcct cgaggccggc aagcagggcg cggagtgcct 420
cttgaggagc agcaaactgg cctcagaggc cctcctcgag ggggcccgcg ttgcagcaac 480
gcggggtttg ctgctggtcg agagcagcaa agacacggtg ctgcgcagca ttccccacac 540
ccaggagaag ctggcccagg cctacagttc tttcctgcgg ggctaccagg gggcagcagc 600
ggggaggtct ctgggctacg gggcccctgc tgctgcttac ggccagcagc agcagcccag 660
cagctacggg gcgcccccg cctccagcca gcagccctcc ggcttcttct ggtagccctg 720
cagcagcagc agcagcagca gcagcagcag cagcgcgggc ggagcccgcg gcggggcccgg 780
ggcgccgctg cagcaacagc agcagccggn nccgctagcg ccgcgagca ctgcagggga 840
actccacagg cagcgggaga gcagcagggga cgagaagcag gtcattgtagc gcaggcagca 900
gcgccagctg cagcagcagc agcagcagca gcagcagcag cagcagctcc tgcaccg 957

<210> 74

<211> 957

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<220>

<221> UNSURE

<222> (809)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (810)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (811)

<223> May be any nucleic acid

<400> 74

tctcgcccca actttttccc ccgcgtccg cagcagcagc agcagcagca gcagcagcag 60

caaaatggca gacctcttca gcggactcgt gggcggcgtc gtcggcgctg ttgctgcagc 120

-233-

agatttgcct gcggagggcg agagggcccc ccgccccgcc cccggcactg cctggacttg 180
ctgctgcagc aaactgcaag aaggggcccg cgagctggag ggttttgtgc agcagctgag 240
ttttgttgca gggaagctgg cctgctgcct gcgggtgggg gcggagcagc tggcgcgctg 300
cgctgcggag gggcggtgc ccagcagcag cagcagcagc agctgctgcg cgctgctgca 360
gctcgagaag caggacctcg agcagagcct cgaggccggc aagcagggcg cggagtgcct 420
cttgaggagc agcaaactgg ccctcgaggc cctcctcgag ggggcccgcg ttgcagcaac 480
gcggggtttg ctgctggtcg agagcagcaa agacacggtg ctgcgcagca ttccccacac 540
ccaggagaag ctggcccagg cctacagttc tttcctccgg ggctaccagg gggcagcagc 600
ggggaggtct ctgggctacg gggcccctgc tgctgcttac ggccagcagc agcagcccag 660
cagctacggg gcgccccccg cctccagcca gcagccctcc ggcttcttct ggtagccctg 720
cagcagcagc agcagcagca gcagcagcag cagcgcgggc ggagccgcg gcggggcccg 780
ggcgccgctg cagcaacagc agcagccggn ncggctagcg ccgcggagca ctcgcaggga 840
actccacagg cagcgggaga gcagcaggga cgagaagcag gtcagttagc gcaggcagca 900
gcgccagctg cagcagcagc agcagcagca gcagcagcag cagcagctcc tgcaccg 957

<210> 75

<211> 1089

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<220>

<221> UNSURE

<222> (376)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (377)

<223> May be any nucleic acid

<220>

<221> UNSURE

<222> (847)

<223> May be any nucleic acid

<220>

<221> UNSURE

-234-

<222> (848)
<223> May be any nucleic acid
<220>
<221> UNSURE
<222> (849)
<223> May be any nucleic acid

<220>
<221> UNSURE
<222> (850)
<223> May be any nucleic acid

<400> 75
gaattccctc caactcttcg cgactctctc tctctcgccc caactttttc ccccgcgccc 60
cgcagcagca gcagcagcag cagcagcaaa atggcagacc tcttcagcgg actcgtgggc 120
ggcgtcgtcg ggcgtgttgc tgcagcagat ttgcctgcgg agggcgagag ggccccccgc 180
ccgcccccg gcactgcctg gacttgctgc tgcagcaaac tgcaagaagg ggcccgcgag 240
ctggagggtt ttctgcagca gctgagtttt gttgcaggga agctggcctg ctgcctgcgg 300
gtgggggagg agcagctggc ggcgtgcgct gcgagggggc ggctgcccag cagcagcagc 360
agcagcagct gctgcnnget gctgcagctc gagaagcagg acctcgagca ggcctcgag 420
gccggcaagc agggcgcgga gtgcctcttg aggagcagca aactggccct cgaggccctc 480
ctcgaagggg cccgcgttgc agcaacgcgg ggtttgctgc tggtcgagag cagcaaagac 540
acggtgctgc gcagcattcc ccacaccag gagaagctgg ctcaggccta cagttctttc 600
ctgccccgct accagggggc agcagcgggg aggtctcttg gctacggggc cctgctgct 660
gcttacggcc agcagcagca gccagcagc tacggggcgc ccccgccctc cagccagcag 720
ccctccgget tcttctggta gccctgcagc agcagcagca gcagcagcag cagcagcagc 780
ggcggcgcca gccgcggcgg ggccggggcg ccgctgcagc aacagcagca gccgcggcgg 840
ctagcgnnnn gagcactcgc agggaaactcc acaggcagcg ggagagcagc agggacgaga 900
agcaggtcta tgtagcgcag gcagcagcgc cagctgcagc agcagcagca gcagcagcag 960
cagcagcagc agctcctgca ccgcagcgtt gtgtcattta ttacgttggc agctctgagg 1020
cctcggcgca gccaacgcgc ctcaggtatc tttcagactc ttttctctaa ggtcttccag 1080
acggaattc 1089

-235-

<210> 76
<211> 1985
<212> DNA
<213> .Unknown

<220>
<223> Description of Unknown Organism:Unknown

<400> 76
cgccgagctt tcggcacctc tgccgggtgg taccgagcct tcccggcgcc ccctcctctc 60
ctcccaccgg cctgcccttc ccgcggggac tatcgccccc acgtttccct cagccctttt 120
ctctcccggc cgagccgcgg cggcagcagc agcagcagca gcagcaggag gaggagcccg 180
gtggcggcgg tggccgggga gcccatggcg tacagtcaag gaggcggcaa aaaaaaagtc 240
tgctactact acgacggtga tattggaaat tattattatg gacaggggtca tcccatgaag 300
cctcatagaa tccgcatgac ccataacttg ctgttaaatt atggcttata cagaaaaatg 360
gaaatatata ggccccataa agccactgcc gaagaaatga caaaatatca cagtgatgag 420
tatatcaa at ttctacggtc aataagacca gataacatgt ctgagtatag taagcagatg 480
catatattta atgttgagga agattgtcca gcgtttgatg gactctttga gttttgtcag 540
ctctcaactg gcggttcagt tgctggagct gtgaagttaa accgacaaca gactgatatg 600
gctgttaatt gggctggagg attacatcat gctaagaaat acgaagcatc aggattctgt 660
tacgttaatg atattgtgct tgccatcctt gaattactaa agtatcatca gagagtctta 720
tatattgata tagatattca tcatggtgat ggtgttgaag aagcttttta tacaacagat 780
cgtgtaatga cggtatcatt ccataaatat ggggaatact ttcctggcac aggagacttg 840
agggatattg gtgctggaaa aggcaaatac tatgctgtca attttccaat gtgtgatggg 900
atagatgatg agtcatatgg gcagatattt aagcctatta tctcaaagggt gatggagatg 960
tatcaacctg gtgctgtggg attacagtgt ggtgcagact cattatctgg tgatagactg 1020
ggttgtttca atctaacagt caaaggatcat gctaaatgtg tagaagttgt aaaaactttt 1080
aaattaccat tactgatgct tggaggaggt ggctacacaa tccgtaatgt tgctcgatgt 1140
tggacatatg agactgcagt tgcccttgat tgtgagattc ccaatgagtt gccatataat 1200
gattactttg agtattttgg accagacttc aaactgcata ttagtccttc aaacatgaca 1260

-236-

aaccagaaca ctccagaata tatggaaaag ataaaacagc gtttgtttga aaatttgcg 1320
atgttacctc atgcacctgg tgtccagatg caagctattc cagaagatgc tgttcatgaa 1380
gacagtggag atgaagatgg agaagatcca gacaagagaa tttctattcg agcatcagac 1440
aagcggatag cttgtgatga agaattctca gattctgagg atgaaggaga aggaggctga 1500
agaaatgtgg ctgatacataa gaaaggagca aagaaagcta gaattgaaga agataagaaa 1560
gaaacagagg acaaaaaaac agacgttaag gaagaagata aatccaagga caacagtgg 1620
gaaaaaacag ataccaaagg aaccaaatca gaacagctca gcaaccctg aatttgacag 1680
tctcaccaat ttcagaaaat cattaataag aaaatattga aaggaaaatg ttttcttttt 1740
gaagacttct ggcttcattt tatactactt tggcatggac tgtatttatt ttcaaaggg 1800
actttttcgt ttttgttttt ctgggcaagt tttattgtga gattttctaa ttatgaagca 1860
aaatttcttt tctccaccat gctttatgtg atagtattta aaattgatgt gagttattat 1920
gtcaaaaaaa ctgatctatt aaagaagtaa ttggcctttc tgagctgaaa aaaaaaaaaa 1980
aaaag 1985

<210> 77

<211> 476

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:Unknown

<400> 77

ccaccctcct cccctcccc cgccacttc gctaacttg tggctgttgt gatgcgtatt 60
cctgtagatc cgagcaccag ccggcgcttc agccccctt ccagcagcct gcagcccg 120
aaaatgagcg acgtgagccc ggtggtggct gcgcaacagc agcagcaaca gcagcagcag 180
caacagcagc agcagcagca gcaacagcag cagcagcagc aggaggcggc ggcggcggt 240
gcggcggcag cggcggtgc ggcggcgga gctgcagtgc cccggttgcg gccgccccac 300
gacaaccgca ccatggtgga gatcatcgcc gaccaccgg ccgaactcgt ccgcaccgac 360
agccccaact tcctgtgctc ggtgctgccc tcgcactggc gctgcaaaa gaccctgccc 420
gtggccttca aggtaagagg ctaccccgcc cccgcctccc ggccgggagc ggcgga 476

-237-

<210> 78
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:DNA Primer

<400> 78
gcattttgga tccgcctttt catg

24

<210> 79
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:DNA Primer

<400> 79
gttgtgtgct gcagattgtt cc

22

<210> 80
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:DNA Primer

<400> 80
gaaaaatggg gatccgaggt g

21

<210> 81
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:DNA Primer

<400> 81
gcaggagaat tccgtccatg

20

<210> 82
<211> 5
<212> PRT

-238-

<213> Homo sapiens

<220>

<221> UNSURE

<222> (3)

<223> Can be any amino acid

<400> 82

Trp Ser Xaa Trp Ser

1 5

<210> 83

<211> 6

<212> PRT

<213> Homo sapiens

<400> 83

Cys Ser Val Thr Cys Gly

1 5

<210> 84

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (4)

<223> Can be any amino acid

<400> 84

Gly Cys Gln Xaa Arg

1 5

<210> 85

<211> 733

<212> DNA

<213> Homo sapiens

<400> 85

gggatccgga gcccaaattct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg 60

aattcgaggg tgcaccgtca gtcttcctct tcccccaaa acccaaggac accctcatga 120

tctcccgga tcttgaggtc acatgcgtgg tgggtggacgt aagccacgaa gaccctgagg 180

tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg 240

aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact 300

-239-

ggctgaatgg caaggagtag aagtgaagg tctccaacaa agccctccca acccccatcg 360
agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc 420
catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct 480
atccaagcga catgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga 540
ccaagcctcc cgtgctggac tccgacggct ctttcttct ctacagcaag ctcaccgtgg 600
acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc 660
acaaccacta cagcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc 720
gactctagag gat 733

<210> 86

<211> 86

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA Primer

<400> 86

gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60

cccgaaatat ctgccatctc aattag

86

<210> 87

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA Primer

<400> 87

gcggcaagct ttttgcaaag cctaggc

27

<210> 88

<211> 271

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR Fragment

<400> 88

-240-

ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60
aaatatctgc catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc 120
gccccfaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 89
<211> 32
<212> DNA
<213> Homo sapiens

<400> 89
gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 90
<211> 31
<212> DNA
<213> Homo sapiens

<400> 90
gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 91
<211> 12
<212> DNA
<213> Homo sapiens

<400> 91
ggggacttcc cc 12

<210> 92
<211> 73
<212> DNA
<213> Homo sapiens

<400> 92
gcggcctcga ggggacttcc ccggggactt tccggggact ttccgggact ttccatcctg 60
ccatctcaat tag 73

<210> 93
<211> 27
<212> DNA

-241-

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR Fragment

<400> 93

gcggcaagct ttttgcaaag cctagggc

27

<210> 94

<211> 652

<212> DNA

<213> Homo sapiens

<400> 94

```
ggcataagat cacacttttag ttcagagaca catttgcata aatacttgaa atggatccac 60
ccctgcaggt ggcagcctga gaacatggcg ctgcaggggg accagggcag cgtctgggtc 120
aggtggacga acagcggtgc catcacgtgg tgcttgccca tgggcccgaa gagccgtgtg 180
cagggccttg agtcgtcgtg gggcatgctg aggacgtgcc ctagtctcat ggccaggggtg 240
tggggcgcct ggagcccctc atcctcgatc acggagcagc ttttggtggg gtcacaaatg 300
gtcccgatgt ctgccacacc caggggtgtca cacagcccct cctgcccaca gaagttctgt 360
ctggtgagca ggatggcgtg gtcgtagtgc tctgggtggc ggtcgtctgg ctggttgaaa 420
cgccgctgcc agttgcagaa gttacgcagt gtaagccccc cattgtcggg cacctctggg 480
ccccattttt catcttctac gatcagcact tttaccacca tcangttgat ggaattcttg 540
atgctggggg gcttgtagaa tcgggcttgc cacgaaaatt aacctcagga tgtggttctg 600
caggtcggcc cgtaaagggc gccatggacg catcggccac caacagcgtt tc 652
```

<210> 95

<211> 716

<212> CDNA

<213> Homo sapiens

<400> 95

```
taagtttgct agtcctttgc aaacagactg acgctgagtg tcctgtctga gtc'aataagt 60
gcacttttac cttttaacct atgccctcta cttgaacccg agcaagggtcc agtccactgg 120
acagttgatg ataggggtctg ccgccccata ccctctctc ttccccctta ggaatttgg 180
cagtactgga ggggttgcgg caatgggagg cctgggtggg ccgtgctgcc ttgatatggc 240
caagggaccc agtcaccaca gtggagaccc ttgtctgcac ctcagtaccg catgtccagg 300
agcacaagac tggccctgc cccctgaat cacagggggc acagctggct ttcgcagggc 360
ttggcatcct cgggtttcag agccttggtg caggtggcag aggcctggcc ggaggggtcc 420
ctgcaactcta cagttgcct ctgccagccg gcccgcagg tgctagagca ctcagaccag 480
tccccagca cccactgtgc gtggagcagc ggctggatga tgttggtggg tgctctctct 540
ttgctgctct gcatgctaaa agtcacgtca ttaggaanca aagaagggtg atttgacttt 600
ttggggggaa gaacctcgcc caggactgtc aggagctgca ctgtcagaag gctctgcnaa 660
ggcccngaag ctctgcangc gctccagggt ggcgatggag ccgtgtactt caggat 716
```

<210> 96

<211> 543

<212> DNA

<213> Homo sapiens

<400> 96

-242-

```

ggcataagat caccacttttag ttcagagaca catttgcata aatacttgaa atggatccac 60
ccctgcaggt ggcagcctga gaacatggcg ctgcaggggg accagggcag cgtctggttc 120
aggtggacga acagcgggtgc catcacgtgg tgccttgcca tggcctcgaa gagccgtgtg 180
cagggccttg agtcgtcgtg ggcatgctg aggcgtgcc ctagtcatg ggccaggggtg 240
tgggcccgtg gagccctcat cctcgatcac ggagcagctt ttgttgggtg cacaaatggg 300
cccgatgtct gccacaccca ggggtgtcaca cagcccctcc tggccacaga agttctgtct 360
ggtagcagc atggccgtgt cgtagtgtc tgggtggcg tgcgtgggct ggttgaaacg 420
ccgctgccag ttgcagaagt tacgcagtgt aaggcccca ttgtcggaca gctctggggc 480
ccatttttca tcttctacga tcagcacttt taaccacatc aggttgatgg aattcttgat 540
gcc 543

```

<210> 97

<211> 377

<212> DNA

<213> Mus musculus

<400> 97

```

gcaaagtgcc accacccttc ggatccaaaa ctagaagcaa gaggtttgtg tccgaggctc 60
gcttcgtgga aacacttctg gtggctgatg cgtccatggc tgccttctat gggaccgacc 120
tgcagaacca catcctcacg gtgatgtcaa tggcagccc aatctacaag cacccgagca 180
tcaagaactc cgtcaacctt gtggtggtga aagtgtctaat agtgaagag gaaggatggg 240
gcccggaggt gtcggacaac ggggggctca cactgcgcaa cttctgcagc tggcaacggc 300
gtttcaacaa gcccagtgac cgccaccgag agcactatga cactgccatc ttgttcacca 360
gacagaactt ctgtggg 377

```

<210> 98

<211> 432

<212> DNA

<213> Rattus norvegicus

<400> 98

```

ctaaagtaca gtggttccat ggccaccctg gagcggctgc anagcttcca agccctccct 60
gagcctctta cagtacagct cctgactgtg tctggtagag tcttccctcc aaaagtcaaa 120
tataccttct tcgtcccaa tgacacggac ttcaacgtgc agagtagcaa agaaagagca 180
agcaccaaca tcattcagtc cttgccctat gcanagtggg tgctggggga ctggtctgaa 240
tgtccaagca catgtggagg tggctggcag cggcggactg tggaatgcag ggaccctca 300
ggtcaggcct ctgacacctg tgatgaggct ctgaaacctg aggatgccaa gccctgtgga 360
agccagccat gtctcctctg atccccttgg tggacatgtc taaggcttat ggatttgggc 420
tactggcggt tt 432

```

<210> 99

<211> 354

<212> DNA

<213> Mus musculus

<400> 99

```

caaagtgcac cacccttcgg atccaaaact agaagcaaga ggtttgtgtc cgaggctcgc 60
ttcgtggaac caottctggt ggctgatgcg tccatggctg ctttctatgg gaccgacctg 120
cagaaccaca tcctcacggt gatgtcaatg gcagccacga atctacaagc acccgagcat 180
caggaactcc gtcaaccttg tgggtggtgaa agtgctaata gtggaagagg aaggatgggg 240
cccggagtgt cggacaacgg ggggctcaca ctgcgcaact tctgcagctg gcaacggcgt 300
ttcaacaagc ccagtgaccg ccaccgggag cactatgaca ctgccatctt gtgc 354

```

-243-

<210> 100
<211> 389
<212> DNA
<213> Homo sapiens

<400> 100
ttgtgcccag aagacactgg ccctggggcc tgggttgagt tcaaaaccaa aagaaagaag 60
aaaagtgtgtg taaattcggg atttctccac cggatgtctc tgcttccgca tgggtgtcac 120
ctccatgccg ttctncctc tttctaggga aaagcttcag ggagcagcag tgtgagaagt 180
ataatgccta caattacact gacatggacg ggaatctcct gcagtgggtc cccaagtatg 240
ctggggtgtc cccccgggac cgcctggcaa gttgttctgc cgagcccggg ggaggagcga 300
gttcaaagtg ttcgaggcca aggtgagaat caccctgggg gacttcagat ccagagatgg 360
ggggagggaa ggtcggcctg ttccccaca 389

<210> 101
<211> 305
<212> DNA
<213> Homo sapiens

<400> 101
catttaagtt tgctagtcct ttgcaaacag actgacgctg agtgtcctgt ctgagtcaat 60
aagtgcactt ttaccttcta acctatgcc tctacttgaa cccgagcaag gtccagtcca 120
ctggacangt tgatgatagg gtctgncgcc ccataccctc tcctcttccc ccttaggaat 180
ttgtgcagta ctggaggggt tgcggaatg ggaggcctgg gtgggccgtg ctgccttgat 240
atggccaagg gaccagtgca ccacagtgga gaccctgtgc tgcacctcag taccgcatgt 300
ccagg 305

<210> 102
<211> 152
<212> DNA
<213> Homo sapiens

<400> 102
atcgtagaag atgaaaaatg gggcccagag gtgtccgaca atggggggct tacactgcgt 60
aacttctgca actggcagcg gcgtttcaac cagcccagcg accgncacc agagcactac 120
gncacggcca tcctnctcac cagacagaac tt 152

<210> 103
<211> 632
<212> DNA
<213> Homo sapiens

<400> 103
tttaataata ataatgcccg gggctttatt atgctgtatc actgctcaga ggttaataat 60
cctcactaac tatcctatca aatttgcaac tggcagttaa ctctgatgat tcaactcctt 120
ttctatctac ccccataatc ccaccttact gataccctc actggttact ggcaagatac 180
gctggatccc tccagccttc ttgctttccc tgcaccagcc ettcctcact ttgccttgcc 240
ctcaaagcta acaccactta aaccacttaa ctgcattctg ccattgtgca aaagtctatg 300
aaatgttttag gtttctttaa aggatcacag ctctcatgag ataacacccc tccatcatgg 360
gacagacact tcaagcttct tttttgttaa cccttccac aagtcttaga acatgatgac 420
cactccccca gctgccactg ggggcaggga tggctgtcac aaggctctgt gctggctggc 480

-244-

```

ttcacttcct ttgcacactc ggaagcaggc tgtccattaa tgtctcggca ttctaccagt 540
cttctctgcc aaccaattc acatgactta gaacattcgc cccactcttc aatgacccat 600
gctgaaaaag tggggatagc attgaaagaa tc 632

```

<210> 104

<211> 519

<212> DNA

<213> Homo sapiens

<400> 104

```

tttttttcta aacttgtaat agatgtaaca aaagaaataa taataataat gcccggggct 60
ttattatgct atatcactgc tcagagggtta ataatcctca ctaactatcc tatcaaattt 120
gcaactggca gtttactctg atgattcaac tccttttcta tctaccccca taatcccacc 180
ttactgatac aactcactgg ttactggcaa gatacgtctg atccctccag ccttcttgct 240
ttccctgcac cagcccttcc tcactttgcc ttgccctcaa agctaacacc acttaaacca 300
cttaactgca ttctgccatt gtgcaaaagt ctatgaaatg tttaggtttc tttaaaggat 360
cacagctctc atgagataac acccctccat catgggacag acacttcaag cttctttttt 420
tgtaaccctt cccacaggtc ttagaacatg atgaccactc cccagctgc cactgggggc 480
agggatgtct gcaacaagggc tgggtgctggc tgcccggac 519

```

<210> 105

<211> 475

<212> DNA

<213> Homo sapiens

<400> 105

```

gagtcgatgat gcgatcacaa ccagctttta cacactgtcc ttgcacacag acagagggtg 60
aatctgggct acatggagta ccatctacaa ccttgggctg caaacgaag aagtagccaa 120
tgcccttggc ttggcagatg agcttgacc tgctcttgg tgagacgcca gcgtacttg 180
gaatccattc caccgcaggc ccaactccaa aggaagcttt tgaaaactcg ttgtgtgctt 240
cacattgttc ctctctaaag gtttttccat tattgtctgg acagtctca aggttacagg 300
atctgtagcg cactcgtttg ccttcacagt acttccctcc attcttggg actgggttgt 360
cacattccct catcgtgtac tggactcctc caccgcacgt tctcgaacag tctccccaag 420
gccccacat tccccagctt ccatgaaaag gcgtatcaaa atgctttctg tcggt 475

```

<210> 106

<211> 455

<212> DNA

<213> Homo sapiens

<400> 106

```

aataataata atgcccgggg ctttattatg ctgtatcact gctcagaggt taataatcct 60
cactaactat cctatcaaat ttgcaactgg cagtttactc tgatgattca actccttttc 120
tatctacccc cataatccca ccttactgat acacctcact ggttactggc aagatacgt 180
ggatccctcc agccttcttg ctttccctgc accagccctt cctcactttg ccttgccctc 240
aaagctaaca ccacttaaac cacttaactg cattctgcca ttgtgcaaaa gtctatgaaa 300
tgtttaggtt tctttaaagg atcacagctc tcatgagata acaccctcc atcatgggac 360
agacattca agcttctttt tttgtaacct tcccacagg tcttagaaca tgatgaccac 420
tccccagct gccactgggg gcagggatgg tctgg 455

```

<210> 107

<211> 515

-245-

<212> DNA

<213> Homo sapiens

<400> 107

```

aacccttccc acaggtctta gaacatgatg accactcccc cagctgccac tgcggggcag 60
ggatggtctg cacaaggtct ggtgctggct ggcttcactt cctttgcaca ctcggaagca 120
ggctgtccat taatgtctcg gcattcttcc agtcttctct gccaacccaa ttcacatgac 180
ttagaacatt cgccccactc ttcaatgacc catgctgaaa aagtggggat agcattgaaa 240
gattccttct tcttctttac gaagtaggtg tatttaattt taggtcgaag ggcattgcca 300
cagtaagaac ctggatggtc aagggtcttt tggagcaggc taaagctgcg aattctttcc 360
aatgccgcag aggagccgct gtacctcaag acaacacctt tgtacataat gtcttgctct 420
aaggtggaca aagtgtagtc accataaaga atatatgtgc catcagcagc ttttgatggc 480
aggaagctgt cattgttctt ggatccctct gtccc 515

```

<210> 108

<211> 359

<212> DNA

<213> Homo sapiens

<400> 108

```

acttcgtaaa gaagaagaag gaatctttca atgctatccc cactttttca gcatgggtca 60
ttgaagagtg gggcgaatgt tctaagtcac gtgaattggg ttggcagaga agactggtag 120
aatgccgaga cattaatgga cagcctgctt ccgagtgtgc aaaggaagtg aagccagcca 180
gcaccagacc ttgtgcagac catccctgcc ccagtggtga gctgggggaa gtggcatca 240
tgttctaaga cctgcgggaa gggttacaaa aaaagaagct ttgaagtgtc ttgtcccatg 300
atggaggggg gttatctcat tgagagctgt gatcctttaa agaaacctaa acatttcat 359

```

<210> 109

<211> 320

<212> DNA

<213> Homo sapiens

<400> 109

```

cagagaacat tgcccccact cttcaatgac ccatgctgaa aaagtgggga tagcattgaa 60
agattccttc ttcttcttta cgaagtaggt gtatttaatt ttaggtcgaa gggcattgcc 120
cacagtaaga acctggatgg tcaagggtc tttgagagg ctaaagctgc gaattctttc 180
caatgccgca gaggagccgc tgtacctcaa gacaacacct ttgtacataa tgtcttgctc 240
taaggtggac aaagtgtagt caccattaag aatatatgtg ccatcagcag ctttgatggc 300
aagaaagctg cccttgttcc 320

```

<210> 110

<211> 316

<212> DNA

<213> Homo sapiens

<400> 110

```

aatgccgaga cattaatgga cagcctgctt ccgagtgtgc aaaggaagtg aagccagcca 60
gcaccagacc ttgtgcagac catccctgcc ccagtggtga gctgggggag tggcatcat 120
gttctaagac ctgtgggaag ggttacaaaa aaagaagctt gaagtgtctg tcccatgatg 180
gagggtgtt atctcatgag agctgtgctc ctttaaagaa acctaaacat ttcatagact 240
tttgacaat ggcagaatgc agttaagtgg ttaagtggg gttagctttg agggcaaggc 300
aaagtgagga agggct 316

```

-246-

<210> 111
 <211> 318
 <212> DNA
 <213> Homo sapiens

<400> 111
 agantnccga gacattaatg gacagcctgc ttccgagtgt gcaaaggaag tgaagccagc 60
 cagcaccaga ccttgtgcag accatccctg cccccagtgg cagctggggg agtggtcac 120
 atgttctaag acctgtggga agggttacaa aaaaagaagc ttgaagtgtc tgtcccatga 180
 tggaggggtg ttatctcatg agagctgtga tcctttaaag aaacctaaac atttcataga 240
 cttttgcaca atggcagaat ncagttaagt ggtttaagtg gtgttagctt tgagggcaag 300
 gcaaagtgaag gaagggt 318

<210> 112
 <211> 314
 <212> DNA
 <213> Homo sapiens

<400> 112
 ttttttttct aaacttgtaa tagatgtaac aaaagaaata ataataataa tgcccggggc 60
 tttattatgc tatatcactg ctgagaggtt aataatcctc actaactatc ctatcaaatt 120
 tgcaactggc agtttactct gatgattcaa ctcttttct atctaccccc ataatcccac 180
 cttactgata cacctcactg gttactggca agatacgtg gatccctcca gccttcttgc 240
 tttccctgca ccagcccttc ctcaacttgc cttgccctca aagctaacac cacttaaacc 300
 acttaactgc attc 314

<210> 113
 <211> 316
 <212> DNA
 <213> Homo sapiens

<400> 113
 aaggaatcct tcaatgctat cccactgtt tcagcatggg tcattgaaga gtggggcgaa 60
 tgttctaagt catgtgaatt gggttggcag aaaagacttg tagaatgccg agacattaat 120
 ggacagcctg cgtccgagtg tgcaaaggaa gtgaagccag ccagcaccag accttgtgca 180
 gaccatccct gccccagtg gcagctgggg ggagtggcca tcattgttcta agacctgtgg 240
 gaaggggtac aaaaaaagag gcgtgaagtg tctgtcccat gatggagggg tttatctcat 300
 gagaactgtg atcctt 316

<210> 114
 <211> 265
 <212> DNA
 <213> Homo sapiens

<400> 114
 agcagtttan ncctntcaaa gagcccttga ccatccaggt tcttactgtg ggcaatgcc 60
 ttcgacctaa aattaaatac acctacttcg taaagangaa gaaggaatct ttcaatgcta 120
 tccccacttt ttcagcatgg gtcattgaag agtggggcga atgttctaag tcattgtgaat 180
 tgggttgcca gagaagactg gtagaatgcc gagacattaa tggacagcct ncttccgagt 240
 gtgcaaagna agtgaagcca gccag 265

-247-

<210> 115
 <211> 334
 <212> DNA
 <213> Mus musculus

<400> 115
 cgtttgtgga ggaaacgggt ccacatgcaa gaagatgtca ggaatagtca ctagtacaag 60
 acctgggtat catgacattg tcacaattcc tgctggagcc accaacattg aagtgaaca 120
 tcggaatcaa aggggggtcca gaaacaatgg cagctttctg gctattagag ccgctgatgg 180
 tacctatatt ctgaatggaa acttcactct gtccacacta gagcaagacc tcacctaca 240
 aggtactgtc ttaaggtaca gtggttcctc ggctgcgctg gagagaatcc gcagctttag 300
 tccactcaaa gaacccttaa ccatccaggt tctt 334

<210> 116
 <211> 528
 <212> DNA
 <213> Mus musculus

<400> 116
 agaattcctg gatgatggtc atggtaattg cttccgtggt aggtctagca aacaattacc 60
 atgaccatca tccaggaatt ctgtgatggg ggctgacgtg catttgacc agggcttgg 120
 tgcacatgat ctggttaagga ttgaagacat taaacgcttg tcttctgtag taccgaagt 180
 ctcttcacag aatttggaat cgtcatgaga aaggccaagt agatgcccaa tttcatgagc 240
 cacagtgaag gctgcatgga ggccatcatc ttcaatcact gcacagctgc gctccggaga 300
 acatatggtc ccaacgtctg ccattcccag ggtgtcacat gaatgatgcc cacataaatc 360
 ctctcgggtg aacaggatgg ctgcatcgta gtgctcttcg tgatcatccc ctagctgggt 420
 atgttggtgc tgccatttgc aaaagttctt gagggtcgtg gccgcattct tgctcacctc 480
 cagactcgtg tccttggtccg tcagcaccac caccttcacc accgccag 528

<210> 117
 <211> 438
 <212> DNA
 <213> Homo sapiens

<400> 117
 atttgatagg atagttagtg aggattatta acctctgagc agtgatatag cataataaag 60
 ccccgggcat tattattatt atttcttttg ttacatctat tacaagttta gaaaaaaca 120
 agcaattgtc aaaaaaagtt agaactatta caaccctgt ttcctggtac ttatcaaata 180
 cttagtatca tgggggttgg gaaatgaaaa gtaggagaaa agtgagattt tactaagacc 240
 tgttttactt tacctcacta acaatggggg gagaaaggag taaaatagg atctttgacc 300
 agcactgttt atgggctgct atggggttca gaggaatgtt tatacattat ttctaccga 360
 ggatttaaaa cttcagattg ttccaaccng gaggggaagg gcttccggcc aacgtggaat 420
 taaccggcaa tnggcctt 438

<210> 118
 <211> 455
 <212> DNA
 <213> Homo sapiens

<400> 118
 atttgatagg atagttagtg aggattatta acctctgagc agtgatatag cataataaag 60
 ccccgggcat tattattatt atttcttttg ttacatctat tacaagttta gaaaaaaca 120

-248-

```

agcaattgtc aaaaaaagtt agaactatta caaccctgt ttcctggtac ttatcaaata 180
cttagtatca tgggggttgg gaaatgaaaa gtaggagaaa agtgagattt tactaagacc 240
tgttttactt tacctcacta acaatggggg gagaaaggag tacaaatagg atctttgacc 300
agcactgttt atggctgcta tggtttcaga gaatgtttat acattatttc taccgaggat 360
taaaacttcc agattgtttc aacatggaga ggaaaggctc aggcaacgtg gaaataacgc 420
aatgggctt cctcttttcc tttttgggac cntct 455

```

<210> 119

<211> 380

<212> DNA

<213> Homo sapiens

<400> 119

```

aatttgatag gatagttagt gaggnattatt aacctctgag cagtgatata gcataataaa 60
gccccgggca ttattattat tattnctttt gttacatcta ttacaagttt agaaaaaaca 120
aagcaattgt caaaaaaagt tagaactatt acaaccctg tttcctggta cttatcaaata 180
acttagtatn atgggggttg ggaaatgaaa agtaggagaa aagtgagatt ttactaagac 240
ctgttttact ttacctcact aacaatgggg ggagaaagga gtacanatag gatctttgac 300
cagcactgtt tatggctgct atgggttcag aggaatgttt atacattatt tctaccgaga 360
nttaaaactt cagattgttc 380

```

<210> 120

<211> 199

<212> DNA

<213> Mus musculus

<400> 120

```

caatggcagc ttgctggcta taatagccgc tgatggtacc tatatactga atggaaactt 60
cactctgtcc aactagagc aagacctcac ctacgaatgt actgtcttaa ggtacagtgg 120
ttcctcggtc ggcaggaaa gagtccgcag ctttagtcca ctcaaataac ccttaaccat 180
ccaggttctt atggtagga 199

```

<210> 121

<211> 439

<212> DNA

<213> Homo sapiens

<400> 121

```

atttaacctc tgagcagtga tatagcataa taaagccccg ggcattatta ttattatttc 60
ttttgttaca tctattacaa gtttagaaaa aacaaagcaa ttgtcaaaaa aagttagaac 120
tattacaacc cctgtttcct ggtacttata aaatacttag tatcatgggg gttgggaaat 180
gaaaagtagg aggaaagnng agnttttact aagacctgtt ttacctttac ctactaaca 240
atggggggag aaaggagtac aaataggatc ttgaccagc actgtttatg gctgctatgg 300
tttcagagaa tgtttataca ttatttctac cgagaattaa aacttcagat tgttcaacat 360
ggagagaaag gctcagcaac gtggaaataa cgcaaatggg cttccccctt tccctttttt 420
gggaccatct caggtcctt 439

```

<210> 122

<211> 471

<212> DNA

<213> Homo sapiens

-249-

<400> 122

```

cagagtaaac tgccagttgc aaatttgata ggatagttag tgaggattat taacctctga 60
gcagtgatat agcataataa agccccgggc attattatta ttattatttc ttttgttaca 120
tctattacaa gtttagaaaa aacaaagcaa ttgtcaaaaa aagttagaac tattacaacc 180
cctgtttcct ggtacttatc aaatacttag tatcatgggg gttgggaaat gaaaagtagg 240
agaaaagtga gattttacta agacctgttt tacttttcct cactaacaat ggggggagaa 300
aggagtacaa ataggatctt tgaccagcac tgtttatggc tgctatggtt tcagagaatg 360
tttatacatt atttctaccc gagaattaaa acttcagatt ggttcaacat gagagaaagg 420
ctccagcaac gtgaaattaa cgccaatggc ttcctccttc ctttttttgg a 471

```

<210> 123

<211> 424

<212> DNA

<213> Homo sapiens

<400> 123

```

cgtgaggatt attaacctct gagcagtgat atagcatant aaagccccgg nattattatt 60
attatttctt ttgttacatc tattacaagt ttagaaaaaa caaagcaatt gtcaaaaaaa 120
gttagaacta ttacaacccc tgtttcctgg tacttatcaa atacttagta tcatgggggt 180
tgggaaatga aaagtaggag aaaagtgaga ttttactaag acctgtttta ctttacctca 240
ctaacaatgg ggggagaaaag gagtacaaat aggatctttg accagcactg tttatggctg 300
ctaattggtt cagagaatgt ttatacatta tttctaccog agaattaaaa cttcagattg 360
ttcaacctga gagaaaggct cagcaacgtg aatnacgcc aatggcttcc tctttccctt 420
tttg 424

```

<210> 124

<211> 458

<212> DNA

<213> Homo sapiens

<400> 124

```

tacatctatt acaagtttag aaaaaacaaa gcaattgtca aaaaaagtta gaactattac 60
aaccctgtt tctgtgtact tatcaaatac ttagtatcat gggggttggg aaatgaaaag 120
taggagaaaa gtgagatttt actaagacct gttttacttt acctactaa caatgggggg 180
agaaaggagt acaaatagga tctttgacca gcactgttta tggctgctat ggtttcagag 240
aatgtttata cattatttct accgagaatt aaaacttcag attgttcaac atgagagaaa 300
ggctcagcaa cgtgaaataa cgcaaatggc ttcctcttct ctttttttgg ccacagccag 360
ccttggtctc cttgcagtgg ctacatgatt acatcatttc tggataatag tcatggggaa 420
tgtttgatgg acaagctcag aatcccatac agntccca 458

```

<210> 125

<211> 968

<212> PRT

<213> Homo sapiens

<400> 125

```

Met Gln Arg Ala Val Pro Glu Gly Phe Gly Arg Arg Lys Leu Gly Ser
  1             5             10            15

```

```

Asp Met Met Gly Asn Ala Glu Arg Ala Pro Gly Ser Arg Ser Phe Gly
          20            25            30

```

-250-

Pro Val Pro Thr Leu Leu Leu Leu Ala Ala Ala Leu Leu Ala Val Ser
 35 40 45
 Asp Ala Leu Gly Arg Pro Ser Glu Glu Asp Glu Glu Leu Val Val Pro
 50 55 60
 Glu Leu Glu Arg Ala Pro Gly His Gly Thr Thr Arg Leu Arg Leu His
 65 70 75 80
 Ala Phe Asp Gln Gln Leu Asp Leu Glu Leu Arg Pro Asp Ser Ser Phe
 85 90 95
 Leu Ala Pro Gly Phe Thr Leu Gln Asn Val Gly Arg Lys Ser Gly Ser
 100 105 110
 Glu Thr Pro Leu Pro Glu Thr Asp Leu Ala His Cys Phe Tyr Ser Gly
 115 120 125
 Thr Val Asn Gly Asp Pro Ser Ser Ala Ala Ala Leu Ser Leu Cys Glu
 130 135 140
 Gly Val Arg Gly Ala Phe Tyr Leu Leu Gly Glu Ala Tyr Phe Ile Gln
 145 150 155 160
 Pro Leu Pro Ala Ala Ser Glu Arg Leu Ala Thr Ala Ala Pro Gly Glu
 165 170 175
 Lys Pro Pro Ala Pro Leu Gln Phe His Leu Leu Arg Arg Asn Arg Gln
 180 185 190
 Gly Asp Val Gly Gly Thr Cys Gly Val Val Asp Asp Glu Pro Arg Pro
 195 200 205
 Thr Gly Lys Ala Glu Thr Glu Asp Glu Asp Glu Gly Thr Glu Gly Glu
 210 215 220
 Asp Glu Gly Pro Gln Trp Ser Pro Gln Asp Pro Ala Leu Gln Gly Val
 225 230 235 240
 Gly Gln Pro Thr Gly Thr Gly Ser Ile Arg Lys Lys Arg Phe Val Ser
 245 250 255
 Ser His Arg Tyr Val Glu Thr Met Leu Val Ala Asp Gln Ser Met Ala
 260 265 270
 Glu Phe His Gly Ser Gly Leu Lys His Tyr Leu Leu Thr Leu Phe Ser
 275 280 285
 Val Ala Ala Arg Leu Tyr Lys His Pro Ser Ile Arg Asn Ser Val Ser
 290 295 300
 Leu Val Val Val Lys Ile Leu Val Ile His Asp Glu Gln Lys Gly Pro

-251-

305		310		315		320
Glu Val Thr Ser Asn Ala Ala Leu Thr Leu Arg Asn Phe Cys Asn Trp						
	325			330		335
Gln Lys Gln His Asn Pro Pro Ser Asp Arg Asp Ala Glu His Tyr Asp						
	340		345			350
Thr Ala Ile Leu Phe Thr Arg Gln Asp Leu Cys Gly Ser Gln Thr Cys						
	355		360			365
Asp Thr Leu Gly Met Ala Asp Val Gly Thr Val Cys Asp Pro Ser Arg						
	370		375			380
Ser Cys Ser Val Ile Glu Asp Asp Gly Leu Gln Ala Ala Phe Thr Thr						
	385		390		395	400
Ala His Glu Leu Gly His Val Phe Asn Met Pro His Asp Asp Ala Lys						
		405		410		415
Gln Cys Ala Ser Leu Asn Gly Val Asn Gln Asp Ser His Met Met Ala						
		420		425		430
Ser Met Leu Ser Asn Leu Asp His Ser Gln Pro Trp Ser Pro Cys Ser						
	435		440			445
Ala Tyr Met Ile Thr Ser Phe Leu Asp Asn Gly His Gly Glu Cys Leu						
	450		455			460
Met Asp Lys Pro Gln Asn Pro Ile Gln Leu Pro Gly Asp Leu Pro Gly						
	465		470		475	480
Thr Ser Tyr Asp Ala Asn Arg Gln Cys Gln Phe Thr Phe Gly Glu Asp						
		485		490		495
Ser Lys His Cys Pro Asp Ala Ala Ser Thr Cys Ser Thr Leu Trp Cys						
		500		505		510
Thr Gly Thr Ser Gly Gly Val Leu Val Cys Gln Thr Lys His Phe Pro						
	515			520		525
Trp Ala Asp Gly Thr Ser Cys Gly Glu Gly Lys Trp Cys Ile Asn Gly						
	530		535			540
Lys Cys Val Asn Lys Thr Asp Arg Lys His Phe Asp Thr Pro Phe His						
	545		550		555	560
Gly Ser Trp Gly Met Trp Gly Pro Trp Gly Asp Cys Ser Arg Thr Cys						
		565		570		575
Gly Gly Gly Val Gln Tyr Thr Met Arg Glu Cys Asp Asn Pro Val Pro						
		580		585		590

-252-

Lys Asn Gly Gly Lys Tyr Cys Glu Gly Lys Arg Val Arg Tyr Arg Ser
 595 600 605

Cys Asn Leu Glu Asp Cys Pro Asp Asn Asn Gly Lys Thr Phe Arg Glu
 610 615 620

Glu Gln Cys Glu Ala His Asn Glu Phe Ser Lys Ala Ser Phe Gly Ser
 625 630 635 640

Gly Pro Ala Val Glu Trp Ile Pro Lys Tyr Ala Gly Val Ser Pro Lys
 645 650 655

Asp Arg Cys Lys Leu Ile Cys Gln Ala Lys Gly Ile Gly Tyr Phe Phe
 660 665 670

Val Leu Gln Pro Lys Val Val Asp Gly Thr Pro Cys Ser Pro Asp Ser
 675 680 685

Thr Ser Val Cys Val Gln Gly Gln Cys Val Lys Ala Gly Cys Asp Arg
 690 695 700

Ile Ile Asp Ser Lys Lys Lys Phe Asp Lys Cys Gly Val Cys Gly Gly
 705 710 715 720

Asn Gly Ser Thr Cys Lys Lys Ile Ser Gly Ser Val Thr Ser Ala Lys
 725 730 735

Pro Gly Tyr His Asp Ile Ile Thr Ile Pro Thr Gly Ala Thr Asn Ile
 740 745 750

Glu Val Lys Gln Arg Asn Gln Arg Gly Ser Arg Asn Asn Gly Ser Phe
 755 760 765

Leu Ala Ile Lys Ala Ala Asp Gly Thr Tyr Ile Leu Asn Gly Asp Tyr
 770 775 780

Thr Leu Ser Thr Leu Glu Gln Asp Ile Met Tyr Lys Gly Val Val Leu
 785 790 795 800

Arg Tyr Ser Gly Ser Ser Ala Ala Leu Glu Arg Ile Arg Ser Phe Ser
 805 810 815

Pro Leu Lys Glu Pro Leu Thr Ile Gln Val Leu Thr Val Gly Asn Ala
 820 825 830

Leu Arg Pro Lys Ile Lys Tyr Thr Tyr Phe Val Lys Lys Lys Lys Glu
 835 840 845

Ser Phe Asn Ala Ile Pro Thr Phe Ser Ala Trp Val Ile Glu Glu Trp
 850 855 860

-253-

Gly Glu Cys Ser Lys Ser Cys Glu Leu Gly Trp Gln Arg Arg Leu Val
 865 870 875 880

Glu Cys Arg Asp Ile Asn Gly Gln Pro Ala Ser Glu Cys Ala Lys Glu
 885 890 895

Val Lys Pro Ala Ser Thr Arg Pro Cys Ala Asp His Pro Cys Pro Gln
 900 905 910

Trp Gln Leu Gly Glu Trp Ser Ser Cys Ser Lys Thr Cys Gly Lys Gly
 915 920 925

Tyr Lys Lys Arg Ser Leu Lys Cys Leu Ser His Asp Gly Gly Val Leu
 930 935 940

Ser His Glu Ser Cys Asp Pro Leu Lys Lys Pro Lys His Phe Ile Asp
 945 950 955 960

Phe Cys Thr Met Ala Glu Cys Ser
 965

<210> 126

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
 oligonucleotide

<400> 126

actgtgtgtg atccgag

17

<210> 127

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
 oligonucleotide

<400> 127

gttgaaagc attgacg

17

<210> 128

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 128

aagaatgcgg ccgcagccac catggggaac gcggagcggg ctcc

44

-254-

<210> 129
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 129
gatcgcggta ccactgcatt ctgccattgt gcaaaagtct atg 43

<210> 130
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 130
gatctatgat cagccacat ggggaacgcg gagcgggctc c 41

<210> 131
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 131
gactgctcta gaactgcatt ctgccattgt gcaaaagtct atg 43

<210> 132
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 132
gatctatgat cagccacat ggggaacgcg gagcgggctc c 41

<210> 133
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 133
gcgtgctcta gaagggctaa agctgcgaat tc 32

<210> 134

-255-

<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 134
gtaccaagc ttttgtgtc. cagtcaccgc

30

<210> 135
<211> 32
<212> DNA
<213> Artificial Sequence


<220>
<223> Description of Artificial Sequence: primer

<400> 135
gcgtgctcta gattactcgt tgtgtgcttc ac

32

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/14462

A. CLASSIFICATION OF SUBJECT MATTER														
IPC(7) : C07K 14/00; C12P 21/00 US CL : 435/6, 69.1; 530/350 According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED														
Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 69.1; 530/350														
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched														
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE, BIOSIS, SCISEARCH, EMBASE, CAPLUS meth1, meth2, protein, angiogenesis														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
Y	VASQUEZ F et al. METH-1 and METH-2 are novel proteins that contain the anti angiogenic domain of thrombospondin 1. FASEB Journal. 28 February 1997. Vol 11. No 3, page 1947 (abstract).	19												
X, P ----- Y, P	VAZQUEZ F et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. Journal of Biological Chemistry. 13 August 1999. Vol 274. No.33. pages 23349-23357, see entire document	1-17 ----- 19												
A	US 5,837,680 A (MOSES et al) 17 November 1998, see entire document.	19-23												
X	WO 99/07850 A1 (MILLENNIUM BIOTHERAPEUTICS, INC.) 18 February 1999, see entire document.	1-7, 15 and 17												
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E* earlier document published on or after the international filing date</td> <td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*Z* document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family													
O document referring to an oral disclosure, use, exhibition or other means														
P document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 26 JULY 2000		Date of mailing of the international search report 03 OCT 2000												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer  STEPHEN SIU Telephone No. (703) 308-0196												

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/14462

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LAWLER. J et al. Characterization of the murine thrombospondin gene. Genomics 1991. Vol 11, pages 587-600, see entire document	17
X	ADAMS, M.D. et al. 3,400 expressed sequence tags identify diversity of transcripts from human brain. Nature Genetics 1993. Vol.4, pages 256-267, see entire document.	14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/14462

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 1-18
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

THE CRF IN THIS CASE IS DEFECTIVE. CLAIMS WHICH RECITE SEQ ID NOS OR DEPEND THEREFROM CANNOT BE SEARCHED OTHER THAN BY A SEQUENCE SEARCH AND ARE THUS HELD UNSEARCHABLE.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.